{
  "url": "https://openlegislation.uk/eu-regulation-2018-669/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2018-669/annex.json",
  "legislation": "eur/2018/669",
  "legislation_title": "Commission Regulation (EU) 2018/669 of 16 April 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2018-669",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "Index No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors\nNotes\nHazard Class andCategory Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n(1)\n(2)\n(3)\n(4)\n(5)\n(6)\n(7)\n(8)\n(9)\n(10)\n(11)\n001-001-00-9\nhydrogen\n215-605-7\n1333-74-0\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n001-002-00-4\naluminium lithium hydride\n240-877-9\n16853-85-3\nWater-react. 1\nSkin Corr. 1A\nH260\nH314\nGHS02\nGHS05\nDgr\nH260\nH314\n001-003-00-X\nsodium hydride\n231-587-3\n7646-69-7\nWater-react. 1\nH260\nGHS02\nDgr\nH260\n001-004-00-5\ncalcium hydride\n232-189-2\n7789-78-8\nWater-react. 1\nH260\nGHS02\nDgr\nH260\n003-001-00-4\nlithium\n231-102-5\n7439-93-2\nWater-react. 1\nSkin Corr. 1B\nH260\nH314\nGHS02\nGHS05\nDgr\nH260\nH314\nEUH014\n003-002-00-X\nn-hexyllithium\n404-950-0\n21369-64-2\nWater-react. 1\nPyr. Sol. 1\nSkin Corr. 1A\nH260\nH250\nH314\nGHS02\nGHS05\nDgr\nH260\nH250\nH314\nEUH014\n003-003-00-5\n(2-methylpropyl)lithium; isobutyllithium\n440-620-2\n920-36-5\nWater-react. 1\nPyr. Liq. 1\nSkin Corr. 1A\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH260\nH250\nH314\nH336\nH400\nH410\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH260\nH250\nH314\nH336\nH410\nEUH014\n004-001-00-7\nberyllium\n231-150-7\n7440-41-7\nCarc. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH350i\nH330\nH301\nH372 **\nH319\nH335\nH315\nH317\nGHS06\nGHS08\nDgr\nH350i\nH330\nH301\nH372 **\nH319\nH335\nH315\nH317\n004-002-00-2\nberyllium compounds with the exception of aluminium beryllium silicates, and with those specified elsewhere in this Annex\n—\n—\nCarc. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH350i\nH330\nH301\nH372 **\nH319\nH335\nH315\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350i\nH330\nH301\nH372 **\nH319\nH335\nH315\nH317\nH411\nA\n004-003-00-8\nberyllium oxide\n215-133-1\n1304-56-9\nCarc. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH350i\nH330\nH301\nH372 **\nH319\nH335\nH315\nH317\nGHS06\nGHS08\nDgr\nH350i\nH330\nH301\nH372 **\nH319\nH335\nH315\nH317\n005-001-00-X\nboron trifluoride\n231-569-5\n7637-07-2\nPress. Gas\nAcute Tox. 2 *\nSkin Corr. 1A\nH330\nH314\nGHS04\nGHS06\nGHS05\nDgr\nH330\nH314\nEUH014\nU\n005-002-00-5\nboron trichloride\n233-658-4\n10294-34-5\nPress. Gas\nAcute Tox. 2 *\nAcute Tox. 2 *\nSkin Corr. 1B\nH330\nH300\nH314\nGHS04\nGHS06\nGHS05\nDgr\nH330\nH300\nH314\nEUH014\nU\n005-003-00-0\nboron tribromide\n233-657-9\n10294-33-4\nAcute Tox. 2 *\nAcute Tox. 2 *\nSkin Corr. 1A\nH330\nH300\nH314\nGHS06\nGHS05\nDgr\nH330\nH300\nH314\nEUH014\n005-004-00-6\ntrialkylboranes, solid\n—\n—\nPyr. Sol. 1\nSkin Corr. 1B\nH250\nH314\nGHS02\nGHS05\nDgr\nH250\nH314\nA\n005-004-01-3\ntrialkylboranes, liquid\n—\n—\nPyr. Liq. 1\nSkin Corr. 1B\nH250\nH314\nGHS02\nGHS05\nDgr\nH250\nH314\nA\n005-005-00-1\ntrimethyl borate\n204-468-9\n121-43-7\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH312\nGHS02\nGHS07\nWng\nH226\nH312\n005-006-00-7\ndibutyltin hydrogen borate\n401-040-5\n75113-37-0\nRepr. 1B\nMuta. 2\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH360FD\nH341\nH372**\nH312\nH302\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH360FD\nH341\nH372**\nH312\nH302\nH318\nH317\nH410\n005-007-00-2\nboric acid; [1]\nboric acid; [2]\n233-139-2 [1]\n234-343-4 [2]\n10043-35-3 [1]\n11113-50-1 [2]\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr.1B;\nH360FD: C ≥ 5,5 %\n005-008-00-8\ndiboron trioxide;\nboric oxide\n215-125-8\n1303-86-2\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr.1B;\nH360FD:C ≥ 3,1 %\n005-009-00-3\ntetrabutylammonium butyltriphenylborate\n418-080-4\n120307-06-4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n005-010-00-9\nN, N-dimethylanilinium tetrakis(pentafluorophenyl)borate\n422-050-6\n118612-00-3\nCarc. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nH351\nH302\nH315\nH318\nGHS08\nGHS05\nGHS07\nDgr\nH351\nH302\nH315\nH318\n005-011-00-4\ndisodium tetraborate, anhydrous; boric acid, disodium salt; [1]\ntetraboron disodium heptaoxide, hydrate; [2]\northoboric acid, sodium salt [3]\n215-540-4 [1]\n235-541-3 [2]\n237-560-2 [3]\n1330-43-4 [1]\n12267-73-1 [2]\n13840-56-7 [3]\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr. 1B; H360FD: C ≥4,5 %\n005-011-01-1\ndisodium tetraborate decahydrate;\nborax decahydrate\n215-540-4\n1303-96-4\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr.1B; H360FD: C ≥ 8,5 %\n005-011-02-9\ndisodium tetraborate pentahydrate;\nborax pentahydrate\n215-540-4\n12179-04-3\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr.B; H360FD: C ≥ 6,5 %\n005-012-00-X\ndiethyl{4-[1,5,5-tris(4-diethylaminophenyl)penta-2,4-dienylidene]cyclohexa-2,5-dienylidene}ammonium butyltriphenylborate\n418-070-1\n141714-54-7\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n005-013-00-5\ndiethylmethoxyborane\n425-380-9\n7397-46-8\nPyr. Liq. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 4\nH250\nH332\nH312\nH302\nH373**\nH314\nH317\nH413\nGHS02\nGHS05\nGHS08\nGHS07\nDgr\nH250\nH332\nH312\nH302\nH373**\nH314\nH317\nH413\n005-014-00-0\n4-formylphenylboronic acid\n438-670-5\n87199-17-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n005-015-00-6\n1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)\n414-380-4\n140681-55-6\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n005-016-00-1\ntetrabutylammonium butyl tris-(4-tert-butylphenyl)borate\n431-370-5\n—\nAquatic Chronic 4\nH413\n—\nH413\n005-017-00-7\nsodium perborate; [1]\nsodium peroxometaborate; [2]\nsodium peroxoborate;\n[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1]\n231-556-4 [2]\n15120-21-5 [1]\n7632-04-4 [2]\nOx. Sol. 2\nRepr. 1B\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH302\nH335\nH318\nGHS03\nGHS05\nGHS08\nGHS07\nDgr\nH272\nH360Df\nH302\nH335\nH318\nRepr.1B; H360Df: C ≥9 % Repr.1B; H360 D: 6,5 % ≤ C <9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 %\n005-017-01-4\nsodium perborate; [1]\nsodium peroxometaborate; [2]\nsodium peroxoborate;\n[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1] 231-556-4 [2]\n15120-21-5 [1]\n7632-04-4 [2]\nOx. Sol. 2\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH331\nH302\nH335\nH318\nGHS03\nGHS06\nGHS05\nGHS08\nDgr\nH272\nH360Df\nH331\nH302\nH335\nH318\nRepr. 1B; H360Df: C ≥9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 %\n005-018-00-2\nperboric acid (H3BO2(O2)), monosodium salt trihydrate; [1]\nperboric acid, sodium salt, tetrahydrate; [2]\nperboric acid (HBO(O2)), sodium salt, tetrahydrate; [3]\nsodium peroxoborate hexahydrate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1]\n234-390-0 [2]\n231-556-4 [3]\n13517-20-9 [1]\n37244-98-7 [2]\n10486-00-7 [3]\nRepr. 1B\nSTOT SE 3\nEye Dam. 1\nH360Df\nH335\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH360Df\nH335\nH318\nRepr. 1B;\nH360Df: C ≥ 14 % Repr. 1B;\nH360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2;\nH319: 22 % ≤ C < 36 %\n005-018-01-X\nperboric acid (H3BO2(O2)), monosodium salt, trihydrate; [1]\nperboric acid, sodium salt, tetrahydrate; [2]\nperboric acid (HBO(O2)), sodium salt, tetrahydrate; [3]\nsodium peroxoborate hexahydrate; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1]\n234-390-0 [2]\n231-556-4 [3]\n13517-20-9 [1]\n37244-98-7 [2]\n10486-00-7 [3]\nRepr. 1B\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH360Df\nH332\nH335\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH360Df\nH332\nH335\nH318\nRepr. 1B; H360\nDf: C ≥ 14 % Repr. 1B; H360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 %\n005-019-00-8\nperboric acid, sodium salt; [1]\nperboric acid, sodium salt, monohydrate; [2]\nperboric acid (HBO(O2)), sodium salt, monohydrate; [3]\nsodium peroxoborate;\n[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n234-390-0 [1]\n234-390-0 [2]\n231-556-4 [3]\n11138-47-9 [1]\n12040-72-1 [2]\n10332-33-9 [3]\nOx. Sol. 3\nRepr. 1B\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH302\nH335\nH318\nGHS03\nGHS05\nGHS08\nGHS07\nDgr\nH272\nH360Df\nH302\nH335\nH318\nRepr. 1B; H360Df: C ≥ 9 %\nRepr. 1B; H360D: 6,5 % ≤ C < 9 %\nEye Dam. 1; H318: C ≥ 22 %\nEye Irrit. 2; H319: 14 % ≤ C < 22 %\n005-019-01-5\nperboric acid, sodium salt; [1]\nperboric acid, sodium salt, monohydrate; [2]\nperboric acid (HBO(O2)), sodium salt, monohydrate;[3]\nsodium peroxoborate;\n[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n234-390-0 [1]\n234-390-0 [2]\n231-556-4 [3]\n11138-47-9 [1]\n12040-72-1 [2]\n10332-33-9 [3]\nOx. Sol. 3\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH331\nH302\nH335\nH318\nGHS03\nGHS06\nGHS05\nGHS08\nDgr\nH272\nH360Df\nH331\nH302\nH335\nH318\nRepr. 1B; H360Df: C ≥\n9 %\nRepr. 1B; H360D: 6,5 %\n≤ C < 9 %\nEye Dam. 1; H318: C ≥ 22 %\nEye Irrit. 2; H319: 14 % ≤ C < 22 %\n006-001-00-2\ncarbon monoxide\n211-128-3\n630-08-0\nFlam. Gas 1\nPress. Gas\nRepr. 1A\nAcute Tox. 3 *\nSTOT RE 1\nH220\nH360D ***\nH331\nH372 **\nGHS02\nGHS04\nGHS06\nGHS08\nDgr\nH220\nH360D *** H331\nH372 **\nU\n006-002-00-8\nphosgene; carbonyl chloride\n200-870-3\n75-44-5\nPress. Gas\nAcute Tox. 2 *\nSkin Corr. 1B\nH330\nH314\nGHS04\nGHS06\nGHS05\nDgr\nH330\nH314\nU\n006-003-00-3\ncarbon disulphide\n200-843-6\n75-15-0\nFlam. Liq. 2\nRepr. 2\nSTOT RE 1\nEye Irrit. 2\nSkin Irrit. 2\nH225\nH361fd\nH372 **\nH319\nH315\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH361fd\nH372 **\nH319\nH315\nRepr. 2; H361fd: C ≥ 1 %\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,2 %\n≤ C < 1 %\n006-004-00-9\ncalcium carbide\n200-848-3\n75-20-7\nWater-react. 1\nH260\nGHS02\nDgr\nH260\nT\n006-005-00-4\nthiram (ISO);\ntetramethylthiuram disulphide\n205-286-2\n137-26-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH373 **\nH319\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH332\nH302\nH373 **\nH319\nH315\nH317\nH410\nM = 10\n006-006-00-X\nhydrogen cyanide;\nhydrocyanic acid\n200-821-6\n74-90-8\nFlam. Liq. 1\nAcute Tox. 2 * Aquatic Acute 1\nAquatic Chronic 1\nH224\nH330\nH400\nH410\nGHS02\nGHS06\nGHS09\nDgr\nH224\nH330\nH410\n006-006-01-7\nhydrogen cyanide … %;\nhydrocyanic acid … %\n200-821-6\n74-90-8\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\nB\n006-007-00-5\nsalts of hydrogen cyanide with the exception of complex cyanides such as ferrocyanides, ferricyanides and mercuric oxycyanide and those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\nEUH032\nA\n006-008-00-0\nantu (ISO);\n1-(1-naphthyl)-2-thiourea\n201-706-3\n86-88-4\nAcute Tox. 2 *\nCarc. 2\nH300\nH351\nGHS06\nGHS08\nDgr\nH300\nH351\n006-009-00-6\n1-isopropyl-3-methylpyrazol-5-yl dimethylcarbamate;\nisolan\n204-318-2\n119-38-0\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n006-010-00-1\n5,5-dimethyl-3-oxocyclohex-1-enyl dimethylcarbamate 5,5-dimethyldihydroresorcinol dimethylcarbamate; dimetan\n204-525-8\n122-15-6\nAcute Tox. 3 *\nH301\nGHS06\nDgr\nH301\n006-011-00-7\ncarbaryl (ISO);\n1-naphthyl methylcarbamate\n200-555-0\n63-25-2\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nH351\nH332\nH302\nH400\nGHS08\nGHS07\nGHS09\nWng\nH351\nH332\nH302\nH400\nM=100\n006-012-00-2\nziram (ISO);\nzinc bis dimethyldithiocarbamate\n205-288-3\n137-30-4\nAcute Tox. 2 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSTOT SE 3\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH302\nH373 **\nH335\nH318\nH317\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH330\nH302\nH373 **\nH335\nH318\nH317\nH410\nM = 100\n006-013-00-8\nmetam-sodium (ISO);\nsodium methyldithiocarbamate\n205-293-0\n137-42-8\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH317\nH410\nEUH031\n006-014-00-3\nnabam (ISO);\ndisodium ethylenebis(N, N'-dithiocarbamate)\n205-547-0\n142-59-6\nAcute Tox. 4 *\nSTOT SE 3\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH335\nH317\nH410\nGHS07\nGHS09\nWng\nH302\nH335\nH317\nH410\n006-015-00-9\ndiuron (ISO);\n3-(3,4-dichlorophenyl)-1,1-dimethylurea\n206-354-4\n330-54-1\nCarc. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH373** H410\nM = 10\n006-016-00-4\npropoxur (ISO);\n2-isopropyloxyphenyl N-methylcarbamate;\n2-isopropoxyphenyl methylcarbamate\n204-043-8\n114-26-1\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\n006-017-00-X\naldicarb (ISO);\n2-methyl-2-(methylthio)propanal-O-(N-methylcarbamoyl)oxime\n204-123-2\n116-06-3\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH311\nH410\n006-018-00-5\naminocarb (ISO);\n4-dimethylamino-3-tolyl methylcarbamate\n217-990-7\n2032-59-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\n006-019-00-0\ndi-allate (ISO);\nS-(2,3-dichloroallyl)-N,N-diisopropylthiocarbamate\n218-961-1\n2303-16-4\nCarc. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH410\n006-020-00-6\nbarban (ISO);\n4-chlorbut-2-ynyl N-(3-chlorophenyl)carbamate\n202-930-4\n101-27-9\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n006-021-00-1\nlinuron (ISO);\n3-(3,4-dichlorophenyl)-1-methoxy-1-methylurea\n206-356-5\n330-55-2\nRepr. 1B Carc. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH351\nH302\nH373 **\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360Df\nH351\nH302\nH373 **\nH410\n006-022-00-7\ndecarbofuran (ISO);\n2,3-dihydro-2-methylbenzofuran-7-yl methylcarbamate\n—\n1563-67-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n006-023-00-2\nmercaptodimethur (ISO);\nmethiocarb (ISO);\n3,5-dimethyl-4-methylthiophenyl N-methylcarbamate\n217-991-2\n2032-65-7\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\n006-024-00-8\nproxan-sodium (ISO);\nsodium O-isopropyldithiocarbonate\n205-443-5\n140-93-2\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Chronic 2\nH302\nH315\nH411\nGHS07\nGHS09\nWng\nH302\nH315\nH411\n006-025-00-3\nallethrin;\n(RS)-3-allyl-2-methyl-4-oxocyclopent-2-enyl (1RS,3RS;1RS,3SR)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate; bioallethrin;\n(RS)-3-allyl-2-methyl-4-oxocyclopent-2-enyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate; [1]\nS-bioallethrin; [3]\n(S)-3-allyl-2-methyl-4-oxocyclopent-2-enyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate; [2]\nesbiothrin;\n(RS)-3-allyl-2-methyl-4-oxocyclopent-2-enyl(1R,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate [3]\n209-542-4 [1]\n249-013-5 [2]-[3]\n584-79-2 [1]\n28434-00-6 [2]\n84030-86-4 [3]\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH410\nC\n006-026-00-9\ncarbofuran (ISO);\n2,3-dihydro-2,2-dimethylbenzofuran-7-yl N-methylcarbamate\n216-353-0\n1563-66-2\nAcute Tox. 2 *\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH410\n006-028-00-X\ndinobuton (ISO);\n2-(1-methylpropyl)-4,6-dinitrophenyl isopropyl carbonate\n213-546-1\n973-21-7\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\n006-029-00-5\ndioxacarb (ISO);\n2-(1,3-dioxolan-2-yl)phenyl N-methylcarbamate\n230-253-4\n6988-21-2\nAcute Tox. 3 * Aquatic Chronic 2\nH301\nH411\nGHS06\nGHS09\nDgr\nH301\nH411\n006-030-00-0\nEPTC (ISO);\nS-ethyl dipropylthiocarbamate\n212-073-8\n759-94-4\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n006-031-00-6\nformetanate (ISO);\n3-[(EZ)-dimethylaminomethyleneamino]phenyl methylcarbamate\n244-879-0\n22259-30-9\nAcute Tox. 2 *\nAcute Tox. 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH317\nH410\n006-032-00-1\nmonolinuron (ISO);\n3-(4-chlorophenyl)-1-methoxy-1-methylurea\n217-129-5\n1746-81-2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 **\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 **\nH410\n006-033-00-7\nmetoxuron (ISO);\n3-(3-chloro-4-methoxyphenyl)-1,1-dimethylurea\n243-433-2\n19937-59-8\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n006-034-00-2\npebulate (ISO);\nN-butyl-N-ethyl-S-propylthiocarbamate\n214-215-4\n1114-71-2\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n006-036-00-3\nbenzthiazuron (ISO);\n1-benzothiazol-2-yl-3-methylurea\n217-685-9\n1929-88-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n006-037-00-9\npromecarb (ISO);\n3-isopropyl-5-methylphenyl N-methylcarbamate\n220-113-0\n2631-37-0\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\n006-038-00-4\nsulfallate (ISO);\n2-chloroallyl N, N-dimethyldithiocarbamate\n202-388-9\n95-06-7\nCarc. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH410\n006-039-00-X\ntri-allate (ISO);\nS-2,3,3-trichloroallyl diisopropylthiocarbamate\n218-962-7\n2303-17-5\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 **\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 **\nH317\nH410\n006-040-00-5\n3-methylpyrazol-5-yl-dimethylcarbamate; monometilan\n—\n2532-43-6\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n006-041-00-0\ndimethylcarbamoyl chloride\n201-208-6\n79-44-7\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH350\nH331\nH302\nH319\nH335\nH315\nGHS06\nGHS08\nDgr\nH350\nH331\nH302\nH319\nH335\nH315\nCarc. 1B;\nH350: C ≥ 0,001 %\n006-042-00-6\nmonuron (ISO);\n3-(4-chlorophenyl)-1,1-dimethylurea\n205-766-1\n150-68-5\nCarc. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH410\n006-043-00-1\n3-(4-chlorophenyl)-1,1-dimethyluronium trichloroacetate;\nmonuron-TCA\n—\n140-41-0\nCarc. 2\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH319\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH319\nH315\nH410\n006-044-00-7\nisoproturon (ISO);\n3-(4-isopropylphenyl)-1,1-dimethylurea\n251-835-4\n34123-59-6\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nM = 10\n006-045-00-2\nmethomyl (ISO);\n1-(methylthio)ethylideneamino N-methylcarbamate\n240-815-0\n16752-77-5\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH410\nM=100\n006-047-00-3\nbufencarb (ISO);\nreaction mass of 3-(1-methylbutyl)phenyl N-methylcarbamate and 3-(1-ethylpropyl)phenyl N-methylcarbamate\n—\n8065-36-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\n006-048-00-9\nethiofencarb (ISO);\n2-(ethylthiomethyl)phenyl N-methylcarbamate\n249-981-9\n29973-13-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n006-049-00-4\ndixanthogen;\nO, O-diethyl dithiobis(thioformate)\n207-944-4\n502-55-6\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n006-050-00-X\n1,1-dimethyl-3-phenyluronium trichloroacetate;\nfenuron-TCA\n—\n4482-55-7\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n006-051-00-5\nferbam (ISO);\niron tris(dimethyldithiocarbamate)\n238-484-2\n14484-64-1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH410\n006-052-00-0\nformetanate hydrochloride;\n3-(N, N-dimethylaminomethyleneamino)phenyl N-methylcarbamate\n245-656-0\n23422-53-9\nAcute Tox. 2 *\nAcute Tox. 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH317\nH410\n006-053-00-6\nisoprocarb (ISO);\n2-isopropylphenyl N-methylcarbamate\n220-114-6\n2631-40-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n006-054-00-1\nmexacarbate (ISO);\n3,5-dimethyl-4-dimethylaminophenyl N-methylcarbamate\n206-249-3\n315-18-4\nAcute Tox. 2 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH312\nH410\n006-055-00-7\nxylylcarb (ISO);\n3,4-dimethylphenyl N-methylcarbamate;\n3,4-xylyl methylcarbamate;\nMPMC\n219-364-9\n2425-10-7\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n006-056-00-2\nmetolcarb (ISO);\nm-tolyl methylcarbamate;\nMTMC\n214-446-0\n1129-41-5\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n006-057-00-8\nnitrapyrin (ISO);\n2-chloro-6-trichloromethylpyridine\n217-682-2\n1929-82-4\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n006-058-00-3\nnoruron (ISO);\n1,1-dimethyl-3-(perhydro-4,7-methanoinden-5-yl)urea\n—\n2163-79-3\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n006-059-00-9\noxamyl (ISO);\nN',N'-dimethylcarbamoyl(methylthio)methylenamine N-methylcarbamate;\n245-445-3\n23135-22-0\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH330\nH300\nH312\nH411\nGHS06\nGHS09\nDgr\nH330\nH300\nH312\nH411\n006-060-00-4\noxycarboxin (ISO);\n2,3-dihydro-6-methyl-5-(N-phenylcarbamoyl)-1,4-oxothiine 4,4-dioxide\n226-066-2\n5259-88-1\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n006-061-00-X\nS-ethyl N-(dimethylaminopropyl)thiocarbamatehydrochloride;\nprothiocarb hydrochloride\n243-193-9\n19622-19-6\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n006-062-00-5\nmethyl 3,4-dichlorophenylcarbanilate;\nSWEP.\n—\n1918-18-9\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n006-063-00-0\nthiobencarb (ISO);\nS-4-chlorobenzyl diethylthiocarbamate\n248-924-5\n28249-77-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n006-064-00-6\nthiofanox (ISO);\n3,3-dimethyl-1-(methylthio)butanone-O-(N-methylcarbamoyl)oxime\n254-346-4\n39196-18-4\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\n006-065-00-1\n3-chloro-6-cyano-bicyclo(2,2,1)heptan-2-one-O-(N-methylcarbamoyl)oxime;\ntriamid\n—\n15271-41-7\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH300\nH311\nH411\nGHS06\nGHS09\nDgr\nH300\nH311\nH411\n006-066-00-7\nvernolate (ISO);\nS-propyl dipropylthiocarbamate\n217-681-7\n1929-77-7\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n006-067-00-2\nXMC;\n3,5-xylyl methylcarbamate\n—\n2655-14-3\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n006-068-00-8\ndiazomethane\n206-382-7\n334-88-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n006-069-00-3\nthiophanate-methyl (ISO);\n1,2-di-(3-methoxycarbonyl-2-thioureido)benzene\n245-740-7\n23564-05-8\nMuta. 2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH332\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH341\nH332\nH317\nH410\n006-070-00-9\nfurmecyclox (ISO);\nN-cyclohexyl-N-methoxy-2,5-dimethyl-3-furamide\n262-302-0\n60568-05-0\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n006-071-00-4\ncyclooct-4-en-1-yl methyl carbonate\n401-620-8\n87731-18-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n006-072-00-X\nprosulfocarb (ISO);\nS-benzyl N, N-dipropylthiocarbamate\n401-730-6\n52888-80-9\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n006-073-00-5\n3-(dimethylamino)propylurea\n401-950-2\n31506-43-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n006-074-00-0\n2-(3-(prop-1-en-2-yl)phenyl)prop-2-yl isocyanate\n402-440-2\n2094-99-7\nAcute Tox. 2 *\nSkin Corr. 1B\nSTOT RE 2 *\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH314\nH373 **\nH334\nH317\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH330\nH314\nH373 **\nH334\nH317\nH410\n006-076-00-1\nmancozeb (ISO);\nmanganese\nethylenebis(dithiocarbamate)\n(polymeric) complex with zinc salt\n—\n8018-01-7\nRepr. 2\nSkin Sens. 1\nAquatic Acute 1\nH361d***\nH317\nH400\nGHS08\nGHS07\nGHS09\nWng\nH361d***\nH317\nH400\nM=10\n006-077-00-7\nmaneb (ISO);\nmanganese\nethylenebis(dithiocarbamate)\n(polymeric)\n235-654-8\n12427-38-2\nRepr. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d***\nH332\nH319\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d***\nH332\nH319\nH317\nH410\nM=10\n006-078-00-2\nzineb (ISO);\nzinc ethylenebis(dithiocarbamate) (polymeric)\n235-180-1\n12122-67-7\nSTOT SE 3\nSkin Sens. 1\nH335\nH317\nGHS07\nWng\nH335\nH317\n006-079-00-8\ndisulfiram;\ntetraethylthiuramdisulfide\n202-607-8\n97-77-8\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 **\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 **\nH317\nH410\n006-080-00-3\ntetramethylthiuram monosulphide\n202-605-7\n97-74-5\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n006-081-00-9\nzinc bis(dibutyldithiocarbamate)\n205-232-8\n136-23-2\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH335\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH317\nH410\n006-082-00-4\nzinc bis(diethyldithiocarbamate)\n238-270-9\n14324-55-1\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH335\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH335\nH315\nH317\nH410\n006-083-00-X\nbutocarboxim (ISO);\n3-(methylthio)-2-butanone O-[(methylamino)carbonyl]oxime\n252-139-3\n34681-10-2\nFlam. Liq. 3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH331\nH311\nH301\nH319\nH400\nH410\nGHS02\nGHS06\nGHS09\nDgr\nH226\nH331\nH311\nH301\nH319\nH410\n006-084-00-5\ncarbosulfan (ISO);\n2,3-dihydro-2,2-dimethyl-7-benzofuryl [(dibutylamino)thio]methylcarbamate\n259-565-9\n55285-14-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH301\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH301\nH317\nH410\n006-085-00-0\nfenobucarb (ISO);\n2-butylphenyl methylcarbamate\n223-188-8\n3766-81-2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n006-086-00-6\nfenoxycarb (ISO);\nethyl [2-(4-phenoxyphenoxy)ethyl]carbamate\n276-696-7\n72490-01-8\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nM = 1\nM = 10 000\n006-087-00-1\nfurathiocarb (ISO);\n2,3-dihydro-2,2-dimethyl-7-benzofuryl 2,4-dimethyl-6-oxa-5-oxo-3-thia-2,4-diazadecanoate\n265-974-3\n65907-30-4\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH301\nH373**\nH319\nH315\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH301\nH373**\nH319\nH315\nH317\nH410\nM = 100\n006-088-00-7\nbenfuracarb (ISO);\nethyl N-[2,3-dihydro-2,2-dimethylbenzofuran-7-yloxycarbonyl(methyl)aminothio]-N-isopropyl-β-alaninate\n—\n82560-54-1\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH361f***\nH331\nH302\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361f***\nH331\nH302\nH410\n006-090-00-8\n2-(3-iodoprop-2-yn-1-yloxy)ethyl phenylcarbamate\n408-010-0\n88558-41-2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH332\nH318\nH412\nGHS05\nGHS07\nDgr\nH332\nH318\nH412\n006-091-00-3\npropineb (ISO);\npolymeric zinc propylenebis(dithiocarbamate)\n—\n9016-72-2\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nH332\nH373**\nH317\nH400\nGHS08\nGHS07\nGHS09\nWng\nH332\nH373**\nH317\nH400\n006-092-00-9\ntert-butyl (1S)-N-[1-((2S)-2-oxiranyl)-2-phenylethyl]carbamate\n425-420-5\n98737-29-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n006-093-00-4\n2,2'-dithio di(ethylammonium)-bis(dibenzyldithiocarbamate)\n427-180-7\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n006-094-00-X\nO-isobutyl-N-ethoxy carbonylthiocarbamate\n434-350-4\n103122-66-3\nFlam. Liq. 3\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH226\nH350\nH340\nH302\nH373**\nH317\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH350\nH340\nH302\nH373**\nH317\nH411\n006-095-00-5\nfosetyl-aluminium (ISO);\naluminium triethyl triphosphonate\n254-320-2\n39148-24-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n006-096-00-0\nchlorpropham (ISO);\nisopropyl 3-chlorocarbanilate\n202-925-7\n101-21-3\nCarc. 2\nSTOT RE 2 *\nAquatic Chronic 2\nH351\nH373**\nH411\nGHS08\nGHS09\nWng\nH351\nH373**\nH411\n006-097-00-6\n1-phenyl-3-(p-toluenesulfonyl)urea\n424-620-1\n13909-63-2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n006-098-00-1\ntert-butyl (1R,5S)-3-azabicyclo[3.1.0]hex-6-ylcarbamate\n429-170-8\n134575-17-0\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH373**\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\nH317\n006-099-00-7\nN-(p-toluenesulfonyl)-N'-(3-(p-toluenesulfonyloxy)phenyl)urea;\n3-][(4-methylphenyl)sulfonyl]carbamoyl}amino)phenyl4-methylbenzenesulfonate\n520-2\n232938-43-1\nAquatic Chronic 2\nH411\nGHS09\nH411\n006-101-00-6\nreaction mass of: N, N''-(methylenedi-4,1-phenylene)bis[N'-phenylurea];\nN-(4-[[4-[[(phenylamino)carbonyl]amino]phenylmethyl]phenyl]-N'-cyclohexylurea;\nN, N''-(methylenedi-4,1-phenylene)bis[N'-cyclohexylurea]\n423-070-8\n—\nAquatic Chronic 4\nH413\n—\nH413\n006-102-00-1\nO-hexyl-N-ethoxycarbonylthiocarbamate\n432-750-3\n—\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH340\nH302\nH373**\nH317\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH340\nH302\nH373**\nH317\nH411\n006-103-00-7\nN, N''-(methylenedi-4,1-phenylene)bis[N'-octyl]urea\n445-760-8\n—\nEye Dam. 1\nResp. Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH334\nH400\nH410\nGHS05\nGHS08\nGHS09\nDgr\nH318\nH334\nH410\nM=100\n007-001-00-5\nammonia, anhydrous\n231-635-3\n7664-41-7\nFlam. Gas 2\nPress. Gas\nAcute Tox. 3 *\nSkin Corr. 1B\nAquatic Acute 1\nH221\nH331\nH314\nH400\nGHS04\nGHS06\nGHS05\nGHS09\nDgr\nH221\nH331\nH314\nH400\nU\n007-001-01-2\nammonia ….%\n215-647-6\n1336-21-6\nSkin Corr. 1B\nAquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\nSTOT SE 3; H335: C ≥ 5 %\nB\n007-002-00-0\nnitrogen dioxide; [1]\ndinitrogen tetraoxide [2]\n233-272-6 [1]\n234-126-4 [2]\n10102-44-0 [1]\n10544-72-6 [2]\nPress. Gas\nOx. Gas 1\nAcute Tox. 2 *\nSkin Corr. 1B\nH270\nH330\nH314\nGHS04\nGHS03\nGHS06\nGHS05\nDgr\nH270\nH330\nH314\n*\nSTOT SE 3; H335: C ≥0,5 %\n5\n007-003-00-6\nchlormequat chloride (ISO);\n2-chloroethyltrimethylammonium chloride\n213-666-4\n999-81-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n007-006-00-2\nethyl nitrite\n203-722-6\n109-95-5\nFlam. Gas 1\nPress. Gas\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH220\nH332\nH312\nH302\nGHS02\nGHS04\nGHS07\nDgr\nH220\nH332\nH312\nH302\nU\n007-007-00-8\nethyl nitrate\n210-903-3\n625-58-1\nUnst. Expl.\nH200\nGHS01\nDgr\nH200\n007-008-00-3\nhydrazine\n206-114-9\n302-01-2\nFlam. Liq. 3\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH350\nH331\nH311\nH301\nH314\nH317\nH400\nH410\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH226\nH350\nH331\nH311\nH301\nH314\nH317\nH410\nSkin Corr. 1B; H314: C ≥ 10 % Skin Irrit. 2; H315: 3 % ≤ C < 10 %\nEye Irrit. 2; H319: 3 % ≤ C < 10 %\n007-009-00-9\ndicyclohexylammonium nitrite\n221-515-9\n3129-91-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH302\nGHS07\nWng\nH332\nH302\n*\n007-010-00-4\nsodium nitrite\n231-555-9\n7632-00-0\nOx. Sol. 3\nAcute Tox. 3 *\nAquatic Acute 1\nH272\nH301\nH400\nGHS03\nGHS06\nGHS09\nDgr\nH272\nH301\nH400\n*\n007-011-00-X\npotassium nitrite\n231-832-4\n7758-09-0\nOx. Sol. 2\nAcute Tox. 3 *\nAquatic Acute 1\nH272\nH301\nH400\nGHS03\nGHS06\nGHS09\nDgr\nH272\nH301\nH400\n*\n007-012-00-5\nN,N-dimethylhydrazine\n200-316-0\n57-14-7\nFlam. Liq. 2\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nAquatic Chronic 2\nH225\nH350\nH331\nH301\nH314\nH411\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH225\nH350\nH331\nH301\nH314\nH411\n007-013-00-0\n1,2-dimethylhydrazine\n—\n540-73-8\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH350\nH331\nH311\nH301\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH311\nH301\nH411\nCarc. 1B; H350: C ≥ 0,01 %\n007-014-00-6\nsalts of hydrazine\n—\n—\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH331\nH311\nH301\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH311\nH301\nH317\nH410\nA\n007-015-00-1\nO-ethylhydroxylamine\n402-030-3\n624-86-2\nFlam. Liq. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH225\nH331\nH311\nH301\nH372 **\nH319\nH317\nH400\nGHS02\nGHS06\nGHS08\nGHS09\nDgr\nH225\nH331\nH311\nH301\nH372 **\nH319\nH317\nH400\n007-016-00-7\nbutyl nitrite\n208-862-1\n544-16-1\nFlam. Liq. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nH225\nH331\nH301\nGHS02\nGHS06\nDgr\nH225\nH331\nH301\n007-017-00-2\nisobutyl nitrite\n208-819-7\n542-56-3\nFlam. Liq. 2\nCarc. 1B\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH350\nH341\nH332\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH350\nH341\nH332\nH302\n007-018-00-8\nsec-butyl nitrite\n213-104-8\n924-43-6\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH332\nH302\nGHS02\nGHS07\nDgr\nH225\nH332\nH302\n007-019-00-3\ntert-butyl nitrite\n208-757-0\n540-80-7\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH332\nH302\nGHS02\nGHS07\nDgr\nH225\nH332\nH302\n007-020-00-9\npentyl nitrite; [1]\n‘amyl nitrite’, mixed isomers [2]\n207-332-7 [1]\n203-770-8 [2]\n463-04-7 [1]\n110-46-3 [2]\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH332\nH302\nGHS02\nGHS07\nDgr\nH225\nH332\nH302\n007-021-00-4\nhydrazobenzene;\n1,2-diphenylhydrazine\n204-563-5\n122-66-7\nCarc. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH410\n007-022-00-X\nhydrazine bis(3-carboxy-4-hydroxybenzensulfonate)\n405-030-1\n—\nCarc. 1B\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH302\nH314\nH317\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH350\nH302\nH314\nH317\nH412\n007-023-00-5\nsodium 3,5-bis(3-(2,4-di-tert-pentylphenoxy)propylcarbamoyl)benzenesulfonate\n405-510-0\n—\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n007-024-00-0\n2-(decylthio)ethylammonium chloride\n405-640-8\n36362-09-1\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH315\nH318\nH400\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH373 **\nH315\nH318\nH410\n007-025-00-6\n(4-hydrazinophenyl)-N-methylmethanesulfonamide hydrochloride\n406-090-1\n81880-96-8\nMuta. 2\nAcute Tox. 3 *\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH301\nH372 **\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH301\nH372 **\nH317\nH410\n007-026-00-1\noxo-((2,2,6,6-tetramethylpiperidin-4-yl)amino)carbonylacetohydrazide\n413-230-5\n122035-71-6\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n007-027-00-7\n1,6-bis(3,3-bis((1-methylpentylidenimino)propyl)ureido)hexane\n420-190-2\n771478-66-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373 **\nH314\nH317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH373 **\nH314\nH317\nH410\n007-028-00-2\nhydroxylammonium nitrate\n236-691-2\n13465-08-2\nExpl. 1.1 ****\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH201\nH351\nH311\nH302\nH373**\nH319\nH315\nH317\nH400\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH351\nH311\nH302\nH373**\nH319\nH315\nH317\nH400\n007-029-00-8\ndiethyldimethylammonium hydroxide\n419-400-5\n95500-19-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n008-001-00-8\noxygen\n231-956-9\n7782-44-7\nOx. Gas 1\nPress. Gas\nH270\nGHS03\nGHS04\nDgr\nH270\nU\n008-003-00-9\nhydrogen peroxide solution… %\n231-765-0\n7722-84-1\nOx. Liq. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH271\nH332\nH302\nH314\nGHS03\nGHS05\nGHS07\nDgr\nH271\nH332\nH302\nH314\nOx. Liq. 1; H271: C ≥70 %****\nOx. Liq. 2; H272: 50 % ≤ C < 70 % ****\n*\nSkin Corr. 1A; H314: C ≥ 70 % Skin Corr. 1B; H314: 50 % ≤ C < 70 %\nSkin Irrit. 2; H315: 35 % ≤ C < 50 %\nEye Dam. 1; H318: 8 % ≤ C < 50 %\nEye Irrit. 2; H319: 5 % ≤ C< 8 % STOT SE 3; H335; C ≥ 35 %\nB\n009-001-00-0\nfluorine\n231-954-8\n7782-41-4\nPress. Gas\nOx. Gas 1\nAcute Tox. 2 *\nSkin Corr. 1A\nH270\nH330\nH314\nGHS04\nGHS03\nGHS06\nGHS05\nDgr\nH270\nH330\nH314\n009-002-00-6\nhydrogen fluoride\n231-634-8\n7664-39-3\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSkin Corr. 1A\nH330\nH310\nH300\nH314\nGHS06\nGHS05\nDgr\nH330\nH310\nH300\nH314\n009-003-00-1\nhydrofluoric acid … %\n231-634-8\n7664-39-3\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSkin Corr. 1A\nH330\nH310\nH300\nH314\nGHS06\nGHS05\nDgr\nH330\nH310\nH300\nH314\nSkin Corr. 1A; H314: C ≥ 7 % Skin Corr. 1B; H314: 1 % ≤ C< 7 % Eye Irrit. 2; H319: 0,1 % ≤C < 1 %\nB\n009-004-00-7\nsodium fluoride\n231-667-8\n7681-49-4\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Irrit. 2\nH301\nH319\nH315\nGHS06\nDgr\nH301\nH319\nH315\nEUH032\n009-005-00-2\npotassium fluoride\n232-151-5\n7789-23-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n009-006-00-8\nammonium fluoride\n235-185-9\n12125-01-8\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n009-007-00-3\nsodium bifluoride;\nsodium hydrogen difluoride\n215-608-3\n1333-83-1\nAcute Tox. 3 *\nSkin Corr. 1B\nH301\nH314\nGHS06\nGHS05\nDgr\nH301\nH314\n*Skin Corr. 1B; H314: C ≥ 1 % Skin Irrit. 2; H315: 0,1 % ≤ C < % Eye Irrit. 2;\nH319: 0,1 % ≤\nC < 1 %\n009-008-00-9\npotassium bifluoride;\npotassium hydrogen difluoride\n232-156-2\n7789-29-9\nAcute Tox. 3 *\nSkin Corr. 1B\nH301\nH314\nGHS06\nGHS05\nDgr\nH301\nH314\n*\nSkin Corr. 1B; H314: C ≥ 1 %\nSkin Irrit. 2; H315: 0,1 % ≤ C < 1 %\nEye Irrit. 2; H319: 0,1 % ≤ C < 1 %\n009-009-00-4\nammonium bifluoride;\nammonium hydrogen difluoride\n215-676-4\n1341-49-7\nAcute Tox. 3 *\nSkin Corr. 1B\nH301\nH314\nGHS06\nGHS05\nDgr\nH301\nH314\n*\nSkin Corr. 1B; H314: C ≥ 1 % Skin Irrit.2; H315: 0,1 % ≤ C < 1 %\nEye Irrit. 2; H319: 0,1 % ≤ C < 1 %\n009-010-00-X\nfluoroboric acid … %\n240-898-3\n16872-11-0\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 %\nEye Irrit. 2; H319: 10 % ≤\nC < 25 %\nB\n009-011-00-5\nfluorosilicic acid … %\n241-034-8\n16961-83-4\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\nB\n009-012-00-0\nalkali fluorosilicates(Na); [1]\nalkali fluorosilicates(K); [2]\nalkali fluorosilicates(NH4) [3]\n240-934-8 [1]\n240-896-2 [2]\n240-968-3 [3]\n16893-85-9 [1]\n16871-90-2 [2]\n16919-19-0 [3]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n*\nA\n009-013-00-6\nfluorosilicates, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n*\nA\n009-014-00-1\nlead hexafluorosilicate\n247-278-1\n25808-74-6\nRepr. 1A\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH332\nH302\nH373 **\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360Df\nH332\nH302\nH373 **\nH410\n1\n009-015-00-7\nsulphuryl difluoride\n220-281-5\n2699-79-8\nPress. Gas\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nH331\nH373 **\nH400\nGHS04\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH373 **\nH400\nU\n009-016-00-2\ntrisodium hexafluoroaluminate [1]\ntrisodium hexafluoroaluminate(cryolite) [2]\n237-410-6 [1]\n239-148-8 [2]\n13775-53-6 [1]\n15096-52-3 [2]\nSTOT RE 1\nAcute Tox. 4\nAquatic Chronic 2\nH372\nH332\nH411\nGHS07\nGHS08\nGHS09\nDgr\nH372\nH332\nH411\n009-017-00-8\npotassium mu-fluoro-bis(triethylaluminium)\n400-040-2\n12091-08-6\nFlam. Sol. 1\nWater-react. 1\nSkin Corr. 1A\nAcute Tox. 4 *\nH228\nH270\nH314\nH332\nGHS02\nGHS05\nGHS07\nDgr\nH228\nH270\nH314\nH332\nEUH014\nT\n009-018-00-3\nmagnesium hexafluorosilicate\n241-022-2\n16949-65-8\nAcute Tox. 3 *\nH301\nGHS06\nDgr\nH301\n*\n011-001-00-0\nsodium\n231-132-9\n7440-23-5\nWater-react. 1\nSkin Corr. 1B\nH260\nH314\nGHS02\nGHS05\nDgr\nH260\nH314\nEUH014\n011-002-00-6\nsodium hydroxide;\ncaustic soda\n215-185-5\n1310-73-2\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1A; H314: C ≥ 5 % Skin Corr. 1B; H314 2 % ≤ C < 5 % Skin Irrit. 2; H315: 0,5 % ≤ C < 2 % Eye Irrit.2; H319: 0,5 % ≤ C < 2 %\n011-003-00-1\nsodium peroxide\n215-209-4\n1313-60-6\nOx. Sol. 1\nSkin Corr. 1A\nH271\nH314\nGHS03\nGHS05\nDgr\nH271\nH314\n011-004-00-7\nsodium azide\n247-852-1\n26628-22-8\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH400\nH410\nEUH032\n011-005-00-2\nsodium carbonate\n207-838-8\n497-19-8\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n011-006-00-8\nsodium cyanate\n213-030-6\n917-61-3\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n011-007-00-3\npropoxycarbazone-sodium\n—\n181274-15-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 10\n012-001-00-3\nmagnesium powder (pyrophoric)\n231-104-6\n7439-95-4\nWater-react. 1\nPyr. Sol. 1\nH260\nH250\nGHS02\nDgr\nH260\nH250\nT\n012-002-00-9\nmagnesium, powder or turnings\n231-104-6\n—\nFlam. Sol. 1\nWater-react. 2\nSelf-heat. 1\nH228\nH261\nH252\nGHS02\nDgr\nH228\nH261\nH252\nT\n012-003-00-4\nmagnesium alkyls\n—\n—\nPyr. Liq. 1\nWater-react. 1\nSkin Corr. 1B\nH250\nH260\nH314\nGHS02\nGHS05\nDgr\nH250\nH260\nH314\nEUH014\nA\n012-004-00-X\naluminium-magnesium-carbonate-hydroxide-perchlorate-hydrate\n422-150-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n013-001-00-6\naluminium powder (pyrophoric)\n231-072-3\n7429-90-5\nWater-react. 2\nPyr. Sol. 1\nH261\nH250\nGHS02\nDgr\nH261\nH250\nT\n013-002-00-1\naluminium powder (stabilised)\n231-072-3\n7429-90-5\nWater-react. 2\nFlam. Sol. 1\nH261\nH228\nGHS02\nDgr\nH261\nH228\nT\n013-003-00-7\naluminium chloride, anhydrous\n231-208-1\n7446-70-0\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n013-004-00-2\naluminium alkyls\n—\n—\nPyr. Liq. 1\nWater-react. 1\nSkin Corr. 1B\nH250\nH260\nH314\nGHS02\nGHS05\nDgr\nH250\nH260\nH314\nEUH014\nA\n013-005-00-8\ndiethyl(ethyldimethylsilanolato) aluminium\n401-160-8\n55426-95-4\nWater-react. 1\nPyr. Liq. 1\nSkin Corr. 1A\nH260\nH250\nH314\nGHS02\nGHS05\nDgr\nH260\nH250\nH314\nEUH014\n013-006-00-3\n(ethyl-3-oxobutanoato-O'1,O'3)(2-dimethylaminoethanolato)(1-methoxypropan-2-olato)aluminium(III), dimerised\n402-370-2\n—\nFlam. Liq. 3\nEye Dam. 1\nH226\nH318\nGHS02\nGHS05\nDgr\nH226\nH318\n013-007-00-9\npoly(oxo(2-butoxyethyl-3-oxobutanoato-O'1,O'3)aluminium)\n403-430-0\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n013-008-00-4\ndi-n-octylaluminium iodide\n408-190-0\n7585-14-0\nPyr. Liq. 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH250\nH314\nH400\nH410\nGHS02\nGHS05\nGHS09\nDgr\nH250\nH314\nH410\nEUH014\n013-009-00-X\nsodium (n-butyl)x(ethyl)y-1,5-dihydro)aluminate x = 0,5 y =1,5\n418-720-2\n—\nFlam. Sol. 1\nWater-react. 1\nPyr. Sol. 1\nAcute Tox. 4 *\nSkin Corr. 1A\nH228\nH260\nH250\nH332\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH228\nH260\nH250\nH332\nH314\nEUH014\nT\n013-010-00-5\nhydroxy aluminium bis(2,4,8,10-tetra-tert-butyl-6-hydroxy-12H-dibenzo[d, g][1.3.2]dioxaphosphocin-6-oxide)\n430-650-4\n151841-65-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-001-00-9\ntrichlorosilane\n233-042-5\n10025-78-2\nFlam. Liq. 1\nPyr. Liq. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH224\nH250\nH332\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH224\nH250\nH332\nH302\nH314\nEUH014\nEUH029\n*\nSTOT SE 3; H335: C ≥ 1 %\nT\n014-002-00-4\nsilicon tetrachloride\n233-054-0\n10026-04-7\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\nEUH014\n014-003-00-X\ndimethyldichlorosilane\n200-901-0\n75-78-5\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH225\nH319\nH335\nH315\nGHS02\nGHS07\nDgr\nH225\nH319\nH335\nH315\n014-004-00-5\ntrichloro(methyl)silane; methyltrichlorosilane\n200-902-6\n75-79-6\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH225\nH319\nH335\nH315\nGHS02\nGHS07\nDgr\nH225\nH319\nH335\nH315\nEUH014\nSkin Irrit.2; H315: C ≥ 1 % Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 %\n014-005-00-0\ntetraethyl silicate;\nethyl silicate\n201-083-8\n78-10-4\nFlam. Liq. 3\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH226\nH332\nH319\nH335\nGHS02\nGHS07\nWng\nH226\nH332\nH319\nH335\n014-006-00-6\nbis(4-fluorophenyl)-methyl-(1,2,4-triazol-4-ylmethyl)silane hydrochloride\n401-380-4\n—\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n014-007-00-1\ntriethoxyisobutylsilane\n402-810-3\n17980-47-1\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n014-008-00-7\n(chloromethyl)bis(4-fluorophenyl)methylsilane\n401-200-4\n85491-26-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-009-00-2\nisobutylisopropyldimethoxysilane\n402-580-4\n111439-76-0\nFlam. Liq. 3\nAcute Tox. 4 *\nSkin Irrit. 2\nH226\nH332\nH315\nGHS02\nGHS07\nWng\nH226\nH332\nH315\n014-010-00-8\ndisodium metasilicate\n229-912-9\n6834-92-0\nSkin Corr. 1B\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\n014-011-00-3\ncyclohexyldimethoxymethylsilane\n402-140-1\n17865-32-6\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n014-012-00-9\nbis(3-(trimethoxysilyl)propyl)amine\n403-480-3\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n014-013-00-4\nα-hydroxypoly(methyl-(3-(2,2,6,6-tetramethylpiperidin-4-yloxy)propyl)siloxane)\n404-920-7\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH312\nH302\nH314\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH314\nH411\n014-014-00-X\netacelasil (ISO);\n6-(2-chloroethyl)-6-(2-methoxyethoxy)-2,5,7,10-tetraoxa-6-silaundecane\n253-704-7\n37894-46-5\nRepr. 1B\nAcute Tox. 4 *\nSTOT RE 2 *\nH360D *** H302\nH373 **\nGHS08\nGHS07\nDgr\nH360D *** H302\nH373 **\n014-015-00-5\nα-trimethylsilanyl-ω-trimethylsiloxypoly[oxy(methyl-3-(2-(2-methoxypropoxy)propoxy)propylsilanediyl]-co-oxy(dimethylsilane))\n406-420-4\n69430-40-6\nAquatic Chronic 4\nH413\n—\nH413\n014-016-00-0\nreaction mass of: 1,3-dihex-5-en-1-yl-1,1,3,3-tetramethyldisiloxane;\n1,3-dihex-n-en-1-yl-1,1,3,3-tetramethyldisiloxane\n406-490-6\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-017-00-6\nflusilazole (ISO);\nbis(4-fluorophenyl)(methyl)(1H-1,2,4-triazol-1-ylmethyl)silane\n—\n85509-19-9\nCarc. 2\nRepr. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH351\nH360D *** H302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360D *** H302\nH411\n014-018-00-1\noctamethylcyclotetrasiloxane\n209-136-7\n556-67-2\nRepr. 2\nAquatic Chronic 4\nH361f *** H413\nGHS08\nWng\nH361f *** H413\n014-019-00-7\nreaction mass of: 4-[[bis-(4-fluorophenyl)methylsilyl]methyl]-4H-1,2,4-triazole;\n1-[[bis-(4-fluorophenyl)methylsilyl]methyl]-1H-1,2,4-triazole\n403-250-2\n—\nCarc. 2\nRepr. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH351\nH360D *** H302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360D *** H302\nH411\n014-020-00-2\nbis(1,1-dimethyl-2-propynyloxy)dimethylsilane\n414-960-7\n53863-99-3\nAcute Tox. 4 *\nH332\nGHS07\nWng\nH332\n014-021-00-8\ntris(isopropenyloxy)phenyl silane\n411-340-8\n52301-18-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH400\nH410\n014-022-00-3\nreaction product of: (2-hydroxy-4-(3-propenoxy)benzophenone and triethoxysilane) with (hydrolysis product of silica and methyltrimethoxysilane)\n401-530-9\n—\nFlam. Sol. 1\nSTOT SE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH228\nH370 **\nH332\nH312\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH228\nH370 **\nH332\nH312\nH302\nT\n014-023-00-9\nα, ω-dihydroxypoly(hex-5-en-1-ylmethylsiloxane)hoxysilane with (hydrolysis product of silica and methyltrimethoxysilane)iazole\n408-160-7\n125613-45-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-024-00-4\n1-((3-(3-chloro-4-fluorophenyl)propyl)dimethylsilanyl)-4-ethoxybenzene\n412-620-2\n121626-74-2\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-025-00-X\n4-[3-(diethoxymethylsilylpropoxy)-2,2,6,6-tetramethyl]piperidine\n411-400-3\n102089-33-8\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH302\nH373 **\nH315\nH318\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH373 **\nH315\nH318\nH412\n014-026-00-5\ndichloro-(3-(3-chloro-4-fluorophenyl)propyl)methylsilane\n407-180-3\n770722-36-6\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\n014-027-00-0\nchloro(3-(3-chloro-4-fluorophenyl)propyl)dimethylsilane\n410-270-5\n770722-46-8\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\n014-028-00-6\nα-[3-(1-oxoprop-2-enyl)l-1-oxypropyl]dimethoxysilyloxy-ω-[3(1-oxoprop-2-enyl)-1-oxypropyl]dimethoxysilyl poly(dimethylsiloxane)\n415-290-8\n193159-06-7\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n014-029-00-1\nO, O'-(ethenylmethylsilylene)di[(4-methylpentan-2-one)oxime]\n421-870-1\n156145-66-3\nRepr. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nH361f *** H302\nH373 **\nGHS08\nGHS07\nWng\nH361f *** H302\nH373 **\n014-030-00-7\n[(dimethylsilylene)bis((1,2,3,3a,7a-η)-1H-inden-1-ylidene)dimethyl]hafnium\n422-060-0\n137390-08-0\nAcute Tox. 2 *\nH300\nGHS06\nDgr\nH300\n014-031-00-2\nbis(1-methylethyl)-dimethoxysilane\n421-540-7\n18230-61-0\nFlam. Liq. 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH226\nH315\nH317\nH412\nGHS02\nGHS07\nWng\nH226\nH315\nH317\nH412\n014-032-00-8\ndicyclopentyldimethoxysilane\n404-370-8\n126990-35-0\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n014-033-00-3\n2-methyl-3-(trimethoxysilyl)propyl-2-propenoate hydrolysis product with silica\n419-030-4\n125804-20-8\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\n014-034-00-9\n3-hexylheptamethyltrisiloxane\n428-700-5\n1873-90-1\nAcute Tox. 4 *\nAquatic Chronic 4\nH332\nH413\nGHS07\nWng\nH332\nH413\n014-035-00-4\n2-(3,4-epoxycyclohexyl)ethyltriethoxy silane\n425-050-4\n10217-34-2\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n014-036-00-X\n(4-ethoxyphenyl)(3-(4-fluoro-3-phenoxyphenyl)propyl)dimethylsilane\n405-020-7\n105024-66-6\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360F*** H400\nH410\nGHS08\nGHS09\nDgr\nH360F*** H410\nM=1000\n014-037-00-5\n2-butanone-O, O',O''-(phenylsilylidyne)trioxime\n433-360-6\n34036-80-1\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH373**\nH317\nH412\nGHS08\nGHS07\nWng\nH373**\nH317\nH412\n014-038-00-0\nS-(3-(triethoxysilyl)propyl)octanethioate\n436-690-9\n220727-26-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n014-039-00-6\n(2,3-dimethylbut-2-yl)-trimethoxysilane\n439-360-2\n142877-45-0\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH315\nH318\nH412\nGHS05\nDgr\nH315\nH318\nH412\n014-041-00-7\nN, N-bis(trimethylsilyl)aminopropylmethyldiethoxysilane\n445-890-5\n201290-01-9\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n014-042-00-2\nreaction mass of: O,O',O'',O'''-silanetetrayl tetrakis(4-methyl-2-pentanone oxime) (3 stereoisomers)\n423-010-0\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n014-043-00-8\nreaction product of amorphous silica (50-85 %), butyl (1-methylpropyl) magnesium (3-15 %), tetraethyl orthosilicate (5-15 %) and titanium tetrachloride (5-20 %)\n432-200-2\n—\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH335\nH315\nH318\nH412\nGHS05\nGHS07\nDgr\nH335\nH315\nH318\nH412\n014-044-00-3\n3-[(4'-acetoxy-3'-methoxyphenyl) propyl]trimethoxysilane\n433-050-0\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-045-00-9\nmagnesium sodium fluoride silicate\n442-650-1\n—\nSTOT RE 2 *\nH373**\nGHS08\nWng\nH373**\n015-001-00-1\nwhite phosphorus\n231-768-7\n12185-10-3\nPyr. Sol. 1\nAcute Tox. 2 *\nAcute Tox. 2 *\nSkin Corr. 1A\nAquatic Acute 1\nH250\nH330\nH300\nH314\nH400\nGHS02\nGHS06\nGHS05\nGHS09\nDgr\nH250\nH330\nH300\nH314\nH400\n015-002-00-7\nred phosphorus\n231-768-7\n7723-14-0\nFlam. Sol. 1\nAquatic Chronic 3\nH228\nH412\nGHS02\nDgr\nH228\nH412\n015-004-00-8\naluminium phosphide\n244-088-0\n20859-73-8\nWater-react. 1\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 1\nAquatic Acute 1\nH260\nH300\nH311\nH330\nH400\nGHS02\nGHS06\nGHS09\nDgr\nH260\nH300\nH311\nH330\nH400\nEUH029\nEUH032\nM = 100\n015-005-00-3\nmagnesium phosphide;\ntrimagnesium diphosphide\n235-023-7\n12057-74-8\nWater-react. 1\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 1\nAquatic Acute 1\nH260\nH300\nH311\nH330\nH400\nGHS02\nGHS06\nGHS09\nDgr\nH260\nH300\nH311\nH330\nH400\nEUH029\nEUH032\nM = 100\n015-006-00-9\ntrizinc diphosphide;\nzinc phosphide\n215-244-5\n1314-84-7\nWater-react. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH260\nH300\nH400\nH410\nGHS02\nGHS06\nGHS09\nDgr\nH260\nH300\nH410\nEUH029\nEUH032\nM=100\nT\n015-007-00-4\nphosphorus trichloride\n231-749-3\n7719-12-2\nAcute Tox. 2 *\nAcute Tox. 2 *\nSTOT RE 2 *\nSkin Corr. 1A\nH330\nH300\nH373 **\nH314\nGHS06\nGHS08\nGHS05\nDgr\nH330\nH300\nH373 **\nH314\nEUH014\nEUH029\n015-008-00-X\nphosphorus pentachloride\n233-060-3\n10026-13-8\nAcute Tox. 2 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nH330\nH302\nH373 **\nH314\nGHS06\nGHS08\nGHS05\nDgr\nH330\nH302\nH373 **\nH314\nEUH014\nEUH029\n015-009-00-5\nphosphoryl trichloride\n233-046-7\n10025-87-3\nAcute Tox. 2 *\nSTOT RE 1\nAcute Tox. 4 *\nSkin Corr. 1A\nH330\nH372 **\nH302\nH314\nGHS06\nGHS08\nGHS05\nDgr\nH330\nH372 **\nH302\nH314\nEUH014\nEUH029\n015-010-00-0\nphosphorus pentoxide\n215-236-1\n1314-56-3\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\n015-011-00-6\nphosphoric acid . %, orthophosphoric acid . %\n231-633-2\n7664-38-2\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 %\nB\n015-012-00-1\ntetraphosphorus trisulphide;\nphosphorus sesquisulphid\n215-245-0\n1314-85-8\nFlam. Sol. 2\nWater-react. 1\nAcute Tox. 4 *\nAquatic Acute 1\nH228\nH260\nH302\nH400\nGHS02\nGHS07\nGHS09\nDgr\nH228\nH260\nH302\nH400\nT\n015-013-00-7\ntriethyl phosphate\n201-114-5\n78-40-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n015-014-00-2\ntributyl phosphate\n204-800-2\n126-73-8\nCarc. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nH351\nH302\nH315\nGHS08\nGHS07\nWng\nH351\nH302\nH315\n015-015-00-8\ntricresyl phosphate (o-o-o-, o-o-m-, o-o-p-, o-m-m-, o-m-p-, o-p-p-); tritolyl phosphate (o-o-o-, o-o-m-, o-o-p-, o-m-m-, o-m-p-, o-p-p-);\n201-103-5\n78-30-8\nSTOT SE 1\nAquatic Chronic 2\nH370 **\nH411\nGHS08\nGHS09\nDgr\nH370 **\nH411\nSTOT SE 1; H370: C ≥ 1 % STOT SE 2; H371: 0,2 % ≤ C < 1 %\nC\n015-016-00-3\ntricresyl phosphate (m-m-m-, m-m-p-, m-p-p-, p-p-p-);\ntritolyl phosphate (m-m-m-, m-m-p-, m-p-p-, p-p-p-);\n201-105-6\n78-32-0\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH312\nH302\nH411\nGHS07\nGHS09\nWng\nH312\nH302\nH411\n*\nC\n015-019-00-X\ndichlorvos (ISO);\n2,2-dichlorovinyl dimethyl phosphate\n200-547-7\n62-73-7\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nH330\nH311\nH301\nH317\nH400\nGHS06\nGHS09\nDgr\nH330\nH311\nH301\nH317\nH400\nM=1000\n015-020-00-5\nmevinphos (ISO);\n2-methoxycarbonyl-1-methylvinyl dimethyl phosphate\n232-095-1\n7786-34-7\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\nM = 10000\n015-021-00-0\ntrichlorfon (ISO);\ndimethyl 2,2,2-trichloro-1-hydroxyethylphosphonate\n200-149-3\n52-68-6\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH400\nH410\nM = 1000\n015-022-00-6\nphosphamidon (ISO);\n2-chloro-2-diethylcarbamoyl-1-methylvinyl dimethyl phosphate\n236-116-5\n13171-21-6\nMuta. 2\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH300\nH311\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH300\nH311\nH410\n015-023-00-1\npyrazoxon;\ndiethyl 3-methylpyrazol-5-yl phosphate\n—\n108-34-9\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nH330\nH310\nH300\nGHS06\nDgr\nH330\nH310\nH300\n015-024-00-7\ntriamiphos (ISO);\n5-amino-3-phenyl-1,2,4-triazol-1-yl-N, N,N',N'-tetramethylphosphonic diamide\n—\n1031-47-6\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-025-00-2\nTEPP (ISO);\ntetraethyl pyrophosphate\n203-495-3\n107-49-3\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nH310\nH300\nH400\nGHS06\nGHS09\nDgr\nH310\nH300\nH400\n015-026-00-8\nschradan (ISO); octamethylpyrophosphoramide\n205-801-0\n152-16-9\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-027-00-3\nsulfotep (ISO);\nO, O,O, O-tetraethyl dithiopyrophosphate\n222-995-2\n3689-24-5\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\nM = 1000\n015-028-00-9\ndemeton-O (ISO);\nO,O-diethyl-O-2-ethylthioethyl phosphorothioate\n206-053-8\n298-03-3\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nH310\nH300\nH400\nGHS06\nGHS09\nDgr\nH310\nH300\nH400\n015-029-00-4\ndemeton-S (ISO);\ndiethyl-S-2-ethylthioethyl phosphorothioate\n204-801-8\n126-75-0\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-030-00-X\ndemeton-O-methyl (ISO);\nO-2-ethylthioethyl O,O-dimethyl phosphorothioate\n212-758-1\n867-27-6\nAcute Tox. 3 *\nH301\nGHS06\nDgr\nH301\n015-031-00-5\ndemeton-S-methyl (ISO);\nS-2-ethylthioethyl dimethyl phosphorothioate\n213-052-6\n919-86-8\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH311\nH301\nH411\nGHS06\nGHS09\nDgr\nH311\nH301\nH411\n015-032-00-0\nprothoate (ISO);\nO,O-diethyl isopropylcarbamoylmethyl phosphorodithioate\n218-893-2\n2275-18-5\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Chronic 3\nH310\nH300\nH412\nGHS06\nDgr\nH310\nH300\nH412\n015-033-00-6\nphorate (ISO);\nO,O-diethyl ethylthiomethyl phosphorodithioate\n206-052-2\n298-02-2\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\nM = 1000\n015-034-00-1\nparathion (ISO);\nO,O-diethyl O-4-nitrophenyl phosphorothioate\n200-271-7\n56-38-2\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH311\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH300\nH311\nH372 **\nH410\nM = 100\n015-035-00-7\nparathion — methyl (ISO);\nO,O-dimethyl O-4-nitrophenyl phosphorothioate\n206-050-1\n298-00-0\nFlam. Liq. 3\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH330\nH300\nH311\nH373 **\nH400\nH410\nGHS02\nGHS06\nGHS08\nGHS09\nDgr\nH226\nH330\nH300\nH311\nH373 **\nH410\nM = 100\n015-036-00-2\nO-ethyl O-4-nitrophenyl phenylphosphonothioate;\nEPN\n218-276-8\n2104-64-5\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\n015-037-00-8\nphenkapton (ISO);\nS-(2,5-dichlorophenylthiomethyl) O, O-diethyl phosphorodithioate\n218-892-7\n2275-14-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\n015-038-00-3\ncoumaphos (ISO);\nO-3-chloro-4-methylcoumarin-7-yl O,O-diethyl phosphorothioate\n200-285-3\n56-72-4\nAcute Tox. 2 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH312\nH410\n015-039-00-9\nazinphos-methyl (ISO);\nO,O-dimethyl-4-oxobenzotriazin-3-ylmethyl phosphorodithioate\n201-676-1\n86-50-0\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH311\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH311\nH317\nH410\n015-040-00-4\ndiazinon (ISO);\nO,O-diethyl O-2-isopropyl-6-methylpyrimidin-4-yl phosphorothioate\n206-373-8\n333-41-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH400\nH410\n015-041-00-X\nmalathion (ISO);\n1,2-bis(ethoxycarbonyl)ethyl O, O-dimethyl phosphorodithioate;\n[containing ≤ 0,03 % isomalathion]\n204-497-7\n121-75-5\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nM=1000\n015-042-00-5\nchlorthion O-(3-chloro-4-nitrophenyl) O, O-dimethyl phosphorothioate\n207-902-5\n500-28-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\nM = 100\n015-043-00-0\nphosnichlor (ISO);\nO-4-chloro-3-nitrophenyl O, O-dimethyl phosphorothioate\n—\n5826-76-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH312\nH302\nGHS07\nWng\nH332\nH312\nH302\n015-044-00-6\ncarbophenothion (ISO);\n4-chlorophenylthiomethyl O, O-diethyl phosphorodithioate\n212-324-1\n786-19-6\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\n015-045-00-1\nmecarbam (ISO);\nN-ethoxycarbonyl-N-methylcarbamoylmethyl O, O-diethyl phosphorodithioate\n219-993-9\n2595-54-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH400\nH410\n015-046-00-7\noxydemeton-methyl;\nS-2-(ethylsulphinyl)ethyl O,O-dimethyl phosphorothioate\n206-110-7\n301-12-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nH311\nH301\nH400\nGHS06\nGHS09\nDgr\nH311\nH301\nH400\n015-047-00-2\nethion (ISO);\nO, O,O',O'-tetraethyl S, S'-methylenedi (phosphorodithioate);\ndiethion\n209-242-3\n563-12-2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH312\nH410\nM = 10000\n015-048-00-8\nfenthion (ISO);\nO, O-dimethyl-O-(4-methylthion-m-tolyl) phosphorothioate\n200-231-9\n55-38-9\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH331\nH312\nH302\nH372**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH331\nH312\nH302\nH372** H410\nM=100\n015-049-00-3\nendothion (ISO);\nS-5-methoxy-4-oxopyran-2-ylmethyl dimethyl phosphorothioate\n220-472-3\n2778-04-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nH311\nH301\nGHS06\nDgr\nH311\nH301\n015-050-00-9\nthiometon (ISO);\nS-2-ethylthioethyl O,O-dimethyl phosphorodithioate\n211-362-6\n640-15-3\nAcute Tox. 3 *\nAcute Tox. 4 *\nH301\nH312\nGHS06\nDgr\nH301\nH312\n015-051-00-4\ndimethoate (ISO);\nO, O-dimethyl methylcarbamoylmethyl phosphorodithioate\n200-480-3\n60-51-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n015-052-00-X\nfenchlorphos (ISO);\nO, O-dimethyl O-2,4,5-trichlorophenyl phosphorothioate\n206-082-6\n299-84-3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n015-053-00-5\nmenazon (ISO);\nS-[(4,6-diamino-1,3,5-triazin-2-yl)methyl] O, O-dimethyl phosphorodithioate\n201-123-4\n78-57-9\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n015-054-00-0\nfenitrothion (ISO);\nO, O-dimethyl O-4-nitro-m-tolyl phosphorothioate\n204-524-2\n122-14-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n015-055-00-6\nnaled (ISO);\n1,2-dibromo-2,2-dichloroethyl dimethyl phosphate\n206-098-3\n300-76-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nH312\nH302\nH319\nH315\nH400\nGHS07\nGHS09\nWng\nH312\nH302\nH319\nH315\nH400\nM = 1000\n015-056-00-1\nazinphos-ethyl (ISO);\nO,O-diethyl 4-oxobenzotriazin-3-ylmethyl phosphorodithioate\n220-147-6\n2642-71-9\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH410\nM=100\n015-057-00-7\nformothion (ISO);\nN-formyl-N-methylcarbamoylmethyl O, O-dimethyl phosphorodithioate\n219-818-6\n2540-82-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n015-058-00-2\nmorphothion (ISO);\nO, O-dimethyl-S-(morpholinocarbonylmethyl) phosphorodithioate\n205-628-0\n144-41-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\n015-059-00-8\nvamidothion (ISO);\nO,O-dimethyl S-2-(1-methylcarbamoylethylthio) ethyl phosphorothioate\n218-894-8\n2275-23-2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nH301\nH312\nH400\nGHS06\nGHS09\nDgr\nH301\nH312\nH400\n015-060-00-3\ndisulfoton (ISO);\nO,O-diethyl 2-ethylthioethyl phosphorodithioate\n206-054-3\n298-04-4\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\n015-061-00-9\ndimefox (ISO); tetramethylphosphorodiamidic fluoride\n204-076-8\n115-26-4\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-062-00-4\nmipafox (ISO);\nN,N'-di-isopropylphosphorodiamidic fluoride\n206-742-3\n371-86-8\nSTOT SE 1\nH370 **\nGHS08\nDgr\nH370 **\n015-063-00-X\ndioxathion (ISO);\n1,4-dioxan-2,3-diyl-O,O,O',O'-tetraethyl di(phosphorodithioate)\n201-107-7\n78-34-2\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH311\nH410\nM = 1000\n015-064-00-5\nbromophos-ethyl (ISO);\nO-4-bromo-2,5-dichlorophenyl\nO,O-diethyl phosphorothioate\n225-399-0\n4824-78-6\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH312\nH410\n015-065-00-0\nS-[2-(ethylsulphinyl)ethyl] O,O-dimethyl phosphorodithioate\n—\n2703-37-9\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Chronic 2\nH330\nH310\nH300\nH411\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH411\n015-066-00-6\nomethoate (ISO);\nO, O-dimethyl S-methylcarbamoylmethyl phosphorothioate\n214-197-8\n1113-02-6\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nH301\nH312\nH400\nGHS06\nGHS09\nDgr\nH301\nH312\nH400\n015-067-00-1\nphosalone (ISO);\nS-(6-chloro-2-oxobenzoxazolin-3-ylmethyl) O, O-diethyl phosphorodithioate\n218-996-2\n2310-17-0\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH332\nH312\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH332\nH312\nH317\nH410\nM=1000\n015-068-00-7\ndichlofenthion (ISO);\nO—2,4-dichlorophenyl O,O-diethyl phosphorothioate\n202-564-5\n97-17-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH400\nH410\n015-069-00-2\nmethidathion (ISO);\n2,3-dihydro-5-methoxy-2-oxo-1,3,4-thiadiazol-3-ylmethyl-O,O-dimethylphosphorodithioate\n213-449-4\n950-37-8\nAcute Tox. 2 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH312\nH410\n015-070-00-8\ncyanthoate (ISO);\nS-(N-(1-cyano-1-methylethyl)carbamoylmethyl) O,O-diethyl phosphorothioate\n223-099-4\n3734-95-0\nAcute Tox. 2 *\nAcute Tox. 3 *\nH300\nH311\nGHS06\nDgr\nH300\nH311\n015-071-00-3\nchlorfenvinphos (ISO);\n2-chloro-1-(2,4 dichlorophenyl)vinyl diethyl phosphate\n207-432-0\n470-90-6\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH410\n015-072-00-9\nmonocrotophos (ISO);\ndimethyl-1-methyl-2-(methylcarbamoyl)vinyl phosphate\n230-042-7\n6923-22-4\nMuta. 2\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH330\nH300\nH311\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH330\nH300\nH311\nH410\n015-073-00-4\ndicrotophos (ISO);\n(Z)-2-dimethylcarbamoyl-1-methylvinyl dimethyl phosphate\n205-494-3\n141-66-2\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH410\n015-074-00-X\ncrufomate (ISO);\n4-tert-butyl-2-chlorophenyl methyl methylphosphoramidate\n206-083-1\n299-86-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n015-075-00-5\nS-[2-(isopropylsulphinyl)ethyl] O,O-dimethyl phosphorothioate\n—\n2635-50-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n015-076-00-0\npotasan;\nO, O-diethyl O-(4-methylcoumarin-7-yl) phosphorothioate\n—\n299-45-6\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\nM = 1000\n015-077-00-6\n2,2-dichlorovinyl 2-ethylsulphinylethyl methyl phosphate\n—\n7076-53-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n015-078-00-1\ndemeton-S-methylsulphon(ISO);\nS-2-ethylsulphonylethyl dimethyl phosphorothioate\n241-109-5\n17040-19-6\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH301\nH312\nH411\nGHS06\nGHS09\nDgr\nH301\nH312\nH411\n015-079-00-7\nacephate (ISO);\nO, S-dimethyl acetylphosphoramidothioate\n250-241-2\n30560-19-1\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n015-080-00-2\namidithion (ISO);\n2-methoxyethylcarbamoylmethyl O,O-dimethyl phosphorodithioate\n—\n919-76-6\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n015-081-00-8\nO,O,O',O'-tetrapropyl dithiopyrophosphate\n221-817-0\n3244-90-4\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n015-082-00-3\nazothoate (ISO);\nO-4-(4-chlorophenylazo)phenyl O,O-dimethyl phosphorothioate\n227-419-3\n5834-96-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH302\nGHS07\nWng\nH332\nH302\n015-083-00-9\nbensulide (ISO);\nO, O-diisopropyl 2-phenylsulphonylaminoethyl phosphorodithioate\n212-010-4\n741-58-2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n015-084-00-4\nchlorpyrifos (ISO);\nO,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphorothioate\n220-864-4\n2921-88-2\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH400\nH410\nM = 10000\n015-085-00-X\nchlorphonium chloride (ISO);\ntributyl (2,4-dichlorobenzyl) phosphonium chloride\n204-105-4\n115-78-6\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH301\nH312\nH319\nH315\nGHS06\nDgr\nH301\nH312\nH319\nH315\n015-086-00-5\ncoumithoate (ISO);\nO,O-diethyl O-7,8,9,10-tetrahydro-6-oxo-benzo(c)chromen-3-yl phosphorothioate\n—\n572-48-5\nAcute Tox. 3 *\nH301\nGHS06\nDgr\nH301\n015-087-00-0\ncyanophos (ISO);\nO-4-cyanophenyl O,O-dimethyl phosphorothioate\n220-130-3\n2636-26-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n015-088-00-6\ndialifos (ISO);\n2-chloro-1-phthalimidoethyl O,O-diethyl phosphorodithioate\n233-689-3\n10311-84-9\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH400\nH410\n015-089-00-1\nethoate-methyl (ISO); ethylcarbamoylmethyl O,O-dimethyl phosphorodithioate\n204-121-1\n116-01-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n015-090-00-7\nfensulfothion (ISO);\nO,O-diethyl O-4-methylsulfinylphenyl phosphorothioate\n204-114-3\n115-90-2\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\n015-091-00-2\nfonofos (ISO);\nO-ethyl phenyl ethylphosphonodithioate\n213-408-0\n944-22-9\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\n015-092-00-8\nphosacetim (ISO);\nO,O-bis(4-chlorophenyl) N-acetimidoylphosphoramidothioate\n223-874-7\n4104-14-7\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\n015-093-00-3\nleptophos (ISO);\nO-4-bromo-2,5-dichlorophenyl O-methyl phenylphosphorothioate\n244-472-8\n21609-90-5\nAcute Tox. 3 *\nSTOT SE 1\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH370 **\nH312\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH370 **\nH312\nH410\n015-094-00-9\nmephosfolan (ISO);\ndiethyl 4-methyl-1,3-dithiolan-2-ylidenephosphoramidate\n213-447-3\n950-10-7\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Chronic 2\nH310\nH300\nH411\nGHS06\nGHS09\nDgr\nH310\nH300\nH411\n015-095-00-4\nmethamidophos (ISO);\nO,S-dimethyl phosphoramidothioate\n233-606-0\n10265-92-6\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nH330\nH300\nH311\nH400\nGHS06\nGHS09\nDgr\nH330\nH300\nH311\nH400\n015-096-00-X\noxydisulfoton (ISO);\nO, O-diethyl S-2-ethylsulphinylethyl phosphorodithioate\n219-679-1\n2497-07-6\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH410\nM = 10\n015-097-00-5\nphenthoate (ISO);\nethyl 2-(dimethoxyphosphinothioylthio)-2-phenylacetate\n219-997-0\n2597-03-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\nM = 100\n015-098-00-0\ntrichloronate (ISO);\nO-ethyl O-2,4,5-trichlorophenyl ethylphosphonothioate\n206-326-1\n327-98-0\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH410\n015-099-00-6\npirimiphos-ethyl (ISO);\nO, O-diethyl O-2-diethylamino-6-methylpyrimidin-4-yl phosphorothioate\n245-704-0\n23505-41-1\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH312\nH410\n015-100-00-X\nphoxim (ISO);\nα-(diethoxyphosphinothioylimino) phenylacetonitrile\n238-887-3\n14816-18-3\nRepr. 2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f*** H302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361f*** H302\nH317\nH410\nM=1000\n015-101-00-5\nphosmet (ISO);\nO, O-dimethyl phthalimidomethyl S-phosphorodithioate\n211-987-4\n732-11-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\nM = 100\n015-102-00-0\ntris(2-chloroethyl)phosphate\n204-118-5\n115-96-8\nCarc. 2\nRepr. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH351\nH360F*** H302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360F*** H302\nH411\n015-103-00-6\nphosphorus tribromide\n232-178-2\n7789-60-8\nSkin Corr. 1B\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\nEUH014\n015-104-00-1\ndiphosphorus pentasulphide;\nphosphorus pentasulphide\n215-242-4\n1314-80-3\nFlam. Sol. 1\nWater-react. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nH228\nH260\nH332\nH302\nH400\nGHS02\nGHS07\nGHS09\nDgr\nH228\nH260\nH332\nH302\nH400\nEUH029\nT\n015-105-00-7\ntriphenyl phosphite\n202-908-4\n101-02-0\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\nSkin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 %\n015-106-00-2\nhexamethylphosphoric triamide; hexamethylphosphoramide\n211-653-8\n680-31-9\nCarc. 1B\nMuta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nCarc. 1B;\nH350: C ≥ 0,01 %\n015-107-00-8\nethoprophos (ISO);\nethyl-S,S-dipropyl phosphorodithioate\n236-152-1\n13194-48-4\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH301\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH301\nH317\nH410\n015-108-00-3\nbromophos (ISO);\nO-4-bromo-2,5-dichlorophenyl O,O-dimethyl phosphorothioate\n218-277-3\n2104-96-3\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM = 100\n015-109-00-9\ncrotoxyphos (ISO);\n1-phenylethyl 3-(dimethoxyphosphinyloxy) isocrotonate\n231-720-5\n7700-17-6\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\nM = 10\n015-110-00-4\ncyanofenphos (ISO);\nO-4-cyanophenyl O-ethyl phenylphosphonothioate\n—\n13067-93-1\nAcute Tox. 3 *\nSTOT SE 1\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 2\nH301\nH370 **\nH312\nH319\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH370 **\nH312\nH319\nH411\n015-111-00-X\nphosfolan (ISO);\ndiethyl 1,3-dithiolan-2-ylidenephosphoramidate\n213-423-2\n947-02-4\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-112-00-5\nthionazin (ISO);\nO,O-diethyl O-pyrazin-2-yl phosphorothioate;\n206-049-6\n297-97-2\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-113-00-0\ntolclofos-methyl (ISO);\nO-(2,6-dichloro-p-tolyl)-O,O-dimethyl thiophosphate\n260-515-3\n57018-04-9\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n015-114-00-6\nchlormephos (ISO);\nS-chloromethyl O,O-diethyl phosphorodithioate\n246-538-1\n24934-91-6\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\nM = 10\n015-115-00-1\nchlorthiophos (ISO);\n[isomeric reaction mass in which O-2,5-dichlorophenyl-4-methylthiophenyl O, O-diethyl phosphorothioate predominates]\n244-663-6\n21923-23-9\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH410\nM = 1000\n015-116-00-7\ndemephion-O (ISO);\nO, O-dimethyl O-2-methylthioethyl phosphorothioate\n211-666-9\n682-80-4\nAcute Tox. 2 *\nAcute Tox. 3 *\nH300\nH311\nGHS06\nDgr\nH300\nH311\n015-117-00-2\ndemephion-S (ISO);\nO, O-dimethyl S-2-methylthioethyl phosphorothioate\n219-971-9\n2587-90-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nH300\nH311\nGHS06\nDgr\nH300\nH311\n015-118-00-8\ndemeton\n—\n8065-48-3\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nH310\nH300\nH400\nGHS06\nGHS09\nDgr\nH310\nH300\nH400\n015-119-00-3\ndimethyl 4-(methylthio)phenyl phosphate\n—\n3254-63-5\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-120-00-9\nditalimfos (ISO);\nO, O-diethyl phthalimidophosphonothioate\n225-875-8\n5131-24-8\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n015-121-00-4\nedifenphos (ISO);\nO-ethyl S, S-diphenyl phosphorodithioate\n241-178-1\n17109-49-8\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH312\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH312\nH317\nH410\n015-122-00-X\netrimfos (ISO);\nO-6-ethoxy-2-ethylpyrimidin-4-yl O, O-dimethylphosphorothioate\n253-855-9\n38260-54-7\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM = 10\n015-123-00-5\nfenamiphos (ISO);\nethyl-4-methylthio-m-tolyl isopropyl phosphoramidate\n244-848-1\n22224-92-6\nAcute Tox. 2\nAcute Tox. 2\nAcute Tox. 2\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH310\nH330\nH319\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH310\nH330\nH319\nH410\nM = 100\nM = 100\n015-124-00-0\nfosthietan (ISO);\ndiethyl 1,3-dithietan-2-ylidenephosphoramidate\n244-437-7\n21548-32-3\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n015-125-00-6\nglyphosine (ISO);\nN,N-bis(phosphonomethyl)glycine\n219-468-4\n2439-99-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n015-126-00-1\nheptenophos (ISO);\n7-chlorobicyclo(3.2.0)hepta-2,6-dien-6-yl dimethyl phosphate\n245-737-0\n23560-59-0\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\nM = 100\n015-127-00-7\niprobenfos(ISO);\nS-benzyl diisopropyl phosphorothioate\n247-449-0\n26087-47-8\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n015-128-00-2\nIPSP;\nS-ethylsulphinylmethyl O,O-diisopropylphosphorodithioate\n—\n5827-05-4\nAcute Tox. 1\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH301\nH410\nM = 100\n015-129-00-8\nisofenphos (ISO);\nO-ethyl O-2-isopropoxycarbonylphenyl-isopropylphosphoramidothioate\n246-814-1\n25311-71-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\nM = 100\n015-130-00-3\nisothioate (ISO);\nS-2-isopropylthioethyl O,O-dimethyl phosphorodithioate;\n—\n36614-38-7\nAcute Tox. 3 *\nAcute Tox. 3 *\nH311\nH301\nGHS06\nDgr\nH311\nH301\n015-131-00-9\nisoxathion (ISO);\nO,O-diethyl O-5-phenylisoxazol-3-ylphosphorothioate\n242-624-8\n18854-01-8\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\n015-132-00-4\nS-(chlorophenylthiomethyl) O,O-dimethylphosphorodithioate; methylcarbophenothione\n—\n953-17-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\nM = 1000\n015-133-00-X\npiperophos (ISO);\nS-2-methylpiperidinocarbonylmethyl-O, O-dipropyl phosphorodithioate\n—\n24151-93-7\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM = 10\n015-134-00-5\npirimiphos-methyl (ISO);\nO-(2-diethylamino-6-methylpyrimidin-4-yl) O, O-dimethyl phosphorothioate\n249-528-5\n29232-93-7\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n015-135-00-0\nprofenofos (ISO)O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate;\n255-255-2\n41198-08-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\nM = 1000\n015-136-00-6\ntrans-isopropyl-3-[[(ethylamino)methoxyfosfinothioyl]oxy]crotonate;\nisopropyl 3-[[(ethylamino)methoxyphosphinothioyl]oxy]isocrotonate; propetamphos (ISO)\n250-517-2\n31218-83-4\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\nM = 100\n015-137-00-1\npyrazophos (ISO);\nO, O-diethyl O-(6-ethoxycarbonyl-5-methylpyrazolo[2,3-a]pyrimidin-2-yl) phosphorothioate\n236-656-1\n13457-18-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH410\n015-138-00-7\nquinalphos (ISO);\nO, O-diethyl-O-quinoxalin-2-yl phosphorothioate\n237-031-6\n13593-03-8\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH312\nH410\nM = 1000\n015-139-00-2\nterbufos (ISO);\nS-tert-butylthiomethyl O, O-diethylphosphorodithioate;\n235-963-8\n13071-79-9\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\nM = 1000\n015-140-00-8\ntriazophos (ISO);\nO, O-diethyl-O-1-phenyl-1H-1,2,4-triazol-3-yl phosphorothioate\n245-986-5\n24017-47-8\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH312\nH410\nM=100\n015-141-00-3\nethylenediammonium O, O-bis(octyl) phosphorodithioate, mixed isomers\n400-520-1\n—\nSkin Corr. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH302\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH302\nH410\n015-142-00-9\nbutyl (dialkyloxy(dibutoxyphosphoryloxy))titanium (trialkyloxy)titanium phosphate\n401-100-0\n—\nFlam. Liq. 2\nEye Irrit. 2\nAquatic Chronic 2\nH225\nH319\nH411\nGHS02\nGHS07\nGHS09\nDgr\nH225\nH319\nH411\nT\n015-143-00-4\nreaction mass of 2-chloroethyl chloropropyl 2-chloroethylphosphonate, reaction mass of isomers and 2-chloroethyl chloropropyl 2-chloropropylphosphonate, reaction mass of isomers\n401-740-0\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n015-144-00-X\nreaction mass of pentyl methylphosphinate and 2-methylbutyl methylphosphinate\n402-090-0\n87025-52-3\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n015-145-00-5\nreaction mass of copper(I) O, O-diisopropyl phosphorodithioate and copper(I) O-isopropyl O-(4-methylpent-2-yl) phosphorodithioate and copper(I) O, O-bis(4-methylpent-2-yl) phosphorodithioate\n401-520-4\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n015-146-00-0\nS-(tricyclo(5.2.1.0 2,6)deca-3-en-8(or 9)-yl O-(isopropyl or isobutyl or 2-ethylhexyl) O-(isopropyl or isobutyl or 2-ethylhexyl) phosphorodithioate\n401-850-9\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n015-147-00-6\nreaction mass of C12-14-tert-alkylammonium diphenyl phosphorothioate and dinonyl sulphide (or disulphide)\n400-930-0\n—\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH411\n015-148-00-1\n2-(diphosphonomethyl)succinic acid\n403-070-4\n51395-42-7\nSkin Corr. 1B\nSkin Sens. 1\nH314\nH317\nGHS05\nGHS07\nDgr\nH314\nH317\n015-149-00-7\nreaction mass of: hexyldioctylphosphineoxide; dihexyloctylphosphineoxide; trioctylphosphineoxide\n403-470-9\n—\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n015-150-00-2\n(2-(1,3-dioxolan-2-yl)ethyl)triphenylphosphonium bromide\n404-940-6\n86608-70-0\nAcute Tox. 4 *\nEye Dam. 1\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH318\nH373 **\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH318\nH373 **\nH412\n015-151-00-8\ntris(isopropyl/tert-butylphenyl)phosphate\n405-010-2\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n015-152-00-3\ndioxabenzofos (ISO);\n2-methoxy-4H-1,3,2-benzodioxaphosphorin 2-sulphide\n223-292-3\n3811-49-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT SE 1\nAquatic Chronic 2\nH311\nH301\nH370 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH311\nH301\nH370 **\nH411\n015-153-00-9\nisazofos (ISO);\nO-(5-chloro-1-isopropyl-1,2,4-triazol-3-yl) O, O-diethyl phosphorothioate\n255-863-8\n42509-80-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH311\nH301\nH373 **\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH311\nH301\nH373 **\nH317\nH410\n015-154-00-4\nethephon;\n2-chloroethylphosphonic acid\n240-718-3\n16672-87-0\nAcute Tox. 3\nAcute Tox. 4\nAcute Tox. 4\nSkin Corr. 1C\nAquatic Chronic 2\nH311\nH332\nH302\nH314\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH332\nH302\nH314\nH411\nEUH071\n015-155-00-X\nglufosinate ammonium (ISO); ammonium 2-amino-4-(hydroxymethylphosphinyl)butyrate\n278-636-5\n77182-82-2\nRepr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nH360Fd\nH332\nH312\nH302\nH373**\nGHS08\nGHS07\nDgr\nH360Fd\nH332\nH312\nH302\nH373**\n015-156-00-5\nmethyl 3-[(dimethoxyphosphinothioyl)oxy]methacrylate; [1]\nmethacrifos (ISO);\nmethyl (E)-3-[(dimethoxyphosphinothioyl)oxy]methacrylate [2]\n250-366-9 [1]-[2]\n30864-28-9 [1]\n62610-77-9 [2]\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n015-157-00-0\nphosphonic acid; [1]\nphosphorous acid [2]\n237-066-7 [1]\n233-663-1 [2]\n13598-36-2 [1]\n10294-56-1 [2]\nAcute Tox. 4 *\nSkin Corr. 1A\nH302\nH314\nGHS05\nGHS07\nDgr\nH302\nH314\n015-158-00-6\n(η-cyclopentadienyl)(η-cumenyl)iron(1+)hexafluorophosphate(1-)\n402-340-9\n32760-80-8\nAquatic Chronic 3\nH412\n—\nH412\n015-159-00-1\nhydroxyphosphonoacetic acid\n405-710-8\n23783-26-8\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nH302\nH373 **\nH314\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH373 **\nH314\nH317\n015-160-00-7\nvanadyl pyrophosphate\n406-260-5\n58834-75-6\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH319\nH317\nH412\nGHS07\nWng\nH319\nH317\nH412\n015-161-00-2\ndivanadyl pyrophosphate\n407-130-0\n65232-89-5\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n015-162-00-8\nvanadium(IV) oxide hydrogen phosphate hemihydrate, lithium, zinc, molybdenum, iron and chlorine-doped\n407-350-7\n—\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nAquatic Chronic 2\nH332\nH373 **\nH318\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH373 **\nH318\nH411\n015-163-00-3\nbis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentylphosphinoxide\n412-010-6\n145052-34-2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n015-164-00-9\ncalcium P, P'-(1-hydroxyethylene)bis(hydrogen phosphonate)dihydrate\n400-480-5\n36669-85-9\nAquatic Chronic 3\nH412\n—\nH412\n015-165-00-4\nreaction mass of: thiobis(4,1-phenylene)-S, S,S',S'-tetraphenyldisulfonium bishexafluorophosphate; diphenyl(4-phenylthiophenyl)sulfonium hexafluorophosphate\n404-986-7\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n015-166-00-X\n3,9-bis(2,6-di-tert-butyl-4-methylphenoxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane\n410-290-4\n80693-00-1\nAquatic Chronic 4\nH413\n—\nH413\n015-167-00-5\n3-(hydroxyphenylphosphinyl)propanoic acid\n411-200-6\n14657-64-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n015-168-00-0\nfosthiazate (ISO);\n(RS)-S-sec-butyl-O-ethyl-2-oxo-1,3-thiazolidin-3-ylphosphonothioate\n—\n98886-44-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH312\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH312\nH317\nH410\nEUH070\n015-169-00-6\ntributyltetradecylphosphonium tetrafluoroborate\n413-520-1\n—\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 **\nH314\nH317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH373 ** H314\nH317\nH410\n015-170-00-1\nreaction mass of: di-(1-octane-N, N,N-trimethylammonium) octylphosphate; 1-octane-N, N,N-trimethylammonium di-octylphosphate; 1-octane-N, N,N-trimethylammonium octylphosphate\n407-490-9\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n015-171-00-7\nO, O,O-tris(2(or 4)-C 9-10-isoalkylphenyl) phosphorothioate\n406-940-1\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n015-172-00-2\nreaction mass of: bis(isotridecylammonium)mono(di-(4-methylpent-2-yloxy)thiophosphorothionylisopropyl)phosphate;\nisotridecylammonium bis(di-(4-methylpent-2-yloxy)thiophosphorothionylisopropyl)phosphate\n406-240-6\n—\nFlam. Liq. 3\nSkin Corr. 1B\nAquatic Chronic 2\nH226\nH314\nH411\nGHS02\nGHS05\nGHS09\nDgr\nH226\nH314\nH411\n015-173-00-8\nmethyl [2-(1,1-dimethylethyl)-6-methoxypyrimidin-4-yl]ethylphosphonothioate\n414-080-3\n117291-73-3\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n015-174-00-3\n1-chloro-N,N-diethyl-1,1-diphenyl-1-(phenylmethyl)phosphoramine\n411-370-1\n82857-68-9\nAcute Tox. 3 *\nEye Dam. 1\nAquatic Chronic 2\nH301\nH318\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH318\nH411\n015-175-00-9\ntert-butyl (triphenylphosphoranylidene) acetate\n412-880-7\n35000-38-5\nAcute Tox. 3 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH373 **\nH319\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH373 ** H319\nH317\nH411\n015-176-00-4\nP, P,P',P'-tetrakis-(o-methoxyphenyl)propane-1,3-diphosphine\n413-430-2\n116163-96-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n015-177-00-X\n((4-phenylbutyl)hydroxyphosphoryl)acetic acid\n412-170-7\n83623-61-4\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH373 **\nH318\nH317\nGHS08\nGHS05\nDgr\nH373 ** H318\nH317\n015-178-00-5\n(R)-α-phenylethylammonium(-)-(1R, 2S)-(1,2-epoxypropyl)phosphonate monohydrate\n418-570-8\n25383-07-7\nRepr. 2\nAquatic Chronic 2\nH361f *** H411\nGHS08\nGHS09\nWng\nH361f *** H411\n015-179-00-0\nUVCB condensation product of: tetrakis-hydroxymethylphosphonium chloride, urea and distilled hydrogenated C16-18 tallow alkylamine\n422-720-8\n166242-53-1\nCarc. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH373 **\nH314\nH317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH351\nH302\nH373 ** H314\nH317\nH410\n015-180-00-6\n[R-(R*,S*)]-[[2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphinyl] acetic acid, (-)-cinchonidine (1:1) salt\n415-820-8\n137590-32-0\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n015-181-00-1\nphosphine\n232-260-8\n7803-51-2\nFlam. Gas 1\nPress. Gas\nAcute Tox. 2 *\nSkin Corr. 1B\nAquatic Acute 1\nH220\nH330\nH314\nH400\nGHS02\nGHS04\nGHS06\nGHS05\nGHS09\nDgr\nH220\nH330\nH314\nH400\nU\n015-182-00-7\ntetrapropan-2-yl (dichloromethanediyl)bis(phosphonate)\n430-630-5\n10596-22-2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH302\nH319\nH317\nGHS07\nWng\nH302\nH319\nH317\n015-183-00-2\n(1-hydroxydodecylidene)diphosphonic acid\n425-230-2\n16610-63-2\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n015-184-00-8\nsalts of glyphosate, with the exception of those specified elsewhere in this Annex\n—\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\nA\n015-186-00-9\nchlorpyrifos-methyl (ISO) O, O-dimethyl O-3,5,6-trichloro-2-pyridyl phosphorothioate\n227-011-5\n5598-13-0\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM = 10000\n015-187-00-4\nreaction mass of: tetrasodium(((2-hydroxyethyl)imino)bis(methylene))bisphosphonate, N-oxide;\ntrisodium ((tetrahydro-2-hydroxy-4H-1,4,2-oxazaphosphorin-4-yl)-methyl)phosphonate, N-oxide, P-oxide\n417-540-1\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n015-189-00-5\nphenyl bis(2,4,6-trimethylbenzoyl)-phosphine oxide\n423-340-5\n162881-26-7\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n015-190-00-0\nbis(2,4-dicumylphenyl)neopentyl diphosphite;\n3,9-bis[2,4-bis(1-methyl-1-phenylethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane\n421-920-2\n154862-43-8\nAquatic Chronic 4\nH413\n—\nH413\n015-191-00-6\ndodecyldiphenyl phosphate\n431-760-5\n27460-02-2\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n015-192-00-1\ntetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate\n432-770-2\n139189-30-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n015-193-00-7\ntriphenyl(phenylmethyl)phosphonium 1,1,2,2,3,3,4,4,4-nonafluoro-N-methyl-1-butanesulfonamide (1:1)\n442-960-7\n332350-93-3\nAcute Tox. 3 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH318\nH400\nH410\nGHS05\nGHS06\nGHS09\nDgr\nH301\nH318\nH410\n015-194-00-2\ntetrabutyl-phosphonium nonafluoro-butane-1-sulfonate\n444-440-5\n220689-12-3\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n015-195-00-8\nreaction mass of: potassium o-toluenephosphonate;\npotassium m-toluenephosphonate; potassium p-toluenephosphonate\n433-860-4\n—\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH319\nH317\nH412\nGHS07\nWng\nH319\nH317\nH412\n015-196-00-3\nreaction mass of: dimethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate;\ndiethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate;\nmethyl ethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate\n435-960-3\n—\nCarc. 1B\nMuta. 1B\nSkin Sens. 1\nH350\nH340\nH317\nGHS08\nGHS07\nDgr\nH350\nH340\nH317\n015-197-00-9\nbis(2,4,4-trimethylpentyl)dithiophosphonic acid\n420-160-9\n107667-02-7\nFlam. Liq. 3\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH226\nH331\nH302\nH314\nH411\nGHS02\nGHS06\nGHS05\nGHS09\nDgr\nH226\nH331\nH302\nH314\nH411\n015-198-00-4\n(4-phenylbutyl)phosphinic acid\n420-450-5\n86552-32-1\nCarc. 2\nEye Dam. 1\nH351\nH318\nGHS05\nGHS08\nDgr\nH351\nH318\n015-199-00-X\ntris[2-chloro-1-chloromethyl)ethyl] phosphate\n237-159-2\n13674-87-8\nCarc. 2\nH351\nGSH08\nWng\nH351\n015-200-00-3\nindium phosphide\n244-959-5\n22398-80-7\nCarc. 1B Repr. 2\nSTOT RE 1\nH350\nH361f\nH372 (lungs)\nGHS08\nDgr\nH350\nH361f\nH372 (lungs)\nSTOT RE 1; H372: C ≥0,1 % Carc 1B;\nH350: C\n≥0,01 % STOT RE 2;\nH373: 0,01 % ≤\nC < 0,1 %\n015-201-00-9\ntrixylyl phosphate\n246-677-8\n25155-23-1\nRepr. 1B\nH360F\nGHS08\nDgr\nH360F\n015-202-00-4\ntris(nonylphenyl) phosphite\n247-759-6\n26523-78-4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n015-203-00-X\ndiphenyl(2,4,6-trimethylbenzoyl)phosphine oxide\n278-355-8\n75980-60-8\nRepr. 2\nH361f (causing atrophy of the testes)\nGHS08\nWng\nH361f (causing atrophy of the testes)\n016-001-00-4\nhydrogen sulphide\n231-977-3\n7783-06-4\nFlam. Gas 1\nPress. Gas\nAcute Tox. 2 *\nAquatic Acute 1\nH220\nH330\nH400\nGHS02\nGHS04\nGHS06\nGHS09\nDgr\nH220\nH330\nH400\nU\n016-002-00-X\nbarium sulphide\n244-214-4\n21109-95-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nH332\nH302\nH400\nGHS07\nGHS09\nWng\nH332\nH302\nH400\nEUH031\n016-003-00-5\nbarium polysulphides\n256-814-3\n50864-67-0\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH319\nH335\nH315\nH400\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH400\nEUH031\n016-004-00-0\ncalcium sulphide\n243-873-5\n20548-54-3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH319\nH335\nH315\nH400\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH400\nEUH031\n016-005-00-6\ncalcium polysulphides\n215-709-2\n1344-81-6\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH319\nH335\nH315\nH400\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH400\nEUH031\n016-006-00-1\ndipotassium sulphide;\npotassium sulphide\n215-197-0\n1312-73-8\nSkin Corr. 1B\nAquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\nEUH031\n016-007-00-7\npotassium polysulphides\n253-390-1\n37199-66-9\nSkin Corr. 1B\nAquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\nEUH031\n016-008-00-2\nammonium polysulphides\n232-989-1\n9080-17-5\nSkin Corr. 1B\nAquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\nEUH031\nEUH031: C ≥1 %\n016-009-00-8\ndisodium sulfide;\nsodium sulfide\n215-211-5\n1313-82-2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nH311\nH302\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH302\nH314\nH400\n016-010-00-3\nsodium polysulphides\n215-686-9\n1344-08-7\nAcute Tox. 3 *\nSkin Corr. 1B\nAquatic Acute 1\nH301\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH314\nH400\nEUH031\n016-011-00-9\nsulphur dioxide\n231-195-2\n7446-09-5\nPress. Gas\nAcute Tox. 3 *\nSkin Corr. 1B\nH331\nH314\nGHS04\nGHS06\nGHS05\nDgr\nH331\nH314\n*\nU5\n016-012-00-4\ndisulphur dichloride;\nsulfur monochloride\n233-036-2\n10025-67-9\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1A\nAquatic Acute 1\nH301\nH332\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH332\nH314\nH400\nEUH014\nEUH029\nSTOT SE 3; H335: C ≥ 1 %\n016-013-00-X\nsulphur dichloride\n234-129-0\n10545-99-0\nSkin Corr. 1B\nSTOT SE 3\nAquatic Acute 1\nH314\nH335\nH400\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH335\nH400\nEUH014\nSTOT SE 3; H335: C ≥ 5 %\n016-014-00-5\nsulphur tetrachloride\n—\n13451-08-6\nSkin Corr. 1B\nAquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\nEUH014\nSTOT SE 3; H335: C ≥ 5 %\n016-015-00-0\nthionyl dichloride;\nthionyl chloride\n231-748-8\n7719-09-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH332\nH302\nH314\nGHS05\nGHS07\nDgr\nH332\nH302\nH314\nEUH014\nEUH029\nSTOT SE 3; H335: C ≥ 1 %\n016-016-00-6\nsulphuryl chloride\n232-245-6\n7791-25-5\nSkin Corr. 1B\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\nEUH014\n016-017-00-1\nchlorosulphonic acid\n232-234-6\n7790-94-5\nSkin Corr. 1A\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\nEUH014\n016-018-00-7\nfluorosulphonic acid\n232-149-4\n7789-21-1\nAcute Tox. 4 *\nSkin Corr. 1A\nH332\nH314\nGHS05\nGHS07\nDgr\nH332\nH314\n016-019-00-2\noleum … % SO3\n—\n—\nSkin Corr. 1A\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\nEUH014\nB\n016-020-00-8\nsulphuric acid … %\n231-639-5\n7664-93-9\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1A; H314: C ≥ 15 % Skin Irrit. 2; H315: 5 % ≤ C\n< 15 %\nEye Irrit. 2; H319: 5 % ≤ C\n< 15 %\nB\n016-021-00-3\nmethanethiol;\nmethyl mercaptan\n200-822-1\n74-93-1\nFlam. Gas. 1\nPress. Gas\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH220\nH331\nH400\nH410\nGHS02\nGHS04\nGHS06\nGHS09\nDgr\nH220\nH331\nH410\nU\n016-022-00-9\nethanethiol;\nethyl mercaptan\n200-837-3\n75-08-1\nFlam. Liq. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH332\nH400\nH410\nGHS02\nGHS07\nGHS09\nDgr\nH225\nH332\nH410\n016-023-00-4\ndimethyl sulphate\n201-058-1\n77-78-1\nCarc. 1B\nMuta. 2\nAcute Tox. 2 *\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nH350\nH341\nH330\nH301\nH314\nH317\nGHS06\nGHS08\nGHS05\nDgr\nH350\nH341\nH330\nH301\nH314\nH317\nCarc. 1B; H350: C ≥ 0,01 % Muta. 2 H341: C ≥ 0,01 % STOT SE 3; H335: C ≥ 5 %\n016-024-00-X\ndimexano(ISO); bis(methoxythiocarbonyl) disulphide\n215-993-8\n1468-37-7\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n016-025-00-5\ndisul (ISO);\n2-(2,4-dichlorophenoxy)ethyl hydrogensulphate;\n2,4-DES\n205-259-5\n149-26-8\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nH302\nH315\nH318\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\n016-026-00-0\nsulphamidic acid;\nsulphamic acid;\nsulfamic acid\n226-218-8\n5329-14-6\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 3\nH319\nH315\nH412\nGHS07\nWng\nH319\nH315\nH412\n016-027-00-6\ndiethyl sulphate\n200-589-6\n64-67-5\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH350\nH340\nH332\nH312\nH302\nH314\nGHS05\nGHS08\nGHS07\nDgr\nH350\nH340\nH332\nH312\nH302\nH314\n016-028-00-1\nsodium dithionite;\nsodium hydrosulphite\n231-890-0\n7775-14-6\nSelf-heat. 1\nAcute Tox. 4 *\nH251\nH302\nGHS02\nGHS07\nDgr\nH251\nH302\nEUH031\n016-029-00-7\np-toluenesulphonic acid, (containing more than 5 % H2SO4)\n—\n—\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 %\nEye Irrit. 2; H319: 10 % ≤ C < 25 %\n016-030-00-2\np-toluenesulphonic acid (containing a maximum of 5 % H2SO4)\n203-180-0\n104-15-4\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\nSTOT SE 3; H335: C ≥ 20 %\n016-031-00-8\ntetrahydrothiophene-1,1-dioxide; sulpholane\n204-783-1\n126-33-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n016-032-00-3\n1,3-propanesultone;\n1,2-oxathiolane 2,2-dioxide\n214-317-9\n1120-71-4\nCarc. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nH350\nH312\nH302\nGHS08\nGHS07\nDgr\nH350\nH312\nH302\nCarc. 1B; H350: C ≥ 0,01 %\n016-033-00-9\ndimethylsulfamoylchloride\n236-412-4\n13360-57-1\nCarc. 1B\nAcute Tox. 2 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH350\nH330\nH312\nH302\nH314\nGHS06\nGHS05\nGHS08\nDgr\nH350\nH330\nH312\nH302\nH314\n016-034-00-4\ntetrasodium 3,3'-(piperazine-1,4-diylbis((6-chloro-1,3,5-triazine-2,4-diyl)imino(2-acetamido)-4,1-phenyleneazo))bis(naphthalene-1,5-disulphonate)\n400-010-9\n81898-60-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-035-00-X\npentasodium 5-anilino-3-(4-(4-(6-chloro-4-(3-sulphonatoanilino)-1,3,5-triazin-2-ylamino)-2,5-dimethylphenylazo)-2,5-disulphonatophenylazo)-4-hydroxynaphthalene-2,7-disulphonate\n400-120-7\n—\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n016-036-00-5\ntetrasodium 5-(4,6-dichloro-5-cyanopyrimidin-2-ylamino)-4-hydroxy-2,3-azodinaphthalene-1,2,5,7-disulphonate\n400-130-1\n—\nResp. Sens. 1\nAquatic Chronic 2\nH334\nH411\nGHS08\nGHS09\nDgr\nH334\nH411\n016-037-00-0\ndisodium 1-amino-4-(4-benzenesulphonamido-3-sulphonatoanilino)anthraquinone-2-sulphonate\n400-350-8\n85153-93-1\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n016-038-00-6\ndisodium 6-((4-chloro-6-(N-methyl)-2-toluidino)-1,3,5-triazin-2-ylamino)-1-hydroxy-2-(4-methoxy-2-sulphonatophenylazo)naphthalene-3-sulphonate\n400-380-1\n86393-35-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-039-00-1\ntetrasodium 2-(6-chloro-4-(4-(2,5-dimethyl-4-(2,5-disulphonatophenylazo)phenylazo)-3-ureidoanilino)-1,3,5-triazin-2-ylamino)benzene-1,4-disulphonate\n400-430-2\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-040-00-7\nreaction mass of disodium 6-(2,4-dihydroxyphenylazo)-3-(4-(4-(2,4-dihydroxyphenylazo)anilino)-3-sulphonatophenylazo)-4-hydroxynaphthalene-2-sulphonate and disodium 6-(2,4-diaminophenylazo)-3-(4-(4-(2,4-diaminophenylazo)anilino)-3-sulphonatophenylazo)-4-hydroxynaphthalene-2-sulphonate and trisodium 6-(2,4-dihydroxyphenylazo)-3-(4-(4-(7-(2,4-dihydroxyphenylazo)-1-hydroxy-3-sulphonato-2-naphthylazo)anilino)-3-sulphonatophenylazo)-4-hydroxynaphthalene-2-sulphonate\n400-570-4\n—\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n016-041-00-2\ncalcium 2,5-dichloro-4-(4-((5-chloro-4-methyl-2-sulphonatophenyl)azo)-5-hydroxy-3-methylpyrazol-1-yl)benzenesulphonate\n400-710-4\n—\nAcute Tox. 4 *\nH332\nGHS07\nWng\nH332\n016-042-00-8\ntetrasodium 5-benzamido-3-(5-(4-fluoro-6-(1-sulphonato-2-naphthylamino)-1,3,5-triazin-2-ylamino)-2-sulphonatophenylazo)-4-hydroxynaphthalene-2,7-disulphonate\n400-790-0\n85665-97-0\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\n016-043-00-3\ndilithium 6-acetamido-4-hydroxy-3-(4-((2-sulphonatooxy)ethylsulphonyl) phenylazo)naphthalene-2-sulphonate\n401-010-1\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-044-00-9\ndisodium S,S-hexane-1,6-diyldi(thiosulphate) dihydrate\n401-320-7\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n016-045-00-4\nlithium sodium hydrogen 4-amino-6-(5-(5-chloro-2,6-difluoropyrimidin-4-ylamino)-2-sulphonatophenylazo)-5-hydroxy-3-(4-(2-(sulphonatooxy)ethylsulphonyl)phenylazo)naphthalene-2,7-disulphonate\n401-560-2\n108624-00-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-046-00-X\nsodium hydrogensulphate\n231-665-7\n7681-38-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n016-047-00-5\nhexasodium 7-(4-(4-(4-(2,5-disulphonatoanilino)-6-fluoro-1,3,5-triazin-2-ylamino)-2-methylphenylazo)-7-sulphonatonaphthylazo)naphthalene-1,3,5-trisulphonate\n401-650-1\n85665-96-9\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-048-00-0\nsodium 3,5-dichloro-2-(5-cyano-2,6-bis(3-hydroxypropylamino)-4-methylpyridin-3-ylazo)benzenesulphonate\n401-870-8\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n016-049-00-6\ncalcium octadecylxylenesulphonate\n402-040-8\n—\nSkin Corr. 1B\nAquatic Chronic 2\nH314\nH411\nGHS05\nGHS09\nDgr\nH314\nH411\n016-050-00-1\npotassium sodium 5-(4-chloro-6-(N-(4-(4-chloro-6-(5-hydroxy-2,7-disulphonato-6-(2-sulphonatophenylazo)-4-naphthylamino)-1,3,5-triazin-2-ylamino) phenyl-N-methyl)amino)-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(2-sulphonatophenylazo)naphthalene-2,7-disulphonat\n402-150-6\n—\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n016-051-00-7\ntrisodium 7-(4-(6-fluoro-4-(2-(2-vinylsulphonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulphonate\n402-170-5\n106359-91-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-052-00-2\nbenzyltributylammonium 4-hydroxynaphthalene-1-sulphonate\n402-240-5\n102561-46-6\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH411\nGHS07\nGHS09\nWng\nH332\nH411\n016-053-00-8\n(C16 or C18-n-alkyl)(C16 or C18-n-alkyl)ammonium 2-((C16 or C18-n-alkyl)(C16 or C18-n-alkyl)carbamoyl)benzenesulphonate\n402-460-1\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n016-054-00-3\nsodium 4-(2,4,4-trimethylpentylcarbonyloxy)benzenesulfonate\n400-030-8\n—\nAcute Tox. 3 *\nSTOT RE 1\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Sens. 1\nH331\nH372 **\nH302\nH319\nH335\nH317\nGHS06\nGHS08\nDgr\nH331\nH372 ** H302\nH319\nH335\nH317\n016-055-00-9\ntetrasodium 4-amino-3,6-bis(5-(6-chloro-4-(2-hydroxyethylamino)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxynaphthalene-2,7-sulfonate (containing > 35 % sodium chloride and sodium acetate)\n400-510-7\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n016-056-00-4\npotassium hydrogensulphate\n231-594-1\n7646-93-7\nSkin Corr. 1B\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\n016-057-00-X\nstyrene-4-sulfonyl chloride\n404-770-2\n2633-67-2\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH315\nH318\nH317\n016-058-00-5\nthionyl chloride, reaction products with 1,3,4-thiadiazol-2,5-dithiol, tert-nonanethiol andC 12-14-tert-alkylamine\n404-820-3\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH315\nH317\nH412\nGHS07\nWng\nH315\nH317\nH412\n016-059-00-0\nN, N,N',N'-tetramethyldithiobis(ethylene)diamine dihydrochloride\n405-300-9\n17339-60-5\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH317\nH410\n016-060-00-6\ndiammonium peroxodisulphate; ammonium persulphate\n231-786-5\n7727-54-0\nOx. Sol. 3\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nH272\nH302\nH319\nH335\nH315\nH334\nH317\nGHS03\nGHS08\nGHS07\nDgr\nH272\nH302\nH319\nH335\nH315\nH334\nH317\n016-061-00-1\ndipotassium peroxodisulphate; potassium persulphate\n231-781-8\n7727-21-1\nOx. Sol. 3\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nH272\nH302\nH319\nH335\nH315\nH334\nH317\nGHS03\nGHS08\nGHS07\nDgr\nH272\nH302\nH319\nH335\nH315\nH334\nH317\n016-062-00-7\nbensultap (ISO);\n1,3-bis(phenylsulfonylthio)-2-(N,N-dimethylamino)propane\n—\n17606-31-4\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n016-063-00-2\nsodium metabisulphite\n231-673-0\n7681-57-4\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\nEUH031\n016-064-00-8\nsodium hydrogensulphite … %;\nsodium bisulphite . . . %\n231-548-0\n7631-90-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\nEUH031\nB\n016-065-00-3\nsodium 1-amino-4-[2-methyl-5-(4-methylphenylsulfonylamino)phenylamino]anthraquinone-2-sulfonate\n400-100-8\n84057-97-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n016-066-00-9\ntetrasodium [5-((4-amino-6-chloro-1,3,5-triazin-2-yl)amino)-2-((2-hydroxy-3,5-disulfonatophenylazo)-2-sulfonatobenzylidenehydrazino)benzoate]copper(II)\n404-070-7\n116912-62-0\nAquatic Chronic 3\nH412\n—\nH412\n016-067-00-4\n(4-methylphenyl)mesitylene sulfonate\n407-530-5\n67811-06-7\nAquatic Chronic 4\nH413\n—\nH413\n016-068-00-X\nsodium 3,5-bis(tetradecyloxycarbonyl)benzenesulfinate\n407-720-8\n155160-86-4\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n016-069-00-5\n3,5-bis-(tetradecyloxycarbonyl)benzenesulfinic acid\n407-990-7\n141915-64-2\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n016-070-00-0\n4-benzyloxy-4'-(2,3-epoxy-2-methylprop-1-yloxy)diphenylsulfone\n408-220-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n016-071-00-6\ntrisodium 3-amino-6,13-dichloro-10-((3-((4-chloro-6-(2-sulfophenylamino)-1,3,5-triazin-2-yl)amino)propyl) amino)-4,11-triphenoxydioxazinedisulfonate\n410-130-3\n136248-03-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n016-072-00-1\n3-amino-4-hydroxy-N-(2-methoxyethyl)-benzenesulfonamide\n411-520-6\n112195-27-4\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n016-073-00-7\ntetrakis(phenylmethyl)thioperoxydi(carbothioamide)\n404-310-0\n10591-85-2\nAquatic Chronic 4\nH413\n—\nH413\n016-074-00-2\n6-fluoro-2-methyl-3-(4-methylthiobenzyl)indene\n405-410-7\n—\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH411\n016-075-00-8\n2,2'-diallyl-4,4'-sulfonyldiphenol\n411-570-9\n41481-66-7\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n016-076-00-3\n2,3-bis((2-mercaptoethyl)thio)-1-propanethiol\n411-290-7\n131538-00-6\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 ** H400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 ** H410\n016-077-00-9\n2-chloro-p-toluenesulfochloride\n412-890-1\n42413-03-6\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH314\nH317\nH412\n016-078-00-4\n4-methyl-N, N-bis(2-(((4-methylphenyl)sulfonyl)amino)ethyl)benzenesulfonamide\n413-300-5\n56187-04-3\nAquatic Chronic 4\nH413\n—\n016-079-00-X\nN, N-bis(2-(p-toluenesulfonyloxy)ethyl)-p-toluenesulfonamide\n412-920-3\n16695-22-0\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n016-080-00-5\nsodium 2-anilino-5-(2-nitro-4-(N-phenylsulfamoyl))anilinobenzenesulfonate\n412-320-1\n31361-99-6\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n016-081-00-0\nhexahydrocyclopenta[c]pyrrole-1-(1H)-ammonium N-ethoxycarbonyl-N-(p-tolylsulfonyl)azanide\n418-350-1\n—\nMuta. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH341\nH302\nH319\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH341\nH302\nH319\nH317\nH411\n016-082-00-6\nethoxysulfuron (ISO);\n1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethoxyphenoxysulfonyl)urea\n—\n126801-58-9\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n016-083-00-1\nacibenzolar-S-methyl; benzo[1,2,3]thiadiazole-7-carbothioic acid S-methyl ester\n420-050-0\n135158-54-2\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH335\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH317\nH410\n016-084-00-7\nprosulfuron (ISO);\n1-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-3-[2-(3,3,3-trifluoropropyl)phenylsulfonyl]urea\n—\n94125-34-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM=100\n016-085-00-2\nflazasulfuron (ISO);\n1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-trifluoromethyl-2-pyridylsulfonyl)urea\n—\n104040-78-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n016-086-00-8\ntetrasodium 10-amino-6,13-dichloro-3-(3-(4-(2,5-disulfonatoanilino)-6-fluoro-1,3,5-triazin-2-ylamino)prop-3-ylamino)-5,12-dioxa-7,14-diazapentacene-4,11-disulfonate\n402-590-9\n109125-56-6\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n016-087-00-3\nreaction mass of: thiobis(4,1-phenylene)-S, S,S',S'-tetraphenyldisulfonium bishexafluorophosphate;\ndiphenyl(4-phenylthiophenyl)sulfonium hexafluorophosphate;\npropylene carbonate\n403-490-8\n104558-95-4\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH317\nH410\n016-088-00-9\n4-(bis(4-(diethylamino)phenyl)methyl)benzene-1,2-dimethanesulfonic acid\n407-280-7\n71297-11-5\nAquatic Chronic 3\nH412\n—\nH412\n016-089-00-4\nreaction mass of esters of 5,5',6,6',7,7'-hexahydroxy-3,3,3',3'-tetramethyl-1,1'-spirobiindan and 2-diazo-1,2-dihydro-1-oxo-5-sulfonaphthalene\n413-840-1\n—\nSelf-react. C ****\nAquatic Chronic 4\nH242\nH413\nGHS02\nDgr\nH242\nH413\n016-090-00-X\n4-methyl-N-(methylsulfonyl)benzenesulfonamide\n415-040-8\n14653-91-9\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH302\nH335\nH318\nGHS05\nGHS07\nDgr\nH302\nH335\nH318\n016-091-00-5\nC12-14-tert-alkyl ammonium 1-amino-9,10-dihydro-9,10-dioxo-4-(2,4,6-trimethylanilino)-anthracen-2-sulfonate\n414-110-5\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n016-092-00-0\nreaction mass of: 4,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol;\n4,8-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol;\n5,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol\n427-050-1\n—\nRepr. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361f\nH315\nH317\nH410\n016-093-00-6\nreaction mass of: 4-(7-hydroxy-2,4,4-trimethyl-2-chromanyl)resorcinol-4-yl-tris(6-diazo-5,6-dihydro-5-oxonaphthalen-1-sulfonate);\n4-(7-hydroxy-2,4,4-trimethyl-2-chromanyl)resorcinolbis(6-diazo-5,6-dihydro-5-oxonaphthalen-1-sulfonate) (2:1)\n414-770-4\n140698-96-0\nSelf-react. C ****\nCarc. 2\nH242\nH351\nGHS02\nGHS08\nDgr\nH242\nH351\n016-094-00-1\nsulfur\n231-722-6\n7704-34-9\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n016-095-00-7\nreaction mass of: reaction product of 4,4'-methylenebis[2-(4-hydroxybenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxo-naphthalenesulfonate (1:2);\nreaction product of 4,4'-methylenebis[2-(4-hydroxybenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxo-naphthalenesulfonate (1:3)\n417-980-4\n—\nSelf-react. C ****\nCarc. 2\nH242\nH351\nGHS02\nGHS08\nDgr\nH242\nH351\n016-096-00-2\nthifensulfuron-methyl (ISO);\nmethyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate\n—\n79277-27-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n016-097-00-8\n1-amino-2-methyl-2-propanethiol hydrochloride\n434-480-1\n32047-53-3\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\nH412\n017-001-00-7\nchlorine\n231-959-5\n7782-50-5\nOx. Gas 1\nPress. Gas\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH270\nH331\nH319\nH335\nH315\nH400\nGHS03\nGHS04\nGHS06\nGHS09\nDgr\nH270\nH331\nH319\nH335\nH315\nH400\nM = 100\nU\n017-002-00-2\nhydrogen chloride\n231-595-7\n7647-01-0\nPress. Gas\nAcute Tox. 3 *\nSkin Corr. 1A\nH331\nH314\nGHS04\nGHS06\nGHS05\nDgr\nH331\nH314\nU5\n017-002-01-X\nhydrochloric acid … %\n231-595-7\n—\nSkin Corr. 1B\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\nSkin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 %\nEyeIrrit. 2; H319: 10 % ≤ C < 25 %\nSTOT SE 3; H335: C ≥ 10 %\nB\n017-003-00-8\nbarium chlorate\n236-760-7\n13477-00-4\nOx. Sol. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH271\nH332\nH302\nH411\nGHS03\nGHS07\nGHS09\nDgr\nH271\nH332\nH302\nH411\n017-004-00-3\npotassium chlorate\n223-289-7\n3811-04-9\nOx. Sol. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH271\nH332\nH302\nH411\nGHS03\nGHS07\nGHS09\nDgr\nH271\nH332\nH302\nH411\n017-005-00-9\nsodium chlorate\n231-887-4\n7775-09-9\nOx. Sol. 1\nAcute Tox. 4 *\nAquatic Chronic 2\nH271\nH302\nH411\nGHS03\nGHS07\nGHS09\nDgr\nH271\nH302\nH411\n017-006-00-4\nperchloric acid … %\n231-512-4\n7601-90-3\nOx. Liq. 1\nSkin Corr. 1A\nH271\nH314\nGHS03\nGHS05\nDgr\nH271\nH314\nSkin Corr. 1A; H314: C ≥ 50 % Skin Corr. 1B; H314: 10 % ≤ C < 50 %\nSkin Irrit. 2; H315: 1 % ≤ C\n< 10 %\nEye Irrit. 2; H319: 1 % ≤ C\n< 10 %\nOx. Liq. 1; H271: C > 50 %:\nOx. Liq. 2; H272: C ≤ 50 %:\nB\n017-007-00-X\nbarium perchlorate\n236-710-4\n13465-95-7\nOx. Sol. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nH271\nH332\nH302\nGHS03\nGHS07\nDgr\nH271\nH332\nH302\n017-008-00-5\npotassium perchlorate\n231-912-9\n7778-74-7\nOx. Sol. 1\nAcute Tox. 4 *\nH271\nH302\nGHS03\nGHS07\nDgr\nH271\nH302\n017-009-00-0\nammonium perchlorate\n232-235-1\n7790-98-9\nExpl. 1.1\nOx. Sol. 1\nH201\nH271\nGHS01\nDgr\nH201\nH271\nT\n017-010-00-6\nsodium perchlorate\n231-511-9\n7601-89-0\nOx. Sol. 1\nAcute Tox. 4 *\nH271\nH302\nGHS03\nGHS07\nDgr\nH271\nH302\n017-011-00-1\nsodium hypochlorite, solution… % Cl active\n231-668-3\n7681-52-9\nSkin Corr. 1B\nAquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\nEUH031\nEUH031: C ≥5 %\nB\n017-012-00-7\ncalcium hypochlorite\n231-908-7\n7778-54-3\nOx. Sol. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nH272\nH302\nH314\nH400\nGHS03\nGHS05\nGHS07\nGHS09\nDgr\nH272\nH302\nH314\nH400\nEUH031\nSkin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 1 % ≤ C\n< 5 %\nEye Dam.1; H318: 3 % ≤ C\n< 5 %\nEye Irrit. 2; H319: 0,5 % ≤ C < 3 %\nM = 10\nT\n017-013-00-2\ncalcium chloride\n233-140-8\n10043-52-4\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n017-014-00-8\nammonium chloride\n235-186-4\n12125-02-9\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n017-015-00-3\n(2-(aminomethyl)phenyl)acetylchloride hydrochloride\n417-410-4\n61807-67-8\nAcute Tox. 4 *\nSkin Corr. 1A\nSkin Sens. 1\nH302\nH314\nH317\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\n017-016-00-9\nmethyltriphenylphosphonium chloride\n418-400-2\n1031-15-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH312\nH302\nH315\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH315\nH318\nH411\n017-017-00-4\n(Z)-13-docosenyl-N,N-bis(2-hydroxyethyl)-N-methyl-ammonium-chloride\n426-210-6\n120086-58-0\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n017-018-00-X\nN, N,N-trimethyl-2,3-bis(stearoyloxy)propylammonium chloride\n405-660-7\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n017-019-00-5\n(R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquinoline hydrochloride\n415-110-8\n54417-53-7\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n017-020-00-0\nethyl propoxy aluminium chloride\n421-790-7\n13014-29-4\nWater-react. 1\nSkin Corr. 1A\nH260\nH314\nGHS02\nGHS05\nDgr\nH260\nH314\nEUH014\n017-021-00-6\nbehenamidopropyl-dimethyl-(dihydroxypropyl) ammonium chloride\n423-420-1\n136920-10-0\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH410\n017-023-00-7\n[phosphinyldynetris(oxy)] tris[3-aminopropyl-2-hydroxy-N, N-dimethyl-N-(C6-18)-alkyl] trichlorides\n425-520-9\n197179-61-6\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n017-026-00-3\nchlorine dioxide\n233-162-8\n10049-04-4\nPress. Gas\nOx. Gas 1\nAcute Tox. 2 *\nSkin Corr. 1B\nAquatic Acute 1\nH270\nH330\nH314\nH400\nGHS04\nGHS03\nGHS06\nGHS05\nGHS09\nDgr\nH270\nH330\nH314\nH400\nM = 10\n5\n017-026-01-0\nchlorine dioxide … %\n233-162-8\n10049-04-4\nAcute Tox. 3 *\nSkin Corr. 1B\nAquatic Acute 1\nH301\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH314\nH400\nSkin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 1 % ≤ C\n< 5 %\nEye Dam.1; H318: 3 % ≤ C\n< 5 %\nEye Irrit. 2; H319: 0,3 % ≤ C < 3 %\nSTOT SE 3; H335: C ≥ 3 % M = 10\nB\n019-001-00-2\npotassium\n231-119-8\n7440-09-7\nWater-react. 1\nSkin Corr. 1B\nH260\nH314\nGHS02\nGHS05\nDgr\nH260\nH314\nEUH014\n019-002-00-8\npotassium hydroxide;\ncaustic potash\n215-181-3\n1310-58-3\nAcute Tox. 4 *\nSkin Corr. 1A\nH302\nH314\nGHS05\nGHS07\nDgr\nH302\nH314\nSkin Corr. 1A; H314: C ≥ 5 % Skin Corr. 1B; H314: 2 % ≤ C\n< 5 %\nSkin Irrit. 2; H315: 0,5 % ≤ C < 2 %\nEye Irrit. 2; H319: 0,5 % ≤ C < 2 %\n020-001-00-X\ncalcium\n231-179-5\n7440-70-2\nWater-react. 2\nH261\nGHS02\nDgr\nH261\n020-002-00-5\ncalcium cyanide\n209-740-0\n592-01-8\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH410\nEUH032\n020-003-00-0\nreaction mass of: dicalcium (bis(2-hydroxy-5-tetra-propenylphenylmethyl)methylamine)dihydroxide;\ntri-calcium (tris(2-hydroxy-5-tetra-propenylphenylmethyl)methylamine)tri-hydroxide;\npoly[calcium ((2-hydroxy-5-tetra-propenyl-phenylmethyl)methylamine)hydroxide]\n420-470-4\n—\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\n022-001-00-5\ntitanium tetrachloride\n231-441-9\n7550-45-0\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\nEUH014\n022-002-00-0\ntitanium(4+) oxalate\n403-260-7\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n022-003-00-6\nbis(η5-cyclopentadienyl)-bis(2,6-difluoro-3-[pyrrol-1-yl]-phenyl)titanium\n412-000-1\n125051-32-3\nFlam. Sol. 1\nRepr. 2\nSTOT RE 2 *\nAquatic Chronic 2\nH228\nH361f *** H373 **\nH411\nGHS02\nGHS08\nGHS09\nDgr\nH228\nH361f *** H373 ** H411\nT\n022-004-00-1\nPotassium titanium oxide(K 2 Ti 6 O 13 )\n432-240-0\n12056-51-8\nCarc. 2\nH351\nGHS08\nWng\nH351\n022-005-00-7\n[N-(1,1-dimethylethyl)-1,1-dimethyl-1-[(1,2,3,4,5-η)-2,3,4,5-tetramethyl-2,4-cyclopentadien-1-yl]silanaminato(2-)-κN][(1,2,3,4-η)-1,3-pentadiene]-titanium\n419-840-8\n169104-71-6\nFlam. Sol. 1****\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 4\nH228\nH314\nH317\nH413\nGHS02\nGHS05\nGHS07\nDgr\nH228\nH314\nH317\nH413\n023-001-00-8\ndivanadium pentaoxide;\nvanadium pentoxide\n215-239-8\n1314-62-1\nMuta. 2\nRepr. 2\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 3\nAquatic Chronic 2\nH341\nH361d *** H372 **\nH332\nH302\nH335\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH341\nH361d *** H372 **\nH332\nH302\nH335\nH411\n024-001-00-0\nchromium (VI) trioxide\n215-607-8\n1333-82-0\nOx. Sol. 1\nCarc. 1A\nMuta. 1B Repr. 2\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nSkin Corr. 1A\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH271\nH350\nH340\nH361f *** H330\nH311\nH301\nH372 **\nH314\nH334\nH317\nH400\nH410\nGHS03\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH271\nH350\nH340\nH361f *** H330\nH311\nH301\nH372 **\nH314\nH334\nH317\nH410\nSTOT SE 3; H335: C ≥ 1 %\n024-002-00-6\npotassium dichromate\n231-906-6\n7778-50-9\nOx. Sol. 2\nCarc. 1B\nMuta. 1B\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAcute Tox. 4 *\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH312\nH314\nH334\nH317\nH400\nH410\nGHS03\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH272\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH312\nH314\nH334\nH317\nH410\nSTOT SE 3; H335: C ≥ 5 %\n3\n024-003-00-1\nammonium dichromate\n232-143-1\n7789-09-5\nOx. Sol. 2 ****\nCarc. 1B\nMuta. 1B\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAcute Tox. 4 *\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH312\nH314\nH334\nH317\nH400\nH410\nGHS03\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH272\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH312\nH314\nH334\nH317\nH410\nSTOT SE 3; H335: C ≥ 5 %\nResp. Sens.; H334: C ≥0,2 %\nSkin Sens.; H317:C ≥0,2 %\nG3\n024-004-00-7\nsodium dichromate\n234-190-3\n10588-01-9\nOx. Sol. 2\nCarc. 1B\nMuta. 1B\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 1\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH350\nH340\nH360FD\nH330\nH301\nH312\nH372**\nH314\nH334\nH317\nH400\nH410\nGHS03\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH272\nH350\nH340\nH360FD\nH330\nH301\nH312\nH372**\nH314\nH334\nH317\nH410\nResp. Sens. 1; H334: C ≥ 0,2 %\nSkin Sens. 1; H317:C ≥0,2 %\nSTOT SE 3; H335: C ≥ 5 %\n3\n024-005-00-2\nchromyl dichloride;\nchromic oxychloride\n239-056-8\n14977-61-8\nOx. Liq. 1\nCarc. 1B\nMuta. 1B\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH271\nH350i\nH340\nH314\nH317\nH400\nH410\nGHS03\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH271\nH350i\nH340\nH314\nH317\nH410\nSkin Corr. 1A; H314: C ≥ 10 % Skin Corr. 1B; H314: 5 % ≤ C\n< 10 %\nSkin Irrit. 2; H315: 0,5 % ≤\nC < 5 %\nEye Irrit. 2; H319: 0,5 % ≤\nC < 5 %\nSTOT SE 3; H335: 0,5 % ≤ C < 5 %\nSkin Sens. 1; H317: C ≥ 0,5 %\nT3\n024-006-00-8\npotassium chromate\n232-140-5\n7789-00-6\nCarc. 1B\nMuta. 1B\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH340\nH319\nH335\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH340\nH319\nH335\nH315\nH317\nH410\nSkin Sens. 1; H317:C ≥ 0,5 %\n3\n024-007-00-3\nzinc chromates including zinc potassium chromate\n—\n—\nCarc. 1A\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH317\nH410\nA\n024-008-00-9\ncalcium chromate\n237-366-8\n13765-19-0\nCarc. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH410\n024-009-00-4\nstrontium chromate\n232-142-6\n7789-06-2\nCarc. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH400\nH410\n024-010-00-X\ndichromium tris(chromate);\nchromium III chromate;\nchromic chromate\n246-356-2\n24613-89-6\nOx. Sol. 1\nCarc. 1B\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH271\nH350\nH314\nH317\nH400\nH410\nGHS03\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH271\nH350\nH314\nH317\nH410\nT\n024-011-00-5\nammonium bis(1-(3,5-dinitro-2-oxidophenylazo)-3-(N-phenylcarbamoyl)-2-naphtholato)chromate(1-)\n400-110-2\n109125-51-1\nSelf-react. C ****\nAquatic Acute 1\nAquatic Chronic 1\nH242\nH400\nH410\nGHS02\nGHS09\nDgr\nH242\nH410\n024-012-00-0\ntrisodium bis(7-acetamido-2-(4-nitro-2-oxidophenylazo)-3-sulphonato-1-naphtholato)chromate(1-)\n400-810-8\n—\nMuta. 2\nH341\nGHS08\nWng\nH341\n024-013-00-6\ntrisodium (6-anilino-2-(5-nitro-2-oxidophenylazo)-3-sulphonato-1-naphtholato)(4-sulphonato-1,1'-azodi-2,2'naphtholato)chromate(1-)\n402-500-8\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n024-014-00-1\ntrisodium bis(2-(5-chloro-4-nitro-2-oxidophenylazo)-5-sulphonato-1-naphtholato)chromate(1-)\n402-870-0\n93952-24-0\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n024-015-00-7\ndisodium (3-methyl-4-(5-nitro-2-oxidophenylazo)-1-phenylpyrazololato)(1-(3-nitro-2-oxido-5-sulfonatophenylazo)-2-naphtholato)chromate(1-)\n404-930-1\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH332\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH318\nH411\n024-016-00-2\ntetradecylammonium bis(1-(5-chloro-2-oxidophenylazo)-2-naphtholato)chromate(1-)\n405-110-6\n88377-66-6\nSTOT RE 2 *\nAquatic Chronic 4\nH373 **\nH413\nGHS08\nWng\nH373 **\nH413\n024-017-00-8\nchromium (VI) compounds, with the exception of barium chromate and of compounds specified elsewhere in this Annex\n—\n—\nCarc. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH317\nH410\nA\n024-018-00-3\nsodium chromate\n231-889-5\n7775-11-3\nCarc. 1B\nMuta. 1B\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAcute Tox. 4 *\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH312\nH314\nH334\nH317\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH312\nH314\nH334\nH317\nH410\nResp. Sens.;\nH334: C ≥ 0,2 %\nSkin Sens.; H317:C ≥ 0,2 %\n3\n024-019-00-9\nMain component: acetoacetic acid anilide/3-amino-1-hydroxybenzene (ATAN-MAP): trisodium {6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato}-{6''-[1-(phenylcarbamoyl)ethylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2''-azobenzene-1'',2'''-diolato}chromate (III); by-product 1: acetoacetic acid anilide/acetoacetic acid anilide (ATAN-ATAN): trisodium bis{6-[1-(phenylcarbamoyl)ethylazo]-5'''-(phenylsulfonyl)-3''-sulfonatonaphthalene-2-azobenzene-1,2'-diolato}chromate (III);\nby-product 2: 3-amino-1-hydroxybenzene/3-amino-1-hydroxybenzene (MAP-MAP): trisodium bis{6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato}chromate (III)\n419-230-1\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n024-020-00-4\ntrisodium bis[(3'-nitro-5'-sulfonato(6-amino-2-[4-(2-hydroxy-1-naphtylazo)phenylsulfonylamino]pyrimidin-5-azo)benzene-2',4-diolato)]chromate(III)\n418-220-4\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n024-021-00-X\npotassium tetrasodium bis[(N,N'-n)-1'-(phenylcarbamoyl)-3,5-disulfonatobenzeneazo-1'-prop-1'-ene-2,2'-diolato]chromate(III)\n425-830-4\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n025-001-00-3\nmanganese dioxide\n215-202-6\n1313-13-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH302\nGHS07\nWng\nH332\nH302\n025-002-00-9\npotassium permanganate\n231-760-3\n7722-64-7\nOx. Sol. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH302\nH400\nH410\nGHS03\nGHS07\nGHS09\nDgr\nH272\nH302\nH410\n025-003-00-4\nmanganese sulphate\n232-089-9\n7785-87-7\nSTOT RE 2 *\nAquatic Chronic 2\nH373 **\nH411\nGHS08\nGHS09\nWng\nH373 ** H411\n025-004-00-X\nbis(N, N',N''-trimethyl-1,4,7-triazacyclononane)-trioxo-dimanganese (IV) di(hexafluorophosphate) monohydrate\n411-760-1\n116633-53-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n025-005-00-5\nreaction mass of: tri-sodium [29H, 31H-phthalocyanine-C, C,C-trisulfonato (6-)-N29, N30, N31, N32] manganate (3-); tetrasodium [29H, 31H-phthalocyanine-C, C,C, C-tetrasulfonato(6-)-N29, N30, N31, N32], manganate (3-);\npentasodium [29H, 31H-phthalocyanine-C, C,C, C,C-pentasulfonato (6-)-N29, N30, N31, N32] manganate (3-)\n417-660-4\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n026-001-00-6\n(η-cumene)-(η-cyclopentadienyl)iron(II) hexafluoroantimonate\n407-840-0\n100011-37-8\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n026-002-00-1\n(η-cumene)-(η-cyclopentadienyl)iron(II) trifluoromethane-sulfonate\n407-880-9\n117549-13-0\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n026-003-00-7\niron (II) sulfate\n231-753-5\n7720-78-7\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH302\nH319\nH315\nGHS07\nWng\nH302\nH319\nH315\n026-003-01-4\niron (II) sulfate (1:1) heptahydrate; sulfuric acid, iron(II) salt (1:1), heptahydrate;\nferrous sulfate heptahydrate\n231-753-5\n7782-63-0\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH302\nH319\nH315\nGHS07\nWng\nH302\nH319\nH315\nSkin Irrit.2; H315: C ≥ 25 %\n026-004-00-2\npotassium ferrite\n430-010-4\n12160-44-0\nSkin Corr. 1B\nSkin Sens. 1\nH314\nH317\nGHS05\nGHS07\nDgr\nH314\nH317\n027-001-00-9\ncobalt\n231-158-0\n7440-48-4\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 4\nH334\nH317\nH413\nGHS08\nDgr\nH334\nH317\nH413\n027-002-00-4\ncobalt oxide\n215-154-6\n1307-96-6\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nM=10\n027-003-00-X\ncobalt sulfide\n215-273-3\n1317-42-6\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM=10\n027-004-00-5\ncobalt dichloride\n231-589-4\n7646-79-9\nCarc. 1B\nMuta. 2\nRepr. 1B\nAcute Tox. 4 *\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F*** H302\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360F*** H302\nH334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 % M=10\n1\n027-005-00-0\ncobalt sulfate\n233-334-2\n10124-43-3\nCarc. 1B\nMuta. 2\nRepr. 1B\nAcute Tox. 4 *\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F*** H302\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360F*** H302\nH334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 % M=10\n1\n027-006-00-6\ncobalt di(acetate)\n200-755-8\n71-48-7\nCarc. 1B\nMuta. 2\nRepr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F*** H334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360F*** H334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 %\nM = 10\n1\n027-007-00-1\nzinc hexacyanocobaltate(III), tertiary butyl alcohol/polypropylene glycol complex\n425-240-7\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n027-008-00-7\ncomplex of cobalt(III)-bis(N-phenyl-4-(5-ethylsulfonyl-2-hydroxyphenylazo)-3-hydroxynaphthylamide), hydrated(n H2O,2<n<3)\n427-390-9\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n027-009-00-2\ncobalt dinitrate\n233-402-1\n10141-05-6\nCarc. 1B\nMuta. 2\nRepr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F*** H334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360F*** H334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 %\nM = 10\n1\n027-010-00-8\ncobalt carbonate\n208-169-4\n513-79-1\nCarc. 1B\nMuta. 2\nRepr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F*** H334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360F*** H334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 % M=10\n1\n028-001-00-1\ntetracarbonylnickel;\nnickel tetracarbonyl\n236-669-2\n13463-39-3\nFlam. Liq. 2\nCarc. 2\nRepr. 1B\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH351\nH360D *** H330\nH400\nH410\nGHS02\nGHS06\nGHS08\nGHS09\nDgr\nH225\nH351\nH360D *** H330\nH410\n028-002-00-7\nnickel\n231-111-4\n7440-02-0\nCarc. 2\nSTOT RE 1\nSkin Sens. 1\nH351\nH372**\nH317\nGHS08\nGHS07\nDgr\nH351\nH372**\nH317\nS7\n028-002-01-4\nnickel powder;\n[particle diameter < 1mm]\n231-111-4\n7440-02-0\nCarc. 2\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 3\nH351\nH372**\nH317\nH412\nGHS08\nGHS07\nDgr\nH351\nH372**\nH317\nH412\n028-003-00-2\nnickel monoxide; [1]\nnickel oxide; [2]\nbunsenite [3]\n215-215-7[1]\n234-323-5[2]-[3]\n1313-99-1 [1]\n11099-02-8 [2]\n34492-97-2 [3]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 4\nH350i\nH372**\nH317\nH413\nGHS08\nGHS07\nDgr\nH350i\nH372**\nH317\nH413\n028-004-00-8\nnickel dioxide\n234-823-3\n12035-36-8\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 4\nH350i\nH372**\nH317\nH413\nGHS08\nGHS07\nDgr\nH350i\nH372**\nH317\nH413\n028-005-00-3\ndinickel trioxide\n215-217-8\n1314-06-3\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 4\nH350i\nH372**\nH317\nH413\nGHS08\nGHS07\nDgr\nH350i\nH372**\nH317\nH413\n028-006-00-9\nnickel (II) sulfide; [1]\nnickel sulfide; [2]\nmillerite [3]\n240-841-2[1]\n234-349-7[2]-[3]\n16812-54-7 [1]\n11113-75-0 [2]\n1314-04-1 [3]\nCarc. 1A\nMuta. 2\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH372**\nH317\nH410\n028-007-00-4\ntrinickel disulfide;\nnickel subsulfide; [1]\nheazlewoodite [2]\n234-829-6[1]\n-[2]\n12035-72-2 [1]\n12035-71-1 [2]\nCarc. 1A\nMuta. 2\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH372** H317\nH410\n028-008-00-X\nnickel dihydroxide; [1]\nnickel hydroxide [2]\n235-008-5 [1]\n234-348-1 [2]\n12054-48-7 [1]\n11113-74-9 [2]\nCarc. 1A\nRepr. 1B\nMuta. 2\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i H360D*** H341\nH372**\nH332\nH302\nH315\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H360D*** H341\nH372**\nH332\nH302\nH315\nH334\nH317\nH410\n028-009-00-5\nnickel sulfate\n232-104-9\n7786-81-4\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH315\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D*** H372** H332\nH302\nH315\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Irrit. 2; H315: C ≥ 20 %\nSkin Sens. 1; H317: C ≥\n0,01 %\nM = 1\n028-010-00-0\nnickel carbonate;\nbasic nickel carbonate;\ncarbonic acid, nickel (2+) salt; [1]\ncarbonic acid, nickel salt; [2]\n[μ-[carbonato(2-)-O:O']]dihydroxy trinickel; [3]\n[carbonato(2-)] tetrahydroxytrinickel [4]\n222-068-2 [1]\n240-408-8 [2]\n265-748-4 [3]\n235-715-9 [4]\n3333-67-3 [1]\n16337-84-1 [2]\n65405-96-1 [3]\n12607-70-4 [4]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH315\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH315\nH334\nH317\nH410\n028-011-00-6\nnickel dichloride\n231-743-0\n7718-54-9\nCarc. 1A Muta. 2\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H331\nH301\nH372**\nH315\nH334\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H331\nH301\nH372**\nH315\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % < C < 1 %\nSkin Irrit. 2; H315: C ≥ 20 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM = 1\n028-012-00-1\nnickel dinitrate; [1]\nnitric acid, nickel salt [2]\n236-068-5 [1]\n238-076-4 [2]\n13138-45-9 [1]\n14216-75-2 [2]\nOx. Sol. 2\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH315\nH318\nH334\nH317\nH400\nH410\nGHS03\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH272\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH315\nH318\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % < C < 1 %\nSkin Irrit. 2; H315: C ≥ 20 %\nSkin Sens. 1; H317 C ≥0,01 %\nM = 1\n028-013-00-7\nnickel matte\n273-749-6\n69012-50-6\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372**\nH317\nH410\n028-014-00-2\nslimes and sludges, copper electrolytic refining, decopperised, nickel sulfate\n295-859-3\n92129-57-2\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH315\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH315\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < %\nSkin Sens. 1; H317:C ≥ 0,01 %\nM=1\n028-015-00-8\nslimes and sludges, copper electrolyte refining, decopperised\n305-433-1\n94551-87-8\nCarc. 1A Muta. 2\nRepr. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\n028-016-00-3\nnickel diperchlorate;\nperchloric acid, nickel(II) salt\n237-124-1\n13637-71-3\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH314\nH334\nH317\nH400\nH410\nGHS05\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH314\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\n028-017-00-9\nnickel dipotassium bis(sulfate); [1]\ndiammonium nickel bis(sulfate) [2]\n237-563-9 [1]\n239-793-2 [2]\n13842-46-1 [1]\n15699-18-0 [2]\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C ≥ 0,01 %\nM=1\n028-018-00-4\nnickel bis(sulfamidate);\nnickel sulfamate\n237-396-1\n13770-89-3\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C ≥ 0,01 %\nM=1\n028-019-00-X\nnickel bis(tetrafluoroborate)\n238-753-4\n14708-14-6\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372** H334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥0,01 %\nM=1\n028-021-00-0\nnickel diformate; [1]\nformic acid, nickel salt; [2]\nformic acid, copper nickel salt [3]\n222-101-0 [1]\n239-946-6 [2]\n268-755-0 [3]\n3349-06-2 [1]\n15843-02-4 [2]\n68134-59-8 [3]\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372** H334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C ≥0,01 %\nM=1\n028-022-00-6\nnickel di(acetate); [1]\nnickel acetate [2]\n206-761-7 [1]\n239-086-1 [2]\n373-02-4 [1]\n14998-37-9 [2]\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH332\nH302\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C≥ 0,01 %\nM = 1\n028-024-00-7\nnickel dibenzoate\n209-046-8\n553-71-9\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C≥ 0,01 %\nM=1\n028-025-00-2\nnickel bis(4-cyclohexylbutyrate)\n223-463-2\n3906-55-6\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C ≥0,01 %\nM=1\n028-026-00-8\nnickel(II) stearate;\nnickel(II) octadecanoate\n218-744-1\n2223-95-2\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C;≥0,01 %\nM=1\n028-027-00-3\nnickel dilactate\n—\n16039-61-5\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372:C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\n028-028-00-9\nnickel(II) octanoate\n225-656-7\n4995-91-9\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nSkin Corr. 1A\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH314\nH334\nH317\nH400\nH410\nGHS05\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH314\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\n028-029-00-4\nnickel difluoride; [1]\nnickel dibromide; [2]\nnickel diiodide; [3]\nnickel potassium fluoride [4]\n233-071-3 [1]\n236-665-0 [2]\n236-666-6 [3]\n-[4]\n10028-18-9 [1]\n13462-88-9 [2]\n13462-90-3 [3]\n11132-10-8 [4]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372** H334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥0,01 %\nM=1\n028-030-00-X\nnickel hexafluorosilicate\n247-430-7\n26043-11-8\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C ≥ 0,01 %\nM=1\n028-031-00-5\nnickel selenate\n239-125-2\n15060-62-5\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C≥0,01 %\nM=1\n028-032-00-0\nnickel hydrogen phosphate; [1]\nnickel bis(dihydrogen phosphate); [2]\ntrinickel bis(orthophosphate); [3]\ndinickel diphosphate; [4]\nnickel bis(phosphinate); [5]\nnickel phosphinate; [6]\nphosphoric acid, calcium nickel salt; [7]\ndiphosphoric acid, nickel(II) salt[8]\n238-278-2 [1]\n242-522-3 [2]\n233-844-5 [3]\n238-426-6 [4]\n238-511-8 [5]\n252-840-4 [6]\n-[7]\n-[8]\n14332-34-4 [1]\n18718-11-1 [2]\n10381-36-9 [3]\n14448-18-1 [4]\n14507-36-9 [5]\n36026-88-7 [6]\n17169-61-8 [7]\n19372-20-4 [8]\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\n028-033-00-6\ndiammonium nickel hexacyanoferrate\n—\n74195-78-1\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i H372** H334\nH317\nH410\n028-034-00-1\nnickel dicyanide\n209-160-8\n557-19-7\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\nEUH032\n028-035-00-7\nnickel chromate\n238-766-5\n14721-18-7\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\n028-036-00-2\nnickel(II) silicate; [1]\ndinickel orthosilicate; [2]\nnickel silicate (3:4); [3]\nsilicic acid, nickel salt; [4]\ntrihydrogen hydroxybis[orthosilicato(4-)]trinickelate(3-) [5]\n244-578-4 [1]\n237-411-1 [2]\n250-788-7 [3]\n253-461-7 [4]\n235-688-3 [5]\n21784-78-1 [1]\n13775-54-7 [2]\n31748-25-1 [3]\n37321-15-6 [4]\n12519-85-6 [5]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372** H317\nH410\n028-037-00-8\ndinickel hexacyanoferrate\n238-946-3\n14874-78-3\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372** H317\nH410\n028-038-00-3\ntrinickel bis(arsenate);\nnickel(II) arsenate\n236-771-7\n13477-70-8\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH372** H317\nH410\n028-039-00-9\nnickel oxalate; [1]\noxalic acid, nickel salt [2]\n208-933-7 [1]\n243-867-2 [2]\n547-67-1 [1]\n20543-06-0 [2]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372** H317\nH410\n028-040-00-4\nnickel telluride\n235-260-6\n12142-88-0\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372** H317\nH410\n028-041-00-X\ntrinickel tetrasulfide\n—\n12137-12-1\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372** H317\nH410\n028-042-00-5\ntrinickel bis(arsenite)\n—\n74646-29-0\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372** H317\nH410\n028-043-00-0\ncobalt nickel gray periclase;\nC.I. Pigment Black 25; C.I. 77332; [1]\ncobalt nickel dioxide; [2]\ncobalt nickel oxide [3]\n269-051-6 [1]\n261-346-8 [2]\n-[3]\n68186-89-0 [1]\n58591-45-0 [2]\n12737-30-3 [3]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i H372** H317\n028-044-00-6\nnickel tin trioxide;\nnickel stannate\n234-824-9\n12035-38-0\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i H372**\nH317\n028-045-00-1\nnickel triuranium decaoxide\n239-876-6\n15780-33-3\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i H372**\nH317\n028-046-00-7\nnickel dithiocyanate\n237-205-1\n13689-92-4\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nEUH032\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C≥0,01 %\nM=1\n028-047-00-2\nnickel dichromate\n239-646-5\n15586-38-6\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372:C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317:C≥0,01 %\nM=1\n028-048-00-8\nnickel(II) selenite\n233-263-7\n10101-96-9\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i H372**\nH334\nH317\nH410\n028-049-00-3\nnickel selenide\n215-216-2\n1314-05-2\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372**\nH317\nH410\n028-050-00-9\nsilicic acid, lead nickel salt\n—\n68130-19-8\nCarc. 1A\nRepr. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH360Df H372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H360Df H372**\nH317\nH410\n028-051-00-4\nnickel diarsenide; [1]\nnickel arsenide [2]\n235-103-1 [1]\n248-169-1 [2]\n12068-61-0 [1]\n27016-75-7 [2]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372**\nH317\nH410\n028-052-00-X\nnickel barium titanium primrose priderite;\nC.I. Pigment Yellow 157; C.I. 77900\n271-853-6\n68610-24-2\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i H372**\nH317\n028-053-00-5\nnickel dichlorate; [1]\nnickel dibromate; [2]\nethyl hydrogen sulfate, nickel(II) salt [3]\n267-897-0 [1]\n238-596-1 [2]\n275-897-7 [3]\n67952-43-6 [1]\n14550-87-9 [2]\n71720-48-4 [3]\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < %\nSkin Sens. 1; H317:C≥0,01%1\nM=1\n028-054-00-0\nnickel(II) trifluoroacetate; [1]\nnickel(II) propionate; [2]\nnickel bis(benzenesulfonate); [3]\nnickel(II) hydrogen citrate; [4]\ncitric acid, ammonium nickel salt; [5]\ncitric acid, nickel salt; [6]\nnickel bis(2-ethylhexanoate); [7]\n2-ethylhexanoic acid, nickel salt; [8]\ndimethylhexanoic acid nickelsalt; [9]\nnickel(II) isooctanoate; [10]\nnickel isooctanoate; [11]\nnickel bis(isononanoate); [12]\nnickel(II) neononanoate; [13]\nnickel(II) isodecanoate; [14]\nnickel(II) neodecanoate; [15] neodecanoic acid, nickel salt;[16]\nnickel(II) neoundecanoate; [17]\nbis(d-gluconato-O 1,O 2)nickel; [18]\nnickel 3,5-bis(tert-butyl)-4-hydroxybenzoate (1:2); [19]\nnickel(II) palmitate; [20]\n(2-ethylhexanoato-O)(isononanoato-O)nickel; [21]\n(isononanoato-O)(isooctanoato-O)nickel; [22]\n(isooctanoato-O)(neodecanoato-O)nickel; [23]\n(2-ethylhexanoato-O)(isodecanoato-O)nickel; [24]\n2-ethylhexanoato-O)(neodecanoato-O)nickel; [25]\n(isodecanoato-O)(isooctanoato-O)nickel; [26]\n(isodecanoato-O)(isononanoato-O)nickel; [27]\n(isononanoato-O)(neodecanoato-O)nickel; [28]\nfatty acids, C6-19-branched, nickel salts; [29]\nfatty acids, C 8-18 and C18-unsaturated, nickel salts; [30]\n2,7-naphthalenedisulfonic acid, nickel(II) salt; [31]\n240-235-8 [1]\n222-102-6 [2]\n254-642-3 [3]\n242-533-3 [4]\n242-161-1 [5]\n245-119-0 [6]\n224-699-9 [7]\n231-480-1 [8]\n301-323-2 [9]\n249-555-2 [10]\n248-585-3 [11]\n284-349-6 [12]\n300-094-6 [13]\n287-468-1 [14]\n287-469-7 [15]\n257-447-1 [16]\n300-093-0 [17]\n276-205-6 [18]\n258-051-1 [19]\n294-302-1 [29]\n283-972-0 [30]\n-[31]\n237-138-8 [20]\n287-470-2 [21]\n287-471-8 [22]\n284-347-5 [23]\n284-351-7 [24]\n285-698-7 [25]\n285-909-2 [26]\n284-348-0 [27]\n287-592-6 [28]\n16083-14-0 [1]\n3349-08-4 [2]\n39819-65-3 [3]\n18721-51-2 [4]\n18283-82-4 [5]\n22605-92-1 [6]\n4454-16-4 [7]\n7580-31-6 [8]\n93983-68-7 [9]\n29317-63-3 [10]\n27637-46-3 [11]\n84852-37-9 [12]\n93920-10-6 [13]\n85508-43-6 [14]\n85508-44-7 [15]\n51818-56-5 [16]\n93920-09-3 [17]\n71957-07-8 [18]\n52625-25-9 [19]\n13654-40-5 [20]\n85508-45-8 [21]\n85508-46-9 [22]\n84852-35-7 [23]\n84852-39-1 [24]\n85135-77-9\n[25]\n85166-19-4 [26]\n84852-36-8 [27]\n85551-28-6 [28]\n91697-41-5 [29]\n84776-45-4 [30]\n72319-19-8 [31]\nCarc. 1A Muta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D*** H372**\nH334\nH317\nH410\nSTOT RE 1;\nH372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥\n0,01 % M=1\n028-055-00-6\nnickel(II) sulfite; [1]\nnickel tellurium trioxide; [2]\nnickel tellurium tetraoxide; [3] molybdenum nickel hydroxide oxide phosphate [4]\n231-827-7 [1]\n239-967-0 [2]\n239-974-9 [3]\n268-585-7 [4]\n7757-95-1 [1]\n15851-52-2 [2]\n15852-21-8 [3]\n68130-36-9 [4]\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i H372**\nH334\nH317\nH410\n028-056-00-1\nnickel boride (NiB); [1]\ndinickel boride; [2]\ntrinickel boride; [3]\nnickel boride; [4]\ndinickel silicide; [5]\nnickel disilicide; [6]\ndinickel phosphide; [7]\nnickel boron phosphide [8]\n234-493-0 [1]\n234-494-6 [2]\n234-495-1 [3]\n235-723-2 [4]\n235-033-1 [5]\n235-379-3 [6]\n234-828-0 [7]\n-[8]\n12007-00-0 [1]\n12007-01-1 [2]\n12007-02-2 [3]\n12619-90-8 [4]\n12059-14-2 [5]\n12201-89-7 [6]\n12035-64-2 [7]\n65229-23-4 [8]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i H372**\nH317\nH410\n028-057-00-7\ndialuminium nickel tetraoxide; [1]\nnickel titanium trioxide; [2]\nnickel titanium oxide; [3]\nnickel divanadium hexaoxide; [4]\ncobalt dimolybdenum nickel octaoxide; [5]\nnickel zirkonium trioxide; [6]\nmolybdenum nickel tetraoxide; [7]\nnickel tungsten tetraoxide; [8]\nolivine, nickel green; [9]\nlithium nickel dioxide; [10]\nmolybdenum nickel oxide; [11]\n234-454-8 [1]\n234-825-4 [2]\n235-752-0 [3]\n257-970-5 [4]\n268-169-5 [5]\n274-755-1 [6]\n238-034-5 [7]\n238-032-4 [8]\n271-112-7 [9]\n-[10]\n-[11]\n12004-35-2 [1]\n12035-39-1 [2]\n12653-76-8 [3]\n52502-12-2 [4]\n68016-03-5 [5]\n70692-93-2 [6]\n14177-55-0 [7]\n14177-51-6 [8]\n68515-84-4 [9]\n12031-65-1 [10]\n12673-58-4 [11]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i H372**\nH317\n028-058-00-2\ncobalt lithium nickel oxide\n442-750-5\n—\nCarc. 1A\nAcute Tox. 2 *\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH330\nH372**\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350i\nH330\nH372**\nH317\nH410\n029-001-00-4\ncopper chloride;\ncopper (I) chloride;\ncuprous chloride\n231-842-9\n7758-89-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH400\nH410\n029-003-00-5\nnaphthenic acids, copper salts;\ncopper naphthenate\n215-657-0\n1338-02-9\nFlam. Liq. 3\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH302\nH400\nH410\nGHS02\nGHS07\nGHS09\nWng\nH226\nH302\nH410\n029-004-00-0\ncopper sulphate\n231-847-6\n7758-98-7\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH315\nH410\n029-005-00-6\n(tris(chloromethyl)phthalocyaninato)copper(II), reaction products with N-methylpiperazine and methoxyacetic acid\n401-260-1\n—\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n029-006-00-1\ntris(octadec-9-enylammonium) (trisulfonatophthalocyaninato)copper(II)\n403-210-4\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n029-007-00-7\n(trisodium (2-((3-(6-(2-chloro-5-sulfonato)anilino)-4-(3-carboxypyridinio)-1,3,5-triazin-2-ylamino)-2-oxido-5-sulfonatophenylazo)phenylmethylazo)-4-sulfonatobenzoato)copper(3-)) hydroxide\n404-670-9\n89797-01-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\nG\n029-008-00-2\ncopper(II) methanesulfonate\n405-400-2\n54253-62-2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n029-009-00-8\nphthalocyanine-N-[3-(diethylamino)propyl]sulfonamide copper complex\n413-650-9\n93971-95-0\nAquatic Chronic 3\nH412\n—\nH412\n029-010-00-3\nreaction mass of compounds from (dodecakis(p-tolylthio)phthalocyaninato)copper(II)to (hexadecakis(p-tolylthio)phthalocyaninato)copper(II)\n407-700-9\n101408-30-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n029-011-00-9\nsodium [29H,31H-phthalocyaninato-(2-)-N29,N30,N31,N32]-((3-(N-methyl-N-(2-hydroxyethyl)amino)propyl)amino)sulfonyl-sulfonato, copper complex\n412-730-0\n150522-10-4\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n029-012-00-4\nsodium ((N-(3-trimethylammoniopropyl)sulfamoyl)methylsulfonatophthalocyaninato)copper(II)\n407-340-2\n124719-24-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n029-013-00-X\ntrisodium(2-(α-(3-(4-chloro-6-(2-(2-(vinylsulfonyl)ethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-2-oxido-5-sulfonatophenylazo)benzylidenehydrazino)-4-sulfonatobenzoato)copper(II)\n407-580-8\n130201-51-3\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n029-014-00-5\nreaction mass of: 2,2'-[[cis-1,2-cyclohexanediylbis(nitrilomethylidene)]bis[phenolate]](2-)N, N',O, O'-copper complex;2,2'-[[trans-1,2-cyclohexanediylbis(nitrilomethylidyne)]bis[phenolate]](2-)N, N',O, O'-copper complex\n419-610-7\n171866-24-3\nSTOT RE 2 *\nAquatic Chronic 2\nH373**\nH411\nGHS08\nGHS09\nWng\nH373**\nH411\n030-001-00-1\nzinc powder — zinc dust (pyrophoric)\n231-175-3\n7440-66-6\nWater-react. 1\nPyr. Sol. 1\nAquatic Acute 1\nAquatic Chronic 1\nH260\nH250\nH400\nH410\nGHS02\nGHS09\nDgr\nH260\nH250\nH410\nT\n030-001-01-9\nzinc powder — zinc dust (stabilised)\n231-175-3\n7440-66-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n030-003-00-2\nzinc chloride\n231-592-0\n7646-85-7\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH410\nSTOT SE 3; H335: C ≥ 5 %\n030-004-00-8\ndimethylzinc; [1]\ndiethylzinc [2]\n208-884-1 [1]\n209-161-3 [2]\n544-97-8 [1]\n557-20-0 [2]\nPyr. Liq. 1\nWater-react. 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH250\nH260\nH314\nH400\nH410\nGHS02\nGHS05\nGHS09\nDgr\nH250\nH260\nH314\nH410\nEUH014\n030-005-00-3\ndiamminediisocyanatozinc\n401-610-3\n—\nAcute Tox. 4 *\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nH302\nH318\nH334\nH317\nH400\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH302\nH318\nH334\nH317\nH400\n030-006-00-9\nzinc sulphate (hydrous) (mono-, hexa-and hepta hydrate); [1]\nzinc sulphate (anhydrous) [2]\n231-793-3 [1]\n231-793-3 [2]\n7446-19-7 [1]\n7733-02-0 [2]\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n030-007-00-4\nbis(3,5-di-tert-butylsalicylato-O 1,O 2)zinc\n403-360-0\n42405-40-3\nFlam. Sol. 1\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH228\nH302\nH400\nH410\nGHS02\nGHS07\nGHS09\nDgr\nH228\nH302\nH410\nT\n030-008-00-X\nhydroxo(2-(benzenesulfonamido)benzoato)zinc(II)\n403-750-0\n113036-91-2\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH411\nGHS07\nGHS09\nWng\nH332\nH411\n030-009-00-5\nzinc-bis(4-(n-octyloxycarbonylamino)salicylate) dihydrate\n417-130-2\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n030-010-00-0\n2-dodec-1-enylbutanedioic acid,4-methyl ester zinc salt\n430-740-3\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n030-011-00-6\ntrizinc bis(orthophosphate)\n231-944-3\n7779-90-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n030-012-00-1\naluminium-magnesium-zinc-carbonate-hydroxide\n423-570-6\n169314-88-9\nAquatic Chronic 4\nH413\nH413\n030-013-00-7\nzinc oxide\n215-222-5\n1314-13-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n030-015-00-8\ntetrazinc(2+)bis(hexacyanocobalt(3+))diacetate\n440-060-9\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n033-001-00-X\narsenic\n231-148-6\n7440-38-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH410\n033-002-00-5\narsenic compounds, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH410\n*\nA1\n033-003-00-0\ndiarsenic trioxide;\narsenic trioxide\n215-481-4\n1327-53-3\nCarc. 1A\nAcute Tox. 2 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH300\nH314\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH350\nH300\nH314\nH410\n033-004-00-6\ndiarsenic pentaoxide;\narsenic pentoxide;\narsenic oxide\n215-116-9\n1303-28-2\nCarc. 1A\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH331\nH301\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH301\nH410\n033-005-00-1\narsenic acid and it salts with the exception of those specified elsewhere in this Annex\n—\n—\nCarc. 1A\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH331\nH301\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH301\nH410\nA\n033-006-00-7\narsine\n232-066-3\n7784-42-1\nFlam. Gas 1\nPress. Gas\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH220\nH330\nH373 **\nH400\nH410\nGHS02\nGHS04\nGHS06\nGHS08\nGHS09\nDgr\nH220\nH330\nH373 ** H410\nU\n033-007-00-2\ntert-butylarsine\n423-320-6\n4262-43-5\nPyr. Liq. 1\nAcute Tox. 2 *\nH250\nH330\nGHS02\nGHS06\nDgr\nH250\nH330\n034-001-00-2\nselenium\n231-957-4\n7782-49-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 4\nH331\nH301\nH373 **\nH413\nGHS06\nGHS08\nDgr\nH331\nH301\nH373 ** H413\n034-002-00-8\nselenium compounds with the exception of cadmium sulphoselenide and those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH373**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH301\nH373**\nH410\nA\n034-003-00-3\nsodium selenite\n233-267-9\n10102-18-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Chronic 2\nH300\nH331\nH317\nH411\nGHS06\nGHS09\nDgr\nH300\nH331\nH317\nH411\nEUH031\n035-001-00-5\nbromine\n231-778-1\n7726-95-6\nAcute Tox. 2 *\nSkin Corr. 1A\nAquatic Acute 1\nH330\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH314\nH400\n035-002-00-0\nhydrogen bromide\n233-113-0\n10035-10-6\nPress. Gas\nSkin Corr. 1A\nSTOT SE 3\nH314\nH335\nGHS04\nGHS05\nGHS07\nDgr\nH314\nH335\nU\n035-002-01-8\nhydrobromic acid … %\n—\n—\nSkin Corr. 1B\nSTOT SE 3\nH314\nH335\nGHS05\nGHS07\nDgr\nH314\nH335\nSkin Corr. 1B; H314: C ≥ 40 % Skin Irrit. 2; H315: 10 % ≤ C < 40 %\nEye Irrit. 2; H319: 10 % ≤ C < 40 %\nSTOT SE 3; H335: C ≥ 10 %\nB\n035-003-00-6\npotassium bromate\n231-829-8\n7758-01-2\nOx. Sol. 1\nCarc. 1B\nAcute Tox. 3 *\nH271\nH350\nH301\nGHS03\nGHS06\nGHS08\nDgr\nH271\nH350\nH301\n035-004-00-1\n2-hydroxyethylammonium perbromide\n407-440-6\n—\nOx. Sol. 2 ****\nAcute Tox. 4 *\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Acute 1\nH272\nH302\nH314\nH317\nH400\nGHS03\nGHS05\nGHS07\nGHS09\nDgr\nH272\nH302\nH314\nH317\nH400\n040-001-00-3\nzirconium powder (pyrophoric)\n231-176-9\n7440-67-7\nWater-react. 1\nPyr. Sol. 1\nH260\nH250\nGHS02\nDgr\nH260\nH250\nT\n040-002-00-9\nzirconium powder, dry (non pyrophoric)\n—\n—\nSelf-heat. 1\nH251\nGHS02\nDgr\nH251\nT\n040-003-00-4\nreaction product of 3,5-di-tert-butylsalicylic acid and zirconium oxychloride, dehydrated, basic Zr: DTBS= 1.0:1.0 to 1.0: 1.5\n430-610-6\n226996-19-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n042-001-00-9\nmolybdenum trioxide\n215-204-7\n1313-27-5\nCarc. 2\nEye Irrit. 2\nSTOT SE 3\nH351\nH319\nH335\nGHS08\nGHS07\nWng\nH351\nH319\nH335\n042-002-00-4\ntetrakis(dimethylditetradecylammonium) hexa-μ-oxotetra-μ3-oxodi-μ5-oxotetradecaoxooctamolybdate(4-)\n404-760-8\n117342-25-3\nAcute Tox. 3 *\nEye Dam. 1\nH331\nH318\nGHS06\nGHS05\nDgr\nH331\nH318\n042-003-00-X\ntetrakis(trimethylhexadecylammonium) hexa-mu-oxotetra-mu3-oxodi-mu5-oxotetradecaoxooctamolybdate(4-)\n404-860-1\n116810-46-9\nFlam. Sol. 1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH228\nH318\nH400\nH410\nGHS02\nGHS05\nGHS09\nDgr\nH228\nH318\nH410\nT\n042-004-00-5\nreaction product of ammonium molybdate and C12-C24-diethoxylated alkylamine (1:5-1:3)\n412-780-3\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH315\nH317\nH411\n042-005-00-0\nreaction mass of: mono-and di-glycerols of canola oil;\ncanola oil acid amide of branched 1,3-propanediamine, N-[3-(tridecyloxy)-propyl];\nN, N-diorgano dithiocarbamate molybdenum complex\n434-240-6\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n046-001-00-X\ntetraammine palladium (II)hydrogen carbonate\n425-270-0\n134620-00-1\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373** H318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH302\nH373** H318\nH317\nH410\n047-001-00-2\nsilver nitrate\n231-853-9\n7761-88-8\nOx. Sol. 2\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH314\nH400\nH410\nGHS03\nGHS05\nGHS09\nDgr\nH272\nH314\nH410\n047-002-00-8\npolyphosphoric acid, copper, sodium, magnesium, calcium, silver and zinc salt\n416-850-4\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n048-001-00-5\ncadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\n*\nA1\n048-002-00-0\ncadmium (non-pyrophoric); [1]\ncadmium oxide (non-pyrophoric) [2]\n231-152-8 [1]\n215-146-2 [2]\n7440-43-9 [1]\n1306-19-0 [2]\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 2 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH341\nH361fd\nH330\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH361fd\nH330\nH372 ** H410\n048-003-00-6\ncadmium diformate;\ncadmiumformate\n224-729-0\n4464-23-7\nAcute Tox. 3 *\nAcute Tox. 3 *\nCarc. 2\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH351\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH301\nH351\nH373 ** H410\n*\nSTOT RE 2; H373: C ≥0,25 %\n048-004-00-1\ncadmium cyanide\n208-829-1\n542-83-6\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nCarc. 2\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH351\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH351\nH373 ** H410\nEUH032\nSTOT RE 2; H373: C ≥0,1 %\nEUH032:C≥1 %\n048-005-00-7\ncadmiumhexafluorosilicate(2-);\ncadmium fluorosilica\n241-084-0\n17010-21-8\nAcute Tox. 3 *\nAcute Tox. 3 *\nCarc. 2\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH351\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH301\nH351\nH373 ** H410\n*\nSTOT RE 2; H373: C ≥0,1 %\n048-006-00-2\ncadmium fluoride\n232-222-0\n7790-79-6\nCarc. 1B\nMuta. 1B\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH340\nH360FD H330\nH301\nH372 ** H410\nCarc. 1B; H350: C ≥ 0,01 %\n* oral\nSTOT RE 1; H372: C ≥ 7 % STOT RE 2:\n0,1 % ≤ C <7 %\n048-007-00-8\ncadmium iodide\n232-223-6\n7790-80-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nCarc. 2\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH351\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH301\nH351\nH373 ** H410\n*\nSTOT RE 2; H373: C ≥ 0,1 %\n048-008-00-3\ncadmium chloride\n233-296-7\n10108-64-2\nCarc. 1B\nMuta. 1B\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH340\nH360FD H330\nH301\nH372 ** H410\nCarc. 1B; H350: C ≥ 0,01 %\n* oral\nSTOT RE 1; H372: C ≥ 7 % STOT RE 2; H373: 0,1 % ≤ C < 7 %\n048-009-00-9\ncadmium sulphate\n233-331-6\n10124-36-4\nCarc. 1B\nMuta. 1B\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH360FD\nH330\nH301\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH340\nH360FD H330\nH301\nH372 ** H410\nCarc. 1B; H350: C ≥ 0,01 %\n* oral\nSTOT RE 1; H372: C ≥ 7 % STOT RE 2; H373 0,1 % ≤ C < 7 %\n048-010-00-4\ncadmium sulphide\n215-147-8\n1306-23-6\nCarc. 1B\nMuta. 2\nRepr. 2\nSTOT RE 1\nAcute Tox. 4 *\nAquatic Chronic 4\nH350\nH341\nH361fd\nH372 **\nH302\nH413\nGHS08\nGHS07\nDgr\nH350\nH341\nH361fd\nH372 ** H302\nH413\n*\nSTOT RE 1; H372: C ≥ 10 % STOT RE 2; H373: 0,1 % ≤ C < 10 %\n1\n048-011-00-X\ncadmium (pyrophoric)\n231-152-8\n7440-43-9\nPyr. Sol. 1\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 2 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH250\nH350\nH341\nH361fd\nH330\nH372 **\nH400\nH410\nGHS02\nGHS06\nGHS08\nGHS09\nDgr\nH250\nH350\nH341\nH361fd\nH330\nH372 ** H410\n050-001-00-5\ntin tetrachloride;\nstannic chloride\n231-588-9\n7646-78-8\nSkin Corr. 1B\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\nSTOT SE 3; H335:C≥5 %\n050-002-00-0\ncyhexatin (ISO); hydroxytricyclohexylstannane; tri(cyclohexyl)tin hydroxide\n236-049-1\n13121-70-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\nM=1000\n050-003-00-6\nfentin acetate (ISO);\ntriphenyltin acetate\n212-984-0\n900-95-8\nCarc. 2\nRepr. 2\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361d*** H330\nH311\nH301\nH372**\nH335\nH315\nH318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH351\nH361d*** H330\nH311\nH301\nH372**\nH335\nH315\nH318\nH410\nM=10\n050-004-00-1\nfentin hydroxide (ISO);\ntriphenyltin hydroxide\n200-990-6\n76-87-9\nCarc. 2\nRepr. 2\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361d*** H330\nH311\nH301\nH372**\nH335\nH315\nH318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH351\nH361d*** H330\nH311\nH301\nH372**\nH335\nH315\nH318\nH410\nM=10\n050-005-00-7\ntrimethyltin compounds, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\n*\nA1\n050-006-00-2\ntriethyltin compounds, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\n*\nA1\n050-007-00-8\ntripropyltin compounds, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\n*\nA1\n050-009-00-9\nfluorotripentylstannane;[1]\nhexapentyldistannoxane [2]\n243-546-7 [1]\n247-143-7 [2]\n20153-49-5 [1]\n25637-27-8 [2]\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\n*\n1\n050-010-00-4\nfluorotrihexylstannane\n243-547-2\n20153-50-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\n*\n1\n050-011-00-X\ntriphenyltin compounds, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\n* M=100\nA1\n050-012-00-5\ntetracyclohexylstannane; [1] chlorotricyclohexylstannane; [2] butyltricyclohexylstannane [3]\n215-910-5 [1]\n221-437-5 [2]\n230-358-5 [3]\n1449-55-4 [1]\n3091-32-5 [2]\n7067-44-9 [3]\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\n*\nA1\n050-013-00-0\ntrioctyltin compounds, with the exception of those specified elsewhere in this Annex\n—\n—\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 4\nH319\nH335\nH315\nH413\nGHS07\nWng\nH319\nH335\nH315\nH413\nSkin Irrit. 2; H315: C ≥ 1 % Eye Irrit.2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 %\nA1\n050-017-00-2\nfenbutatin oxide (ISO);\nbis(tris(2-methyl-2-phenylpropyl)tin)oxide\n236-407-7\n13356-08-6\nAcute Tox. 2 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH319\nH315\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH319\nH315\nH410\n050-018-00-8\ntin(II) methanesulphonate\n401-640-7\n53408-94-9\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH302\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH302\nH317\nH411\n050-019-00-3\nazocyclotin (ISO);\n1-(tricyclohexylstannyl)-1H-1,2,4-triazole\n255-209-1\n41083-11-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH301\nH335\nH315\nH318\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH301\nH335\nH315\nH318\nH410\n050-020-00-9\ntrioctylstannane\n413-320-4\n869-59-0\nSTOT RE 1\nSkin Irrit. 2\nAquatic Chronic 4\nH372 **\nH315\nH413\nGHS08\nGHS07\nDgr\nH372 ** H315\nH413\n050-021-00-4\ndichlorodioctyl stannane\n222-583-2\n3542-36-7\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Chronic 3\nH331\nH372**\nH412\nGHS06\nGHS08\nDgr\nH331\nH372**\nH412\n050-022-00-X\ndibutyltin dichloride;\n(DBTC)\n211-670-0\n683-18-1\nMuta. 2\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH360FD\nH330\nH301\nH312\nH372**\nH314\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH341\nH360FD H330\nH301\nH312\nH372**\nH314\nH410\nSkin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 0,01 % ≤ C < 5 %\nEye Dam.1; H318: 3 % ≤ C\n< 5 %\nEye Irrit. 2; H319: 0,01 % ≤ C < 3 %\nM=10\n050-023-00-5\nreaction mass of: bis[(2-ethyl-1-oxohexyl)oxy]dioctyl stannane;\nbis[((2-ethyl-1-oxohexyl)oxy)dioctylstannyl]oxide; bis(1-phenyl-1,3-decanedionyl)dioctyl stannane;\n((2-ethyl-1-oxohexyl)oxy)-(1-phenyl-1,3-decanedionyl)dioctyl stannane\n422-920-5\n—\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\nM=10\n050-024-00-0\nreaction mass of: tri-p-tolyltin hydroxide; hexa-p-tolyl-distannoxane\n432-230-6\n—\nSTOT RE 1\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH372**\nH302\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH372**\nH302\nH315\nH318\nH317\nH410\n050-025-00-6\ntrichloromethylstannane\n213-608-8\n993-16-8\nRepr. 2\nH361d\nGHS08\nWng\nH361d\n050-026-00-1\n2-ethylhexyl 10-ethyl-4-[[2-[(2-ethylhexyl)oxy]-2-oxoethyl]thio]-4-methyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate\n260-828-5\n57583-34-3\nRepr. 2\nH361d\nGHS08\nWng\nH361d\n050-027-00-7\n2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate\n239-622-4\n15571-58-1\nRepr. 1B\nH360D\nGHS08\nDgr\nH360D\n050-028-00-2\n2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate\n260-829-0\n57583-35-4\nRepr. 2\nAcute Tox. 4\nSTOT RE 1\nSkin Sens. 1A\nH361d\nH302\nH372\n(nervous system, immune system)\nH317\nGHS08\nGHS07\nDgr\nH361d\nH302\nH372 (nervous system, immune system)\nH317\n050-029-00-8\ndimethyltin dichloride\n212-039-2\n753-73-1\nRepr. 2\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 3\nSTOT RE 1\nSkin Corr. 1B\nH361d\nH330\nH301\nH311\nH372\n(nervous system, immune system)\nH314\nGHS08\nGHS06\nGHS05\nDgr\nH361d\nH330\nH301\nH311\nH372 (nervous system, immune system)\nH314\nEUH071\n051-001-00-8\nantimony trichloride\n233-047-2\n10025-91-9\nSkin Corr. 1B\nAquatic Chronic 2\nH314\nH411\nGHS05\nGHS09\nDgr\nH314\nH411\nSTOT SE3; H335: C ≥ 5 %\n051-002-00-3\nantimony pentachloride\n231-601-8\n7647-18-9\nSkin Corr. 1B\nAquatic Chronic 2\nH314\nH411\nGHS05\nGHS09\nDgr\nH314\nH411\nSTOT SE 3; H335: C ≥ 5 %\n051-003-00-9\nantimony compounds, with the exception of the tetroxide (Sb2O4), pentoxide (Sb2O5), trisulphide (Sb2S3), pentasulphide (Sb2S5) and those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH302\nH411\nGHS07\nGHS09\nWng\nH332\nH302\nH411\n*\nA1\n051-004-00-4\nantimony trifluoride\n232-009-2\n7783-56-4\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH331\nH311\nH301\nH411\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH411\n051-005-00-X\nantimony trioxide\n215-175-0\n1309-64-4\nCarc. 2\nH351\nGHS08\nWng\nH351\n051-006-00-5\ndiphenyl(4-phenylthiophenyl)sulfonium hexafluoroantimonate\n403-500-0\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n051-007-00-0\nbis(4-dodecylphenyl)iodonium hexafluoroantimonate\n404-420-9\n71786-70-4\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n053-001-00-3\niodine\n231-442-4\n7553-56-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nH332\nH312\nH400\nGHS07\nGHS09\nWng\nH332\nH312\nH400\n053-002-00-9\nhydrogen iodide\n233-109-9\n10034-85-2\nPress. Gas\nSkin Corr. 1A\nH314\nGHS04\nGHS05\nDgr\nH314\nSkin Corr. 1A; H314: C ≥ 10 % Skin Corr. 1B; H314: 0,2 % ≤ C < 10 %\nSkin Irrit. 2; H315: 0,02 % ≤ C < 0,2 %\nEye Irrit. 2; H319: 0,02 % ≤ C < 0,2 %\nSTOT SE 3; H335: C ≥0,02 %\nU5\n053-002-01-6\nhydriodic acid … %\n—\n—\nSkin Corr. 1B\nH314\nGHS05\nDgr\nSkin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 %\nEye Irrit. 2; H319: 10 % ≤ C < 25 %\nB\n053-003-00-4\niodoxybenzene\n—\n696-33-3\nExpl. ****\n****\n****\n****\n053-004-00-X\ncalcium iodoxybenzoate\n—\n—\nExpl. ****\n****\n****\n****\nC\n053-005-00-5\n(4-(1-methylethyl)phenyl)-(4-methylphenyl)iodonium tetrakis(pentafluorophenyl)borate(1-)\n422-960-3\n178233-72-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373 **\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH312\nH302\nH373 ** H410\n056-001-00-1\nbarium peroxide\n215-128-4\n1304-29-6\nOx. Sol. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nH272\nH332\nH302\nGHS03\nGHS07\nDgr\nH272\nH332\nH302\n056-002-00-7\nbarium salts, with the exception of barium sulphate, salts of 1-azo-2-hydroxynaphthalenyl aryl sulphonic acid, and of salts specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH302\nGHS07\nWng\nH332\nH302\n*\nA1\n056-003-00-2\nbarium carbonate\n208-167-3\n513-77-9\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n056-004-00-8\nbarium chloride\n233-788-1\n10361-37-2\nAcute Tox. 3 *\nAcute Tox. 4 *\nH301\nH332\nGHS06\nDgr\nH301\nH332\n064-001-00-8\ngadolinium(III)sulfite trihydrate\n456-900-2\n51285-81-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n072-001-00-4\nhafnium tetra-n-butoxide\n411-740-2\n22411-22-9\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n074-001-00-X\nhexasodium tungstate hydrate\n412-770-9\n12141-67-2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n074-002-00-5\nreaction products of tungsten hexachloride with 2-methylpropan-2-ol, nonylphenol and pentane-2,4-dione\n408-250-6\n—\nFlam. Liq. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH332\nH314\nH317\nH400\nH410\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH225\nH332\nH314\nH317\nH410\n076-001-00-5\nosmium tetraoxide;\nosmic acid\n244-058-7\n20816-12-0\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSkin Corr. 1B\nH330\nH310\nH300\nH314\nGHS06\nGHS05\nDgr\nH330\nH310\nH300\nH314\n078-001-00-0\ntetrachloroplatinates with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH318\nH334\nH317\nA\n078-002-00-6\ndiammonium tetrachloroplatinate\n237-499-1\n13820-41-2\nAcute Tox. 3 *\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH315\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH315\nH318\nH334\nH317\n078-003-00-1\ndisodium tetrachloroplatinate\n233-051-4\n10026-00-3\nAcute Tox. 3 *\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH315\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH315\nH318\nH334\nH317\n078-004-00-7\ndipotassium tetrachloroplatinate\n233-050-9\n10025-99-7\nAcute Tox. 3 *\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH315\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH315\nH318\nH334\nH317\n078-005-00-2\nhexachloroplatinates with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH318\nH334\nH317\nA\n078-006-00-8\ndisodium hexachloroplatinate\n240-983-5\n16923-58-3\nAcute Tox. 3 *\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH318\nH334\nH317\n078-007-00-3\ndipotassium hexachloroplatinate\n240-979-3\n16921-30-5\nAcute Tox. 3 *\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH318\nH334\nH317\n078-008-00-9\ndiammonium hexachloroplatinate\n240-973-0\n16919-58-7\nAcute Tox. 3 *\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH301\nH318\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH318\nH334\nH317\n078-009-00-4\nhexachloroplatinic acid\n241-010-7\n16941-12-1\nAcute Tox. 3 *\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nH301\nH314\nH334\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH301\nH314\nH334\nH317\n078-010-00-X\ntetraammine platinum (II)\nhydrogen carbonate\n426-730-3\n123439-82-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n078-011-00-5\nhydroxydisulfito platinum(II)acid\n423-310-1\n61420-92-6\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1A\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH373\nH314\nH334\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373\nH314\nH334\nH317\nH412\n078-012-00-0\nplatinum(IV) nitrate/nitric acid solution\n432-400-1\n—\nSkin Corr. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n080-001-00-0\nmercury\n231-106-7\n7439-97-6\nRepr. 1B\nAcute Tox. 2 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D*** H330\nH372**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360D*** H330\nH372**\nH410\n080-002-00-6\nInorganic compounds of mercury with the exception of mercuric sulphide and those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 ** H410\n*\nSTOT RE 2; H373: C ≥ 0,1 %\nA1\n080-003-00-1\ndimercury dichloride;\nmercurous chloride;\ncalomel\n233-307-5\n10112-91-1\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH335\nH315\nH410\n080-004-00-7\norganic compounds of mercury with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 ** H410\n*\nSTOT RE 2; H373: C ≥0,1 %\nA1\n080-005-00-2\nmercury difulminate;\nmercuric fulminate;\nfulminate of mercury\n211-057-8\n628-86-4\nUnst. Expl.\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH200\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH200\nH331\nH311\nH301\nH373 ** H400\nH410\n080-005-01-X\nmercury difulminate;\nmercuric fulminate;\nfulminate of mercury [≥ 20 % phlegmatiser]\n211-057-8\n628-86-4\nExpl. 1.1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH331\nH311\nH301\nH373 ** H400\nH410\n080-006-00-8\ndimercury dicyanide oxide;\nmercuric oxycyanide\n215-629-8\n1335-31-5\nExpl. 1.1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH331\nH311\nH301\nH373**\nH400\nH410\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH331\nH311\nH301\nH373**\nH410\n080-007-00-3\ndimethylmercury; [1]\ndiethylmercury [2]\n209-805-3 [1]\n211-000-7 [2]\n593-74-8 [1]\n627-44-1 [2]\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 ** H410\n*\nSTOT RE 2; H373: C ≥0,05 %\n1\n080-008-00-9\nphenylmercury nitrate; [1] phenylmercury hydroxide; [2]\nbasic phenylmercury nitrate [3]\n200-242-9 [1]\n202-866-7 [2]\n-[3]\n55-68-5 [1]\n100-57-2 [2]\n8003-05-2 [3]\nAcute Tox. 3 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH372 **\nH314\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH301\nH372 ** H314\nH410\n080-009-00-4\n2-methoxyethylmercury chloride\n204-659-7\n123-88-6\nAcute Tox. 3 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH372 **\nH314\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH301\nH372 ** H314\nH410\n080-010-00-X\nmercury dichloride;\nmercuric chloride\n231-299-8\n7487-94-7\nMuta. 2\nRepr. 2\nAcute Tox. 2 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH361f*** H300\nH372**\nH314\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH341\nH361f*** H300\nH372**\nH314\nH410\n080-011-00-5\nphenylmercury acetate\n200-532-5\n62-38-4\nAcute Tox. 3 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH372 **\nH314\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH301\nH372 ** H314\nH410\n081-001-00-3\nthallium\n231-138-1\n7440-28-0\nAcute Tox. 2 *\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 4\nH330\nH300\nH373 **\nH413\nGHS06\nGHS08\nDgr\nH330\nH300\nH373 ** H413\n081-002-00-9\nthallium compounds, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 2\nH330\nH300\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH300\nH373 ** H411\nA\n081-003-00-4\ndithallium sulphate;\nthallic sulphate\n231-201-3\n7446-18-6\nAcute Tox. 2 *\nSTOT RE 1\nSkin Irrit. 2\nAquatic Chronic 2\nH300\nH372 **\nH315\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH300\nH372 ** H315\nH411\n082-001-00-6\nlead compounds with the exception of those specified elsewhere in this Annex\n—\n—\nRepr. 1A\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH332\nH302\nH373 **\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360Df\nH332\nH302\nH373 ** H410\nRepr.2 H361f: C ≥ 2,5 %\n*\nSTOT RE 2; H373: C ≥0,5 %\nA1\n082-002-00-1\nlead alkyls\n—\n—\nRepr. 1A\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH330\nH310\nH300\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360Df\nH330\nH310\nH300\nH373 ** H410\nRepr.1A; H360D: C≥ 0,1 %\n*\nSTOT RE 2; H373: C ≥0,05 %\nA1\n082-003-00-7\nlead diazide;\nlead azide\n236-542-1\n13424-46-9\nUnst. Expl. Repr. 1A\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH200\nH360Df\nH332\nH302\nH373 **\nH400\nH410\nGHS01\nGHS08\nGHS07\nGHS09\nDgr\nH200\nH360Df\nH332\nH302\nH373 ** H410\n1\n082-003-01-4\nlead diazide;\nlead azide [≥ 20 % phlegmatiser]\n236-542-1\n13424-46-9\nExpl. 1.1\nRepr. 1A\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH360Df\nH332\nH302\nH373 **\nH400\nH410\nGHS01\nGHS08\nGHS07\nGHS09\nDgr\nH201\nH360Df\nH332\nH302\nH373 ** H410\n1\n082-004-00-2\nlead chromate\n231-846-0\n7758-97-6\nCarc. 1B\nRepr. 1A\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH360Df H373**\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH360Df H373**\nH410\n1\n082-005-00-8\nlead di(acetate)\n206-104-4\n301-04-2\nRepr. 1A\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH373 **\nH400\nH410\nGHS08\nGHS09\nDgr\nH360Df\nH373 ** H410\n1\n082-006-00-3\ntrilead bis(orthophosphate)\n231-205-5\n7446-27-7\nRepr. 1A\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH373 **\nH400\nH410\nGHS08\nGHS09\nDgr\nH360Df\nH373 ** H410\n1\n082-007-00-9\nlead acetate, basic\n215-630-3\n1335-32-6\nCarc. 2\nRepr. 1A\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH360Df\nH373 **\nH400\nH410\nGHS08\nGHS09\nDgr\nH351\nH360Df\nH373 ** H410\n1\n082-008-00-4\nlead(II) methanesulphonate\n401-750-5\n17570-76-2\nRepr. 1A\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nH360Df\nH332\nH302\nH373 **\nH315\nH318\nGHS08\nGHS05\nGHS07\nDgr\nH360Df\nH332\nH302\nH373 ** H315\nH318\n1\n082-009-00-X\nlead sulfochromate yellow; C.I. Pigment Yellow 34;\n[This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 77603.]\n215-693-7\n1344-37-2\nCarc. 1B\nRepr. 1A\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH360Df H373**\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH360Df H373**\nH410\n1\n082-010-00-5\nlead chromate molybdate sulfate red; C.I. Pigment Red 104;\n[This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 77605.]\n235-759-9\n12656-85-8\nCarc. 1B\nRepr. 1A\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH360Df H373**\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH360Df H373**\nH410\n1\n082-011-00-0\nlead hydrogen arsenate\n232-064-2\n7784-40-9\nCarc. 1A\nRepr. 1A\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH360Df\nH331\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH360Df\nH331\nH301\nH373 ** H410\n1\n082-012-00-6\nbarium calcium cesium lead samarium strontium bromide chloride fluoride iodide europium doped\n431-780-4\n199876-46-5\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH302\nH373**\nH411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH411\n092-001-00-8\nuranium\n231-170-6\n7440-61-1\nAcute Tox. 2 *\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 4\nH330\nH300\nH373 **\nH413\nGHS06\nGHS08\nDgr\nH330\nH300\nH373 ** H413\n092-002-00-3\nuranium compounds with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nSTOT RE 2\nAquatic Chronic 2\nH330\nH300\nH373**\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH300\nH373**\nH411\nA\n601-001-00-4\nmethane\n200-812-7\n74-82-8\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n601-002-00-X\nethane\n200-814-8\n74-84-0\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n601-003-00-5\npropane\n200-827-9\n74-98-6\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n601-004-00-0\nbutane; [1] and isobutane [2]\n203-448-7 [1]\n200-857-2 [2]\n106-97-8 [1]\n75-28-5 [2]\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nC U\n601-004-01-8\nbutane (containing ≥ 0,1 % butadiene (203-450-8)); [1]\nisobutane (containing ≥ 0,1 % butadiene (203-450-8)) [2]\n203-448-7 [1]\n200-857-2 [2]\n106-97-8 [1]\n75-28-5 [2]\nFlam. Gas 1\nPress. Gas\nCarc. 1A\nMuta. 1B\nH220\nH350\nH340\nGHS02\nGHS04\nGHS08\nDgr\nH220\nH350\nH340\nC S U\n601-005-00-6\n2,2-dimethylpropane;\nneopentane\n207-343-7\n463-82-1\nFlam. Gas 1\nPress. Gas\nAquatic Chronic 2\nH220\nH411\nGHS02\nGHS04\nGHS09\nDgr\nH220\nH411\nU\n601-006-00-1\npentane\n203-692-4\n109-66-0\nFlam. Liq. 2\nAsp. Tox. 1\nSTOT SE 3\nAquatic Chronic 2\nH225\nH304\nH336\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH304\nH336\nH411\nEUH066\nC\n601-007-00-7\nhexane (containing < 5 % n-hexane (203-777-6));\n2-methylpentane;[1]\n3-methylpentane; [2]\n2,2-dimethylbutane; [3]\n2,3-dimethylbutane [4]\n203-523-4 [1]\n202-481-4 [2]\n200-906-8 [3]\n201-193-6 [4]\n107-83-5 [1]\n96-14-0 [2]\n75-83-2 [3]\n79-29-8 [4]\nFlam. Liq. 2\nAsp. Tox. 1\nSkin Irrit. 2\nSTOT SE 3\nAquatic Chronic 2\nH225\nH304\nH315\nH336\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH304\nH315\nH336\nH411\nC\n601-008-00-2\nheptane; n-heptane; [1]\n2,4-dimethylpentane; [2]\n2,2,3-trimethylbutane; [3]\n3,3-dimethylpentane; [4]\n2,3-dimethylpentane; [5]\n3-methylhexane; [6]\n2,2-dimethylpentane; [7]\n2-methylhexane; [8]\n3-ethylpentane; [9]\nisoheptane; [10]\n205-563-8 [1]\n203-548-0 [2]\n207-346-3 [3]\n209-230-8 [4]\n209-280-0 [5]\n209-643-3 [6]\n209-680-5 [7]\n209-730-6 [8]\n210-529-0 [9]\n250-610-8 [10]\n142-82-5 [1]\n108-08-7 [2]\n464-06-2 [3]\n562-49-2 [4]\n565-59-3 [5]\n589-34-4 [6]\n590-35-2 [7]\n591-76-4 [8]\n617-78-7 [9]\n31394-54-4 [10]\nFlam. Liq. 2\nAsp. Tox. 1\nSkin Irrit. 2\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH304\nH315\nH336\nH400\nH410\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH304\nH315\nH336\nH410\nC\n601-009-00-8\noctane; n-octane; [1]\n2,2,4-trimethylpentane; [2]\n2,3,3-trimethylpentane; [3]\n3,3-dimethylhexane; [4]\n2,2,3-trimethylpentane; [5]\n2,3,4-trimethylpentane; [6]\n3,4-dimethylhexane; [7]\n2,3-dimethylhexane; [8]\n2,4-dimethylhexane; [9]\n4-methylheptane; [10]\n3-methylheptane; [11]\n2,2-dimethylhexane; [12]\n2,5-dimethylhexane; [13]\n2-methylheptane; [14]\n2,2,3,3-tetramethylbutane; [15]\n3-ethyl-2-methylpentane; [16]\n3-ethylhexane; [17]\n3-ethyl-3-methylpentane; [18]\nisooctane; [19]\n203-892-1 [1]\n208-759-1 [2]\n209-207-2 [3]\n209-243-9 [4]\n209-266-4 [5]\n209-292-6 [6]\n209-504-7 [7]\n209-547-1 [8]\n209-649-6 [9]\n209-650-1 [10]\n209-660-6 [11]\n209-689-4 [12]\n209-745-8 [13]\n209-747-9 [14]\n209-855-6 [15]\n210-187-2 [16]\n210-621-0 [17]\n213-923-0 [18]\n247-861-0 [19]\n111-65-9 [1]\n540-84-1 [2]\n560-21-4 [3]\n563-16-6 [4]\n564-02-3 [5]\n565-75-3 [6]\n583-48-2 [7]\n584-94-1 [8]\n589-43-5 [9]\n589-53-7 [10]\n589-81-1 [11]\n590-73-8 [12]\n592-13-2 [13]\n592-27-8 [14]\n594-82-1 [15]\n609-26-7 [16]\n619-99-8 [17]\n1067-08-9 [18]\n26635-64-3 [19]\nFlam. Liq. 2\nAsp. Tox. 1\nSkin Irrit. 2\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH304\nH315\nH336\nH400\nH410\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH304\nH315\nH336\nH410\nC\n601-010-00-3\nethylene\n200-815-3\n74-85-1\nFlam. Gas 1\nPress. Gas\nSTOT SE 3\nH220\nH336\nGHS02\nGHS04\nGHS07\nDgr\nH220\nH336\nU\n601-011-00-9\npropene;\npropylene\n204-062-1\n115-07-1\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n601-012-00-4\nbut-1-ene; [1]\nbutene, mixed-1-and-2-isomers; [2]\n2-methylpropene; [3]\n(Z)-but-2-ene; [4]\n(E)-but-2-ene [5]\n203-449-2 [1]\n203-452-9 [2]\n204-066-3 [3]\n209-673-7 [4]\n210-855-3 [5]\n106-98-9 [1]\n107-01-7 [2]\n115-11-7 [3]\n590-18-1 [4]\n624-64-6 [5]\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nC U\n601-013-00-X\n1,3-butadiene;\nbuta-1,3-diene\n203-450-8\n106-99-0\nFlam. Gas 1\nPress. Gas\nCarc. 1A\nMuta. 1B\nH220\nH350\nH340\nGHS02\nGHS04\nGHS08\nDgr\nH220\nH350\nH340\nD U\n601-014-00-5\nisoprene (stabilised)\n2-methyl-1,3-butadiene\n201-143-3\n78-79-5\nFlam. Liq. 1\nCarc. 1B Muta. 2\nAquatic Chronic 3\nH224\nH350\nH341\nH412\nGHS02\nGHS08\nDgr\nH224\nH350\nH341\nH412\nD\n601-016-00-6\ncyclopropane\n200-847-8\n75-19-4\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n601-017-00-1\ncyclohexane\n203-806-2\n110-82-7\nFlam. Liq. 2\nAsp. Tox. 1\nSkin Irrit. 2\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH304\nH315\nH336\nH400\nH410\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH304\nH315\nH336\nH410\n601-018-00-7\nmethylcyclohexane\n203-624-3\n108-87-2\nFlam. Liq. 2\nAsp. Tox. 1\nSkin Irrit. 2\nSTOT SE 3\nAquatic Chronic 2\nH225\nH304\nH315\nH336\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH304\nH315\nH336\nH411\n601-019-00-2\n1,4-dimethylcyclohexane\n209-663-2\n589-90-2\nFlam. Liq. 2\nAsp. Tox. 1\nSkin Irrit. 2\nSTOT SE 3\nAquatic Chronic 2\nH225\nH304\nH315\nH336\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH304\nH315\nH336\nH411\n601-020-00-8\nbenzene\n200-753-7\n71-43-2\nFlam. Liq. 2\nCarc. 1a\nMuta. 1B\nSTOT RE 1\nAsp. Tox. 1\nEye Irrit. 2\nSkin Irrit. 2\nH225\nH350\nH340\nH372 **\nH304\nH319\nH315\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH350\nH340\nH372 ** H304\nH319\nH315\nE\n601-021-00-3\ntoluene\n203-625-9\n108-88-3\nFlam. Liq. 2\nRepr. 2\nAsp. Tox. 1\nSTOT RE 2 *\nSkin Irrit. 2\nSTOT SE 3\nH225\nH361d *** H304\nH373 **\nH315\nH336\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH361d *** H304\nH373 ** H315\nH336\n601-022-00-9\no-xylene; [1]\np-xylene; [2]\nm-xylene; [3]\nxylene [4]\n202-422-2 [1]\n203-396-5 [2]\n203-576-3 [3]\n215-535-7 [4]\n95-47-6 [1]\n106-42-3 [2]\n108-38-3 [3]\n1330-20-7 [4]\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nH226\nH332\nH312\nH315\nGHS02\nGHS07\nWng\nH226\nH332\nH312\nH315\n*\nC\n601-023-00-4\nethylbenzene\n202-849-4\n100-41-4\nFlam. Liq. 2\nAcute Tox. 4*\nSTOT RE 2\nAsp. Tox. 1\nH225\nH332\nH373\n(hearing organs)\nH304\nGHS02\nGHS07\nGHS08\nDgr\nH225\nH332\nH373\n(hearing organs)\nH304\n601-024-00-X\ncumene; [1]\npropylbenzene [2]\n202-704-5 [1]\n203-132-9 [2]\n98-82-8 [1]\n103-65-1 [2]\nFlam. Liq. 3\nAsp. Tox. 1\nSTOT SE 3\nAquatic Chronic 2\nH226\nH304\nH335\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH304\nH335\nH411\nC\n601-025-00-5\nmesitylene;\n1,3,5-trimethylbenzene\n203-604-4\n108-67-8\nFlam. Liq. 3\nSTOT SE 3\nAquatic Chronic 2\nH226\nH335\nH411\nGHS02\nGHS07\nGHS09\nWng\nH226\nH335\nH411\nSTOT SE 3; H335: C ≥ 25 %\n601-026-00-0\nstyrene\n202-851-5\n100-42-5\nFlam. Liq. 3\nRepr. 2\nAcute Tox. 4*\nSTOT RE 1\nSkin Irrit. 2\nEye Irrit. 2\nH226\nH361d\nH332\nH372\n(hearing organs)\nH315\nH319\nGHS02\nGHS08\nGHS07\nDgr\nH226\nH361d\nH332\nH372\n(hearing organs)\nH315\nH319\n*\nD\n601-027-00-6\n2-phenylpropene;\nα-methylstyrene\n202-705-0\n98-83-9\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nAquatic Chronic 2\nH226\nH319\nH335\nH411\nGHS02\nGHS07\nGHS09\nWng\nH226\nH319\nH335\nH411\nSTOT SE 3; H335: C ≥ 25 %\n601-028-00-1\n2-methylstyrene;\n2-vinyltoluene\n210-256-7\n611-15-4\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH411\nGHS07\nGHS09\nWng\nH332\nH411\n601-029-00-7\ndipentene; limonene;[1]\n(R)-p-mentha-1,8-diene;\nd-limonene; [2]\n(S)-p-mentha-1,8-diene; l-limonene; [3]\ntrans-1-methyl-4-(1-methylvinyl)cyclohexene; [4]\n(±)-1-methyl-4-(1-methylvinyl)cyclohexene [5]\n205-341-0 [1]\n227-813-5 [2]\n227-815-6 [3]\n229-977-3 [4]\n231-732-0 [5]\n138-86-3 [1]\n5989-27-5 [2]\n5989-54-8 [3]\n6876-12-6 [4]\n7705-14-8 [5]\nFlam. Liq. 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH315\nH317\nH400\nH410\nGHS02\nGHS07\nGHS09\nWng\nH226\nH315\nH317\nH410\nC\n601-030-00-2\ncyclopentane\n206-016-6\n287-92-3\nFlam. Liq. 2\nAquatic Chronic 3\nH225\nH412\nGHS02\nDgr\nH225\nH412\n601-031-00-8\n2,4,4-trimethylpent-1-ene\n203-486-4\n107-39-1\nFlam. Liq. 2\nAquatic Chronic 2\nH225\nH411\nGHS02\nGHS09\nDgr\nH225\nH411\n601-032-00-3\nbenzo[a]pyrene;\nbenzo[def]chrysene\n200-028-5\n50-32-8\nCarc. 1B\nMuta. 1B\nRepr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH360FD\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH340\nH360FD H317\nH410\nCarc. 1B; H350: C ≥ 0,01 %\n601-033-00-9\nbenz[a]anthracene\n200-280-6\n56-55-3\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\nM=100\n601-034-00-4\nbenz[e]acephenanthrylene\n205-911-9\n205-99-2\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n601-035-00-X\nbenzo[j]fluoranthene\n205-910-3\n205-82-3\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n601-036-00-5\nbenzo[k]fluoranthene\n205-916-6\n207-08-9\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n601-037-00-0\nn-hexane\n203-777-6\n110-54-3\nFlam. Liq. 2\nRepr. 2\nAsp. Tox. 1\nSTOT RE 2 *\nSkin Irrit. 2\nSTOT SE 3\nAquatic Chronic 2\nH225\nH361f *** H304\nH373 **\nH315\nH336\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH361f *** H304\nH373 ** H315\nH336\nH411\nSTOT RE 2; H373: C ≥ 5 %\n601-041-00-2\ndibenz[a,h]anthracene\n200-181-8\n53-70-3\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\nCarc. 1B; H350: C ≥ 0,01 % M=100\n601-042-00-8\nbiphenyl;\ndiphenyl\n202-163-5\n92-52-4\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH410\n601-043-00-3\n1,2,4-trimethylbenzene\n202-436-9\n95-63-6\nFlam. Liq. 3\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 2\nH226\nH332\nH319\nH335\nH315\nH411\nGHS02\nGHS07\nGHS09\nWng\nH226\nH332\nH319\nH335\nH315\nH411\n601-044-00-9\n3a,4,7,7a-tetrahydro-4,7-methanoindene\n201-052-9\n77-73-6\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 2\nH225\nH332\nH302\nH319\nH335\nH315\nH411\nGHS02\nGHS07\nGHS09\nDgr\nH225\nH332\nH302\nH319\nH335\nH315\nH411\n601-045-00-4\n1,2,3,4-tetrahydronaphthalene\n204-340-2\n119-64-2\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH319\nH315\nH411\nGHS07\nGHS09\nWng\nH319\nH315\nH411\nEUH019\n601-046-00-X\n7-methylocta-1,6-diene\n404-210-7\n42152-47-6\nFlam. Liq. 3\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH400\nH410\nGHS02\nGHS09\nWng\nH226\nH410\n601-047-00-5\nm-mentha-1,3(8)-diene\n404-150-1\n17092-80-7\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n601-048-00-0\nchrysene\n205-923-4\n218-01-9\nCarc. 1B Muta. 2\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH341\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH341\nH410\n601-049-00-6\nbenzo[e]pyrene\n205-892-7\n192-97-2\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n601-051-00-7\n4-phenylbut-1-ene\n405-980-7\n768-56-9\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n601-052-00-2\nnaphthalene\n202-049-5\n91-20-3\nCarc. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH351\nH302\nH410\n601-053-00-8\nnonylphenol; [1]\n4-nonylphenol, branched [2]\n246-672-0 [1]\n284-325-5 [2]\n25154-52-3 [1]\n84852-15-3 [2]\nRepr. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH361fd\nH302\nH314\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH361fd\nH302\nH314\nH410\n601-054-00-3\nreaction mass of isomers of: dibenzylbenzene; dibenzyl(methyl)benzene; dibenzyl(dimethyl)benzene; dibenzyl(trimethyl)benzene\n405-570-8\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n601-055-00-9\nreaction mass of isomers of: mono-(2-tetradecyl)naphthalenes; di-(2-tetradecyl)naphthalenes; tri-(2-tetradecyl)naphthalenes\n410-190-0\n132983-41-6\nEye Irrit. 2\nAquatic Chronic 4\nH319\nH413\nGHS07\nWng\nH319\nH413\n601-056-00-4\nreaction mass of isomers of: methyldiphenylmethane; dimethyldiphenylmethane\n405-470-4\n73807-39-3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n601-057-00-X\nN-dodecyl-[3-(4-(dimethylamino)benzamido)-propyl]dimethylammonium tosylate\n421-130-8\n156679-41-3\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH410\n601-058-00-5\ndi-L-para-menthene\n417-870-6\n83648-84-4\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n601-059-00-0\nmethyl 2-benzylidene-3-oxobutyrate\n420-940-9\n15768-07-7\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH319\nH315\nH411\nGHS07\nGHS09\nWng\nH319\nH315\nH411\n601-060-00-6\n1,2-bis[4-fluoro-6-{4-sulfo-5-(2-(4-sulfonaphtalene-3-ylazo)-1-hydroxy-3,6-disulfo-8-aminonaphthalene-7-ylazo)phenylamino}-1,3,5-triazin-2ylamino]ethane;\nx-sodium, y-potassium salts x = 7,755 y =0,245\n417-610-1\n155522-09-1\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n601-061-00-1\n(ethyl-1,2-ethanediyl)[-2-[[[(2-hydroxyethyl)methylamino]acetyl]-propyl]ω-(nonylphenoxy)poly]oxy-(methyl-1,2-ethanediyl)\n418-960-8\n—\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH411\n601-062-00-7\nreaction mass of: branched triacontane;\nbranched dotriacontane;\nbranched tetratriacontane;\nbranched hexatriacontane\n417-030-9\n151006-59-6\nAquatic Chronic 4\nH413\n—\nH413\n601-063-00-2\nreaction mass of isomers of branched tetracosane\n417-060-2\n151006-61-0\nAcute Tox. 4 *\nAquatic Chronic 4\nH332\nH413\nGHS07\nWng\nH332\nH413\n601-064-00-8\nbranched hexatriacontane\n417-070-7\n151006-62-1\nAquatic Chronic 4\nH413\n—\nH413\n601-065-00-3\nreaction mass of: (1'α, 3'α, 6'α)-2,2,3' ,7', 7'-pentamethylspiro(1,3-dioxane-5,2'-norcarane);\n(1'α, 3'β, 6'α)-2,2,3', 7', 7'-pentamethylspiro(1,3-dioxane-5,2'-norcarane)\n416-930-9\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n601-066-00-9\n1-(4-(trans-4-heptylcyclohexyl)phenyl) ethanone\n426-820-2\n78531-60-9\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n601-067-00-4\ntriethyl arsenate\n427-700-2\n15606-95-8\nCarc. 1A\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH331\nH301\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH301\nH410\n601-068-00-X\n1,2-diacetoxybut-3-ene\n421-720-5\n18085-02-4\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n601-069-00-5\n2-ethyl-1-(2-(1,3-dioxanyl)ethyl)-pyridinium bromide\n422-680-1\n287933-44-2\nAquatic Chronic 3\nH412\n—\nH412\n601-070-00-0\nreaction mass of: branched icosane; branched docosane; branched tetracosane\n417-050-8\n151006-58-5\nAcute Tox. 4 *\nAquatic Chronic 4\nH332\nH413\nGHS07\nWng\nH332\nH413\n601-071-00-6\n1-dimethoxymethyl-2-nitro-benzene\n423-830-9\n20627-73-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n601-072-00-1\nreaction mass of: 1-(4-isopropylphenyl)-1-phenylethane;\n1-(3-isopropylphenyl)-1-phenylethane;\n1-(2-isopropylphenyl)-1-phenylethane\n430-690-2\n52783-21-8\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n601-073-00-7\n1-bromo-3,5-difluorobenzene\n416-710-2\n461-96-1\nFlam. Liq. 3\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH302\nH373 ** H315\nH317\nH400\nH410\nGHS02\nGHS08\nGHS07\nGHS09\nWng\nH226\nH302\nH373 ** H315\nH317\nH410\n601-074-00-2\nreaction mass of: 4-(2,2,3-trimethylcyclopent-3-en-1-yl)-1-methyl-2-oxabicyclo[2.2.2]octane;\n1-(2,2,3-trimethylcyclopent-3-en-1-yl)-5-methyl-6-oxabicyclo[3.2.1]octane; spiro[cyclohex-3-en-1-yl-[(4,5,6,6a-tetrahydro-3,6',6',6'a-tetramethyl)-1,3'(3'aH)-[2H]cyclopenta[b]furan]; spiro[cyclohex-3-en-1-yl-[4,5,6,6a-tetrahydro-4,6',6',6'a-tetramethyl)-1,3'(3'aH)-[2H]cyclopenta[b]]furan]\n422-040-1\n—\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH319\nH315\nH411\nGHS07\nGHS09\nWng\nH319\nH315\nH411\n601-075-00-8\n4,4'-bis(N-carbamoyl-4-methylbenzenesulfonamide)diphenylmethane\n418-770-5\n151882-81-4\nCarc. 2\nH351\nGHS08\nWng\nH351\n601-076-00-3\nethynyl cyclopropane\n425-430-1\n6746-94-7\nFlam. Liq. 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH225\nH315\nH318\nH412\nGHS02\nGHS05\nDgr\nH225\nH315\nH318\nH412\n601-077-00-9\nreaction mass of: 1-heptyl-4-ethyl-2,6,7-trioxabicyclo[2.2.2]octane;\n1-nonyl-4-ethyl-2,6,7-trioxabicyclo[2.2.2]octane\n426-510-7\n196965-91-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n601-078-00-4\nreaction mass of: 1,7-dimethyl-2-[(3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane;\n2,3-dimethyl-2-[(3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane\n427-040-5\n—\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n601-079-00-X\nreaction mass of: trans-trans-cyclohexadeca-1,9-diene;\ncis-trans-cyclohexadeca-1,9-diene\n429-620-3\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n601-080-00-5\nreaction mass of: sec-butylphenyl(phenyl)methane, mixed isomers;\n1-(sec-butylphenyl(phenyl)-2-phenylethane, mixed isomers;\n1-(sec-butylphenyl-1-phenylethane, mixed isomers\n431-100-6\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n601-081-00-0\ncyclohexadeca-1,9-diene\n431-730-1\n4277-06-9\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n601-082-00-6\nreaction mass of: endo-2-methyl-exo-3-methyl-exo-2-[(exo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane;\nexo-2-methyl-exo-3-methyl-endo-2-[(endo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane\n434-420-4\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n601-083-00-1\n5-endo-hexyl-bicyclo[2.2.1]hept-2-ene\n435-000-3\n22094-83-3\nAsp. Tox. 1\nSkin Irrit. 2\nAquatic Chronic 4\nH304\nH315\nH413\nGHS08\nGHS07\nDgr\nH304\nH315\nH413\n601-084-00-7\nreaction mass of:5-endo-butyl-bicyclo[2.2.1]hept-2-ene;\n5-exo-butyl-bicyclo[2.2.1]hept-2-ene (80:20)\n435-180-3\n—\nAsp. Tox. 1\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH304\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH304\nH315\nH410\n601-085-00-2\nisopentane;\n2-methylbutane\n201-142-8\n78-78-4\nFlam. Liq. 1\nAsp. Tox. 1\nSTOT SE 3\nAquatic Chronic 2\nH224\nH304\nH336\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH224\nH304\nH336\nH411\nEUH066\n601-087-00-3\n2,4,4-trimethylpentene\n246-690-9\n25167-70-8\nFlam. Liq. 2\nAsp. Tox. 1\nSTOT SE 3\nH225\nH304\nH336\nGHS02\nGHS07\nGHS08\nDgr\nH225\nH304\nH336\nD\n601-088-00-9\n4-vinylcyclohexene\n202-848-9\n100-40-3\nCarc. 2\nH351\nGHS08\nWng\nH351\n601-089-00-4\nmuscalure; cis-tricos-9-ene\n248-505-7\n27519-02-4\nSkin Sens. 1B\nH317\nGHS07\nWng\nH317\n602-001-00-7\nchloromethane;\nmethyl chloride\n200-817-4\n74-87-3\nFlam. Gas 1\nPress. Gas\nCarc. 2\nSTOT RE 2 *\nH220\nH351\nH373 **\nGHS02\nGHS04\nGHS08\nDgr\nH220\nH351\nH373 **\nU\n602-002-00-2\nbromomethane;\nmethylbromide\n200-813-2\n74-83-9\nPress. Gas\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nOzone 1\nH341\nH331\nH301\nH373**\nH319\nH335\nH315\nH400\nH420\nGHS04\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH331\nH301\nH373 ** H319\nH335\nH315\nH400\nH420\nU\n602-003-00-8\ndibromomethane\n200-824-2\n74-95-3\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH412\nGHS07\nWng\nH332\nH412\n*\n602-004-00-3\ndichloromethane;\nmethylene chloride\n200-838-9\n75-09-2\nCarc. 2\nH351\nGHS08\nWng\nH351\n602-005-00-9\nmethyl iodide;\niodomethane\n200-819-5\n74-88-4\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT SE 3\nSkin Irrit. 2\nH351\nH312\nH331\nH301\nH335\nH315\nGHS06\nGHS08\nDgr\nH351\nH312\nH331\nH301\nH335\nH315\n602-006-00-4\nchloroform;\ntrichloromethane\n200-663-8\n67-66-3\nCarc. 2\nRepr. 2\nAcute Tox. 3\nAcute Tox. 4\nSTOT RE 1\nEye Irrit. 2\nSkin Irrit. 2\nH351\nH361d\nH331\nH302\nH372\nH319\nH315\nGHS06\nGHS08\nDgr\nH351\nH361d\nH331\nH302\nH372\nH319\nH315\n602-007-00-X\nbromoform;\ntribromomethane\n200-854-6\n75-25-2\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH331\nH302\nH319\nH315\nH411\nGHS06\nGHS09\nDgr\nH331\nH302\nH319\nH315\nH411\n602-008-00-5\ncarbon tetrachloride;\ntetrachloromethane\n200-262-8\n56-23-5\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic\nChronic 3\nOzone 1\nH351\nH331\nH311\nH301\nH372**\nH412\nH420\nGHS06\nGHS08\nDgr\nH351\nH331\nH311\nH301\nH372 ** H412\nH420\n*\nSTOT RE 1; H372:C≥1 % STOT RE 2; H373:0,2 % ≤C\n< 1 %\n602-009-00-0\nchloroethane\n200-830-5\n75-00-3\nFlam. Gas 1\nPress. Gas\nCarc. 2\nAquatic Chronic 3\nH220\nH351\nH412\nGHS02\nGHS04\nGHS08\nDgr\nH220\nH351\nH412\nU\n602-010-00-6\n1,2-dibromoethane\n203-444-5\n106-93-4\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 2\nH350\nH331\nH311\nH301\nH319\nH335\nH315\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH311\nH301\nH319\nH335\nH315\nH411\n*\n602-011-00-1\n1,1-dichloroethane\n200-863-5\n75-34-3\nFlam. Liq. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nAquatic Chronic 3\nH225\nH302\nH319\nH335\nH412\nGHS02\nGHS07\nDgr\nH225\nH302\nH319\nH335\nH412\n*\n602-012-00-7\n1,2-dichloroethane;\nethylene dichloride\n203-458-1\n107-06-2\nFlam. Liq. 2\nCarc. 1B\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH225\nH350\nH302\nH319\nH335\nH315\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH350\nH302\nH319\nH335\nH315\n602-013-00-2\n1,1,1-trichloroethane;\nmethyl chloroform\n200-756-3\n71-55-6\nAcute Tox. 4 *\nOzone 1\nH332\nH420\nGHS07\nWng\nH332\nH420\nF\n602-014-00-8\n1,1,2-trichloroethane\n201-166-9\n79-00-5\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH351\nH332\nH312\nH302\nGHS08\nGHS07\nWng\nH351\nH332\nH312\nH302\nEUH066\n*\n602-015-00-3\n1,1,2,2-tetrachloroethane\n201-197-8\n79-34-5\nAcute Tox. 2 *\nAcute Tox. 1\nAquatic Chronic 2\nH330\nH310\nH411\nGHS06\nGHS09\nDgr\nH330\nH310\nH411\n602-016-00-9\n1,1,2,2-tetrabromoethane\n201-191-5\n79-27-6\nAcute Tox. 2 *\nEye Irrit. 2\nAquatic Chronic 3\nH330\nH319\nH412\nGHS06\nDgr\nH330\nH319\nH412\n602-017-00-4\npentachloroethane\n200-925-1\n76-01-7\nCarc. 2\nSTOT RE 1\nAquatic Chronic 2\nH351\nH372 **\nH411\nGHS08\nGHS09\nDgr\nH351\nH372 ** H411\nSTOT RE 1; H372: C≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 %\n602-018-00-X\n1-chloropropane; [1]\n2-chloropropane [2]\n208-749-7 [1]\n200-858-8 [2]\n540-54-5 [1]\n75-29-6 [2]\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH332\nH312\nH302\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\nC\n602-019-00-5\n1-bromopropane;\nn-propyl bromide\n203-445-0\n106-94-5\nFlam. Liq. 2\nRepr. 1B\nSTOT RE 2 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSTOT SE 3\nH225\nH360FD\nH373 **\nH319\nH335\nH315\nH336\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH360FD H373 **\nH319\nH335\nH315\nH336\n602-021-00-6\n1,2-dibromo-3-chloropropane\n202-479-3\n96-12-8\nCarc. 1B\nMuta. 1B\nRepr. 1A\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 3\nH350\nH340\nH360F *** H301\nH373 **\nH412\nGHS06\nGHS08\nDgr\nH350\nH340\nH360F *** H301\nH373 ** H412\n602-022-00-1\n1-chloropentane; [1]\n2-chloropentane; [2]\n3-chloropentane [3]\n208-846-4 [1]\n210-885-7 [2]\n210-467-4 [3]\n543-59-9 [1]\n625-29-6 [2]\n616-20-6 [3]\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH332\nH312\nH302\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\nC\n602-023-00-7\nvinyl chloride;\nchloroethylene\n200-831-0\n75-01-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A\nH220\nH350\nGHS02\nGHS08\nDgr\nH220\nH350\nD U\n602-024-00-2\nbromoethylene\n209-800-6\n593-60-2\nPress. Gas\nFlam. Gas 1\nCarc. 1B\nH220\nH350\nGHS02\nGHS08\nDgr\nH220\nH350\nU\n602-025-00-8\n1,1-dichloroethylene;\nvinylidene chloride\n200-864-0\n75-35-4\nFlam. Liq. 1\nCarc. 2\nAcute Tox. 4 *\nH224\nH351\nH332\nGHS02\nGHS08\nGHS07\nDgr\nH224\nH351\nH332\n*\nD\n602-026-00-3\n1,2-dichloroethylene; [1]\ncis-dichloroethylene; [2]\ntrans-dichloroethylene [3]\n208-750-2 [1]\n205-859-7 [2]\n205-860-2 [3]\n540-59-0 [1]\n156-59-2 [2]\n156-60-5 [3]\nFlam. Liq. 2\nAcute Tox. 4 *\nAquatic Chronic 3\nH225\nH332\nH412\nGHS02\nGHS07\nDgr\nH225\nH332\nH412\n*\nC\n602-027-00-9\ntrichloroethylene;\ntrichloroethene\n201-167-4\n79-01-6\nCarc. 1B\nMuta. 2\nEye Irrit. 2\nSkin Irrit. 2\nSTOT SE 3\nAquatic Chronic 3\nH350\nH341\nH319\nH315\nH336\nH412\nGHS08\nGHS07\nDgr\nH350\nH341\nH319\nH315\nH336\nH412\n602-028-00-4\ntetrachloroethylene\n204-825-9\n127-18-4\nCarc. 2\nAquatic Chronic 2\nH351\nH411\nGHS08\nGHS09\nWng\nH351\nH411\n602-029-00-X\n3-chloropropene;\nallyl chloride\n203-457-6\n107-05-1\nFlam. Liq. 2\nCarc. 2\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH225\nH351\nH341\nH332\nH312\nH302\nH373 ** H319\nH335\nH315\nH400\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH351\nH341\nH332\nH312\nH302\nH373 ** H319\nH335\nH315\nH400\nD\n602-030-00-5\n1,3-dichloropropene; [1]\n(Z)-1,3-dichloropropene [2]\n208-826-5 [1]\n233-195-8 [2]\n542-75-6 [1]\n10061-01-5 [2]\nFlam. Liq. 3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nAsp. Tox. 1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH311\nH301\nH332\nH304\nH319\nH335\nH315\nH317\nH400\nH410\nGHS02\nGHS06\nGHS08\nGHS09\nDgr\nH226\nH311\nH301\nH332\nH304\nH319\nH335\nH315\nH317\nH410\nC D\n602-031-00-0\n1,1-dichloropropene\n209-253-3\n563-58-6\nFlam. Liq. 2\nAcute Tox. 3 *\nAquatic Chronic 3\nH225\nH301\nH412\nGHS02\nGHS06\nDgr\nH225\nH301\nH412\n602-032-00-6\n3-chloro-2-methylpropene\n209-251-2\n563-47-3\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH225\nH332\nH302\nH314\nH317\nH411\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH225\nH332\nH302\nH314\nH317\nH411\n602-034-00-7\n1,2-dichlorobenzene;\no-dichlorobenzene\n202-425-9\n95-50-1\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH335\nH315\nH410\n*\n602-035-00-2\n1,4-dichlorobenzene;\np-dichlorobenzene\n203-400-5\n106-46-7\nCarc. 2\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH319\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH319\nH410\n602-036-00-8\nchloroprene (stabilised);\n2-chlorobuta-1,3-diene (stabilised)\n204-818-0\n126-99-8\nFlam. Liq. 2\nCarc. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH225\nH350\nH332\nH302\nH373 **\nH319\nH335\nH315\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH350\nH332\nH302\nH373 ** H319\nH335\nH315\nD\n602-037-00-3\nα-chlorotoluene;\nbenzyl chloride\n202-853-6\n100-44-7\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH350\nH331\nH302\nH373 **\nH335\nH315\nH318\nGHS06\nGHS08\nGHS05\nDgr\nH350\nH331\nH302\nH373 ** H335\nH315\nH318\n602-038-00-9\nα, α, α-trichlorotoluene;\nbenzotrichloride\n202-634-5\n98-07-7\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH350\nH331\nH302\nH335\nH315\nH318\nGHS06\nGHS08\nGHS05\nDgr\nH350\nH331\nH302\nH335\nH315\nH318\n602-039-00-4\npolychlorobiphenyls;\nPCB\n215-648-1\n1336-36-3\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH400\nH410\nGHS08\nGHS09\nWng\nH373 ** H410\nSTOT RE 2; H373: C ≥ 0,005 %\nC\n602-040-00-X\n2-chlorotoluene; [1]\n3-chlorotoluene; [2]\n4-chlorotoluene; [3]\nchlorotoluene [4]\n202-424-3 [1]\n203-580-5 [2]\n203-397-0 [3]\n246-698-2 [4]\n95-49-8 [1]\n108-41-8 [2]\n106-43-4 [3]\n25168-05-2 [4]\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH411\nGHS07\nGHS09\nWng\nH332\nH411\nC\n602-041-00-5\npenthachloronaphthalene\n215-320-8\n1321-64-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH319\nH315\nH410\nC\n602-042-00-0\n1,2,3,4,5,6-hexachlorcyclohexanes with the exception of those specified elsewhere in this Annex\n—\n—\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH301\nH312\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH301\nH312\nH410\nA C\n602-043-00-6\nlindane (ISO);\nγ-HCH or γ-BHC;\nγ-1,2,3,4,5,6-hexachlorocyclohexane\n200-401-2\n58-89-9\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH332\nH312\nH373 **\nH362\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH332\nH312\nH373 ** H362\nH410\nM=10\n602-044-00-1\ncamphechlor (ISO);\ntoxaphene;\n232-283-3\n8001-35-2\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH301\nH312\nH335\nH315\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH301\nH312\nH335\nH315\nH410\n602-045-00-7\nDDT (ISO);\nclofenotane (INN);\ndicophane;1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane; dichlorodiphenyltrichloroethane\n200-024-3\n50-29-3\nCarc. 2\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH301\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH301\nH372 ** H410\n602-046-00-2\nheptachlor (ISO);\n1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindene\n200-962-3\n76-44-8\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH311\nH301\nH373 ** H410\n602-047-00-8\nchlordane (ISO);\n1,2,4,5,6,7,8,8-octachloro-3a,4,7,7a-tetrahydro-4,7-methanoindan\n200-349-0\n57-74-9\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH312\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH312\nH302\nH410\n602-048-00-3\naldrin (ISO)\n206-215-8\n309-00-2\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH311\nH301\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH311\nH301\nH372 ** H410\n602-049-00-9\ndieldrin (ISO)\n200-484-5\n60-57-1\nCarc. 2\nAcute Tox. 1\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH310\nH301\nH372 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH310\nH301\nH372 ** H410\n602-050-00-4\nisodrin;\n(1α,4α,4aβ, 5β,8β,8aβ)-1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthalene\n207-366-2\n465-73-6\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\nM=100\n602-051-00-X\nendrin (ISO);\n1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-1,4:5,8-dimethanonaphthalene\n200-775-7\n72-20-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH300\nH311\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH311\nH410\n602-052-00-5\nendosulfan (ISO);\n1,2,3,4,7,7-hexachloro-8,9,10-trinorborn-2-en-5,6-ylenedimethylene sulfite;\n1,4,5,6,7,7-hexachloro-8,9,10-trinorborn-5-en-2,3-ylenedimethylene sulfite\n204-079-4\n115-29-7\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH312\nH410\n602-053-00-0\nisobenzan (ISO);\n1,3,4,5,6,7,8,8-octachloro-1,3,3a,4,7,7a-hexahydro-4,7-methanoisobenzofuran\n206-045-4\n297-78-9\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nH310\nH300\nH400\nGHS06\nGHS09\nDgr\nH310\nH300\nH400\n602-054-00-6\n3-iodpropene;\nallyl iodide\n209-130-4\n556-56-9\nFlam. Liq. 2\nSkin Corr. 1B\nH225\nH314\nGHS02\nGHS05\nDgr\nH225\nH314\n602-055-00-1\nbromoethane;\nethyl bromide\n200-825-8\n74-96-4\nFlam. Liq. 2\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH351\nH332\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH351\nH332\nH302\n602-056-00-7\nα, α, α-trifluorotoluene;\nbenzotrifluoride\n202-635-0\n98-08-8\nFlam. Liq. 2\nAquatic Chronic 2\nH225\nH411\nGHS02\nGHS09\nDgr\nH225\nH411\n602-057-00-2\nα-bromotoluene;\nbenzyl bromide\n202-847-3\n100-39-0\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\n602-058-00-8\nα, α-dichlorotoluene;\nbenzylidene chloride;\nbenzal chloride\n202-709-2\n98-87-3\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH351\nH331\nH302\nH335\nH315\nH318\nGHS06\nGHS08\nGHS05\nDgr\nH351\nH331\nH302\nH335\nH315\nH318\n602-059-00-3\n1-chlorobutane;\nbutyl chloride\n203-696-6\n109-69-3\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n602-060-00-9\nbromobenzene\n203-623-8\n108-86-1\nFlam. Liq. 3\nSkin Irrit. 2\nAquatic Chronic 2\nH226\nH315\nH411\nGHS02\nGHS07\nGHS09\nWng\nH226\nH315\nH411\n602-061-00-4\nhexafluoropropene;\nhexafluoropropylene\n204-127-4\n116-15-4\nPress. Gas\nAcute Tox. 4 *\nSTOT SE 3\nH332\nH335\nGHS07\nWng\nH332\nH335\nU\n602-062-00-X\n1,2,3-trichloropropane\n202-486-1\n96-18-4\nCarc. 1B\nRepr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH350\nH360F *** H332\nH312\nH302\nGHS08\nGHS07\nDgr\nH350\nH360F *** H332\nH312\nH302\nD\n602-063-00-5\nheptachlor epoxide;\n2,3-epoxy-1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindane\n213-831-0\n1024-57-3\nCarc. 2\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH301\nH373 ** H410\n602-064-00-0\n1,3-dichloro-2-propanol\n202-491-9\n96-23-1\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nH350\nH301\nH312\nGHS06\nGHS08\nDgr\nH350\nH301\nH312\n602-065-00-6\nhexachlorobenzene\n204-273-9\n118-74-1\nCarc. 1B\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH372 **\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH372 ** H410\n602-066-00-1\ntetrachloro-p-benzoquinone\n204-274-4\n118-75-2\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\n602-067-00-7\n1,3-dichlorbenzene\n208-792-1\n541-73-1\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n602-068-00-2\nethylene bis(trichloroacetate)\n219-732-9\n2514-53-6\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n602-069-00-8\ndichloroacetylene\n—\n7572-29-4\nUnst. Expl. Carc. 2\nSTOT RE 2 *\nH200\nH351\nH373 **\nGHS01\nGHS08\nWng\nH200\nH351\nH373 **\n602-070-00-3\n3-chloro-4,5,α, α, α-pentafluorotoluene\n401-930-3\n77227-99-7\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nH226\nH332\nH302\nH400\nGHS02\nGHS07\nGHS09\nWng\nH226\nH332\nH302\nH400\n602-071-00-9\nbromobenzylbromotoluene, reaction mass of isomers\n402-210-1\n99688-47-8\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373 ** H317\nH410\n602-072-00-4\ndichloro [(dichlorophenyl)methyl]methylbenzene, reaction mass of isomers; (dichlorophenyl)(dichlorotolyl)methane, reaction mass of isomers (IUPAC)\n278-404-3\n76253-60-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n602-073-00-X\n1,4-dichlorobut-2-ene\n212-121-8\n764-41-0\nCarc. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH330\nH311\nH301\nH314\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH350\nH330\nH311\nH301\nH314\nH410\nCarc. 1B; H350: C ≥ 0,01 % STOT SE 3; H335:C≥5 %\n602-074-00-5\npentachlorobenzene\n210-172-0\n608-93-5\nFlam. Sol. 1\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH228\nH302\nH400\nH410\nGHS02\nGHS07\nGHS09\nDgr\nH228\nH302\nH410\nT\n602-075-00-0\n4,4,5,5-tetrachloro-1,3-dioxolan-2-one\n404-060-2\n22432-68-4\nAcute Tox. 2 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH330\nH302\nH314\nGHS06\nGHS05\nDgr\nH330\nH302\nH314\n602-076-00-6\n2,3,4-trichlorobut-1-ene\n219-397-9\n2431-50-7\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH331\nH302\nH319\nH335\nH315\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH331\nH302\nH319\nH335\nH315\nH410\nCarc. 2; H351: C\n≥ 0,1 %\n602-077-00-1\ndodecachloropentacyclo[5.2.1.02,6.03,9.05,8]decane;\nmirex\n219-196-6\n2385-85-5\nCarc. 2\nRepr. 2\nLact.\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361fd\nH362\nH312\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH361fd\nH362\nH312\nH302\nH410\n602-078-00-7\nhexachlorocyclopentadiene\n201-029-3\n77-47-4\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH311\nH302\nH314\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH311\nH302\nH314\nH410\n602-079-00-2\n2,3-dichloropropene;\n2,3-dichloropropylene\n201-153-8\n78-88-6\nFlam. Liq. 2\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH225\nH341\nH332\nH312\nH302\nH335\nH315\nH318\nH412\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH225\nH341\nH332\nH312\nH302\nH335\nH315\nH318\nH412\n602-080-00-8\nalkanes, C10-13, chloro; chlorinated paraffins, C10-13\n287-476-5\n85535-84-8\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nEUH066\n602-081-00-3\n2-chloro-4,5-difluorobenzoic acid\n405-380-5\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH312\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH312\nH302\nH318\nH317\n602-082-00-9\n2,2,6,6-tetrakis(bromomethyl)-4-oxaheptane-1,7-diol\n408-020-5\n109678-33-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n602-083-00-4\ndiphenyl ether, pentabromo derivative pentabromodiphenyl ether\n251-084-2\n32534-81-9\nSTOT RE 2 *\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH362\nH400\nH410\nGHS08\nGHS09\nWng\nH373 ** H362\nH410\n602-084-00-X\n1,1-dichloro-1-fluoroethane\n404-080-1\n1717-00-6\nAquatic\nChronic 3\nOzone 1\nH412\nH420\nGHS07\nWng\nH412\nH420\n602-085-00-5\n2-bromopropane\n200-855-1\n75-26-3\nFlam. Liq. 2\nRepr. 1a\nSTOT RE 2 *\nH225\nH360F *** H373 **\nGHS02\nGHS08\nDgr\nH225\nH360F *** H373 **\nEUH066\n602-086-00-0\ntrifluoroiodomethane;\ntrifluoromethyl iodide\n219-014-5\n2314-97-8\nMuta. 2\nH341\nGHS08\nWng\nH341\n602-087-00-6\n1,2,4-trichlorobenzene\n204-428-0\n120-82-1\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH315\nH410\n602-088-00-1\n2,3-dibromopropan-1-ol;\n2,3-dibromo-1-propanol\n202-480-9\n96-13-9\nCarc. 1B Repr. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH350\nH361f *** H311\nH332\nH302\nH412\nGHS08\nGHS07\nDgr\nH350\nH361f *** H311\nH332\nH302\nH412\n602-089-00-7\n4-bromo-2-chlorofluorobenzene\n405-580-2\n60811-21-4\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH315\nH410\n602-090-00-2\n1-allyl-3-chloro-4-fluorobenzene\n406-630-6\n121626-73-1\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n602-091-00-8\n1,3-dichloro-4-fluorobenzene\n406-160-1\n1435-48-9\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nH302\nH373 **\nH315\nH411\nGHS08\nGHS07\nWng\nH302\nH373 ** H315\nH411\n602-092-00-3\n1-bromo-3,4,5-trifluorobenzene\n418-480-9\n138526-69-9\nFlam. Liq. 3\nCarc. 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH226\nH351\nH315\nH318\nH411\nGHS02\nGHS08\nGHS05\nGHS09\nDgr\nH226\nH351\nH315\nH318\nH411\n602-093-00-9\nα, α, α,4-tetrachlorotoluene;\np-chlorobenzotrichloride\n226-009-1\n5216-25-1\nCarc. 1B Repr. 2\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nH350\nH361f *** H372 **\nH312\nH302\nH335\nH315\nGHS08\nGHS07\nDgr\nH350\nH361f *** H372 ** H312\nH302\nH335\nH315\n602-094-00-4\ndiphenylether;\noctabromo derivate\n251-087-9\n32536-52-0\nRepr. 1B\nH360Df\nGHS08\nDgr\nH360Df\n602-095-00-X\nalkanes, C14-17, chloro;\nchlorinated paraffins, C14-17\n287-477-0\n85535-85-9\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH362\nH400\nH410\nGHS09\nWng\nH362\nH410\nEUH066\n602-096-00-5\nmalachite green hydrochloride; [1]\nmalachite green oxalate [2]\n209-322-8 [1]\n219-441-7 [2]\n569-64-2 [1]\n2437-29-8 [2]\nRepr. 2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H302\nH318\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH361d *** H302\nH318\nH410\n602-097-00-0\n1-bromo-9-(4,4,5,5,5-pentafluoropentylthio)nonane\n422-850-5\n148757-89-5\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n602-098-00-6\n2-(3-bromophenoxy)tetrahydro-2H-pyran\n429-030-6\n57999-49-2\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n602-099-00-1\n3-(4-fluorophenyl)-2-methylpropionylchloride\n426-370-7\n—\nSkin Corr. 1A\nAcute Tox. 4 *\nAquatic Chronic 3\nH314\nH302\nH412\nGHS05\nGHS07\nDgr\nH314\nH302\nH412\nEUH014\nEUH029\n602-100-00-5\nreaction mass of: (R, R)-1,1,1,2,2,3,4,5,5,5-decafluoropentane;\n(S, S)-1,1,1,2,2,3,4,5,5,5-decafluoropentane\n420-640-8\n—\nAquatic Chronic 3\nH412\n—\nH412\n602-101-00-0\n2-chloro-4-fluoro-5-nitrophenyl(isobutyl)carbonate\n427-020-6\n141772-37-4\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373**\nH317\nH410\n602-102-00-6\n1,1,1,3,3-pentafluorobutane\n430-250-1\n406-58-6\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n602-103-00-1\n1-(chlorophenylmethyl)-2-methylbenzene\n431-450-1\n41870-52-4\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n602-104-00-7\n1,1,2,2,3,3,4-heptafluorocyclopentane\n430-710-1\n15290-77-4\nAquatic Chronic 3\nH412\n—\nH412\n602-105-00-2\nsodium 1,1,2,2,3,3,4,4,4-nonafluoro-1-butanesulfinate\n422-100-7\n102061-82-5\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n602-106-00-8\n2-bromo-4,6-difluoroaniline\n429-430-0\n444-14-4\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n602-107-00-3\n3,3,4,4-tetrafluoro-4-iodo-1-butene\n439-500-2\n33831-83-3\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Chronic 2\nH302\nH315\nH411\nGHS07\nGHS09\nWng\nH302\nH315\nH411\n602-108-00-9\n(2,3,5,6-tetrafluorophenyl)methanol\n443-840-7\n4084-38-2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH302\nH319\nH317\nGHS07\nWng\nH302\nH319\nH317\n602-109-00-4\nhexabromocyclododecane [1]\n1,2,5,6,9,10-hexabromocyclododecane [2]\n247-148-4 [1]\n221-695-9[2]\n25637-99-4[1]\n3194-55-6[2]\nRepr. 2\nLact.\nH361\nH362\nGHS08\nWng\nH361\nH362\n603-001-00-X\nmethanol\n200-659-6\n67-56-1\nFlam. Liq. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT SE 1\nH225\nH331\nH311\nH301\nH370 **\nGHS02\nGHS06\nGHS08\nDgr\nH225\nH331\nH311\nH301\nH370 **\n*\nSTOT SE 1; H370: C≥10 %\nSTOT SE 2; H371: 3 % ≤ C<10 %\n603-002-00-5\nethanol;\nethyl alcohol\n200-578-6\n64-17-5\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n603-003-00-0\npropan-1-ol;\nn-propanol\n200-746-9\n71-23-8\nFlam. Liq. 2\nEye Dam. 1\nSTOT SE 3\nH225\nH318\nH336\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH318\nH336\n603-004-00-6\nbutan-1-ol;\nn-butanol\n200-751-6\n71-36-3\nFlam. Liq. 3\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSTOT SE 3\nH226\nH302\nH335\nH315\nH318\nH336\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH302\nH335\nH315\nH318\nH336\n603-005-00-1\n2-methylpropan-2-ol;\ntert-butyl alcohol\n200-889-7\n75-65-0\nFlam. Liq. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH225\nH332\nH319\nH335\nGHS02\nGHS07\nDgr\nH225\nH332\nH319\nH335\n603-006-00-7\npentanol isomers, with the exception of those specified elsewhere in this Annex\n250-378-8\nFlam. Liq. 3\nAcute Tox. 4 * STOT SE 3\nH226\nH332\nH335\nGHS02\nGHS07\nWng\nH226\nH332\nH335\nEUH066\nC\n603-007-00-2\n2-methylbutan-2-ol;\ntert-pentanol\n200-908-9\n75-85-4\nFlam. Liq. 2\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nH225\nH332\nH335\nH315\nGHS02\nGHS07\nDgr\nH225\nH332\nH335\nH315\n603-008-00-8\n4-methylpentan-2-ol;\nmethyl isobutyl carbinol\n203-551-7\n108-11-2\nFlam. Liq. 3\nSTOT SE 3\nH226\nH335\nGHS02\nGHS07\nWng\nH226\nH335\nSTOT SE 3; H335: C ≥ 25 %\n603-009-00-3\ncyclohexanol\n203-630-6\n108-93-0\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nH332\nH302\nH335\nH315\nGHS07\nWng\nH332\nH302\nH335\nH315\n603-010-00-9\n2-methylcyclohexanol, mixed isomers; [1]\ncis-2-methylcyclohexanol; [2]\ntrans-2-methylcyclohexanol [3]\n209-512-0 [1]\n231-187-9 [2]\n231-186-3 [3]\n583-59-5 [1]\n7443-70-1 [2]\n7443-52-9 [3]\nAcute Tox. 4 *\nH332\nGHS07\nWng\nH332\nC\n603-011-00-4\n2-methoxyethanol;\nethylene glycol monomethyl ether\n203-713-7\n109-86-4\nFlam. Liq. 3\nRepr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH226\nH360FD\nH332\nH312\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH226\nH360FD H332\nH312\nH302\n603-012-00-X\n2-ethoxyethanol;\nethylene glycol monoethyl ether\n203-804-1\n110-80-5\nFlam. Liq. 3\nRepr. 1B\nAcute Tox. 3\nAcute Tox. 4\nH226\nH360FD\nH331\nH302\nGHS02\nGHS08\nGHS06\nDgr\nH226\nH360FD H331\nH302\n603-013-00-5\n2-isopropoxyethanol;\nethylene glycol monoisopropyl ether\n203-685-6\n109-59-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nH332\nH312\nH319\nGHS07\nWng\nH332\nH312\nH319\n603-014-00-0\n2-butoxyethanol;\nethyleneglycol monobutyl ether;\nbutyl cellosolve\n203-905-0\n111-76-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH332\nH312\nH302\nH319\nH315\nGHS07\nWng\nH332\nH312\nH302\nH319\nH315\n603-015-00-6\nallyl alcohol\n203-470-7\n107-18-6\nFlam. Liq. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH225\nH331\nH311\nH301\nH319\nH335\nH315\nH400\nGHS02\nGHS06\nGHS09\nDgr\nH225\nH331\nH311\nH301\nH319\nH335\nH315\nH400\n603-016-00-1\n4-hydroxy-4-methylpentan-2-one; diacetone alcohol\n204-626-7\n123-42-2\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\nEye Irrit. 2; H319: C≥ 10 %\n603-018-00-2\nfurfuryl alcohol\n202-626-1\n98-00-0\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSTOT SE 3\nH351\nH331\nH312\nH302\nH373**\nH319\nH335\nGHS06\nGHS08\nDgr\nH351\nH331\nH312\nH302\nH373**\nH319\nH335\n603-019-00-8\ndimethyl ether\n204-065-8\n115-10-6\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n603-020-00-3\nethyl methyl ether\n—\n540-67-0\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nU\n603-021-00-9\nmethyl vinyl ether\n203-475-4\n107-25-5\nFlam. Gas 1\nPress. Gas\nH220\nGHS02\nGHS04\nDgr\nH220\nD U\n603-022-00-4\ndiethyl ether;\nether\n200-467-2\n60-29-7\nFlam. Liq. 1\nAcute Tox. 4 *\nSTOT SE 3\nH224\nH302\nH336\nGHS02\nGHS07\nDgr\nH224\nH302\nH336\nEUH019\nEUH066\n603-023-00-X\nethylene oxide;\noxirane\n200-849-9\n75-21-8\nPress. Gas\nFlam. Gas 1\nCarc. 1B\nMuta. 1B\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH220\nH350\nH340\nH331\nH319\nH335\nH315\nGHS02\nGHS04\nGHS06\nGHS08\nDgr\nH220\nH350\nH340\nH331\nH319\nH335\nH315\nU\n603-024-00-5\n1,4-dioxane\n204-661-8\n123-91-1\nFlam. Liq. 2\nCarc. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH351\nH319\nH335\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH351\nH319\nH335\nEUH019\nEUH066\nD\n603-025-00-0\ntetrahydrofuran\n203-726-8\n109-99-9\nFlam. Liq. 2\nCarc. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH351\nH319\nH335\nGHS02\nGHS07\nGHS08\nDgr\nH225\nH351\nH319\nH335\nEUH019\nSTOT SE 3; H335: C≥25 % Eye Irrit.2;\nH319: C ≥ 25 %\n603-026-00-6\n1-chloro-2,3-epoxypropane; epichlorhydrin\n203-439-8\n106-89-8\nFlam. Liq. 3\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nH226\nH350\nH331\nH311\nH301\nH314\nH317\nGHS02\nGHS06\nGHS08\nGHS05\nDgr\nH226\nH350\nH331\nH311\nH301\nH314\nH317\n*\n603-027-00-1\nethanediol;\nethylene glycol\n203-473-3\n107-21-1\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n603-028-00-7\n2-chloroethanol;\nethylene chlorohydrin\n203-459-7\n107-07-3\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nH330\nH310\nH300\nGHS06\nDgr\nH330\nH310\nH300\n603-029-00-2\nbis(2-chloroethyl) ether\n203-870-1\n111-44-4\nCarc. 2\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nH351\nH330\nH310\nH300\nGHS06\nGHS08\nDgr\nH351\nH330\nH310\nH300\n603-030-00-8\n2-aminoethanol;\nethanolamine\n205-483-3\n141-43-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH332\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH332\nH312\nH302\nH314\nSTOT SE 3; H335: C ≥ 5 %\n603-031-00-3\n1,2-dimethoxyethane;\nethylene glycol dimethyl ether;\nEGDME\n203-794-9\n110-71-4\nFlam. Liq. 2\nRepr. 1B\nAcute Tox. 4 *\nH225\nH360FD\nH332\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH360FD H332\nEUH019\n603-032-00-9\nethylene dinitrate;\nethylene glycol dinitrate\n211-063-0\n628-96-6\nUnst. Expl.\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2\nH200\nH330\nH310\nH300\nH373**\nGHS01\nGHS06\nGHS08\nDgr\nH200\nH330\nH310\nH300\nH373**\n603-033-00-4\noxydiethylene dinitrate;\ndiethylene glycol dinitrate;\ndigol dinitrate\n211-745-8\n693-21-0\nUnst. Expl\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 3\nH200\nH330\nH310\nH300\nH373 **\nH412\nGHS01\nGHS06\nGHS08\nDgr\nH200\nH330\nH310\nH300\nH373 **\nH412\n603-033-01-1\noxydiethylene dinitrate;\ndiethylene glycol dinitrate;\ndigol dinitrate;\n[>25 % phlegmatiser]\n211-745-8\n693-21-0\nExpl. 1.1\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 3\nH201\nH330\nH310\nH300\nH373 **\nH412\nGHS01\nGHS06\nGHS08\nDgr\nH201\nH330\nH310\nH300\nH373 ** H412\n603-034-00-X\nglycerol trinitrate; nitroglycerine\n200-240-8\n55-63-0\nUnst. Expl.\nAcute Tox. 2 * Acute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 2\nH200\nH330\nH310\nH300\nH373 ** H411\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH200\nH330\nH310\nH300\nH373 ** H411\n603-034-01-7\nglycerol trinitrate; nitroglycerine; [>40 % phlegmatiser]\n200-240-8\n55-63-0\nExpl. 1.1\nAcute Tox. 2 * Acute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 2\nH201\nH330\nH310\nH300\nH373 ** H411\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH330\nH310\nH300\nH373 ** H411\n603-035-00-5\npentaerythritol tetranitrate; pentaerythrite tetranitrate; P.E.T.N.\n201-084-3\n78-11-5\nUnst. Expl.\nH200\nGHS01\nDgr\nH200\n603-035-01-2\npentaerythritol tetranitrate; pentaerythrite tetranitrate; P.E.T.N.;[>20 % phlegmatiser]\n201-084-3\n78-11-5\nExpl. 1.1\nH201\nGHS01\nDgr\nH201\nT\n603-036-00-0\nmannitol hexanitrate; nitromannite\n239-924-6\n15825-70-4\nUnst. Expl.\nH200\nGHS01\nDgr\nH200\n603-036-01-8\nmannitol hexanitrate; nitromannite;[>40 % phlegmatiser]\n239-924-6\n15825-70-4\nExpl. 1.1\nH201\nGHS01\nDgr\nH201\n603-037-00-6\ncellulose nitrate; nitrocellulose\n—\n—\nExpl. 1.1\nH201\nGHS01\nDgr\nH201\nT\n603-038-00-1\nallyl glycidyl ether; allyl 2,3-epoxypropyl ether; prop-2-en-1-yl 2,3-epoxypropyl ether\n203-442-4\n106-92-3\nFlam. Liq. 3\nCarc. 2\nMuta. 2\nRepr. 2\nAcute Tox. 4 * Acute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH226\nH351\nH341\nH361f *** H332\nH302\nH335\nH315\nH318\nH317\nH412\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH226\nH351\nH341\nH361f *** H332\nH302\nH335\nH315\nH318\nH317\nH412\n603-039-00-7\nbutyl glycidyl ether; butyl 2,3-epoxypropyl ether\n219-376-4\n2426-08-6\nFlam. Liq. 3\nCarc. 2\nMuta. 2\nAcute Tox. 4 * Acute Tox. 4 * STOT SE 3\nSkin Sens. 1\nAquatic Chronic 3\nH226\nH351\nH341\nH332\nH302\nH335\nH317\nH412\nGHS02\nGHS08\nGHS07\nWng\nH226\nH351\nH341\nH332\nH302\nH335\nH317\nH412\n603-040-00-2\nsodium methanolate; sodium methoxide; [1] potassium methanolate; potassium methoxide; [2] lithium methanolate; lithium methoxide [3]\n204-699-5 [1]\n212-736-1 [2]\n212-737-7 [3]\n124-41-4 [1]\n865-33-8 [2]\n865-34-9 [3]\nSelf-heat 1\nSkin Corr. 1B\nH251\nH314\nGHS02\nGHS05\nDgr\nH251\nH314\nEUH014\nT\n603-041-00-8\npotassium ethanolate; potassium ethoxide; [1] sodium ethanolate; sodium ethoxide [2]\n213-029-0 [1]\n205-487-5 [2]\n917-58-8 [1]\n141-52-6 [2]\nSelf-heat 1\nSkin Corr. 1B\nH251\nH314\nGHS02\nGHS05\nDgr\nH251\nH314\nEUH014\nT\n603-042-00-3\naluminium-tri-isopropoxide\n209-090-8\n555-31-7\nFlam. Sol. 1\nH228\nGHS02\nDgr\nH228\nT\n603-043-00-9\ntriarimol (ISO); 2,4-dichloro-α-(pyrimidin-5-yl)benzhydryl alcohol\n—\n26766-27-8\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n603-044-00-4\ndicofol (ISO); 2,2,2-trichloro-1,1-bis(4-chlorophenyl)ethanol\n204-082-0\n115-32-2\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH315\nH317\nH410\n603-045-00-X\ndiisopropyl ether; [1] dipropyl ether [2]\n203-560-6 [1]\n203-869-6 [2]\n108-20-3 [1]\n111-43-3 [2]\nFlam. Liq. 2\nSTOT SE 3\nH225\nH336\nGHS02\nGHS07\nDgr\nH225\nH336\nEUH019\nEUH066\nC\n603-046-00-5\nbis(chloromethyl) ether; oxybis(chloromethane)\n208-832-8\n542-88-1\nFlam. Liq. 2\nCarc. 1A\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 *\nH225\nH350\nH330\nH311\nH302\nGHS02\nGHS06\nGHS08\nDgr\nH225\nH350\nH330\nH311\nH302\nCarc. 1A; H350: C ≥ 0,001 %\n603-047-00-0\n2-dimethylaminoethanol; N,N-dimethylethanolamine\n203-542-8\n108-01-0\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1B\nH226\nH332\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH332\nH312\nH302\nH314\nSTOT SE 3; H335: C≥5 %\n603-048-00-6\n2-diethylaminoethanol; N,N-diethylethanolamine\n202-845-2\n100-37-8\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1B\nH226\nH332\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH226\nH332\nH312\nH302\nH314\nSTOT SE 3; H335: C≥5 %\n603-049-00-1\nchlorfenethol (ISO); 1,1-bis (4-chlorophenyl) ethanol\n201-246-3\n80-06-8\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n603-050-00-7\n1-(2-butoxypropoxy)propan-2-ol\n246-011-6\n24083-03-2\nAcute Tox. 4 * Acute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n603-051-00-2\n2-ethylbutan-1-ol\n202-621-4\n97-95-0\nAcute Tox. 4 * Acute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n603-052-00-8\n3-butoxypropan-2-ol; propylene glycol monobutyl ether\n225-878-4\n5131-66-8\nEye Irrit. 2\nSkin Irrit. 2\nH319\nH315\nGHS07\nWng\nH319\nH315\n603-053-00-3\n2-methylpentane-2,4-diol\n203-489-0\n107-41-5\nEye Irrit. 2\nSkin Irrit. 2\nH319\nH315\nGHS07\nWng\nH319\nH315\n603-054-00-9\ndi-n-butyl ether; dibutyl ether\n205-575-3\n142-96-1\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 3\nH226\nH319\nH335\nH315\nH412\nGHS02\nGHS07\nWng\nH226\nH319\nH335\nH315\nH412\nSTOT SE 3; H335: C≥10 %\n603-056-00-X\n[(p-tolyloxy)methyl]oxirane; [1] [(m-tolyloxy)methyl]oxirane; [2]2,3-epoxypropyl o-tolyl ether; [3] [(tolyloxy)methyl]oxirane; cresyl glycidyl ether [4]\n218-574-8 [1]\n218-575-3 [2]\n218-645-3 [3]\n247-711-4 [4]\n2186-24-5 [1]\n2186-25-6 [2]\n2210-79-9 [3]\n26447-14-3 [4]\nMuta. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH341\nH315\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH341\nH315\nH317\nH411\nC\n603-057-00-5\nbenzyl alcohol\n202-859-9\n100-51-6\nAcute Tox. 4 * Acute Tox. 4 *\nH332\nH302\nGHS07\nWng\nH332\nH302\n603-058-00-0\n1,3-propylene oxide\n207-964-3\n503-30-0\nFlam. Liq. 2\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nH225\nH332\nH312\nH302\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\n603-059-00-6\nhexan-1-ol\n203-852-3\n111-27-3\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n603-060-00-1\n2,2'-bioxirane; 1,2:3,4-diepoxybutane\n215-979-1\n1464-53-5\nCarc. 1B Muta. 1B\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nH350\nH340\nH330\nH311\nH301\nH314\nGHS06\nGHS08\nGHS05\nDgr\nH350\nH340\nH330\nH311\nH301\nH314\n603-061-00-7\ntetrahydro-2-furyl-methanol; tetrahydrofurfuryl alcohol\n202-625-6\n97-99-4\nRepr. 1B Eye Irrit. 2\nH360Df\nH319\nGHS08\nGHS07\nDgr\nH360Df\nH319\n603-062-00-2\ntetrahydrofuran-2,5-diyldimethanol\n203-239-0\n104-80-3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\nSTOT SE 3; H335: C ≥10 %\n603-063-00-8\n2,3-epoxypropan-1-ol; glycidol; oxiranemethanol\n209-128-3\n556-52-5\nCarc. 1B Muta. 2\nRepr. 1B\nAcute Tox. 3 * Acute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH350\nH341\nH360F *** H331\nH312\nH302\nH319\nH335\nH315\nGHS06\nGHS08\nDgr\nH350\nH341\nH360F *** H331\nH312\nH302\nH319\nH335\nH315\n603-064-00-3\n1-methoxy-2-propanol; monopropylene glycol methyl ether\n203-539-1\n107-98-2\nFlam. Liq. 3\nSTOT SE 3\nH226\nH336\nGHS02\nGHS07\nWng\nH226\nH336\n603-065-00-9\nresorcinol diglycidyl ether;1,3-bis(2,3-epoxypropoxy)benzene\n202-987-5\n101-90-6\nCarc. 2\nMuta. 2\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH351\nH341\nH312\nH302\nH319\nH315\nH317\nH412\nGHS08\nGHS07\nWng\nH351\nH341\nH312\nH302\nH319\nH315\nH317\nH412\n603-066-00-4\n1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide\n203-437-7\n106-87-6\nCarc. 2\nAcute Tox. 3 * Acute Tox. 3 *\nAcute Tox. 3 *\nH351\nH331\nH311\nH301\nGHS06\nGHS08\nDgr\nH351\nH331\nH311\nH301\n*\n603-067-00-X\nphenyl glycidyl ether; 2,3-epoxypropyl phenyl ether;1,2-epoxy-3-phenoxypropane\n204-557-2\n122-60-1\nCarc. 1B Muta. 2\nAcute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH341\nH332\nH335\nH315\nH317\nH412\nGHS08\nGHS07\nDgr\nH350\nH341\nH332\nH335\nH315\nH317\nH412\n603-068-00-5\n2,3-epoxypropyl-2-ethylcyclohexyl ether; ethylcyclohexylglycidyl ether\n—\n130014-35-6\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\n603-069-00-0\n2,4,6-tris(dimethylaminomethyl)phenol\n202-013-9\n90-72-2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH302\nH319\nH315\nGHS07\nWng\nH302\nH319\nH315\n603-070-00-6\n2-amino-2-methylpropanol\n204-709-8\n124-68-5\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 3\nH319\nH315\nH412\nGHS07\nWng\nH319\nH315\nH412\n603-071-00-1\n2,2'-iminodiethanol; diethanolamine\n203-868-0\n111-42-2\nAcute Tox. 4 * STOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nH302\nH373 ** H315\nH318\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH373 ** H315\nH318\n603-072-00-7\n1,4-bis(2,3 epoxypropoxy)butane; butanedioldiglycidyl ether\n219-371-7\n2425-79-8\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH332\nH312\nH319\nH315\nH317\nGHS07\nWng\nH332\nH312\nH319\nH315\nH317\n603-073-00-2\nbis-[4-(2,3-epoxipropoxi)phenyl]propane\n216-823-5\n1675-54-3\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nEye Irrit. 2; H319: C≥ 5 % Skin Irrit. 2; H315: C≥5 %\n603-074-00-8\nreaction product: bisphenol-A-(epichlorhydrin); epoxy resin (number average molecular weight ≤ 700)\n500-033-5\n25068-38-6\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH319\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH319\nH315\nH317\nH411\nEye Irrit. 2; H319: C ≥ 5 % Skin Irrit 2; H315: C≥ 5 %\n603-075-00-3\nchlormethyl methyl ether; chlorodimethyl ether\n203-480-1\n107-30-2\nFlam. Liq. 2\nCarc. 1A\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nH225\nH350\nH332\nH312\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH350\nH332\nH312\nH302\n603-076-00-9\nbut-2-yne-1,4-diol; 2-butyne-1,4-diol\n203-788-6\n110-65-6\nSkin Corr. 1B\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 *\nSkin Sens. 1\nH314\nH331\nH301\nH312\nH373 ** H317\nGHS06\nGHS05\nGHS08\nDgr\nH314\nH331\nH301\nH312\nH373 ** H317\nSkin Corr. 1B; H314: C≥50 % Skin Irrit. 2; H315: 25 %≤ C < 50 %\nEye Irrit. 2; H319: 25 %≤\nC<50 %\nD\n603-077-00-4\n1-dimethylaminopropan-2-ol; dimepranol (INN)\n203-556-4\n108-16-7\nFlam. Liq. 3\nAcute Tox. 4 *\nSkin Corr. 1B\nH226\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH302\nH314\n603-078-00-X\nprop-2-yn-1-ol; propargyl alcohol\n203-471-2\n107-19-7\nFlam. Liq. 3\nAcute Tox. 3 * Acute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nAquatic Chronic 2\nH226\nH331\nH311\nH301\nH314\nH411\nGHS02\nGHS06\nGHS05\nGHS09\nDgr\nH226\nH331\nH311\nH301\nH314\nH411\n603-079-00-5\n2,2'-(methylimino)diethanol; N-methyldiethanolamine\n203-312-7\n105-59-9\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-080-00-0\n2-methylaminoethanol; N-methylethanolamine; N-methyl-2-ethanolamine; N-methyl-2-amino ethanol; 2-(methylamino)ethanol\n203-710-0\n109-83-1\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1B\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\nSTOT SE 3; H335: C≥5 %\n603-081-00-6\n2,2'-thiodiethanol; thiodiglycol\n203-874-3\n111-48-8\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-082-00-1\n1-aminopropan-2-ol; isopropanolamine\n201-162-7\n78-96-6\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n603-083-00-7\n1,1'-iminodipropan-2-ol; di-isopropanolamine\n203-820-9\n110-97-4\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-084-00-2\nstyrene oxide;(epoxyethyl)benzene; phenyloxirane\n202-476-7\n96-09-3\nCarc. 1B\nAcute Tox. 4 *\nEye Irrit. 2\nH350\nH312\nH319\nGHS08\nGHS07\nDgr\nH350\nH312\nH319\n603-085-00-8\nbronopol (INN); 2-bromo-2-nitropropane-1,3-diol\n200-143-0\n52-51-7\nAcute Tox. 4 * Acute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nH312\nH302\nH335\nH315\nH318\nH400\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH335\nH315\nH318\nH400\nM=10\n603-086-00-3\nethirimol (ISO); 5-butyl-2-ethylamino-6-methylpyrimidin-4-ol\n245-949-3\n23947-60-6\nAcute Tox. 4 *\nH312\nGHS07\nWng\nH312\n603-087-00-9\n2-ethylhexane-1,3-diol; octylene glycol; ethoexadiol\n202-377-9\n94-96-2\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n603-088-00-4\n2-(octylthio)ethanol; 2-hydroxyethyl octyl sulphide\n222-598-4\n3547-33-9\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n603-089-00-X\n7,7-dimethyl-3-oxa-6-azaoctan-1-ol\n400-390-6\n—\nSkin Corr. 1A\nAcute Tox. 4 *\nH314\nH302\nGHS05\nGHS07\nDgr\nH314\nH302\n603-090-00-5\n2-(2-bromoethoxy)anisole\n402-010-4\n4463-59-6\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n603-091-00-0\nexo-1-methyl-4-(1-methylethyl)-7-oxabicyclo[2.2.1]heptan-2-ol\n402-470-6\n87172-89-2\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n603-092-00-6\n2-methyl-4-phenylpentanol\n402-770-7\n92585-24-5\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n603-093-00-1\ncinmethylin (ISO); exo-(±)-1-methyl-2-(2-methylbenzyloxy)-4-isopropyl-7-oxabicyclo(2.2.1)heptane\n402-410-9\n87818-31-3\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH411\nGHS07\nGHS09\nDgr\nH332\nH411\n603-094-00-7\n1,3-bis(2,3-epoxypropoxy)-2,2-dimethylpropane\n241-536-7\n17557-23-2\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n603-095-00-2\n2-(propyloxy)ethanol; EGPE\n220-548-6\n2807-30-9\nAcute Tox. 4 *\nEye Irrit. 2\nH312\nH319\nGHS07\nWng\nH312\nH319\n603-096-00-8\n2-(2-butoxyethoxy)ethanol; diethylene glycol monobutyl ether\n203-961-6\n112-34-5\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-097-00-3\n1,1’,1’-nitrilotripropan-2-ol; triisopropanolamine\n204-528-4\n122-20-3\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-098-00-9\n2-phenoxyethanol\n204-589-7\n122-99-6\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n603-099-00-4\n3-(N-methyl-N-(4-methylamino-3-nitrophenyl)amino)propane-1,2-diol hydrochloride\n403-440-5\n93633-79-5\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n603-100-00-8\n1,2-dimethoxypropane\n404-630-0\n7778-85-0\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\nEUH019\n603-101-00-3\ntetrahydro-2-isobutyl-4-methylpyran-4-ol, mixed isomers (cis and trans)\n405-040-6\n—\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-103-00-4\noxirane, mono[(C12-14-alkyloxy)methyl] derivs.\n271-846-8\n68609-97-2\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n603-104-00-X\nfenarimol (ISO); 2,4'-dichloro-α-(pyrimidin-5-yl)benzhydryl alcohol\n262-095-7\n60168-88-9\nRepr. 2\nLact.\nAquatic Chronic 2\nH361fd\nH362\nH411\nGHS08\nGHS09\nWng\nH361fd\nH362\nH411\n603-105-00-5\nfuran\n203-727-3\n110-00-9\nFlam. Liq. 1\nCarc. 1B Muta. 2\nAcute Tox. 4 * Acute Tox. 4 * STOT RE 2 *\nSkin Irrit. 2\nAquatic Chronic 3\nH224\nH350\nH341\nH332\nH302\nH373 ** H315\nH412\nGHS02\nGHS08\nGHS07\nDgr\nH224\nH350\nH341\nH332\nH302\nH373 ** H315\nH412\nEUH019\n603-106-00-0\n2-methoxypropanol\n216-455-5\n1589-47-5\nFlam. Liq. 3\nRepr. 1B\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH226\nH360D *** H335\nH315\nH318\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH226\nH360D *** H335\nH315\nH318\n603-107-00-6\n2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether\n203-906-6\n111-77-3\nRepr. 2\nH361d ***\nGHS08\nWng\nH361d ***\n603-108-00-1\n2-methylpropan-1-ol; iso-butanol\n201-148-0\n78-83-1\nFlam. Liq. 3\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSTOT SE 3\nH226\nH335\nH315\nH318\nH336\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH335\nH315\nH318\nH336\n603-109-00-7\nreaction mass of: 1-ethoxy-1,1,2,3,3,3-hexafluoro-2-(trifluoromethyl)propane; 1-ethoxy-1,1,2,2,3,3,4,4,4-nonafluorobutane\n425-340-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n603-110-00-2\nreaction mass of: cis-2-isobutyl-5-methyl 1,3-dioxane; trans-2-isobutyl-5-methyl 1,3-dioxane\n426-130-1\n166301-21-9\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n603-111-00-8\nreaction mass of: 1-(1,1-dimethylpropyl)-4-ethoxy-cis-cyclohexane; 1-(1,1-dimethylpropyl)-4-ethoxy-trans-cyclohexane\n426-530-6\n—\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n603-112-00-3\ncyclopentyl 2-phenylethyl ether\n428-340-9\n—\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n603-113-00-9\n6-glycidyloxynapht-1-yl oxymethyloxirane\n429-960-2\n27610-48-6\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH341\nH312\nH315\nH317\nH412\nGHS08\nGHS07\nWng\nH341\nH312\nH315\nH317\nH412\n603-114-00-4\n9-(2-propenyloxy)tricyclo[5.2.1.0(2,6)]dec-3(or-4-)-ene\n430-830-2\n26912-64-1\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n603-115-00-X\nreaction mass of: O, O',O''-(methylsilanetriyl)tris(4-methyl-2-pentanone oxime) (3 stereoisomers)\n423-580-0\n—\nSTOT RE 2 *\nAquatic Chronic 4\nH373** H413\nGHS08\nWng\nH373** H413\n603-116-00-5\n(Z)-(2,4-difluorophenyl)piperidin-4-ylmethanone oxime monohydrochloride\n424-740-2\n138271-16-6\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n603-117-00-0\npropan-2-ol; isopropyl alcohol; isopropanol\n200-661-7\n67-63-0\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\n603-118-00-6\n6-dimethylaminohexan-1-ol\n404-680-3\n1862-07-3\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 3\nH302\nH314\nH412\nGHS05\nGHS07\nDgr\nH302\nH314\nH412\n603-119-00-1\n1,1'-(1,3-phenylenedioxy)bis(3-(2-(prop-2-enyl)phenoxy)propan-2-ol)\n405-840-5\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n603-120-00-7\n2-methyl-5-phenylpentanol\n405-890-8\n25634-93-9\nEye Irrit. 2\nSkin Irrit. 2\nH319\nH315\nGHS07\nWng\nH319\nH315\n603-121-00-2\n4-[4-(1,3-dihydroxyprop-2-yl)phenylamino]-1,8-dihydroxy-5-nitroanthraquinone\n406-057-1\n114565-66-1\nCarc. 2\nSkin Sens. 1\nAquatic Chronic 4\nH351\nH317\nH413\nGHS08\nGHS07\nWng\nH351\nH317\nH413\n603-122-00-8\nsodium 2-ethylhexanolate\n406-150-7\n38411-13-1\nFlam. Sol. 1\nSkin Corr. 1B\nAquatic Chronic 3\nH228\nH314\nH412\nGHS02\nGHS05\nDgr\nH228\nH314\nH412\nT\n603-123-00-3\n4-methyl-8-methylenetricyclo[3.3.1.1 3,7]decan-2-ol\n406-330-5\n122760-84-3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH315\nH317\nH411\n603-124-00-9\n1,4-bis[2-(vinyloxy)ethoxy]benzene\n406-900-3\n84563-49-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-125-00-4\n2-(2,4-dichlorophenyl)-1-(1H—1,2,4-triazol-1-yl)pent-4-en-2-ol\n407-850-5\n89544-40-1\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n603-126-00-X\n2-((4-methyl-2-nitrophenyl)amino)ethanol\n408-090-7\n100418-33-5\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n603-127-00-5\nbutan-2-ol; [1](S)-butan-2-ol; [2] (R)-butan-2-ol; [3](±)-butan-2-ol [4]\n201-158-5 [1]\n224-168-1 [2]\n238-967-8 [3]\n240-029-8 [4]\n78-92-2 [1]\n4221-99-2 [2]\n14898-79-4 [3]\n15892-23-6 [4]\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nSTOT SE 3\nH226\nH319\nH335\nH336\nGHS02\nGHS07\nWng\nH226\nH319\nH335\nH336\nC\n603-128-00-0\n2-(phenylmethoxy)naphthalene\n405-490-3\n613-62-7\nAquatic Chronic 4\nH413\n—\nH413\n603-129-00-6\n1-tert-butoxypropan-2-ol\n406-180-0\n57018-52-7\nFlam. Liq. 3\nEye Dam. 1\nH226\nH318\nGHS02\nGHS05\nDgr\nH226\nH318\n603-130-00-1\nreaction mass of isomers of: α-((dimethyl)biphenyl)-ω-hydroxypoly(oxyethylene)\n406-325-8\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n603-131-00-7\nreaction mass of: 1-deoxy-1-[methyl-(1-oxododecyl)amino]-D-glucitol; 1-deoxy-1-[methyl-(1-oxotetradecyl)amino]-D-glucitol (3:1)\n407-290-1\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n603-132-00-2\n2-hydroxymethyl-9-methyl-6-(1-methylethyl)-1,4-dioxaspiro[4.5]decane\n408-200-3\n63187-91-7\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH315\nH318\nH412\nGHS05\nDgr\nH315\nH318\nH412\n603-133-00-8\nreaction mass of: 3-[(4-amino-2-chloro-5-nitrophenyl)amino]-propane-1,2-diol; 3,3'-(2-chloro-5-nitro-1,4-phenylenediimino)bis(propan-1,2-diol)\n408-240-1\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n603-134-00-3\nreaction mass of substituted dodecyl and/or tetradecyl, diphenyl ethers. The substance is produce by the Friedel Crafts reaction. The catalyst is removed from the reaction product. Diphenyl ether is substituted by C1-C10 alkyl groups. The alkyl groups are bonded randomly between C1 and C6 Linear C12 and C14, 50/50 used.\n410-450-3\n—\nAquatic Chronic 4\nH413\n—\nH413\n603-135-00-9\nbis[[2,2',2''-nitrilotris-[ethanolato]]-1-N,O]-bis[2-(2-methoxyethoxy)ethoxy]-titanium\n410-500-4\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n603-136-00-4\n3-((4-(bis(2-hydroxyethyl)amino)-2-nitrophenyl)amino)-1-propanol\n410-910-3\n104226-19-9\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n603-137-00-X\nreaction mass of:1-deoxy-1-[methyl-(1-oxohexadecyl)amino]-D-glucitol; 1-deoxy-1-[methyl-(1-oxooctadecyl)amino]-D-glucitol\n411-130-6\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n603-138-00-5\n3-(2,2-dimethyl-3-hydroxypropyl)toluene;(alt.): 2,2-dimethyl-3-(3-methylphenyl)propanol\n403-140-4\n103694-68-4\nAquatic Chronic 3\nH412\n—\nH412\n603-139-00-0\nbis(2-methoxyethyl) ether\n203-924-4\n111-96-6\nFlam. Liq. 3\nRepr. 1B\nH226\nH360FD\nGHS02\nGHS08\nDgr\nH226\nH360FD\nEUH019\n603-140-00-6\n2,2' -oxybisethanol; diethylene glycol\n203-872-2\n111-46-6\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n603-141-00-1\nreaction mass of: dodecyloxy-1-methyl-1-[oxy-poly-(2-hydroxymethylethanoxy)]pentadecane; dodecyloxy-1-methyl-1-[oxy-poly-(2-hydroxymethylethanoxy)]heptadecane\n413-780-6\n—\nAquatic Chronic 3\nH412\n—\nH412\n603-142-00-7\n2-(2-(2-hydroxyethoxy)ethyl)-2-aza-bicyclo[2.2.1]heptane\n407-360-1\n116230-20-7\nAcute Tox. 4 * Acute Tox. 4 * STOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nH312\nH302\nH373 ** H315\nH318\nGHS06\nGHS08\nGHS05\nDgr\nH312\nH302\nH373 ** H315\nH318\n603-143-00-2\nR—2,3-epoxy-1-propanol\n404-660-4\n57044-25-4\nSelf-react. C **** Carc. 1B\nMuta. 2\nRepr. 1B\nAcute Tox. 3 * Acute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH242\nH350\nH341\nH360F *** H331\nH312\nH302\nH314\nGHS02\nGHS06\nGHS08\nGHS05\nDgr\nH242\nH350\nH341\nH360F *** H331\nH312\nH302\nH314\n603-144-00-8\nReaction mass of: 2,6,9-trimethyl-2,5,9-cyclododecatrien-1-ol; 6,9-dimethyl-2-methylen-5,9-cyclododecadien-1-ol\n413-530-6\n111850-00-1\nAquatic Chronic 2\nH411\nGHS09\nH411\n603-145-00-3\n2-isopropyl-2-(1-methylbutyl)-1,3-dimethoxypropane\n406-970-5\n129228-11-1\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n603-146-00-9\n2-[(2-[2-(dimethylamino)ethoxy]ethyl)methylamino]ethanol\n406-080-7\n83016-70-0\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 3\nH302\nH314\nH412\nGHS05\nGHS07\nDgr\nH302\nH314\nH412\n603-147-00-4\n(-)-trans-4-(4'-fluorophenyl)-3-hydroxymethyl-N-methylpiperidine\n406-030-4\n105812-81-5\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n603-148-00-X\n1,4-bis[(vinyloxy)methyl]cyclohexane\n413-370-7\n17351-75-6\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n603-149-00-5\nreaction mass of: diastereoisomers of 1-(1-hydroxyethyl)-4-(1-methylethyl)cyclohexane\n407-640-3\n63767-86-2\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH319\nH315\nH411\nGHS07\nGHS09\nWng\nH319\nH315\nH411\n603-150-00-0\n(±) trans—3,3-dimethyl-5-(2,2,3-trimethyl-cyclopent-3-en-1-yl)-pent-4-en-2-ol\n411-580-3\n107898-54-4\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n603-151-00-6\n(±)-2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-1-ol\n413-570-4\n—\nAquatic Chronic 3\nH412\n—\nH412\n603-152-00-1\n2-(4-tert-butylphenyl)ethanol\n410-020-5\n5406-86-0\nRepr. 2\nSTOT RE 2 *\nEye Dam. 1\nAquatic Chronic 2\nH361f *** H373 ** H318\nH411\nGHS08\nGHS05\nGHS09\nDgr\nH361f *** H373 ** H318\nH411\n603-153-00-7\n3-((2-nitro-4-(trifluoromethyl)phenyl)amino)propane-1,2-diol\n410-010-0\n104333-00-8\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n603-154-00-2\n1-[(2-tert-butyl)cyclohexyloxy]-2-butanol\n412-300-2\n139504-68-0\nAquatic Chronic 2\nH411\nGHS09\nH411\n603-156-00-3\n2-(2,4-dichlorophenyl)-2-(2-propenyl)oxirane\n411-210-0\n89544-48-9\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n603-157-00-9\n6,9-bis(hexadecyloxymethyl)-4,7-dioxanonane-1,2,9-triol\n411-450-6\n143747-72-2\nAquatic Chronic 4\nH413\n—\nH413\n603-158-00-4\nreaction mass of: 4 diastereoisomers of 2,7-dimethyl-10-(1-methylethyl)-1-oxaspiro[4.5]deca-3,6-diene\n412-460-3\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n603-159-00-X\n2-cyclododecylpropan-1-ol\n411-410-8\n118562-73-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-160-00-5\n1,2-diethoxypropane\n412-180-1\n10221-57-5\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\nEUH019\n603-161-00-0\n1,3-diethoxypropane\n413-140-6\n3459-83-4\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\n603-162-00-6\nα[2-[[[(2-hydroxyethyl)methylamino]acetyl]amino]propyl]-ω nonylphenoxy)poly[oxo(methyl-1,2-ethanediyl)]\n413-420-8\n144736-29-8\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH411\n603-163-00-1\n2-phenyl-1,3-propanediol\n411-810-2\n1570-95-2\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n603-164-00-7\n2-butyl-4-chloro-4,5-dihydro-5-hydroxymethyl-1-[2'-(2-triphenylmethyl-1,2,3,4-2H-tetrazol-5-yl)-1,1'-biphenyl-4-methyl]-1H-imidazole\n412-420-5\n133909-99-6\nAquatic Chronic 4\nH413\n—\nH413\n603-165-00-2\nreaction mass of: 4-allyl-2,6-bis(2,3-epoxypropyl)phenol; 4-allyl-6-[3-[6-[3-[6-[3-(4-allyl-2,6-bis(2,3-epoxypropyl)phenoxy)-2-hydroxypropyl]-4-allyl-2-(2,3-epoxypropyl)phenoxy]-2-hydroxypropyl]-4-allyl-2-(2,3-epoxypropyl)phenoxy]-2-hydroxypropyl]-2-(2,3-epoxypropyl)phenol; 4-allyl-6-[3-(4-allyl-2,6-bis(2,3-epoxypropyl)phenoxy)-2-hydroxypropyl]-2-(2,3-epoxypropyl)phenol; 4-allyl-6-[3-[6-[3-(4-allyl-2,6-bis(2,3-epoxypropyl)phenoxy)-2-hydroxypropyl]-4-allyl-2-(2,3-epoxypropyl)phenoxy]-2-hydroxypropyl]-2-(2,3-epoxypropyl)phenol\n417-470-1\n—\nMuta. 2\nSkin Sens. 1\nH341\nH317\nGHS08\nGHS07\nWng\nH341\nH317\n603-166-00-8\nR-1-chloro-2,3-epoxypropane\n424-280-2\n51594-55-9\nFlam. Liq. 3\nCarc. 1B\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nH226\nH350\nH331\nH311\nH301\nH314\nH317\nGHS02\nGHS06\nGHS08\nGHS05\nDgr\nH226\nH350\nH331\nH311\nH301\nH314\nH317\n603-167-00-3\n3,3',5,5'-tetra-tert-butylbiphenyl-2,2'-diol\n407-920-5\n6390-69-8\nAquatic Chronic 4\nH413\nGHS05\nDgr\nH413\n603-168-00-9\n3-(2-ethylhexyloxy)propane-1,2-diol\n408-080-2\n70445-33-9\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n603-169-00-4\n(±)-trans-4-(4-fluorophenyl)-3-hydroxymethyl-N-methylpiperidine\n415-550-0\n109887-53-8\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n603-170-00-X\nreaction mass of: 2-methyl-1-(6-methylbicyclo[2.2.1]hept-5-en-2-yl)pent-1-en-3-ol; 2-methyl-1-(1-methylbicyclo[2.2.1]hept-5-en-2-yl)-pent-1-en-3-ol; 2-methyl-1-(5-methylbicyclo[2.2.1]hept-5-en-2-yl)pent-1-en-3-ol\n415-990-3\n67739-11-1\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n603-171-00-5\n5-thiazolylmethanol\n414-780-9\n38585-74-9\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n603-172-00-0\nmono-2-[2-(4-dibenzo[b, f][1,4]thiazepin-11-yl)piperazinium-1-yl]ethoxy)ethanol trans-butenedioate\n415-180-1\n773058-82-5\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n603-173-00-6\n4,4-dimethyl-3,5,8-trioxabicyclo[5.1.0]octane\n421-750-9\n57280-22-5\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n603-174-00-1\n4-cyclohexyl-2-methyl-2-butanol\n420-630-3\n83926-73-2\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n603-175-00-7\n2-(2-hexyloxyethoxy)ethanol; DEGHE; diethylene glycol monohexyl ether; 3,6-dioxa-1-dodecanol; hexyl carbitol; 3,6-dioxadodecan-1-ol\n203-988-3\n112-59-4\nAcute Tox. 4 *\nEye Dam. 1\nH312\nH318\nGHS05\nGHS07\nDgr\nH312\nH318\n603-176-00-2\n1,2-bis(2-methoxyethoxy)ethane; TEGDME; triethylene glycol dimethyl ether; triglyme\n203-977-3\n112-49-2\nRepr. 1B\nH360Df\nGHS08\nDgr\nH360Df\nEUH019\n603-177-00-8\n1-ethoxypropan-2-ol; 2PG1EE; 1-ethoxy-2-propanol; propylene glycol monoethyl ether; [1] 2-ethoxy-1-methylethyl acetate; 2PG1EEA [2]\n216-374-5 [1]\n259-370-9 [2]\n1569-02-4 [1]\n54839-24-6 [2]\nFlam. Liq. 3\nSTOT SE 3\nH226\nH336\nGHS02\nGHS07\nWng\nH226\nH336\n603-178-00-3\n2-hexyloxyethanol; ethylene glycol monohexyl ether; n-hexylglycol\n203-951-1\n112-25-4\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1B\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n603-179-00-9\nergocalciferol (ISO); Vitamin D2\n200-014-9\n50-14-6\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1\nH330\nH311\nH301\nH372 **\nGHS06\nGHS08\nDgr\nH330\nH311\nH301\nH372 **\n603-180-00-4\ncolecalciferol; Vitamin D3\n200-673-2\n67-97-0\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1\nH330\nH311\nH301\nH372 **\nGHS06\nGHS08\nDgr\nH330\nH311\nH301\nH372 **\n603-181-00-X\ntert-butyl methyl ether; MTBE; 2-methoxy-2-methylpropane\n216-653-1\n1634-04-4\nFlam. Liq. 2\nSkin Irrit. 2\nH225\nH315\nGHS02\nGHS07\nDgr\nH225\nH315\n603-182-00-5\nreaction product of: saturated, monounsaturated and multiple unsaturated long-chained partly estrified alcohols of vegetable origin (Brassica napus L., Brassica rapa L., Helianthus annuus L., Glycine hispida, Gossypium hirsutum L., Cocos nucifera L., Elaeis guineensis) with O, O-diisobutyldithiophosphate and 2-ethylhexylamine and hydrogen peroxide\n428-630-5\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n603-183-00-0\n2-[2-(2-butoxyethoxy)ethoxy]ethanol; TEGBE; triethylene glycol monobutylether; butoxytriethylene glycol\n205-592-6\n143-22-6\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\nEye Dam.1; H318: C≥30 % Eye Irrit. 2; H319: 20 % ≤C< 30 %\n603-184-00-6\n2-(hydroxymethyl)-2-[[2-hydroxy-3-(isooctadecyloxy)propoxy]methyl]-1,3-propanediol\n416-380-1\n146925-83-9\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-185-00-1\n2,4-dichloro-3-ethyl-6-nitrophenol\n420-740-1\n99817-36-4\nAcute Tox. 3 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH318\nH317\nH410\n603-186-00-7\ntrans-(5RS,6SR)-6-amino-2,2-dimethyl-1,3-dioxepan-5-ol\n419-050-3\n79944-37-9\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n603-187-00-2\n2-((4,6-bis(4-(2-(1-methylpyridinium-4-yl)vinyl)phenylamino)-1,3,5-triazin-2-yl)(2-hydroxyethyl)amino)ethanol dichloride\n419-360-9\n163661-77-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-188-00-8\nreaction mass of: 6,7-epoxy-1,2,3,4,5,6,7,8-octahydro-1,1,2,4,4,7-hexamethylnaphthalene; 7,8-epoxy-1,2,3,4,6,7,8,8a-octahydro-1,1,2,4,4,7-hexamethylnaphthalene\n426-970-9\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-189-00-3\nreaction mass of complexes of: titanium, 2,2'-oxydiethanol, ammonium lactate, nitrilotris(2-propanol) and ethylene glycol\n405-250-8\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n603-190-00-9\n8,8-dimethyl-7-isopropyl-6,10-dioxaspiro[4.5]decane\n424-030-2\n62406-73-9\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n603-191-00-4\n2-(4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl)-5-(3-((2-ethylhexyl)oxy)-2-hydroxypropoxy)phenol\n419-740-4\n137658-79-8\nAquatic Chronic 4\nH413\n—\nH413\n603-192-00-X\n(E,E)-3,7,11-trimethyldodeca-1,4,6,10-tetraen-3-ol\n423-240-1\n125474-34-2\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n603-193-00-5\ndisodium 9,10-anthracenedioxide\n426-030-8\n46492-07-3\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\n603-194-00-0\n2-(2-aminoethylamino)ethanol; (AEEA)\n203-867-5\n111-41-1\nRepr. 1B\nSkin Corr. 1B\nSkin Sens. 1\nH360Df\nH314\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH360Df\nH314\nH317\nSTOT SE 3; H335: C≥5 %\n603-195-00-6\n2-[4-(4-methoxyphenyl)-6-phenyl-1,3,5-triazin-2-yl]-phenol\n430-810-3\n154825-62-4\nAquatic Chronic 3\nH412\n—\nH412\n603-196-00-1\n2-(7-ethyl-1H-indol-3-yl)ethanol\n431-020-1\n41340-36-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH302\nH373 ** H411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 ** H411\n603-199-00-8\netoxazol (ISO); (RS)-5-tert-butyl-2-[2-(2,6-difluorophenyl)-4,5-dihydro-1,3-oxazol-4-yl]phenetole\n—\n153233-91-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 100\n603-200-00-1\n1-pentanol; [1] 3-pentanol [2]\n200-752-1 [1]\n209-526-7 [2]\n71-41-0 [1]\n584-02-1 [2]\nFlam. Liq. 3\nAcute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nH226\nH332\nH335\nH315\nGHS02\nGHS07\nWng\nH226\nH332\nH335\nH315\n603-201-00-7\n(E)-(7R,11R)-3,7,11,15-tetramethylhexadec-2-ene-1-ol\n416-120-5\n—\nSkin Irrit. 2\nAquatic Chronic 4\nH315\nH413\nGHS07\nWng\nH315\nH413\n603-202-00-2\n4,4,5,5,5-pentafluoropentan-1-ol\n421-360-9\n148043-73-6\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n603-203-00-8\n(1R,3S,7R,8R,10R,13R)-5,5,7,9,9,13-hexamethyl-4,6-dioxatetracyclo[6.5.1.01,10.03,7]tetradecane\n427-580-1\n—\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n603-204-00-3\nreaction mass of: 2,2'-(heptane-1,7-diyl)bis-1,3-dioxolane; 2,2'-(heptane-1,6-diyl)bis-1,3-dioxolane\n428-110-8\n—\nAquatic Chronic 3\nH412\n—\nH412\n603-205-00-9\n(1S-cis)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol hydrochloride\n426-200-1\n172015-79-1\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH372** H302\nH318\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH372** H302\nH318\nH317\nH412\n603-206-00-4\n2,2-dichloro-1,3-benzodioxol\n426-850-6\n2032-75-9\nFlam. Liq. 3\nSkin Corr. 1A\nAcute Tox. 4 *\nSkin Sens. 1\nH226\nH314\nH302\nH317\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH314\nH302\nH317\nEUH014\n603-207-00-X\n2-isobutyl-2-isopropyl-1,3-dimethoxypropane\n430-800-9\n129228-21-3\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n603-208-00-5\n1,2-diethoxyethane\n211-076-1\n629-14-1\nFlam. Liq. 2\nRepr. 1A Eye Irrit. 2\nH225\nH360Df\nH319\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH360Df\nH319\nEUH019\n603-209-00-0\nspinosad (ISO) (reaction mass of spinosyn A and spinosyn D in ratios between 95:5 to 50:50); reaction mass of 50-95 % of (2R, 3aS, 5aR, 5bS, 9S, 13S,14R, 16aS, 16bR)-2-(6-deoxy-2,3,4-tri-O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethylamino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-14-methyl-1H-8-oxacyclododeca[b]as-indacene-7,15-dione and 50-5 % (2S, 3aR, 5aS,5bS, 9S, 13S, 14R, 16aS, 16bS)-2-(6-deoxy-2,3,4-tri-O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethylamino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-4,14-dimethyl-1H-8-oxacyclododeca[b]as-indacene-7,15-dione; [1] spinosyn A; [2] spinosyn D [3]\n-[1]\n-[2]\n-[3]\n-[1]\n131929-60-7 [2]\n131929-63-0 [3]\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=10\n603-210-00-6\n2,4-diethyl-1,5-pentanediol\n429-310-8\n57987-55-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n603-211-00-1\n2,3-epoxypropyltrimethylammonium chloride … %; glycidyl trimethylammonium chloride … %\n221-221-0\n3033-77-0\nCarc. 1B Muta. 2\nRepr. 2\nAcute Tox. 4 * Acute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH341\nH361f*** H312\nH302\nH373** H318\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH350\nH341\nH361f*** H312\nH302\nH373** H318\nH317\nH412\nB\n603-212-00-7\n1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyran; galaxolide;(HHCB)\n214-946-9\n1222-05-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-213-00-2\n2-methoxy-2-methylbutane; tert-amyl methyl ether\n213-611-4\n994-05-8\nFlam. Liq. 2\nAcute Tox. 4 * STOT SE 3\nH225\nH302\nH336\nGHS02\nGHS07\nDgr\nH225\nH302\nH336\n603-214-00-8\n1,1-diisopropoxycyclohexane\n413-740-8\n1132-95-2\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n603-215-00-3\n1-hydroxy-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)\n418-330-2\n162241-33-0\nExpl. 1.1****\nAcute Tox. 4 * STOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH302\nH373** H318\nH317\nH400\nH410\nGHS01\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH201\nH302\nH373** H318\nH317\nH410\n603-216-00-9\ncis-1-amino-2,3-dihydro-1H-inden-2-ol\n422-660-2\n7480-35-5\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n603-217-00-4\n2,4,6-tri-tert-butylphenyl 2-butyl-2-ethyl-1,3-propanediolphosphite\n423-560-1\n161717-32-4\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n603-220-00-0\n1-{]benzyl[}2-(2-methoxyphenoxy)ethyl]amino}-3-(9H-carbazol-4-yloxy)propan-2-ol\n432-890-5\n72955-94-3\nAquatic Chronic 4\nH413\n—\nH413\n603-221-00-6\n1-(2-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing < 0,1 % 4-chloroaniline (EC No 203-401-0)]\n433-580-2\n214353-17-0\nAcute Tox. 4 *\nSkin Corr. 1B Aquatic Chronic 2\nH302\nH314\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH411\n603-221-01-3\n1-(2-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing ≥ 0,1 % 4-chloroaniline (EC No 203-401-0)]\n433-580-2\n214353-17-0\nCarc. 1B\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH350\nH302\nH314\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH314\nH411\n603-222-00-1\n(2R, 3S, 4R, 5R, 7R, 9R, 10R,11S, 12S, 13R)-10-[(4-dimethylamino-3-hydroxy-6-methyltetrahydropyran-2-yl)oxy]-2-ethyl-3,4,12-trihydroxy-9-methoxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-1-oxacyclotetradecane\n433-820-6\n118058-74-5\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-223-00-7\n2-cyclopentylidene cyclopentanol 1,1'-bi(cyclopentyliden)-2-ol\n434-270-1\n6261-30-9\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH315\nH318\nH412\nGHS05\nDgr\nH315\nH318\nH412\n603-224-00-2\n3-ethoxy-1,1,1,2,3,4,4,5,5,6,6,6-dodecafluoro-2-(trifluoromethyl)-hexane\n435-790-1\n297730-93-9\nAquatic Chronic 4\nH413\n—\nH413\n603-225-00-8\nerythromycin A9-oxime (E);(3R, 4S, 5S, 6R, 7R, 9R, 11R,12R, 13S, 14R)-4-((2,6-didesoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopiranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-tridesoxy-3-dimethylamino-β-d-xylohexapiranosyl)oxy)oxacyclotetradecan-2-ona-10-oxime (E)\n437-070-0\n13127-18-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n603-226-00-3\n4,4'(4-(4-methoxyphenyl)-1,3,5-triazin-2,4-diyl)bisbenzene-1,3-diol\n444-500-0\n1440-00-2\nAquatic Chronic 3\nH412\n—\nH412\n603-227-00-9\nα-hydro-ω-[[[(1,1-dimethylethyl)dioxy]carbonyl]oxy]-poly[oxy(methyl-1,2-ethanediyl)] ether with 2,2-bis(hydroxymethyl)-1,3-propanediol (4:1); reaction product of: α-hydro-ω-((chlorocarbonyl)oxy)-poly(oxy(methyl-1,2-ethanediyl)) ether with 2,2-bis(hydroxymethyl)-1,3-propanediol with potassium 1,1-dimethylethylperoxalate\n445-060-2\n203574-04-3\n****\nAquatic Acute 1\nAquatic Chronic 1\n**** H400\nH410\n**** GHS09\nWng\n**** H410\n603-228-00-4\n(+/–)-(R*,R*)-6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran; 6-fluoro-2-(2-oxiranyl)chromane\n419-620-1\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n603-229-00-X\nsodium (Z)-3-chloro-3-(4-chlorophenyl)-1-hydroxy-2-propene-1-sulfonate\n420-800-7\n—\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n603-230-00-5\n2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan\n440-030-5\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 4\nH315\nH318\nH413\nGHS05\nDgr\nH315\nH318\nH413\n603-231-00-0\n(S)-1,1-diphenyl-1,2-propanediol\n443-220-6\n—\nAquatic Chronic 3\nH412\n—\nH412\n603-232-00-6\n3,3,8,8,10,10-hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undecane\n444-420-6\n—\nAquatic Chronic 4\nH413\n—\nH413\n603-233-00-1\nreaction mass of: 4-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 4-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 1-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol; 1-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-1H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-3H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol\n444-430-0\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n603-234-00-7\n(1R, 4R)-4-methoxy-2,2,7,7-tetramethyltricyclo(6.2.1.0(1,6))undec-5-ene\n444-480-3\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n604-001-00-2\nphenol; carbolic acid; monohydroxybenzene; phenylalcohol\n203-632-7\n108-95-2\nMuta. 2\nAcute Tox. 3 * Acute Tox. 3 *\nAcute Tox. 3 * STOT RE 2 *\nSkin Corr. 1B\nH341\nH331\nH311\nH301\nH373 ** H314\nGHS06\nGHS08\nGHS05\nDgr\nH341\nH331\nH311\nH301\nH373 ** H314\n*\nSkin Corr. 1B; H314: C ≥ 3 %\nSkin Irrit. 2; H315 1 % ≤ C<3 %\nEye Irrit. 2; H319:1 % ≤C<3 %\n604-002-00-8\npentachlorophenol\n201-778-6\n87-86-5\nCarc. 2\nAcute Tox. 2 * Acute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH330\nH311\nH301\nH319\nH335\nH315\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH330\nH311\nH301\nH319\nH335\nH315\nH410\n604-003-00-3\nsodiumpentachlorophenolate; [1] potassium pentachlorophenolate[2]\n205-025-2 [1]\n231-911-3 [2]\n131-52-2 [1]\n7778-73-6 [2]\nCarc. 2\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH330\nH311\nH301\nH319\nH335\nH315\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH330\nH311\nH301\nH319\nH335\nH315\nH410\n604-004-00-9\nm-cresol; [1] o-cresol; [2] p-cresol; [3] mix-cresol [4]\n203-577-9 [1]\n202-423-8 [2]\n203-398-6 [3]\n215-293-2 [4]\n108-39-4 [1]\n95-48-7 [2]\n106-44-5 [3]\n1319-77-3 [4]\nAcute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nH311\nH301\nH314\nGHS06\nGHS05\nDgr\nH311\nH301\nH314\n*\nC\n604-005-00-4\n1,4-dihydroxybenzene; hydroquinone; quinol\n204-617-8\n123-31-9\nCarc. 2\nMuta. 2\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH351\nH341\nH302\nH318\nH317\nH400\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH341\nH302\nH318\nH317\nH400\nM=10\n604-006-00-X\n3,4-xylenol; [1] 2,5-xylenol; [2] 2,4-xylenol; [3] 2,3-xylenol; [4] 2,6-xylenol; [5] xylenol; [6] 2,4(or 2,5)-xylenol [7]\n202-439-5 [1]\n202-461-5 [2]\n203-321-6 [3]\n208-395-3 [4]\n209-400-1 [5]\n215-089-3 [6]\n276-245-4 [7]\n95-65-8 [1]\n95-87-4 [2]\n105-67-9 [3]\n526-75-0 [4]\n576-26-1 [5]\n1300-71-6 [6]\n71975-58-1 [7]\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nAquatic Chronic 2\nH311\nH301\nH314\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH301\nH314\nH411\nC\n604-007-00-5\n2-naphthol\n205-182-7\n135-19-3\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nH332\nH302\nH400\nGHS07\nGHS09\nWng\nH332\nH302\nH400\n604-008-00-0\n2-chlorophenol; [1] 4-chlorophenol; [2] 3-chlorophenol; [3] chlorophenol [4]\n202-433-2 [1]\n203-402-6 [2]\n203-582-6 [3]\n246-691-4 [4]\n95-57-8 [1]\n106-48-9 [2]\n108-43-0 [3]\n25167-80-0 [4]\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH312\nH302\nH411\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH411\nC\n604-009-00-6\npyrogallol; 1,2,3-trihydroxybenzene\n201-762-9\n87-66-1\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH341\nH332\nH312\nH302\nH412\nGHS08\nGHS07\nWng\nH341\nH332\nH312\nH302\nH412\n*\n604-010-00-1\nresorcinol; 1,3-benzenediol\n203-585-2\n108-46-3\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nH302\nH319\nH315\nH400\nGHS07\nGHS09\nWng\nH302\nH319\nH315\nH400\n*\n604-011-00-7\n2,4-dichlorophenol\n204-429-6\n120-83-2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH311\nH302\nH314\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH302\nH314\nH411\n604-012-00-2\n4-chloro-o-cresol; 4-chloro-2-methylphenol\n216-381-3\n1570-64-5\nAcute Tox. 3 *\nSkin Corr. 1A Aquatic Acute 1\nH331\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH314\nH400\nSTOT SE 3; H335: C≥1 %\n604-013-00-8\n2,3,4,6-tetrachlorophenol\n200-402-8\n58-90-2\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH319\nH315\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH319\nH315\nH410\n*\nEye Irrit. 2; H319:C≥5 % Skin Irrit. 2;\nH315: C≥5 %\n604-014-00-3\nchlorocresol; 4-chloro-m-cresol; 4-chloro-3-methylphenol\n200-431-6\n59-50-7\nAcute Tox. 4 * Acute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH312\nH302\nH318\nH317\nH400\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH318\nH317\nH400\n*\n604-015-00-9\n2,2'-methylenebis-(3,4,6-trichlorophenol); hexachlorophene\n200-733-8\n70-30-4\nAcute Tox. 3 *\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH301\nH410\n*\n604-016-00-4\n1,2-dihydroxybenzene; pyrocatechol\n204-427-5\n120-80-9\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH312\nH302\nH319\nH315\nGHS07\nWng\nH312\nH302\nH319\nH315\n604-017-00-X\n2,4,5-trichlorophenol\n202-467-8\n95-95-4\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH315\nH410\n*\nEye Irrit. 2; H319: C≥5 %\nSkin Irrit.2; H315: C ≥5 %\n604-018-00-5\n2,4,6-trichlorophenol\n201-795-9\n88-06-2\nCarc. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH319\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH319\nH315\nH410\n604-019-00-0\ndichlorophen (ISO)\n202-567-1\n97-23-4\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH410\n604-020-00-6\n2-phenylphenol (ISO)biphenyl-2-ol; 2-hydroxybiphenyl;\n201-993-5\n90-43-7\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH319\nH335\nH315\nH400\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH400\n604-021-00-1\nsodium 2-biphenylate; 2-phenylphenol, sodium salt\n205-055-6\n132-27-4\nAcute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nH302\nH335\nH315\nH318\nH400\nGHS05\nGHS07\nGHS09\nWng\nH302\nH335\nH315\nH318\nH400\n604-022-00-7\n2,2-dimethyl-1,3-benzodioxol-4-ol\n400-900-7\n22961-82-6\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n604-023-00-2\n2,4-dichloro-3-ethylphenol\n401-060-4\n—\nSkin Corr. 1B Aquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n604-024-00-8\n4,4-isobutylethylidenediphenol\n401-720-1\n6807-17-6\nRepr. 1B\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH360F *** H319\nH400\nH410\nGHS08\nGHS09\nDgr\nH360F *** H319\nH410\n604-025-00-3\n2,5-bis(1,1-dimethylbutyl)hydroquinone\n400-220-0\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n604-026-00-9\n2,2-spirobi(6-hydroxy-4,4,7-trimethylchromane)\n400-270-3\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n604-027-00-4\n2-methyl-5-(1,1,3,3-tetramethylbutyl)hydroquinone\n400-530-6\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n604-028-00-X\n4-amino-3-fluorophenol\n402-230-0\n399-95-1\nCarc. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH302\nH317\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH317\nH411\n604-029-00-5\n1-naphtol\n201-969-4\n90-15-3\nAcute Tox. 4 * Acute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH312\nH302\nH335\nH315\nH318\nGHS05\nGHS07\nDgr\nH312\nH302\nH335\nH315\nH318\n604-031-00-6\nguaiacol\n201-964-7\n90-05-1\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH302\nH319\nH315\nGHS07\nWng\nH302\nH319\nH315\n604-032-00-1\nthymol\n201-944-8\n89-83-8\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH302\nH314\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH411\n604-033-00-7\nisobutyl but-3-enoate\n401-170-2\n24342-03-8\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\n604-034-00-2\n4,4'-thiodi-o-cresol\n403-330-7\n24197-34-0\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n604-035-00-8\n4-nonylphenol, reaction products with formaldehyde and dodecane-1-thiol\n404-160-6\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n604-036-00-3\n4,4'-oxybis(ethylenethio)diphenol\n404-590-4\n90884-29-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n604-037-00-9\n3,5-xylenol; 3,5-dimethylphenol\n203-606-5\n108-68-9\nAcute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nH311\nH301\nH314\nGHS06\nGHS05\nDgr\nH311\nH301\nH314\n604-038-00-4\n4-chloro-3,5-dimethylphenol; [1] chloroxylenol [2]\n201-793-8 [1]\n215-316-6 [2]\n88-04-0 [1]\n1321-23-9 [2]\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH302\nH319\nH315\nH317\nGHS07\nWng\nH302\nH319\nH315\nH317\n604-039-00-X\nethyl 2-[4-[(6-chlorobenzoxazol-2-yl)oxy]phenoxy]propionate; fenoxaprop-ethyl\n266-362-9\n66441-23-4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n604-040-00-5\nfomesafen (ISO); 5-[2-chloro-4-(trifluoromethyl)phenoxy]-N-(methylsulphonyl)-2-nitrobenzamide\n276-439-9\n72178-02-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n604-041-00-0\nacifluorfen (ISO); 5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoic acid [1] sodium 5-[2-chloro-4-(trifluoromethyl) phenoxy]-2-nitrobenzoate; acifluorfen-sodium [2]\n256-634-5 [1]\n263-560-7 [2]\n50594-66-6 [1]\n62476-59-9 [2]\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH315\nH318\nH410\n604-042-00-6\n4-nitrosophenol\n203-251-6\n104-91-6\nMuta. 2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH341\nH302\nH318\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH341\nH302\nH318\nH411\n604-043-00-1\nmonobenzone; 4-hydroxyphenyl benzyl ether; hydroquinone monobenzyl ether\n203-083-3\n103-16-2\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n604-044-00-7\nmequinol; 4-methoxyphenol; hydroquinone monomethyl ether\n205-769-8\n150-76-5\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH302\nH319\nH317\nGHS07\nWng\nH302\nH319\nH317\n604-045-00-2\n2,3,5-trimethylhydroquinone\n211-838-3\n700-13-0\nAcute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH335\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH335\nH315\nH318\nH317\nH410\n604-046-00-8\n4-(4-isopropoxyphenylsulfonyl)phenol\n405-520-5\n95235-30-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n604-047-00-3\n4-(4-tolyloxy)biphenyl\n405-730-7\n51601-57-1\nSTOT RE 2 *\nAquatic Chronic 4\nH373 ** H413\nGHS08\nWng\nH373 ** H413\n604-048-00-9\n4,4',4''-(ethan-1,1,1-triyl)triphenol\n405-800-7\n27955-94-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n604-049-00-4\n4-4'-methylenebis(oxyethylenethio)diphenol\n407-480-4\n93589-69-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n604-051-00-5\n3,5-bis((3,5-di-tert-butyl-4-hydroxy)benzyl)-2,4,6-trimethylphenol\n401-110-5\n87113-78-8\nAquatic Chronic 3\nH412\n—\nH412\n604-052-00-0\n2,2'-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)\n403-800-1\n103597-45-1\nAquatic Chronic 4\nH413\n—\nH413\n604-053-00-6\n2-methyl-4-(1,1-dimethylethyl)-6-(1-methyl-pentadecyl)-phenol\n410-760-9\n157661-93-3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n604-054-00-1\nreaction mass of: 2-methoxy-4-(tetrahydro-4-methylene-2H-pyran-2-yl)-phenol; 4-(3,6-dihydro-4-methyl-2H-pyran-2-yl)-2-methoxyphenol\n412-020-0\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n604-055-00-7\n2,2'-((3,3', 5,5'-tetramethyl-(1,1'-biphenyl)-4,4'-diyl)-bis(oxymethylene))-bis-oxirane\n413-900-7\n85954-11-6\nCarc. 2\nSkin Sens. 1\nH351\nH317\nGHS08\nGHS07\nWng\nH351\nH317\n604-056-00-2\n2-(2-hydroxy-3,5-dinitroanilino)ethanol\n412-520-9\n99610-72-7\nFlam. Sol. 2\nRepr. 2\nAcute Tox. 4 *\nH228\nH361f *** H302\nGHS02\nGHS07\nGHS08\nDgr\nH228\nH361f *** H302\n604-058-00-3\n1,2-bis(3-methylphenoxy)ethane\n402-730-9\n54914-85-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-059-00-9\n2-n-hexadecylhydroquinone\n406-400-5\n—\nSTOT RE 2 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH373 ** H315\nH317\nH413\nGHS08\nGHS07\nWng\nH373 ** H315\nH317\nH413\n604-060-00-4\n9,9-bis(4-hydroxyphenyl)fluorene\n406-950-6\n3236-71-3\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\n604-061-00-X\nreaction mass of: 2-chloro-5-sec-tetradecylhydroquinones where sec-tetradecyl = 1-methyltridecyl; 1-ethyldodecyl; 1-propylundecyl; 1-butyldecyl; 1-pentylnonyl; 1-hexyloctyl\n407-740-7\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH315\nH317\nH412\nGHS07\nWng\nH315\nH317\nH412\n604-062-00-5\n2,4-dimethyl-6-(1-methyl-pentadecyl)phenol\n411-220-5\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n604-063-00-0\n5,6-dihydroxyindole\n412-130-9\n3131-52-0\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n604-064-00-6\n2-(4,6-diphenyl-1,3,5-triazin-2-yl)-5-((hexyl)oxy)-phenol\n411-380-6\n147315-50-2\nAquatic Chronic 4\nH413\n—\nH413\n604-065-00-1\n4,4',4''-(1-methylpropan-1-yl-3-ylidene)tris(2-cyclohexyl-5-methylphenol)\n407-460-5\n111850-25-0\nAquatic Chronic 2\nH411\nGHS09\nH411\n604-066-00-7\nreaction mass of: phenol, 6-(1,1-dimethylethyl)-4-tetrapropyl-2-[(2-hydroxy-5-tetra-propylphenyl)methyl (C41-compound) and methane, 2,2'-bis[6-(1,1-dimethyl-ethyl)-1-hydroxy-4-tetrapropyl-phenyl)]-(C45-compound); 2,6-bis(1,1-dimethylethyl)-4-tetra-propyl-phenol and 2-(1,1-dimethylethyl)-4-tetrapropyl-phenol; 2,6-bis[(6-(1,1-dimethylethyl)-1-hydroxy-4-tetrapropylphenyl)methyl]-4-(tetrapropyl)phenol and 2-[(6-(1,1-dimethylethyl)-1-hydroxy-4-tetrapropylphenylmethyl]-6-[1-hydroxy-4-tetrapropylphenyl)methyl]-4-(tetrapropyl)phenol\n414-550-8\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-067-00-2\nreaction mass of: 2,2'-[[(2-hydroxyethyl)imino]bis(methylene)bis[4-dodecylphenol]; formaldehyde, oligomer with 4-dodecyl phenol and 2-aminoethanol(n = 2); formaldehyde, oligomer with 4-dodecyl phenol and 2-aminoethanol(n = 3, 4 and higher)\n414-520-4\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n604-068-00-8\n(±)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride\n415-170-5\n90274-24-1\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Sens. 1\nH332\nH302\nH317\nGHS07\nWng\nH332\nH302\nH317\n604-069-00-3\n2-(1-methylpropyl)-4-tert-butylphenol\n421-740-4\n51390-14-8\nSkin Corr. 1B\nAquatic Chronic 2\nH314\nH411\nGHS05\nGHS09\nDgr\nH314\nH411\n604-070-00-9\ntriclosan;2,4,4'-trichloro-2'-hydroxy-diphenyl-ether; 5-chloro-2-(2,4-dichlorophenoxy)phenol\n222-182-2\n3380-34-5\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\nM = 100\n604-071-00-4\n4,4'-(1-{4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl}ethylidene)diphenol\n425-600-3\n110726-28-8\nAquatic Chronic 4\nH413\n—\nH413\n604-072-00-X\n1,2-bis(phenoxymethyl)benzene\n428-620-0\n10403-74-4\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-073-00-5\n(E)-3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol\n428-010-4\n82413-20-5\nCarc. 2\nRepr. 1B Skin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH360F*** H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360F*** H317\nH410\n604-074-00-0\ntetrabromobisphenol-A; 2,2', 6,6'-tetrabromo-4,4'-isopropylidenediphenol\n201-236-9\n79-94-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-075-00-6\n4-(1,1,3,3-tetramethylbutyl)phenol; 4-tert-octylphenol\n205-426-2\n140-66-9\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\nM=10\n604-076-00-1\nphenolphthalein\n201-004-7\n77-09-8\nCarc. 1B Muta. 2\nRepr. 2\nH350\nH341\nH361f***\nGHS08\nDgr\nH350\nH341\nH361f***\nCarc. 1B; H350: C ≥1 %\n604-077-00-7\n2-benzotriazol-2-yl-4-methyl-6-(2-methylallyl)phenol\n419-750-9\n98809-58-6\nAquatic Chronic 4\nH413\n—\nH413\n604-079-00-8\n4,4'-(1,3-phenylene-bis(1-methylethylidene))bis-phenol\n428-970-4\n13595-25-0\nRepr. 2\nSkin Sens. 1\nAquatic Chronic 2\nH361f*** H317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH361f*** H317\nH411\n604-080-00-3\n4-fluoro-3-trifluoromethylphenol\n432-560-0\n61721-07-1\nAcute Tox. 4 *\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Chronic 2\nH332\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH314\nH317\nH411\n604-081-00-9\n1,1-bis(4-hydroxyphenyl)-1-phenylethane\n433-130-5\n1571-75-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-082-00-4\n2-chloro-6-fluoro-phenol\n433-890-8\n2040-90-6\nMuta. 1B Repr. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH340\nH361f*** H302\nH314\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH340\nH361f*** H302\nH314\nH317\nH411\n604-083-00-X\n4,4'-sulfonylbisphenol, polymer with ammonium chloride(NH4Cl), pentachlorophosphorane and phenol\n439-270-3\n260408-02-4\nAquatic Chronic 4\nH413\n—\nH413\n604-084-00-5\n1-ethoxy-2,3-difluorobenzene\n441-000-4\n121219-07-6\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n604-087-00-1\nreaction mass of: 1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)monoester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol; 1,2-naphthoquinonediazide-5-sulfonylchloride(or sulfonicacid)diester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol; 1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)triester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol\n433-640-8\n—\nPyr. Sol. 1\nAquatic Chronic 4\nH250\nH413\nGHS02\nDgr\nH250\nH413\nEUH044\n604-089-00-2\n2-methyl-5-tert-butylthiophenol\n444-970-7\n—\nFlam. Liq. 3\nRepr. 2\nSTOT RE 2 *\nAsp. Tox. 1\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH361d*** H373** H304\nH319\nH315\nH317\nH336\nH400\nH410\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH361d*** H373** H304\nH319\nH315\nH317\nH336\nH410\n604-090-00-8\n4-tert-butylphenol\n202-679-0\n98-54-4\nRepr. 2\nSkin Irrit. 2\nEye Dam. 1\nH361f\nH315\nH318\nGHS08\nGHS05\nDgr\nH361f\nH315\nH318\n604-091-00-3\netofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether\n407-980-2\n80844-07-1\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH362\nH400\nH410\nGHS09\nWng\nH362\nH410\nM = 100\nM = 1 000\n605-001-00-5\nformaldehyde …%\n200-001-8\n50-00-0\nCarc. 1B Muta. 2\nAcute Tox. 3* Acute Tox. 3* Acute Tox. 3*\nSkin Corr. 1B\nSkin Sens. 1\nH350\nH341\nH301\nH311\nH331\nH314\nH317\nGHS08\nGHS06\nGHS05\nDgr\nH350\nH341\nH301\nH311\nH331\nH314\nH317\n*\nSkin Corr. 1B; H314: C ≥25 % Skin Irrit. 2; H315: 5 % ≤C\n< 25 %\nEye Irrit. 2; H319: 5 % ≤ C\n<25 %\nSTOT SE 3; H335: C ≥ 5 % SkinSens.; H317: C ≥ 0,2 %\nB, D\n605-002-00-0\n1,3,5-trioxan; trioxymethylene\n203-812-5\n110-88-3\nFlam. Sol. 1\nRepr. 2\nSTOT SE 3\nH228\nH361d *** H335\nGHS02\nGHS08\nGHS07\nDgr\nH228\nH361d *** H335\nT\n605-003-00-6\nacetaldehyde; ethanal\n200-836-8\n75-07-0\nFlam. Liq. 1\nCarc. 2\nEye Irrit. 2\nSTOT SE 3\nH224\nH351\nH319\nH335\nGHS02\nGHS08\nGHS07\nDgr\nH224\nH351\nH319\nH335\n605-004-00-1\n2,4,6-trimethyl-1,3,5-trioxane; paraldehyde\n204-639-8\n123-63-7\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\n605-005-00-7\n2,4,6,8-tetramethyl-1,3,5,7-tetraoxacyclooctane; metaldehyde\n203-600-2\n108-62-3\nFlam. Sol. 2\nAcute Tox. 4 *\nH228\nH302\nGHS02\nGHS07\nWng\nH228\nH302\n605-006-00-2\nbutyraldehyde\n204-646-6\n123-72-8\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n605-007-00-8\n1,1-dimethoxyethane; dimethyl acetal\n208-589-8\n534-15-6\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n605-008-00-3\nacrolein; prop-2-enal; acrylaldehyde\n203-453-4\n107-02-8\nFlam. Liq. 2\nAcute Tox. 1\nAcute Tox. 2\nAcute Tox. 3\nSkin Corr. 1B Aquatic Acute 1\nAquatic Chronic 1\nH225\nH330\nH300\nH311\nH314\nH400\nH410\nGHS02\nGHS06\nGHS05\nGHS09\nDgr\nH225\nH330\nH300\nH311\nH314\nH410\nEUH071\nSkin Corr. 1B; H314:C≥ 0,1 %\nM = 100\nM = 1\nD\n605-009-00-9\ncrotonaldehyde; 2-butenal; [1] (E)-2-butenal; (E)-crotonaldehyde [2]\n224-030-0 [1]\n204-647-1 [2]\n4170-30-3 [1]\n123-73-9 [2]\nFlam. Liq. 2\nMuta. 2\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * STOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nH225\nH341\nH330\nH311\nH301\nH373 ** H335\nH315\nH318\nH400\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH225\nH341\nH330\nH311\nH301\nH373 ** H335\nH315\nH318\nH400\n605-010-00-4\n2-furaldehyde\n202-627-7\n98-01-1\nCarc. 2\nAcute Tox. 3 * Acute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH351\nH331\nH301\nH312\nH319\nH335\nH315\nGHS06\nGHS08\nDgr\nH351\nH331\nH301\nH312\nH319\nH335\nH315\n605-011-00-X\n2-chlorobenzaldehyde; o-chlorobenzaldehyde\n201-956-3\n89-98-5\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n605-012-00-5\nbenzaldehyde\n202-860-4\n100-52-7\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n605-014-00-6\nchloral hydrate; 2,2,2-trichloroethane-1,1-diol\n206-117-5\n302-17-0\nAcute Tox. 3 * Eye Irrit. 2\nSkin Irrit. 2\nH301\nH319\nH315\nGHS06\nDgr\nH301\nH319\nH315\n605-015-00-1\n1,1-diethoxyethane; acetal\n203-310-6\n105-57-7\nFlam. Liq. 2\nEye Irrit. 2\nSkin Irrit. 2\nH225\nH319\nH315\nGHS02\nGHS07\nDgr\nH225\nH319\nH315\n605-016-00-7\nglyoxal…%; ethandial…%\n203-474-9\n107-22-2\nMuta. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH341\nH332\nH319\nH315\nH317\nGHS07\nGHS08\nWng\nH341\nH332\nH319\nH315\nH317\n*\nB\n605-017-00-2\n1,3-dioxolane\n211-463-5\n646-06-0\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n605-018-00-8\npropanal; propionaldehyde\n204-623-0\n123-38-6\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH225\nH319\nH335\nH315\nGHS02\nGHS07\nDgr\nH225\nH319\nH335\nH315\n605-019-00-3\ncitral\n226-394-6\n5392-40-5\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n605-020-00-9\nsafrole; 5-allyl-1,3-benzodioxole\n202-345-4\n94-59-7\nCarc. 1B Muta. 2\nAcute Tox. 4 *\nH350\nH341\nH302\nGHS08\nGHS07\nDgr\nH350\nH341\nH302\n605-021-00-4\nformaldehyde, reaction products with butylphenol\n294-145-9\n91673-30-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n605-024-00-0\n2-bromo-5-hydroxy-4-methoxybenzaldehyde\n426-540-0\n2973-59-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n605-025-00-6\nchloroacetaldehyde\n203-472-8\n107-20-0\nCarc. 2\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nAquatic Acute 1\nH351\nH330\nH311\nH301\nH314\nH400\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH351\nH330\nH311\nH301\nH314\nH400\nSTOT SE 3; H335: C≥ 5 %\n605-026-00-1\n2,5,7,7-tetramethyloctanal\n405-690-0\n114119-97-0\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH315\nH317\nH411\n605-027-00-7\nreaction mass of: 3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-indene-6-carboxaldehyde; 3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-indene-5-carboxaldehyde\n410-480-7\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n605-028-00-2\nβ-methyl-3-(1-methylethyl)-benzenepropanal\n412-050-4\n125109-85-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n605-029-00-8\n2-cyclohexylpropanal\n412-270-0\n2109-22-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n605-030-00-3\n1-(p-methoxyphenyl)acetaldehyde oxime\n411-510-1\n3353-51-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n605-031-00-9\nreaction mass of: 2,2-dimethoxyethanal [this component is considered to be anhydrous in terms of identity, structure and composition. However, 2,2-dimethoxyethanal will exist in a hydrated form. 60 % anhydrous is equivalent to 70,4 % hydrate; water (Including free water and water in hydrated 2,2-dimethoxyethanal)]\n421-890-0\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n605-032-00-4\n3-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-(E)-2-propenal\n425-370-4\n93957-50-7\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n605-033-00-X\nReaction mass of: 3,7,11-trimethyl-cis-6,10-dodecadienal; 3,7,11-trimethyl-trans-6,10-dodecadienal\n425-910-9\n32480-08-3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n605-034-00-5\nreaction mass of: (1RS, 2RS,3SR, 6RS, 9SR)-9-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde; (1RS, 2RS, 3RS, 6RS, 8SR)-8-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde; (1RS, 2RS, 4SR, 6RS, 8SR)-8-methoxytricyclo[5.2.1.0(2,6)]decane-4-carbaldehyde\n429-860-9\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n605-035-00-0\n(E)-3-(4-(4-fluorophenyl)-5-methoxymethyl-2,6-bis(1-methoxymethyl)pyridin-3-yl)prop-2-enal\n426-330-9\n177964-68-0\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH319\nH317\nH413\nGHS07\nWng\nH319\nH317\nH413\n605-036-00-6\n2-bromomalonaldehyde\n430-470-6\n2065-75-0\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n605-037-00-1\ntrans-3-[2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde; 3-[(E)-2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde\n421-800-1\n120578-03-2\nAquatic Chronic 4\nH413\n—\nH413\n605-038-00-7\n3-methyl-5-phenylpentan-1-al\n433-900-0\n55066-49-4\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH315\nH317\nH411\n605-039-00-2\n3,4-dihydroxy-5-nitrobenzaldehyde\n441-810-8\n116313-85-0\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\n606-001-00-8\nacetone; propan-2-one; propanone\n200-662-2\n67-64-1\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\nEUH066\n606-002-00-3\nbutanone; ethyl methyl ketone\n201-159-0\n78-93-3\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\nEUH066\n606-003-00-9\nheptan-3-one; butyl ethyl ketone\n203-388-1\n106-35-4\nFlam. Liq. 3\nAcute Tox. 4 *\nEye Irrit. 2\nH226\nH332\nH319\nGHS02\nGHS07\nWng\nH226\nH332\nH319\n606-004-00-4\n4-methylpentan-2-one; isobutyl methyl ketone\n203-550-1\n108-10-1\nFlam. Liq. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH225\nH332\nH319\nH335\nGHS02\nGHS07\nDgr\nH225\nH332\nH319\nH335\nEUH066\n606-005-00-X\n2,6-dimethylheptan-4-one; di-isobutyl ketone\n203-620-1\n108-83-8\nFlam. Liq. 3\nSTOT SE 3\nH226\nH335\nGHS02\nGHS07\nWng\nH226\nH335\nSTOT SE 3; H335: C ≥ 10 %\n606-006-00-5\npentan-3-one; diethyl ketone\n202-490-3\n96-22-0\nFlam. Liq. 2\nSTOT SE 3\nSTOT SE 3\nH225\nH335\nH336\nGHS02\nGHS07\nDgr\nH225\nH335\nH336\nEUH066\n606-007-00-0\n3-methylbutan-2-one; methyl isopropyl ketone\n209-264-3\n563-80-4\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n606-009-00-1\n4-methylpent-3-en-2-one; mesityl oxide\n205-502-5\n141-79-7\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 *\nAcute Tox. 4 *\nH226\nH332\nH312\nH302\nGHS02\nGHS07\nWng\nH226\nH332\nH312\nH302\n*\n606-010-00-7\ncyclohexanone\n203-631-1\n108-94-1\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH332\nGHS02\nGHS07\nWng\nH226\nH332\n606-011-00-2\n2-methylcyclohexanone\n209-513-6\n583-60-8\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH332\nGHS02\nGHS07\nWng\nH226\nH332\n606-012-00-8\n3,5,5-trimethylcyclohex-2-enone; isophorone\n201-126-0\n78-59-1\nCarc. 2\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH351\nH312\nH302\nH319\nH335\nGHS08\nGHS07\nWng\nH351\nH312\nH302\nH319\nH335\nSTOT SE 3; H335: C ≥10 %\n606-013-00-3\np-benzoquinone; quinone\n203-405-2\n106-51-4\nAcute Tox. 3 * Acute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nH331\nH301\nH319\nH335\nH315\nH400\nGHS06\nGHS09\nDgr\nH331\nH301\nH319\nH335\nH315\nH400\nM=10\n606-016-00-X\npindone (ISO); 2-pivaloylindan-1,3-dione\n201-462-8\n83-26-1\nAcute Tox. 3 * STOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH372 ** H400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH372 ** H410\n606-017-00-5\ndiketene; diketen\n211-617-1\n674-82-8\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH332\nGHS02\nGHS07\nWng\nH226\nH332\nD\n606-018-00-0\ndichlone (ISO); 2,3-dichloro-1,4-naphthoquinone\n204-210-5\n117-80-6\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH315\nH410\n606-019-00-6\nchlordecone (ISO); perchloropentacyclo[5,3,0,02,6,03,9,0 4,8]decan-5-one; decachloropentacyclo[5,2,1,02,6,03,9,05,8]decan-4-one\n205-601-3\n143-50-0\nCarc. 2\nAcute Tox. 3 * Acute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH311\nH301\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH311\nH301\nH410\n606-020-00-1\n5-methylheptan-3-one\n208-793-7\n541-85-5\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nH226\nH319\nH335\nGHS02\nGHS07\nWng\nH226\nH319\nH335\nSTOT SE 3; H335: C≥10 %\n606-022-00-2\n1-phenyl-3-pyrazolidone\n202-155-1\n92-43-3\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n606-023-00-8\n4-methoxy-4-methylpentan-2-one\n203-512-4\n107-70-0\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH332\nGHS02\nGHS07\nWng\nH226\nH332\n606-024-00-3\nheptan-2-one; methyl amyl ketone\n203-767-1\n110-43-0\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 *\nH226\nH332\nH302\nGHS02\nGHS07\nWng\nH226\nH332\nH302\n606-025-00-9\ncyclopentanone\n204-435-9\n120-92-3\nFlam. Liq. 3\nEye Irrit. 2\nSkin Irrit. 2\nH226\nH319\nH315\nGHS02\nGHS07\nWng\nH226\nH319\nH315\n606-026-00-4\n5-methylhexan-2-one; isoamyl methyl ketone\n203-737-8\n110-12-3\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH332\nGHS02\nGHS07\nWng\nH226\nH332\n606-027-00-X\nheptan-4-one; di-n-propyl ketone\n204-608-9\n123-19-3\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH332\nGHS02\nGHS07\nWng\nH226\nH332\n606-028-00-5\n2,4-dimethylpentan-3-one; di-isopropyl ketone\n209-294-7\n565-80-0\nFlam. Liq. 2\nAcute Tox. 4 *\nH225\nH332\nGHS02\nGHS07\nDgr\nH225\nH332\n606-029-00-0\npentane-2,4-dione; acetylacetone\n204-634-0\n123-54-6\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH302\nGHS02\nGHS07\nWng\nH226\nH302\n606-030-00-6\nhexan-2-one; methyl butyl ketone; butyl methyl ketone; methyl-n-butyl ketone\n209-731-1\n591-78-6\nFlam. Liq. 3\nRepr. 2\nSTOT RE 1\nSTOT SE 3\nH226\nH361f *** H372 ** H336\nGHS02\nGHS08\nGHS07\nDgr\nH226\nH361f *** H372 ** H336\n606-031-00-1\n3-propanolide;1,3-propiolactone\n200-340-1\n57-57-8\nCarc. 1B\nAcute Tox. 2 *\nEye Irrit. 2\nSkin Irrit. 2\nH350\nH330\nH319\nH315\nGHS06\nGHS08\nDgr\nH350\nH330\nH319\nH315\n606-032-00-7\nhexachloroacetone\n204-129-5\n116-16-5\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n606-033-00-2\n2-(3,4-dichlorophenyl)-4-methyl-1,2,4-oxadiazolidinedione; methazole\n243-761-6\n20354-26-1\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH312\nH302\nH319\nH315\nH411\nGHS07\nGHS09\nWng\nH312\nH302\nH319\nH315\nH411\n606-034-00-8\nmetribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one\n244-209-7\n21087-64-9\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM=10\n606-035-00-3\nchloridazon (ISO); 5-amino-4-chloro-2-phenylpyridazine-3-(2H)-one; pyrazon\n216-920-2\n1698-60-8\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n606-036-00-9\nquinomethionate; chinomethionat (ISO); 6-methyl-1,3-dithiolo(4,5-b)quinoxalin-2-one\n219-455-3\n2439-01-2\nRepr. 2\nAcute Tox. 4 * Acute Tox. 4 *\nAcute Tox. 4 * STOT RE 2 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f *** H332\nH312\nH302\nH373 ** H319\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361f *** H332\nH312\nH302\nH373 ** H319\nH317\nH410\n606-037-00-4\ntriadimefon (ISO); 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butanone\n256-103-8\n43121-43-3\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n606-038-00-X\ndiphacinone (ISO); 2-diphenylacetylindan-1,3-dione\n201-434-5\n82-66-6\nAcute Tox. 2 * STOT RE 1\nH300\nH372 **\nGHS06\nGHS08\nDgr\nH300\nH372 **\n606-039-00-5\n5(or 6)-tert-butyl-2'-chloro-6'-ethylamino-3',7'-dimethylspiro(isobenzofuran-1(1H),9'-xanthene)-3-one\n400-680-2\n—\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH332\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH410\n606-040-00-0\n(N-benzyl-N-ethyl)amino-3-hydroxyacetophenone hydrochloride\n401-840-4\n55845-90-4\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n606-042-00-1\nacetophenone\n202-708-7\n98-86-2\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n606-043-00-7\n2,4-di-tert-butylcyclohexanone\n405-340-7\n13019-04-0\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n606-044-00-2\n2,4,6-trimethylbenzophenone\n403-150-9\n954-16-5\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH410\n606-045-00-8\noxadiazon (ISO); 3-[2,4-dichloro-5-(1-methylethoxy)phenyl]-5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2(3H)-one\n243-215-7\n19666-30-9\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-046-00-3\nreaction mass of cis-and trans-cyclohexadec-8-en-1-one\n401-700-2\n3100-36-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-047-00-9\n2-benzyl-2-dimethylamino-4-morpholinobutyrophenone\n404-360-3\n119313-12-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-048-00-4\n2'-anilino-3'-methyl-6'-dipentylaminospiro(isobenzofuran-1(1H),9'-xanthen)-3-one\n406-480-1\n—\nAquatic Chronic 4\nH413\n—\nH413\n606-049-00-X\n4-(trans-4-propylcyclohexyl)acetophenone\n406-700-6\n78531-61-0\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-050-00-5\n6-anilino-1-benzoyl-4-(4-tert-pentylphenoxy)naphto[1,2,3-de]quinoline-2,7-(3H)-dione\n412-480-2\n72453-58-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-051-00-0\n4-pentylcyclohexanone\n406-670-4\n61203-83-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-052-00-6\n4-(N,N-dibutylamino)-2-hydroxy-2'-carboxybenzophenone\n410-410-5\n54574-82-2\nAquatic Chronic 3\nH412\n—\nH412\n606-053-00-1\nflurtamone (ISO); (RS)-5-methylamino-2-phenyl-4-(α, α,α-trifluoro-m-tolyl)furan-3(2H)-one\n—\n96525-23-4\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-055-00-2\n1-(2,3-dihydro-1,3,3,6-tetramethyl-1-(1-methylethyl)-1H-inden-5-yl)ethanone\n411-180-9\n92836-10-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH302\nH373 ** H411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 ** H411\n606-056-00-8\n4-chloro-3',4'-dimethoxybenzophenone\n404-610-1\n116412-83-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-057-00-3\n4-propylcyclohexanone\n406-810-4\n40649-36-3\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n606-058-00-9\n4'-fluoro-2,2-dimethoxyacetophenone\n407-500-1\n21983-80-2\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n606-059-00-4\n2,4-difluoro-α-(1H-1,2,4-triazol-1-yl)acetophenone hydrochloride\n412-390-3\n86386-75-6\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\n606-060-00-X\nReaction mass of: trans-2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalene-2-yl)-1,3-dioxolane; cis-2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalene-2-yl)-1,3-dioxolane\n412-950-7\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-061-00-5\n(3-chlorophenyl)-(4-methoxy-3-nitrophenyl)methanone\n423-290-4\n66938-41-8\nMuta. 2\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH400\nH410\nGHS08\nGHS09\nWng\nH341\nH410\n606-062-00-0\ntetrahydrothiopyran-3-carboxaldehyde\n407-330-8\n61571-06-0\nRepr. 1B\nEye Dam. 1\nAquatic Chronic 3\nH360D *** H318\nH412\nGHS08\nGHS05\nDgr\nH360D *** H318\nH412\n606-063-00-6\n(E)-3-(2-chlorophenyl)-2-(4-fluorophenyl)propenal\n410-980-5\n112704-51-5\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n606-064-00-1\npregn-5-ene-3,20-dione bis(ethylene ketal)\n407-450-0\n7093-55-2\nAquatic Chronic 4\nH413\n—\nH413\n606-065-00-7\n1-(4-morpholinophenyl)butan-1-one\n413-790-0\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-066-00-2\n(E)-5[(4-chlorophenyl)methylene]-2,2-dimethylcyclopentanone\n410-440-9\n164058-20-2\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-067-00-8\nreaction mass of: 1-(2,3,6,7,8,9-hexahydro-1,1-dimethyl-1H-benz(g)inden-4-yl)ethanone; 1-(2,3,5,6,7,8-hexahydro-1,1-dimethyl-1H-benz(f)inden-4-yl)ethanone; 1-(2,3,6,7,8,9-hexahydro-1,1-dimethyl-1H-benz(g)inden-5-yl)ethanone; 1-(2,3,6,7,8,9-hexahydro-3,3-dimethyl-1H-benz(g)inden-5-yl)ethanone\n414-870-8\n96792-67-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-068-00-3\n2,7,11-trimethyl-13-(2,6,6-trimethylcyclohex-1-en-1-yl)tridecahexaen-2,4,6,8,10,12-al\n415-770-7\n1638-05-7\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH373 ** H317\nH412\nGHS08\nGHS07\nWng\nH373 ** H317\nH412\n606-069-00-9\nspiro[1,3-dioxolane-2,5'-(4',4',8',8'-tetramethyl-hexahydro-3',9'-methanonaphthalene)]\n415-460-1\n154171-76-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-070-00-4\nbutroxydim (ISO); 5-(3-butyryl-2,4,6-trimethylphenyl)-2-[1-(ethoxyimino)propyl]-3-hydroxycyclohex-2-en-1-one\n414-790-3\n138164-12-2\nRepr. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH361fd\nH302\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361fd\nH302\nH315\nH410\n606-071-00-X\n17-spiro(5,5-dimethyl-1,3-dioxan-2-yl)androsta-1,4-diene-3-one\n421-050-3\n13258-43-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-072-00-5\n3-acetyl-1-phenyl-pyrrolidine-2,4-dione\n421-600-2\n719-86-8\nSTOT RE 2 *\nAquatic Chronic 2\nH373 ** H411\nGHS08\nGHS09\nWng\nH373 ** H411\n606-073-00-0\n4,4'-bis(dimethylamino)benzophenone; Michler's ketone\n202-027-5\n90-94-8\nCarc. 1B Muta. 2\nEye Dam. 1\nH350\nH341\nH318\nGHS08\nGHS05\nDgr\nH350\nH341\nH318\n606-074-00-6\nreaction mass of: (1R*, 2S*)-2-acetyl-1,2,3,4,5,6,7,8-octahydro-1,2,8,8-tetramethylnaphthalene; (2R*,3S*)-2-acetyl-1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethylnaphthalene\n425-570-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-075-00-1\n1-benzyl-5-ethoxyimidazolidine-2,4-dione\n417-340-4\n65855-02-9\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n606-076-00-7\n1-((2-quinolinyl-carbonyl)oxy)-2,5-pyrrolidinedione\n418-630-3\n136465-99-1\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n606-077-00-2\n(3S,4S)-3-hexyl-4-[(R)-2-hydroxytridecyl]-2-oxetanone\n418-650-2\n104872-06-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-078-00-8\n1-octylazepin-2-one\n420-040-6\n59227-88-2\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH411\n606-079-00-3\n2-n-butyl-benzo[d]isothiazol-3-one\n420-590-7\n4299-07-4\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n606-081-00-4\n(3β, 5α, 6β)-3-(acetyloxy)-5-bromo-6-hydroxy-androstan-17-one\n419-790-7\n4229-69-0\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n606-082-00-X\nreaction mass of: butan-2-one oxime; syn-O,O'-di(butan-2-one oxime)diethoxysilane\n406-930-7\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 3\nH372 ** H317\nH412\nGHS08\nGHS07\nDgr\nH372 ** H317\nH412\n606-083-00-5\n2-chloro-5-sec-hexadecylhydroquinone\n407-750-1\n137193-60-3\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH319\nH315\nH317\nH412\nGHS07\nWng\nH319\nH315\nH317\nH412\n606-084-00-0\n1-(4-methoxy-5-benzofuranyl)-3-phenyl-1,3-propanedione\n414-540-3\n484-33-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-085-00-6\n(1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one\n418-530-1\n79200-56-9\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\n606-086-00-1\n1-(3,3-dimethylcyclohexyl)pent-4-en-1-one\n422-330-8\n56973-87-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-087-00-7\n6-ethyl-5-fluoro-4(3H)-pyrimidone\n422-460-5\n137234-87-8\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n606-088-00-2\n2,4,4,7-tetramethyl-6-octen-3-one\n422-520-0\n74338-72-0\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n606-089-00-8\nreaction mass of: 1,4-diamino-2-chloro-3-phenoxyanthraquinone; 1,4-diamino-2,3-bis-phenoxyanthraquinone\n423-220-2\n12223-77-7\nAquatic Chronic 4\nH413\n—\nH413\n606-090-00-3\n1-[3-[(dimethylamino)methyl]-4-hydroxyphenyl]ethanone\n430-920-1\n73096-98-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n606-091-00-9\n6-chloro-5-(2-chloroethyl)-1,3-dihydroindol-2-one\n421-320-0\n118289-55-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-092-00-4\nreaction mass of: (E)-oxacyclohexadec-12-en-2-one; (E)-oxacyclohexadec-13-en-2-one; a) (Z)-oxacyclohexadec-(12)-en-2-one and b) (Z)-oxacyclohexadec-(13)-en-2-one\n422-320-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-093-00-X\n5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one\n414-470-3\n95885-13-5\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n606-094-00-5\nN-[ethyl(3-methylbutyl)amino]-3-methyl-1-phenyl-spiro[[1]benzo-pyrano[2,3-c]pyrazole-4(1H), 1'(3'H)-isobenzofuran]-3'-one\n417-460-7\n—\nAquatic Chronic 4\nH413\n—\nH413\n606-095-00-0\n(R, S)-2-azabicyclo[2.2.1]hept-5-en-3-one\n421-830-3\n49805-30-3\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n606-096-00-6\n3-(6-O-(6-desoxy-α-l-mannopyranosyl-O-(α-d-glucopyranosyl)-(β-d-glucopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one\n424-170-4\n130603-71-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n606-097-00-1\n2,2''-dihydroxy-4,4''-(2-hydroxy-propane-1,3-diyldioxy)dibenzophenone\n424-210-0\n23911-85-5\nAquatic Chronic 4\nH413\n—\nH413\n606-098-00-7\n1-benzyl-5-(hexadecyloxy)-2,4-imidazolidinedione\n431-220-9\n158574-65-3\nAquatic Chronic 4\nH413\n—\nH413\n606-099-00-2\n5-methoxy-4'-(trifluoromethyl)valerophenone\n425-000-1\n61718-80-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-100-00-6\n2-butyryl-3-hydroxy-5-thiocyclohexan-3-yl-cyclohex-2-en-1-one\n425-150-8\n94723-86-1\nRepr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH360F*** H302\nH317\nH412\nGHS08\nGHS07\nDgr\nH360F*** H302\nH317\nH412\n606-101-00-1\nreaction mass of: 1,5-bis[(2-ethylhexyl)amino]-9,10-anthracenedione; 1-[(2-ethylhexyl)amino]-5-[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracenedione; 1,5-bis[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracenedione; 1-[(2-ethylhexyl)amino]-5-[(3-methoxypropyl)amino]-9,10-anthracenedione; 1-[3-[(2-ethylhexyl)oxy]propyl]amino-5-[(3-methoxypropyl)amino]-9,10-anthracenedione; 1,5-bis[(3-methyloxypropyl)amino]-9,10-anthracenedione\n426-050-7\n165038-51-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-102-00-7\n4-(3-triethoxysilylpropoxy)-2-hydroxybenzophenone\n431-490-8\n79876-59-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-103-00-2\n1-(4-(trans-4-ethylcyclohexyl)phenyl)ethanone\n426-460-6\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n606-104-00-8\n1-(4-(trans-4-pentylcyclohexyl)phenyl)ethanone\n426-830-7\n78531-59-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-105-00-3\n3,4,3', 4'-tetraphenyl-1,1'-ethandiylbispyrol-2,5-dione\n431-500-0\n226065-73-2\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-106-00-9\n1-(4-(trans-4-butylcyclohexyl)phenyl)ethanone\n427-320-7\n83626-30-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-107-00-4\n8-azaspiro[4.5]decane-7,9-dione\n427-770-4\n1075-89-4\nAcute Tox. 3 *\nAquatic Chronic 2\nH301\nH411\nGHS06\nGHS09\nDgr\nH301\nH411\n606-108-00-X\n1,1,1,2,2,4,5,5,5-nonafluoro-4-(trifluoromethyl)-3-pentanone\n436-710-6\n756-13-8\nAquatic Chronic 3\nH412\n—\nH412\n606-109-00-5\n2-(4-methyl-3-pentenyl)anthraquinone\n428-320-1\n71308-16-2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 4\nH302\nH317\nH413\nGHS07\nWng\nH302\nH317\nH413\n606-110-00-0\n5-ethoxy-5H-furan-2-one\n428-330-4\n2833-30-9\nSkin Corr. 1B\nAcute Tox. 4 * Acute Tox. 4 * STOT RE 2 *\nSkin Sens. 1\nH314\nH312\nH302\nH373** H317\nGHS05\nGHS08\nGHS07\nDgr\nH314\nH312\nH302\nH373** H317\n606-111-00-6\n5-amino-6-methyl-1,3-dihydrobenzoimidazol-2-one\n428-410-9\n67014-36-2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n606-112-00-1\n(4aR*,8aR*)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-one\n428-690-2\n1668-86-6\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 3\nH302\nH319\nH412\nGHS07\nWng\nH302\nH319\nH412\n606-113-00-7\n1-[4-(4-benzoylphenylsulfanyl)phenyl]-2-methyl-2-(4-methylphenylsulfonyl)propan-1-one\n429-040-0\n272460-97-6\nEye Dam. 1\nAquatic Chronic 4\nH318\nH413\nGHS05\nDgr\nH318\nH413\n606-114-00-2\n4,4', 5,5', 6,6', 7,7'-octachloro-(2,2')biisoindolyl-1,1', 3,3'-tetraone\n429-150-9\n67887-47-2\nAquatic Chronic 4\nH413\n—\nH413\n606-115-00-8\nprofoxydim (ISO); 2-{(EZ)-1-[(2RS)-2-(4-chlorophenoxy)propoxyimino]butyl}-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one\n—\n139001-49-3\nCarc. 2\nRepr. 2\nSkin Sens. 1\nH351\nH361d\nH317\nGHS08\nGHS07\nWng\nH351\nH361d\nH317\n606-116-00-3\ntepraloxydim (ISO); (RS)-(EZ)-2-{1-[(2E)-3-chloroallyloxyimino]propyl}-3-hydroxy-5-perhydropyran-4-ylcyclohex-2-en-1-one\n—\n149979-41-9\nCarc. 2\nRepr. 2\nH351\nH361fd\nGHS08\nWng\nH351\nH361fd\n606-117-00-9\n2,6-bis(1,1-dimethylethyl)-4-(phenylenemethylene)cyclohexa-2,5-dien-1-one\n429-460-4\n7078-98-0\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-118-00-4\nN-(1,3-dimethylbutyl)-N'-(phenyl)-1,4-benzoquinonediimine\n429-640-2\n52870-46-9\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH410\n606-119-00-X\n(E)-3-methyl-5-cyclopentadecen-1-one\n429-900-5\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n606-120-00-5\n2,5-dihydroxy-5-methyl-3-(morpholin-4-yl)-2-cyclopenten-1-one\n430-170-5\n114625-74-0\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n606-121-00-0\n(+)-(1S, 2S, 3S, 5R)-2,6,6-trimethylbicyclo[3.1.1]heptane-3-spiro-1'-(cyclohex-2'-en-4'-one)\n430-460-1\n133636-82-5\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n606-122-00-6\n3-(2-bromopropionoyl)-4,4-dimethyl-1,3-oxazolan-2-one\n430-820-8\n114341-88-7\nAcute Tox. 4 * STOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373** H315\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH302\nH373** H315\nH318\nH317\nH410\n606-123-00-1\n4-hexadecyl-1-phenylpyrazolidin-3-one\n430-840-7\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-124-00-7\n1-cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)-1,3-propanedione\n421-080-7\n161462-35-7\nSTOT RE 2 * Aquatic Acute 1\nAquatic Chronic 1\nH373** H400\nH410\nGHS08\nGHS09\nWng\nH373** H410\n606-125-00-2\n1-benzylimidazolidine-2,4-dione\n421-340-1\n6777-05-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n606-126-00-8\n1,4-bis(2,3-dihydroxypropylamino)anthraquinone\n421-470-7\n99788-75-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-128-00-9\n2,2'-(1,3-phenylene)bis[5-chloro-1H-isoindole]-1,3(2H)-dione\n422-650-8\n148935-94-8\nAquatic Chronic 4\nH413\n—\nH413\n606-129-00-4\n5-amino-[2S-di(methylphenyl)amino]-1,6-diphenyl-4Z-hexen-3-one; (2S, 4Z)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one\n423-090-7\n156732-13-7\nAquatic Chronic 4\nH413\n—\nH413\n606-130-00-X\n4-(1,4-dioxa-spiro[4.5]dec-8-yl)-cyclohexanone\n423-860-2\n56309-94-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n606-131-00-5\ncyclic 3-(1,2-ethanediylacetale)-estra-5(10),9(11)-diene-3,17-dione\n427-230-8\n5571-36-8\nRepr. 1B\nSTOT RE 2 *\nAquatic Chronic 2\nH360F*** H373** H411\nGHS08\nGHS09\nDgr\nH360F*** H373** H411\n606-132-00-0\n(6β)-6,19-epoxyandrost-4-ene-3,17-dione\n433-490-3\n6563-83-3\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n606-134-00-1\nandrosta-1,4,9(11)-triene-3,17-dione\n433-560-3\n15375-21-0\nRepr. 2\nH361f***\nGHS08\nWng\nH361f***\n606-135-00-7\ncyclohexadecanone\n438-930-8\n2550-52-9\nAquatic Chronic 4\nH413\n—\nH413\n606-136-00-2\n(3S, 6R, 9S, 12R, 15S, 18R, 21S,24R)-6,18-dibenzyl-3,9,15,21-tetraisobutyl-4,10,12,16,22,24-hexamethyl-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclo-tetracosane-2,5,8,11,14,17,20,23-octaone\n444-350-6\n133413-70-4\nEye Irrit. 2\nAquatic Chronic 4\nH319\nH413\nGHS07\nWng\nH319\nH413\n606-137-00-8\ntrans-7,7'-dimethyl-(4H,4H')-(2,2')bi[benzo[1,4]thiazinylidene]-3,3'-dione\n444-750-0\n211387-26-7\nAquatic Chronic 4\nH413\n—\nH413\n606-138-00-3\n(2-butyl-5-nitrobenzofuran-3-yl)[4-(3-dibutylaminopropoxy)phenyl]methanone\n444-800-1\n141645-23-0\nFlam. Liq. 3\nAcute Tox. 4 * STOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH302\nH373** H315\nH318\nH317\nH400\nH410\nGHS02\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH302\nH373** H315\nH318\nH317\nH410\nM=10\n606-139-00-9\n(S)-4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one\n444-830-5\n124379-29-9\nAquatic Chronic 4\nH413\n—\nH413\n606-140-00-4\n2-hydroxy-1-(4-(4-(2-hydroxy-2-methylpropionyl)benzyl)phenyl)-2-methylpropan-1-one\n444-860-9\n474510-57-1\nSTOT RE 2 * Aquatic Acute 1\nAquatic Chronic 1\nH373** H400\nH410\nGHS08\nGHS09\nWn\nH373** H410\n606-141-00-X\nsodium 3-(methoxycarbonyl)-4-oxo-3,4,5,6-tetrahydro-2-pyridinolate\n418-410-7\n—\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n606-142-00-5\nreaction mass of: (1RS, 2SR,7SR, 8SR, E) 9 and 10-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one; (1RS, 2SR, 7SR, 8SR, Z)-10-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one; (1RS, 2SR, 7SR, 8SR, Z)-9-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one\n434-290-9\n—\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n606-143-00-0\nabamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] avermectin B1a (purity ≥ 80 %); [2]\n_ [1]\n265-610-3 [2]\n71751-41-2 [1]\n65195-55-3 [2]\nRepr. 2\nAcute Tox. 2\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH300\nH330\nH372 (nervous system) H400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d\nH300\nH330\nH372 (nervous system) H410\nSTOT RE 1; H372: C ≥ 5 % STOT RE 2; H373: 0,5 %\n≤C< 5 %\nM = 10 000\n606-144-00-6\nacequinocyl (ISO); 3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate\n—\n57960-19-7\nSkin Sens. 1\nSTOT SE 1\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH370 (lung) (inhalation) H373 (blood system)\nH400\nH410\nGHS07\nGHS08\nGHS09\nDgr\nH317\nH370 (lung) (inhalation) H373 (blood system)\nH410\nM = 1 000\n606-145-00-1\nsulcotrione (ISO); 2-[2-chloro-4-(methylsulfonyl)benzoyl]cyclohexane-1,3-dione\n99105-77-8\nRepr. 2\nSTOT RE 2\nSkin Sens. 1A Aquatic Acute 1\nAquatic Chronic 1\nH361d H373 (kidneys) H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d H373 (kidneys) H317\nH410\nM = 1\nM = 10\n606-146-00-7\ntralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one\n—\n87820-88-0\nCarc. 2\nAcute Tox. 4\nAquatic Chronic 2\nH351\nH302\nH411\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH411\n606-147-00-2\ncycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one\n405-230-9\n101205-02-1\nRepr. 2\nH361d\nGHS08\nWng\nH361d\n607-001-00-0\nformic acid … %\n200-579-1\n64-18-6\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 %\nSkin Irrit. 2; H315: 2 % ≤C\n< 10 %\nEye Irrit. 2; H319: 2 %≤\n<10 %\nB\n607-002-00-6\nacetic acid … %\n200-580-7\n64-19-7\nFlam. Liq. 3\nSkin Corr. 1A\nH226\nH314\nGHS02\nGHS05\nDgr\nH226\nH314\nSkin Corr. 1A; H314: C ≥90 % Skin Corr. 1B; H314: 25 %≤ C <90 %\nSkin Irrit. 2; H315: 10 % ≤C <25 %\nEye Irrit. 2; H319: 10 % ≤ C < 25 %\nB\n607-003-00-1\nchloroacetic acid\n201-178-4\n79-11-8\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B Aquatic Acute 1\nH331\nH311\nH301\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH311\nH301\nH314\nH400\nSTOT SE 3; H335: C≥ 5 %\n607-004-00-7\nTCA (ISO); trichloroacetic acid\n200-927-2\n76-03-9\nSkin Corr. 1A Aquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\nSTOT SE 3; H335: C ≥ 1 %\n607-005-00-2\nTCA-sodium (ISO); sodium trichloroacetate\n211-479-2\n650-51-1\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH335\nH400\nH410\nGHS07\nGHS09\nWng\nH335\nH410\n607-006-00-8\noxalic acid\n205-634-3\n144-62-7\nAcute Tox. 4 * Acute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n*\n607-007-00-3\nsalts of oxalic acid (with the exception of those specified elsewhere in this Annex)\n—\n—\nAcute Tox. 4 * Acute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n*\nA\n607-008-00-9\nacetic anhydride\n203-564-8\n108-24-7\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1B\nH226\nH332\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH332\nH302\nH314\nSkin Corr. 1B; H314: C ≥ 2 % Skin Irrit. 2; H315: 5 % ≤C\n< 25 %\nEye Dam. 1; H318: 5 % ≤ C\n< 25 %\nEye Irrit. 2; H319: 1 % ≤C\n< 5 %\nSTOT SE 3; H335: C ≥ 5 %\n607-009-00-4\nphthalic anhydride\n201-607-5\n85-44-9\nAcute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH302\nH335\nH315\nH318\nH334\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH335\nH315\nH318\nH334\nH317\n607-010-00-X\npropionic anhydride\n204-638-2\n123-62-6\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 %\nEye Irrit. 2; H319: 10 % ≤ C < 25 %\n607-011-00-5\nacetyl chloride\n200-865-6\n75-36-5\nFlam. Liq. 2\nSkin Corr. 1B\nH225\nH314\nGHS02\nGHS05\nDgr\nH225\nH314\nEUH014\n607-012-00-0\nbenzoyl chloride\n202-710-8\n98-88-4\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH332\nH312\nH302\nH314\nH317\nGHS05\nGHS07\nDgr\nH332\nH312\nH302\nH314\nH317\n607-013-00-6\ndimethyl carbonate\n210-478-4\n616-38-6\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n607-014-00-1\nmethyl formate\n203-481-7\n107-31-3\nFlam. Liq. 1\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH224\nH332\nH302\nH319\nH335\nGHS02\nGHS07\nDgr\nH224\nH332\nH302\nH319\nH335\n607-015-00-7\nethyl formate\n203-721-0\n109-94-4\nFlam. Liq. 2\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH225\nH332\nH302\nH319\nH335\nGHS02\nGHS07\nDgr\nH225\nH332\nH302\nH319\nH335\n607-016-00-2\npropyl formate; [1] isopropyl formate [2]\n203-798-0 [1]\n210-901-2 [2]\n110-74-7 [1]\n625-55-8 [2]\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nSTOT SE 3\nH225\nH319\nH335\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH335\nH336\nC\n607-017-00-8\nbutyl formate; [1] tert-butyl formate; [2] isobutyl formate [3]\n209-772-5 [1]\n212-105-0 [2]\n208-818-1 [3]\n592-84-7 [1]\n762-75-4 [2]\n542-55-2 [3]\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH335\nGHS02\nGHS07\nDgr\nH225\nH319\nH335\nC\n607-018-00-3\nisopentyl formate; [1] 2-methylbutyl formate [2]\n203-769-2 [1]\n252-343-2 [2]\n110-45-2 [1]\n35073-27-9 [2]\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH335\nGHS02\nGHS07\nDgr\nH225\nH319\nH335\nC\n607-019-00-9\nmethyl chloroformate\n201-187-3\n79-22-1\nFlam. Liq. 2\nAcute Tox. 2 * Acute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH225\nH330\nH312\nH302\nH314\nGHS02\nGHS06\nGHS05\nDgr\nH225\nH330\nH312\nH302\nH314\n607-020-00-4\nethyl chloroformate\n208-778-5\n541-41-3\nFlam. Liq. 2\nAcute Tox. 2 * Acute Tox. 4 *\nSkin Corr. 1B\nH225\nH330\nH302\nH314\nGHS02\nGHS06\nGHS05\nDgr\nH225\nH330\nH302\nH314\n607-021-00-X\nmethyl acetate\n201-185-2\n79-20-9\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\nEUH066\n607-022-00-5\nethyl acetate\n205-500-4\n141-78-6\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\nEUH066\n607-023-00-0\nvinyl acetate\n203-545-4\n108-05-4\nFlam. Liq. 2\nCarc. 2\nAcute Tox. 4\nSTOT SE 3\nH225\nH351\nH332\nH335\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH351\nH332\nH335\nD\n607-024-00-6\npropyl acetate; [1] isopropyl acetate [2]\n203-686-1 [1]\n203-561-1 [2]\n109-60-4 [1]\n108-21-4 [2]\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\nEUH066\nC\n607-025-00-1\nn-butyl acetate\n204-658-1\n123-86-4\nFlam. Liq. 3\nSTOT SE 3\nH226\nH336\nGHS02\nGHS07\nWng\nH226\nH336\nEUH066\n607-026-00-7\nsec-butyl acetate; [1] isobutyl acetate; [2] tert-butyl acetate [3]\n203-300-1 [1]\n203-745-1 [2]\n208-760-7 [3]\n105-46-4 [1]\n110-19-0 [2]\n540-88-5 [3]\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\nEUH066\nC\n607-027-00-2\nmethyl propionate\n209-060-4\n554-12-1\nFlam. Liq. 2\nAcute Tox. 4 *\nH225\nH332\nGHS02\nGHS07\nDgr\nH225\nH332\n607-028-00-8\nethyl propionate\n203-291-4\n105-37-3\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n607-029-00-3\nn-butyl propionate; [1] sec-butyl propionate; [2] iso-butyl propionate [3]\n209-669-5 [1]\n-[2]\n208-746-0 [3]\n590-01-2 [1]\n591-34-4 [2]\n540-42-1 [3]\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\nC\n607-030-00-9\npropyl propionate\n203-389-7\n106-36-5\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH332\nGHS02\nGHS07\nWng\nH226\nH332\n607-031-00-4\nbutyl butyrate\n203-656-8\n109-21-7\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\nC\n607-032-00-X\nethyl acrylate\n205-438-8\n140-88-5\nFlam. Liq. 2\nAcute Tox. 4 * Acute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH225\nH332\nH312\nH302\nH319\nH335\nH315\nH317\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH319\nH335\nH315\nH317\nSkin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % STOT SE 3; H335: C ≥ 5 %\nD\n607-033-00-5\nn-butyl methacrylate\n202-615-1\n97-88-1\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH226\nH319\nH335\nH315\nH317\nGHS02\nGHS07\nWng\nH226\nH319\nH335\nH315\nH317\nD\n607-034-00-0\nmethyl acrylate; methyl propenoate\n202-500-6\n96-33-3\nFlam. Liq. 2\nAcute Tox. 4 * Acute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH225\nH332\nH312\nH302\nH319\nH335\nH315\nH317\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH319\nH335\nH315\nH317\nD\n607-035-00-6\nmethyl methacrylate; methyl 2-methylprop-2-enoate; methyl 2-methylpropenoate\n201-297-1\n80-62-6\nFlam. Liq. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH225\nH335\nH315\nH317\nGHS02\nGHS07\nDgr\nH225\nH335\nH315\nH317\nD\n607-036-00-1\n2-methoxyethyl acetate; methylglycol acetate\n203-772-9\n110-49-6\nRepr. 1B\nAcute Tox. 4 * Acute Tox. 4 *\nAcute Tox. 4 *\nH360FD H332\nH312\nH302\nGHS08\nGHS07\nDgr\nH360FD H332\nH312\nH302\n607-037-00-7\n2-ethoxyethyl acetate; ethylglycol acetate\n203-839-2\n111-15-9\nFlam. Liq. 3\nRepr. 1B\nAcute Tox. 4 * Acute Tox. 4 *\nAcute Tox. 4 *\nH226\nH360FD H332\nH312\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH226\nH360FD H332\nH312\nH302\n607-038-00-2\n2-butoxyethyl acetate; butylglycol acetate\n203-933-3\n112-07-2\nAcute Tox. 4 * Acute Tox. 4 *\nH332\nH312\nGHS07\nWng\nH332\nH312\n607-039-00-8\n2,4-D (ISO); 2,4-dichlorophenoxyacetic acid\n202-361-1\n94-75-7\nAcute Tox. 4 * STOT SE 3\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH335\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH335\nH318\nH317\nH412\n607-040-00-3\nsalts of 2,4-D\n—\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\nA\n607-041-00-9\n2,4,5-T (ISO); 2,4,5-trichlorophenoxy acetic acid\n202-273-3\n93-76-5\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH335\nH315\nH410\n607-042-00-4\nsalts and esters of 2,4,5-T; salts and esters of 2,4,5-trichlorophenoxy acetic acid\n—\n—\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH335\nH315\nH410\nA\n607-043-00-X\ndicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid\n217-635-6\n1918-00-9\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n607-044-00-5\n3,6-dichloro-o-anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro-o-anisate[2]\n218-951-7 [1]\n233-002-7 [2]\n2300-66-5 [1]\n10007-85-9 [2]\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n607-045-00-0\ndichlorprop (ISO); 2-(2,4-dichlorophenoxy)propionic acid\n204-390-5\n120-36-5\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nH312\nH302\nH315\nH318\nGHS05\nGHS07\nDgr\nH312\nH302\nH315\nH318\n607-046-00-6\nsalts of dichlorprop\n—\n—\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nH332\nH312\nH302\nGHS07\nWng\nH332\nH312\nH302\nA\n607-047-00-1\nfenoprop (ISO); 2-(2,4,5-trichlorophenoxy)propionic acid\n202-271-2\n93-72-1\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH315\nH410\n607-048-00-7\nsalts of fenoprop; salts of 2-(2,4,5-trichlorophenoxy)propionic acid\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\nA\n607-049-00-2\nmecoprop (ISO); 2-(4-chloro-o-tolyloxy)propionic acid; (RS)-2-(4-chloro-o-tolyloxy)propionic acid; [1] 2-(4-chloro-2-methylphenoxy)propionic acid [2]\n230-386-8 [1]\n202-264-4 [2]\n7085-19-0 [1]\n708519-0 [2]\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH315\nH318\nH410\nM=100\n607-050-00-8\nsalts of mecoprop\n—\n—\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH315\nH318\nH410\nA\n607-051-00-3\nMCPA (ISO); 4-chloro-o-tolyloxyacetic acid\n202-360-6\n94-74-6\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH315\nH318\nH410\n607-052-00-9\nsalts and esters of MCPA\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\nA\n607-053-00-4\nMCPB (ISO); 4-(4-chloro-o-tolyloxy) butyric acid\n202-365-3\n94-81-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-054-00-X\nsalts and esters of MCPB\n—\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\nA\n607-055-00-5\nendothal-sodium (ISO); disodium 7-oxabicyclo(2,2,1)heptane-2,3-dicarboxylate\n204-959-8\n129-67-9\nAcute Tox. 3 * Acute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH301\nH312\nH319\nH335\nH315\nGHS06\nDgr\nH301\nH312\nH319\nH335\nH315\n607-057-00-6\ncoumachlor (ISO); 3-[1-(4-chlorophenyl)-3-oxobutyl]-4-hydroxycoumarin\n201-378-1\n81-82-3\nSTOT RE 2 *\nAquatic Chronic 3\nH373 ** H412\nGHS08\nWng\nH373 ** H412\n607-058-00-1\ncoumafuryl (ISO); fumarin; (RS)-3-(1-(2-furyl)-3-oxobutyl)4-hydroxycoumarin; 4-hydroxy-3-[3-oxo-1-(2-furyl)butyl]coumarin\n204-195-5\n117-52-2\nAcute Tox. 3 * STOT RE 1\nAquatic Chronic 3\nH301\nH372 ** H412\nGHS06\nGHS08\nDgr\nH301\nH372 ** H412\n607-060-00-2\ndicoumarol; 4,4'-dihydroxy-3,3'-methylenebis(2H-chromen-2-one)\n200-632-9\n66-76-2\nSTOT RE 1\nAcute Tox. 4 *\nAquatic Chronic 2\nH372 ** H302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH372 ** H302\nH411\n607-061-00-8\nacrylic acid; prop-2-enoic acid\n201-177-9\n79-10-7\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1A Aquatic Acute 1\nH226\nH332\nH312\nH302\nH314\nH400\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH226\nH332\nH312\nH302\nH314\nH400\nSTOT SE 3; H335: C ≥ 1 %\nD\n607-062-00-3\nn-butyl acrylate\n205-480-7\n141-32-2\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH226\nH319\nH335\nH315\nH317\nGHS02\nGHS07\nWng\nH226\nH319\nH335\nH315\nH317\nD\n607-063-00-9\nisobutyric acid\n201-195-7\n79-31-2\nAcute Tox. 4 * Acute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n607-064-00-4\nbenzyl chloroformate\n207-925-0\n501-53-1\nSkin Corr. 1B Aquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\nSTOT SE 3; H335: C ≥ 5 %\n607-065-00-X\nbromoacetic acid\n201-175-8\n79-08-3\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Acute 1\nH331\nH311\nH301\nH314\nH317\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH311\nH301\nH314\nH317\nH400\n607-066-00-5\ndichloroacetic acid\n201-207-0\n79-43-6\nSkin Corr. 1A Aquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\n607-067-00-0\ndichloroacetyl chloride\n201-199-9\n79-36-7\nSkin Corr. 1A Aquatic Acute 1\nH314\nH400\nGHS05\nGHS09\nDgr\nH314\nH400\n607-068-00-6\niodoacetic acid\n200-590-1\n64-69-7\nAcute Tox. 3 *\nSkin Corr. 1A\nH301\nH314\nGHS06\nGHS05\nDgr\nH301\nH314\n607-069-00-1\nethyl bromoacetate\n203-290-9\n105-36-2\nAcute Tox. 2 * Acute Tox. 1\nAcute Tox. 2 *\nH330\nH310\nH300\nGHS06\nDgr\nH330\nH310\nH300\n607-070-00-7\nethyl chloroacetate\n203-294-0\n105-39-5\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 * Aquatic Acute 1\nH331\nH311\nH301\nH400\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH400\n607-071-00-2\nethyl methacrylate\n202-597-5\n97-63-2\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH225\nH319\nH335\nH315\nH317\nGHS02\nGHS07\nDgr\nH225\nH319\nH335\nH315\nH317\nD\n607-072-00-8\n2-hydroxyethyl acrylate\n212-454-9\n818-61-1\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nH311\nH314\nH317\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH314\nH317\nH400\n*\nSkin Sens. 1; H317: C ≥ 0,2 %\nD\n607-073-00-3\n4-CPA (ISO); 4-chlorophenoxyacetic acid\n204-581-3\n122-88-3\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-074-00-9\nchlorfenac(ISO); 2,3,6-trichlorophenylacetic acid\n201-599-3\n85-34-7\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-075-00-4\nchlorfenprop-methyl; methyl 2-chloro-3-(4-chlorophenyl)propionate\n238-413-5\n14437-17-3\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n607-076-00-X\ndodine(ISO); dodecylguanidinium acetate\n219-459-5\n2439-10-3\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH315\nH410\n607-077-00-5\nerbon (ISO); 2-(2,4,5-trichlorophenoxy)ethyl2,2-dichloropropionate\n—\n136-25-4\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-078-00-0\nfluenetil (ISO); 2-fluoroethyl biphenyl-4-ylacetate\n—\n4301-50-2\nAcute Tox. 1\nAcute Tox. 2 *\nH310\nH300\nGHS06\nDgr\nH310\nH300\n607-079-00-6\nkelevan (ISO); ethyl 5-(perchloro-5-hydroxypentacyclo[5,3,0,02,6,03,9,04,8]decan-5-yl)-4-oxopentanoate; ethyl 5-(1,2,3,5,6,7,8,9,10,10-decachloro-4-hydroxypentacyclo(5,2,1,02,6,03,9,05,8)dec-4-yl)-4-oxovalerate\n—\n4234-79-1\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH311\nH302\nH411\nGHS06\nGHS09\nDgr\nH311\nH302\nH411\n607-080-00-1\nchloroacetyl chloride\n201-171-6\n79-04-9\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1\nSkin Corr. 1A Aquatic Acute 1\nH331\nH311\nH301\nH372 ** H314\nH400\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH331\nH311\nH301\nH372 ** H314\nH400\nEUH014\nEUH029\n607-081-00-7\nfluoroacetic acid\n205-631-7\n144-49-0\nAcute Tox. 2 * Aquatic Acute 1\nH300\nH400\nGHS06\nGHS09\nDgr\nH300\nH400\n607-082-00-2\nfluoroacetates, soluble\n—\n—\nAcute Tox. 2 * Aquatic Acute 1\nH300\nH400\nGHS06\nGHS09\nDgr\nH300\nH400\nA\n607-083-00-8\n2,4-DB (ISO); 4-(2,4-dichlorophenoxy)butyric acid\n202-366-9\n94-82-6\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-084-00-3\nsalts of 2,4-DB\n—\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\nA\n607-085-00-9\nbenzyl benzoate\n204-402-9\n120-51-4\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-086-00-4\ndiallyl phthalate\n205-016-3\n131-17-9\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n607-088-00-5\nmethacrylic acid; 2-methylpropenoic acid\n201-204-4\n79-41-4\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1A\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\nSTOT SE 3; H335: C ≥ 1 %\nD\n607-089-00-0\npropionic acid … %\n201-176-3\n79-09-4\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\nSkin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H319 10 % ≤ C < 25 %\nEye Irrit. 2; H319: 10 % ≤\nC < 25 %\nSTOT SE 3; H335: C ≥ 10 %\nB\n607-090-00-6\nthioglycolic acid\n200-677-4\n68-11-1\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nH331\nH311\nH301\nH314\nGHS06\nGHS05\nDgr\nH331\nH311\nH301\nH314\n*\n607-091-00-1\ntrifluoroacetic acid . . . %\n200-929-3\n76-05-1\nAcute Tox. 4 *\nSkin Corr. 1A\nAquatic Chronic 3\nH332\nH314\nH412\nGHS05\nGHS07\nDgr\nH332\nH314\nH412\n*\nB\n607-092-00-7\nmethyl lactate; [1] methyl (±)-lactate; [2] methyl (R)-lactate; [3] methyl (S)-(-)-lactate [4]\n208-930-0 [1]\n218-449-8 [2]\n241-420-6 [3]\n248-704-9 [4]\n547-64-8 [1]\n2155-30-8 [2]\n17392-83-5 [3]\n27871-49-4 [4]\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nH226\nH319\nH335\nGHS02\nGHS07\nWng\nH226\nH319\nH335\nC\n607-093-00-2\npropionyl chloride\n201-170-0\n79-03-8\nFlam. Liq. 2\nSkin Corr. 1B\nH225\nH314\nGHS02\nGHS05\nDgr\nH225\nH314\nEUH014\nB D\n607-094-00-8\nperacetic acid . . . %\n201-186-8\n79-21-0\nFlam. Liq. 3\nOrg. Perox. D **** Acute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A Aquatic Acute 1\nH226\nH242\nH332\nH312\nH302\nH314\nH400\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH226\nH242\nH332\nH312\nH302\nH314\nH400\n*\nSTOT SE 3; H335: C ≥ 1 %\nB D\n607-095-00-3\nmaleic acid\n203-742-5\n110-16-7\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH302\nH319\nH335\nH315\nH317\nGHS07\nWng\nH302\nH319\nH335\nH315\nH317\nSkin Sens. 1; H317: C ≥0,1 %\n607-096-00-9\nmaleic anhydride\n203-571-6\n108-31-6\nAcute Tox. 4 *\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nH302\nH314\nH334\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH314\nH334\nH317\n607-097-00-4\nbenzene-1,2,4-tricarboxylic acid 1,2-anhydride; trimellitic anhydride\n209-008-0\n552-30-7\nSTOT SE 3\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH335\nH318\nH334\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH335\nH318\nH334\nH317\n607-098-00-X\nbenzene-1,2:4,5-tetracarboxylic dianhydride; benzene-1,2:4,5-tetracarboxylic dianhydride; pyromellitic dianhydride\n201-898-9\n89-32-7\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH318\nH334\nH317\nGHS08\nGHS05\nDgr\nH318\nH334\nH317\n607-099-00-5\n1,2,3,6-tetrahydrophthalic anhydride; [1] cis-1,2,3,6-tetrahydrophthalicanhydride; [2] 3,4,5,6-tetrahydrophthalic anhydride; [3] tetrahydrophthalic anhydride [4]\n201-605-4 [1]\n213-308-7 [2]\n219-374-3 [3]\n247-570-9 [4]\n85-43-8 [1]\n935-79-5 [2]\n2426-02-0 [3]\n26266-63-7 [4]\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH334\nH317\nH412\nGHS08\nGHS05\nDgr\nH318\nH334\nH317\nH412\nC\n607-100-00-9\nbenzophenone-3,3',4,4'-tetracarboxylic dianhydride; 4,4'-carbonyldi(phthalic anhydride)\n219-348-1\n2421-28-5\nEye Irrit. 2\nSTOT SE 3\nH319\nH335\nGHS07\nWng\nH319\nH335\nEye Irrit 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 %\n607-101-00-4\n1,4,5,6,7,7-hexachlorobicyclo [2,2,1]hept-5-ene-2,3-dicarboxylicanhydride chlorendic anhydride\n204-077-3\n115-27-5\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\nSkin Irrit.2; H315: C ≥ 1 % Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 %\n607-102-00-X\ncyclohexane-1,2-dicarboxylic anhydride; [1] cis-cyclohexane-1,2-dicarboxylicanhydride; [2] trans-cyclohexane-1,2-dicarboxylic anhydride [3]\n201-604-9 [1]\n236-086-3 [2]\n238-009-9 [3]\n85-42-7 [1]\n13149-00-3 [2]\n14166-21-3 [3]\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH318\nH334\nH317\nGHS08\nGHS05\nDgr\nH318\nH334\nH317\nC\n607-103-00-5\nsuccinic anhydride\n203-570-0\n108-30-5\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH302\nH319\nH335\nGHS07\nWng\nH302\nH319\nH335\n*\nEye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 %\n607-104-00-0\ncyclopentane-1,2,3,4-tetracarboxylic dianhydride\n227-964-7\n6053-68-5\nEye Irrit. 2\nSTOT SE 3\nH319\nH335\nGHS07\nWng\nH319\nH335\nEye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 %\n607-105-00-6\n8,9,10-trinorborn-5-ene-2,3-dicarboxylic anhydride; [1] 1,2,3,6-tetrahydro-3,6-methanophthalic anhydride; [2] (1α,2α,3β,6β)-1,2,3,6-tetrahydro-3,6-methanophthalic anhydride [3]\n204-957-7 [1]\n212-557-9 [2]\n220-384-5 [3]\n129-64-6 [1]\n826-62-0 [2]\n2746-19-2 [3]\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH318\nH334\nH317\nGHS08\nGHS05\nDgr\nH318\nH334\nH317\nC\n607-106-00-1\n8,9-dinorborn-5-ene-2,3-dicarboxylic anhydride\n—\n123748-85-6\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH302\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH302\nH319\nH335\nH315\nH334\nSTOT SE 3; H335: C ≥ 10 %\nC\n607-107-00-7\n2-ethylhexyl acrylate\n203-080-7\n103-11-7\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH335\nH315\nH317\nGHS07\nWng\nH335\nH315\nH317\nD\n607-108-00-2\n2-hydroxy-1-methylethylacrylate; [1] 2-hydroxypropylacrylate; [2] acrylic acid, monoester with propane-1,2-diol [3]\n220-852-9 [1]\n213-663-8 [2]\n247-118-0 [3]\n2918-23-2 [1]\n999-61-1 [2]\n25584-83-2 [3]\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nH331\nH311\nH301\nH314\nH317\nGHS06\nGHS05\nDgr\nH331\nH311\nH301\nH314\nH317\n*\nSkin Sens. 1; H317:C ≥0,2 %\nC D\n607-109-00-8\nhexamethylene diacrylate; hexane-1,6-diol diacrylate\n235-921-9\n13048-33-4\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nD\n607-110-00-3\npentaerythritol triacrylate\n222-540-8\n3524-68-3\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nD\n607-111-00-9\n2,2-bis(acryloyloxymethyl)butyl acrylate; trimethylolpropane triacrylate\n239-701-3\n15625-89-5\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nD\n607-112-00-4\n2,2-dimethyltrimethylene diacrylate; neopentyl glycol diacrylate\n218-741-5\n2223-82-7\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH311\nH319\nH315\nH317\nGHS06\nDgr\nH311\nH319\nH315\nH317\n*\nD\n607-113-00-X\nisobutyl methacrylate\n202-613-0\n97-86-9\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH226\nH319\nH335\nH315\nH317\nH400\nGHS02\nGHS07\nGHS09\nWng\nH226\nH319\nH335\nH315\nH317\nH400\nD\n607-114-00-5\nethylene dimethacrylate\n202-617-2\n97-90-5\nSTOT SE 3\nSkin Sens. 1\nH335\nH317\nGHS07\nWng\nH335\nH317\nSTOT SE 3; H335: C ≥ 10 %\nD\n607-115-00-0\nisobutyl acrylate\n203-417-8\n106-63-8\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nH226\nH332\nH312\nH315\nH317\nGHS02\nGHS07\nWng\nH226\nH332\nH312\nH315\nH317\nD\n607-116-00-6\ncyclohexyl acrylate\n221-319-3\n3066-71-5\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 2\nH335\nH315\nH411\nGHS07\nGHS09\nWng\nH335\nH315\nH411\nSTOT SE 3; H335: C ≥ 10 %\nD\n607-117-00-1\n2,3-epoxypropyl acrylate; glycidyl acrylate\n203-440-3\n106-90-1\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nH331\nH311\nH301\nH314\nH317\nGHS06\nGHS05\nDgr\nH331\nH311\nH301\nH314\nH317\n*\nSkin Sens. 1; H317:C ≥0,2 %\nD\n607-118-00-7\n1-methyltrimethylene diacrylate; 1,3-butylene glycol diacrylate\n243-105-9\n19485-03-1\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH312\nH314\nH317\nGHS05\nGHS07\nDgr\nH312\nH314\nH317\nD\n607-119-00-2\ntetramethylene diacrylate; 1,4-butyleneglycol diacrylate\n213-979-6\n1070-70-8\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH312\nH314\nH317\nGHS05\nGHS07\nDgr\nH312\nH314\nH317\nD\n607-120-00-8\n2,2'-oxydiethyl diacrylate; diethylene glycol diacrylate\n223-791-6\n4074-88-8\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH311\nH319\nH315\nH317\nGHS06\nDgr\nH311\nH319\nH315\nH317\n*\nSkin Sens. 1; H317:C≥0,2 %\nD\n607-121-00-3\n8,9,10-trinorborn-2-yl acrylate\n—\n10027-06-2\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nH312\nH315\nH317\nGHS07\nWng\nH312\nH315\nH317\nD\n607-122-00-9\npentaerythritol tetraacrylate\n225-644-1\n4986-89-4\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nD\n607-124-00-X\n2-hydroxyethyl methacrylate\n212-782-2\n868-77-9\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nD\n607-125-00-5\n2-hydroxypropyl methacrylate; [1] 3-hydroxypropyl methacrylate[2]\n213-090-3 [1]\n220-426-2 [2]\n923-26-2 [1]\n2761-09-3 [2]\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\nC D\n607-126-00-0\n2,2'-(ethylenedioxy)diethyl diacrylate; triethylene glycol diacrylate\n216-853-9\n1680-21-3\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nD\n607-127-00-6\n2-diethylaminoethyl methacrylate\n203-275-7\n105-16-8\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH332\nH319\nH315\nH317\nGHS07\nWng\nH332\nH319\nH315\nH317\nD\n607-128-00-1\n2-tert-butylaminoethyl methacrylate\n223-228-4\n3775-90-4\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\nD\n607-129-00-7\nethyl lactate; ethyl DL-lactate; [1] ethyl (S)-2-hydroxypropionate; ethyl L-lactate; ethyl-(S)-lactate [2]\n202-598-0 [1]\n211-694-1 [2]\n97-64-3 [1]\n687-47-8 [2]\nFlam. Liq. 3\nSTOT SE 3\nEye Dam. 1\nH226\nH335\nH318\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH335\nH318\nC\n607-130-00-2\npentyl acetate; [1] isopentyl acetate; [2] 1-methylbutyl acetate; [3] 2-methylbutyl acetat; [4] 2(or 3)-methylbutyl acetate [5]\n211-047-3 [1]\n204-662-3 [2]\n210-946-8 [3]\n210-843-8 [4]\n282-263-3 [5]\n628-63-7 [1]\n123-92-2 [2]\n626-38-0 [3]\n624-41-9 [4]\n84145-37-9 [5]\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\nEUH066\nC\n607-131-00-8\nisopentyl propionate; [1] pentyl propionate; [2] 2-methylbutyl propionate [3]\n203-322-1 [1]\n210-852-7 [2]\n219-449-0 [3]\n105-68-0 [1]\n624-54-4 [2]\n2438-20-2 [3]\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\nC\n607-132-00-3\n2-dimethylaminoethyl methacrylate\n220-688-8\n2867-47-2\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH312\nH302\nH319\nH315\nH317\nGHS07\nWng\nH312\nH302\nH319\nH315\nH317\nD\n607-133-00-9\nmonoalkylor monoaryl or monoalkylaryl esters of acrylic acid with the exception of those specified elsewhere in this Annex\n—\n—\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 2\nH319\nH335\nH315\nH411\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH411\nSTOT SE 3; H335: C ≥ 10 %\nA\n607-134-00-4\nmonoalkyl or monoaryl or monoalkyaryl esters of methacrylic acid with the exception of those specified elsewhere in this Annex\n—\n—\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\nSTOTSE 3; H335: C ≥ 10 %\nA\n607-135-00-X\nbutyric acid\n203-532-3\n107-92-6\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n607-136-00-5\nbutyryl chloride\n205-498-5\n141-75-3\nFlam. Liq. 2\nSkin Corr. 1B\nH225\nH314\nGHS02\nGHS05\nDgr\nH225\nH314\n607-137-00-0\nmethyl acetoacetate\n203-299-8\n105-45-3\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-138-00-6\nbutyl chloroformate; chloroformic acid butyl ester\n209-750-5\n592-34-7\nFlam. Liq. 3\nAcute Tox. 3 *\nSkin Corr. 1B\nH226\nH331\nH314\nGHS02\nGHS06\nGHS05\nDgr\nH226\nH331\nH314\n607-139-00-1\n2-chloropropionic acid\n209-952-3\n598-78-7\nAcute Tox. 4 *\nSkin Corr. 1A\nH302\nH314\nGHS05\nGHS07\nDgr\nH302\nH314\n607-140-00-7\nisobutyryl chloride\n201-194-1\n79-30-1\nFlam. Liq. 2\nSkin Corr. 1A\nH225\nH314\nGHS02\nGHS05\nDgr\nH225\nH314\n607-141-00-2\noxydiethylene bis(chloroformate)\n203-430-9\n106-75-2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH302\nH315\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH315\nH318\nH411\n607-142-00-8\npropyl chloroformate; chloroformic acid propylester; n-propyl chloroformate\n203-687-7\n109-61-5\nFlam. Liq. 2\nAcute Tox. 3 *\nSkin Corr. 1B\nH225\nH331\nH314\nGHS02\nGHS06\nGHS05\nDgr\nH225\nH331\nH314\n607-143-00-3\nvaleric acid\n203-677-2\n109-52-4\nSkin Corr. 1B\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\n607-144-00-9\nadipic acid\n204-673-3\n124-04-9\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-145-00-4\nmethanesulphonic acid\n200-898-6\n75-75-2\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n607-146-00-X\nfumaric acid\n203-743-0\n110-17-8\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-147-00-5\noxalic acid diethylester; diethyl oxalate\n202-464-1\n95-92-1\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n607-148-00-0\nguanidinium chloride; guanadine hydrochloride\n200-002-3\n50-01-1\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH302\nH319\nH315\nGHS07\nWng\nH302\nH319\nH315\n607-149-00-6\nurethane (INN); ethyl carbamate\n200-123-1\n51-79-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n607-150-00-1\nendothal (ISO); 7-oxabicyclo(2,2,1)heptane-2,3-dicarboxylic acid\n205-660-5\n145-73-3\nAcute Tox. 3 * Acute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH301\nH312\nH319\nH335\nH315\nGHS06\nDgr\nH301\nH312\nH319\nH335\nH315\n607-151-00-7\npropargite (ISO); 2-(4-tert-butylphenoxy)cyclohexyl prop-2-ynyl sulphite\n219-006-1\n2312-35-8\nCarc. 2\nAcute Tox. 3 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH331\nH315\nH318\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH351\nH331\nH315\nH318\nH410\nM = 10\n607-152-00-2\n2,3,6-TBA (ISO); 2,3,6-trichlorobenzoic acid\n200-026-4\n50-31-7\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-153-00-8\nbenazolin (ISO); 4-chloro-2,3-dihydro-2-oxo-1,3-benzothiazol-3-ylacetic acid\n223-297-0\n3813-05-6\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 3\nH319\nH315\nH412\nGHS07\nWng\nH319\nH315\nH412\n607-154-00-3\nethyl N-benzoyl-N-(3,4-dichlorophenyl)-DL-alaninate; benzoylprop-ethyl (ISO)\n244-845-5\n22212-55-1\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n607-155-00-9\n3-(3-amino-5-(1-methylguanidino)-1-oxopentylamino-6-(4-amino-2-oxo-2,3-dihydro-pyrimidin-1-yl)-2,3-dihydro-(6H)-pyran-2-carboxylic acid; blasticidin-s\n—\n2079-00-7\nAcute Tox. 2 *\nH300\nGHS06\nDgr\nH300\n607-156-00-4\nchlorfenson (ISO); 4-chlorophenyl 4-chlorobenzenesulfonate\n201-270-4\n80-33-1\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH315\nH410\n607-158-00-5\nsodium salt of chloroacetic acid; sodium chloroacetate\n223-498-3\n3926-62-3\nAcute Tox. 3 *\nSkin Irrit. 2\nAquatic Acute 1\nH301\nH315\nH400\nGHS06\nGHS09\nDgr\nH301\nH315\nH400\n607-159-00-0\nchlorobenzilate (ISO); ethyl 2,2-di(4-chlorophenyl)-2-hydroxyacetate; ethyl 4,4'-dichlorobenzilate\n208-110-2\n510-15-6\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n607-160-00-6\nisobutyl 2-(4-(4-chlorophenoxy)phenoxy)propionate; clofop-isobutyl (ISO)\n—\n51337-71-4\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-161-00-1\ndiethanolamine salt of 4-CPA\n—\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-162-00-7\ndalapon; 2,2-dichloropropionic acid; [1] dalapon-sodium; sodium 2,2-dichloropropionate[2]\n200-923-0 [1]\n204-828-5 [2]\n75-99-0 [1]\n127-20-8 [2]\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH315\nH318\nH412\nGHS05\nDgr\nH315\nH318\nH412\n607-163-00-2\n3-acetyl-6-methyl-2H-pyran-2,4(3H)-dione; dehydracetic acid\n208-293-9\n520-45-6\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-164-00-8\nsodium 1-(3,4-dihydro-6-methyl-2,4-dioxo-2H-pyran-3-ylidene)ethonolate; sodium dehydracetate\n224-580-1\n4418-26-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-165-00-3\ndiclofop-methyl (ISO)methyl 2-(4-(2,4-dichlorophenoxy)phenoxy)propionate; methyl (RS)-2-[4-(2,4-dichlorophenoxy)phenoxy]propionate;\n257-141-8\n51338-27-3\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n607-166-00-9\nmedinoterb acetate (ISO); 6-tert-butyl-3-methyl-2,4-dinitrophenyl acetate\n219-634-6\n2487-01-6\nAcute Tox. 3 * Acute Tox. 4 *\nH301\nH312\nGHS06\nDgr\nH301\nH312\n607-167-00-4\nsodium 3-chloroacrylate\n—\n4312-97-4\nAcute Tox. 4 * Acute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n607-168-00-X\ndipropyl 6,7-methylenedioxy-1,2,3,4-tetrahydro-3-methylnaphthalene-1,2-dicarboxylate; propylisome\n—\n83-59-0\nAcute Tox. 3 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH311\nH302\nH400\nH410\nGHS06\nGHS09\nDgr\nH311\nH302\nH410\n607-169-00-5\nsodium fluoroacetate\n200-548-2\n62-74-8\nAcute Tox. 2 * Acute Tox. 1\nAcute Tox. 2 * Aquatic Acute 1\nH330\nH310\nH300\nH400\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH400\n607-170-00-0\nbis(1,2,3-trithiacyclohexyldimethylammonium) oxalate; thiocyclam-oxalate\n250-859-2\n31895-22-4\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n607-173-00-7\ndimethyl (3-methyl-4-(5-nitro-3-ethoxycarbonyl-2-thienyl)azo)phenylnitrilodipropionate\n400-460-6\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-174-00-2\nreaction mass of dodecyl 3-(2,2,4,4-tetramethyl-21-oxo-7-oxa-3,20-diazadispiro(5,1,11,2)henicosan-20-yl)propionate and tetradecyl 3-(2,2,4,4-tetramethyl-21-oxo-7-oxa-3,20-diazadispiro(5,1,11,2)henicosan-20-yl)propionate\n400-580-9\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-175-00-8\nmethyl 2-(2-nitrobenzylidene)acetoacetate\n400-650-9\n39562-27-1\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-176-00-3\nreaction mass of α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene) and α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)\n400-830-7\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-177-00-9\ntribenuron-methyl (ISO); 2-[4-methoxy-6-methyl-1,3,5-triazin-2-yl(methyl)carbamoylsulfamoyl]benzoic acid methyl ester; methyl 2-(3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-3methylureidosulfonyl)benzoate\n401-190-1\n101200-48-0\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM = 100\n607-178-00-4\nmethyl α-((4,6-dimethoxypyrimidin-2-yl)ureidosulphonyl)-o-toluate\n401-340-6\n83055-99-6\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-179-00-X\n(benzothiazol-2-ylthio)succinic acid\n401-450-4\n95154-01-1\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-180-00-5\npotassium 2-hydroxycarbazole-1-carboxylate\n401-630-2\n96566-70-0\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nAquatic Chronic 3\nH302\nH319\nH335\nH412\nGHS07\nWng\nH302\nH319\nH335\nH412\n607-181-00-0\n3,5-dichloro-2,4-difluorobenzoyl fluoride\n401-800-6\n101513-70-6\nAcute Tox. 3 *\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH331\nH314\nH302\nH317\nH412\nGHS06\nGHS05\nDgr\nH331\nH314\nH302\nH317\nH412\nEUH029\n607-182-00-6\nmethyl 3-sulphamoyl-2-thenoate\n402-050-2\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-183-00-1\nzinc 2-hydroxy-5-C13-18 alkylbenzoate\n402-280-3\n—\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH319\nH315\nH411\nGHS07\nGHS09\nWng\nH319\nH315\nH411\n607-184-00-7\nS-(3-trimethoxysilyl)propyl 19-isocyanato-11-(6-isocyanatohexyl)-10,12-dioxo-2,9,11,13-tetraazanonadecanethioate\n402-290-8\n85702-90-5\nFlam. Liq. 3\nResp. Sens. 1\nSkin Sens. 1\nH226\nH334\nH317\nGHS02\nGHS08\nDgr\nH226\nH334\nH317\n607-185-00-2\nethyl trans-3-dimethylaminoacrylate\n402-650-4\n1117-37-9\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-186-00-8\nquinclorac (ISO); 3,7-dichloroquinoline-8-carboxylic acid\n402-780-1\n84087-01-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-187-00-3\nbis(2,2,6,6-tetramethyl-4-piperidyl) succinate\n402-940-0\n62782-03-0\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n607-188-00-9\nhydrogen sodium N-carboxylatoethyl-N-octadec-9-enylmaleamate\n402-970-4\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-189-00-4\ntrimethylenediaminetetraacetic acid\n400-400-9\n1939-36-2\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n607-190-00-X\nmethyl acrylamidomethoxyacetate (containing ≥ 0,1 % acrylamid)\n401-890-7\n77402-03-0\nCarc. 1B Muta. 1B\nAcute Tox. 4 *\nEye Irrit. 2\nH350\nH340\nH302\nH319\nGHS08\nGHS07\nDgr\nH350\nH340\nH302\nH319\n607-191-00-5\nisobutyl 3,4-epoxybutyrate\n401-920-9\n100181-71-3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n607-192-00-0\ndisodium N-carboxymethyl-N-(2-(2-hydroxyethoxy)ethyl)glycinate\n402-360-8\n92511-22-3\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-194-00-1\npropylene carbonate\n203-572-1\n108-32-7\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-195-00-7\n2-methoxy-1-methylethyl acetate\n203-603-9\n108-65-6\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\n607-196-00-2\nheptanoic acid\n203-838-7\n111-14-8\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n607-198-00-3\npropyl 3,4,5-trihydroxybenzoate\n204-498-2\n121-79-9\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n607-199-00-9\noctyl 3,4,5-trihydroxybenzoate\n213-853-0\n1034-01-1\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n607-200-00-2\ndodecyl 3,4,5-trihydroxybenzoate\n214-620-6\n1166-52-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-201-00-8\nthiocarbonyl chloride\n207-341-6\n463-71-8\nAcute Tox. 3 * Acute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH331\nH302\nH319\nH335\nH315\nGHS06\nDgr\nH331\nH302\nH319\nH335\nH315\n607-203-00-9\n2-ethylhexyl[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]thio]acetate\n279-452-8\n80387-97-9\nRepr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH360D *** H317\nH412\nGHS08\nGHS07\nDgr\nH360D *** H317\nH412\n607-204-00-4\n(chlorophenyl)(chlorotolyl)methane, mixed isomers\n400-140-6\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-205-00-X\nmethyl chloroacetate\n202-501-1\n96-34-4\nFlam. Liq. 3\nAcute Tox. 3 * Acute Tox. 3 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH226\nH331\nH301\nH335\nH315\nH318\nGHS02\nGHS06\nGHS05\nDgr\nH226\nH331\nH301\nH335\nH315\nH318\n607-206-00-5\nisopropyl chloroacetate\n203-301-7\n105-48-6\nFlam. Liq. 3\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH226\nH301\nH319\nH335\nH315\nGHS02\nGHS06\nDgr\nH226\nH301\nH319\nH335\nH315\n607-207-00-0\nhaloxyfop-etotyl (ISO); 2-ethoxyethyl 2-(4-(3-chloro-5-trifluoromethyl-2-pyridyloxy)phenoxy)propionate; haloxyfop-(2-ethoxyethyl)\n402-560-5\n87237-48-7\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n607-208-00-6\n4,8,12-trimethyltrideca-3,7,11-trienoic acid, mixed isomers\n403-000-2\n91853-67-7\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n607-209-00-1\nreaction mass of O, O'-diisopropyl (pentathio)dithioformate and O, O'-diisopropyl (trithio)dithioformate and O, O'-diisopropyl (tetrathio)dithioformate\n403-030-6\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n607-210-00-7\nmethyl acrylamidoglycolate (containing ≥ 0,1 % acrylamide)\n403-230-3\n77402-05-2\nCarc. 1B Muta. 1B\nSkin Corr. 1B\nSkin Sens. 1\nH350\nH340\nH314\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH350\nH340\nH314\nH317\n607-211-00-2\nmethyl 3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionate\n403-270-1\n6386-39-6\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-212-00-8\npoly(oxypropylenecarbonyl-co-oxy(ethylethylene)carbonyl), containing 27 % hydroxyvalerate\n403-300-3\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-213-00-3\nethyl 3,3-bis(tert-pentylperoxy)butyrate\n403-320-2\n67567-23-1\nOrg. Perox. D**** Flam. Liq. 3\nAquatic Chronic 2\nH242\nH226\nH411\nGHS02\nGHS09\nDgr\nH242\nH226\nH411\n607-214-00-9\nN, N-hydrazinodiacetic acid\n403-510-5\n19247-05-3\nAcute Tox. 3 * STOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH301\nH373 ** H317\nH412\nGHS06\nGHS08\nDgr\nH301\nH373 ** H317\nH412\n607-215-00-4\n3-(3-tert-butyl-4-hydroxyphenyl)propionic acid\n403-920-4\n107551-67-7\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n607-216-00-X\nglutamic acid, reaction products with N-(C12-14-alkyl)propylenediamine\n403-950-8\n—\nAcute Tox. 2 * Acute Tox. 4 *\nSkin Corr. 1B Aquatic Acute 1\nH330\nH302\nH314\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH302\nH314\nH400\n607-217-00-5\n2-ethoxyethyl 2-(4-(2,6-dihydro-2,6-dioxo-7-phenyl-1,5-dioxaindacen-3-yl)phenoxy)acetate\n403-960-2\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-218-00-0\ndichlorprop-P (ISO); (+)-R-2-(2,4-dichlorophenoxy)propionic acid\n403-980-1\n15165-67-0\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH302\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH317\n607-219-00-6\nbis(2-ethylhexyl) dithiodiacetate\n404-510-8\n62268-47-7\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n607-221-00-7\n6-docosyloxy-1-hydroxy-4-(1-(4-hydroxy-3-methylphenanthren-1-yl)-3-oxo-2-oxaphenalen-1-yl)naphthalene-2-carboxylic acid\n404-550-6\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-222-00-2\n6-(2,3-dimethylmaleimido)hexyl methacrylate\n404-870-6\n63740-41-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-223-00-8\ntransfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl trans-2-(2,2-dichlorovinyl)-3,3-dimethylcyclopropanecarboxylate\n405-060-5\n118712-89-3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n607-224-00-3\nmethyl 2-(3-nitrobenzylidene)acetoacetate\n405-270-7\n39562-17-9\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-225-00-9\n3-azidosulfonylbenzoic acid\n405-310-3\n15980-11-7\nSelf-React. C **** STOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH241\nH373 ** H318\nH317\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH241\nH373 ** H318\nH317\n607-226-00-4\nreaction mass of 2-acryloyloxyethyl hydrogen cyclohexane-1,2-dicarboxylate and 2-methacryloyloxyethyl hydrogen cyclohexane-1,2-dicarboxylate\n405-360-6\n—\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH315\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH315\nH318\nH317\nH412\n607-227-00-X\npotassium 2-amino-2-methylpropionate octahydrate\n405-560-3\n120447-91-8\nAcute Tox. 4 *\nSkin Corr. 1A\nH302\nH314\nGHS05\nGHS07\nDgr\nH302\nH314\n607-228-00-5\nbis(2-methoxyethyl) phthalate\n204-212-6\n117-82-8\nRepr. 1B\nH360Df\nGHS08\nDgr\nH360Df\n607-229-00-0\ndiethylcarbamoyl chloride\n201-798-5\n88-10-8\nCarc. 2\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH351\nH332\nH302\nH319\nH335\nH315\nGHS08\nGHS07\nWng\nH351\nH332\nH302\nH319\nH335\nH315\n607-230-00-6\n2-ethylhexanoic acid\n205-743-6\n149-57-5\nRepr. 2\nH361d ***\nGHS08\nWng\nH361d ***\n607-231-00-1\nclopyralid (ISO); 3,6-dichloropyridine-2-carboxylic acid\n216-935-4\n1702-17-6\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-232-00-7\npyridate (ISO); O-(6-chloro-3-phenylpyridazin-4-yl) S-octyl thiocarbonate\n259-686-7\n55512-33-9\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n607-233-00-2\nhexyl acrylate\n219-698-5\n2499-95-8\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH319\nH335\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH317\nH411\n607-234-00-8\nflurenol (ISO); 9-hydroxy-9H-fluorene-9-carboxylic acid\n207-397-1\n467-69-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-235-00-3\nmecrilate; methyl 2-cyanoacrylate\n205-275-2\n137-05-3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\nSTOT SE 3; H335: C ≥ 10 %\n607-236-00-9\nethyl 2-cyanoacrylate\n230-391-5\n7085-85-0\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\nSTOT SE 3; H335: C ≥ 10 %\n607-237-00-4\nbenzyl 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylate; flurazole\n276-942-3\n72850-64-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-238-00-X\ntau-fluvalinate (ISO); cyano-(3-phenoxyphenyl)methyl N-[2-chloro-4-(trifluoromethyl)phenyl]-D-valinate\n—\n102851-06-9\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH315\nH410\n607-239-00-5\nfenpropathrin (ISO); α-cyano-3-phenoxybenzyl 2,2,3,3-tetramethylcyclopropanecarboxylate\n254-485-0\n39515-41-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH330\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH301\nH312\nH410\n607-240-00-0\ncis-1,2,3,6-tetrahydro-4-methylphthalic anhydride; [1] 1,2,3,6-tetrahydro-4-methylphthalic anhydride; [2] 1,2,3,6-tetrahydro-3-methylphthalic anhydride; [3] tetrahydromethylphthalicanhydride; [4] 1,2,3,6-tetrahydromethylphthalic anhydride; [5] tetrahydro-4-methylphthalicanhydride; [6] 2,3,5,6-tetrahydro-2-methylphthalic anhydride [7]\n216-906-6 [1]\n222-323-8 [2]\n226-247-6 [3]\n234-290-7 [4]\n247-830-1 [5]\n251-823-9 [6]\n255-853-3 [7]\n1694-82-2 [1]\n3425-89-6 [2]\n5333-84-6 [3]\n11070-44-3 [4]\n26590-20-5 [5]\n34090-76-1 [6]\n42498-58-8 [7]\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH318\nH334\nH317\nGHS08\nGHS05\nDgr\nH318\nH334\nH317\nC\n607-241-00-6\nhexahydro-4-methylphthalic anhydride; [1] hexahydromethylphthalic anhydride; [2] hexahydro-1-methylphthalic anhydride; [3] hexahydro-3-methylphthalicanhydride [4]\n243-072-0 [1]\n247-094-1 [2]\n256-356-4 [3]\n260-566-1 [4]\n19438-60-9 [1]\n25550-51-0 [2]\n48122-14-1 [3]\n57110-29-9 [4]\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH318\nH334\nH317\nGHS08\nGHS05\nDgr\nH318\nH334\nH317\nC\n607-242-00-1\ntetrachlorophthalic anhydride\n204-171-4\n117-08-8\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH334\nH317\nH400\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH318\nH334\nH317\nH410\n607-243-00-7\nsodium 3,6-dichloro-o-anisate; [1] 3,6-dichloro-o-anisic acid, compound with 2,2'-iminodiethanol (1:1); [2] 3,6-dichloro-o-anisic acid, compound with 2-aminoethanol (1:1) [3]\n217-846-3 [1]\n246-590-5 [2]\n258-527-9 [3]\n1982-69-0 [1]\n25059-78-3 [2]\n53404-28-7 [3]\nAquatic Chronic 3\nH412\n—\nH412\n607-244-00-2\nisooctyl acrylate\n249-707-8\n29590-42-9\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH410\nSTOT SE 3; H335: C ≥ 10 %\n607-245-00-8\ntert-butyl acrylate\n216-768-7\n1663-39-4\nFlam. Liq. 2\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH225\nH332\nH312\nH302\nH335\nH315\nH317\nH411\nGHS02\nGHS07\nGHS09\nDgr\nH225\nH332\nH312\nH302\nH335\nH315\nH317\nH411\nD\n607-246-00-3\nallyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester\n202-473-0\n96-05-9\nFlam. Liq. 3\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nH226\nH331\nH312\nH302\nH400\nGHS02\nGHS06\nGHS09\nDgr\nH226\nH331\nH312\nH302\nH400\n607-247-00-9\ndodecyl methacrylate\n205-570-6\n142-90-5\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH335\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH410\nSTOT SE 3; H335: C ≥ 10 %\n607-248-00-4\nnaptalam-sodium (ISO); sodium N-naphth-1-ylphthalamate\n205-073-4\n132-67-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-249-00-X\n(1-methyl-1,2-ethanediyl)bis[oxy(methyl-2,1-ethanediyl)] diacrylate\n256-032-2\n42978-66-5\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH319\nH335\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH317\nH411\nSTOT SE 3; H335: C ≥ 10 %\n607-250-00-5\n4H-3,1-benzoxazine-2,4(1H)-dione\n204-255-0\n118-48-9\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n607-251-00-0\n2-methoxypropyl acetate\n274-724-2\n70657-70-4\nFlam. Liq. 3\nRepr. 1B\nSTOT SE 3\nH226\nH360D *** H335\nGHS02\nGHS08\nGHS07\nDgr\nH226\nH360D *** H335\n607-252-00-6\nlambda-cyhalothrin (ISO); reaction mass of (S)-α-cyano-3-phenoxybenzyl(Z)-(1R)-cis-3-(2-chloro-3,3,3-trifluoropropenyl)-2,2-dimethylcyclopropanecarboxylate and (R)-α-cyano-3-phenoxybenzyl (Z)-(1S)-cis-3-(2-chloro-3,3,3-trifluoropropenyl)-2,2-dimethylcyclopropanecarboxylate (1:1)\n415-130-7\n91465-08-6\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH330\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH301\nH312\nH410\nM=10000\n607-253-00-1\ncyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate\n269-855-7\n68359-37-5\nAcute Tox. 2 *\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH300\nH331\nH400\nH410\nGHS06\nGHS09\nDgr\nH300\nH331\nH410\nM=1000\n607-254-00-7\nα-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; beta-cyfluthrin\n269-855-7\n68359-37-5\nAcute Tox. 2 *\nAcute Tox. 2 * Aquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH410\n607-255-00-2\nfluroxypyr (ISO);4-amino-3,5-dichloro-6-fluoro-2-pyridyloxyacetic acid\n—\n69377-81-7\nAquatic Chronic 3\nH412\n—\nH412\n607-256-00-8\nazoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate\n—\n131860-33-8\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH331\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH410\n607-257-00-3\nisopropyl propionate\n211-300-8\n637-78-5\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n607-258-00-9\ndodecyl 3-(2-(3-benzyl-4-ethoxy-2,5-dioxoimidazolidin-1-yl)-3-(4-methoxybenzoyl)acetamido)-4-chlorobenzoate\n403-990-6\n70950-45-7\nAquatic Chronic 4\nH413\n—\nH413\n607-259-00-4\nmethyl 2R,3S-(-)-3-(4-methoxyphenyl)oxiranecarboxylate\n404-130-2\n105560-93-8\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-260-00-X\nethyl 2-(3-nitrobenzylidene)acetoacetate\n404-490-0\n39562-16-8\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-261-00-5\niso(C10-C14)alkyl (3,5-di-tert-butyl-4-hydroxyphenyl)methylthioacetate\n404-800-4\n118832-72-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-262-00-0\n7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid\n405-050-0\n86393-33-1\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n607-263-00-6\npotassium iron(III) 1,3-propanediamine-N, N,N',N'-tetraacetate hemihydrate\n405-680-6\n—\nSelf-heat. 2 **** Aquatic Chronic 2\nH252\nH411\nGHS02\nGHS09\nWng\nH252\nH411\n607-264-00-1\n2-chloro-4-(methylsulfonyl)benzoic acid\n406-520-8\n53250-83-2\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-265-00-7\nethyl-2-chloro-2,2-diphenylacetate\n406-580-5\n52460-86-3\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n607-266-00-2\nreaction mass of: hydroxyaluminium bis[2-hydroxy-3,5-di-tert-butylbenzoate]; 3,5-di-tert-butyl-salicylic acid\n406-890-0\n130296-87-6\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n607-267-00-8\ntert-butyl (5S,6R,7R)-3-bromomethyl-5,8-dioxo-7-(2-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylate\n407-620-4\n33610-13-8\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH334\nH317\nH412\nGHS08\nDgr\nH334\nH317\nH412\n607-268-00-3\n2-methylpropyl (R)-2-hydroxypropanoate\n407-770-0\n61597-96-4\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-269-00-9\n(R)-2-(4-hydroxyphenoxy)propanoic acid\n407-960-3\n94050-90-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-270-00-4\n3,9-bis(2-(3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy-1,1-dimethylethyl)-2,4,8,10-tetraoxaspiro[5.5]undecane\n410-730-5\n90498-90-1\nAcute Tox. 4 *\nH312\nGHS07\nWng\nH312\n607-271-00-X\n2-isopropyl-5-methylcyclohexyloxycarbonyloxy-2-hydroxypropane\n417-420-9\n156324-82-2\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n607-272-00-5\nfluroxypyr-meptyl (ISO); methylheptyl, O-(4-amino-3,5-dichloro-6-fluoro-2-pyridyloxy) acetate; [1] fluroxypyr-butometyl (ISO); 2-butoxy-1-methylethyl, O-(4-amino-3,5-dichloro-6-fluoro-2-pyridyloxy) acetate [2]\n279-752-9 [1]\n-[2]\n81406-37-3 [1]\n154486-27-8 [2]\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-273-00-0\nammonium 7-(2,6-dimethyl-8-(2,2-dimethylbutyryloxy)-1,2,6,7,8,8a-hexahydro-1-naphthyl)-3,5-dihydroxyheptanoate\n404-520-2\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-274-00-6\n2-(N-benzyl-N-methylamino)ethyl 3-amino-2-butenoate\n405-350-1\n54527-73-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-275-00-1\nsodium benzoyloxybenzene-4-sulfonate\n405-450-5\n66531-87-1\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-276-00-7\nbis[(1-methylimidazol)-(2-ethyl-hexanoate)], zinc complex\n405-635-0\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n607-277-00-2\nreaction mass of: 2-(hexylthio)ethylamine hydrochloride; sodium propionate\n405-720-2\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n607-278-00-8\nreaction mass of isomers of: sodium phenethylnaphthalenesulfonate; sodium naphthylethylbenzenesulfonate\n405-760-0\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-279-00-3\nreaction mass of n-octadecylaminodiethyl bis(hydrogen maleate); n-octadecylaminodiethyl hydrogen maleate hydrogenphthalate\n405-960-8\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-280-00-9\nsodium 4-chloro-1-hydroxybutane-1-sulfonate\n406-190-5\n54322-20-2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH302\nH319\nH317\nGHS07\nWng\nH302\nH319\nH317\n607-281-00-4\nreaction mass of branched and linear C7-C9 alkyl 3-[3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxyphenyl]propionates\n407-000-3\n127519-17-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-282-00-X\n2-acetoxymethyl-4-benzyloxybut-1-yl acetate\n407-140-5\n131266-10-9\nAquatic Chronic 3\nH412\n—\nH412\n607-283-00-5\nE-ethyl-4-oxo-4-phenylcrotonate\n408-040-4\n15121-89-8\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH315\nH318\nH317\nH410\n607-284-00-0\nreaction mass of: sodium 3,3'-(1,4-phenylenebis(carbonylimino-3,1-propanediylimino))bis(10-amino-6,13-dichloro-4,11-triphenodioxazinedisulfonate); lithium 3,3'-(1,4-phenylenebis-(carbonylimino-3,1-propanediyl-imino))bis(10-amino-6,13-dichloro)-4,11-triphenodioxazinedisulfonate (9:1)\n410-040-4\n136213-76-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-285-00-6\nreaction mass of: 7-(((3-aminophenyl)sulfonyl)amino)-naphthalene-1,3-disulfonic acid; sodium 7-(((3-aminophenyl)sulfonyl)amino)-naphthalene-1,3-disulfonate; potassium 7-(((3-aminophenyl)sulfonyl)amino)-naphthalene-1,3-disulfonate\n410-065-0\n—\nSkin Sens. 1\nH317\nGHS07\nWng\n607-286-00-1\nreaction mass of: sodium/potassium 7-[[[3-[[4-((2-hydroxy-naphthyl)azo)phenyl]azo]phenyl]sulfonyl]amino]-naphthalene-1,3-disulfonate\n410-070-8\n141880-36-6\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-287-00-7\nO'-methyl O-(1-methyl-2-methacryloyloxy-ethyl)-1,2,3,6-tetrahydrophthalate\n410-140-8\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-288-00-2\ntetrasodium (c-(3-(1-(3-(e-6-dichloro-5-cyanopyrimidin-f-yl(methyl)amino)propyl)-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo)-4-sulfonatophenylsulfamoyl)phthalocyanine-a, b,d-trisulfonato(6-))nickelato II, where a is 1 or 2 or 3 or 4,b is 8 or 9 or 10 or 11,c is 15 or 16 or 17 or 18, d is 22 or 23 or 24 or 25 and where e and f together are 2 and 4 or 4 and 2 respectively\n410-160-7\n148732-74-5\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH319\nH317\nH412\nGHS07\nWng\nH319\nH317\nH412\n607-289-00-8\n3-(3-(4-(2,4-bis(1,1-dimethylpropyl)phenoxy)butylaminocarbonyl-4-hydroxy-1-naphthalenyl)thio)propanoic acid\n410-370-9\n105488-33-3\nAquatic Chronic 4\nH413\n—\nH413\n607-290-00-3\nreaction mass (ratio not known) of: ammonium 1-C14-C18-alkyloxycarbonyl-2-(3-allyloxy-2-hydroxypropoxycarbonyl)ethane-1-sulfonate; ammonium 2-C14-C18-alkyloxycarbonyl-1-(3-allyloxy-2-hydroxypropoxycarbonyl)ethane-1-sulfonate\n410-540-2\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n607-291-00-9\ndodecyl-ω-(C5/C6-cycloalkyl)alkyl carboxylate\n410-630-1\n104051-92-5\nAquatic Chronic 4\nH413\n—\nH413\n607-292-00-4\nreaction mass of: [1-(methoxymethyl)-2-(C12-alkoxy)-ethoxy]acetic acid; [1-(methoxymethyl)-2-(C14-alkoxy)-ethoxy]acetic acid\n410-640-6\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n607-293-00-X\nreaction mass of: N-aminoethylpiperazonium mono-2,4,6-trimethylnonyldiphenyl ether di-sulfonate; N-aminoethylpiperazonium di-2,4,6-trimethylnonyldiphenyl ether di-sulfonate\n410-650-0\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n607-294-00-5\nsodium 2-benzoyloxy-1-hydroxyethane-sulfonate\n410-680-4\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-295-00-0\nreaction mass of: tetrasodium phosphonoethane-1,2-dicarboxylate; hexasodium phosphonobutane-1,2,3,4-tetracarboxylate\n410-800-5\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-296-00-6\nreaction mass of: pentaerythriol tetraesters with heptanoic acid and 2-ethylhexanoic acid\n410-830-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-297-00-1\n(E-E)-3,3'-(1,4-phenylenedimethylidene)bis(2-oxobornane-10-sulfonic acid)\n410-960-6\n92761-26-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-298-00-7\n2-(trimethylammonium)ethoxycarboxybenzene-4-sulfonate\n411-010-3\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-299-00-2\nmethyl 3-(acetylthio)-2-methyl-propanoate\n411-040-7\n97101-46-7\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n607-300-00-6\ntrisodium [2-(5-chloro-2,6-difluoropyrimidin-4-ylamino)-5-(b-sulfamoyl-c, d-sulfonatophthalocyanin-a-yl-K4, N29, N30, N31, N32-sulfonylamino)benzoato(5-)]cuprate(II) where a =1,2,3,4 b = 8,9,10,11 c = 15,16,17,18 d = 22,23,24,25\n411-430-7\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-301-00-1\nreaction mass of: dodecanoic acid; poly(1-7)lactate esters of dodecanoic acid\n411-860-5\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-302-00-7\nreaction mass of: tetradecanoic acid; poly(1-7)lactate esters of tetradecanoic acid\n411-910-6\n—\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH411\n607-303-00-2\n1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid\n413-760-7\n93107-30-3\nRepr. 2\nAquatic Chronic 3\nH361f *** H412\nGHS08\nWng\nH361f *** H412\n607-304-00-8\nfluazifop-butyl (ISO); butyl (RS)-2-[4-(5-trifluoromethyl-2-pyridyloxy)phenoxy]propionate\n274-125-6\n69806-50-4\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360D *** H400\nH410\nGHS08\nGHS09\nDgr\nH360D *** H410\n607-305-00-3\nfluazifop-P-butyl (ISO); butyl (R)-2-[4-(5-trifluoromethyl-2-pyridyloxy)phenoxy]propionate\n—\n79241-46-6\nRepr. 2\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H400\nH410\nGHS08\nGHS09\nWng\nH361d *** H410\n607-306-00-9\nchlozolinate (ISO); ethyl (RS)-3-(3,5-dichlorophenyl)-5-methyl-2,4-dioxo-oxazolidine-5-carboxylate\n282-714-4\n84332-86-5\nCarc. 2\nAquatic Chronic 2\nH351\nH411\nGHS08\nGHS09\nWng\nH351\nH411\n607-307-00-4\nvinclozolin (ISO); N-3,5-dichlorophenyl-5-methyl-5-vinyl-1,3-oxazolidine-2,4-dione\n256-599-6\n50471-44-8\nCarc. 2\nRepr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH351\nH360FD H317\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360FD H317\nH411\n607-308-00-X\nesters of 2,4-D\n—\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nA\n607-309-00-5\ncarfentrazone-ethyl (ISO); ethyl (RS)-2-chloro-3-[2-chloro-4-fluoro-5-[4-difluoromethyl-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]phenyl]propionate\n—\n128639-02-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-310-00-0\nkresoxim-methyl (ISO); methyl (E)-2-methoxyimino-[2-(o-tolyloxymethyl)phenyl]acetate\n—\n143390-89-0\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n607-311-00-6\nbenazolin-ethyl; ethyl 4-chloro-2-oxo-2H-benzothiazole-3-acetate\n246-591-0\n25059-80-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-312-00-1\nmethoxyacetic acid\n210-894-6\n625-45-6\nRepr. 1B\nAcute Tox. 4 *\nSkin Corr. 1B\nH360FD H302\nH314\nGHS08\nGHS05\nGHS07\nDgr\nH360FD H302\nH314\nSTOT SE 3; H335: C ≥ 5 %\n607-313-00-7\nneodecanoyl chloride\n254-875-0\n40292-82-8\nAcute Tox. 2 * Acute Tox. 4 *\nSkin Corr. 1B\nH330\nH302\nH314\nGHS06\nGHS06\nDgr\nH330\nH302\nH314\nSTOT SE 3; H335: C ≥ 5 %\n607-314-00-2\nethofumesate (ISO); (±)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-ylmethanesulfonate\n247-525-3\n26225-79-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-315-00-8\nglyphosate (ISO); N-(phosphonomethyl)glycine\n213-997-4\n1071-83-6\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n607-316-00-3\nglyphosate-trimesium; glyphosate-trimethylsulfonium\n—\n81591-81-3\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-317-00-9\nbis(2-ethylhexyl) phthalate; di-(2-ethylhexyl) phthalate; DEHP\n204-211-0\n117-81-7\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\n607-318-00-4\ndibutyl phthalate; DBP\n201-557-4\n84-74-2\nRepr. 1B\nAquatic Acute 1\nH360Df\nH400\nGHS08\nGHS09\nDgr\nH360Df\nH400\n607-319-00-X\ndeltamethrin (ISO); (S)-α-cyano-3-phenoxybenzyl(1R, 3R)-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropanecarboxylate\n258-256-6\n52918-63-5\nAcute Tox. 3 *\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH410\nM=1000000\n607-320-00-5\nbis[4-(ethenyloxy)butyl] 1,3-benzenedicarboxylate\n413-930-0\n130066-57-8\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-321-00-0\n(S)-methyl-2-chloropropionate\n412-470-8\n73246-45-4\nFlam. Liq. 3\nSTOT RE 2 *\nEye Irrit. 2\nH226\nH373 ** H319\nGHS02\nGHS08\nWng\nH226\nH373 ** H319\n607-322-00-6\n4-(4,4-dimethyl-3-oxo-pyrazolidin-1-yl)-benzoic acid\n413-120-7\n107144-30-9\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-323-00-1\n2-(1-(2-hydroxy-3,5-di-tert-pentyl-phenyl)ethyl)-4,6-di-tert-pentylphenyl acrylate\n413-850-6\n123968-25-2\nAquatic Chronic 4\nH413\n—\nH413\n607-324-00-7\nreaction mass of: N, N-di(hydrogenated alkyl C14-C18)phtalamic acid; dihydrogenated alkyl (C14-C18)amine\n413-800-3\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-325-00-2\n(S)-2-chloropropionic acid\n411-150-5\n29617-66-1\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Corr. 1A\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n607-326-00-8\nreaction mass of: isobutyl hydrogen 2-(α-2,4,6-trimethylnon-2-enyl)succinate; isobutyl hydrogen 2-(ß-2,4,6-trimetyhylnon-2-enyl)succinate\n410-720-0\n141847-13-4\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n607-327-00-3\n2-(2-iodoethyl)-1,3-propanediol diacetate\n411-780-0\n127047-77-2\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-328-00-9\nmethyl 4-bromomethyl-3-methoxybenzoate\n410-310-1\n70264-94-7\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n607-329-00-4\nreaction mass of: sodium 2-(C12-18-n-alkyl)amino-1,4-butandioate; sodium 2-octadecenyl-amino-1,4-butandioate\n411-250-9\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-330-00-X\n(S)-2,3-dihydro-1H-indole-2-carboxylic acid\n410-860-2\n79815-20-6\nRepr. 2\nSTOT RE 2 *\nSkin Sens. 1\nH361f *** H373 ** H317\nGHS08\nGHS07\nWng\nH361f *** H373 ** H317\n607-331-00-5\nreaction mass of: bis(2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-1,10-decanedioate; 1,8-bis[(2,2,6,6-tetramethyl-4-((2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-decan-1,10-dioyl)piperidin-1-yl)oxy]octane\n406-750-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-332-00-0\ncyclopentyl chloroformate\n411-460-0\n50715-28-1\nFlam. Liq. 3\nAcute Tox. 3 * Acute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH226\nH331\nH302\nH373 ** H318\nH317\nGHS02\nGHS06\nGHS08\nGHS05\nDgr\nH226\nH331\nH302\nH373 ** H318\nH317\n607-333-00-6\nreaction mass of: dodecyl N-(2,2,6,6-tetramethylpiperidin-4-yl)-β-alaninate; tetradecyl N-(2,2,6,6-tetramethylpiperidin-4-yl)-β-alaninate\n405-670-1\n—\nAcute Tox. 4 * STOT RE 2 *\nSkin Corr. 1B Aquatic Acute 1\nAquatic Chronic 1\nH302\nH373 ** H314\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH373 ** H314\nH410\n607-334-00-1\nethyl 1-ethyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate\n405-880-3\n100501-62-0\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-335-00-7\nmethyl (R)-2-(4-(3-chloro-5-trifluoromethyl-2-pyridyloxy)phenoxy)propionate\n406-250-0\n72619-32-0\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n607-336-00-2\n4-methyl-8-methylenetricyclo[3.3.1.13,7]dec-2-yl acetate\n406-560-6\n122760-85-4\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH315\nH317\nH411\n607-337-00-8\ndi-tert-(C12-14)-alkylammonium 2-benzothiazolylthiosuccinate\n406-052-4\n125078-60-6\nFlam. Liq. 3\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH226\nH302\nH315\nH318\nH411\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH226\nH302\nH315\nH318\nH411\n607-338-00-3\n2-methylpropyl 2-hydroxy-2-methylbut-3-enoate\n406-235-9\n72531-53-4\nEye Irrit. 2\nSkin Irrit. 2\nH319\nH315\nGHS07\nWng\nH319\nH315\n607-339-00-9\n2,3,4,5-tetrachlorobenzoylchloride\n406-760-3\n42221-52-3\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH302\nH314\nH317\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\n607-340-00-4\n1,3-bis(4-benzoyl-3-hydroxyphenoxy)prop-2-yl acetate\n406-990-4\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-341-00-X\n(9S)-9-amino-9-deoxyerythromycin\n406-790-7\n26116-56-3\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n607-342-00-5\n4-chlorobutyl veratrate\n410-950-1\n69788-75-6\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-343-00-0\n4,7-methanooctahydro-1H-indene-diyldimethyl bis(2-carboxybenzoate)\n407-410-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-344-00-6\nreaction mass of: 3-(N-(3-dimethylaminopropyl)-(C4-8)perfluoroalkylsulfonamido)propionic acid; N-[dimethyl-3-(C4-8-perfluoroalkylsulfonamido)propylammonium propionate; 3-(N-(3-dimethyl-propylammonium)-(C4-8)perfluoroalkylsulfonamido)propionic acid propionate\n407-810-7\n—\nSTOT RE 2 *\nH373 **\nGHS08\nWng\nH373 **\n607-345-00-1\npotassium 2-(2,4-dichlorophenoxy)-(R)-propionate\n413-580-9\n113963-87-4\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH302\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH317\n607-346-00-7\n3-icosyl-4-henicosylidene-2-oxetanone\n401-210-9\n83708-14-9\nAquatic Chronic 4\nH413\n—\nH413\n607-347-00-2\nsodium (R)-2-(2,4-dichlorophenoxy)propionate\n413-340-3\n119299-10-4\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH302\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH317\n607-348-00-8\nmagnesium bis((R)-2-(2,4-dichlorophenoxy)propionate)\n413-360-2\n—\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH302\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH317\n607-349-00-3\nmono-(tetrapropylammonium)hydrogen 2,2'-dithiobisbenzoate\n411-270-8\n—\nAquatic Chronic 3\nH412\nH412\n607-350-00-9\nbis(4-(1,2-bis(ethoxycarbonyl)ethylamino)-3-methylcyclohexyl)methane\n412-060-9\n136210-32-7\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-351-00-4\nmethyl O-(4-amino-3,5-dichloro-6-fluoropyridin-2-yloxy)acetate\n407-550-4\n69184-17-4\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-352-00-X\n4,4'-oxydiphthalic anhydride\n412-830-4\n1823-59-2\nAquatic Chronic 3\nH412\n—\nH412\n607-353-00-5\nreaction mass of: ethyl exo-tricyclo[5.2.1.02,6]decane-endo-2-carboxylate; ethyl endo-tricyclo[5.2.1.02,6]decane-exo-2-carboxylate\n407-520-0\n80657-64-3\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-354-00-0\nethyl 2-cyclohexylpropionate\n412-280-5\n2511-00-4\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-355-00-6\np-tolyl 4-chlorobenzoate\n411-530-0\n15024-10-9\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-356-00-1\nethyl trans-2,2,6-trimethylcyclohexanecarboxylate\n412-540-8\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-357-00-7\nreaction mass of: trans-4-acetoxy-4-methyl-2-propyl-tetrahydro-2H-pyran; cis-4-acetoxy-4-methyl-2-propyl-tetrahydro-2H-pyran\n412-450-9\n131766-73-9\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-358-00-2\n(1S,3S,5R,6R)-(4-nitrophenylmethyl)-1-dioxo-6-phenylacetamido-penam-3-carboxylate\n412-670-5\n54275-93-3\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n607-359-00-8\n(1S,4R,6R,7R)-(4-nitrophenylmethyl)3-methylene-1-oxo-7-phenylacetamido-cepham-4-carboxylateido-penam-3-carboxylate\n412-800-0\n76109-32-5\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n607-360-00-3\nsodium 3-acetoacetylamino-4-methoxytolyl-6-sulfonate\n411-680-7\n133167-77-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-361-00-9\nmethyl (R)-2-(4-hydroxyphenoxy)propionate\n411-950-4\n96562-58-2\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-362-00-4\nreaction mass of: (3-methoxy)propylammonium/[tris-(2-hydroxyethyl)]ammonium 2-(2-(bis(2-hydroxyethyl)amino)ethoxycarbonylmethyl)hexadec-4-enoate; (3-methoxy)propylammonium/ [tris-(2-hydroxyethyl)]ammonium 2-(2-(bis(2-hydroxyethyl)amino)ethoxycarbonylmethyl)tetradec-4-enoate; (3-methoxy)propylammonium/[tris-(2-hydroxyethyl)]ammonium 2-(3-methoxypropylcarbamoylmethyl)hexadec-4-enoate; (3-methoxy)propylammonium/ [tris-(2-hydroxyethyl)]ammonium 2-(3-methoxypropylcarbamoylmethyl)tetradec-4-enoate\n413-500-2\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH315\nH318\nH411\nGHS05\nGHS09\nDgr\nH315\nH318\nH411\n607-363-00-X\nmethyl-3-methoxyacrylate\n412-900-4\n5788-17-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-364-00-5\n3-phenyl-7-[4-(tetrahydrofurfuryloxy)phenyl]-1,5-dioxa-s-indacen-2,6-dione\n413-330-9\n134724-55-3\nAquatic Chronic 4\nH413\nH413\n607-365-00-0\n2-(2-amino-1,3-thiazol-4-yl)-(Z)-2-methoxyiminoacetyl chloride hydrochloride\n410-620-7\n119154-86-8\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH302\nH314\nH317\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\n607-366-00-6\n3,5-dimethylbenzoyl chloride\n413-010-9\n6613-44-1\nSkin Corr. 1B\nSkin Sens. 1\nH314\nH317\nGHS05\nGHS07\nDgr\nH314\nH317\n607-367-00-1\npotassium bis(N-carboxymethyl)-N-methyl-glycinato-(2-)N, O,O, N)-ferrate-(1-)monohydrate\n411-640-9\n153352-59-1\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-368-00-7\n1-(N,N-dimethylcarbamoyl)-3-tert-butyl-5-carbethoxymethylthio-1H-1,2,4-triazole\n411-650-3\n110895-43-7\nAcute Tox. 3 *\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH410\n607-369-00-2\nreaction mass of: trans-(2R)-5-acetoxy-1,3-oxathiolane-2-carboxylic acid; cis-(2R)-5-acetoxy-1,3-oxathiolane-2-carboxylic acid\n411-660-8\n147027-04-1\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH302\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH317\n607-370-00-8\n2-[[2-(acetyloxy)-3-(1,1-dimethyl-ethyl)-5-methylphenyl]methyl]-6-(1,1-dimethylethyl)-4-methylphenol\n412-210-3\n41620-33-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-371-00-3\n3-ethyl 5-methyl 4-(2-chlorophenyl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-(2)isoindol-2-yl)-ethoxymethyl]-6-methyl-3,5-pyridinedicarboxylate\n413-410-3\n88150-62-3\nAquatic Chronic 4\nH413\n—\nH413\n607-372-00-9\nethoxylated bisphenol A di-(norbornene carboxylate)\n412-410-0\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-373-00-4\n(±) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate\n414-200-4\n119738-06-6\nMuta. 2\nRepr. 1B\nAcute Tox. 4 * STOT RE 2 * Aquatic Acute 1\nAquatic Chronic 1\nH341\nH360Df\nH302\nH373 ** H400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH341\nH360Df\nH302\nH373 ** H410\n607-374-00-X\n5-amino-2,4,6-triiodo-1,3-benzenedicarbonyldichloride\n417-220-1\n37441-29-5\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-376-00-0\nbenzyl 2,4-dibromobutanoate\n420-710-8\n23085-60-1\nRepr. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f *** H315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361f *** H315\nH317\nH410\n607-377-00-6\ntrans-4-cyclohexyl-L-proline monohydrochloride\n419-160-1\n90657-55-9\nRepr. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH361f *** H302\nH315\nH318\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH361f *** H302\nH315\nH318\nH317\n607-378-00-1\nammonium (Z)-α-methoxyimino-2-furylacetate\n405-990-1\n97148-39-5\nFlam. Sol. 2\nH228\nGHS02\nDgr\nH228\nT\n607-379-00-7\nreaction mass of: 2-[N-(2-hydroxyethyl)stearamido]ethyl stearate; sodium [bis[2-(stearoyloxy)ethyl]amino]methylsulfonate; sodium [bis(2-hydroxyethyl)amino]methylsulfonate; N, N-bis(2-hydroxyethyl)stearamide\n401-230-8\nAquatic Chronic 3\nH412\n—\nH412\n607-380-00-2\nreaction mass of: ammonium-1,2-bis(hexyloxycarbonyl)ethanesulfonate; ammonium-1-hexyloxycarbonyl-2-octyloxycarbonylethanesulfonate; ammonium-2-hexyloxycarbonyl-1-octyloxycarbonylethanesulfonate\n407-320-3\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH315\nH318\nH412\nGHS05\nDgr\nH315\nH318\nH412\n607-381-00-8\nreaction mass of triesters of 2,2-bis(hydroxymethyl)butanol with C7-alkanoic acids and 2-ethylhexanoic acid\n413-710-4\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-382-00-3\n2-((4-amino-2-nitrophenyl)amino)benzoic acid\n411-260-3\n117907-43-4\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-383-00-9\nreaction mass of: 2,2,6,6-tetramethylpiperidin-4-yl-hexadecanoate; 2,2,6,6-tetramethylpiperidin-4-yl-octadecanoate\n415-430-8\n86403-32-9\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH410\n607-384-00-4\nreaction mass of: esters of C14-C15 branched alcohols with 3,5-di-t-butyl-4-hydroxyphenyl propionic acid; C15 branched and linear alkyl 3,5-bis(1,1-dimethylethyl)-4-hydroxybenzenepropanoate; C13 branched and linear alkyl 3,5-bis(1,1-dimethylethyl)-4-hydroxybenzenepropanoate\n413-750-2\n171090-93-0\nAquatic Chronic 4\nH413\n—\nH413\n607-385-00-X\ncopolymer of vinyl-alcohol and vinyl acetate partially acetilized with 4-(2-(4-formylphenyl)ethenyl)-1-methylpyridinium methylsulfate\n414-590-6\n125229-74-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-386-00-5\nreaction mass of: tetradecanoic acid (42,5-47,5 %); poly(1-7)lactate esters of tetradecanoic acid (52,5-57,5 %)\n412-580-6\n174591-51-6\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n607-387-00-0\nreaction mass of: dodecanoic acid (35-40 %); poly(1-7)lactate esters of dodecanoic acid (60-65 %)\n412-590-0\n58856-63-6\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n607-388-00-6\n4-ethylamino-3-nitrobenzoic acid\n412-090-2\n2788-74-1\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n607-389-00-1\ntrisodium N, N-bis(carboxymethyl)-3-amino-2-hydroxypropionate\n414-130-4\n119710-96-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-390-00-7\n1,2,3,4-tetrahydro-6-nitro-quinoxaline\n414-270-6\n41959-35-7\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-391-00-2\ndimethylcyclopropane-1,1-dicarboxylate\n414-240-2\n6914-71-2\nAquatic Chronic 3\nH412\n—\nH412\n607-392-00-8\n2-phenoxyethyl 4-((5-cyano-1,6-dihydro-2-hydroxy-1,4-dimethyl-6-oxo-3-pyridinyl)azo)benzoate\n414-260-1\n88938-37-8\nAquatic Chronic 4\nH413\n—\nH413\n607-393-00-3\n3-(cis-1-propenyl)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid\n415-750-8\n106447-44-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-394-00-9\n5-methylpyrazine-2-carboxylic acid\n413-260-9\n5521-55-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-395-00-4\nreaction mass of: sodium 1-tridecyl-4-allyl-(2 or 3)-sulfobutanedioate; sodium 1-dodecyl-4-allyl-(2 or 3)-sulfobutanedioate\n410-230-7\n—\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH411\n607-396-00-X\nbis(1,2,2,6,6-pentamethyl-4-piperidinyl) 2-(4-methoxybenzylidene)malonate\n414-840-4\n147783-69-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-397-00-5\nreaction mass of: Ca salicylates (branched C10-14 and C18-30 alkylated); Ca phenates (branched C10-14 and C18-30 alkylated); Ca sulfurised phenates(branched C10-14 and C18-30 alkylated)\n415-930-6\n—\nRepr. 2\nSkin Sens. 1\nH361f*** H317\nGHS08\nGHS07\nWng\nH361f*** H317\n607-398-00-0\nethyl N-(5-chloro-3-(4-(diethylamino)-2-methylphenylimino)-4-methyl-6-oxo-1,4-cyclohexadienyl)carbamate\n414-820-5\n125630-94-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-399-00-6\n2,2-dimethyl 3-methyl-3-butenyl propanoate\n415-610-6\n104468-21-5\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n607-400-00-X\nmethyl 3-[[(dibutylamino)thioxomethyl]thio]propanoate\n414-400-1\n32750-89-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-401-00-5\nethyl 3-hydroxy-5-oxo-3-cyclohexene-1-carboxylate\n414-450-4\n88805-65-6\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH315\nH318\nH317\n607-402-00-0\nmethyl N-(phenoxycarbonyl)-L-valinate\n414-500-5\n153441-77-1\nAquatic Chronic 3\nH412\n—\nH412\n607-403-00-6\nreaction mass of: bis(1S,2S,4S)-(1-benzyl-4-tert-butoxycarboxamido-2-hydroxy-5-phenyl)pentylammonium succinate; isopropyl alcohol\n414-810-0\n—\nSTOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 ** H318\nH400\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH373 ** H318\nH410\n607-404-00-1\nreaction mass of: ((Z)-3,7-dimethyl-2,6-octadienyl)oxycarbonylpropanoic acid; di-((E)-3,7-dimethyl-2,6-octadienyl) butandioate; di-((Z)-3,7-dimethyl-2,6-octadienyl) butandioate; (Z)-3,7-dimethyl-2,6-octadienyl butandioate; ((E)-3,7-dimethyl-2,6-octadienyl)oxycarbonylpropanoic acid\n415-190-4\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-405-00-7\n2-hexyldecyl-p-hydroxybenzoate\n415-380-7\n148348-12-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-406-00-2\npotassium 2,5-dichlorobenzoate\n415-700-5\n184637-62-5\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n607-407-00-8\nethyl 2-carboxy-3-(2-thienyl)propionate\n415-680-8\n143468-96-6\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH315\nH318\nH317\n607-408-00-3\npotassium N-(4-fluorophenyl)glycinate\n415-710-1\n184637-63-6\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH373 ** H318\nH317\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH373 ** H318\nH317\nH412\n607-409-00-9\nreaction mass of: (3R)-[1S-(1α,2α, 6β-((2S)-2-methyl-1-oxo-butoxy)-8aγ)hexahydro-2,6-dimethyl-1-naphthalene]-3,5-dihydroxyheptanoic acid; inert biomass from Aspergillus terreus\n415-840-7\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-410-00-4\nmono[2-(dimethylamino)ethyl]monohydrogen-2-(hexadec-2-enyl)butanedioate and/or mono[2-(dimethylamino)ethyl]monohydrogen-3-(hexadec-2-enyl)butanedioate\n415-880-5\n779343-34-9\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n607-411-00-X\noxiranemethanol, 4-methylbenzene-sulfonate, (S)-\n417-210-7\n70987-78-9\nCarc. 1B Muta. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH341\nH318\nH317\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH350\nH341\nH318\nH317\nH411\n607-412-00-5\nethyl 2-(1-cyanocyclohexyl)acetate\n415-970-4\n133481-10-4\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373 ** H412\nGHS08\nGHS07\nWng\nH302\nH373 ** H412\n607-413-00-0\ntrans-4-phenyl-L-proline\n416-020-1\n96314-26-0\nRepr. 2\nSkin Sens. 1\nH361f *** H317\nGHS08\nGHS07\nWng\nH361f *** H317\n607-414-00-6\ntris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino)tribenzoate\n402-070-1\n88122-99-0\nAquatic Chronic 4\nH413\n—\nH413\n607-415-00-1\npoly-(methyl methacrylate)-co-(butylmethacrylate)-co-(4-acryloxybutyl-isopropenyl-α, α-dimethylbenzyl carbamate)-co-(maleicanhydride)\n419-590-1\n—\nFlam. Sol. 1\nSkin Sens. 1\nH228\nH317\nGHS02\nGHS07\nDgr\nH228\nH317\nT\n607-416-00-7\n4-(2-carboxymethylthio)ethoxy-1-hydroxy-5-isobutyloxycarbonylamino-N-(3-dodecyloxypropyl)-2-naphthamide\n420-730-7\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-417-00-2\n3-chloropropyl chloroformiate\n425-770-9\n628-11-5\nAcute Tox. 3 * Acute Tox. 4 * STOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH331\nH302\nH373** H315\nH318\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH331\nH302\nH373** H315\nH318\nH317\n607-418-00-8\n2-ethylhexyl 4-aminobenzoate\n420-170-3\n26218-04-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-419-00-3\n(3'-carboxymethyl-5-(2-(3-ethyl-3H-benzothiazol-2-ylidene)-1-methyl-ethylidene)-4,4'-dioxo-2'-thioxo-(2,5')bithiazolidinyliden-3-yl)-acetic acid\n422-240-9\n166596-68-5\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-420-00-9\n2,2-bis(hydroxymethyl)butanoic acid\n424-090-1\n10097-02-6\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-421-00-4\ncypermethrin cis/trans +/-40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate\n257-842-9\n52315-07-8\nAcute Tox. 4 * Acute Tox. 4 * STOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH335\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH335\nH410\n607-422-00-X\nα-cypermethrin (ISO); racemate comprising (R)-α-cyano-3-phenoxybenzyl (1S,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; (S)-α-cyano-3-phenoxybenzyl(1R, 3R)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate\n257-842-9\n67375-30-8\nAcute Tox. 3 * STOT RE 2 * STOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH373** H335\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH373** H335\nH410\nM=1000\n607-423-00-5\nesters of mecoprop and of mecoprop-P\n—\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nA\n607-424-00-0\ntrifloxystrobin (ISO); (E, E)-α-methoxyimino-{2-[[[[1-[3-(trifluoromethyl)phenyl]ethylidene]amino]oxy]methyl]benzeneacetic acid methyl ester\n—\n141517-21-7\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-425-00-6\nmetalaxyl (ISO); methyl-N-(2,6-dimethylphenyl)-N-(methoxyacetyl)-DL-alaninate\n260-979-7\n57837-19-1\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n607-426-00-1\n1,2-benzenedicarboxylic acid, dipentylester, branched and linear; [1] n-pentyl-isopentylphthalate; [2] di-n-pentyl phthalate; [3] diisopentylphthalate [4]\n284-032-2 [1]\n-[2]\n205-017-9 [3]\n210-088-4 [4]\n84777-06-0 [1]\n-[2]\n131-18-0 [3]\n605-50-5 [4]\nRepr. 1B\nAquatic Acute 1\nH360FD H400\nGHS08\nGHS09\nDgr\nH360FD H400\n607-427-00-7\nbromoxynil heptanoate (ISO); 2,6-dibromo-4-cyanophenyl heptanoate\n260-300-4\n56634-95-8\nRepr. 2\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H332\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d *** H332\nH302\nH317\nH410\n607-428-00-2\ntetrasodium ethylene diamine tetraacetate\n200-573-9\n64-02-8\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n607-429-00-8\nedetic acid; (EDTA)\n200-449-4\n60-00-4\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-430-00-3\nBBP; benzyl butyl phthalate e\n201-622-7\n85-68-7\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH400\nH410\nGHS08\nGHS09\nDgr\nH360Df\nH410\n607-431-00-9\nprallethrin (ISO); ETOC; 2-methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate\n245-387-9\n23031-36-9\nAcute Tox. 3 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH331\nH302\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH302\nH410\n607-432-00-4\nS-metolachlor; reaction mass of (S)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] (R)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2]\n-[1]\n-[2]\n87392-12-9 [1]\n178961-20-1 [2]\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-433-00-X\ncypermethrin cis/trans +/-80/20; (RS)-α-cyano-3-phenoxybenzyl (1RS;3RS; 1RS, 3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate\n257-842-9\n52315-07-8\nAcute Tox. 4 * STOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH335\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH335\nH315\nH317\nH410\n607-434-00-5\nmecoprop-P [1] and its salts; (R)-2-(4-chloro-2-methylphenoxy)propionic acid\n240-539-0\n16484-77-8\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n607-435-00-0\n2S-isopropyl-5R-methyl-1R-cyclohexyl 2,2-dihydroxyacetate\n416-810-6\n111969-64-3\nSTOT RE 2 *\nEye Dam. 1\nAquatic Chronic 2\nH373 ** H318\nH411\nGHS08\nGHS05\nGHS09\nDgr\nH373 ** H318\nH411\n607-436-00-6\n2-hydroxy-3-(2-ethyl-4-methylimidazoyl)propyl neodecanoate\n417-350-9\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n607-437-00-1\n3-(4-aminophenyl)-2-cyano-2-propenoic acid\n417-480-6\n252977-62-1\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-438-00-7\nmethyl-2-[(aminosulfonyl)methyl]benzoate\n419-010-5\n112941-26-1\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n607-439-00-2\nmethyl tetrahydro-2-furancarboxylate\n420-670-1\n37443-42-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-440-00-8\nmethyl 2-aminosulfonyl-6-(trifluoromethyl)pyridine-3-c arboxylate\n421-220-7\n144740-59-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-441-00-3\n3-[3-(2-dodecyloxy-5-methylphenylcarbamoyl)-4-hydroxy-1-naphthylthio]propionic acid\n421-490-6\n167684-63-1\nAquatic Chronic 4\nH413\n—\nH413\n607-442-00-9\nbenzyl [hydroxy-(4-phenylbutyl)phosphinyl] acetate\n416-050-5\n87460-09-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-444-00-X\nreaction mass of: cis-1,4-dimethylcyclohexyl dibenzoate; trans-1,4-dimethylcyclohexyl dibenzoate\n416-230-3\n35541-81-2\nAquatic Chronic 4\nH413\n—\nH413\n607-445-00-5\nIron (III) tris(4-methylbenzenesulfonate)\n420-960-8\n77214-82-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-446-00-0\nmethyl 2-[4-(2-chloro-4-nitrophenylazo)-3-(1-oxopropyl)amino]phenylaminopropionate\n416-240-8\n155522-12-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-447-00-6\nsodium 4-[4-(4-hydroxyphenylazo)phenylamino]-3-nitrobenzenesulfonate\n416-370-5\n156738-27-1\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-448-00-1\n2,3,5,6-tetrafluorobenzoic acid\n416-800-1\n652-18-6\nSkin Irrit. 2\nEye Dam. 1\nH315\nH318\nGHS05\nDgr\nH315\nH318\n607-449-00-7\nreaction mass of: 4,4',4''-[(2,4,6-trioxo-1,3,5(2H,4H,6H)-triazine-1,3,5-triyl)tris[methylene(3,5,5-trimethyl-3,1-cyclohexanediyl)iminocarbonyloxy-2,1-ethanediyl(ethyl)amino]]trisbenzenediazoniumtri[bis(2-methylpropyl)naphthalenesulfonate];4,4',4'',4'''-[[5,5'-[carbonylbis[imino(1,5,5-trimethyl-3,1-cyclohexanediyl)methylene]]-2,4,6-trioxo-1,3,5(2H,4H,6H)-triazine-1,1',3,3'-tetrayl]tetrakis[methylene(3,5,5-trimethyl-3,1-cyclohexanediyl)iminocarbonyloxy-2,1-ethanediyl(ethyl)amino]]tetrakisbenzenediazoniumtetra[bis(2-methylpropyl)naphthalenesulfonate]\n417-080-1\n—\nSelf-react. D ****\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH242\nH317\nH400\nH410\nGHS02\nGHS07\nGHS09\nDgr\nH242\nH317\nH410\n607-450-00-2\n2-mercaptobenzothiazolyl-(Z)-(2-aminothiazol-4-yl)-2-(tert-butoxycarbonyl) isopropoxyiminoacetate\n419-040-9\n89604-92-2\nAquatic Chronic 4\nH413\n—\nH413\n607-451-00-8\n4-[4-amino-5-hydroxy-3-(4-(2-sulfoxyethylsulfonyl)phenylazo)-2,7-disulfonapht-6-ylazo]-6-[3-(4-amino-5-hydroxy-3-(4-(2-sulfoxyethylsulfonyl)phenylazo)-2,7-disulfonapht-6-ylazo]phenylcarbonylamino]benzenesulfonic acid, sodium salt\n417-640-5\n161935-19-9\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-453-00-9\n4-benzyl-2,6-dihydroxy-4-aza-heptylene bis (2,2-dimethyloctanoate)\n418-100-1\n172964-15-7\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-454-00-4\nreaction mass of: trans-2-(1-methylethyl)-1,3-dioxane-5-carboxylic acid; cis-2-(1-methylethyl)-1,3-dioxane-5-carboxylic acid\n418-170-3\n116193-72-7\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-455-00-X\n1-amino-4-(3-[4-chloro-6-(2,5-di-sulfophenylamino)-1,3,5-triazin-2-ylamino]-2,2-dimethyl-propylamino)-anthraquinone-2-sulfonic acid, sodium/lithium salt\n419-520-8\n172890-93-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-456-00-5\n3-amino-4-chlorobenzoic acid, hexadecyl ester\n419-700-6\n143269-74-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-457-00-0\ntetrasodium dihydrogen 1,1''-dihydroxy-8,8''-[p-phenylbis(imino-{6-[4-(2-aminoethyl)piperazin-1-yl]}-1,3,5-triazine-4,2-diyl-imino)]bis(2,2'-azonaphthalene-1',3,6-trisulfonate)\n420-350-1\n172277-97-3\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n607-458-00-6\nreaction mass of: 2-ethyl-[2,6-dibromo-4-[1-[3,5-dibromo-4-(2-hydroxyethoxy)phenyl]-1-methylethyl]phenoxy]propenoate; 2,2'-diethyl-[4,4'-bis(2,6-dibromophenoxy)-1-methylethylidene] dipropenoate;2,2'-[(1-methylethylidene)bis[[2,6-dibromo-4,1-phenylene)oxy]ethanol]]\n420-850-1\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-459-00-1\nisopentyl 4-{2-[5-cyano-1,2,3,6-tetrahydro-1-(2-isopropoxyethoxy-carbonylmethyl)-4-methyl-2,6-dioxo-3-pyridylidene]hydrazino}benzoate\n418-930-4\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-460-00-7\n3-tridecyloxy-propyl-ammonium 9-octadecenoate\n418-990-1\n778577-53-0\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH373 ** H319\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373 ** H319\nH315\nH410\n607-461-00-2\nreaction mass of: pentasodium 2-{4-{3-methyl-4-[6-sulfonato-4-(2-sulfonato-phenylazo)-naphthalen-1-ylazo]-phenylamino}-6-[3-(2-sulfato-ethanesulfonyl)-phenylamino]-1,3,5-triazin-2-ylamino}-benzene-1,4-disulfonate; pentasodium 2-{4-{3-methyl-4-[7-sulfonato-4-(2-sulfonato-phenylazo)-naphthalen-1-ylazo]-phenylamino}-6-[3-(2-sulfato-ethanesulfonyl)-phenylamino]-1,3,5-triazin-2-ylamino}-benzene-1,4-disulfonate\n421-160-1\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-462-00-8\nreaction mass of: 1-hexyl acetate; 2-methyl-1-pentyl acetate; 3-methyl-1-pentyl acetate; 4-methyl-1-pentyl acetate; other mixed linear and branched C6-alkyl acetates\n421-230-1\n88230-35-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-463-00-3\n3-(phenothiazin-10-yl)propionic acid\n421-260-5\n362-03-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-464-00-9\nreaction mass of: 7-chloro-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid; 5-chloro-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid\n421-280-4\nAquatic Chronic 3\nH412\n—\nH412\n607-465-00-4\ntris(2-hydroxyethyl)ammonium 7-{4-[4-(2-cyanoamino-4-hydroxy-6-oxidopyrimidin-5-ylazo)benzamido]-2-ethoxy-phenylazo}naphthalene-1,3-disulfonate\n421-440-3\n778583-04-3\nAquatic Chronic 3\nH412\n—\nH412\n607-466-00-X\nreaction mass of: phenyl 1-(1-[2-chloro-5-(hexadecyloxycarbonyl)phenylcarbamoyl]-3,3-dimethyl-2-oxobutyl)-1H-2,3,3a,7a-tetrahydrobenzotriazole-5-carboxylate; phenyl 2-(1-(2-chloro-5-(hexadecyloxycarbonyl)phenylcarbamoyl)-3,3-dimethyl-2-oxobutyl)-1H-2,3,3a,7a-tetrahydrobenzotriazole-5-carboxylate; phenyl 3-(1-(2-chloro-5-(hexadecyloxycarbonyl)phenylcarbamoyl)-3,3-dimethyl-2-oxobutyl)-1H-2,3,3a,7a-tetrahydrobenzotriazole-5-carboxylate\n421-480-1\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-467-00-5\n1,1,3,3-tetrabutyl-1,3-ditinoxydicaprylate\n419-430-9\n56533-00-7\nAcute Tox. 4 * Acute Tox. 4 * STOT RE 2 *\nSkin Corr. 1B Aquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373 ** H314\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH373 ** H314\nH410\n607-468-00-0\nreaction mass of: monosodium 4-((4-(5-sulfonato-2-methoxyphenylamino)-6-chloro-1,3,5-triazine-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridine-3-yl)azo)benzenesulfonate; disodium 4-((4-(5-sulfonato-2-methoxyphenylamino)-6-chloro-1,3,5-triazine-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridine-3-yl)azo)benzenesulfonate; trisodium 4-((4-(5-sulfonato-2-methoxyphenylamino)-6-chloro-1,3,5-triazine-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridine-3-yl)azo)benzenesulfonate; tetrasodium 4-((4-(5-sulfonato-2-methoxyphenylamino)-6-chloro-1,3,5-triazine-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridine-3-yl)azo)benzenesulfonate\n419-450-8\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-469-00-6\ndisodium 7-((4,6-bis(3-diethylaminopropylamino)-1,3,5-triazine-2-yl)amino)-4-hydroxy-3-(4-(4-sulfonatophenylazo)phenylazo)-2-naphthalene sulfonate\n419-460-2\n120029-06-3\nAquatic Chronic 3\nH412\n—\nH412\n607-470-00-1\npotassium sodium 6,13-dichloro-3,10-bis{2-[4-[3-(2-hydroxysulphonyloxyethanesulfonyl)phenylamino]-6-(2,5-disulfonatophenylamino)-1,3,5-triazin-2-ylamino]ethylamino}benzo[5,6][1,4]oxazino[2,3-b]phenoxazine-4,11-disulfonate\n414-100-0\n154336-20-6\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-471-00-7\n1,6-bis((dibenzylthiocarbamoyl)disulfanyl)hexane\n429-280-6\n151900-44-6\nAquatic Chronic 4\nH413\n—\nH413\n607-473-00-8\npentaerythritol, dipentaerythritol, fatty acids, C6-10, mixed esters with adipic acid, heptanoic acid and isostearic acid\n426-590-3\n187412-41-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-474-00-3\n(4-(4-(4-dimethylaminobenzyliden-1-yl)-3-methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid\n410-430-4\n117573-89-4\nAquatic Chronic 4\nH413\n—\nH413\n607-475-00-9\nreaction mass of: tetrasodium 7-(4-[4-chloro-6-[methyl-(3-sulfonatophenyl)amino]-1,3,5-triazin-2-ylamino]-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate; tetrasodium 7-(4-[4-chloro-6-[methyl-(4-sulfonatophenyl)amino]-1,3,5-triazin-2-ylamino]-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate (1:1)\n412-940-2\n148878-18-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-476-00-4\ntrisodium N, N-bis(carboxymethyl)-β-alanine\n414-070-9\n129050-62-0\nSkin Corr. 1B\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\n607-477-00-X\n(1α5α6α)-6-nitro-3-benzyl-3-azabicyclo[3.1.0]hexane methanesulfonate salt\n426-740-8\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n607-478-00-5\ntetramethylammonium hydrogen phthalate\n416-900-5\n79723-02-7\nAcute Tox. 3 * STOT RE 2 * Aquatic Acute 1\nH301\nH373 ** H400\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH373 ** H400\n607-479-00-0\nhexadecyl 4-chloro-3-[2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-4,4-dimethyl-3-oxopentamido]benzoate\n418-550-9\n168689-49-4\nAquatic Chronic 4\nH413\n—\nH413\n607-480-00-6\n1,2-benzenedicarboxylic acid; di-C7-11-branched and linear alkylesters\n271-084-6\n68515-42-4\nRepr. 1B\nH360Df\nGHS08\nDgr\nH360Df\n607-481-00-1\nreaction mass of: trihexyl citrate; dihexyloctyl citrate; dioctylhexyl citrate; dihexyldecyl citrate\n430-290-8\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-482-00-7\nN-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N-carboxyanhydride\n430-360-8\n84793-24-8\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-483-00-2\n1,2-benzenedicarboxylic acid; di-C6-8-branched alkylesters, C7-rich\n276-158-1\n71888-89-6\nRepr. 1B\nH360D***\nGHS08\nDgr\nH360D***\n607-484-00-8\nethyl 2-{[3-acetylamino-4-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)phenyl{]ethylamino[}propionate\n430-480-0\n221452-67-1\nAquatic Chronic 4\nH413\n—\nH413\n607-485-00-3\n(3S-trans)-phenyl-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinecarboxylate\n430-510-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-486-00-9\npotassium sodium 5'-(6-chloro-4-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-4'-hydroxy-2,3'-azodinaphthalene-1,2', 5,7'-disulfonate\n402-110-8\n110081-40-8\nAquatic Chronic 3\nH412\n—\nH412\n607-487-00-4\nreaction mass of: disodium 4-(3-ethoxycarbonyl-4-(5-(3-ethoxycarbonyl-5-hydroxy-1-(4-sulfonatophenyl)pyrazol-4-yl)penta-2,4-dienylidene)-4,5-dihydro-5-oxopyrazol-1-yl)benzenesulfonate; trisodium 4-(3-ethoxycarbonyl-4-(5-(3-ethoxycarbonyl-5-oxido-1-(4-sulfonatophenyl)pyrazol-4-yl)penta-2,4-dienylidene)-4,5-dihydro-5-oxopyrazol-1-yl)benzenesulfonate\n402-660-9\n—\nRepr. 1B\nAquatic Chronic 3\nH360D *** H412\nGHS08\nDgr\nH360D *** H412\n607-488-00-X\nethyl (2-acetylamino-5-fluoro-4-isothiocyanatophenoxy)acetate\n414-210-9\n147379-38-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-489-00-5\nreaction mass of: 2-ethylhexyl linolenate, linoleate and oleate; 2-ethylhexyl epoxyoleate; 2-ethylhexyl diepoxylinoleate; 2-ethylhexyl triepoxylinolenate\n414-890-7\n71302-79-9\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-490-00-0\nN-[2-hydroxy-3-(C12-16-alkyloxy)propyl]-N-methyl glycinate\n415-060-7\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-491-00-6\nreaction mass of: diester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxonaphthalene-1-sulfonic acid (1:2); triester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxonaphthalene-1-sulfonic acid (1:3)\n427-140-9\n—\nCarc. 2\nH351\nGHS08\nWng\nH351\n607-492-00-1\n2-(1-(3',3'-dimethyl-1'-cyclohexyl)ethoxy)-2-methyl propyl propanoate\n415-490-5\n141773-73-1\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-493-00-7\nmethyl (3aR,4R,7aR)-2-methyl-4-(1S,2R,3-triacetoxypropyl)-3a,7a-dihydro-4H-pyrano[3,4-d]oxazole-6-carboxylate\n415-670-3\n78850-37-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-494-00-2\nbis(2-ethylhexyl)octylphosphonate\n417-170-0\n52894-02-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-495-00-8\nsodium 4-sulfophenyl-6-((1-oxononyl)amino)hexanoate\n417-550-6\n168151-92-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-496-00-3\n2,2'-methylenebis(4,6-di-tert-butyl-phenyl)-2-ethylhexyl phosphite\n418-310-3\n126050-54-2\nAquatic Chronic 4\nH413\n—\nH413\n607-497-00-9\ncerium oxide isostearate\n419-760-3\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-498-00-4\n(E)-3,7-dimethyl-2,6-octadienylhexadecanoate\n421-370-3\n3681-73-0\nSkin Irrit. 2\nAquatic Chronic 4\nH315\nH413\nGHS07\nWng\nH315\nH413\n607-499-00-X\nbis(dimethyl-(2-hydroxyethyl)ammonium) 1,2-ethanediyl-bis(2-hexadecenylsuccinate)\n421-660-1\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n607-500-00-3\ncalcium 2,2,bis[(5-tetrapropylene-2-hydroxy)phenyl]ethanoate\n421-670-4\n—\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n607-501-00-9\nreaction mass of: triphenylthiophosphate and tertiary butylated phenyl derivatives\n421-820-9\n192268-65-8\nAquatic Chronic 4\nH413\n—\nH413\n607-502-00-4\n(N-benzyl-N, N,N-tributyl)ammonium 4-dodecylbenzenesulfonate\n422-200-0\n178277-55-9\nSkin Corr. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH314\nH302\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH302\nH411\n607-503-00-X\n2,4,6-tri-n-propyl-2,4,6-trioxo-1,3,5,2,4,6-trioxatriphosphorinane\n422-210-5\n68957-94-8\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n607-504-00-5\ndiammonium 1-hydroxy-2-(4-(4-carboxyphenylazo)-2,5-dimethoxyphenylazo)-7-amino-3-naphthalenesulfonate\n422-670-7\n—\nRepr. 2\nAcute Tox. 3 * STOT RE 2 * Aquatic Acute 1\nAquatic Chronic 1\nH361f\nH301\nH373** H400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361f\nH301\nH373** H410\n607-505-00-0\npentasodium 7-(4-(4-(5-amino-4-sulfonato-2-(4-((2-(sulfonato-ethoxy)sulfonyl)phenylazo)phenylamino)-6-chloro-1,3,5-triazin-2-yl)amino-2-ureidophenylazo)naphtalene-1,3,6-trisulfonate\n422-930-1\nAquatic Chronic 3\nH412\n—\nH412\n607-506-00-6\nreaction mass of: strontium (4-chloro-2-((4,5-dihydro-3-methyl-5-oxo-1-(3-sulfonatophenyl)-1H-pyrazol-4-yl)azo)-5-methyl)benzenesulfonate; disodium (4-chloro-2-((4,5-dihydro-3-methyl-5-oxo-1-(3-sulfonatophenyl)-1H-pyrazol-4-yl)azo)-5-methyl)benzenesulfonate\n422-970-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-507-00-1\npotassium, sodium 2,4-diamino-3-[4-(2-sulfonatoethoxysulfonyl)phenylazo]-5-[4-(2-sulfonatoethoxysulfonyl)-2-sulfonatophenylazo]-benzenesulfonate\n422-980-2\n187026-95-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-508-00-7\ndisodium 3,3'-[iminobis[sulfonyl-4,1-phenylene-(5-hydroxy-3-methylpyrazole-1,4-diyl)azo-4,1-phenylenesulfonylimino-(4-amino-6-hydroxypyrimidine-2,5-diyl)azo-4,1-phenylenesulfonylimino(4-amino-6-hydroxypyrimidine-2,5-diyl)azo]bis(benzenesulfonate)]\n423-110-4\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-509-00-2\n2-phenoxyethyl 4-aminobenzoate\n430-880-5\n88938-23-2\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-510-00-8\n(2S, 5R)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide\n427-200-4\n76646-91-8\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH302\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH317\n607-511-00-3\nreaction mass of: 4-[(3-decyloxypropyl)(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)amino]-4-oxobutyric acid; 4-[(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)(3-octyloxypropyl)amino]-4-oxobutyric acid\n423-750-4\n—\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n607-512-00-9\ntrisodium 2,4-diamino-3,5-bis-[4-(2-sulfonatoethoxy)sulfonyl)phenylazo]benzenesulfonate\n423-970-0\n182926-43-8\nAquatic Chronic 3\nH412\n—\nH412\n607-513-00-4\nreaction mass of: trisodium 4-benzoylamino-6-(6-ethenesulfonyl-1-sulfato-naphthalen-2-ylazo)-5-hydroxynaphthalene-2,7-disulfonate; 5-(benzoylamino)-4-hydroxy-3-((1-sulfo-6-((2-(sulfooxy)ethyl)sulfonyl)-2-naphthyl)azo)naphthalene-2,7-disulfonic acid sodium salt; 5-(benzoylamino)-4-hydroxy-3-((1-sulfo-6-((2-(sulfooxy)ethyl)sulfonyl)-2-naphthyl)azo)naphthalene-2,7-disulfonic acid\n423-200-3\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-514-00-X\npotassium N-(1-methoxy-1-oxobut-2-en-3-yl)valinate\n427-240-2\n134841-35-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-515-00-5\nreaction mass of: disodium hexyldiphenyl ether disulphonate; disodium dihexyldiphenyl ether disulphonate\n429-650-7\n147732-60-3\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n607-516-00-0\nN, N'-bis(trifluoroacetyl)-S, S'-bis-L-homocysteine\n429-670-6\n105996-54-1\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-517-00-6\n(S)-α-(acetylthio)benzenepropanoic acid\n430-300-0\n76932-17-7\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\n607-518-00-1\n3-oxoandrost-4-ene-17-β-carboxylic acid\n414-990-0\n302-97-6\nRepr. 2\nAquatic Chronic 4\nH361f\nH413\nGHS08\nWng\nH361f\nH413\n607-519-00-7\npoly-[((4-((4-ethyl-ethylene)amino)phenyl)-((4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)cyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate]\n427-280-0\n176429-27-9\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH335\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH335\nH315\nH318\nH410\n607-520-00-2\nreaction mass of: sodium 4,5-dihydro-2-[(propionato)(C6-18)alkyl]-3H-imidazolium-N-ethylphosphate; disodium 4,5-dihydro-2-[(dipropionato)(C6-18)alkyl]-3H-imidazolium-N-ethylphosphate\n427-740-0\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-521-00-8\ntetraethyl N, N'-(methylenedicyclohexane-4,1-diyl)bis-DL-aspartate\n429-270-1\n136210-30-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-522-00-3\nsodium salt of the polymer of:sodium 2-methyl-buta-1,3-diene-1-sulfonate with acrylic acid and 2-hydroxyethyl-2-methylacrylate\n429-720-7\n184246-86-4\nAquatic Chronic 3\nH412\n—\nH412\n607-523-00-9\nreaction mass of mono to tetra(lithium and/or sodium)3-amino-10-[4-(4-amino-3-sulfonatoanilino)-6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to tetra(lithium and/or sodium)3-amino-10-[4,6-bis(4-amino-3-sulfonatoanilino)-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to penta(lithium and/or sodium)10,10'-diamino-6,6',13,13'-tetrachloro-3,3'-[6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10-amino-6,6', 13,13'-tetrachloro-10'[4-(4-amino-3-sulfonatoanilino)-[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10,10'-diamino-6,6',3,3'[(2-sulfonato)-1,4-phenylenediiminobis[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate\n430-200-7\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-524-00-4\ntall oil 2-[(tetrahydro-2H-pyran-2-yl) thio]ethyl esters\n430-310-5\n—\nAquatic Chronic 4\nH413\nH413\n607-525-00-X\n(Z)-2-methoxymino-2-[2-(tritylamino)thiazol-4-yl]acetic acid\n431-520-1\n64485-90-1\nFlam. Sol. 1**** Carc. 2\nAquatic Chronic 3\nH228\nH351\nH412\nGHS02\nGHS08\nDgr\nH228\nH351\nH412\n607-526-00-5\ncartap (ISO); 1,3-bis(carbamoylthio)-2-(dimethylamino)propane\n—\n15263-53-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-527-00-0\nReaction mass of: 1-(1'H,1'H,2'H,2'H-tridecafluorooctyl)-12-(1''H,1''H,2''H,2''H-tridecafluorooctyl)dodecanedioate; 1-(1'H,1'H,2'H,2'H-tridecafluorooctyl)-12-(1''H,1''H,2''H,2''H-heptdecafluorodecyl)dodecanedioate; 1-(1'H,1'H,2'H,2'H-tridecafluorooctyl)-12-(1''H,1''H,2''H,2''H-heneicosafluorododecyl)dodecanedioate; 1-(1'H,1'H,2'H,2'H-tridecafluorooctyl)-12-(1''H,1''H,2''H,2''H-pentacosafluorotetradecyl)dodecanedioate; 1-(1'H,1'H,2'H,2'H-heptadecafluorodecyl)-12-(1''H,1''H,2''H,2''H-heptadecafluorodecyl)dodecanedioate; 1-(1'H,1'H,2'H,2'H-heptadecafluorodecyl)-12-(1''H,1''H,2''H,2''H-heneicosafluorododecyl)dodecanedioate\n423-180-6\n—\nSTOT RE 2 *\nH373 **\nGHS08\nWng\nH373 **\n607-528-00-6\n(S)-3-methyl-2-(2-oxotetrahydropyrimidine-1-yl)butyric acid\n430-900-2\n192725-50-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-529-00-1\nbenzyl cis-4-ammonium-4'-toluenesulfonato-1-cyclohexanecarboxylate\n426-070-6\n67299-45-0\nAquatic Chronic 3\nH412\n—\nH412\n607-530-00-7\nreaction mass of isomers of: C7-9-alkyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate\n406-040-9\n125643-61-0\nAquatic Chronic 4\nH413\n—\nH413\n607-531-00-2\nmethyl 3-amino-4,6-dibromo-2-methyl-benzoate\n425-190-6\n119916-05-1\nSTOT RE 2 *\nAquatic Chronic 2\nH373** H411\nGHS08\nGHS09\nWng\nH373** H411\n607-532-00-8\n(S)-1-[2-tert-butoxycarbonyl-3-(2-methoxyethoxy)propyl]-1-cyclopentanecarboxylic acid, cyclohexylamine salt\n425-510-4\n167944-94-7\nAquatic Chronic 3\nH412\n—\nH412\n607-533-00-3\npentasodium monohydrogen 6-chloro-3,10-bis[2-[4-chloro-6-(2,4-disulfophenylamino)-1,3,5-triazin-2-yl-amino]ethylamino]-13-ethylbenzo[5.6][1.4]oxazino[2,3-b]phenoxazine-4,11-disulfonate\n414-910-4\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-534-00-9\nethyl 2-(3-benzoylphenyl)propanoate\n414-920-9\n60658-04-0\nAcute Tox. 3 * STOT RE 1\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH372** H317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH372** H317\nH411\n607-535-00-4\npotassium 4-iodo-2-sulfonato-benzoic acid\n426-620-5\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-536-00-X\n(2,6-xylyloxy) acetic acid\n430-910-7\n13335-71-2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n607-537-00-5\nisopropylammonium 2-(3-benzoylphenyl)propionate\n417-970-1\n—\nAcute Tox. 3 * Acute Tox. 4 * STOT RE 1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH372** H318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH301\nH312\nH372** H318\nH410\n607-539-00-6\npropyl((4-(5-oxo-3-propylisoxazolidin-4-ylidenmethin)phenyl)propoxycarbonylmethyleneamino)acetate\n431-000-2\n198705-81-6\nAquatic Chronic 4\nH413\n—\nH413\n607-540-00-1\n1-(mercaptomethyl)cyclopropylacetic acid\n420-240-3\n162515-68-6\nSkin Corr. 1B\nAcute Tox. 4 * Acute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH312\nH302\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH312\nH302\nH317\nH411\n607-541-00-7\n[(1-methyl-1,2-ethanediyl)bis[nitrilobis(methylene)]]tetrakis(phosphonic acid)\n421-940-1\n28698-31-9\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n607-542-00-2\nmethyl 2-(4-butanesulfonamidophenoxy)tetradecanoate\n422-110-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-543-00-8\npoly-[((4-((4-(ethyl-ethylene)amino)phenyl)-(4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)-3-methylcyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate]\n427-480-8\n176429-22-4\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH335\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH335\nH315\nH318\nH410\n607-544-00-3\nethyl 6,8-difluoro-1-(formylmethylamino)-1,4-dihydro-7-(4-methyl)piperazin-1-yl)-4-oxo-quinoline-3-carboxylate\n427-490-2\n158585-86-5\nAquatic Chronic 3\nH412\n—\nH412\n607-545-00-9\n1,2-dimethyl-3-(1-methylethenyl)cyclopentyl acetate\n424-070-0\n94346-09-5\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-546-00-4\nreaction mass of: methyl {[5-acetylamino-4-(2-chloro-4-nitrophenylazo)phenyl]methoxycarbonylmethylamino}acetate; methyl {[5-acetylamino-4-(2-chloro-4-nitrophenylazo)phenyl]ethoxycarbonylmethylamino}acetate\n424-290-7\n188070-47-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-547-00-X\n18-methylnonadecyl 2,2-dimethylpropanoate\n424-370-1\n125496-22-2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n607-548-00-5\n1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone methanesulfonate\n431-010-7\n154486-26-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n607-549-00-0\nmethyl (E)-2((3-(1,3-benzodioxol-5-yl)-2-methyl-1-propenyl)amino)benzoate\n424-430-7\n125778-19-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-550-00-6\n2-amino-4-bromo-5-chlorobenzoic acid\n424-700-4\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-551-00-1\ntetrabutylammonium 2-amino-6-iodopurinate\n424-710-9\n156126-48-6\nAcute Tox. 4 * Acute Tox. 4 * STOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH312\nH302\nH373** H315\nH318\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH312\nH302\nH373** H315\nH318\nH317\nH411\n607-552-00-7\nhexadecyl -amino-4-isopropoxybenzoate\n424-830-1\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-553-00-2\n7-amino-4-hydroxy-2-naphthalenesulfonic acid, coupled with 5 (or 8) -amino-8 (or 5)-[[4-[[4-[[4-amino-6(or 7)-sulfo-1-naphthyl]azo]phenyl]amino]-3-sulfophenyl]azo]-2-naphthalenesulfonic acid and 4-hydroxy-7-(phenylamino)-2-naphthalenesulfonic acid, sodium salt\n424-850-0\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-554-00-8\n2,4-diamino-5-[4-[(2-sulfoxyl ethyl)sulfonyl]phenylazo]benzenesulfonic acid\n424-870-1\n27624-67-5\nExpl. 1.1\nEye Dam. 1\nAquatic Chronic 3\nH201\nH318\nH412\nGHS01\nGHS05\nDgr\nH201\nH318\nH412\n607-555-00-3\n1,1,3,3-tetramethylbutylperoxypivalate\n424-980-8\n22288-41-1\nFlam. Liq. 2\nOrg. Perox. D\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH225\nH242\nH315\nH317\nH411\nGHS02\nGHS07\nGHS09\nDgr\nH225\nH242\nH315\nH317\nH411\n607-556-00-9\n2-acetoxymethylene-4-acetylphenylacetate\n425-160-2\n24085-06-1\nAcute Tox. 4 * STOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373** H318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09 Dgr\nH302\nH373** H318\nH317\nH410\n607-557-00-4\nsalt of: (1S-cis)-1-amino-2,3-dihydro-1H-inden-2-ol and [R-[R*R*]]-2,3-dihydroxybutanedioic acid\n425-210-3\n169939-84-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-558-00-X\n2S-isopropyl-5R-methyl-1R-cyclohexyl (2R, 5S)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-[1.3]-oxathiolane-2-carboxylate\n425-250-1\n147027-10-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-559-00-5\ncoconut oil, reaction products with glycerol esters of 3,5-bis(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid\n425-400-6\n179986-09-5\nAquatic Chronic 4\nH413\n—\nH413\n607-560-00-0\n(R, S)-2-butyloctanedioic acid\n431-210-4\n50905-10-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-561-00-6\nsodium 4-hydroxy-3-(N'-(2-(2-hydroxyethylenesulfonyl)ethylene)ureido)-5-nitrobenzenesulfonate\n425-460-3\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-562-00-1\nreaction mass of: (2R, 3R)-3-(2-ethoxyphenoxy)-2-hydroxy-3-phenylpropylammonium methanesulfonate; (2S, 3S)-3-(2-ethoxyphenoxy)-2-hydroxy-3-phenylpropylammonium methanesulfonate\n425-530-3\n98769-75-6\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n607-563-00-7\n5,7-dichloro-4-hydroxyquinoline-3-carboxylic acid\n431-250-2\n171850-30-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-564-00-2\n1,6-hexanediammonium, sodium 5-sulfato-1,3-benzenedicarboxylate\n425-730-0\n51178-75-7\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-565-00-8\n3-ethyl 5 methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate\n425-820-1\n88150-42-9\nAcute Tox. 3 * STOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH373** H318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH301\nH373** H318\nH410\n607-566-00-3\nreaction mass of: dodecylphenyl dodecylhydroxybenzenecarboxylate; bis(dodecylphenyl)dodecyl hydroxybenzenedicarboxylate\n426-140-6\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-567-00-9\npotassium 3-iodo-6-methylbenzenesulfonate\n426-300-5\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-568-00-4\npotassium 2-chloro-3-(benzyloxy)propionate\n426-350-8\n138666-92-9\nAcute Tox. 4 * STOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH373** H318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373** H318\nH317\n607-569-00-X\nreaction mass of: sodium 2-amino-4-(2,6-difluoropyrimidin-4-ylamino)benzenesulfonate; sodium 2-amino-4-(4,6-difluoropyrimidin-4-ylamino)benzenesulfonate\n426-470-0\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-570-00-5\nsodium (6R-trans)-7-amino-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate monohydrate\n426-520-1\n71420-85-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-571-00-0\n2-cyclopentene-1-acetic acid, 3-hydroxy-2-pentyl-, methyl ester acetate\n431-400-7\n57374-49-9\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-572-00-6\ndiethyl thiophosphoryl (Z)-(2-aminothiazol-4-yl)methoxyimino acetate\n426-790-0\n162208-27-7\nAcute Tox. 4 * Acute Tox. 4 * STOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373** H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH312\nH302\nH373** H317\nH410\n607-573-00-1\nreaction mass of: disodium 7-(2,4-difluoropyrimidin-6-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalene-2-sulfonate; disodium; 7-(4,6-difluoropyrimidin-2-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalene-2-sulfonate\n426-840-1\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-574-00-7\n[1R-(1-α, 2β,5α)]-mono[5-methyl-2-(1-methylethyl)cyclohexyl]butanedioate\n426-890-4\n77341-67-4\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-575-00-2\n4-(5-(5-[1-(4-carboxyphenyl)hexahydro-2,4,6-trioxopyrimidin-5-ylidene]penta-1,3-dienyl)-1,2,3,4-tetrahydro-6-hydroxy-2,4-dioxopyrimidin-1-yl)benzoic acid-triethylamine salt\n426-900-7\n—\nSTOT SE 3\nAquatic Chronic 3\nH335\nH412\nGHS07\nWng\nH335\nH412\n607-576-00-8\nbranched, octyl 3-[3,5-di(tert-butyl)-4-hydroxyphenyl]propanoate\n427-030-0\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-577-00-3\n(2R*, 3S*)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (1R)-10-camphorsulfonate\n427-100-0\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n607-578-00-9\nethyl 4-((4-diethylamino-2-methylphenyl)imino)-4,5-dihydro-1-isopropyl-5-oxo-1H-pyrazole-3-carboxylate\n427-110-5\n—\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 4\nH302\nH373** H413\nGHS08\nGHS07\nWng\nH302\nH373** H413\n607-579-00-4\ndiethyl[(p-ethoxyanilino)methylene]malonate\n431-430-0\n103976-28-9\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-580-00-X\nethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate\n422-360-1\n100491-29-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-581-00-5\nethyl 2-ethoxy-4-carboxymethylbenzoate\n427-630-2\n99469-99-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-582-00-0\nreaction mass of: tetrasodium 7-(4-(4-fluoro-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate; tetrasodium 7-(4-(4-hydroxy-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate\n427-650-1\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-583-00-6\n4-amino-3-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]-1-naphthalene sulfonic acid\n427-680-5\n188907-52-0\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-584-00-1\ntrisodium 3-[2-acetylamino-4-[4-chloro-6-[4-(2-sulfonatoxyethylsulfonyl)phenylamino]-1,3,5-triazine-2-ylamino]phenylazo]naphthalene-1,5-disulfonate\n427-710-7\n215612-56-9\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-585-00-7\nstrontium 2-[(2-hydroxy-6-sulfonato-1-naphthyl)azo]naphthalene-1-sulfonate\n427-930-3\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-586-00-2\ndodecyl 3-amino-4-chlorobenzoate\n428-020-9\n6195-20-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-587-00-8\nethyl cis-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine-1-carboxylate\n428-030-3\n67914-69-6\nAcute Tox. 4 * STOT RE 2 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH373** H400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373** H410\n607-588-00-3\nreaction mass of: 2-ethylhexyl 2,3,4,5-tetrabromobenzoate; bis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate\n428-050-2\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-589-00-9\ntetrakis(1,2,2,6,6-pentamethyl-4-piperidyl)-1,2,3,4-butanetetracarboxylate\n428-070-1\n91788-83-9\nSTOT RE 1\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH372** H302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH372** H302\nH410\n607-590-00-4\nhexadecyl 3-[2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-4,4-dimethyl-3-oxovaleramido]-4-isopropoxybenzoate\n428-140-1\n210706-50-6\nAquatic Chronic 4\nH413\n—\nH413\n607-591-00-X\nreaction mass of: trisodium 5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(4-(2-sulfooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate; disodium 3-(4-ethenesulfonylphenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxynaphthalene-2,7-disulfonate\n428-400-4\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-592-00-5\ndi(C9-11-alkyl) cyclohexane-1,4-dicarboxylate\n428-870-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-593-00-0\n4-(2-methylacryloyloxy)phenyl4-allyloxybenzoate\n429-000-2\n159235-16-2\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-594-00-6\nethyl (1S, 5R, 6S)-5-(1-ethylpropoxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate\n429-020-1\n204254-96-6\nSTOT RE 2 *\nSkin Sens. 1\nH373** H317\nGHS08\nGHS07\nWng\nH373** H317\n607-595-00-1\nN-amidino-N-methylglycine-2-oxopropionate\n429-120-5\n208535-04-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-596-00-7\nethyl 2-(4-phenoxyphenyl)lactate\n429-220-9\n132584-17-9\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-597-00-2\ntetrasodium 4,4'-bis{4-[4-(2-hydroxyethylamino)-6-(4-sulfonatoanilino)-1,3,5-triazin-2-ylamino]phenylazo}stilbene-2,2'-disulfonate\n429-230-3\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-598-00-8\ntrisodium 3-amino-4-[4-[4-(2-(2-ethenylsulfonylethoxy)ethylamino)-6-fluoro-1,3,5-triazine-2-ylamino]-2-sulfophenylazo]-5-hydroxynaphthalene-2,7-disulfonate\n429-240-8\n212652-59-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-599-00-3\n1,1-dimethylpropyl 3,5,5-trimethylperoxyhexanoate\n431-610-9\n68860-54-8\nOrg. Perox. D\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH242\nH317\nH400\nH410\nGHS02\nGHS07\nGHS09\nDgr\nH242\nH317\nH410\n607-600-00-7\n(1S, 1'R)-[1-(3', 3'-dimethyl-1'-cyclohexyl)ethoxycarbonyl]methyl propanoate\n431-700-8\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-601-00-2\n1,4-dihydroxy-2,2,6,6-tetramethyl piperidinium-2-hydroxy-1,2,3-propanetricarboxylate\n429-370-5\n220410-74-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-602-00-8\nethyl (3-cyanomethyl-3,4-dihydro-4-oxophthalazin-1-yl)acetate\n429-680-0\n122665-86-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-603-00-3\nlithium sodium 4,4', 4''-(nitrilotris(ethane-2,1-diylimino(6-chloro-1,3,5-triazine-4,2-diyl)imino))tris(5-hydroxy-6-(1-sulfonaphthalene-2-ylazo)-2,7-naphthalene)disulfonate\n429-730-1\n193562-37-7\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-604-00-9\nguanidinium benzoate\n429-820-0\n26739-54-8\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-605-00-4\nmethyl 4-iodo-2-(3-(4-methoxy-6-methyl-1,3,5-triazine-2-yl)ureidosulfonyl)benzoate\n429-890-2\n144550-06-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-606-00-X\n(Z)-2-(2-t-butoxycarbonylamino-4-thiazolyl)pent-2-enoic acid\n430-100-3\n86978-24-7\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-607-00-5\nreaction mass of: calcium bis(C10-14 branched alkyl salicylate); calcium bis(C18-30-alkyl salicylate); calcium C10-14 branched alkylsalicylato-C18-30-alkyl salicylate; calcium bis (C10-14 branched alkyl phenolate); calcium bis (C18-30-alkyl phenolate); calcium C10-14 branched alkylphenolato-C18-30-alkyl phenolate; C10-14 branched alkyl phenol; C18-30-alkyl phenol\n430-180-1\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-608-00-0\npentapotassium 2-(4-{5-[1-(2,5-disulfophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-(2-pyrrolidinone-1-yl)-1,3-pentadienyl}-3-methylcarbamoyl-5-oxopyrazol-1-yl)benzene-1,4-disulfonate\n430-210-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-609-00-6\nethyl (3R)-4-cyano-3-hydroxybutanoate\n430-220-6\n141942-85-0\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-610-00-1\ntrisodium 4-hydroxy-6-(sulfonatomethylamino)-5-(2-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2-sulfonate\n430-280-3\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-611-00-7\nmethyl 3-amino-2,2,3-trimethylbutyrate\n431-720-7\n90886-53-6\nSkin Corr. 1B\nAcute Tox. 4 *\nAquatic Chronic 3\nH314\nH302\nH412\nGHS05\nGHS07\nDgr\nH314\nH302\nH412\n607-612-00-2\nReaction mass of: 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-octanesulfonic acid; ammonium 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-octanesulfonate\n432-190-1\n182176-52-9\nAcute Tox. 4 * STOT RE 2 *\nEye Dam. 1\nH302\nH373** H318\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373** H318\n607-613-00-8\nreaction mass of: succinic acid; monopersuccinic acid; dipersuccinic acid monomethyl ester of succinic acid monomethyl ester of persuccinic acid dimethyl succinate glutaric acid monoperglutaric acid diperglutaric acid monomethyl ester of glutaric acid monomethyl ester of perglutaric acid dimethyl glutarate adipic acid monoperadipic acid diperadipic acid monomethyl ester of adipic acid monomethyl ester of peradipic aciddimethyl adipate hydrogen peroxide methanolwater\n432-790-1\nAcute Tox. 4* Acute Tox. 4* Acute Tox. 4*\nSkin Corr. 1B STOT SE 2\nH332\nH312\nH302\nH314\nH371 (eyes)\nGHS07\nGHS05\nGHS08\nDgr\nH332\nH312\nH302\nH314\nH371 (eyes)\n607-614-00-3\n2-(10-oxo-10H-9-oxa-10-phosphaphenanthren-10-ylmethyl)succinic acid\n426-480-5\n63562-33-4\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-615-00-9\nreaction product of thioglycerol and mercaptoacetic acid consisting mainly of 3-mercapto-1,2-bismercaptoacetoxypropane and oligomers of this substance\n431-120-5\n—\nAcute Tox. 3 * Acute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH331\nH302\nH319\nH317\nGHS06\nDgr\nH331\nH302\nH319\nH317\n607-616-00-4\n2,4-dichloro-5-fluorobenzoylchloride\n428-390-1\n86393-34-2\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH335\nH315\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH335\nH315\nH318\nH317\nH412\n607-617-00-X\nbis(2-ethylhexyl)-4,5-epoxycyclohexane-1,2-dicarboxylate\n430-700-5\n10138-36-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-618-00-5\nmenadione sodium bisulfite; 2-naphthalenesulfonic acid,1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-, sodium salt\n204-987-0\n130-37-0\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\n607-619-00-0\nmenadione nicotinamide bisulfite; 1,2,3,4-tetrahydro-2-methyl-1,4-dioxonaphthalene-2-sulfonicacid, compound with nicotin-3-amide (1:1)\n277-543-7\n73581-79-0\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\n607-620-00-6\ntrisodium nitrilotriacetate\n225-768-6\n5064-31-3\nCarc. 2\nAcute Tox. 4 *\nEye Irrit. 2\nH351\nH302\nH319\nGHS08\nGHS07\nWng\nH351\nH302\nH319\nCarc. 2; H351: C\n≥ 5 %\n607-621-00-1\nmilbemectin (ISO); [reaction mass of milbemycin A3 (CAS No 51596-10-2) and milbemycin A4 (CAS No 51596-11-3) (30:70)]\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH410\nM=100\n607-622-00-7\n2-ethylhexyl-2-ethylhexanoate\n231-057-1\n7425-14-1\nRepr. 2\nH361d***\nGHS08\nWng\nH361d***\n607-624-00-8\nperfluorooctane sulfonic acid; heptadecafluorooctane-1-sulfonic acid; [1] potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate; [2] diethanolamine perfluorooctane sulfonate; [3] ammonium perfluorooctanesulfonate; ammonium heptadecafluorooctanesulfonate; [4] lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate [5]\n217-179-8 [1]\n220-527-1 [2]\n274-460-8 [3]\n249-415-0 [4]\n249-644-6 [5]\n1763-23-1 [1]\n2795-39-3 [2]\n70225-14-8 [3]\n29081-56-9 [4]\n29457-72-5 [5]\nCarc. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 * Acute Tox. 4 *\nLact.\nAquatic Chronic 2\nH351\nH360D*** H372**\nH332\nH302\nH362\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360D*** H372**\nH332\nH302\nH362\nH411\n607-625-00-3\nclodinafop-propargyl (ISO)\n—\n105512-06-9\nAcute Tox. 4 * STOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373** H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373** H317\nH410\nSkin Sens. 1; H317: C ≥ 0,001 %\nM=1\n607-626-00-9\nethyl 1-(2,4-dichlorophenyl)-5-(trichloromethyl)-1H-1,2,4-triazole-3-carboxylate\n401-290-5\n103112-35-2\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n607-627-00-4\n[(4S, 5S)-4-benzyl-2-oxo-5-oxazolidinyl]methyl 4-nitrobenzenesulfonate\n416-360-0\n162221-28-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-628-00-X\n4-oxo-4-(p-tolyl)butyric acid adduct with 4-ethylmorpholine\n419-240-6\n171054-89-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-629-00-5\n[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl] acetic acid\n419-270-1\n123599-82-6\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-630-00-0\nacrylic acid, 3-(trimethoxysilyl)propyl ester\n419-560-6\n4369-14-6\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH332\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH332\nH314\nH317\nH412\n607-631-00-6\nreaction mass of: 2-(2-((oxo(phenyl)acetyl)oxy)ethoxy)ethyl oxo(phenyl)acetate; (2-(2-hydroxyethoxy)ethyl)oxo(phenyl)acetate\n442-300-8\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-632-00-1\nN-[3-(2,4-di-(1,1-dimethyl-propyl)phenoxy)-propyl]-1-hydroxy-5-(2-methylpropyl-oxycarbonylamino)-naphthamide\n420-210-1\n111244-14-5\nAquatic Chronic 4\nH413\n—\nH413\n607-633-00-7\ntrisodium 5-{[4-chloro-6-(1-naphthylamino)-1,3,5-triazin-2-yl]amino}-4-hydroxy-3-[(E)-(4-methoxy-2-sulfonatophenyl)diazenyl]-2,7-naphthalenedisulfonate\n440-480-2\n341026-59-3\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-634-00-2\n(S)-(–)-2-acetoxypropionylchloride; (1S)-2-chloro-1-methyl-2-oxoethyl acetate\n420-610-4\n36394-75-9\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH302\nH314\nH317\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\n607-635-00-8\ntrisodium N-(3-propionato)-l-aspartate\n422-090-4\n172737-80-3\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-636-00-3\n1-bromo-2-methylpropyl propionate\n422-900-6\n158894-67-8\nFlam. Liq. 3\nCarc. 2\nSkin Corr. 1B\nSkin Sens. 1\nH226\nH351\nH314\nH317\nGHS02\nGHS05\nGHS08\nGHS07\nDgr\nH226\nH351\nH314\nH317\n607-637-00-9\ndisodium 8-amino-5-{4-[2-(sulfonatoethoxy)sulfonyl]phenylazo}naphthalene-2-sulfonate\n423-730-5\n250688-43-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-638-00-4\n2-hydroxybenzoic acid 2-butyloctyl ester\n431-090-3\n190085-41-7\nAquatic Chronic 4\nH413\n—\nH413\n607-639-00-X\n2-(2-oxo-5-(1,1,3,3-tetramethylbutyl)-2,3-dihydro-1-benzofuran-3-yl)-4-(1,1,3,3-tetramethylbutyl)phenyl acetate\n431-770-1\n216698-07-6\nAquatic Chronic 4\nH413\n—\nH413\n607-641-00-0\n2-(formylamino)-3-thiophenecarboxylic acid; 2-formamido-3-thiophenecarboxylic acid\n431-930-9\n43028-69-9\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n607-642-00-6\n3,6,9-trithiaundecamethylene-1,11-dimethacrylate\n432-210-7\n141631-22-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-643-00-1\ndimethyl (2S)-2-hydroxysuccinate\n432-310-0\n617-55-0\nFlam. Liq. 3\nEye Dam. 1\nSkin Sens. 1\nH226\nH318\nH317\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH318\nH317\n607-644-00-7\nmethyl 2,2-dimethyl-6-methylenecyclohexanecarboxylate\n432-350-9\n81752-87-6\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n607-645-00-2\ntetrasodium 2-(4-fluoro-6-(methyl-(2-(sulfatoethylsulfonyl)ethyl)amino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-methyl-2-sulfonatophenylazo)naphthalene-1,7-disulfonate\n432-550-6\n243858-01-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-646-00-8\nD-erythro-hexanoic acid 2,4-dideoxy-3,5-O-(1-methylethylidene)-1,1-dimethylethylester; tert-butyl 2-[(4R, 6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate\n432-960-5\n124655-09-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-647-00-3\n5-acetoxy-2-(R, S)butyryloxymethyl-1,3-oxathiolane\n433-530-1\n143446-73-5\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nH302\nH317\nH400\nGHS07\nGHS09\nWng\nH302\nH317\nH400\n607-649-00-4\n[3-(chlorocarbonyl)-2-methylphenyl]acetate\n433-690-0\n167678-46-8\nSkin Corr. 1A\nSkin Sens. 1\nH314\nH317\nGHS05\nGHS07\nDgr\nH314\nH317\n607-650-00-X\n2-methyl-1,5-pentanediamine-1,3-benzenedicarboxylate\n433-910-5\n145153-52-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-651-00-5\nsodium 2-(nonanoyloxy)benzenesulfonate\n434-360-9\n91125-43-8\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-652-00-0\nethyl N2-dodecanoyl-l-argininate hydrochloride\n434-630-6\n60372-77-2\nEye Dam. 1\nAquatic Acute 1\nH318\nH400\nGHS05\nGHS09\nDgr\nH318\nH400\n607-653-00-6\ntetrakis(bis(2-hydroxyethyl)methylammonium) 3-(4-(7-acetylamino-1-hydroxy-3-sulfonatonaphthalen-2-ylazo)-5-methoxy-2-sulfonatophenylazo)-7-(4-amino-3-sulfonatophenylamino)-4-hydroxynaphthalene-2-sulfonate\n434-840-8\n225786-91-4\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-654-00-1\n(S)-3-hydroxy-γ-butyrolactone\n434-990-4\n7331-52-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-655-00-7\nethyl 6,8-dichlorooctanoate\n435-080-1\n1070-64-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-656-00-2\nsodium salt of 4-amino-3,6-bis[[5-[[4-chloro-6-[(2-methyl-4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-5-hydroxy-2,7-naphthalenedisulfonic acid\n435-350-7\n141250-43-3\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-657-00-8\npentasodium 7-(4-(4-(3-(2-sulfatoethanesulfonyl)phenylamino)-6-(4-(2-sulfatoethanesulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate\n436-920-8\n172399-10-9\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-658-00-3\n3,10-diamino-6,13-dichloro-2-((6-(((4-(1,1-dimethylethyl)phenyl)sulfonyl)amino)-2-naphthalenyl)sulfonyl)-4,11-triphenodioxazinedisulfonic acid, lithium potassium sodium salt\n440-770-9\n371921-63-0\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-659-00-9\npentasodium N-[5-[[4-[[3-[(aminocarbonyl)amino]-4-[(3,6,8-trisulfonatonaphthalen-2-yl)azo]phenyl]amino]-6-chloro-1,3,5-triazin-2-yl]amino]-2-sulfonato-4-[[4-[[-2-(oxysulfonato)ethyl] sulfonyl]phenyl]azo]phenyl]-3-aminopropanoic acid\n442-030-0\n321912-47-4\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-660-00-4\n2-{4-[4-[4-fluoro-6-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino]phenylazophenylazo}naphthalene-4,6,8-trisulfonate, trisodium salt\n442-230-8\n321679-52-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-661-00-X\n1,1-dimethylethyl 4'-(bromomethyl)biphenyl-2-carboxylate\n442-850-9\n114772-40-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-662-00-5\nmethyl 2-(acetylamino)-3-chloropropionate\n442-860-3\n87333-22-0\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-663-00-0\nbis(2-ethylhexyl) naphthalene-2,6-dicarboxylate\n442-980-6\n127474-91-3\nAquatic Chronic 4\nH413\n—\nH413\n607-664-00-6\nmethyl 2-chlorosulfonyl-4-(methanesulfonylaminomethyl) benzoate\n443-120-2\n393509-79-0\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n607-665-00-1\ntrans-methyl-2-ethyl-but-2-enoate\n443-150-6\n101226-85-1\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\n607-666-00-7\n(2S)-5-(benzyloxy)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxopentanoic acid\n443-560-5\n88784-33-2\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-667-00-2\nchloro-1-ethylcyclohexyl carbonate\n444-950-8\n99464-83-2\nMuta. 2\nSkin Sens. 1\nH341\nH317\nGHS08\nGHS07\nWng\nH341\nH317\n607-668-00-8\ntrans-2-isopropyl-5-carboxy-1,3-dioxane\n445-770-2\n42031-28-7\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-669-00-3\nmethyl (9-acetoxy-3,8,10-triethyl-7,8,10-trimethyl-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl)octadecanoate\n445-990-9\n376588-17-9\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-670-00-9\ndibutyl-3-(4-(5-ammonio-2-butyl)benzofuran-3-yl)carbonyl)phenoxy)propyl ammonium oxalate; (5-amino-2-butylbenzofuran-3-yl) [4-(3-dibutylaminopropoxy)phenyl]methanone, dioxalate\n448-700-9\n500791-70-8\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373** H318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH373** H318\nH317\nH410\nM=10\n607-671-00-4\ndiethyl 1,4-cyclohexanedicarboxylate\n417-310-0\n72903-27-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-672-00-X\nreaction mass of: 2-hydroxy-3-(methacryloyloxy)propyl (2-benzoyl)benzoate; 1-hydroxymethyl-2-(methacryloyloxy)ethyl (2-benzoyl)benzoate; x-hydroxy-y-(methacryloyloxy)propyl(or -ethyl) (2-benzoyl)benzoate\n419-000-0\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-673-00-5\n1-ethyl-5,6,7,8-tetrahydroquinolinium tosylate\n419-570-0\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n607-675-00-6\nreaction mass of: cis-9-octadecenedioic acid; cis-9-cis-12-octadecadienedioic acid; hexadecanedioic acid; octadecanedioic acid\n422-260-8\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n607-676-00-1\nreaction mass of: 2-methylnonanedioic acid; 2,4-dimethyl-4-methoxycarbonylundecanedioic acid; 2,4,6-trimethyl-4,6-dimethoxycarbonyltridecanedioic acid; 8,9-dimethyl-8,9-dimethoxycarbonylhexadecanedioic acid\n423-670-1\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-677-00-7\n2,5-dioxopyrrolidin-1-yl N-{[methyl[[2-(1-methylethyl)-4-thiazoly]methyl]amino]carbonyl}-L-Valinate\n424-660-8\n—\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH373** H318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH373** H318\nH317\n607-678-00-2\nreaction mass of: ethyl (2R, 3R)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate; ethyl (2S, 3S)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate\n427-090-8\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-679-00-8\nreaction mass of: 3-{5-[3-(4-{1,6-dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo[}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(methyl)ammonium di(acetate); 3-{5-[4-(3-{1,6-dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido]phenylazo-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate); 3-{5-[3-(4-{1-[3-(dimethylammonio)propyl]-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammoniumdi(acetate)\n431-440-5\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n607-680-00-3\ntert-butyl(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylvinyl}(4S, 6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate\n432-810-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-681-00-9\nreaction mass of: 9-nonyl-10-octyl-19-carbonyloxyhexadecylnonadecanoic acid; 9-nonyl-10-octyl-19-carbonyloxyoctadecylnonadecanoic acid; dihexadecyl 9-nonyl-10-octylnonadecandioate; 1-octadecyl, 19-hexadecyl 9-nonyl-10-octylnonadecandioate; dioctadecyl 9-nonyl-10-octylnonadecandioate\n432-910-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-682-00-4\ncomplex reaction mass of Chinese gum rosin post reacted with acrylic acid\n434-230-1\n144413-22-9\nAquatic Chronic 4\nH413\n—\nH413\n607-683-00-X\nreaction mass of: methyl 3-((1E)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate; methyl 3-((1Z)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate (20:80)\n435-450-0\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-684-00-5\nalkenes, C12-14, hydroformylation products, distn. residues, C-(hydrogen sulfobutanedioates), disodium salts\n435-660-2\n243662-67-1\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n607-685-00-0\nammonium 2-cocoyloxyethanesulfonate\n441-050-7\n—\nSkin Irrit. 2\nEye Dam. 1\nH315\nH318\nGHS05\nDgr\nH315\nH318\n607-686-00-6\n6,6'-bis(diazo-5,5', 6,6'-tetrahydro-5,5'-dioxo)[methylene-bis(5-(6-diazo-5,6-dihydro-5-oxo-1-naphthylsulphonyloxy)-6-methyl-2-phenylene]di(naphthalene-1-sulfonate)\n441-550-5\n—\nSelf-react. C **** Carc. 2\nH242\nH351\nGHS02\nGHS08\nDgr\nH242\nH351\n607-687-00-1\nreaction mass of: 2-{3,6-bis-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl[}-benzenesulfonate (2-10 %); 2-{3,6-bis-[(2,3-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3,6-bis-[(2,4-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3,6-bis-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,4-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,5-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2,4-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,4-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %)\n442-800-6\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-688-00-7\n(R)-1-cyclohexa-1,4-dienyl-1-methoxycarbonyl-methylammoniumchloride\n444-320-2\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-689-00-2\nreaction mass of: methyl 1,4-dimethylcyclohexanecarboxylate (‘para-isomer’ including cis-and trans-isomers); methyl 1,3-dimethylcyclohexanecarboxylate (‘meta-isomer’including cis-and trans-isomers)\n444-920-4\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-690-00-8\ndimethyl[2S, 2S']-6,6,6'6'-tetramethoxy-2,2'-[N, N'-bis(trifluoracetyl)-S, S'-bi(L-homocysteinyl) diimino]dihexanoate\n432-860-1\n255387-46-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-691-00-3\nmagnesium salts, fatty acids, C16-18 and C18 unsaturated, branched and linear\n448-690-6\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-692-00-9\nzinc salts, fatty acids, C16-18 and C18 unsaturated, branched and linear\n446-470-4\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-693-00-4\nhexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl)benzoate\n443-860-6\n302776-68-7\nAquatic Chronic 4\nH413\n—\nH413\n607-694-00-X\nethyl 5,5-diphenyl-2-isoxazoline-3-carboxylate\n443-870-0\n163520-33-0\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n607-696-00-0\npentyl formate\n211-340-6\n638-49-3\nFlam. Liq. 3\nEye Irrit. 2\nSTOT SE 3\nH226\nH319\nH335\nGHS02\nGHS07\nDgr\nH226\nH319\nH335\nC\n607-697-00-6\ntert-butyl propionate\n—\n20487-40-5\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\nC\n607-698-00-1\n4-tert-butylbenzoic acid\n202-696-3\n98-73-7\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4\nH360F H372\nH302\nGHS07\nGHS08\nDgr\nH360F H372\nH302\n607-699-00-7\nbifenthrin (ISO); (2-methylbiphenyl-3-yl)methylrel-(1R,3R)-3-[(1Z)-2-chloro-3,3,3-trifluoroprop-1-en-1-yl]-2,2-dimethylcyclopropanecarboxylate\n82657-04-3\nCarc. 2\nAcute Tox. 3\nAcute Tox. 2\nSTOT RE 1\nSkin Sens. 1B Aquatic Acute 1\nAquatic Chronic 1\nH351\nH331\nH300\nH372 (nervous\nsystem) H317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH331\nH300\nH372 (nervous\nsystem) H317\nH410\nM = 10 000\nM = 100 000\n607-700-00-0\nindoxacarb (ISO); methyl (4aS)-7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate [1] reaction mass of (S)-Indoxacarb and (R)-Indoxacarb 75:25; methyl 7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate [2]\n173584-44-6 [1]\n144171-61-9 [2]\nAcute Tox. 3\nAcute Tox. 4\nSTOT RE 1\nSkin Sens. 1B Aquatic Acute 1\nAquatic Chronic 1\nH301\nH332\nH372 (blood, nervous system, heart)\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH332\nH372 (blood, nervous system, heart)\nH317\nH410\nM = 1\nM = 1\n607-702-00-1\ndihexyl phthalate\n201-559-5\n84-75-3\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\n607-703-00-7\nammoniumpentadeca-fluorooctanoate\n223-320-4\n3825-26-1\nCarc. 2\nRepr. 1B Lact.\nAcute Tox. 4\nAcute Tox. 4\nSTOT RE 1\nEye Dam.1\nH351\nH360D H362\nH332\nH302\nH372 (liver) H318\nGHS08\nGHS07\nGHS05\nDgr\nH351\nH360D H362\nH332\nH302\nH372 (liver) H318\n607-704-00-2\nperfluorooctanoic acid\n206-397-9\n335-67-1\nCarc. 2\nRepr. 1B Lact.\nAcute Tox. 4\nAcute Tox. 4\nSTOT RE 1\nEye Dam. 1\nH351\nH360D H362\nH332\nH302\nH372 (liver) H318\nGHS08\nGHS07\nGHS05\nDgr\nH351\nH360D H362\nH332\nH302\nH372 (liver) H318\n607-705-00-8\nbenzoic acid\n200-618-2\n65-85-0\nSTOT RE 1\nSkin Irrit. 2\nEye Dam. 1\nH372 (lungs) (inhalation) H315\nH318\nGHS08\nGHS05\nDgr\nH372 (lungs) (inhalation) H315\nH318\n607-706-00-3\nmethyl 2,5-dichlorobenzoate\n220-815-7\n2905-69-3\nAcute Tox. 4\nSTOT SE 3\nAquatic Chronic 2\nH302\nH336\nH411\nGHS07\nGHS09\nWng\nH302\nH336\nH411\n608-001-00-3\nacetonitrile; cyanomethane\n200-835-2\n75-05-8\nFlam. Liq. 2\nAcute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nH225\nH332\nH312\nH302\nH319\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH319\n608-002-00-9\ntrichloroacetonitrile\n208-885-7\n545-06-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH331\nH311\nH301\nH411\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH411\n608-003-00-4\nacrylonitrile\n203-466-5\n107-13-1\nFlam. Liq. 2\nCarc. 1B\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH225\nH350\nH331\nH311\nH301\nH335\nH315\nH318\nH317\nH411\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH225\nH350\nH331\nH311\nH301\nH335\nH315\nH318\nH317\nH411\n*\nD\n608-004-00-X\n2-hydroxy-2-methylpropionitrile; 2-cyanopropan-2-ol; acetone cyanohydrin\n200-909-4\n75-86-5\nAcute Tox. 2 * Acute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\n608-005-00-5\nn-butyronitrile\n203-700-6\n109-74-0\nFlam. Liq. 2\nAcute Tox. 3 * Acute Tox. 3 *\nAcute Tox. 3 *\nH225\nH331\nH311\nH301\nGHS02\nGHS06\nDgr\nH225\nH331\nH311\nH301\n608-006-00-0\nbromoxynil (ISO) 3,5-dibromo-4-hydroxybenzonitrile; bromoxynil phenol\n216-882-7\n1689-84-5\nRepr. 2\nAcute Tox. 2 * Acute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H330\nH301\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d *** H330\nH301\nH317\nH410\nM = 10\n608-007-00-6\nioxynil (ISO) 4-hydroxy-3,5-diiodobenzonitrile\n216-881-1\n1689-83-4\nRepr. 2\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H331\nH301\nH312\nH373 ** H319\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d *** H331\nH301\nH312\nH373 ** H319\nH410\nM = 10\n608-008-00-1\nchloroacetonitrile\n203-467-0\n107-14-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH331\nH311\nH301\nH411\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH411\n608-009-00-7\nmalononitrile\n203-703-2\n109-77-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\n608-010-00-2\nmethacrylonitrile; 2-methyl-2-propene nitrile\n204-817-5\n126-98-7\nFlam. Liq. 2\nAcute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 *\nSkin Sens. 1\nH225\nH331\nH311\nH301\nH317\nGHS02\nGHS06\nDgr\nH225\nH331\nH311\nH301\nH317\n*\nSkin Sens. 1; H317: C ≥0,2 %\nD\n608-011-00-8\noxalonitrile; cyanogen\n207-306-5\n460-19-5\nPress. Gas\nFlam. Gas 1\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH220\nH331\nH400\nH410\nGHS02\nGHS04\nGHS06\nGHS09\nDgr\nH220\nH331\nH410\nU\n608-012-00-3\nbenzonitrile\n202-855-7\n100-47-0\nAcute Tox. 4 * Acute Tox. 4 *\nH312\nH302\nGHS07\nWng\nH312\nH302\n608-013-00-9\n2-chlorobenzonitrile\n212-836-5\n873-32-5\nAcute Tox. 4 * Acute Tox. 4 *\nEye Irrit. 2\nH312\nH302\nH319\nGHS07\nWng\nH312\nH302\nH319\n608-014-00-4\nchlorothalonil (ISO); tetrachloroisophthalonitrile\n217-588-1\n1897-45-6\nCarc. 2\nAcute Tox. 2 * STOT SE 3\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH330\nH335\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH351\nH330\nH335\nH318\nH317\nH410\nM=10\n608-015-00-X\ndichlobenil (ISO); 2,6-dichlorobenzonitrile\n214-787-5\n1194-65-6\nAcute Tox. 4 *\nAquatic Chronic 2\nH312\nH411\nGHS07\nGHS09\nWng\nH312\nH411\n608-016-00-5\n1,4-Dicyano-2,3,5,6-tetra-chloro-benzene\n401-550-8\n1897-41-2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n608-017-00-0\nbromoxynil octanoate (ISO); 2,6-dibromo-4-cyanophenyl octanoate\n216-885-3\n1689-99-2\nRepr. 2\nAcute Tox. 3 * Acute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H331\nH302\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d *** H331\nH302\nH317\nH410\nM = 10\n608-018-00-6\nioxynil octanoate (ISO); 4-cyano-2,6-diiodophenyl octanoate\n223-375-4\n3861-47-0\nRepr. 2\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H301\nH319\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d *** H301\nH319\nH317\nH410\nM = 10\n608-019-00-1\n2,2'-dimethyl-2,2'-azodipropiononitrile; ADZN\n201-132-3\n78-67-1\nSelf-react. C\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Chronic 3\nH242\nH332\nH302\nH412\nGHS02\nGHS07\nDgr\nH242\nH332\nH302\nH412\nT\n608-020-00-7\ndiphenoxymethylenecyanamide\n427-300-8\n79463-77-7\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n608-021-00-2\n3-(2-(diaminomethyleneamino)thiazol-4-ylmethylthio)propionitrile\n403-710-2\n76823-93-3\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n608-022-00-8\n3,7-dimethyloctanenitrile\n403-620-3\n40188-41-8\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH315\nH317\nH411\n608-023-00-3\nfenbuconazole (ISO); 4-(4-chlorophenyl)-2-phenyl-2-[(1H-1,2,4-triazol-1-yl)methyl]butanenitrile\n406-140-2\n114369-43-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n608-024-00-9\n2-(4-(N-butyl-N-phenethylamino)phenyl)ethylene-1,1,2-tricarbonitrile\n407-650-8\n97460-76-9\nAquatic Chronic 4\nH413\n—\nH413\n608-025-00-4\n2-nitro-4,5-bis(benzyloxy)phenylacetonitrile\n410-970-0\n117568-27-1\nAquatic Chronic 4\nH413\n—\nH413\n608-026-00-X\n3-cyano-3,5,5-trimethylcyclohexanone\n411-490-4\n7027-11-4\nAcute Tox. 4 * STOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH373 ** H317\nH412\nGHS08\nGHS07\nWng\nH302\nH373 ** H317\nH412\n608-027-00-5\nreaction mass of: 3-(4-ethylphenyl)-2,2-dimethylpropanenitrile; 3-(2-ethylphenyl)-2,2-dimethylpropanenitrile; 3-(3-ethylphenyl)-2,2-dimethylpropanenitrile\n412-660-0\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n608-028-00-0\n4-(2-cyano-3-phenylamino acryloyloxymethyl)-cyclohexyl-methyl 2-cyano-3-phenylamino)-acrylate\n413-510-7\n147374-67-2\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH373 ** H317\nH411\nGHS08\nGHS09\nWng\nH373 ** H317\nH411\n608-029-00-6\n1,2-dihydro-6-hydroxy-4-methyl-1-[3-(1-methylethoxy)propyl]-2-oxo-3-pyridinecarbonitrile\n411-990-2\n68612-94-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n608-030-00-1\nN-acetyl-N-[5-cyano-3-(2-dibutylamino-4-phenylthyazol-5-yl-methylene)-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyridin-1-yl]benzamide\n412-340-0\n147741-93-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n608-031-00-7\n2-benzyl-2-methyl-3-butenitrile\n407-870-4\n97384-48-0\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n608-032-00-2\nacetamiprid (ISO);\n(E)-N 1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine\n—\n135410-20-7\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n608-033-00-8\nN-butyl-3-(2-chloro-4-nitrophenylhydrazono)-1-cyano-2-methylprop-1-ene-1,3-dicarboximide\n407-970-8\n75511-91-0\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n608-034-00-3\nchlorfenapyr (ISO); 4-bromo-2-(4-chlorophenyl)-1-ethoxymethyl-5-trifluoromethylpyrrole-3-carbonitrile\n—\n122453-73-0\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH302\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH302\nH410\nM=100\n608-035-00-9\n(±)-α-[(2-acetyl-5-methylphenyl)-amino]-2,6-dichlorobenzene-aceto-nitrile\n419-290-9\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n608-036-00-4\n3-(2-{4-[2-(4-cyanophenyl)vinyl]phenyl}vinyl)benzonitrile\n419-060-8\n79026-02-1\nAquatic Chronic 4\nH413\n—\nH413\n608-037-00-X\nreaction mass of: (E)-2,12-tridecadiennitrile; (E)-3,12-tridecadiennitrile; (Z)-3,12-tridecadiennitrile\n422-190-8\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n608-038-00-5\n2,2,4-trimethyl-4-phenyl-butane-nitrile\n422-580-8\n75490-39-0\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n608-039-00-0\n2-phenylhexanenitrile\n423-460-8\n3508-98-3\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n608-040-00-6\n4,4'-dithiobis(5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile)\n423-490-1\n130755-46-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n608-041-00-1\n4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-ene-3-yl)methyl)(1,1'-biphenyl)-2-carbonitrile\n423-500-4\n138401-24-8\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n608-042-00-7\n(S)-2,2-diphenyl-2-(3-pyrrolidinyl)acetonitrile hydrobromide\n421-810-4\n194602-27-2\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n608-043-00-2\n3-(cis-3-hexenyloxy)propanenitril\n415-220-6\n142653-61-0\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH302\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH302\nH410\n608-044-00-8\n2-cyclohexylidene-2-phenylacetonitrile\n423-740-1\n10461-98-0\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n608-046-00-9\n5-(4-chloro-2-nitro-phenylazo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-pyridine-3-carbonitrile\n425-310-7\n77889-90-8\nAquatic Chronic 4\nH413\n—\nH413\n608-047-00-4\n2-piperidin-1-yl-benzonitrile\n427-330-1\n72752-52-4\nAquatic Chronic 2\nH411\nGHS09\nH411\n608-048-00-X\n1-(3-cyclopentyloxy-4-methoxyphenyl)-4-oxo-cyclohexanecarbonitrile\n427-450-4\n152630-47-2\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH373**\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH317\nH411\n608-049-00-5\n2-(4-(4-(butyl-(1-methylhexyl)amino)phenyl)-3-cyano-5-oxo-1,5-dihydropyrrol-2-ylidene)propandinitrile\n429-180-2\n157362-53-3\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n608-050-00-0\nreaction mass of: 5-(2-cyano-4-nitrophenylazo)-2-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-6-phenylaminonicotinonitrile;\n5-(2-cyano-4-nitrophenylazo)-6-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-2-phenylaminonicotinonitrile\n429-760-5\n—\nAquatic Chronic 4\nH413\n—\nH413\n608-051-00-6\n(R)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile\n430-760-2\n219861-18-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n608-052-00-1\n(S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile\n430-770-7\n128173-52-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n608-053-00-7\n(R,S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile\n430-780-1\n103146-25-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n608-054-00-2\n(R,S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)3-(hydroxymethyl)benzonitrile hemisulfate\n430-790-6\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n608-056-00-3\nN-methyl-N-cyanomethylmorpholiniummethylsulfate\n429-340-1\n—\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n608-057-00-9\n4-(cyanomethyl)-4-methylmorpholin-4-ium hydrogen sulfate\n431-200-1\n208538-34-5\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\n608-058-00-4\nesfenvalerate (ISO);\n(S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate\n—\n66230-04-4\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH317\nH410\nM = 10000\n608-059-00-X\n5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile\n421-240-6\n120068-79-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n608-060-00-5\n5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile\n421-300-1\n138564-59-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n608-062-00-6\n2-fluoro-4-hydroxybenzonitrile\n422-810-7\n82380-18-5\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n608-063-00-1\n(S)-α-hydroxy-3-phenoxy-benzeneacetonitrile\n441-070-6\n61826-76-4\nAcute Tox. 3 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH318\nH317\nH410\n608-064-00-7\ncyanomethyltrimethylammoniummethylsulfate\n433-720-2\n—\nAquatic Chronic 3\nH412\n—\nH412\n608-065-00-2\nsalts of bromoxynil with the exception of those specified elsewhere in this Annex\n—\n—\nRepr. 2\nAcute Tox. 2 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H330\nH301\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d *** H330\nH301\nH317\nH410\nM = 10\nA\n608-066-00-8\nsalts of ioxynil with the exception of those specified elsewhere in this Annex\n—\n—\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH361d *** H331\nH301\nH312\nH373 **\nH319\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d *** H331\nH301\nH312\nH373 **\nH319\nH410\nM = 10\nA\n609-001-00-6\n1-nitropropane\n203-544-9\n108-03-2\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH226\nH332\nH312\nH302\nGHS02\nGHS07\nWng\nH\n226\nH332\nH312\nH302\n*\n609-002-00-1\n2-nitropropane\n201-209-1\n79-46-9\nFlam. Liq. 3\nCarc. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nH226\nH350\nH332\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH226\nH350\nH332\nH302\n609-003-00-7\nnitrobenzene\n202-716-0\n98-95-3\nCarc. 2. Repr. 1B\nAcute Tox. 3\nAcute Tox. 3\nAcute Tox. 3\nSTOT RE 1\nAquatic Chronic 3\nH351\nH360F\nH301\nH331\nH311\nH372 (blood) H412\nGHS06\nGHS08\nDgr\nH351\nH360F\nH301\nH331\nH311\nH372 (blood) H412\n609-004-00-2\ndinitrobenzene; [1]\n1,4-dinitrobenzene; [2]\n1,3-dinitrobenzene; [3]\n1,2-dinitrobenzene [4]\n246-673-6 [1]\n202-833-7 [2]\n202-776-8 [3]\n208-431-8 [4]\n25154-54-5 [1]\n100-25-4 [2]\n99-65-0 [3]\n528-29-0 [4]\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 **\nH410\n609-005-00-8\n1,3,5-trinitrobenzene\n202-752-7\n99-35-4\nExpl. 1.1\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH330\nH310\nH300\nH373**\nH400\nH410\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH330\nH310\nH300\nH373**\nH410\n609-006-00-3\n4-nitrotoluene\n202-808-0\n99-99-0\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH411\n609-007-00-9\n2,4-dinitrotoluene; [1]\ndinitrotoluene [2]\n204-450-0 [1]\n246-836-1 [2]\n121-14-2 [1]\n25321-14-6 [2]\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH341\nH361f***\nH331\nH311\nH301\nH373**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH361f***\nH331\nH311\nH301\nH373**\nH410\n609-008-00-4\n2,4,6-trinitrotoluene; TNT\n204-289-6\n118-96-7\nExpl. 1.1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH201\nH331\nH311\nH301\nH373 **\nH411\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH331\nH311\nH301\nH373 **\nH411\n609-009-00-X\n2,4,6-trinitrophenol;\npicric acid\n201-865-9\n88-89-1\nExpl. 1.1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH201\nH331\nH311\nH301\nGHS01\nGHS06\nDgr\nH201\nH331\nH311\nH301\n609-010-00-5\nsalts of picric acid\n—\n—\nUnst. Expl\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH201\nH331\nH311\nH301\nGHS01\nGHS06\nDgr\nH201\nH331\nH311\nH301\nT\n609-011-00-0\n2,4,6-trinitroanisole\n—\n606-35-9\nExpl. 1.1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH201\nH332\nH312\nH302\nH411\nGHS01\nGHS07\nGHS09\nWng\nH201\nH332\nH312\nH302\nH411\n609-012-00-6\n2,4,6-trinitro-m-cresol\n210-027-1\n602-99-3\nExpl. 1.1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH201\nH332\nH312\nH302\nGHS01\nGHS07\nWng\nH201\nH332\nH312\nH302\n609-013-00-1\n2,4,6-trinitro-m-xylene\n211-187-5\n632-92-8\nExpl. 1.1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nH201\nH332\nH312\nH302\nH373 **\nGHS01\nGHS08\nGHS07\nWng\nH201\nH332\nH312\nH302\nH373 **\n609-015-00-2\n4-nitrophenol;\np-nitrophenol\n202-811-7\n100-02-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nH332\nH312\nH302\nH373 **\nGHS08\nGHS07\nWng\nH332\nH312\nH302\nH373 **\n609-016-00-8\ndinitrophenol (reaction mass of isomers); [1]\n2,4(or 2,6)-dinitrophenol [2]\n247-096-2 [1]\n275-732-9 [2]\n25550-58-7 [1]\n71629-74-8 [2]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH410\n609-018-00-9\n2,4,6-trinitroresorcinol;\nstyphnic acid\n201-436-6\n82-71-3\nExpl. 1.1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH201\nH332\nH312\nH302\nGHS01\nGHS07\nDgr\nH201\nH332\nH312\nH302\n609-019-00-4\nlead 2,4,6-trinitro-m-phenylene dioxide; lead 2,4,6-trinitroresorcinoxide;\nlead styphnate\n239-290-0\n15245-44-0\nUnst. Expl\nRepr. 1A\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH200\nH360Df\nH332\nH302\nH373 **\nH400\nH410\nGHS01\nGHS08\nGHS07\nGHS09\nDgr\nH200\nH360Df\nH332\nH302\nH373 **\nH410\n1\n609-019-01-1\nlead 2,4,6-trinitro-m-phenylene dioxide;\nlead 2,4,6-trinitroresorcinoxide;\nlead styphnate (≥ 20 % phlegmatiser)\n239-290-0\n15245-44-0\nExpl. 1.1\nRepr. 1A\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH360Df\nH332\nH302\nH373 **\nH400\nH410\nGHS01\nGHS08\nGHS07\nGHS09\nDgr\nH201\nH360Df\nH332\nH302\nH373 **\nH410\n1\n609-020-00-X\nDNOC (ISO);\n4,6-dinitro-o-cresol\n208-601-1\n534-52-1\nMuta. 2\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH330\nH310\nH300\nH315\nH318\nH317\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH341\nH330\nH310\nH300\nH315\nH318\nH317\nH410\nEUH044\n609-021-00-5\nsodium salt of DNOC;\nsodium 4,6-dinitro-o-cresolate; [1]\npotassium salt of DNOC; potassium 4,6-dinitro-o-cresolate [2]\n219-007-7 [1]\n-[2]\n2312-76-7 [1]\n5787-96-2 [2]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH410\n609-022-00-0\nammonium salt of DNOC; ammonium 4,6-dinitro-o-tolyl oxide\n221-037-0\n2980-64-5\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 **\nH410\n609-023-00-6\ndinocap (ISO);\n(RS)-2,6-dinitro-4-octylphenyl crotonates and (RS)-2,4-dinitro-6-octylphenyl crotonates in which \"octyl\" is a reaction mass of 1-methylheptyl, 1-ethylhexyl and 1-propylpentyl groups\n254-408-0\n39300-45-3\nRepr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D***\nH332\nH302\nH373**\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360D***\nH332\nH302\nH373**\nH315\nH317\nH410\nM=100\n609-024-00-1\nbinapacryl (ISO);\n2-sec-butyl-4,6-dinitrophenyl-3-methylcrotonate\n207-612-9\n485-31-4\nRepr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH360D *** H312\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360D *** H312\nH302\nH410\n609-025-00-7\ndinoseb (ISO);\n6-sec-butyl-2,4-dinitrophenol\n201-861-7\n88-85-7\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH311\nH301\nH319\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360Df\nH311\nH301\nH319\nH410\nEUH044\n609-026-00-2\nsalts and esters of dinoseb, with the exception of those specified elsewhere in this Annex\n—\n—\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH311\nH301\nH319\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360Df\nH311\nH301\nH319\nH410\nEUH044\nA\n609-027-00-8\ndinocton;\nreaction mass of isomers:\nmethyl 2-octyl-4,6-dinitrophenyl carbonate, methyl 4-octyl-2,6-dinitrophenyl carbonate\n—\n63919-26-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n609-028-00-3\ndinex (ISO);\n2-cyclohexyl-4,6-dinitrophenol\n205-042-5\n131-89-5\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\n609-029-00-9\nsalts and esters of dinex\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\nA\n609-030-00-4\ndinoterb (ISO);\n2-tert-butyl-4,6-dinitrophenol\n215-813-8\n1420-07-1\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH360D *** H300\nH311\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360D *** H300\nH311\nH410\nEUH044\n609-031-00-X\nsalts and esters of dinoterb\n—\n—\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH360D *** H300\nH311\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360D *** H300\nH311\nH410\nA\n609-032-00-5\nbromofenoxim (ISO);\n3,5-dibromo-4-hydroxybenzaldehyde-O-(2,4-dinitrophenyl)-oxime\n236-129-6\n13181-17-4\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n609-033-00-0\ndinosam (ISO);\n2-(1-methylbutyl)-4,6-dinitrophenol\n—\n4097-36-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\n609-034-00-6\nsalts and esters of dinosam\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH410\nA\n609-035-00-1\nnitroethane\n201-188-9\n79-24-3\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nH226\nH332\nH302\nGHS02\nGHS07\nWng\nH226\nH332\nH302\n*\n609-036-00-7\nnitromethane\n200-876-6\n75-52-5\nFlam. Liq. 3\nAcute Tox. 4 *\nH226\nH302\nGHS02\nGHS07\nWng\nH226\nH302\n*\n609-037-00-2\n5-nitroacenaphthene\n210-025-0\n602-87-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n609-038-00-8\n2-nitronaphthalene\n209-474-5\n581-89-5\nCarc. 1B\nAquatic Chronic 2\nH350\nH411\nGHS08\nGHS09\nDgr\nH350\nH411\n609-039-00-3\n4-nitrobiphenyl\n202-204-7\n92-93-3\nCarc. 1B\nAquatic Chronic 2\nH350\nH411\nGHS08\nGHS09\nDgr\nH350\nH411\n609-040-00-9\nnitrofen (ISO);\n2,4-dichlorophenyl 4-nitrophenyl ether\n217-406-0\n1836-75-5\nCarc. 1B\nRepr. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH360D *** H302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH360D *** H302\nH410\n609-041-00-4\n2,4-dinitrophenol\n200-087-7\n51-28-5\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nH331\nH311\nH301\nH373 **\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH400\n609-042-00-X\npendimethalin (ISO);\nN-(1-ethylpropyl)-2,6-dinitro-3,4-xylidine\n254-938-2\n40487-42-1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n609-043-00-5\nquintozene (ISO);\npentachloronitrobenzene\n201-435-0\n82-68-8\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n609-044-00-0\ntecnazene (ISO);\n1,2,4,5-tetrachloro-3-nitrobenzene\n204-178-2\n117-18-0\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n609-045-00-6\nreaction mass of: 4,6-dinitro-2-(3-octyl)phenyl methyl carbonate and 4,6-dinitro-2-(4-octyl)phenyl methyl carbonate; dinocton-6\n—\n8069-76-9\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n609-046-00-1\ntrifluralin (ISO) (containing <0.5 ppm NPDA);\nα, α, α-trifluoro-2,6-dinitro-N, N-dipropyl-p-toluidine (containing\n< 0,5 ppm NPDA);\n2,6-dinitro-N, N-dipropyl-4-trifluoromethylaniline (containing < 0,5 ppm NPDA);\nN, N-dipropyl-2,6-dinitro-4-trifluoromethylaniline (containing < 0.5 ppm NPDA)\n216-428-8\n1582-09-8\nCarc. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH317\nH410\nM=10\n609-047-00-7\n2-nitroanisole\n202-052-1\n91-23-6\nCarc. 1B\nAcute Tox. 4 *\nH350\nH302\nGHS08\nGHS07\nDgr\nH350\nH302\n609-048-00-2\nsodium 3-nitrobenzenesulphonate\n204-857-3\n127-68-4\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n609-049-00-8\n2,6-dinitrotoluene\n210-106-0\n606-20-2\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 3\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH412\nGHS06\nGHS08\nDgr\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH412\n609-050-00-3\n2,3-dinitrotoluene\n210-013-5\n602-01-7\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH410\n609-051-00-9\n3,4-dinitrotoluene\n210-222-1\n610-39-9\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH411\n609-052-00-4\n3,5-dinitrotoluene\n210-566-2\n618-85-9\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 3\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH412\nGHS06\nGHS08\nDgr\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH412\n609-053-00-X\nhydrazine-trinitromethane\n414-850-9\n—\nExpl. 1.1 ****\nSelf-react. A\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Sens. 1\nH201\nH240\nH350\nH331\nH301\nH317\nGHS01\nGHS06\nGHS08\nDgr\nH201\nH240\nH350\nH331\nH301\nH317\n609-054-00-5\n2,3-dinitrophenol; [1]\n2,5-dinitrophenol; [2]\n2,6-dinitrophenol; [3]\n3,4-dinitrophenol; [4]\nsalts of dinitrophenol [5]\n200-628-7 [1]\n206-348-1 [2]\n209-357-9 [3]\n209-415-3 [4]-[5]\n66-56-8 [1]\n329-71-5 [2]\n573-56-8 [3]\n577-71-9 [4]-[5]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH411\n609-055-00-0\n2,5-dinitrotoluene\n210-581-4\n619-15-8\nCarc. 1B Muta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH361f ***\nH331\nH311\nH301\nH373 **\nH411\n609-056-00-6\n2,2-dibromo-2-nitroethanol\n412-380-9\n69094-18-4\nExpl. 1.1\nCarc. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH351\nH302\nH373 **\nH314\nH317\nH400\nH410\nGHS01\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH201\nH351\nH302\nH373 **\nH314\nH317\nH410\n*\nSTOT SE 3; H335: C ≥ 1 %\nT\n609-057-00-1\n3-chloro-2,4-difluoronitrobenzene\n411-980-8\n3847-58-3\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH317\nH410\n609-058-00-7\n2-nitro-2-phenyl-1,3-propanediol\n410-360-4\n5428-02-4\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH372 ** H312\nH302\nH317\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH372 **\nH312\nH302\nH317\nH411\nEUH070\n609-059-00-2\n2-chloro-6-(ethylamino)-4-nitrophenol\n411-440-1\n131657-78-8\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n609-060-00-8\n4-[(3-hydroxypropyl)amino]-3-nitrophenol\n406-305-9\n92952-81-3\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n609-061-00-3\n(E, Z)-4-chlorophenyl(cyclopropyl)ketone O-(4-nitrophenylmethyl)oxime\n406-100-4\n94097-88-8\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n609-062-00-9\n2-bromo-2-nitropropanol\n407-030-7\n24403-04-1\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH311\nH302\nH373 **\nH314\nH317\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH311\nH302\nH373 **\nH314\nH317\nH410\n609-063-00-4\n2-[(4-chloro-2-nitrophenyl)amino]ethanol\n413-280-8\n59320-13-7\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n609-064-00-X\nmesotrione(ISO);\n2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione\n—\n104206-82-8\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n609-065-00-5\n2-nitrotoluene\n201-853-3\n88-72-2\nCarc. 1B\nMuta. 1B\nRepr. 2\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH340\nH361f *** H302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH340\nH361f *** H302\nH411\n609-066-00-0\nlithium sodium 3-amino-10-{4-(10-amino-6,13-dichloro-4,11-disulfonatobenzo[5,6][1,4]oxazino[2,3-b]phenoxazine-3-ylamino)-6-[methyl(2-sulfonato-ethyl)amino]-1,3,5-triazin-2-ylamino}-6,13-dichlorobenzo[5,6][1,4]oxazino[2,3-b]phenoxazine-4,11-disulfonate\n418-870-9\n154212-58-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 2 **\nH332\nH312\nH302\nH371 **\nGHS08\nGHS07\nDgr\nH332\nH312\nH302\nH371 **\n609-067-00-6\nsodium and potassium 4-(3-aminopropylamino)-2,6-bis[3(4-methoxy-2-sulfophenylazo)4-hydroxy-2-sulfo-7-naphthylamino]-1,3,5-triazine\n416-280-6\n156769-97-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n609-068-00-1\nmusk xylene;\n5-tert-butyl-2,4,6-trinitro-m-xylene\n201-329-4\n81-15-2\nExpl. 1.1\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH351\nH400\nH410\nGHS01\nGHS08\nGHS09\nWng\nH201\nH351\nH410\nT\n609-069-00-7\nmusk ketone;\n3,5-dinitro-2,6-dimethyl-4-tert-butylacetophenone;\n4'-tert-butyl-2', 6'-dimethyl-3',\n5'-dinitroacetophenone\n201-328-9\n81-14-1\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n609-070-00-2\n1,4-dichloro-2-(1,1,2,3,3,3-hexafluoropropoxy)-5-nitrobenzene\n415-580-4\n130841-23-5\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n609-071-00-8\nreaction mass of: 2-methylsulfanyl-4,6-bis-(2-hydroxy-4-methoxy-phenyl)-1,3,5-triazine;\n2-(4,6-bis-methylsulfanyl-1,3,5-triazin-2-yl)-5-methoxy-phenol\n423-520-3\n156137-33-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n609-072-00-3\n4-mesyl-2-nitrotoluene\n430-550-0\n1671-49-4\nRepr. 2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH361f***\nH302\nH317\nH412\nGHS08\nGHS07\nWng\nH361f***\nH302\nH317\nH412\n609-073-00-9\nlithium potassium sodium N,N''-bis{6-[7-[4-(4-chloro-1,3,5-triazin-2-yl)amino-4-(2-ureidophenylazo)]naphthalene-1,3,6-trisulfonato}-N'-(2-aminoethyl)piperazine\n427-850-9\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n610-001-00-3\ntrichloronitromethane;\nchloropicrin\n200-930-9\n76-06-2\nAcute Tox. 2 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH330\nH302\nH319\nH335\nH315\nGHS06\nDgr\nH330\nH302\nH319\nH335\nH315\n610-002-00-9\n1,1-dichloro-1-nitroethane\n209-854-0\n594-72-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\n610-003-00-4\nchlorodinitrobenzene\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH410\nC\n610-004-00-X\n2-chloro-1,3,5-trinitrobenzene\n201-864-3\n88-88-0\nExpl. 1.1\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH330\nH310\nH300\nH400\nH410\nGHS01\nGHS06\nGHS09\nDgr\nH201\nH330\nH310\nH300\nH410\n610-005-00-5\n1-chloro-4-nitrobenzene\n202-809-6\n100-00-5\nCarc. 2\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH351\nH341\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH341\nH331\nH311\nH301\nH373 **\nH411\n610-006-00-0\nchloronitroanilines with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 2\nH330\nH310\nH300\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 **\nH411\nA C\n610-007-00-6\n1-chloro-1-nitropropane\n209-990-0\n600-25-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH302\nGHS07\nWng\nH332\nH302\n*\n610-008-00-1\n2,6-dichloro-4-nitroanisole\n403-350-6\n17742-69-7\nAcute Tox. 3 *\nAquatic Chronic 2\nH301\nH411\nGHS06\nGHS09\nDgr\nH301\nH411\n610-009-00-7\n2-chloro-4-nitroaniline\n204-502-2\n121-87-9\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n610-010-00-2\n2-bromo-1-(2-furyl)-2-nitroethylene\n406-110-9\n35950-52-8\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 **\nH314\nH317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH373 **\nH314\nH317\nH410\n611-001-00-6\nazobenzene\n203-102-5\n103-33-3\nCarc. 1B Muta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH341\nH332\nH302\nH373 **\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH341\nH332\nH302\nH373 **\nH410\n611-002-00-1\nazoxybenzene\n207-802-1\n495-48-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH302\nGHS07\nWng\nH332\nH302\n611-003-00-7\nfenaminosulf (ISO);\nsodium 4-dimethylaminobenzenediazosulphonate\n205-419-4\n140-56-7\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH301\nH312\nH412\nGHS06\nDgr\nH301\nH312\nH412\n611-004-00-2\nmethyl-ONN-azoxymethyl acetate;\nmethyl azoxy methyl acetate\n209-765-7\n592-62-1\nCarc. 1B Repr. 1B\nH350\nH360D ***\nGHS08\nDgr\nH350\nH360D ***\n611-005-00-8\ndisodium {5-[(4'-((2,6-hydroxy3-((2-hydroxy-5-sulphophenyl)azo)phenyl)azo)(1,1'-biphenyl)-4-yl)azo]salicylato (4-)}cuprate(2-);\nCI Direct Brown 95\n240-221-1\n16071-86-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n611-006-00-3\n4-o-tolylazo-o-toluidine;\n4-amino-2',3-dimethylazobenzene;\nfast garnet GBC base; AAT;\no-aminoazotoluene\n202-591-2\n97-56-3\nCarc. 1B\nSkin Sens. 1\nH350\nH317\nGHS08\nDgr\nH350\nH317\n611-007-00-9\ntricyclazole (ISO);\n5-methyl-1,2,4-triazolo(3,4-b)benzo-1,3-thiazole;\n255-559-5\n41814-78-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n611-008-00-4\n4-aminoazobenzene;\n4-phenylazoaniline\n200-453-6\n60-09-3\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n611-009-00-X\nsodium (1-(5-(4-(4-anilino-3-sulphophenylazo)-2-methyl-5-methylsulphonamidophenylazo)4-hydroxy-2-oxido-3-(phenylazo)phenylazo)-5-nitro-4-sulphonato-2-naphtholato)iron(II)\n401-220-3\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH412\nGHS07\nWng\nH332\nH412\n611-010-00-5\n2'-(2-cyano-4,6-dinitrophenylazo)-5'-(N, N-dipropylamino)propionanilide\n403-010-7\n106359-94-8\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n611-011-00-0\nN, N,N',N'-tetramethyl-3,3'-(propylenebis(iminocarbonyl-4,1-phenylenazo(1,6-dihydro-2-hydroxy-4-methyl-6-oxopyridine-3,1-diyl)))di(propylammonium) dilactate\n403-340-1\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDg\nH318\nH411\n611-012-00-6\nreaction mass of 2,2-iminodiethanol 6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazole-7-sulfonate and 2-methylaminoethanol 6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazole-7-sulfonate and N, N-diethylpropane-1,3-diamine 6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazole-7-sulfonate\n403-410-1\n114565-65-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-013-00-1\ntrilithium-1-hydroxy-7-(3-sulfonatoanilino)-2-(3-methyl-4-(2-methoxy-4-(3-sulfonatophenylazo)phenylazo)phenylazo)naphthalene-3-sulfonate\n403-650-7\n117409-78-6\nExpl. 1.3 ****\nAquatic Chronic 2\nH203\nH411\nGHS01\nGHS09\nDgr\nH203\nH411\n611-014-00-7\n(tetrasodium 1-(4-(3-acetamido-4-(4'-nitro-2,2'-disulfonatostilben-4-ylazo)anilino)-6-(2,5-disulfonatoanilino)-1,3,5-triazin-2-yl)-3-carboxypyridinium) hydroxide\n404-250-5\n115099-55-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-015-00-2\ntetrasodium 4-amino-5-hydroxy-6-(4-(2-(2-(sulfonatooxy)ethylsulfonyl)ethylcarbamoyl)phenylazo)-3-(4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate\n404-320-5\n116889-78-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-016-00-8\nreaction mass of 1,1'-((dihydroxyphenylene)bis(azo-3,1-phenylenazo(1-(3-dimethylaminopropyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxopyridine-5,3-diyl)))dipyridinium dichloride dihydrochloride, mixed isomers and 1-(1-(3-dimethylaminopropyl)-5-(3-((4-(1-(3-dimethylaminopropyl)-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-5-pyridinio-3-pyridylazo)phenylazo)-2,4(or 2,6 or 3,5)-dihydroxyphenylazo)phenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-3-pyridyl)pyridinium dichloride\n404-540-1\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-017-00-3\n2-(4-(diethylaminopropylcarbamoyl)phenylazo)-3-oxo-N-(2,3-dihydro-2-oxobenzimidazol-5-yl)butyramide\n404-910-2\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-018-00-9\ntetraammonium 5-(4-(7-amino-1-hydroxy-3-sulfonato-2-naphthylazo)-6-sulfonato-1-naphthylazo)isophthalate\n405-130-5\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-019-00-4\ntetralithium 6-amino-4-hydroxy-3-(7-sulfonato-4-(4-sulfonatophenylazo)-1-naphthylazo)naphthalene-2,7-disulfonate\n405-150-4\n106028-58-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-020-00-X\ntetrakis(tetramethylammonium)\n6-amino-4-hydroxy-3-(7-sulfonato-4-(4-sulfonatophenylazo)-1-naphthylazo)naphthalene-2,7-disulfonate\n405-170-3\n116340-05-7\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Chronic 3\nH301\nH317\nH412\nGHS06\nDgr\nH301\nH317\nH412\n611-021-00-5\n2-(4-(4-cyano-3-methylisothiazol-5-ylazo)-N-ethyl-3-methylanilino)ethyl acetate\n405-480-9\n—\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nAquatic Chronic 4\nH302\nH373 ** H315\nH413\nGHS08\nGHS07\nWng\nH302\nH373 **\nH315\nH413\n611-022-00-0\n4-dimethylaminobenzenediazonium 3-carboxy-4-hydroxybenzenesulfonate\n404-980-4\n—\nSelf-react. C\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH242\nH331\nH301\nH312\nH373 **\nH318\nH317\nH400\nH410\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH242\nH331\nH301\nH312\nH373 **\nH318\nH317\nH410\nT\n611-023-00-6\ndisodium 7-(4,6-dichloro-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo) naphthalene-2-sulfonate\n404-600-7\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-024-00-1\nbenzidine based azo dyes;\n4,4'-diarylazobiphenyl dyes, with the exception of those specified elsewhere in this Annex\n—\n—\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nA\n611-025-00-7\ndisodium 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)naphtalene-2,7-disulphonate;\nC.I. Direct Black 38\n217-710-3\n1937-37-7\nCarc. 1B Repr. 2\nH350\nH361d ***\nGHS08\nDgr\nH350\nH361d ***\n611-026-00-2\ntetrasodium 3,3'-[[1,1'-biphenyl]-4,4'diylbis(azo)]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonate];\nC.I. Direct Blue 6\n220-012-1\n2602-46-2\nCarc. 1B Repr. 2\nH350\nH361d ***\nGHS08\nDgr\nH350\nH361d ***\n611-027-00-8\ndisodium 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis(4-aminonaphthalene-1-sulphonate); C.I. Direct Red 28\n209-358-4\n573-58-0\nCarc. 1B Repr. 2\nH350\nH361d ***\nGHS08\nDgr\nH350\nH361d ***\n611-028-00-3\nC,C'-azodi(formamide)\n204-650-8\n123-77-3\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\nG\n611-029-00-9\no-dianisidine based azo dyes;\n4,4'-diarylazo-3,3'-dimethoxybiphenyl dyes with the exception of those mentioned elsewhere in this Annex\n—\n—\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nA\n611-030-00-4\no-tolidine based dyes;\n4,4'-diarylazo-3,3'-dimethylbiphenyl dyes, with the exception of those mentioned elsewhere in this Annex\n—\n—\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nA\n611-031-00-X\n4,4'-(4-iminocyclohexa-2,5-dienylidenemethylene)dianiline hydrochloride;\nC.I. Basic Red 9\n209-321-2\n569-61-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n611-032-00-5\n1,4,5,8-tetraaminoanthra\nquinone;\nC.I. Disperse Blue 1\n219-603-7\n2475-45-8\nCarc. 1B\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH350\nH315\nH318\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH350\nH315\nH318\nH317\n611-033-00-0\nhexasodium [4,4''-azoxybis(2,2'-disulfonatostilbene-4,4'diylazo)]-bis[5'-sulfonatobenzene-2,2'-diolato-O(2), O(2), N(1)]-copper(II)\n400-020-3\n82027-60-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-034-00-6\nN-(5-(bis(2-methoxyethyl)amino)-2-((5-nitro-2,1-benzisothiazol-3-yl)azo)phenylacetamide\n402-430-8\n105076-77-5\nAquatic Chronic 4\nH413\n—\nH413\n611-035-00-1\ntetralithium 6-amino-4-hydroxy-3-[7-sulfonato-4-(5-sulfonato-2-naphthylazo)-1-naphthylazo]naphthalene-2,7-disulfonate\n403-660-1\n107246-80-0\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-036-00-7\n2-(4-(5,6(or 6,7)-dichloro-1,3-benzothiazol-2-ylazo)-N-methyl-m-toluidino)ethyl acetate\n405-440-0\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-037-00-2\n3(or 5)-(4-(N-benzyl-N-ethylamino)-2-methylphenylazo)1,4-dimethyl-1,2,4-triazolium methylsulphate\n406-055-0\n124584-00-5\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n611-038-00-8\ntrisodium 1-hydroxynaphthalene-2-azo-4'(5',5''-dimethylbiphenyl)-4''-azo(4''-phenylsulfonyloxybenzene)-2',2'',4-trisulfonate\n406-820-9\n—\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n611-039-00-3\n7-[((4,6-dichloro-1,3,5-triazin-2-yl)amino)-4-hydroxy-3-(4-((2-sulfoxy)ethyl)sulfonyl)phenylazo]naphthalene-2-sulfonic acid\n407-050-6\n117715-57-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-040-00-9\n3-(5-acetylamino-4-(4-[4,6-bis(3-diethylaminopropylamino)-1,3,5-triazin-2-ylamino]phenylazo)-2-(2-methoxyethoxy)phenylazo)-6-amino-4-hydroxy-2-naphthalenesulfonic acid\n407-670-7\n115099-58-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n611-041-00-4\n2-[[4[[4,6-bis[[3-(diethylamino)propyl]amino]-1,3,5-triazine-2-yl]amino]phenyl]azo]-N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-3-oxobutanamide\n407-680-1\n98809-11-1\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n611-042-00-X\ntrisodium 5-amino-3-[5-(2-bromoacryloylamino)-2-sulfonatophenylazo]-4-hydroxy-6-(4-vinylsulfonylphenylazo)naphthalene-2,7-disulfonate\n411-770-6\n136213-71-3\nAquatic Chronic 3\nH412\n—\nH412\n611-043-00-5\nreaction mass of: trisodium N(1')-N(2):N(1''')-N(2'')-η-6-[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]-6''-(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'-azobenzene-1,2'-diolato-O(1), O(2'))-chromate;\ntrisodium N(1')-N(2):N(1''')N(2'')-η-6,6''-bis(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''disulfamoyl-3,3''-disulfonato\nbis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate;\ntrisodium N(1')-N(2):N(1''')N(2'')-η-6,6''-bis[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]5',5'''disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate (2:1:1)\n402-850-1\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-044-00-0\nreaction mass of: tert-alkyl(C12-C14)ammonium bis[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium bis[1-[(2-hydroxy-4-nitrophenyl)azo]-2-naphthalenolato(2)]-chromate(1-); tert-alkyl(C12-C14)ammonium bis[1-[[5-(1,1-dimethylpropyl)-2-hydroxy-3-nitrophenyl]azo]-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium [[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalenolato(2)]-[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalenolato(2-)]]-chromate(1-);\ntert-alkyl(C12-C14)ammonium [[1-[[5-(1,1-dimethylpropyl)-2-hydroxy-3-nitrophenyl]azo]-2-naphthalenolato(2-)]-[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalenolato(2-)]]-chromate(1-); tert-alkyl(C12-C14)ammonium\n((1-(4(or 5)-nitro-2-oxidophenylazo)-2-naphtholato)(1-(3-nitro-2-oxido-5-pentylphenylazo)-2-naphtholato))chromate(1-)\n403-720-7\n117527-94-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-045-00-6\n2-[4-[N-(4-acetoxybutyl)-N-ethyl]amino-2-methylphenylazo]-3-acetyl-5-nitrothiophene\n404-830-8\n—\nAquatic Chronic 4\nH413\n—\nH413\n611-046-00-1\n4,4'-diamino-2-methylazobenzene\n407-590-2\n43151-99-1\nAcute Tox. 3 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH373 **\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH373 **\nH317\nH410\n611-047-00-7\nreaction mass of: 2-[[4-[N-ethyl-N-(2-acetoxyethyl)amino]phenyl]azo]-5,6-dichlorobenzothiazole; 2-[[4-[N-ethyl-N-(2-acetoxyethyl)amino]phenyl]azo]-6,7-dichlorobenzothiazole (1:1)\n407-890-3\n111381-11-4\nAquatic Chronic 4\nH413\n—\nH413\n611-048-00-2\nreaction mass of: 2-[[4-[bis(2-acetoxyethyl)amino]phenyl]azo]-5,6-dichlorobenzothiazole; 2-[[4-[bis(2-acetoxyethyl)amino]phenyl]azo]-6,7-dichlorobenzothiazole (1:1)\n407-900-6\n111381-12-5\nAquatic Chronic 4\nH413\n—\nH413\n611-049-00-8\nreaction mass of 7-[4-(3-diethylaminopropylamino)-6-(3-diethylammoniopropylamino)-1,3,5-triazin-2-ylamino]-4-hydroxy-3-(4-phenylazophenylazo)-naphthalene-2-sulfonate, acetic acid, lactic acid (2:1:1)\n408-000-6\n118658-98-3\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH373 **\nH317\nH412\nGHS08\nWng\nH373 **\nH317\nH412\n611-050-00-3\nreaction mass of: pentasodium\n7-amino-3-[[4-[[4-[[4-[[4-[(6-amino-1-hydroxy-3-sulfonato-2-naphthyl]azo]-7-sulfonato-1naphthyl]azo]phenyl]amino]-3-sulfonatophenyl]azo]-6-sulfonato-1-naphthyl]azo]-4-hydroxynaphthalen-2-sulfonate;\npentasodium 7-amino-8-[4-[4-[4-[4-(2-amino-5-hydroxy-7-sulfonato-naphthalen-1-ylazo)-7-sulfonatonaphthalen-1-ylazo]-phenylamino]-3-sulfonato-phenylazo]-6-sulfonato-naphthalen-1-ylazo]-4-hydroxy-naphthalene-2-sulfonate;\npentasodium 7-amino-8-[4-[4-[4-[4-(6-amino-1-hydroxy-3-sulfonato-naphthalen-1-ylazo)-7-sulfonatonaphthalen-1-ylazo]-phenylamino]-3-sulfonato-phenylazo]-6-sulfonato-naphthalen-1-ylazo]-4-hydroxy-naphthalene-2-sulfonate;\ntetrasodium 7-amino-4-hydroxy-3-[4-[4-[4-(4-hydroxy-7-sulfonato-naphthalen-1-ylazo)-2-sulfonato-phenylamino]phenylazo]-6-sulfonato-naphthalen-1-ylazo]naphthalene-2-sulfonate;\ntetrasodium 7-amino-4-hydroxy-3-[4-[4-[4-(4-amino-7-sulfonato-naphthalen-1-ylazo)-2-sulfonatophenylamino]phenylazo]-6-sulfonato-naphthalen-1-ylazo]naphthalene-2-sulfonate\n415-350-3\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-051-00-9\n2-(4-(N-ethyl-N-(2-hydroxy)ethyl)amino-2-methylphenyl)azo-6-methoxy-3-methyl-benzothiazolium chloride\n411-110-7\n136213-74-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n611-052-00-4\nmonosodium aqua-[5-[[2,4-dihydroxy-5-[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]azo]-2-naphthalensulfonate], iron complex\n400-720-9\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-053-00-X\n2,2'-azobis[2-methylpropionamidine] dihydrochloride\n221-070-0\n2997-92-4\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n611-055-00-0\nC.I. Disperse Yellow 3;\nN-[4-[(2-hydroxy-5-methylphenyl)azo]phenyl]acetamide\n220-600-8\n2832-40-8\nCarc. 2\nSkin Sens. 1\nH351\nH317\nGHS08\nGHS07\nWng\nH351\nH317\n611-056-00-6\nC.I. Solvent Yellow 14;\n1-phenylazo-2-naphthol\n212-668-2\n842-07-9\nCarc. 2\nMuta. 2\nSkin Sens. 1\nAquatic Chronic 4\nH351\nH341\nH317\nH413\nGHS08\nGHS07\nWng\nH351\nH341\nH317\nH413\n611-057-00-1\n6-hydroxy-1-(3-isopropoxypropyl)-4-methyl-2-oxo-5-[4-(phenylazo)phenylazo]-1,2-dihydro-3-pyridinecarbonitrile\n400-340-3\n85136-74-9\nCarc. 1B\nAquatic Chronic 4\nH350\nH413\nGHS08\nWng\nH350\nH413\n611-058-00-7\n(6-(4-hydroxy-3-(2-methoxyphenylazo)-2-sulfonato-7-naphthylamino)-1,3,5-triazin-2,4-diyl)bis[(amino-1-methylethyl)ammonium] formate\n402-060-7\n108225-03-2\nCarc. 1B\nEye Dam. 1\nAquatic Chronic 2\nH350\nH318\nH411\nGHS08\nGHS05\nGHS09\nDgr\nH350\nH318\nH411\n611-059-00-2\noctasodium 2-(6-(4-chloro-6-(3-(N-methyl-N-(4-chloro-6-(3,5-disulfonato-2-naphthylazo)-1-hydroxy-6-naphthylamino)-1,3,5-triazin-2-yl)aminomethyl)phenylamino)-1,3,5-triazin-2-ylamino)-3,5-disulfonato-1-hydroxy-2-naphthylazo)naphthalene-1,5-disulfonate\n412-960-1\n148878-21-1\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n611-060-00-8\nreaction mass of: sodium 5-[8-[4-[4-[4-[7-(3,5-dicarboxylatophenylazo)-8-hydroxy-3,6-disulfonatonaphthalen-1-ylamino]-6-hydroxy-1,3,5-triazin-2-yl]-2,5-dimethylpiperazin-1-yl]-6-hydroxy-1,3,5-triazin-2-ylamino]-1-hydroxy-3,6-disulfonatonaphthalen-2-ylazo]-isophthalate;\nammonium 5-[8-[4-[4-[4-[7-(3,5-dicarboxylatophenylazo)-8-hydroxy-3,6-disulfonatonaphthalen-1-ylamino]-6-hydroxy-1,3,5-triazin-2-yl]-2,5-dimethylpiperazin-1-yl]-6-hydroxy-1,3,5-triazin-2-ylamino]-1-hydroxy 3,6-disulfonatonaphthalen-2-ylazo]-isophthalate;\n5-[8-[4-[4-[4-[7-(3,5-dicarboxylatophenylazo)-8-hydroxy-3,6-disulfonatonaphthalen-1-ylamino]-6-hydroxy-1,3,5-triazin-2-yl]-2,5-dimethylpiperazin-1-yl]-6-hydroxy-1,3,5-triazin-2-ylamino]-1-hydroxy-3,6-disulfonaphthalen-2-ylazo]-isophthalic acid\n413-180-4\n187285-15-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-061-00-3\ndisodium 5-[5-[4-(5-chloro-2,6-difluoropyrimidin-4-ylamino)benzamido]-2-sulfonatophenylazo]-1-ethyl-6-hydroxy-4-methyl-2-oxo-3-pyridylmethylsulfonate\n412-530-3\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-062-00-9\noctasodium 2-(8-(4-chloro-6-(3-((4-chloro-6-(3,6-disulfonato-2-(1,5-disulfonatonaphthalen-2-ylazo)-1-hydroxynaphthalen-8-ylamino)-1,3,5-triazin-2-yl)aminomethyl)phenylamino)-1,3,5-triazin-2-ylamino)-3,6-disulfonato-1-hydroxynaphthalen-2-ylazo)naphthalene-1,5-disulfonate\n413-550-5\n—\nSkin Irrit. 2\nEye Dam. 1\nH315\nH318\nGHS05\nDgr\nH315\nH318\n611-063-00-4\ntrisodium [4'-(8-acetylamino-3,6-disulfonato-2-naphthylazo)-4''-(6-benzoylamino-3-sulfonato2-naphthylazo)-biphenyl 1,3',3'',1'''-tetraolato-O,O',O'',O''']copper(II)\n413-590-3\n164058-22-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n611-064-00-X\n4-(3,4-dichlorophenylazo)-2,6-di-sec-butyl-phenol\n410-600-8\n124719-26-2\nSTOT RE 2 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373 **\nH315\nH410\n611-065-00-5\n4-(4-nitrophenylazo)-2,6-di-sec-butyl-phenol\n410-610-2\n111850-24-9\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH319\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373 **\nH319\nH315\nH317\nH410\n611-066-00-0\ntetrasodium 5-[4-chloro-6-(N-ethyl-anilino)-1,3,5-triazin-2-ylamino]-4-hydroxy-3-(1,5-disulfonatonaphthalen-2-ylazo)-naphthalene-2,7-disulfonate\n411-540-5\n130201-57-9\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n611-067-00-6\nreaction mass of: bis(tris(2-(2-hydroxy(1-methyl)ethoxy)ethyl)ammonium) 7-anilino-4-hydroxy-3-(2-methoxy-5-methyl-4-(4-sulfonatophenylazo)phenylazo)naphthalene-2-sulfonate; bis(tris(2-(2-hydroxy(2-methyl)ethoxy)ethyl)ammonium) 7-anilino-4-hydroxy-3-(2-methoxy-5-methyl-4-(4-sulfonatophenylazo)phenylazo)naphthalene-2-sulfonate\n406-910-8\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n611-068-00-1\ntetrasodium 4-amino-3,6-bis(5-[4-chloro-6-(2-hydroxyethylamino)-1,3,5-triazin-2-ylamino]-2-sulfonatophenylazo)-5-hydroxynaphthalene-2,7-disulfonate\n400-690-7\n85665-98-1\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-069-00-7\nN,N-di-[poly(oxyethylene)-co-poly(oxypropylene)]-4-[(3,5-dicyano-4-methyl-2-thienyl)azo)]-3-methylaniline\n413-380-1\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-070-00-2\nreaction mass of: disodium (6-(4-anisidino)-3-sulfonato-2-(3,5-dinitro-2-oxidophenylazo)-1-naphtholato)(1-(5-chloro-2-oxidophenylazo)-2-naphtholato)chromate(1-);\ntrisodium bis(5-(4-anisidino)-3-sulfonato-2-(3,5-dinitro-2-oxidophenylazo)-1-naphtholato)chromate(1-)\n405-665-4\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n611-071-00-8\ntris(tetramethylammonium) 5-hydroxy-1-(4-sulphonatophenyl)-4-(4-sulphonatophenylazo)pyrazole-3-carboxylate\n406-073-9\n131013-81-5\nAcute Tox. 3 *\nAquatic Chronic 3\nH301\nH412\nGHS06\nDgr\nH301\nH412\n611-072-00-3\n2,4-bis[2,2'-[2-(N, N-dimethylamino)ethyloxycarbonyl]phenylazo]-1,3-dihydroxybenzene, dihydrochloride\n407-010-8\n118208-02-9\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n611-073-00-9\ndimethyl 3,3'-(N-(4-(4-bromo-2,6-dicyanophenylazo)-3-hydroxyphenyl)imino)dipropionate\n407-310-9\n122630-55-1\nAquatic Chronic 4\nH413\n—\nH413\n611-074-00-4\nreaction mass of: sodium/potassium (3-(4-(5-(5-chloro-2,6-difluoropyrimidin-4-ylamino)-2-methoxy-3-sulfonatophenylazo)-2-oxidophenylazo)-2,5,7-trisulfonato-4-naphtholato)copper(II);\nsodium/potassium (3-(4-(5-(5-chloro-4,6-difluoropyrimidin-2-ylamino)-2-methoxy-3-sulfonatophenylazo)-2-oxidophenylazo)-2,5,7-trisulfonato-4-naphtholato)copper(II)\n407-100-7\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-075-00-X\nreaction mass of: tris(3,5,5-trimethylhexylammonium) 4-amino-3-(4-(4-(2-amino-4-hydroxyphenylazo)anilino)-3-sulfonatophenylazo)-5,6-dihydro-5-oxo-6-phenylhydrazononaphthalene-2,7-disulfonate;\ntris(3,5,5-trimethylhexylammonium) 4-amino-3-(4-(4-(4-amino-2-hydroxyphenylazo)anilino)-3-sulfonatophenylazo)-5,6-dihydro-5-oxo-6-phenylhydrazononaphthalene-2,7-disulfonate (2:1)\n406-000-0\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n611-076-00-5\n3-(2,6-dichloro-4-nitrophenylazo)-1-methyl-2-phenylindole\n406-280-4\n117584-16-4\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n611-077-00-0\ndilithium disodium (5,5'-diamino-(μ-4,4'-dihydroxy-1:2κ-2,O4,O4',-3,3'-[3,3'-dihydroxy-1:2-κ-2-O3,O3'-biphenyl-4,4'-ylenebisazo-1:2-(N3, N4-η:N3', N4'-η)]-dinaphthalene-2,7-disulfonato(8)))dicuprate(2-)\n407-230-4\n126637-70-5\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n611-078-00-6\n(2,2'-(3,3'-dioxidobiphenyl-4,4'-diyldiazo)bis(6-(4-(3-(diethylamino)propylamino)-6-(-3-(diethylammonio)propylamino)1,3,5-triazin-2-ylamino)-3-sulfonato-1-naphtholato))dicopper(II) acetate lactate\n407-240-9\n159604-94-1\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-079-00-1\ndisodium 7-[4-chloro-6-(N-ethyl-o-toluidino)-1,3,5-triazin2-ylamino]-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)2-naphthalenesulfonate\n410-390-8\n147703-64-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-080-00-7\nsodium 3-(2-acetamido-4-(4-(2-hydroxybutoxy)phenylazo)phenylazo)benzenesulfonate\n410-150-2\n147703-65-9\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-081-00-2\ntetrasodium [7-(2,5-dihydroxy-KO2-7-sulfonato-6-[4-(2,5,6-trichloro-pyrimidin-4-ylamino)phenylazo]-(N1,N7-N)1-naphthylazo)-8-hydroxy-KO8-naphthalene-1,3,5-trisulfonato(6)]cuprate(II)\n411-470-5\n141048-13-7\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n611-082-00-8\nreaction mass of: pentasodium bis(1-(3(or 5)-(4-anilino-3-sulfonatophenylazo)-4-hydroxy-2-oxidophenylazo)-6-nitro-4-sulfonato-2-naphtholato)ferrate(1-); pentasodium [(1-(3-(4-anilino-3-sulfonatophenylazo)-4-hydroxy-2-oxidophenylazo)-6-nitro-4-sulfonato-2-naphtholato)-(5-(4anilino-3-sulfonatophenylazo)-4-hydroxy-2-oxidophenylazo)-6-nitro-4-sulfonato-2-naphtholato]ferrate(1-)\n407-570-3\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-083-00-3\nreaction mass of: 2-[N-ethyl-4-[(5,6-dichlorobenzothiazol-2-yl)azo]-m-toludino]ethyl acetate;\n2-[N-ethyl-4-[(6,7-dichlorobenzothiazol-2-yl)azo]-m-toludino]ethyl acetate (1:1)\n411-560-4\n—\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 2\nH372 ** H317\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH372 ** H317\nH411\n611-085-00-4\nreaction mass of: 3-cyano-5-(2-cyano-4-nitro-phenylazo)-2-(2-hydroxy-ethylamino)-4-methyl-6-[3-(2-phenoxyethoxy)propylamino]pyridine; 3-cyano-5-(2-cyano-4-nitro-phenylazo)-6-(2-hydroxy-ethylamino)-4-methyl-2-[3-(2-phenoxyethoxy)propylamino]pyridine;\n3-cyano-5-(2-cyano-4-nitro-phenylazo)-2-amino-4-methyl-6-[3-(3-hydroxypropoxy)propylamino]pyridine;\n3-cyano-5-(2-cyano-4-nitro-phenylazo)-6-amino-4-methyl-2-[3-(3-methoxypropoxy)propylamino]pyridine\n411-880-4\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-086-00-X\nmonolithium 5-[[2,4-dihydroxy-5-[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]azo]-2-naphthalenesulfonate], iron complex,\nmonohydrate\n411-360-7\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-087-00-5\nreaction mass of: 3-((5-cyano-1,6-dihydro-1,4-dimethyl-2-hydroxyl-6-oxo-3-pyridinyl)azo)-benzoyloxy-2-phenoxyethane;\n3-((5-cyano-1,6-dihydro-1,4-dimethyl-2-hydroxy-6-oxo-3-pyridinyl)azo)-benzoyloxy-2-ethyloxy-2-(ethylphenol)\n411-710-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n611-088-00-0\nreaction mass of: trilithium 4-amino-3-((4-((4-((2-amino-4-hydroxyphenyl)azo)phenyl)amino)-3-sulfophenyl)azo)5-hydroxy-6-(phenylazo)naphthalene-2,7-disulfonate;\ntrilithium 4-amino-3-((4-((4-((4-amino-2-hydroxyphenyl)azo)phenyl)amino)-3-sulfophenyl)azo)-5-hydroxy-6-(phenylazo)naphthalene-2,7-disulfonate\n411-890-9\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n611-089-00-6\n2-((4-(ethyl-(2-hydroxyethyl)amino)-2-methylphenyl)azo)-6-methoxy-3-methyl-benzothiazolium methylsulfate\n411-100-2\n136213-73-5\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 ** H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373 ** H317\nH410\n611-090-00-1\n2,5-dibutoxy-4-(morpholin-4-yl)benzenediazonium 4-methylbenzenesulfonate\n413-290-2\n93672-52-7\nSelf-react. C\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH242\nH302\nH318\nH317\nH412\nGHS02\nGHS05\nGHS07\nDgr\nH242\nH302\nH318\nH317\nH412\nT\n611-091-00-7\nsodium (1,0-1,95)/lithium (0,051) 5-((5-((5-chloro-6-fluoro-pyrimidin-4-yl)amino)-2-sulfonatophenyl)azo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-3-pyridinemethylsulfonate\n413-470-0\n134595-59-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-092-00-2\ntert-(dodecyl/tetradecyl)-ammonium bis(3-(4-((5-(1,1-dimethyl-propyl)-2-hydroxy-3-nitrophenyl)azo)-3-methyl-5-hydroxy-(1H)-pyrazol-1-yl)benzenesulfonamidato)chromate\n413-210-6\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-093-00-8\nsodium 2-(4-(4-fluoro-6-(2-sulfo-ethylamino)-[1,3,5]triazin-2-ylamino)-2-ureido-phenylazo)-5-(4-sulfophenylazo)benzene-1-sulfonate\n410-770-3\n146177-84-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-094-00-3\nreaction mass of: 2-[2-acetylamino-4-[N, N-bis[2-ethoxy-carbonyloxy)ethyl]amino]phenylazo]-5,6-dichloro-1,3-benzothiazole;\n2-[2-acetylamino-4-[N, N-bis[2-ethoxy-carbonyloxy)ethyl]amino]phenylazo]-6,7-dichloro-1,3-benzotriazole (1:1)\n411-600-0\n143145-93-1\nAquatic Chronic 4\nH413\n—\nH413\n611-095-00-9\nhexasodium 1,1'-[(1-amino-8-hydroxy-3,6-disulfonate-2,7-naphthalenediyl)bis(azo(4-sulfonate-1,3-phenyl)imino[6[(4-chloro-3-sulfonatophenyl)amino]-1,3,5-triazin-2,4-diyl]]]bis[3-carboxypyridinium] dihydroxide\n412-240-7\n89797-03-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-096-00-4\nmethyl N-[3-acetylamino)-4-(2-cyano-4-nitrophenylazo)phenyl]-N-[(1-methoxy)acetyl]glycinate\n413-040-2\n149850-30-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-097-00-X\nreaction mass of iron complexes of: 1,3-dihydroxy-4-[(5-phenylaminosulfonyl)-2-hydroxyphenylazo]-n-(5-amino-sulfonyl-2-hydroxyphenylazo)benzene\nand: 1,3-dihydroxy-4-[(5-phenylaminosulfonyl)-2-hydroxyphenylazo]-n-[4-(4-nitro-2-sulfophenylamino)phenylazo]benzene (n=2,5,6)\n414-150-3\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-098-00-5\ntetrakis(tetramethylammonium)3,3'-(6-(2-hydroxyethylamino)1,3,5-triazine-2,4-diylbisimino(2-methyl-4,1-phenyleneazo))bisnaphthalene-1,5-disulfonate\n405-950-3\n131013-83-7\nAcute Tox. 3 * Aquatic Chronic 3\nH301\nH412\nGHS06\nDgr\nH301\nH412\n611-099-00-0\n(methylenebis(4,1-phenylenazo(1-(3-(dimethylamino)propyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxopyridine-5,3-diyl)))-1,1'dipyridinium dichloride dihydrochloride\n401-500-5\n118658-99-4\nCarc. 1B\nAquatic Chronic 2\nH350\nH411\nGHS08\nGHS09\nDgr\nH350\nH411\n611-100-00-4\npotassium sodium 3,3'-(3(or 4)-methyl-1,2-phenylenebis(imino(6-chloro)-1,3,5-triazine-4,2-diylimino(2-acetamido-5-methoxy)-4,1-phenylenazo)dinaphthalene-1,5-disulfonate\n403-810-6\n140876-13-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-101-00-X\n2'-(4-chloro-3-cyano-5-formyl-2-thienyl)azo-5'-diethylaminoacetanilide\n405-200-5\n104366-25-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-102-00-5\nreaction product of: C.I. Leuco Sulfur Black 1 and reaction mass of: disodium-4-{4-[8-amino-1-hydroxy-7-(4-sulfamoylphenylazo)-3,6-disulfonato-2-naphthylazo]phenylsulfonylamino}benzendiazoniumchlorid; disodium-4-{4-[2,6-dihydroxy-3-(8-hydroxy-3,6-disulfonato-1-naphthylazo)phenylazo]phenylsulfonylamino}benzen-diazoniumchlorid\n424-500-7\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-103-00-0\ntrisodium (1-(3-carboxylato-2-oxido-5-sulfonatophenylazo)-5-hydroxy-7-sulfonatonaphthalen-2-amido)nickel(II)\n407-110-1\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n611-104-00-6\nreaction mass of: trisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(or 4 or 6)-(3,5-dinitro-2-oxidophenylazo)5-hydroxy-4(or 2 or 6)-(4-(4-nitro-2-sulfonatoanilino)phenylazo)phenolato)ferrate(1-); trisodium bis(2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)ferrate(1-);\ntrisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(or 4 or 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(or 2 or 6)-(4-nitro-2-sulfonatophenylazo)phenolato)ferrate(1-); trisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(or 4 or 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(or 2 or 6)-(3-sulfonatophenylazo)phenolato)ferrate(1-);\ndisodium 3,3'-(2,4-dihydroxy1,3(or 1,5 or 3,5)-phenylenediazo)dibenzenesulfonate\n406-870-1\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-105-00-1\nsodium 4-(4-chloro-6-(N-ethylanilino)-1,3,5-triazin-2-ylamino)-2-(1-(2-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo)benzenesulfonate\n407-800-2\n136213-75-7\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-106-00-7\nhexasodium 4,4'-dihydroxy-3,3'-bis[2-sulfonato-4-(4-sulfonatophenylazo)phenylazo]-7,7'[p-phenylenebis[imino(6-chloro-1,3,5-triazine-4,2-diyl)imino]]dinaphthalene-2-sulfonate\n410-180-6\n157627-99-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-107-00-2\npotassium sodium 4-(4-chloro-6-(3,6-disulfonato-7-(5,8-disulfonato-naphthalen-2-ylazo)-8-hydroxy-naphthalen-1-ylamino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-(2-sulfatoethanesulfonyl)-phenylazo)-naphthalene-1,7-disulfonate\n412-490-7\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-108-00-8\ndisodium 5-((4-((4-chloro-3-sulfonatophenyl)azo)-1-naphthyl)azo)-8-(phenylamino)-1-naphthalenesulfonate\n413-600-6\n6527-62-4\nAquatic Chronic 3\nH412\n—\nH412\n611-109-00-3\nreaction products of: copper(II) sulfate and tetrasodium 2,4-bis[6-(2-methoxy-5-sulfonatophenylazo)-5-hydroxy-7-sulfonato-2-naphthylamino]-6-(2-hydroxyethylamino)-1,3,5-triazine (2:1)\n407-710-3\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-110-00-9\ntetra-sodium/lithium 4,4'-bis-(8-amino-3,6-disulfonato-1-naphthol-2-ylazo)-3-methylazobenzene\n408-210-8\n124605-82-9\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-111-00-4\ndisodium 2-[[4-(2-chloroethylsulfonyl)phenyl]-[(2-hydroxy-5-sulfo-3-[3-[2-(2-(sulfooxy)ethylsulfonyl)ethylazo]-4-sulfobenzoato(3-)cuprate(1-)\n414-230-8\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-112-00-X\ntetrasodium 4-hydroxy-5-[4-[3-(2-sulfatoethanesulfonyl)phenylamino]-6-morpholin-4-yl-1,3,5-triazin-2-ylamino]-3-(1-sulfonatonaphthalen-2-ylazo)naphthalene-2,7-disulfonate\n413-070-6\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-113-00-5\nlithium sodium (2-(((5-((2,5-dichlorophenyl)azo)-2-hydroxyphenyl)methylene)amino)benzoato(2-))(2-((4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo)-5-sulfobenzoato(3-)) chromate(2-)\n414-280-0\n149626-00-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-114-00-0\nlithium sodium (4-((5-chloro-2-hydroxyphenyl)azo)-2,4-dihydro-5-methyl-3H-pyrazol-3-onato(2-))(3-((4,5-dihydro-3-methyl-1-(4-methylphenyl)-5-oxo-1H-pyrazol-4-yl)azo)-4-hydroxy-5-nitrobenzenesulfonato(3-)) chromate(2-)\n414-250-7\n149564-66-9\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n611-115-00-6\ntrilithium bis(4-((4-(diethylamino)-2-hydroxyphenyl)azo)-3-hydroxy-1-naphthalenesulfonato(3-))chromate(3-)\n414-290-5\n149564-65-8\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n611-116-00-1\nreaction mass of: trisodium 5{4-chloro-6-[2-(2,6-dichloro-5-cyanopyrimidin-4-ylamino)-propylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalene-2-ylazo)-naphthalene-2,7-disulfonate;\ntrisodium 5-{4-chloro-6-[2-(2,6-dichloro-5-cyanopyrimidin-4-ylamino)-1-methyl-ethylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalene-2-ylazo)-naphthalene-2,7-disulfonate;\ntrisodium 5-{4-chloro-6-[2-(4,6-dichloro-5-cyanopyrimidin-2-ylamino)-propylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalen-2-ylazo)-naphthalene-2,7-disulfonate;\ntrisodium 5-{4-chloro-6-[2-(4,6-dichloro-5-cyanopyrimidin-2-ylamino)-1-methyl-ethylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalen-2-ylazo)-naphthalene-2,7-disulfonate\n414-620-8\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-117-00-7\n1,3-bis{6-fluoro-4-[1,5-disulfo-4-(3-aminocarbonyl-1-ethyl-6-hydroxy-4-methyl-pyrid-2-on-5-ylazo)-phenyl-2-ylamino]-1,3,5-triazin-2-ylamino}propane lithium-, sodium salt\n415-100-3\n149850-29-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-118-00-2\nsodium 1,2-bis[4-[4-{4-(4-sulfophenylazo)-2-sulfophenylazo}-2-ureido-phenyl-amino]-6-fluoro-1,3,5-triazin-2-ylamino]-propane, sodium salt\n413-990-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-119-00-8\ntetrasodium 4-[4-chloro-6-(4-methyl-2-sulfophenylamino)-1,3,5-triazin-2-ylamino]-6-(4,5-dimethyl-2-sulfophenylazo)-5-hydroxynaphthalene-2,7-disulfonate\n415-400-4\n148878-22-2\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-120-00-3\n5-{4-[5-amino-2-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-sulfo-phenylamino]-6-chloro-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfo-naphthalen-2-ylazo)-naphthalene-2,7-disulfonicacid sodium salt\n418-340-7\n157707-94-3\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-121-00-9\nmain component 6 (isomer): asym. 1:2 Cr(III)-complex of: A: 3-hydroxy-4-(2-hydroxy-naphthalene-1-ylazo)naphthalene-1-sulfonic acid, Na-salt and B: 1-[2-hydroxy-5-(4-methoxy-phenylazo)phenylazo]naphthalene-2-ol;\nmain component 8 (isomer):\nasym. 1:2 Cr-complex of: A:\n3-hydroxy-4-(2-hydroxy-naphthalene-1-ylazo)-naphthalene-1-sulfonic acid, Na-salt and B: 1-[2-hydroxy-5-(4-methoxy-phenylazo)-phenylazo]-naphthalene-2-ol\n417-280-9\n30785-74-1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n611-122-00-4\nhexasodium (di[N-(3-(4-[5-(5-amino-3-methyl-1-phenylpyrazol-4-yl-azo)-2,4-disulfo-anilino]-6-chloro-1,3,5-triazin-2-ylamino)phenyl)-sulfamoyl](di-sulfo)-phthalocyaninato)nickel\n417-250-5\n151436-99-6\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-123-00-X\n3-(2,4-bis(4-((5-(4,6-bis(2-aminopropylamino)-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-disulfonaphthalen-3-yl)azo)phenylamino)-1,3,5-triazin-6-ylamino)propyldiethylammonium lactate\n424-310-4\n178452-66-9\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-124-00-5\nreaction mass of: pentasodium\n5-amino-3-(5-{4-chloro-6-[4-(2-sulfoxyethoxysulfonato)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-6-[5-(2,3-dibromopropionylamino)-2-sulfonatophenylazo]-4-hydroxynaphthalene-2,7-disulfonate;\npentasodium 5-amino-6-[5-(2-bromoacryloylamino)-2-sulfonatophenylazo]-3-(5-{4-chloro-6-[4-(2-sulfoxyethoxysulfonato)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-4-hydroxynaphthalene-2,7-disulfonate;\ntetrasodium 5-amino-3-[5-{4-chloro-6-[4-(vinylsulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo]-6-[5-(2,3-dibromopropionylamino)-2-sulfonatophenylazo]-4-hydroxynaphthalene-2,7-disulfonate\n424-320-9\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n611-125-00-0\nreaction mass of: disodium 6-[3-carboxy-4,5-dihydro-5-oxo-4-sulfonatophenyl)pyrazolin-4-yl-azo]-3-[2-oxido-4-(ethensulfonyl)-5-methoxyphenylazo]-4-oxidonaphthalene-2-sulfonate copper (II) complex;\ndisodium 6-[3-carboxy-4,5-dihydro-5-oxo-4-sulfonatophenyl)pyrazolin-4-yl-azo]-3-[2-oxido-4-(2-hydroxyethylsulfonyl)-5-methoxyphenylazo]-4-oxidonaphthalene-2-sulfonate copper (II) complex\n423-940-7\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n611-126-00-6\n2,6-bis-(2-(4-(4-amino-phenylamino)-phenylazo)-1,3-dimethyl-3H-imidazolium)-4-dimethylamino-1,3,5-triazine, dichloride\n424-120-1\n174514-06-8\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n611-127-00-1\npentasodium 4-amino-6-(5-(4-(2-ethyl-phenylamino)-6-(2-sulfatoethanesulfonyl)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate\n423-790-2\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\nG\n611-128-00-7\nN,N'-bis{6-chloro-4-[6-(4-vinylsulfonylphenylazo)-2,7-disulfonicacid-5-hydroxynapht-4-ylamino]-1,3,5-triazin-2-yl}-N-(2-hydroxyethyl)ethane-1,2-diamine, sodium salt\n419-500-9\n171599-85-2\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-129-00-2\nreaction mass of: 5-[(4-[(7-amino-1-hydroxy-3-sulfo-2-naphthyl)azo]-2,5-diethoxyphenyl)azo]-2-[(3-phosphonophenyl)azo]benzoic acid;\n5-[(4-[(7-amino-1-hydroxy-3-sulfo-2-naphthyl)azo]-2,5-diethoxyphenyl)azo]-3-[(3-phosphonophenyl)azo]benzoic acid\n418-230-9\n163879-69-4\nExpl. 1.3 ****\nRepr. 2\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH203\nH361f ***\nH373 **\nH317\nH411\nGHS01\nGHS08\nGHS07\nGHS09\nDgr\nH203\nH361f ***\nH373 **\nH317\nH411\n611-130-00-8\ntetra-ammonium 2-[6-[7-(2-carboxylato-phenylazo)-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4-hydroxy-1,3,5-triazin-2-ylamino]benzoate\n418-520-5\n183130-96-3\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n611-131-00-3\n2-[2-hydroxy-3-(2-chlorophenyl)carbamoyl-1-naphthylazo]-7-[2-hydroxy-3-(3-methylphenyl)carbamoyl-1-naphthylazo]fluoren-9-one\n420-580-2\n151798-26-4\nRepr. 1B\nAquatic Chronic 4\nH360D *** H413\nGHS08\nDgr\nH360D *** H413\n611-132-00-9\npentasodium bis{7-[4-(1-butyl-5-cyano-1,2-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo)phenylsulfonylamino]-5'-nitro-3,3'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato} chromate (III)\n419-210-2\n178452-71-6\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-133-00-4\nproduct by process iron complex of azo dyestuffs obtained by coupling a mixture of diazotized 2-amino-1-hydroxybenzene-4-sulfanilide and 2-amino-1-hydroxybenzene-4-sulfonamide with resorcin, the obtained mixture being subsequently submitted to a second coupling reaction with a mixture of diazotized 3-aminobenzene-1-sulfonic acid (metanilic acid) and 4'-amino-4-nitro-1,1'-diphenylamine-2-sulfonic acid and metallization with ferric chloride, sodium salt\n419-260-5\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n611-134-00-X\ntrisodium 2-{α[2-hydroxy-3-[4-chloro-6-[4-(2,3-dibromopropionylamino)-2-sulfonatophenylamino]-1,3,5-triazin-2-ylamino]-5-sulfonatophenylazo]-benzylidenehydrazino}-4-sulfonatobenzoate, copper complex\n423-770-3\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n611-135-00-5\nreaction product of: 2-[[4-amino-2-ureidophenylazo]-5-[(2-(sulfooxy)ethyl)sulfonyl]]benzenesulfonic acid with 2,4,6-trifluoropyrimidine and partial hydrolysis to the corresponding vinylsulfonyl derivative, mixed potassium/sodium salt\n424-250-9\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-136-00-0\n2-{4-(2-ammoniopropylamino)-6-[4-hydroxy-3-(5-methyl-2-methoxy-4-sulfamoylphenylazo)-2-sulfonatonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-2-aminopropyl formate\n424-260-3\n—\nRepr. 2\nEye Dam. 1\nAquatic Chronic 2\nH361f ***\nH318\nH411\nGHS05\nGHS08\nGHS09\nDgr\nH361f ***\nH318\nH411\n611-137-00-6\n6-tert-butyl-7-chloro-3-tridecyl-7,7a-dihydro-1H-pyrazolo[5,1-c]-1,2,4-triazole\n419-870-1\n159038-16-1\nAquatic Chronic 4\nH413\n—\nH413\n611-138-00-1\n2-(4-aminophenyl)-6-tert-butyl-1H-pyrazolo[1,5-b][1,2,4]triazole\n415-910-7\n152828-25-6\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n611-139-00-7\nreaction product of: C.I. Leuco Sulfur Black 1 with (3-chloro-2-hydroxypropyl)trimethylammonium chloride\n424-510-1\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n611-140-00-2\nazafenidin (ISO);\n2-(2,4-dichloro-5-prop-2-ynyloxyphenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridine-3(2H)-one\n—\n68049-83-2\nRepr. 1B\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360Df\nH373 ** H400\nH410\nGHS08\nGHS09\nDgr\nH360Df\nH373 **\nH410\nM = 1 000\n611-141-00-8\n5-(4-[4-[4-(3,5-dicarboxy-phenyl-azo)phenylamino]-6-morpholin-4-yl-1,3,5-triazin-2-ylamino]phenylazo)isophthalic acid, mixed monosodium and diammonium salt\n414-410-6\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-142-00-3\nproduct-by-process definition polyazodyestuff obtained by coupling 4-[4-(1-amino-8-hydroxy-3,6-disulfo-2-naphthylazo)phenylsulfonylamino] benzenediazonium with reaction mass of 4-carboxybenzenediazonium and diphenylamine-3-sulfo-4,4'-bisdiazonium, and further coupling of the obtained compounds with reaction mass of naphth-2-ol and 3-aminophenol, sodium salts;\nsodium chloride\n425-740-5\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-143-00-9\nreaction mass of: trisodium 2-(2-[α-(2-carboxylato-κ-O-4-sulfonatophenylazo)benzylidene]hydrazino-κ-N')-6-(2,6-difluoropyrimidin-4-ylamino)-4-sulfonatophenolatocuprate (II); trisodium 2-(2-[α-(2-carboxylato-κ-O-4-sulfonatophenylazo)benzylidene]hydrazino-κ-N')-6-(4,6-difluoropyrimidin-2-ylamino)-4-sulfonatophenolatocuprate (II)\n428-260-4\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-144-00-4\nreaction mas of: 7-amino-3,8-bis-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2-sulfonic acid, Na/K salt;\n7-amino-3-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxy-8-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]naphthalene-2-sulfonic acid, Na/K salt; 7-amino-8-[4-(2-sulfoxyethylsulfonyl)-phenylazo]-4-hydroxy-3-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]naphthalene-2-sulfonic acid, Na/K salt; 7-amino-3,8-bis-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]-4-hydroxynaphthalene-2-sulfonic acid, Na/K salt\n429-070-4\n214362-06-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-145-00-X\nreaction mass of: tetrasodium 3-(1,5-disulfonatonaphthalene-2-ylazo)-4-hydroxy-7-{4-chloro-6-[4-(2-sulfoxyethylsulfonyl)phenylamino]-1,3,5-triazine-2-ylamino}naphthalene-2-sulfonate;\n3-(2,5-disulfophenylazo)-4-hydroxy-7-{4-chloro-6-[4-(2-sulfoxyethylsulfonyl)phenylamino{-1,3,5-triazine-2-ylamino}naphthalene-2-sulfonic acid, sodium salt\n429-440-5\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-146-00-5\nreaction mass of: pentasodium\n3-(4-(4-(7-(2,4-diamino-5-sulfonato-3-(4-sulfonatophenylazo)phenylazo)-1-hydroxy-3-sulfonatonaphthalen-2-ylazo)-2-sulfonatophenylamino)phenylazo)-4-hydroxy-6-(2-oxo-1-phenylcarbamoylpropylazo)naphthalene-2-sulfonate; pentasodium 6-((2,4-diamino-5-sulfonatophenyl)azo)-3-((4-((4-((7-((2,4-diamino-5-sulfonatophenyl)azo)-1-hydroxy-3-sulfonatonaphthalen-2-yl)azo)phenyl)amino)-2-sulfonatophenyl)azo)-4-hydroxynaphthalene2-sulfonate;\npentasodium 6-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-3-((4-((4-((1,7-dihydroxy-3-sulfonatonaphthalen-2-yl)azo)-2-sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalene-2-sulfonate; hexasodium 6-((2,4-diamino-5-sulfonatophenyl)azo)-3-((4-((4-((7-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-1-hydroxy-3-sulfonatonaphthalen-2-yl)azo)-2-sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalene-2-sulfonate\n430-070-1\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-147-00-0\nsodium, potassium, lithium 5-amino-3,6-bis(5-(4-chloro-6-(methyl-(2-methylaminoacetyl)amino)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-4-hydroxynaphthalene-2,7-disulfonate\n430-090-0\n205764-96-1\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-148-00-6\nreaction mass of: 2-(3-(2,6-dichloro-4-nitrophenylazo)carbazol-9-yl)ethanol;\n2-(2-(3-(2,6-dichloro-4-nitro-phenylazo)-carbazol-9-yl)ethoxy)ethanol;\n3-(2,6-dichloro-4-nitrophenylazo)carbazol\n429-590-1\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n611-149-00-1\n2-(2-chloroacetoxy)ethyl 3-((4-(2,5-dichloro-4-fluorosulfonylphenylazo)-3-methylphenyl)ethylamino)propionate\n427-570-7\n193486-83-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-150-00-7\ntetralithium 2-[6-[7-[2-(carboxylato)phenylazo]-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4-hydroxy-1,3,5-triazine-2-ylamino]benzoate\n440-460-3\n—\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n611-151-00-2\nchrysoidine;\n4-(phenylazo)benzene-1,3-diamine\n207-803-7\n495-54-5\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH302\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH341\nH302\nH315\nH410\n611-152-00-8\nchrysoidine monohydrochloride;\n4-phenylazophenylene-1,3-diamine monohydrochloride; [1] chrysoidine monoacetate;\n4-(phenylazo)benzene-1,3-diamine monoacetate; [2]\nchrysoidine acetate;\n4-(phenylazo)benzene-1,3-diamine acetate; [3]\nchrysoidine-p-dodecylbenzenesulfonate; dodecylbenzenesulfonic acid, compound with 4-(phenylazo)benzene-1,3-diamine (1:1); [4]\nchrysoidine dihydrochloride;\n4-(phenylazo)benzene-1,3-diamine dihydrochloride; [5]\nchrysoidine sulfate;\nbis[4-(phenylazo)benzene-1,3-diamine] sulfate [6]\n208-545-8 [1]\n278-290-5 [2]\n279-116-0 [3]\n264-409-8 [4]\n281-549-5 [5]\n282-432-1 [6]\n532-82-1 [1]\n75660-25-2 [2]\n79234-33-6 [3]\n63681-54-9 [4]\n83968-67-6 [5]\n84196-22-5 [6]\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH302\nH315\nH318\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH341\nH302\nH315\nH318\nH410\n611-153-00-3\nchrysoidine C10-14-alkyl derivatives;\nbenzenesulfonic acid, mono-C10-14-alkyl derivatives, compounds\nwith 4-(phenylazo)-1,3-benzenediamine; [1]\nchrysoidine compound with dibutylnaphthalene sulfonic acid;\ndibutylnaphthalenesulfonic acid, compound with 4-(phenylazo)benzene-1,3-diamine (1:1) [2]\n286-946-7 [1]\n304-236-8 [2]\n85407-90-5 [1]\n94247-67-3 [2]\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nH341\nH302\nH315\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH341\nH302\nH315\nH318\n611-154-00-9\ntrisodium 5-benzamido-4-hydroxy-3-(4-methyl-2-sulfonatophenylazo)naphthalene-2,7-disulfonate\n403-670-6\n92408-46-3\nAquatic Chronic 3\nH412\n—\nH412\n611-155-00-4\n4,4'-oxybis(benzenesulfonylazide)\n431-850-4\n7456-68-0\nExpl. 1.1****\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH373**\nH400\nH410\nGHS01\nGHS08\nGHS09\nDgr\nH201\nH373**\nH410\n611-156-00-X\ntriammonium 4-[4-[7-(4-carboxylatoanilino)-1-hydroxy3-sulfonato-2-naphthylazo]-2,5-dimethoxyphenylazo]benzoate\n432-270-4\n221354-37-6\nRepr. 2\nSTOT RE 2 *\nAquatic Chronic 2\nH361f*** H373**\nH411\nGHS08\nGHS09\nWng\nH361f*** H373**\nH411\n611-157-00-5\nbenzenesulfonic acid, 3,3'-(methylenebis((dihydroxyphenylene)azo)) bis-, potassium sodium salt;\npotassium sodium 3-[(E)-(6{3,4-dihydroxy-2-}(Z)-(3-sulfonatophenyl)diazenyl]benzyl}-2,3-dihydroxyphenyl)diazenyl]benzenesulfonate\n432-590-4\n243869-48-9\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n611-158-00-0\nreaction product of: 2,3,4,2', 3',\n4'-hexahydroxy-5,5'-diacethyl-diphenylmethane and 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonylchloride and 3-diazo-3,4-dihydro-6-methoxy-4-oxo-1-naphthalenesulfonylchloride\n421-520-8\n—\n****\nAquatic Chronic 4\n**** H413\n****\n**** H413\n611-159-00-6\ndisodium 4-amino-6-((4-((4-(2,4-diaminophenyl)azo)phenylsulfamoyl)phenyl)azo)-5-hydroxy-3-((4-nitrophenyl)azo)naphthalene-2,7-disulfonate\n421-880-6\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-160-00-1\nreaction mass of: 1,1,1-tris(phenyl-4'-(3''-diazo-3'', 4''-dihydro-4''-oxo-naphthalene-1''-sulfonato)ethane; 1,1,1-tris(phenyl-4'-(6''-diazo-5'',\n6''-dihydro-5''-oxo-naphthalene1''-sulfonato)ethane;\nreaction product of 1,1,1-tris(p-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (2:1);\nreaction product of 1,1,1-tris(p-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (1:2)\n422-760-6\n—\n****\nAquatic Chronic 4\n**** H413\n****\n**** H413\n611-161-00-7\ntrisodium [1,2'-(2-(8-amino-3,5-disulfonatonaphthalene)azo)-(4'-nitrobenzene)diolato-O, O,N][(Z)-2,2-((phenylcarbamoylprop-1'-enyl)azo)-5-sulfamoylbenzene)diolato-O, O,N]chromate(III)\n423-100-1\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-162-00-2\n2,4-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzene-1,3-diolbis(methanesulfonate)\n429-600-4\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n611-163-00-8\n2,4-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzene-1,3-diol sulfate\n429-610-9\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n611-164-00-3\nreaction mass of: 2,2’-dimethyl-2,2’-azobutanenitrile;\n2-methylpentanenitrile-2-azo-2’-(2’-methylpropanenitrile);\n2,2’-dimethyl-2,2’-azoheptanenitrile;\n2-methylheptanenitrile-2-azo-2’-(2’-methylpropanenitrile);\n2-methylheptanenitrile-2-azo-2’-(2’-methylbutanenitrile)\n429-710-2\n—\nSelf-react. D\nAcute Tox. 4 *\nAquatic Chronic 2\nH242\nH302\nH411\nGHS02\nGHS07\nGHS09\nDgr\nH242\nH302\nH411\n611-165-00-9\nreaction mass of: tetrasodium - 4-amino-6-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate; tetrasodium 4-amino-6-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate\n431-830-5\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-166-00-4\nreaction mass of: pentasodium\n4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}naphthalene-2,7-disulfonate;\ntetrasodium 4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium - 4-amino-5-hydroxy-6-(E)-2-sulfonato-4-}2-(sulfonatooxy)ethylsulfonyl{phenylazo}-3-[(E)-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate\n432-100-9\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-167-00-X\nsodium bis[tris(2-hydroxyethyl)ammonium][6-anilino-4'-(4,8-disulfonato-2-naphthylazo)-5'-methyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cuprate(II)\n435-240-9\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-168-00-5\nreaction mass of: 3-[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-5-[[4-chloro-6-[[8-hydroxy-3,6-disulfo-7-[(2-sulfophenyl)azo]-1-naphthalenyl]amino]-1,3,5-triazin-2yl]amino]benzoic acid;\n3,5-bis[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid\n435-440-6\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-169-00-0\nsodium 5-(2-carboxyphenylazo)-6-hydroxynaphthalene-2-sulfonate\n435-800-2\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-170-00-6\nreaction mas of: trisodium 2-((1-(2-hydroxy-κ-O-5-(2-sulfonatoethansulfonyl)phenylazo-κ-N2)-1-phenylmethyl)azo-κ-N1)4-sulfonatobenzoate(5-)-κ-O)cuprate(II);\ndisodium 2-((1-(5-ethenesulfonyl-2-hydroxy-κ-O-phenylazo-κ-N2)-1-phenylmethyl)azo-κ-N1)-4-sulfonatobenzoate-κ-O-(5))cuprate(II)\n435-880-9\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-171-00-1\nreaction mass of trisodium 3-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate;\ntrisodium 3-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate\n436-890-6\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-172-00-7\nreaction mass of: triammonium\n6-amino-3-((2,5-diethoxy-4-(3-phosphonophenyl)azo)phenyl)azo-4-hydroxy-2-naphthalenesulfonate;\ndiammonium 3-((4-((7-amino-1-hydroxy-3-sulfo-naphthalen-2-yl)azo)-2,5-diethoxyphenyl)azo)benzoate\n438-310-7\n—\nSelf-react. C****\nRepr. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH242\nH361f***\nH302\nH373**\nH412\nGHS02\nGHS08\nGHS07\nDgr\nH242\nH361f***\nH302\nH373**\nH412\n611-173-00-2\nreaction mass of: 3-[3-carbamoyl-5-(5-{4-chloro-6[4-(2-sulfonatooxyethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propanoic acid, trisodium salt; 3-[3-carbamoyl-5-(5-{4-chloro-6-[4-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2oxo-1-pyridyl]propanoicacid, disodium salt\n440-510-4\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-174-00-8\nreaction mass of: 3-[5-(4-ethenesulfonylbutyrylamino)-2-sulfophenylazo]-5-4-chloro-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino]-1,3,5-triazin-2-ylamino[-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt;\n3-[5-(4-(2-chloroethanesulfonyl)butyrylamino)-2-sulfophenylazo]-5-4-chloro-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino]-1,3,5-triazin-2-ylamino}-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt\n442-290-5\n457624-86-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-175-00-3\nreaction mass of: trisodium 5-{4-chloro-6-[N-ethyl-(3-(2-sulfonatooxy)ethylsulfonyl)aniline]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(vinylsulfonyl)phenylazo{naphthalene-2,7-disulfonate; trisodium 5-4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ndisodium 5-4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[(4-vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ntetrasodium 5-4-chloro-6-[N-ethyl-3-(2-(sulfonatooxy)ethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-3-[4(2-(sulfonatooxy)ethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2,7-disulfonate\n444-050-5\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-176-00-9\n2,6-bis(2,3,4-trihydroxybenzyl)-p-cresol ester with 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonate\n444-250-2\n—\nSelf-react. C**** Aquatic Chronic 2\nH242\nH411\nGHS02\nGHS09\nDgr\nH242\nH411\n611-177-00-4\nreaction mass of: pentasodium bis[6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); tetrasodium [6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato][6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); trisodium bis[6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III)\n444-290-0\n508202-43-5\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n611-178-00-X\nreaction mass of: pentasodium\n4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}naphthalene-2,7-disulfonate;\ntetrasodium 4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium 4-amino-5-hydroxy-6-{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-3-[(E)-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; trisodium 4-amino-5-hydroxy-3-[(E)-4-(vinylsulfonyl)phenylazo]-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ntrisodium 4-amino-5-hydroxy-3-[(2-hydroxyethylsulfonyl)-phenylazo]-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ntrisodium 4-amino-5-hydroxy-3-[(E)-4-(vinylsulfonyl)phenylazo]-6-[-2-sulfonato-4-(2-hydroxyethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate\n445-280-9\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n611-179-00-5\nreaction mass of: pentasodium\n2-[[8-[[4-chloro-6-[[4-(2-sulfonatethylsulfonyl)]phenyl]amino]-1,3,5-triazin-2-yl]amino-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate;\n2-[[8-[[4-chloro-6-[[4-[[2-ethenyl]sulfonyl]phenyl]amino]1,3,5-triazin-2-yl]amino]-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate\n450-010-8\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-180-00-0\niron, complexes with diazotised\n4-aminobenzenesulfonamide, diazotized 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide, diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol, sodium salts\n417-850-7\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-001-00-9\nmono-methylamine; [1]\ndi-methylamine; [2]\ntri-methylamine [3]\n200-820-0 [1]\n204-697-4 [2]\n200-875-0 [3]\n74-89-5 [1]\n124-40-3 [2]\n75-50-3 [3]\nFlam. Gas 1\nPress. Gas\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH220\nH332\nH335\nH315\nH318\nGHS02\nGHS04\nGHS05\nGHS07\nDgr\nH220\nH332\nH335\nH315\nH318\n*\nSkin Irrit. 2;\nH315: C ≥ 5 %\nEye Dam. 1; H318: C ≥ 5 % Eye Irrit. 2;\nH319: 0,5 % ≤\nC < 5 %\nSTOT SE 3; H335: C ≥ 5 %\nU5\n612-001-01-6\nmono-methylamine … %; [1]\ndi-methylamine … %; [2]\ntri-methylamine … % [3]\n200-820-0 [1]\n204-697-4 [2]\n200-875-0 [3]\n74-89-5 [1]\n124-40-3 [2]\n75-50-3 [3]\nFlam. Liq. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH224\nH332\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH224\nH332\nH302\nH314\n*\nSTOT SE 3; H335: C ≥ 5 %\nB\n612-002-00-4\nethylamine\n200-834-7\n75-04-7\nFlam. Gas 1\nPress. Gas\nEye Irrit. 2\nSTOT SE 3\nH220\nH319\nH335\nGHS02\nGHS04\nGHS07\nDgr\nH220\nH319\nH335\nU\n612-003-00-X\ndiethylamine\n203-716-3\n109-89-7\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH225\nH332\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH314\nSTOT SE 3; H335: C ≥ 1 %\n612-004-00-5\ntriethylamine\n204-469-4\n121-44-8\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH225\nH332\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH314\nSTOT SE 3; H335: C ≥ 1 %\n612-005-00-0\nbutylamine\n203-699-2\n109-73-9\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH225\nH332\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH314\nSTOT SE 3; H335: C ≥ 1 %\n612-006-00-6\nethylenediamine;\n1,2-diaminoethane\n203-468-6\n107-15-3\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nH226\nH312\nH302\nH314\nH334\nH317\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH226\nH312\nH302\nH314\nH334\nH317\n612-007-00-1\n2-aminopropane;\nisopropylamine\n200-860-9\n75-31-0\nFlam. Liq. 1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH224\nH319\nH335\nH315\nGHS02\nGHS07\nDgr\nH224\nH319\nH335\nH315\n612-008-00-7\nniline\n200-539-3\n62-53-3\nCarc. 2\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH351\nH341\nH331\nH311\nH301\nH372 **\nH318\nH317\nH400\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH351\nH341\nH331\nH311\nH301\nH372 **\nH318\nH317\nH400\n*\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,2 % ≤ C < 1 %\n612-009-00-2\nsalts of aniline\n—\n—\nCarc. 2\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH351\nH341\nH331\nH311\nH301\nH372 **\nH318\nH317\nH400\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH351\nH341\nH331\nH311\nH301\nH372 **\nH318\nH317\nH400\n*\nSTOT RE 1; H372: C ≥ 1 % STOT RE 2;\nH373: 0,2 % ≤\nC < 1 %\nA\n612-010-00-8\nchloroanilines (with exception of those specified elsewhere in this Annex)\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH410\nC\n612-011-00-3\n4-nitrosoaniline\n211-535-6\n659-49-4\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH312\nH302\nGHS07\nWng\nH332\nH312\nH302\n612-012-00-9\no-nitroaniline; [1] m-nitroaniline; [2] p-nitroaniline [3]\n201-855-4 [1]\n202-729-1 [2]\n202-810-1 [3]\n88-74-4 [1]\n99-09-2 [2]\n100-01-6 [3]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 3\nH331\nH311\nH301\nH373 **\nH412\nGHS06\nGHS08\nDgr\nH331\nH311\nH301\nH373 **\nH412\nC\n612-013-00-4\n3-aminobenzene sulphonic acid;\nmetanilic acid\n204-473-6\n121-47-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH312\nH302\nGHS07\nWng\nH332\nH312\nH302\n612-014-00-X\nsulphanilic acid;\n4-aminobenzenesulphonic acid\n204-482-5\n121-57-3\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH315\nH317\nGHS07\nWng\nH319\nH315\nH317\n612-015-00-5\nN-methylaniline\n202-870-9\n100-61-8\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH410\n612-016-00-0\nN,N-dimethylaniline\n204-493-5\n121-69-7\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH351\nH331\nH311\nH301\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH331\nH311\nH301\nH411\n612-017-00-6\nN-methyl-N-2,4,6-tetranitroaniline; tetryl\n207-531-9\n479-45-8\nExpl. 1.1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2\nH201\nH331\nH311\nH301\nH373**\nGHS01\nGHS06\nGHS08\nDgr\nH201\nH331\nH311\nH301\nH373**\n612-018-00-1\nbis(2,4,6-trinitrophenyl)amine;\nhexyl\n205-037-8\n131-73-7\nExpl. 1.1\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2\nAquatic Chronic 2\nH201\nH330\nH310\nH300\nH373**\nH411\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH330\nH310\nH300\nH373**\nH411\n612-019-00-7\ndipicrylamine, ammonium salt\n220-639-0\n2844-92-0\nExpl. 1.1\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2\nAquatic Chronic 2\nH201\nH330\nH310\nH300\nH373**\nH411\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH330\nH310\nH300\nH373**\nH411\n612-020-00-2\n1-naphthylamine\n205-138-7\n134-32-7\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n612-022-00-3\n2-naphthylamine\n202-080-4\n91-59-8\nCarc. 1A\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH411\nCarc. 1A; H350: C ≥ 0,01 %\n612-023-00-9\nphenylhydrazine; [1] phenylhydrazinium chloride; [2] phenylhydrazine hydrochloride; [3]\nphenylhydrazinium sulphate\n(2:1) [4]\n202-873-5 [1]\n200-444-7 [2]\n248-259-0 [3]\n257-622-2 [4]\n100-63-0 [1]\n59-88-1 [2]\n27140-08-5 [3]\n52033-74-6 [4]\nCarc. 1B\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH350\nH341\nH331\nH311\nH301\nH372 **\nH319\nH315\nH317\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH331\nH311\nH301\nH372 **\nH319\nH315\nH317\nH400\n612-024-00-4\nm-toluidine;\n3-aminotoluene\n203-583-1\n108-44-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nH331\nH311\nH301\nH373 **\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH400\n612-025-00-X\nnitrotoluidines, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH411\nC\n612-026-00-5\ndiphenylamine\n204-539-4\n122-39-4\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH373 **\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH410\n612-027-00-0\nxylidines with the exception of those specified elsewhere in this Annex;\ndimethyl anilines with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH411\nC\n612-028-00-6\np-phenylenediamine\n203-404-7\n106-50-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH319\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH319\nH317\nH410\n612-029-00-1\nbenzene-1,4-diamine dihydrochloride;\np-phenylenediamine dihydrochloride\n210-834-9\n624-18-0\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH319\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH301\nH319\nH317\nH410\n612-030-00-7\n2-methyl-p-phenylenediamine sulphate [1]\n210-431-8 [1]\n228-871-4 [2]\n615-50-9 [1]\n6369-59-1 [2]\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH332\nH312\nH317\nH411\nGHS06\nGHS09\nDgr\nH301\nH332\nH312\nH317\nH411\n612-031-00-2\nN,N-dimethylbenzene-1,3-diamine; [1]\n4-amino-N,N-dimethylaniline;\n3-amino-N,N'-dimethylaniline [2]\n220-623-3 [1]\n202-807-5 [2]\n2836-04-6 [1]\n99-98-9 [2]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH331\nH311\nH301\nGHS06\nDgr\nH331\nH311\nH301\nC\n612-032-00-8\nN, N,N',N'-tetramethyl-p-phenylenediamine\n202-831-6\n100-22-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH312\nH302\nGHS07\nWng\nH332\nH312\nH302\n612-033-00-3\n2-aminophenol\n202-431-1\n95-55-6\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nH341\nH332\nH302\nGHS08\nGHS07\nWng\nH341\nH332\nH302\n612-034-00-9\n2-amino-4,6-dinitrophenol;\npicramic acid\n202-544-6\n96-91-3\nExpl. 1.1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH201\nH332\nH312\nH302\nH412\nGHS01\nGHS07\nDgr\nH201\nH332\nH312\nH302\nH412\n612-034-01-6\n2-amino-4,6-dinitrophenol;\npicramic acid; [≥ 20 % water]\n202-544-6\n96-91-3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH312\nH302\nH412\nGHS07\nWng\nH332\nH312\nH302\nH412\nG\n612-035-00-4\n2-methoxyaniline;\no-anisidine\n201-963-1\n90-04-0\nCarc. 1B Muta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nH350\nH341\nH331\nH311\nH301\nGHS06\nGHS08\nDgr\nH350\nH341\nH331\nH311\nH301\n612-036-00-X\n3,3'-dimethoxybenzidine;\no-dianisidine\n204-355-4\n119-90-4\nCarc. 1B\nAcute Tox. 4 *\nH350\nH302\nGHS08\nGHS07\nDgr\nH350\nH302\n612-037-00-5\nsalts of 3,3'-dimethoxybenzidine; salts of o-dianisidine\n—\n—\nCarc. 1B\nAcute Tox. 4 *\nH350\nH302\nGHS08\nGHS07\nDgr\nH350\nH302\nA\n612-038-00-0\n2-nitro-p-anisidine;\n4-methoxy-2-nitroaniline\n202-547-2\n96-96-8\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 3\nH330\nH310\nH300\nH373 **\nH412\nGHS06\nGHS08\nDgr\nH330\nH310\nH300\nH373 **\nH412\n612-039-00-6\n2-ethoxyaniline;\no-phenetidine\n202-356-4\n94-70-2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nH331\nH311\nH301\nH373 **\nGHS06\nGHS08\nDgr\nH331\nH311\nH301\nH373 **\n612-040-00-1\n2,4-dinitroaniline\n202-553-5\n97-02-9\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Chronic 2\nH330\nH310\nH300\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 **\nH411\n612-041-00-7\n4,4'-bi-o-toluidine\n204-358-0\n119-93-7\nCarc. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH411\n612-042-00-2\nbenzidine;\n1,1'-biphenyl-4,4'-diamine;\n4,4'-diaminobiphenyl;\nbiphenyl-4,4'-ylenediamine\n202-199-1\n92-87-5\nCarc. 1A\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH410\nCarc. 1A; H350: C ≥ 0,01 %\n612-043-00-8\nN,N'-dimethylbenzidine\n—\n2810-74-4\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH332\nH312\nH302\nGHS07\nWng\nH332\nH312\nH302\n612-044-00-3\nN,N'-diacetylbenzidine\n210-338-2\n613-35-4\nCarc. 1B Muta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH350\nH341\nH332\nH312\nH302\nGHS08\nGHS07\nDgr\nH350\nH341\nH332\nH312\nH302\n612-046-00-4\nallylamine\n203-463-9\n107-11-9\nFlam. Liq. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH225\nH331\nH311\nH301\nH411\nGHS02\nGHS06\nGHS09\nDgr\nH225\nH331\nH311\nH301\nH411\n612-047-00-X\nbenzylamine\n202-854-1\n100-46-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n612-048-00-5\ndipropylamine\n205-565-9\n142-84-7\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH225\nH332\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH314\nSTOT SE 3; H335: C ≥ 1 %\n612-049-00-0\ndi-n-butylamine; [1]\ndi-sec-butylamine [2]\n203-921-8 [1]\n210-937-9 [2]\n111-92-2 [1]\n626-23-3 [2]\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH226\nH332\nH312\nH302\nGHS02\nGHS07\nWng\nH226\nH332\nH312\nH302\n612-050-00-6\ncyclohexylamine\n203-629-0\n108-91-8\nFlam. Liq. 3\nRepr. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH226\nH361f***\nH312\nH302\nH314\nGHS02\nGHS05\nGHS08\nGHS07\nDgr\nH226\nH361f***\nH312\nH302\nH314\n612-051-00-1\n4,4'-diaminodiphenylmethane;\n4,4'-methylenedianiline\n202-974-4\n101-77-9\nCarc. 1B\nMuta. 2\nSTOT SE 1\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH341\nH370 **\nH373 **\nH317\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH341\nH370 **\nH373 **\nH317\nH411\n612-052-00-7\n(S)-sec-butylamine;\n(S)-2-aminobutane; [1] (R)-sec-butylamine;\n(R)-2-aminobutane; [2]\nsec-butylamine;\n2-aminobutane [3]\n208-164-7 [1]\n236-232-6 [2]\n237-732-7 [3]\n513-49-5 [1]\n13250-12-9 [2]\n13952-84-6 [3]\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nAquatic Acute 1\nH225\nH332\nH302\nH314\nH400\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH225\nH332\nH302\nH314\nH400\nC\n612-053-00-2\nN-ethylaniline\n203-135-5\n103-69-5\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nH331\nH311\nH301\nH373 **\nGHS06\nGHS08\nDgr\nH331\nH311\nH301\nH373 **\n612-054-00-8\nN,N-diethylaniline\n202-088-8\n91-66-7\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH411\n*\n612-055-00-3\nN-methyl-o-toluidine; [1] N-methyl-m-toluidine; [2] N-methyl-p-toluidine [3]\n210-260-9 [1]\n211-795-0 [2]\n210-769-6 [3]\n611-21-2 [1]\n696-44-6 [2]\n623-08-5 [3]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 3\nH331\nH311\nH301\nH373 **\nH412\nGHS06\nGHS08\nDgr\nH331\nH311\nH301\nH373 **\nH412\nC\n612-056-00-9\nN,N-dimethyl-p-toluidine; [1] N,N-dimethyl-m-toluidine; [2] N,N-dimethyl-o-toluidine [3]\n202-805-4 [1]\n204-495-6 [2]\n210-199-8 [3]\n99-97-8 [1]\n121-72-2 [2]\n609-72-3 [3]\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 3\nH331\nH311\nH301\nH373 **\nH412\nGHS06\nGHS08\nDgr\nH331\nH311\nH301\nH373 **\nH412\n*\nC\n612-057-00-4\npiperazine; [solid]\n203-808-3\n110-85-0\nRepr. 2\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nH361fd\nH314\nH334\nH317\nGHS05\nGHS08\nDgr\nH361fd\nH314\nH334\nH317\n612-057-01-1\npiperazine; [liquid]\n203-808-3\n110-85-0\nRepr. 2\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nH361fd\nH314\nH334\nH317\nGHS05\nGHS08\nDgr\nH361fd\nH314\nH334\nH317\n612-058-00-X\n2,2'-iminodiethylamine;\ndiethylenetriamine\n203-865-4\n111-40-0\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH312\nH302\nH314\nH317\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\nH317\n612-059-00-5\n3,6-diazaoctanethylenediamin;\ntriethylenetetramine\n203-950-6\n112-24-3\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH312\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH312\nH314\nH317\nH412\n612-060-00-0\n3,6,9-triazaundecamethylenediamine; tetraethylenepentamine\n203-986-2\n112-57-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH312\nH302\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH314\nH317\nH411\n612-061-00-6\n3-aminopropyldimethylamine; N,N-dimethyl-1,3-diaminopropane\n203-680-9\n109-55-7\nFlam. Liq. 3\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH226\nH302\nH314\nH317\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH302\nH314\nH317\n612-062-00-1\n3-aminopropyldiethylamine;\nN,N-diethyl-1,3-diaminopropane\n203-236-4\n104-78-9\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH226\nH312\nH302\nH314\nH317\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH312\nH302\nH314\nH317\n612-063-00-7\n3,3'-iminodi(propylamine);\ndipropylenetriamine\n200-261-2\n56-18-8\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1A\nSkin Sens. 1\nH330\nH311\nH302\nH314\nH317\nGHS06\nGHS05\nDgr\nH330\nH311\nH302\nH314\nH317\n612-064-00-2\n3,6,9,12-tetra-azatetradecamethylenediamine; pentacthylenehexamine\n223-775-9\n4067-16-7\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n612-065-00-8\npolyethlyenepolyamines with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH314\nH317\nH410\n612-066-00-3\ndicyclohexylamine\n202-980-7\n101-83-7\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH410\n612-067-00-9\n3-aminomethyl-3,5,5-trimethylcyclohexylamine\n220-666-8\n2855-13-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH312\nH302\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\nH317\nH412\n612-068-00-4\n3,3'-dichlorobenzidine;\n3,3'-dichlorobiphenyl-4,4'-ylenediamine\n202-109-0\n91-94-1\nCarc. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH312\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH312\nH317\nH410\n612-069-00-X\nsalts of 3,3'-dichlorobenzidine;\nsalts of 3,3'-dichlorobiphenyl-4,4'-ylenediamine\n—\n—\nCarc. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH312\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH312\nH317\nH410\nA\n612-070-00-5\nsalts of benzidine\n208-519-6\n208-520-1\n244-236-4\n252-984-8\n531-85-1\n531-86-2\n21136-70-9\n36341-27-2\nCarc. 1A\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH410\nA\n612-071-00-0\nsalts of 2-naphthylamine\n209-030-0\n210-313-6\n553-00-4\n612-52-2\nCarc. 1A\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH411\nA\n612-072-00-6\nbiphenyl-4-ylamine;\nxenylamine;\n4-aminobiphenyl\n202-177-1\n92-67-1\nCarc. 1A\nAcute Tox. 4 *\nH350\nH302\nGHS08\nGHS07\nDgr\nH350\nH302\n612-073-00-1\nsalts of biphenyl-4-ylamine;\nsalts of xenylamine;\nsalts of 4-aminobiphenyl\n—\n—\nCarc. 1A\nAcute Tox. 4 *\nH350\nH302\nGHS08\nGHS07\nDgr\nH350\nH302\nA\n612-074-00-7\nbenzyldimethylamine\n203-149-1\n103-83-3\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 3\nH226\nH332\nH312\nH302\nH314\nH412\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH332\nH312\nH302\nH314\nH412\n612-075-00-2\n2-aminoethyldimethylamine;\n2-dimethylaminoethylamine\n203-541-2\n108-00-9\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH225\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH312\nH302\nH314\n612-076-00-8\nethyldimethylamine\n209-940-8\n598-56-1\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH225\nH332\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH332\nH302\nH314\n612-077-00-3\ndimethylnitrosoamine;\nN-nitrosodimethylamine\n200-549-8\n62-75-9\nCarc. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Chronic 2\nH350\nH330\nH301\nH372 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH330\nH301\nH372 **\nH411\nCarc. 1B; H350: C ≥ 0,001 %\n612-078-00-9\n2,2'-dichloro-4,4'-methylenedianiline;\n4,4'-methylene bis(2-chloroaniline)\n202-918-9\n101-14-4\nCarc. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH410\n612-079-00-4\nsalts of 2,2'-dichloro-4,4'-methylenedianiline;\nsalts of 4,4'-methylenebis(2-chloroaniline)\n—\n—\nCarc. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH410\nA\n612-080-00-X\n4-amino-N,N-diethylaniline;\nN,N-diethyl-p-phenylendiamine\n202-214-1\n93-05-0\nAcute Tox. 3 *\nSkin Corr. 1B\nH301\nH314\nGHS06\nGHS05\nDgr\nH301\nH314\n612-081-00-5\nsalts of 4,4'-bi-o-toluidine;\nsalts of 3,3'-dimethylbenzidine;\nsalts of o-tolidine\n210-322-5\n265-294-7\n277-985-0\n612-82-8\n64969-36-4\n74753-18-7\nCarc. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH411\nA\n612-082-00-0\nthiourea;\nthiocarbamide\n200-543-5\n62-56-6\nCarc. 2\nRepr. 2\nAcute Tox. 4 *\nAquatic Chronic 2\nH351\nH361d *** H302\nH411\nGHS08\nGHS07\nGHS09\nWng\nH351\nH361d *** H302\nH411\n612-083-00-6\n1-methyl-3-nitro-1-nitrosoguanidine\n200-730-1\n70-25-7\nCarc. 1B\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH350\nH332\nH319\nH315\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH332\nH319\nH315\nH411\nCarc. 1B; H350: C ≥ 0,01 %\n612-084-00-1\ndapsone;\n4,4'-diamino diphenyl sulfone\n201-248-4\n80-08-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n612-085-00-7\n4,4'-methylenedi-o-toluidine\n212-658-8\n838-88-0\nCarc. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH317\nH410\n612-086-00-2\namitraz (ISO);\nN,N-bis(2,4-xylyliminomethyl)\nmethylamine\n251-375-4\n33089-61-1\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 **\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 ** H317\nH410\nM = 10\n612-087-00-8\nguazatine (ISO)\n108173-90-6\nAcute Tox. 2 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH312\nH302\nH335\nH315\nH318\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH312\nH302\nH335\nH315\nH318\nH410\n612-088-00-3\nsimazine (ISO);\n6-chloro-N,N'-diethyl-1,3,5-triazine-2,4-diamine\n204-535-2\n122-34-9\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n612-089-00-9\n1,5-naphthylenediamine\n218-817-8\n2243-62-1\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n612-090-00-4\n2,2'-(nitrosoimino)bisethanol\n214-237-4\n1116-54-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n612-091-00-X\no-toluidine;\n2-aminotoluene\n202-429-0\n95-53-4\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nAquatic Acute 1\nH350\nH331\nH301\nH319\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH301\nH319\nH400\n612-092-00-5\nN, N'-(2,2-dimethylpropylidene)hexamethylenediamine\n401-660-6\n1000-78-8\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n612-093-00-0\n3,5-dichloro-4-(1,1,2,2-tetrafluoroethoxy)aniline\n401-790-3\n104147-32-2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n612-094-00-6\n4-(2-chloro-4-trifluoromethyl)phenoxy-2-fluoroaniline hydrochloride\n402-190-4\n113674-95-6\nSTOT RE 1\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH372**\nH302\nH373**\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH372**\nH302\nH373**\nH318\nH317\nH410\n612-095-00-1\nbenzyl-2-hydroxydodecyldi\nmethylammonium benzoate\n402-610-6\n113694-52-3\nSkin Corr. 1B\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH302\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH302\nH410\n612-096-00-7\n4,4'-carbonimidoylbis[N, N-dimethylaniline]\n207-762-5\n492-80-8\nCarc. 2\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 2\nH351\nH302\nH319\nH411\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH319\nH411\n612-097-00-2\nsalts of 4,4'-carbonimidoylbis[N, N-dimethylaniline]\n—\n—\nCarc. 2\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 2\nH351\nH302\nH319\nH411\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH319\nH411\nA\n612-098-00-8\nnitrosodipropylamine\n210-698-0\n621-64-7\nCarc. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH411\nCarc. 1B; H350: C ≥ 0,001 %\n612-099-00-3\n4-methyl-m-phenylenediamine;\n2,4-toluenediamine\n202-453-1\n95-80-7\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH341\nH361f***\nH301\nH312\nH373**\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH361f***\nH301\nH312\nH373**\nH317\nH411\n612-100-00-7\npropylenediamine\n201-155-9\n78-90-0\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH226\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH312\nH302\nH314\n612-101-00-2\nmethenamine;\nhexamethylenetetramine\n202-905-8\n100-97-0\nFlam. Sol. 2\nSkin Sens. 1\nH228\nH317\nGHS02\nGHS07\nWng\nH228\nH317\n612-102-00-8\nN, N-bis(3-aminopropyl)methylamine\n203-336-8\n105-83-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH331\nH311\nH302\nH314\nGHS06\nGHS05\nDgr\nH331\nH311\nH302\nH314\n612-103-00-3\nN, N,N',N'-tetramethylethylenediamine\n203-744-6\n110-18-9\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH225\nH332\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH332\nH302\nH314\n612-104-00-9\nhexamethylenediamine\n204-679-6\n124-09-4\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Corr. 1B\nH312\nH302\nH335\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH335\nH314\n612-105-00-4\n2-piperazin-1-ylethylamine\n205-411-0\n140-31-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH312\nH302\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\nH317\nH412\n612-106-00-X\n2,6-diethylaniline\n209-445-7\n579-66-8\nAcute Tox. 4 *\nH302\n—\nH302\n612-107-00-5\n1-phenylethylamine; [1]\nDL-α-methylbenzylamine [2]\n202-706-6 [1]\n210-545-8 [2]\n98-84-0 [1]\n618-36-0 [2]\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n612-108-00-0\n3-aminopropyltriethoxysilane\n213-048-4\n919-30-2\nAcute Tox. 4 *\nSkin Corr. 1B\nH302\nH314\nGHS05\nGHS07\nDgr\nH302\nH314\n612-109-00-6\nbis(2-dimethylaminoethyl)(methyl)amine\n221-201-1\n3030-47-5\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH311\nH302\nH314\nGHS06\nGHS05\nDgr\nH311\nH302\nH314\n612-110-00-1\n2,2'-dimethyl-4,4'-methylenebis(cyclohexylamine)\n229-962-1\n6864-37-5\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1A\nAquatic Chronic 2\nH331\nH311\nH302\nH314\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH311\nH302\nH314\nH411\n612-111-00-7\n2-methyl-m-phenylenediamine;\n2,6-toluenediamine\n212-513-9\n823-40-5\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH341\nH312\nH302\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH341\nH312\nH302\nH317\nH411\n612-112-00-2\np-anisidine;\n4-methoxyaniline\n203-254-2\n104-94-9\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSTOT RE 2 *\nAquatic Acute 1\nH330\nH310\nH300\nH373 **\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH310\nH300\nH373 **\nH400\n612-113-00-8\n6-methyl-2,4-bis(methylthio)phenylene-1,3-diamine\n403-240-8\n106264-79-3\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n612-114-00-3\nR, R-2-hydroxy-5-(1-hydroxy-2-(4-phenylbut-2-ylamino)ethyl)benzamide hydrogen 2,3-bis(benzoyloxy)succinate\n404-390-7\n—\nFlam. Sol. 1\nSkin Sens. 1\nAquatic Chronic 3\nH228\nH317\nH412\nGHS02\nGHS07\nWng\nH228\nH317\nH412\n612-115-00-9\ndimethyldioctadecylammonium hydrogen sulfate\n404-050-8\n123312-54-9\nEye Irrit. 2\nAquatic Chronic 4\nH319\nH413\nGHS07\nWng\nH319\nH413\n612-116-00-4\nC8-18 alkylbis(2-hydroxyethyl)ammonium bis(2-ethylhexyl)phosphate\n404-690-8\n68132-19-4\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH314\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH314\nH317\nH410\n612-117-00-X\nC12-14-tert-alkylamine, methylphosphonic acid salt\n404-750-3\n119415-07-5\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH302\nH314\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH411\n612-118-00-5\nA reaction mass of: (1,3-dioxo-2H-benz(de)isoquinolin-2-ylpropyl)hexadecyldimethylammonium 4-toluenesulfonate; (1,3-dioxo-2H-benz(de)isoquinolin-2-ylpropyl)hexadecyldimethylammonium bromide\n405-080-4\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n612-119-00-0\nbenzyldimethyloctadecylammonium 3-nitrobenzenesulfonate\n405-330-2\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n612-120-00-6\naclonifen (ISO);\n2-chloro-6-nitro-3-phenoxyaniline\n277-704-1\n74070-46-5\nCarc. 2\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH317\nH400\nH410\nGHS08\nGHS07\nGH09\nWng\nH351\nH317\nH410\nM = 100\nM = 10\n612-121-00-1\namines, polyethylenepoly-; HEPA\n268-626-9\n68131-73-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH314\nH317\nH410\n612-122-00-7\nhydroxylamine … %\n[> 55 % in aqueous solution]\n232-259-2\n7803-49-8\nUnst. Expl. Met. Corr. 1\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH200\nH290\nH351\nH312\nH302\nH373**\nH335\nH315\nH318\nH317\nH400\nGHS01\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH200\nH290\nH351\nH312\nH302\nH373**\nH335\nH315\nH318\nH317\nH400\nB\n612-122-01-4\nhydroxylamine …% [≤ 55 % in aqueous solution]\n232-259-2\n7803-49-8\nMet. Corr. 1\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH290\nH351\nH312\nH302\nH373**\nH335\nH315\nH318\nH317\nH400\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH290\nH351\nH312\nH302\nH373**\nH335\nH315\nH318\nH317\nH400\nB\n612-123-00-2\nhydroxylammonium chloride; hydroxylamine hydrochloride; [1] bis(hydroxylammonium) sulfate;\nhydroxylamine sulfate (2:1) [2]\n226-798-2 [1]\n233-118-8 [2]\n5470-11-1 [1]\n10039-54-0 [2]\nMet. Corr. 1\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH290\nH351\nH312\nH302\nH373**\nH319\nH315\nH317\nH400\nGHS05\nGHS08\nGHS07\nGHS09\nWng\nH290\nH351\nH312\nH302\nH373**\nH319\nH315\nH317\nH400\n612-124-00-8\nN,N,N-trimethylanilinium chloride\n205-319-0\n138-24-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nH311\nH301\nGHS06\nDgr\nH311\nH301\n612-125-00-3\n2-methyl-p-phenylenediamine;\n2,5-toluenediamine\n202-442-1\n95-70-5\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH332\nH312\nH317\nH411\nGHS06\nGHS09\nDgr\nH301\nH332\nH312\nH317\nH411\n612-126-00-9\ntoluene-2,4-diammonium sulphate;\n4-methyl-m-phenylenediamine sulfate\n265-697-8\n65321-67-7\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH301\nH312\nH319\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH301\nH312\nH319\nH317\nH411\n612-127-00-4\n3-aminophenol\n209-711-2\n591-27-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH302\nH411\nGHS07\nGHS09\nWng\nH332\nH302\nH411\n612-128-00-X\n4-aminophenol\n204-616-2\n123-30-8\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH332\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH341\nH332\nH302\nH410\n612-129-00-5\ndiisopropylamine\n203-558-5\n108-18-9\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH225\nH332\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH332\nH302\nH314\nSTOT SE 3; H335: C ≥ 5 %\n612-130-00-0\n2,6-diamino-3,5-diethyltoluene;\n4,6-diethyl-2-methyl-1,3-benzenediamine; [1]\n2,4-diamino-3,5-diethyltoluene;\n2,4-diethyl-6-methyl-1,3-benzenediamine; [2] diethylmethylbenzenediamine [3]\n218-255-3 [1]\n218-256-9 [2]\n270-877-4 [3]\n2095-01-4 [1]\n2095-02-5 [2]\n68479-98-1 [3]\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373 **\nH319\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH312\nH302\nH373 **\nH319\nH410\nC\n612-131-00-6\ndidecyldimethylammonium chloride\n230-525-2\n7173-51-5\nAcute Tox. 4 *\nSkin Corr. 1B\nH302\nH314\nGHS05\nGHS07\nDgr\nH302\nH314\n612-132-00-1\nN, N'-diphenyl-p-phenylenediamine;\nN, N'-diphenyl-1,4-benzenediamine\n200-806-4\n74-31-7\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n612-133-00-7\n(4-ammonio-m-tolyl)ethyl(2-hydroxyethyl)ammonium sulphate;\n4-(N-ethyl-N-2-hydroxyethyl)-2-methylphenylenediamine sulphate\n247-162-0\n25646-77-9\nAcute Tox. 3 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH373 **\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH373 **\nH317\nH410\n612-134-00-2\nN-(2-(4-amino-N-ethyl-m-toluidino)ethyl)methanesulphonamide sesquisulphate;\n4-(N-ethyl-N-2-methanesulphonylaminoethyl)-2-methylphenylenediamine sesquisulphate monohydrate\n247-161-5\n25646-71-3\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n612-135-00-8\nN-2-naphthylaniline;\nN-phenyl-2-naphthylamine\n205-223-9\n135-88-6\nCarc. 2\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH351\nH319\nH315\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH351\nH319\nH315\nH317\nH411\n612-136-00-3\nN-isopropyl-N'-phenyl-p-phenylenediamine\n202-969-7\n101-72-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nSkin Sens. 1; H317:C ≥0,1 %\n612-137-00-9\n4-chloroaniline\n203-401-0\n106-47-8\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH331\nH311\nH301\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH311\nH301\nH317\nH410\n612-138-00-4\nfuralaxyl (ISO);\nmethyl N-(2,6-dimethylphenyl)-N-(2-furylcarbonyl)-DL-alaninate\n260-875-1\n57646-30-7\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n612-139-00-X\nmefenacet (ISO);\n2-(benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide\n277-328-8\n73250-68-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-140-00-5\nquaternary ammonium compounds, benzyl-C8-18-alkyldimethyl, chlorides\n264-151-6\n63449-41-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nH312\nH302\nH314\nH400\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH314\nH400\n612-141-00-0\n4,4'-methylenebis(2-ethylaniline);\n4,4'-methylenebis(2-ethylbenzeneamine)\n243-420-1\n19900-65-3\nCarc. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH410\n612-142-00-6\nbiphenyl-2-ylamine\n201-990-9\n90-41-5\nCarc. 2\nAcute Tox. 4 * Aquatic Chronic 3\nH351\nH302\nH412\nGHS08\nGHS07\nWng\nH351\nH302\nH412\n612-143-00-1\nN5,N5-diethyltoluene-2,5-diamine monohydrochloride;\n4-diethylamino-2-methylaniline monohydrochloride\n218-130-3\n2051-79-8\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH319\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH319\nH317\nH410\n612-144-00-7\nflumetralin (ISO);\nN-(2-chloro-6-fluorobenzyl)-N-ethyl-α, α,α-trifluoro-2,6-dinitro-p-toluidine\n—\n62924-70-3\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH317\nH410\n612-145-00-2\no-phenylenediamine\n202-430-6\n95-54-5\nCarc. 2\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH341\nH301\nH332\nH312\nH319\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH341\nH301\nH332\nH312\nH319\nH317\nH410\n612-146-00-8\no-phenylenediamine dihydrochloride\n210-418-7\n615-28-1\nCarc. 2\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH341\nH301\nH332\nH312\nH319\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH341\nH301\nH332\nH312\nH319\nH317\nH410\n612-147-00-3\nm-phenylenediamine\n203-584-7\n108-45-2\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH331\nH311\nH301\nH319\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH331\nH311\nH301\nH319\nH317\nH410\n612-148-00-9\nm-phenylenediamine dihydrochloride\n208-790-0\n541-69-5\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH331\nH311\nH301\nH319\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH331\nH311\nH301\nH319\nH317\nH410\n612-149-00-4\n1,3-diphenylguanidine\n203-002-1\n102-06-7\nRepr. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 2\nH361f ***\nH302\nH319\nH335\nH315\nH411\nGHS08\nGHS07\nGHS09\nWng\nH361f ***\nH302\nH319\nH335\nH315\nH411\n612-151-00-5\nmethyl-phenylene diamine;\ndiaminotoluene;\n[technical product — reaction mass of 4-methyl-m-phenylene diamine (EC No 202-453-1) and 2-methyl-m-phenylene diamine (EC No 212-513-9)]\n—\n—\nCarc. 1B Muta. 2\nRepr. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH341\nH361f***\nH301\nH312\nH373**\nH319\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH361f***\nH301\nH312\nH373**\nH319\nH317\nH411\n612-152-00-0\nN, N-diethyl-N',N'-dimethylpropan-1,3-diyl-diamine\n406-610-7\n62478-82-4\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1A\nAquatic Chronic 3\nH226\nH332\nH302\nH373 **\nH314\nH412\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH226\nH332\nH302\nH373 **\nH314\nH412\n612-153-00-6\n4-[N-ethyl-N-(2-hydroxyethyl)amino]-1-(2-hydroxyethyl)amino-2-nitrobenzene, monohydrochloride\n407-020-2\n132885-85-9\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n612-154-00-1\n6'-(isobutylethylamino)-3'-methyl-2'-phenylamino-spiro[isobenzo-2-oxofuran-7,9'-[9H]-xanthene]\n410-890-6\n95235-29-3\nAquatic Chronic 4\nH413\n—\nH413\n612-155-00-7\n2'-anilino-6'-((3-ethoxypropyl)ethylamino)-3'-methylspiro(isobenzo-3-oxofuran)-1-(1H)-9'-xanthene\n411-730-8\n93071-94-4\nAquatic Chronic 4\nH413\n—\nH413\n612-156-00-2\nreaction mass of: trihexadecylmethylammonium chloride; dihexadecyldimethylammonium chloride\n405-620-9\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n612-157-00-8\n(Z)-1-benzo[b]thien-2-ylethanone oxime hydrochloride\n410-780-8\n—\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH373 **\nH318\nH317\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH373 **\nH318\nH317\nH411\n612-158-00-3\nreaction mass of: bis(5-dodecyl-2-hydroxybenzald-oximate) copper (II) C12-alkyl group is branched;\n4-dodecylsalicylaldoxime\n410-820-4\n—\nAquatic Chronic 4\nH413\n—\nH413\n612-159-00-9\nreaction products of: trimethylhexamethylene diamine (a mixture of 2,2,4-trimethyl-1,6-hexanediamine and 2,4,4-trimethyl-1,6-hexanediamine, EINECS listed), Epoxide 8 (mono[(C10-C16-alkyloxy)methyl]oxirane derivatives) and p-toluene-sulfonic acid\n410-880-1\n—\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH410\n612-160-00-4\np-toluidine;\n4-aminotoluene; [1]\ntoluidinium chloride; [2]\ntoluidine sulphate (1:1) [3]\n203-403-1 [1]\n208-740-8 [2]\n208-741-3 [3]\n106-49-0 [1]\n540-23-8 [2]\n540-25-0 [3]\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH351\nH331\nH311\nH301\nH319\nH317\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH351\nH331\nH311\nH301\nH319\nH317\nH400\n612-161-00-X\n2,6-xylidine;\n2,6-dimethylaniline\n201-758-7\n87-62-7\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 2\nH351\nH332\nH312\nH302\nH335\nH315\nH411\nGHS08\nGHS07\nGHS09\nWng\nH351\nH332\nH312\nH302\nH335\nH315\nH411\n612-162-00-5\ndimethyldioctadecylammonium chloride;\nDODMAC\n203-508-2\n107-64-2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n612-163-00-0\nmetalaxyl-M (ISO);\nmefenoxam;\n(R)-2-[(2,6-dimethylphenyl)-methoxyacetylamino]propionic acid methyl ester\n—\n70630-17-0\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n612-164-00-6\n2-butyl-2-ethyl-1,5-diaminopentane\n412-700-7\n137605-95-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH312\nH302\nH373 **\nH314\nH317\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH312\nH302\nH373 **\nH314\nH317\nH412\n612-165-00-1\nN,N'-diphenyl-N,N'-bis(3-methylphenyl)-(1,1'-diphenyl)-4,4'-diamine\n413-810-8\n65181-78-4\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-166-00-7\nreaction mass of: cis-(5-ammonium-1,3,3-trimethyl)-cyclohexanemethylammonium phosphate (1:1);\ntrans-(5-ammonium-1,3,3-trimethyl)-cyclohexanemethylammonium phosphate (1:1)\n411-830-1\n114765-88-7\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n612-167-00-2\n5-acetyl-3-amino-10,11-dihydro-5H-dibenz[b, f]azepine-hydrochloride\n410-490-1\n—\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH373 **\nH318\nH317\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH373 **\nH318\nH317\nH411\n612-168-00-8\n3,5-dichloro-2,6-difluoropyrdine-4-amine\n220-630-1\n2840-00-8\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Chronic 2\nH312\nH302\nH411\nGHS07\nGHS09\nWng\nH312\nH302\nH411\n612-169-00-3\nbis(N-methyl-N-phenylhydrazine)sulfate\n423-170-1\n618-26-8\nFlam. Liq. 2\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH372**\nH302\nH318\nH317\nH400\nH410\nGHS02\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH372**\nH302\nH318\nH317\nH410\n612-170-00-9\n4-chlorophenyl cyclopropyl ketone O-(4-aminobenzyl)oxime\n405-260-2\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n612-171-00-4\nN,N,N',N'-tetraglycidyl-4,4'-diamino-3,3'-diethyldiphenylmethane\n410-060-3\n130728-76-6\nMuta. 2\nSkin Sens. 1\nAquatic Chronic 2\nH341\nH317\nH411\nGHS08\nGHS09\nWng\nH341\nH317\nH411\n612-172-00-X\n4,4'-methylenebis(N,N'-dimethylcyclohexanamine\n412-840-9\n13474-64-1\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1A\nAquatic Chronic 3\nH302\nH373 **\nH314\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH373 **\nH314\nH412\n612-173-00-5\nlithium 1-amino-4-(4-tert-butylanilino)anthraquinone-2-sulfonate\n411-140-0\n125328-86-1\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n612-174-00-0\n4,4-dimethoxybutylamine\n407-690-6\n19060-15-2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\nH412\n612-175-00-6\n2-(O-aminooxy)ethylamine dihydrochloride\n412-310-7\n37866-45-8\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n612-176-00-1\npolymer of 1,3-dibromopropane and N,N-diethyl-N',N'-dimethyl-1,3-propanediamine\n410-570-6\n143747-73-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n612-177-00-7\n2-naphthylamino-6-sulfomethylamide\n412-120-4\n104295-55-8\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH373 **\nH317\nH411\nGHS08\nGHS09\nWng\nH373 **\nH317\nH411\n612-178-00-2\n1,4,7,10-tetraazacyclododecane disulfate\n412-080-8\n112193-77-8\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nAquatic Chronic 3\nH302\nH335\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH335\nH318\nH412\n612-179-00-8\n1-(2-propenyl)pyridinium chloride\n412-740-5\n25965-81-5\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n612-180-00-3\n3-aminobenzylamine\n412-230-2\n4403-70-7\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH302\nH314\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH411\n612-181-00-9\n2-phenylthioaniline\n413-030-8\n1134-94-7\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n612-182-00-4\n1-ethyl-1-methylmorpholinium bromide\n418-210-1\n65756-41-4\nMuta. 2\nH341\nGHS08\nWng\nH341\n612-183-00-X\n1-ethyl-1-methylpyrrolidinium bromide\n418-200-5\n69227-51-6\nMuta. 2\nH341\nGHS08\nWng\nH341\n612-184-00-5\n6'-(dibutylamino)-3'-methyl-2'-(phenylamino)spiro[isobenzofuran-1(3H),9-(9H)-xanthen]-3-one\n403-830-5\n89331-94-2\nAquatic Chronic 3\nH412\n—\nH412\n612-185-00-0\n1-[3-[4-((heptadecafluorononyl)oxy)-benzamido]propyl]-N, N,N-trimethylammonium iodide\n407-400-8\n59493-72-0\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n612-186-00-6\nbis(N-(7-hydroxy-8-methyl-5-phenylphenazin-3-ylidene)dimethylammonium) sulfate\n406-770-8\n149057-64-7\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH318\nH317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH373 **\nH318\nH317\nH410\n612-187-00-1\n2,3,4-trifluoroaniline\n407-170-9\n3862-73-5\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH312\nH302\nH373 **\nH315\nH318\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH373 **\nH315\nH318\nH411\n612-188-00-7\n4,4'-(9H-fluoren-9-ylidene)bis(2-chloroaniline)\n407-560-9\n107934-68-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-189-00-2\n4-amino-2-(aminomethyl)phenol dihydrochloride\n412-510-4\n135043-64-0\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n612-190-00-8\n4,4'-methylenebis(2-isopropyl-6-methylaniline)\n415-150-6\n16298-38-7\nSTOT RE 2 *\nAquatic Chronic 2\nH373 **\nH411\nGHS08\nGHS09\nWng\nH373 **\nH411\n612-191-00-3\npolymer of allylamine hydrochloride\n415-050-2\n71550-12-4\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n612-192-00-9\n2-isopropyl-4-(N-methyl)aminomethylthiazole\n414-800-6\n154212-60-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH312\nH302\nH315\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH315\nH318\nH411\n612-193-00-4\n3-methylaminomethylphenylamine\n414-570-7\n18759-96-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH314\nH317\nH410\n612-194-00-X\n2-hydroxy-3-[(2-hydroxyethyl)-[2-(1-oxotetradecyl)amino]ethyl]amino]-N,N,N-trimethyl-1-propanammonium chloride\n414-670-0\n141890-30-4\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n612-195-00-5\nbis[tributyl 4-(methylbenzyl)ammonium] 1,5-naphthalenedisulfonate\n415-210-1\n160236-81-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH302\nH318\nH410\n612-196-00-0\n4-chloro-o-toluidine; [1]\n4-chloro-o-toluidine hydrochloride [2]\n202-441-6[1]\n221-627-8[2]\n95-69-2[1]\n3165-93-3[2]\nCarc. 1B\nMuta. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH341\nH331\nH311\nH301\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH341\nH331\nH311\nH301\nH410\n612-197-00-6\n2,4,5-trimethylaniline; [1]\n2,4,5-trimethylaniline hydrochloride [2]\n205-282-0[1]-[2]\n137-17-7 [1]\n21436-97-5[2]\nCarc. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH350\nH331\nH311\nH301\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH331\nH311\nH301\nH411\n612-198-00-1\n4,4'-thiodianiline and its salts\n205-370-9\n139-65-1\nCarc. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH411\n612-199-00-7\n4,4'-oxydianiline and its salts;\np-aminophenyl ether\n202-977-0\n101-80-4\nCarc. 1B Muta.\n1B Repr. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 2\nH350\nH340\nH361f ***\nH331\nH311\nH301\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH350\nH340\nH361f ***\nH331\nH311\nH301\nH411\n612-200-00-0\n2,4-diaminoanisole;\n4-methoxy-m-phenylenediamine; [1]\n2,4-diaminoanisole sulphate [2]\n210-406-1 [1]\n254-323-9 [2]\n615-05-4 [1]\n39156-41-7 [2]\nCarc. 1B Muta. 2\nAcute Tox. 4 *\nAquatic Chronic 2\nH350\nH341\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH341\nH302\nH411\n612-201-00-6\nN,N,N',N'-tetramethyl-4,4'-methylendianiline\n202-959-2\n101-61-1\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n612-202-00-1\n3,4-dichloroaniline\n202-448-4\n95-76-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH311\nH301\nH318\nH317\nH410\n612-203-00-7\nC8-10 alkyl dimethyl hydroxyethyl ammoniumchloride (chain < C8: <3 %, chain = C8: 15 %-70 %, chain = C10: 30 %- 85 %, chain > C10: <3 %)\n417-360-3\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nH312\nH302\nH315\nGHS07\nWng\nH312\nH302\nH315\n612-204-00-2\nC.I. Basic Violet 3;\n4-[4,4'-bis(dimethylamino) benzhydrylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammonium chloride\n208-953-6\n548-62-9\nCarc. 2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH318\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH351\nH302\nH318\nH410\n612-205-00-8\nC.I. Basic Violet 3 with ≥ 0,1 % of Michler's ketone (EC no.202-027-5)\n208-953-6\n548-62-9\nCarc. 1B\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH302\nH318\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH350\nH302\nH318\nH410\n612-206-00-3\nfamoxadone (ISO);\n3-anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidine-2,4-dione\n—\n131807-57-3\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH400\nH410\nGHS08\nGHS09\nWng\nH373 **\nH410\n612-207-00-9\n4-ethoxyaniline;\np-phenetidine\n205-855-5\n156-43-4\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH341\nH332\nH312\nH302\nH319\nH317\nGHS08\nGHS07\nWng\nH341\nH332\nH312\nH302\nH319\nH317\n612-208-00-4\nN-methylbenzene-1,2-diammonium hydrogen phosphate\n424-460-0\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n612-209-00-X\n6-methoxy-m-toluidine;\np-cresidine\n204-419-1\n120-71-8\nCarc. 1B\nAcute Tox. 4 *\nH350\nH302\nGHS08\nGHS07\nDgr\nH350\nH302\n612-210-00-5\n5-nitro-o-toluidine; [1]\n5-nitro-o-toluidine hydrochloride [2]\n202-765-8 [1]\n256-960-8 [2]\n99-55-8 [1]\n51085-52-0 [2]\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nAquatic Chronic 3\nH351\nH331\nH311\nH301\nH412\nGHS06\nGHS08\nDgr\nH351\nH331\nH311\nH301\nH412\n612-211-00-0\nN-[(benzotriazole-1-yl)methyl)]4-carboxy-benzenesulfonamide\n416-470-9\n170292-97-4\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n612-212-00-6\n2,6-dichloro-4-trifluoromethylaniline\n416-430-0\n24279-39-8\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH315\nH317\nH410\n612-213-00-1\nisobutylidene-(2-(2-isopropyl-4,4-dimethyloxazolidine-3-yl)-1,1-dimethylethyl)amine\n419-850-2\n148348-13-4\nSkin Corr. 1B\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\n612-214-00-7\n4-(2,2-diphenylethenyl)-N,N-di-phenylbenzenamine\n421-390-2\n89114-90-9\nAquatic Chronic 4\nH413\n—\nH413\n612-215-00-2\n3-chloro-2-(isopropylthio)aniline\n421-700-6\n179104-32-6\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n612-216-00-8\n1-amino-1-cyanamino-2,2-dicyanoethylene, sodium salt\n425-870-2\n19450-38-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n612-217-00-3\n1-methoxy-2-propylamine\n422-550-4\n37143-54-7\nFlam. Liq. 2\nSkin Corr. 1B\nAcute Tox. 4 *\nAquatic Chronic 3\nH225\nH314\nH302\nH412\nGHS02\nGHS05\nGHS07\nDgr\nH225\nH314\nH302\nH412\n612-219-00-4\n(2-hydroxy-3-(3,4-dimethyl-9-oxo-10-thiaanthracen-2-yloxy)propyl)trimethylammonium chloride\n402-200-7\n—\nAquatic Chronic 3\nH412\n—\nH412\n612-220-00-X\nN-nitro-N-(3-methyl-3,6-dihydro-2H-1,3,5-oxadiazin-4-yl)amine\n431-060-1\n153719-38-1\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n612-221-00-5\n2-amino-4-(trifluoromethyl)benzenethiol hydrochloride\n429-560-8\n4274-38-8\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nH314\nH332\nH312\nH302\nH373**\nH317\nH400\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH314\nH332\nH312\nH302\nH373**\nH317\nH400\n612-222-00-0\ncis-1-(3-(4-fluorophenoxy)propyl)-3-methoxy-4-piperidinamine\n425-080-8\n104860-26-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373**\nH318\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH312\nH302\nH373**\nH318\nH410\n612-223-00-6\nN-benzyl-N-ethyl-(4-(5-nitro-benzo[c]isothiazol-3-ylazo)phenyl)amine\n425-300-2\n186450-73-7\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n612-224-00-1\nN2,N4,N6-tris{4-[(1,4-dimethylpentyl)amino]phenyl}-1,3,5-triazine-2,4,6-triamine\n426-150-0\n121246-28-4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n612-225-00-7\n1,4,7,10-tetraazacyclododecane\n425-450-9\n294-90-6\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH312\nH302\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH312\nH302\nH410\n612-226-00-2\n3-(2'-phenoxyethoxy)propylamine\n427-870-8\n6903-18-0\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH302\nH315\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH412\n612-227-00-8\nbenzyl-N-(2-(2-methoxyphenoxy)ethyl)amine hydrochloride\n428-290-8\n120606-08-8\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n612-228-00-3\nreaction mass of: N-(3-(trimethoxysilyl)propyl)ethylenediamine;\nN-benzyl-N-(3-(trimethoxysilyl)propyl)ethylenediamine; N-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine;\nN, N'-bis-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine; N, N,N'-tris-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine;\nN, N-bis-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine\n414-340-6\n—\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH226\nH332\nH312\nH302\nH371\nH318\nH317\nH412\nGHS02\nGHS05\nGHS08\nGHS07\nDgr\nH226\nH332\nH312\nH302\nH371\nH318\nH317\nH412\n612-229-00-9\nmepanipyrim;\n4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine\n—\n110235-47-7\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n612-230-00-4\nN,N-bis(cocoyl-2-oxypropyl)-N,N-dibutylammonium bromide\n431-530-4\n—\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n612-231-00-X\n3-((C12-18)-acylamino)-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-N,N-dimethyl-1-propanaminium chloride\n427-370-1\n164288-56-6\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n612-232-00-5\nreaction mass of: triisopropanolamine salt of 1-amino-4-(3-propionamidoanilino)anthraquinone-2-sulfonic acid; triisopropanolamine salt of 1-amino-4-[3,4-dimethyl-5-(2-hydroxyethylaminosulfonyl)anilino]anthraquinone-2-sulfonic acid\n430-410-9\n186148-38-9\nAquatic Chronic 3\nH412\n—\nH412\n612-237-00-2\nhydroxylammonium hydrogensulfate;\nhydroxylamine sulfate(1:1); [1]\nhydroxylamine phosphate; [2]\nhydroxylamine dihydrogenphos\nphate; [3] hydroxylamine 4-methylben\nzenesulfonate [4]\n233-154-4 [1]\n244-077-0 [2]\n242-818-2 [3]\n258-872-5 [4]\n10046-00-1 [1]\n20845-01-6 [2]\n19098-16-9 [3]\n53933-48-5 [4]\nExpl. 1.1\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH201\nH351\nH312\nH302\nH373**\nH319\nH315\nH317\nH400\nGHS01\nGHS08\nGHS07\nGHS09\nDgr\nH201\nH351\nH312\nH302\nH373**\nH319\nH315\nH317\nH400\nT\n612-238-00-8\n(3-chloro-2-hydroxypropyl)\ntrimethylammonium chloride …%\n222-048-3\n3327-22-8\nCarc. 2\nAquatic Chronic 3\nH351\nH412\nGHS08\nWng\nH351\nH412\nB\n612-239-00-3\nbiphenyl-3,3', 4,4'-tetrayltetraamine;\ndiaminobenzidine\n202-110-6\n91-95-2\nCarc. 1B Muta. 2\nH350\nH341\nGHS08\nDgr\nH350\nH341\n612-240-00-9\npyrimethanil (ISO);\nN-(4,6-dimethylpyrimidin-2-yl)aniline\n—\n53112-28-0\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-241-00-4\npiperazine hydrochloride; [1] piperazine dihydrochloride; [2] piperazine phosphate [3]\n228-042-7 [1]\n205-551-2 [2]\n217-775-8 [3]\n6094-40-2 [1]\n142-64-3 [2]\n1951-97-9 [3]\nRepr. 2\nEye Irrit. 2\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH361fd\nH319\nH315\nH334\nH317\nH412\nGHS08\nDgr\nH361fd\nH319\nH315\nH334\nH317\nH412\n612-242-00-X\ncyprodinil (ISO);\n4-cyclopropyl-6-methyl-N-phenylpyrimidin-2-amine\n—\n121552-61-2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM=10\n612-243-00-5\n(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine 2-hydroxy-2-phenylacetate\n420-560-3\n79617-97-3\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\nM=10\n612-244-00-0\n3-(piperazin-1-yl)-benzo[d]isothiazole hydrochloride\n421-310-6\n87691-88-1\nRepr. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f***\nH302\nH319\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361f***\nH302\nH319\nH317\nH410\n612-245-00-6\n2-ethylphenylhydrazine hydrochloride\n421-460-2\n19398-06-2\nCarc. 2\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH372**\nH302\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH372**\nH302\nH318\nH317\nH410\nM=10\n612-246-00-1\n(2-chloroethyl)(3-hydroxypropyl)ammonium chloride\n429-740-6\n40722-80-3\nCarc. 1B\nMuta. 1B\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH340\nH373**\nH317\nH412\nGHS08\nGHS07\nDgr\nH350\nH340\nH373**\nH317\nH412\n612-247-00-7\nN-[3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-hydroxy-4-nitrobenzenecarboximidamide\n423-530-8\n152828-23-4\nSTOT RE 1\nAcute Tox. 4 *\nAquatic Chronic 3\nH372** H302\nH412\nGHS08\nGHS07\nDgr\nH372**\nH302\nH412\n612-248-00-2\nreaction product of diphenylamine, phenothiazine, and alkenes, branched (C8-10, C9-rich)\n439-540-0\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n612-249-00-8\n4-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1,2-benzenediamine dihydrochloride\n425-030-5\n159939-85-2\nRepr. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH361f***\nH302\nH314\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH361f***\nH302\nH314\nH317\nH411\n612-250-00-3\nchloro-N, N-dimethylformiminium chloride\n425-970-6\n3724-43-4\nRepr. 1B\nAcute Tox. 4 *\nSkin Corr. 1A\nH360D***\nH302\nH314\nGHS05\nGHS08\nGHS07\nDgr\nH360D***\nH302\nH314\nEUH014\n612-251-00-9\ncis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride\n426-020-3\n51229-78-8\nFlam. Sol. 2\nRepr. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH228\nH361d***\nH302\nH315\nH317\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nWng\nH228\nH361d***\nH302\nH315\nH317\nH411\n612-252-00-4\nimidacloprid (ISO);\n1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine\n428-040-8\n138261-41-3\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n612-253-00-X\n7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing < 0,5 % formamide (EC No 200-842-0)]\n429-400-7\n199327-61-2\nAquatic Chronic 3\nH412\n—\nH412\n612-253-01-7\n7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing ≥ 0,5 % formamide (EC No 200-842-0)]\n429-400-7\n199327-61-2\nRepr. 1B\nAquatic Chronic 3\nH360D***\nH412\nGHS08\nDgr\nH360D***\nH412\n612-254-00-5\nreaction products of diisopropanolamine with formaldehyde (1:4)\n432-440-8\n220444-73-5\nCarc. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH351\nH302\nH314\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH302\nH314\nH317\nH411\n612-255-00-0\n1-(3-methoxypropyl)-4-piperidinamine\n431-950-8\n179474-79-4\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 3\nH312\nH302\nH314\nH412\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\nH412\n612-256-00-6\nbenzyl(S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyrate\n427-470-3\n137864-22-3\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n612-257-00-1\ntripropylammonium dihydrogenphosphate\n433-700-3\n35687-90-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n612-259-00-2\nN-ethyl-3-trimethoxysilyl-2-methyl-propanamine\n437-720-3\n227085-51-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n612-261-00-3\n3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)aniline\n441-190-9\n121451-05-6\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nM=10\n612-265-00-5\nbis(2-hydroxyethyl)-(2-hydroxypropyl)ammonium acetate\n444-360-0\n191617-13-7\nAquatic Chronic 3\nH412\n—\nH412\n612-266-00-0\n3-chloro-4-(3-fluorobenzyloxy)aniline\n445-590-4\n202197-26-0\nMuta. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH341\nH302\nH373**\nH410\n612-267-00-6\nbis(hydrogenated tallow C16-18-alkyl)hydroxylamine\n418-370-0\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n612-269-00-7\nreaction mass of: 1-[di(4-octylphenyl)aminomethyl]-5-methyl-1H-benzotriazole;\n1-[di(4-octylphenyl)aminomethyl]-4-methyl-1H-benzotriazole;\nreaction mass of: N-[(5-methyl-1H-benzotriazol-1-yl)methyl]-4-octyl-N-(4-octylphenyl)aniline;\nN-[(4-methyl-1H-benzotriazol-1yl)methyl]-4-octyl-N-(4-octylphenyl)aniline\n420-720-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n612-270-00-2\n(S)-azetidine-2-carboxylic acid\n4-cyanobenzylamide hydrochloride\n433-010-2\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n612-271-00-8\nreaction mass of: ethyl 2-((4-(5,6-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate;\nethyl 2-((4-(6,7-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate\n434-970-5\n160987-57-5\nAquatic Chronic 4\nH413\n—\nH413\n612-272-00-3\nammonium (η-6-2-(2-(1,2-dicarboxylatoethylamino)ethylamino)butane-1,4-dioato(4))iron(3+) monohydrate\n435-210-5\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-273-00-9\nalkyl(rapeseed oil), bis(2-hydroxyethyl)ammonium fluoride\n435-650-8\n—\nAcute Tox. 4 *\nSkin Corr. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH410\n612-274-00-4\n(R, S)-1-[2-amino-1(4-methoxyphenyl)ethyl]cyclohexanol acetate\n445-750-3\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n612-275-00-X\nfatty acids, C18-unsatd., dimers, reaction products with 1-piperazineethanamine and tall oil\n447-880-6\n206565-89-1\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\nM=10\n612-276-00-5\n1-amino-4-[(4-amino-2-sulfofenyl)amino]-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, disodium salt, reaction products with 2-[[3-[(4,6-dichloro-1,3,5-triazin-2-yl)ethylamino]phenyl]sulfonyl]ethyl hydrogen sulfate, sodium salts\n451-430-4\n500717-36-2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n612-277-00-0\nreaction mass of: 4-amino-3-(4-ethenesulfonyl-2-sulfonatophenylazo)-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonatooxyethanesulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)naphthalene-2,7-disulfonate potassium/sodium;\n4-amino-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonatooxyethanesulfonyl)phenylamino]1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-3-(2-sulfonato-4-(2-sulfonatooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate potassium/sodium\n451-440-9\n586372-44-3\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n612-278-00-6\nethidium bromide;\n3,8-diamino-1-ethyl-6-phenylphenantridinium bromide\n214-984-6\n1239-45-8\nMuta. 2\nAcute Tox. 2 *\nAcute Tox. 4 *\nH341\nH330\nH302\nGHS06\nGHS08\nDgr\nH341\nH330\nH302\n612-279-00-1\n(R, S)-2-amino-3,3-dimethylbutane amide\n447-860-7\n144177-62-8\nRepr. 2\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH361f*** H373** H319\nH315\nH317\nGHS08\nGHS07\nWng\nH361f*** H373**\nH319\nH315\nH317\n612-280-00-7\n3-amino-9-ethyl carbazole;\n9-ethylcarbazol-3-ylamine\n205-057-7\n132-32-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n612-281-00-2\nleucomalachite green; N, N,N',N'-tetramethyl-4,4'-benzylidenedianiline\n204-961-9\n129-73-7\nCarc. 2\nMuta. 2\nH351\nH341\nGHS08\nWng\nH351\nH341\n612-282-00-8\noctadecylamine\n204-695-3\n124-30-1\nAsp. Tox. 1\nSTOT RE 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH304\nH373 (gastrointestinal tract, liver, immune\nsystem)\nH315\nH318\nH400\nH410\nGHS05\nGHS08\nGHS09\nDgr\nH304\nH373 (gastrointestinal tract, liver, immune\nsystem)\nH315\nH318\nH410\nM = 10\nM = 10\n612-283-00-3\n(Z)-octadec-9-enylamine\n204-015-5\n112-90-3\nAcute Tox. 4\nAsp Tox. 1\nSTOT SE 3\nSTOT RE 2\nSkin Corr. 1B Aquatic Acute 1\nAquatic Chronic 1\nH302\nH304\nH335\nH373 (gastro-intestinal tract, liver, immune system)\nH314\nH400\nH410\nGHS05\nGHS07\nGHS08\nGHS09\nDgr\nH302\nH304\nH335\nH373 (gastro-intestinal tract, liver, immune system)\nH314\nH410\nM = 10\nM = 10\n612-284-00-9\namines, hydrogenated tallow alkyl\n262-976-6\n61788-45-2\nAsp Tox. 1\nSTOT RE 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH304\nH373 (gastro-intestinal tract, liver, immune system)\nH315\nH318\nH400\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH304\nH373 (gastro-intestinal tract, liver, immune system)\nH315\nH318\nH410\nM = 10\nM = 10\n612-285-00-4\namines, coco alkyl\n262-977-1\n61788-46-3\nAcute Tox. 4\nAsp. Tox. 1\nSTOT SE 3\nSTOT RE 2\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH304\nH335\nH373 (gastro-intestinal tract, liver, immune system)\nH314\nH400\nH410\nGHS05\nGHS07\nGHS08\nGHS09\nDgr\nH302\nH304\nH335\nH373 (gastro-intestinal tract, liver, immune system)\nH314\nH410\nM = 10\nM = 10\n612-286-00-X\namines, tallow alkyl\n263-125-1\n61790-33-8\nAcute Tox. 4\nAsp. Tox. 1\nSTOT RE 2\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH304\nH373 (gastro-intestinal tract, liver, immune system)\nH314\nH400\nH410\nGHS05\nGHS07\nGHS08\nGHS09\nDgr\nH302\nH304\nH373 (gastro-intestinal tract, liver, immune system)\nH314\nH410\nM = 10\nM = 10\n612-287-00-5\nfluazinam (ISO); 3-chloro-N-[3- chloro-2,6-dinitro-4-(trifluor omethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine\n—\n79622-59-6\nRepr. 2\nAcute Tox. 4\nEye Dam. 1\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH332\nH318\nH317\nH400\nH410\nGHS08\nGHS07\nGHS05\nGHS09\nDgr\nH361d\nH332\nH318\nH317\nH410\nM = 10\nM = 10\n613-001-00-1\nethyleneimine; aziridine\n205-793-9\n151-56-4\nFlam. Liq. 2\nCarc. 1B\nMuta. 1B\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nSkin Corr. 1B\nAquatic Chronic 2\nH225\nH350\nH340\nH330\nH310\nH300\nH314\nH411\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH225\nH350\nH340\nH330\nH310\nH300\nH314\nH411\nD\n613-002-00-7\npyridine\n203-809-9\n110-86-1\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH225\nH332\nH312\nH302\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\n*\n613-003-00-2\n1,2,3,4-tetranitrocarbazole\n—\n6202-15-9\nExpl. 1.1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH201\nH332\nH312\nH302\nGHS01\nGHS07\nDgr\nH201\nH332\nH312\nH302\n613-004-00-8\ncrimidine (ISO);2-chloro-6-methylpyrimidin-4- yldimethylamine\n208-622-6\n535-89-7\nAcute Tox. 2 *\nH300\nGHS06\nDgr\nH300\n613-007-00-4\ndesmetryne (ISO);6-isopropylamino-2-methylamino-4-methylthio-1,3,5- triazine\n213-800-1\n1014-69-3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n613-008-00-X\ndazomet (ISO);tetrahydro-3,5-dimethyl-1,3,5- thiadiazine-2-thione\n208-576-7\n533-74-4\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH410\n613-009-00-5\n2,4,6-trichloro-1,3,5-triazine; cyanuric chloride\n203-614-9\n108-77-0\nAcute Tox. 2 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH330\nH302\nH314\nH317\nGHS06\nGHS05\nDgr\nH330\nH302\nH314\nH317\nEUH014\nSTOT SE 3; H335: C ≥ 5 %\n613-010-00-0\nametryn (ISO);N-ethyl-N'-isopropyl-6-(methyl-thio)-1,3,5-triazine-2,4-diamine\n212-634-7\n834-12-8\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM = 100\n613-011-00-6\namitrole (ISO);1,2,4-triazol-3-ylamine\n200-521-5\n61-82-5\nRepr. 2\nSTOT RE 2 *\nAquatic Chronic 2\nH361d *** H373 **\nH411\nGHS08\nGHS09\nWng\nH361d *** H373 **\nH411\n613-012-00-1\nbentazone (ISO);3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide\n246-585-8\n25057-89-0\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH319\nH317\nH412\nGHS07\nWng\nH302\nH319\nH317\nH412\n613-013-00-7\ncyanazine (ISO);2-(4-chloro-6-ethylamino-1,3,5- triazine-2-ylamino)-2-methylpropionitrile\n244-544-9\n21725-46-2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-014-00-2\nethoxyquin (ISO); 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline\n202-075-7\n91-53-2\nAcute Tox. 4*\nH302\nGHS07\nWng\nH302\n613-015-00-8\nfenazaflor (ISO); phenyl 5,6-dichloro-2-trifluor-omethylbenzimidazole-1-carboxylate\n238-134-9\n14255-88-0\nAcute Tox. 4*\nAcute Tox. 4*\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n613-016-00-3\nfuberidazole (ISO);2-(2-furyl-)-1H-benzimidazole\n223-404-0\n3878-19-1\nCarc. 2\nAcute Tox. 4\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH373 (heart)\nH317\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH351\nH302\nH373 (heart)\nH317\nH410\nM = 1\n613-017-00-9\nbis(8-hydroxyquinolinium) sulphate\n205-137-1\n134-31-6\nAcute Tox. 4*\nH302\nGHS07\nWng\nH302\n613-018-00-4\nmorfamquat (ISO); 1,1'-bis(3,5-dimethylmorpholinocarbonylmethyl)-4,4'-bipyridilium ion\n7411-47-4\nAcute Tox. 4*\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 3\nH302\nH319\nH335\nH315\nH412\nGHS07\nWng\nH302\nH319\nH335\nH315\nH412\n613-019-00-X\nthioquinox(ISO); 2-thio-1,3-dithiolo(4,5,b)quinoxaline\n202-272-8\n93-75-4\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n613-020-00-5\ntridemorph (ISO); 2,6-dimethyl-4-tridecylmorpholine\n246-347-3\n24602-86-6\nRepr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH360D *** H332\nH302\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360D *** H332\nH302\nH315\nH410\n613-021-00-0\ndithianon (ISO); 5,10-dihydro-5,10-dioxonaphtho(2,3-b)(1,4)dithiazine-2,3- dicarbonitrile\n222-098-6\n3347-22-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-022-00-6\npyrethrins including cinerins, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\nA\n613-023-00-1\n2-methyl-4-oxo-3-(penta-2,4- dienyl)cyclopent-2-enyl [1R- [1α[S*(Z)],3β]]-chrysanthemate; pyrethrin I\n204-455-8\n121-21-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\n613-024-00-7\n2-methyl-4-oxo-3-(penta-2,4- dienyl)cyclopent-2-enyl[1R- [1α[S*(Z)](3β)]]-3-(3-methoxy-2-methyl-3-oxoprop-1-enyl)-2,2- dimethylcyclopropanecar boxylate; pyrethrin II\n204-462-6\n121-29-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\n613-025-00-2\ncinerin I; 3-(but-2-enyl)-2-methyl-4- oxocyclopent-2-enyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate\n246-948-0\n25402-06-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-026-00-8\ncinerin II; 3-(but-2-enyl)-2-methyl-4- oxocyclopent-2-enyl 2,2-dimethyl-3-(3-methoxy-2-methyl-3-oxoprop-1-enyl)cyclopropanecarboxylate\n204-454-2\n121-20-0\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-027-00-3\npiperidine\n203-813-0\n110-89-4\nFlam. Liq. 2\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nH225\nH331\nH311\nH314\nGHS02\nGHS06\nGHS05\nDgr\nH225\nH331\nH311\nH314\n*\n613-028-00-9\nmorpholine\n203-815-1\n110-91-8\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH226\nH332\nH312\nH302\nH314\nGHS02\nGHS05\nGHS07\nDg\nH226\nH332\nH312\nH302\nH314\n613-029-00-4\ndichloro-1,3,5-triazinetrione; dichloroisocyanuric acid\n220-487-5\n2782-57-2\nOx. Sol. 2\nAcute Tox. 4 * Eye Irrit. 2\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH302\nH319\nH335\nH400\nH410\nGHS03\nGHS07\nGHS09\nDgr\nH272\nH302\nH319\nH335\nH410\nEUH031\nT\n613-030-00-X\ntroclosene potassium; [1] troclosene sodium [2]\n218-828-8 [1]\n220-767-7 [2]\n2244-21-5 [1]\n2893-78-9 [2]\nOx. Sol. 2\nAcute Tox. 4 * Eye Irrit. 2\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH302\nH319\nH335\nH400\nH410\nGHS03\nGHS07\nGHS09\nDgr\nH272\nH302\nH319\nH335\nH410\nEUH031\n*\nSTOT SE 3;\nH335: C ≥ 10 % EUH031: C ≥10 %\nG\n613-030-01-7\ntroclosene sodium, dihydrate\n220-767-7\n51580-86-0\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH335\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH335\nH410\nEUH031\n613-031-00-5\nsymclosene; trichloroisocyanuric acid; trichloro-1,3,5-triazinetrion\n201-782-8\n87-90-1\nOx. Sol. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH302\nH319\nH335\nH400\nH410\nGHS03\nGHS07\nGHS09\nDgr\nH272\nH302\nH319\nH335\nH410\nEUH031\n613-032-00-0\nmethyl-2,3,5,6-tetrachloro-4- pyridylsulphone;2,3,5,6-tetrachloro-4-(methylsulphonyl)pyridine\n236-035-5\n13108-52-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH312\nH302\nH319\nH317\nGHS07\nWng\nH312\nH302\nH319\nH317\n613-033-00-6\n2-methylaziridine; propyleneimine\n200-878-7\n75-55-8\nFlam. Liq. 2\nCarc. 1B\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nEye Dam. 1\nAquatic Chronic 2\nH225\nH350\nH330\nH310\nH300\nH318\nH411\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH225\nH350\nH330\nH310\nH300\nH318\nH411\nCarc. 1B;\nH350: C ≥ 0,01 %\n613-034-00-1\n1,2-dimethylimidazole\n217-101-2\n1739-84-0\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nH302\nH315\nH318\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\n613-035-00-7\n1-methylimidazole\n210-484-7\n616-47-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n613-036-00-2\n2-methylpyridine; 2-picoline\n203-643-7\n109-06-8\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nH226\nH332\nH312\nH302\nH319\nH335\nGHS02\nGHS07\nWng\nH226\nH332\nH312\nH302\nH319\nH335\n613-037-00-8\n4-methylpyridine; 4-picoline\n203-626-4\n108-89-4\nFlam. Liq. 3\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH226\nH311\nH332\nH302\nH319\nH335\nH315\nGHS02\nGHS06\nDgr\nH226\nH311\nH332\nH302\nH319\nH335\nH315\n613-038-00-3\n6-phenyl-1,3,5-triazine-2,4- diyldiamine; 6-phenyl-1,3,5-triazine-2,4-diamine; benzoguanamine\n202-095-6\n91-76-9\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n613-039-00-9\nethylene thiourea; imidazolidine-2-thione; 2-imidazoline-2-thiol\n202-506-9\n96-45-7\nRepr. 1B\nAcute Tox. 4 *\nH360D *** H302\nGHS08\nGHS07\nDgr\nH360D *** H302\n613-040-00-4\nazaconazole (ISO);1-{[2-(2,4-dichlorophenyl)-1,3- dioxolan-2-yl]methyl}-1H-1,2.4- triazole\n262-102-3\n60207-31-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n613-041-00-X\nmorpholine-4-carbonyl chloride\n239-213-0\n15159-40-7\nCarc. 2\nEye Irrit. 2\nSkin Irrit. 2\nH351\nH319\nH315\nGHS08\nWng\nH351\nH319\nH315\nEUH014\n613-043-00-0\nimazalil sulphate (ISO) powder; 1-[2-(allyloxy)ethyl-2-(2,4- dichlorophenyl)]-1H-imid azolium hydrogen sulphate; [1](±)-1-[2-(allyloxy)ethyl-2-(2,4- dichlorophenyl)]-1H-imid azolium hydrogen sulphate [2]\n261-351-5 [1]\n281-291-3 [2]\n58594-72-2 [1]\n83918-57-4 [2]\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n613-043-01-8\nimazalil sulphate (ISO), aqueous solution; 1-[2-(allyloxy)ethyl-2-(2,4- dichlorophenyl)]-1H-imidazolium hydrogen sulphate; [1] (±)-1-[2-(allyloxy)ethyl-2-(2,4- dichlorophenyl)]-1H-imid azolium hydrogen sulphate [2]\n261-351-5 [1]\n281-291-3 [2]\n58594-72-2 [1]\n83918-57-4 [2]\nAcute Tox. 4 * Skin Corr. 1B Skin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nWng\nH302\nH314\nH317\nH410\nSkin Corr. 1B; H314: C ≥ 50 % Skin Irrit. 2; H315: 30 % ≤ C < 50 %\nEye Dam. 1; H318: 15 % ≤ C < 50 %\nEye Irrit. 2; H319: 5 % ≤ C < 15 %\n613-044-00-6\ncaptan (ISO);1,2,3,6-tetrahydro-N-(trichloromethylthio)phthalimide\n205-087-0\n133-06-2\nCarc. 2\nAcute Tox. 3 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH351\nH331\nH318\nH317\nH400\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH351\nH331\nH318\nH317\nH400\nM=10\n613-045-00-1\nfolpet (ISO);N-(trichloromethylthio)phthalimide\n205-088-6\n133-07-3\nCarc. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH351\nH332\nH319\nH317\nH400\nGHS08\nGHS07\nGHS09\nWng\nH351\nH332\nH319\nH317\nH400\nM=10\n613-046-00-7\ncaptafol (ISO);1,2,3,6-tetrahydro-N-(1,1,2,2- tetrachloroethylthio)phthalimide\n219-363-3\n2425-06-1\nCarc. 1B Skin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH317\nH410\n613-047-00-2\n1-dimethylcarbamoyl-5-methyl pyrazol-3-yl dimethylcarbamate; dimetilan (ISO)\n211-420-0\n644-64-4\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH312\nH410\n613-048-00-8\ncarbendazim (ISO);methyl benzimidazol-2-ylcarbamate\n234-232-0\n10605-21-7\nMuta. 1B Repr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH340\nH360FD H400\nH410\nGHS08\nGHS09\nDgr\nH340\nH360FD H410\n613-049-00-3\nbenomyl (ISO);methyl 1-(butylcarbamoyl)benzimidazol-2-ylcarbamate\n241-775-7\n17804-35-2\nMuta. 1B Repr. 1B STOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH340\nH360FD H335\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH340\nH360FD H335\nH315\nH317\nH410\nM = 10\n613-050-00-9\ncarbadox (INN);methyl 3-(quinoxalin-2-ylmethylene)carbazate 1,4-dioxide; 2-(methoxycarbonylhydrazonomethyl) quinoxaline 1,4-dioxide\n229-879-0\n6804-07-5\nFlam. Sol. 1\nCarc. 1B\nAcute Tox. 4 *\nH228\nH350\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH228\nH350\nH302\nT\n613-051-00-4\nmolinate (ISO);S-ethyl 1-perhydroazepinecarbothioate; S-ethyl perhydroazepine-1-carbothioate\n218-661-0\n2212-67-1\nCarc. 2\nRepr. 2\nAcute Tox. 4 * Acute Tox. 4 *\nSTOT RE 2 * Skin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361f *** H332\nH302\nH373 ** H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH361f *** H332\nH302\nH373 ** H317\nH410\nM = 100\n613-052-00-X\ntrifenmorph (ISO);4-tritylmorpholine\n215-812-2\n1420-06-0\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-053-00-5\nanilazine (ISO);2-chloro-N-(4,6-dichloro-1,3,5- triazin-2-yl)aniline\n202-910-5\n101-05-3\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\n613-054-00-0\nthiabendazol (ISO);2-(thiazole-4-yl)benzimidazole\n205-725-8\n148-79-8\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-056-00-1\n1,2-dimethyl-3,5-diphenylpyra zolium methylsulphate; difenzoquat methyl sulfate\n256-152-5\n43222-48-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS09\nWng\nH302\nH410\n613-058-00-2\npermethrin (ISO);m-phenoxybenzyl 3-(2,2-dichorovinyl)-2,2-dimethylcyclopro panecarboxylate\n258-067-9\n52645-53-1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH317\nH410\nM = 1 000\n613-059-00-8\nprofluralin (ISO);N-(cyclopropylmethyl)-α, α,α- trifluoro-2,6-dinitro-N-propyl-p-toluidine\n247-656-6\n26399-36-0\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH410\n613-060-00-3\nresmethrin (ISO);5-benzyl-3-furylmethyl (±)-cis-trans-chrysanthemate\n233-940-7\n10453-86-8\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM=1000\n613-061-00-9\n6-(1α,5aβ,8aβ,9-pentahydroxy-7β-isopropyl-2β,5β,8β-trimethylperhydro-8bα,9-epoxy-5,8-ethanocyclopenta[1,2-b]indenyl) pyrrole-2-carboxylate; ryania\n239-732-2\n15662-33-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n613-062-00-4\nsabadilla (ISO);veratrine\n—\n8051-02-3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH319\nH335\nH315\nGHS07\nWng\nH319\nH335\nH315\n613-063-00-X\nsecbumeton (ISO);2-sec-butylamino-4-ethylamino-6-methoxy-1,3,5-triazine\n247-554-1\n26259-45-0\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH410\n613-064-00-5\n5-(3,6,9-trioxa-2-undecy loxy)benzo(d)-1,3-dioxolane; sesamex\n—\n51-14-9\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n613-065-00-0\nsimetryn (ISO);2,4-bis(ethylamino)-6- methylthio-1,3,5-triazine\n213-801-7\n1014-70-6\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-066-00-6\nterbumeton (ISO);2-tert-butylamino-4-ethylamino-6-methoxy-1,3,5-triazine\n251-637-8\n33693-04-8\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-067-00-1\npropazine (ISO);2-chloro-4,6-bis(isopropylamino)-1,3,5-triazine\n205-359-9\n139-40-2\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n613-068-00-7\natrazine (ISO);2-chloro-4-ethylamine-6- isopropylamine-1,3,5-triazine\n217-617-8\n1912-24-9\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 ** H317\nH400\nH410\nGHS08\nGHS09\nWng\nH373 ** H317\nH410\n613-069-00-2\nε-caprolactam\n203-313-2\n105-60-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nH332\nH302\nH319\nH335\nH315\nGHS07\nWng\nH332\nH302\nH319\nH335\nH315\n613-070-00-8\npropylenethiourea\n—\n2122-19-2\nRepr. 2\nAcute Tox. 4 *\nAquatic Chronic 3\nH361d *** H302\nH412\nGHS08\nGHS07\nWng\nH361d *** H302\nH412\n613-071-00-3\n2-fluoro-5-trifluoromethylpyridine\n400-290-2\n69045-82-5\nFlam. Liq. 3\nSkin Sens. 1\nAquatic Chronic 3\nH226\nH317\nH412\nGHS02\nGHS07\nWng\nH226\nH317\nH412\n613-072-00-9\nN, N-bis(2-ethylhexyl)-((1,2,4- triazol-1-yl)methyl)amine\n401-280-0\n91273-04-0\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH411\n613-073-00-4\nN, N-dimethyl-2-(3-(4-chloro phenyl)-4,5-dihydropyrazol-1- ylphenylsulphonyl)ethylamine\n401-410-6\n10357-99-0\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH373 ** H317\nH411\nGHS08\nGHS09\nWng\nH373 ** H317\nH411\n613-074-00-X\n3-(3-methylpent-3-yl)isoxazol-5- ylamine\n401-460-9\n82560-06-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nEye Dam. 1\nAquatic Chronic 3\nH331\nH301\nH318\nH412\nGHS06\nGHS05\nDgr\nH331\nH301\nH318\nH412\n613-075-00-5\n1,3-dichloro-5-ethyl-5-methylimidazolidine-2,4-dione\n401-570-7\n89415-87-2\nOx. Sol. 1 ****\nAcute Tox. 3 *\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nH271\nH331\nH314\nH302\nH317\nH400\nGHS03\nGHS06\nGHS05\nGHS09\nDgr\nH271\nH331\nH314\nH302\nH317\nH400\n613-076-00-0\n3-chloro-5-trifluoromethyl-2- pyridylamine\n401-670-0\n79456-26-1\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n613-077-00-6\nreaction mass of 5-heptyl-1,2,4- triazol-3-ylamine and 5-nonyl-1,2,4-triazol-3-ylamine\n401-940-8\n—\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 2\nH302\nH319\nH411\nGHS07\nGHS09\nWng\nH302\nH319\nH411\n613-078-00-1\nN,N,N,N-tetrakis(4,6-bis(butyl- (N-methyl-2,2,6,6-tetramethyl piperidin-4-yl)amino)triazin-2- yl)-4,7-diazadecane-1,10- diamine\n401-990-0\n106990-43-6\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n613-079-00-7\n4-(1(or 4 or 5 or 6)-methyl-8,9,10-trinorborn-5-en-2- yl)pyridine, reaction mass of isomers\n402-520-7\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH315\nH317\nH410\n613-080-00-2\n3-(bis(2-ethylhexyl)amino methyl)benzothiazole-2(3H)- thione\n402-540-6\n105254-85-1\nSkin Corr. 1B Skin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n613-081-00-8\n1-butyl-2-methylpyridinium bromide\n402-680-8\n26576-84-1\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n613-082-00-3\n2-methyl-1-pentylpyridinium bromide\n402-690-2\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH312\nH302\nH412\nGHS07\nWng\nH312\nH302\nH412\n613-083-00-9\n2-(4-(3-(4-chlorophenyl)-2-pyra zolin-1-yl)phenylsulfonyl)ethyldimethylammonium formate\n402-120-2\n—\nSkin Corr. 1B STOT RE 2 * Skin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH373 ** H317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH373 ** H317\nH410\n613-084-00-4\n2-(4-(3-(4-chlorophenyl)-4,5- dihydropyrazolyl)phenylsulphonyl) ethyldimethylammonium hydrogen phosphonate\n402-490-5\n106359-93-7\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH410\n613-085-00-X\nreaction mass of 1,1'-(methylenebis(4,1-phenylene))dipyrrole-2,5-dione and N-(4-(4-(2,5-dioxopyrrol-1-yl)benzyl)phenyl)acetamide and 1-(4-(4-(5- oxo-2H-2-furylide namino)benzyl)phenyl)pyrrole-2,5-dione\n401-970-1\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n613-086-00-5\ncaffeine\n200-362-1\n58-08-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n613-087-00-0\ntetrahydrothiophene\n203-728-9\n110-01-0\nFlam. Liq. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 3\nH225\nH332\nH312\nH302\nH319\nH315\nH412\nGHS02\nGHS07\nDgr\nH225\nH332\nH312\nH302\nH319\nH315\nH412\n613-088-00-6\n1,2-benzisothiazol-3(2H)-one;1,2-benzisothiazolin-3-one\n220-120-9\n2634-33-5\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH302\nH315\nH318\nH317\nH400\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH315\nH318\nH317\nH400\nSkin Sens. 1; H317: C≥0,05 %\n613-089-00-1\ndiquat dibromide; [1]diquat dichloride; [2]6,7-dihydrodipyrido[1,2-α:2',1'- c]pyrazinediylium dihydroxide [3]\n201-579-4 [1]\n223-714-6 [2]\n301-467-6 [3]\n85-00-7 [1]\n4032-26-2 [2]\n94021-76-8 [3]\nAcute Tox. 2 * STOT RE 1\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH372 ** H302\nH319\nH335\nH315\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH372 ** H302\nH319\nH335\nH315\nH317\nH410\n613-090-00-7\nparaquat dichloride;1,1-dimethyl-4,4'-bipyridinium dichloride; [1]paraquat dimethylsulfate;1,1-dimethyl-4,4'-bipyridinium dimethyl sulphate [2]\n217-615-7 [1]\n218-196-3 [2]\n1910-42-5 [1]\n2074-50-2 [2]\nAcute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH311\nH301\nH372 ** H319\nH335\nH315\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH311\nH301\nH372 ** H319\nH335\nH315\nH410\n613-091-00-2\nmorfamquat dichloride; [1]morfamquat sulfate [2]\n225-062-8 [1] [2]\n4636-83-3 [1]\n29873-36-7 [2]\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Chronic 3\nH302\nH319\nH335\nH315\nH412\nGHS07\nWng\nH302\nH319\nH335\nH315\nH412\n613-092-00-8\n1,10-phenanthroline\n200-629-2\n66-71-7\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\n613-093-00-3\nhexasodium 6,13-dichloro-3,10- bis((4-(2,5-disulfonatoanilino)-6- fluoro-1,3,5-triazin-2- ylamino)prop-3-ylamino)-5,12- dioxa-7,14-diazapentacene-4,11- disulfonate\n400-050-7\n85153-92-0\nResp. Sens. 1\nSkin Sens. 1\nH334\nH317\nGHS08\nDgr\nH334\nH317\n613-094-00-9\n4-methoxy-N,6-dimethyl-1,3,5- triazin-2-ylamine\n401-360-5\n5248-39-5\nAcute Tox. 4 * STOT RE 2 *\nH302\nH373 **\nGHS08\nGHS07\nWng\nH302\nH373 **\n613-095-00-4\nsodium 3-(2H-benzotriazol-2- yl)-5-sec-butyl-4-hydroxyben zenesulfonate\n403-080-9\n92484-48-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-096-00-X\n2-amino-6-ethoxy-4-methylamino-1,3,5-triazine\n403-580-7\n62096-63-3\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n613-097-00-5\n7-amino-3-((5-carboxymethyl-4- methyl-1,3-thiazol-2- ylthio)methyl)-8-oxo-5-thia-1- azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid\n403-690-5\n111298-82-9\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH334\nH317\nH412\nGHS08\nDgr\nH334\nH317\nH412\n613-098-00-0\nN-(n-octyl)-2-pyrrolidone\n403-700-8\n2687-94-7\nSkin Corr. 1B Aquatic Chronic 2\nH314\nH411\nGHS05\nGHS09\nDgr\nH314\nH411\n613-099-00-6\n1-dodecyl-2-pyrrolidone\n403-730-1\n2687-96-9\nSkin Corr. 1B Skin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n613-100-00-X\n2,9-bis(3-(diethylamino)propylsulfamoyl)quino(2,3-b)acridine-7,14-dione\n404-230-6\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n613-101-00-5\nN—tert-pentyl-2-benzothiazolesulfenamide\n404-380-2\n110799-28-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-102-00-0\ndimethomorph (ISO);4-(3-(4-chlorophenyl)-3-(3,4- dimethoxyphenyl)acryloyl)morpholine\n404-200-2\n110488-70-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-103-00-6\nsodium 5-n-butylbenzotriazole\n404-450-2\n118685-34-0\nAcute Tox. 4 * Skin Corr. 1B Skin Sens. 1\nAquatic Chronic 2\nH302\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH317\nH411\n613-104-00-1\n5-tert-butyl-3-isoxazolylamine hydrochloride\n404-840-2\n—\nAcute Tox. 4 * STOT RE 2 * Eye Dam. 1\nAquatic Chronic 3\nH302\nH373 ** H318\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH373 ** H318\nH412\n613-105-00-7\nhexakis(tetramethylammonium) 4,4'-vinylenebis((3-sulfonato-4,1-phenylene)imino(6- morpholino-1,3,5-triazine-4,2- diyl)imino)bis(5-hydroxy-6-phenylazonaphthalene-2,7- disulfonate)\n405-160-9\n124537-30-0\nAcute Tox. 3 * Skin Sens. 1\nAquatic Chronic 3\nH301\nH317\nH412\nGHS06\nDgr\nH301\nH317\nH412\n613-106-00-2\ntetrapotassium 2-(4-(5-(1-(2,5- disulfonatophenyl)-3-ethoxycar bonyl-5-hydroxypyrazol-4- yl)penta-2,4-dienylidene)-3- ethoxycarbonyl-5-oxo-2-pyra zolin-1-yl)benzene-1,4- disulfonate\n405-240-3\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-107-00-8\nhexasodium 2,2'-vinylenebis((3- sulfonato-4,1-pheny lene)imino(6-(N-cyanoethyl-N-(2-hydroxypropyl)amino)-1,3,5-triazine-4,2-diyl)imino)dibenzene-1,4-disulfonate\n405-280-1\n76508-02-6\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n613-108-00-3\nbenzothiazole-2-thiol\n205-736-8\n149-30-4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n613-109-00-9\nbis(piperidinothiocarbonyl) disulphide\n202-328-1\n94-37-1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nH319\nH335\nH315\nH317\nGHS07\nWng\nH319\nH335\nH315\nH317\n613-110-00-4\ndimepiperate (ISO);S-(1-methyl-1-phenylethyl) piperidine-1-carbothioate\n262-784-2\n61432-55-1\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n613-111-00-X\n1,2,4-triazole\n206-022-9\n288-88-0\nRepr. 2\nAcute Tox. 4 *\nEye Irrit. 2\nH361d *** H302\nH319\nGHS08\nGHS07\nWng\nH361d *** H302\nH319\n613-112-00-5\nocthilinone (ISO);2-octyl-2H-isothiazol-3-one\n247-761-7\n26530-20-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH302\nH314\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH311\nH302\nH314\nH317\nH410\nSkin Sens. 1; H317: C≥0,05 %\n613-113-00-0\n2-(morpholinothio)benzothiazole\n203-052-4\n102-77-2\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH319\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH319\nH315\nH317\nH411\n613-114-00-6\n2,2',2''-(hexahydro-1,3,5- triazine-1,3,5-triyl)triethanol;1,3,5-tris(2-hydroxyethyl)hexahydro-1,3,5-triazine\n225-208-0\n4719-04-4\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\nSkin Sens. 1; H317: C ≥\n0,1 %\n613-115-00-1\nhymexazol (ISO);3-hydroxy-5-methylisoxazole\n233-000-6\n10004-44-1\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n613-116-00-7\ntolylfluanid (ISO);dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide;[containing ≥0.1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n211-986-9\n731-27-1\nAcute Tox. 2 * STOT RE 1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH330\nH372** H319\nH335\nH315\nH317\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH372** H319\nH335\nH315\nH317\nH400\nM=10\n613-116-01-4\ntolylfluanid (ISO);dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide;[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n211-986-9\n731-27-1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH319\nH335\nH315\nH317\nH400\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH317\nH400\nM=10\n613-117-00-2\ndiniconazole (ISO);(E)-β-[(2,4-dichlorophenyl)methylene]-α-(1,1-dimethylethyl)-1H—1,2,4-triazol-1- ethanol;(E)-(RS)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1H—1,2,4- triazol-1-yl)pent-1-en-3-ol\n—\n76714-88-0\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-118-00-8\nflubenzimine (ISO);N-[3-phenyl-4,5-bis[(trifluoromethyl)imino]thiazolidin-2- ylidene]aniline\n253-703-1\n37893-02-0\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH410\n613-119-00-3\n(benzothiazol-2-ylthio)methyl thiocyanate; TCMTB\n244-445-0\n21564-17-0\nAcute Tox. 2 * Acute Tox. 4 * Eye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH302\nH319\nH315\nH317\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH302\nH319\nH315\nH317\nH410\n613-120-00-9\nbioresmethrin (ISO);(5-benzyl-3-furyl)methyl (1R)-2,2-dimethyl-3-(2-methylprop-1- en-1-yl)cyclopropanecarboxylate\n249-014-0\n28434-01-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1000\n613-122-00-X\ndiclobutrazole (ISO);(R*, R*)-(±)-β-[(2,4-dichlorop henyl)methyl]-α-(1,1-dimethylethyl)-1H-1,2,4-triazole-1-ethanol; (2RS, 3RS)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2- (1H—1,2,4-triazol-1yl)pentan-3-ol\n—\n75736-33-3\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n613-123-00-5\n5,6-dihydro-3H-imidazo[2,1-c]-1,2,4-dithiazole-3-thione; etem\n251-684-4\n33813-20-6\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-124-00-0\nfenpropimorph (ISO);cis-4-[3-(p-tert-butylphenyl)-2- methylpropyl]-2,6-dimethylmorpholine\n266-719-9\n67564-91-4\nRepr. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Chronic 2\nH361d *** H302\nH315\nH411\nGHS08\nGHS07\nGHS09\nWng\nH361d *** H302\nH315\nH411\n613-125-00-6\nhexythiazox(ISO);trans-5-(4-chlorophenyl)-N- cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide\n—\n78587-05-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-126-00-1\nimazapyr (ISO);2-[4,5-dihydro-4-methyl-4-(1- methylethyl)-5-oxo-1H- imidazol-2-yl]-3-pyridine carboxylate\n—\n81334-34-1\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n613-127-00-7\n1,1-dimethylpiperidinium chloride; mepiquat chloride\n246-147-6\n24307-26-4\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n613-128-00-2\nprochloraz (ISO);N-propyl-N-[2-(2,4,6-trichlorop henoxy)ethyl]-1H-imidazole-1- carboxamide\n266-994-5\n67747-09-5\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-129-00-8\nmetamitron (ISO);4-amino-3-methyl-6-phenyl-1,2,4-triazin-5-one\n255-349-3\n41394-05-2\nAcute Tox. 4 *\nAquatic Acute 1\nH302\nH400\nGHS07\nGHS09\nWng\nH302\nH400\n613-131-00-9\npyroquilon (ISO);1,2,5,6-tetrahydropyrrolo[3,2,1- ij]quinolin-4-one\n—\n57369-32-1\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n613-132-00-4\nhexazinone (ISO);3-cyclohexyl-6-dimethylamino-1-methyl-1,2,3,4-tetrahydro-1,3,5-triazine-2,4-dione\n257-074-4\n51235-04-2\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH410\n613-134-00-5\nmyclobutanil(ISO);2-(4-chlorophenyl)-2-(1H-1,2,4- triazol-1-ylmethyl)hexanenitrile\n—\n88671-89-0\nRepr. 2\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 2\nH361d *** H302\nH319\nH411\nGHS08\nGHS07\nGHS09\nWng\nH361d *** H302\nH319\nH411\n613-135-00-0\ndi(benzothiazol-2-yl) disulphide\n204-424-9\n120-78-5\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nEUH031\n613-136-00-6\nN-cyclohexylbenzothiazole-2- sulphenamide\n202-411-2\n95-33-0\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n613-137-00-1\nmethabenzthiazuron (ISO);1-(1,3-benzothiazol-2-yl)1,3- dimethylurea\n242-505-0\n18691-97-9\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-138-00-7\nquinoxyfen (ISO);5,7-dichloro-4-(4-fluorophenoxy)quinoline\n—\n124495-18-7\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n613-139-00-2\nmetsulfuron-methyl (ISO); methyl-2-{[(4-methoxy-6- methyl-1,3,5-triazin-2-yl)carbamoyl]sulfamoyl}benzoate\n—\n74223-64-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1000\n613-140-00-8\ncycloheximide (ISO);4-{(2R)-2-[(1S,3S,5S)-3,5- dimethyl-2-oxocyclohexyl]-2- hydroxyethyl}piperidine-2,6- dione\n200-636-0\n66-81-9\nMuta. 2\nRepr. 1B\nAcute Tox. 2 *\nAquatic Chronic 2\nH341\nH360D *** H300\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH341\nH360D *** H300\nH411\n613-141-00-3\n1,4-diamino-2-(2-butyltetrazol-5-yl)-3-cyanoanthraquinone\n401-470-3\n93686-63-6\nAquatic Chronic 4\nH413\n—\nH413\n613-142-00-9\ntrans—N-methyl-2-styryl-[4'- aminomethine-(1-acetyl-1-(2- methoxyphenyl)acetamido)]py ridinium acetate\n405-860-4\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n613-143-00-4\n1-(3-phenylpropyl)-2-methylpyridinium bromide\n405-930-4\n10551-42-5\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 3\nH302\nH319\nH412\nGHS07\nWng\nH302\nH319\nH412\n613-144-00-X\nreaction products of: poly(vinyl acetate), partially hydrolyzed, with (E)-2-(4-formylstyryl)-3,4- dimethylthiazoliummethylsulfate\n406-460-2\n125139-08-4\nAquatic Chronic 3\nH412\n—\nH412\n613-145-00-5\n(S)-3-benzyloxycarbonyl-1,2,3,4-tetrahydro-isoquinolinium 4-methylbenzenesulfonate\n406-960-0\n77497-97-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-146-00-0\nN-ethyl-N-methylpiperidinium iodide\n407-780-5\n4186-71-4\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n613-147-00-6\n4-[2-(1-methyl-2-(4-morpholinyl)ethoxy)ethyl]morpholine\n407-940-4\n111681-72-2\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-148-00-1\ntetrasodium 1,2-bis(4-fluoro-6- [5-(1-amino-2-sulfonatoanthra chinon-4-ylamino)-2,4,6- trimethyl-3-sulfonatopheny lamino]-1,3,5-triazin-2- ylamino)ethane\n411-240-4\n143683-23-2\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-150-00-2\n2,2'-[3,3'-(piperazine-1,4-diyl)di propyl]bis(1H-benzimidazo[2,1—b]benzo[l, m,n][3,8]phenanthroline-1,3,6-trione\n406-295-6\n—\nAquatic Chronic 4\nH413\n—\nH413\n613-151-00-8\n1-(3-mesyloxy-5-trityloxymethyl-2-D-threofuryl)thymine\n406-360-9\n104218-44-2\nAquatic Chronic 4\nH413\n—\nH413\n613-152-00-3\nphenyl N-(4,6-dimethoxypyrimidin-2-yl)carbamate\n406-600-2\n89392-03-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n613-153-00-9\n2,3,5-trichloropyridine\n407-270-2\n16063-70-0\nAquatic Chronic 3\nH412\n—\nH412\n613-154-00-4\n2-amino-4-chloro-6-methoxypyrimidine\n410-050-9\n5734-64-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n613-155-00-X\n5-chloro-2,3-difluoropyridine\n410-090-7\n89402-43-7\nFlam. Liq. 3\nAcute Tox. 4 *\nAquatic Chronic 3\nH226\nH302\nH412\nGHS02\nGHS07\nWng\nH226\nH302\nH412\n613-156-00-5\n2-butyl-4-chloro-5-formylimidazole\n410-260-0\n83857-96-9\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n613-157-00-0\n2,4-diamino-5-methoxymethylpyrimidine\n410-330-0\n54236-98-5\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nH302\nH373 ** H319\nGHS08\nGHS07\nWng\nH302\nH373 ** H319\n613-158-00-6\n2,3-dichloro-5-trifluoromethyl- pyridine\n410-340-5\n69045-84-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH332\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH302\nH318\nH317\nH411\n613-159-00-1\nfenazaquin (ISO);4-[2-[4-(1,1-dimethylethyl)phenyl]-ethoxy]quinazoline\n410-580-0\n120928-09-8\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH332\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH332\nH410\n613-160-00-7\n(1S)-2-methyl-2,5-diazobicyclo[2.2.1]heptanes dihydrobromide\n411-000-9\n125224-62-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-161-00-2\n(2,4-diaminopteridin-6-yl)methanol hydrobromide\n430-620-0\n76145-91-0\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH373** H317\nH412\nGHS08\nGHS07\nWng\nH373** H317\nH412\n613-162-00-8\n(6R-trans)-1-((7-ammonio-2- carboxylato-8-oxo-5-thia-1- azabicyclo-[4.2.0]oct-2-en-3- yl)methyl)pyridinium iodide\n423-260-0\n100988-63-4\nMuta. 2\nSkin Sens. 1\nAquatic Chronic 2\nH341\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH341\nH317\nH411\n613-163-00-3\nazimsulfuron (ISO);1-(4,6-dimethoxypyrimidin-2-yl)-3-[1-methyl-4-(2-methyl-2H- tetrazol-5-yl)pyrazol-5-ylsulfonyl]urea\n—\n120162-55-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=1000\n613-164-00-9\nflufenacet (ISO);N-(4-fluorophenyl)-N-isopropyl-2-(5-trifluoromethyl-[1,3,4]thiadiazol-2-yloxy)acetamide\n—\n142459-58-3\nAcute Tox. 4 * STOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373** H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373** H317\nH410\nM=100\n613-165-00-4\nflupyrsulfuron-methyl-sodium(ISO);methyl 2-[[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-6-trifluoromethyl]nicotinate, monosodium salt\n—\n144740-54-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=100\n613-167-00-5\nreaction mass of: 5-chloro-2- methyl-4-isothiazolin-3-one [EC no. 247-500-7]and 2-methyl-2H -isothiazol-3- one [EC no. 220-239-6] (3:1); reaction mass of: 5-chloro-2- methyl-4-isothiazolin-3-one [EC no. 247-500-7]and 2-methyl-4-isothiazolin-3- one [EC no. 220-239-6] (3:1)\n—\n55965-84-9\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH314\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH311\nH301\nH314\nH317\nH410\nSkin Corr. 1B; H314: C ≥0,6 %\nSkin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %\nEye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %\nSkin Sens. 1; H317: C ≥ 0,0015 %\n613-168-00-0\n1-vinyl-2-pyrrolidone\n201-800-4\n88-12-0\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 * STOT RE 2 *\nSTOT SE 3\nEye Dam. 1\nH351\nH332\nH312\nH302\nH373 ** H335\nH318\nGHS06\nGHS05\nGHS09\nDgr\nH351\nH332\nH312\nH302\nH373 ** H335\nH318\nD\n613-169-00-6\n9-vinylcarbazole\n216-055-0\n1484-13-5\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH312\nH302\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH341\nH312\nH302\nH315\nH317\nH410\nM=100\n613-170-00-1\n2,2-ethylmethylthiazolidine\n404-500-3\n694-64-4\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n613-171-00-7\nhexaconazole (ISO);(RS)-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2- ol\n413-050-7\n79983-71-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n613-172-00-2\n5-chloro-1,3-dihydro-2H-indol-2-one\n412-200-9\n17630-75-0\nRepr. 2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH361f *** H302\nH317\nH412\nGHS08\nGHS07\nWng\nH361f *** H302\nH317\nH412\n613-173-00-8\nfluquinconazole (ISO);3-(2,4-dichlorophenyl)-6-fluoro-2-(1H-1,2,4-triazol-1-yl)quinazolin-4-(3H)-one\n411-960-9\n136426-54-5\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH372 ** H312\nH315\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH301\nH372 ** H312\nH315\nH410\n613-174-00-3\ntetraconazole (ISO);\n(±) 2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether\n407-760-6\n112281-77-3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 2\nH332\nH302\nH411\nGHS07\nGHS09\nWng\nH332\nH302\nH411\n613-175-00-9\nepoxiconazole (ISO); (2RS,3SR)-3-(2-chlorophenyl)-2-(4-fluorophenyl)-[(1H-1,2,4-triazol-1-yl)methyl]oxirane\n406-850-2\n133855-98-8\nCarc. 2\nRepr. 1B\nAquatic Chronic 2\nH351\nH360Df\nH411\nGHS08\nGHS09\nDgr\nH351\nH360Df\nH411\n613-176-00-4\n2-methyl-2-azabicyclo[2.2.1]heptane\n404-810-9\n4524-95-2\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nH226\nH312\nH302\nH373 **\nH314\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH226\nH312\nH302\nH373 **\nH314\n613-177-00-X\n8-amino-7-methylquinoline\n412-760-4\n5470-82-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH312\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH312\nH302\nH317\nH411\n613-178-00-5\n4-ethyl-2-methyl-2-isopentyl-1,3-oxazolidine\n410-470-2\n137796-06-6\nSkin Corr. 1B\nSkin Sens. 1\nH314\nH317\nGHS05\nGHS07\nDgr\nH314\nH317\nSTOT SE 3; H335: C ≥ 5 %\n613-179-00-0\nlithium 3-oxo-1,2(2H)-benzisothiazol-2-ide\n411-690-1\n111337-53-2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH314\nH317\nH411\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\nH411\n613-180-00-6\nN-(1,1-dimethylethyl)bis(2-benzothiazolesulfen)amide\n407-430-1\n3741-80-8\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-181-00-1\n5,5-dimethyl-perhydro-pyrimidin-2-one α-(4-trifluoromethylstyryl)-α-(4-trifluoromethyl)cinnamylidenehydrazone\n405-090-9\n67485-29-4\nSTOT RE 1\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH372 **\nH302\nH319\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH372 **\nH302\nH319\nH410\n613-182-00-7\n1-(1-naphthylmethyl)quinolinium chloride\n406-220-7\n65322-65-8\nCarc. 2\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH351\nH341\nH302\nH315\nH318\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH351\nH341\nH302\nH315\nH318\nH412\n613-183-00-2\nreaction mass of: 5-(N-methylperfluorooctylsulfonamido)methyl-3-octadecyl-1,3-oxazolidin-2-one; 5-(N-methylperfluoroheptylsulfonamido)methyl-3-octadecyl-1,3-oxazolidin-2-one\n413-640-4\n—\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH400\nH410\nGHS08\nGHS09\nWng\nH373 **\nH410\n613-184-00-8\nnitrilotriethyleneammoniopropane-2-ol 2-ethylhexanoate\n413-670-8\n—\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n613-185-00-3\n2,3,5,6-tetrahydro-2-methyl-2H-cyclopenta[d]-1,2-thiazol-3-one\n407-630-9\n82633-79-2\nAcute Tox. 3 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH318\nH317\nH410\n613-186-00-9\n(2R,3R)-3-((R)-1-(tert-butyldimethylsiloxy)ethyl)-4-oxoazetidin-2-yl acetate\n408-050-9\n76855-69-1\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH319\nH317\nH411\nGHS07\nGHS09\nWng\nH319\nH317\nH411\n613-187-00-4\n5-(2-amino-5-cyano-6-[2-(2-hydroxyethoxy)ethylamino]-4-methylpyridin-3-ylazo)-3-methyl-2,4-dicarbonitrilethiophene\n410-530-8\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-188-00-X\n1-(3-(4-fluorophenoxy)propyl)3-methoxy-4-piperidinone\n411-500-7\n116256-11-2\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n613-189-00-5\n1,4,7,10-tetrakis(p-toluensulfonyl)-1,4,7,10-tetraazacyclododecane\n414-030-0\n52667-88-6\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n613-190-00-0\ndisodium 1-amino-4-(2-(5-chloro-6-fluoro-pyrimidin-4-ylamino-methyl)-4-methyl-6-sulfo-phenylamino)-9,10-dioxo-9,10-dihydro-anthracene-2-sulfonate\n414-040-5\n149530-93-8\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n613-191-00-6\n3-ethyl-2-methyl-2-(3-methylbutyl)-1,3-oxazolidine\n421-150-7\n143860-04-2\nRepr. 1B\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360F *** H314\nH400\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH360F *** H314\nH410\n613-192-00-1\n3-benzyl-exo-6-nitro-2,4-dioxo-3-aza-cis-bicyclo[3.1.0]hexane\n426-750-2\n151860-15-0\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-193-00-7\npentakis[3-(dimethylammonio)propylsulfamoyl]-[(6-hydroxy-4,4,8,8-tetramethyl-4,8-diazoniaundecane-1,11-diyldisulfamoyl)di[phthalocyaninecopper(II)]] heptalactate\n414-930-3\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-194-00-2\n6,13-dichloro-3,10-bis{2-[4-fluoro-6-(2-sulfophenylamino)-1,3,5-triazin-2-ylamino]propylamino}benzo[5,6][1,4]oxazino[2,3-.b.]phenoxazine-4,11-disulphonic acid, lithium-, sodium salt\n418-000-8\n163062-28-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-195-00-8\n2,2-(1,4-phenylene)bis((4H—3,1-benzoxazine-4-one)\n418-280-1\n18600-59-4\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n613-196-00-3\n5-[[4-chloro-6-[[2-[[4-fluoro-6-[[5-hydroxy-6-[(4-methoxy-2-sulfophenyl)azo]-7-sulfo-2-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-1-methylethyl]amino]-1,3,5-triazin-2-yl]amino]-3-[[4-(ethenylsulfonyl)phenyl]azo]-4-hydroxy-naphtalene-2,7-disulfonic acid, sodium salt\n418-380-5\n168113-78-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-197-00-9\nreaction mass of: 2,4,6-tri(butylcarbamoyl)-1,3,5-triazine;\n2,4,6-tri(methylcarbamoyl)-1,3,5-triazine;\n[(2-butyl-4,6-dimethyl)tricarbamoyl]-1,3,5-triazine;\n[(2,4-dibutyl-6-methyl)tricarbamoyl]-1,3,5-triazine\n420-390-1\n187547-46-2\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n613-198-00-4\n2-amino-4-dimethylamino-6-trifluoroethoxy-1,3,5-triazine\n415-500-8\n145963-84-4\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n613-199-00-X\nreaction mass of: 1,3,5-tris(3-aminomethylphenyl)-1,3,5-(1H,3H,5H)-triazine-2,4,6 trione;\nreaction mass of oligomers of\n3,5-bis(3-aminomethylphenyl)1-poly[3,5-bis(3-aminomethylphenyl)-2,4,6-trioxo-1,3,5-(1H,3H,5H)-triazin-1-yl]-1,3,5(1H,3H,5H)-triazine-2,4,6-trione\n421-550-1\n—\nCarc. 1B\nRepr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH360D *** H317\nH412\nGHS08\nDgr\nH350\nH360D *** H317\nH412\n613-200-00-3\nreaction product of: copper, (29H,31H-phthalocyaninato(2-)-N29,N30,N31,N32)-, chlorosulfuric acid and 3-(2-sulfooxyethylsulfonyl)aniline, sodium salts\n420-980-7\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-201-00-9\n(R)-5-bromo-3-(1-methyl-2-pyrrolidinyl methyl)-1H-indole\n422-390-5\n143322-57-0\nRepr. 2\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f *** H372 **\nH332\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH361f *** H372 **\nH332\nH302\nH317\nH410\nEUH070\n613-202-00-4\npymetrozine (ISO);\n(E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one\n—\n123312-89-0\nCarc. 2\nAquatic Chronic 3\nH351\nH412\nGHS08\nWng\nH351\nH412\n613-203-00-X\npyraflufen-ethyl (ISO);\n2-chloro-5-(4-chloro-5-difluoromethoxy-1-methylpyrazol-3-yl)-4-fluorophenoxyacetic acid ethyl ester; [1] pyraflufen (ISO);\n2-chloro-5-(4-chloro-5-difluoromethoxy-1-methylpyrazol-3-yl)-4-fluorophenoxyacetic acid [2]\n-[1]\n-[2]\n129630-19-9 [1]\n129630-17-7 [2]\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=1000\n613-204-00-5\noxadiargyl (ISO);\n3-[2,4-dichloro-5-(2-propynyloxy)phenyl]-5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2(3H)-one\n254-637-6\n39807-15-3\nRepr. 2\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH361d*** H373**\nH400\nH410\nGHS08\nGHS09\nWng\nH361d*** H373**\nH410\nM = 1000\n613-205-00-0\npropiconazole(ISO);\n(±) 1-[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-ylmethyl]-1H—1,2,4-triazole\n262-104-4\n60207-90-1\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n613-206-00-6\nfenamidone (ISO);\n(S)-5-methyl-2-methylthio-5-phenyl-3-phenylamino-3,5-dihydroimidazol-4-one\n—\n161326-34-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-208-00-7\nimazamox (ISO);\n(RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid\n—\n114311-32-9\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-209-00-2\ncis-1-(3-chloropropyl)-2,6-dimethyl-piperidin hydrochloride\n417-430-3\n63645-17-0\nAcute Tox. 3 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH373 **\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH373 **\nH317\nH411\n613-210-00-8\n2-(3-chloropropyl)-2,5,5-trimethyl-1,3-dioxane\n417-650-1\n88128-57-8\nSTOT RE 2 *\nAquatic Chronic 3\nH373 **\nH412\nGHS08\nWng\nH373 **\nH412\n613-211-00-3\nN-methyl-4-(p-formylstyryl)pyridinium methylsulfate\n418-240-3\n74401-04-0\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-212-00-9\n4-[4-(2-ethylhexyloxy)phenyl](1,4-thiazinane-1,1-dioxide)\n418-320-8\n133467-41-1\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-213-00-4\ncis-1-benzoyl-4-[(4-methylsulfonyl)oxy]-L-proline\n416-040-0\n120807-02-5\nAquatic Chronic 3\nH412\n—\nH412\n613-214-00-X\nN, N-di-n-butyl-2-(1,2-dihydro-3-hydroxy-6-isopropyl-2-quinolylidene)-1,3-dioxoindan-5-carboxamide\n416-260-7\n147613-95-4\nAquatic Chronic 4\nH413\n—\nH413\n613-215-00-5\n2-chloromethyl-3,4-dimethoxypyridinium chloride\n416-440-5\n72830-09-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH312\nH302\nH373 **\nH315\nH318\nH317\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH312\nH302\nH373 **\nH315\nH318\nH317\nH411\n613-216-00-0\n6-tert-butyl-7-(6-diethylamino-2-methyl-3-pyridylimino)-3-(3-methylphenyl)pyrazolo[3,2-c][1,2,4]triazole\n416-490-8\n162208-01-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-217-00-6\n4-[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyloxy]-1-[2-[3-(3,5-di-tert-butyl-4-hydrophenyl)propionyloxy]ethyl]-2,2,6,6-tetramethylpiperidine\n416-770-1\n73754-27-5\nAquatic Chronic 4\nH413\n—\nH413\n613-218-00-1\n6-hydroxyindole\n417-020-4\n2380-86-1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n613-219-00-7\n7a-ethyl-3,5-bis(1-methylethyl)-2,3,4,5-tetrahydrooxazolo[3,4-c]-2,3,4,5-tetrahydrooxazole\n417-140-7\n79185-77-6\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n613-220-00-2\ntrans-(4S,6S)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-4-ol, 7,7-dioxide\n417-290-3\n147086-81-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n613-221-00-8\n2-chloro-5-methyl-pyridine\n418-050-0\n18368-64-4\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Chronic 3\nH312\nH302\nH315\nH412\nGHS07\nWng\nH312\nH302\nH315\nH412\n613-222-00-3\n4-(1-oxo-2-propenyl)-morpholine\n418-140-1\n5117-12-4\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH373 **\nH318\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH302\nH373 **\nH318\nH317\n613-223-00-9\nN-isopropyl-3-(4-fluorophenyl)-1H-indole\n418-790-4\n93957-49-4\nAquatic Chronic 4\nH413\n—\nH413\n613-224-00-4\n2,5-dimercaptomethyl-1,4-dithiane\n419-770-8\n136122-15-1\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH317\nH410\n613-225-00-X\nreaction mass of:[2-(anthraquinon-1-ylamino)-6-[(5-benzoylamino)-anthraquinone-1-ylamino]-4-phenyl]-1,3,5-triazine;\n2,6-bis-[(5-benzoylamino)-anthraquinon-1-ylamino]-4-phenyl-1,3,5-triazine.\n421-290-9\n—\nSTOT RE 2 *\nAquatic Chronic 4\nH373 **\nH413\nGHS08\nWng\nH373 **\nH413\n613-226-00-5\n1-(2-(ethyl(4-(4-(4-(4-(ethyl(2-pyridinoethyl)amino)-2-methylphenylazo)benzoylamino)-phenylazo)-3-methylphenyl)amino)ethyl)-pyridinium dichloride\n420-950-3\n163831-67-2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n613-227-00-0\n(±)-[(R*,R*) and (R*,S*)]-6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran\n419-600-2\n99199-90-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n613-228-00-6\n(±)-(R*,S*)-6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran\n419-630-6\n793669-26-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-229-00-1\n1-acetyl-4-(3-dodecyl-2,5-dioxo-1-pyrrolidinyl)-2,2,6,6-tetramethylpiperidine\n411-930-5\n106917-31-1\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n613-230-00-7\nflorasulam (ISO);\n2',6',8-trifluoro-5-methoxy-5-triazolo[1,5-c];\npyrimidine-2-sulfonanilide\n—\n145701-23-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-231-00-2\n2,6-diamino-3-((pyridine-3-yl)azo)pyridine\n421-430-9\n28365-08-4\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH302\nH373**\nH411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH411\n613-232-00-8\n3-(benzo[b]thien-2-yl)-5,6-dihydro-1,4,2-oxathiazine-4-oxide\n431-030-6\n163269-30-5\nAcute Tox. 3 *\nSTOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH373**\nH318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH331\nH373**\nH318\nH410\n613-233-00-3\n4,4'-(oxy-(bismethylene))-bis-1,3-dioxolane\n423-230-7\n56552-15-9\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-234-00-9\nimidazo[1,2-b]pyridazin hydrochloride\n431-510-5\n18087-70-2\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n613-235-00-4\n2,3-dihydro-2,2-dimethyl-1H-perimidine\n424-060-6\n6364-17-6\nAcute Tox. 4*\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH317\nH410\n613-236-00-X\n2-chloro-3-trifluoromethylpyridine\n424-520-6\n65753-47-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Chronic 3\nH311\nH301\nH372**\nH314\nH412\nGHS06\nGHS05\nGHS08\nDgr\nH311\nH301\nH372**\nH314\nH412\n613-237-00-5\n6-tert-butyl-3-(3-dodecylsulfonyl)propyl-7H-1,2,4-triazolo[3.4b][1,3,4]thiadiazine\n424-950-4\n133949-92-5\nAquatic Chronic 4\nH413\n—\nH413\n613-238-00-0\nsodium 2-[[4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]sulfonyl]ethyl sulfate\n430-890-1\n81992-66-7\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n613-239-00-6\n2-[3-(methylamino)propyl]-1H-benzimidazole\n425-760-4\n64137-52-6\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n613-241-00-7\n3-(2H-tetrazol-5-yl)pyridine\n426-810-8\n3250-74-6\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-242-00-2\nreaction products of 3,10-bis((2-aminopropyl)amino)-6,13-dichloro-4,11-triphenodioxazinedisulfonic acid with 2-amino-1,4-benzenedisulfonic acid, 2-((4-aminophenyl)sulfonyl)ethyl hydrogen sulfate and 2,4,6-trifluoro-1,3,5-triazine, sodium salts\n426-860-0\n191877-09-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-243-00-8\n4,4'-(1,6-hexamethylenebis(formylimino))bis(2,2,6,6-tetramethyl-1-oxylpiperidine)\n427-350-0\n182235-14-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-244-00-3\n5,7-dichloro-4-hydroxyquinoline\n427-420-0\n21873-52-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-245-00-9\n2-fluoro-6-trifluoromethylpyridine\n428-100-3\n94239-04-0\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH226\nH332\nH302\nH412\nGHS02\nGHS07\nWng\nH226\nH332\nH302\nH412\n613-246-00-4\n2-hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine\n428-200-7\n103577-66-8\nAquatic Chronic 3\nH412\n—\nH412\n613-247-00-X\n3-(2-methoxy-4-methoxycarboxybenzyl)-5-nitroindole\n428-910-7\n107786-36-7\nAquatic Chronic 4\nH413\n—\nH413\n613-248-00-5\n3,4-dimethyl-1H-pyrazole\n429-130-1\n2820-37-3\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n613-249-00-0\n1-(2-hydroxyethyl)-1H-pyrazol-4,5-diyldiammoniumsulfate\n429-300-3\n155601-30-2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n613-250-00-6\nreaction mass of: carbonato-bis-N-ethyl-2-isopropyl-1,3-oxazolidine;\nmethyl carbonato-N-ethyl-2-isopropyl-1,3-oxazolidine;\n2-isopropyl-N-hydroxyethyl 1,3-oxazolidine\n429-990-6\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n613-251-00-1\n(R)-3-[(1-methylpyrrolidin-2-yl)methyl]-5-[2-(phenylsulfonyl)ethenyl]-1H-indole\n430-560-5\n180637-89-2\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH373**\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\nH317\n613-253-00-2\n2,2-dialkyl-4-hydroxymethyl1,3-dioxolane;\nreaction products with ethylene oxide (alkyl is C1-12 and the sum to C13, average degree of ethoxylation is 3,5)\n430-580-4\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\nEUH019\n613-254-00-8\nforchlorfenuron (ISO);\n1-(2-chloro-4-pyridyl)-3-phenylurea\n—\n68157-60-8\nCarc. 2\nAquatic Chronic 2\nH351\nH411\nGHS08\nGHS09\nWng\nH351\nH411\n613-255-00-3\nreaction mass of isomers of: sodium [(2-hydroxyethylsulfamoyl){][}2-(2-piperazin-1-ylethylamino)ethylsulfamoyl][2-(4-aminoethylpiperazine-1-yl)ethylsulfamoyl{](sulfamoyl)[}(sulfonatophthalocyaninato)]copper(II)\n424-270-8\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-256-00-9\n3'5'-anhydro thymidine\n425-810-5\n38313-48-3\nAquatic Chronic 3\nH412\n—\nH412\n613-257-00-4\n2-phthalimidoethyl N-[4-(2-cyano-4-nitrophenylazo)phenyl]-N-methyl-β-alaninate\n426-400-9\n170222-39-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n613-258-00-X\nreaction mass of: 4-chloro-7-methylbenzotriazole sodium salt;\n4-chloro-5-methylbenzotriazole sodium salt;\n5-chloro-4-methylbenzotriazole sodium salt\n427-730-6\n202420-04-0\nSkin Corr. 1B\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\n613-259-00-5\nreaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate;\n[2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate\n428-790-6\n72963-72-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-260-00-0\n(±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolin\n430-730-9\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n613-261-00-6\npyrazole-1-carboxamidine monohydrochloride\n429-520-1\n4023-02-3\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH373** H318\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\nH317\nH412\n613-262-00-1\ndisodium (E)-1,2-bis-(4-(4-methylamino-6-(4-methylcarbamoylphenylamino)-1,3,5-triazin-2-ylamino)phenyl-2-sulfonato)ethene\n427-310-2\n180850-95-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-263-00-7\nmonosodium 3-cyano-5-fluoro-6-hydroxypyridine-2-olate\n429-570-2\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-266-00-3\n2-chloro-5-chloromethylthiazole\n429-830-5\n105827-91-6\nAcute Tox. 3 *\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH311\nH314\nH302\nH317\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH314\nH302\nH317\nH411\n613-267-00-9\nthiamethoxam (ISO);\n3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine\n428-650-4\n153719-23-4\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM=10\n613-268-00-4\n(4aS-cis-)-6-benzyl-octahydropyrrolo[3.4-b]pyridine\n425-930-8\n151213-39-7\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH314\nH332\nH302\nH373**\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH314\nH332\nH302\nH373**\nH411\n613-269-00-X\n2-thiazolidinylidenecyanamide\n427-720-1\n26364-65-8\nAcute Tox. 4*\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n613-270-00-5\n5-amino-N-(2,6-dichloro-3-methylphenyl)-1H-1,2,4-triazole-3-sulfonamide\n428-150-6\n113171-13-4\nAquatic Chronic 3\nH412\n—\nH412\n613-271-00-0\ntritosulfuron (ISO) (containing ≤0,02 % AMTT);\n1-[4-methoxy-6-(trifluoromethyl)-1,3,5-triazin-2-yl]-3-[2-(trifluoromethyl)benzenesulfonyl]urea (containing ≤ 0,02 % AMTT)\n—\n142469-14-5\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM=10\n613-272-00-6\npyraclostrobin (ISO);\nmethyl N-{2-[1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl]phenyl}(N-methoxy)carbamate\n—\n—\nAcute Tox. 3 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH315\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH315\nH410\nM=100\n613-273-00-1\ntetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine\n427-600-9\n192439-46-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-274-00-7\n2,6-dichloro-1-fluoropyridiniumtetrafluoroborate\n427-400-1\n140623-89-8\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH302\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH302\nH317\nH410\n613-275-00-2\n3-(2-chloroethyl)-6,7,8,9-tetra-hydro-2-methyl-4H-pyrido[1,2-a] pyrimidin-4-one monohydrochloride\n424-530-0\n93076-03-0\nAcute Tox. 3 *\nSTOT SE 2\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH371**\nH373**\nH318\nH317\nH411\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH301\nH371**\nH373**\nH318\nH317\nH411\n613-276-00-8\n1-(2-chlorophenyl)-1,2-dihydro-5H-tetrazol-5-one\n426-110-2\n98377-35-6\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-277-00-3\n(4-(6-diethylamino-2-methylpyridin-3-yl)imino-4,5-dihydro-3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-one\n427-070-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n613-278-00-9\n(3-aminophenyl)pyridin-3-ylmethanone\n428-230-0\n79568-06-2\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\n613-279-00-4\n2-ethyl-2,3-dihydro-2-methyl-1H-perimidine\n424-380-6\n43057-68-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH410\n613-280-00-X\ntetrahydro-1,3-dimethyl-1H-pyrimidin-2-one;\ndimethyl propyleneurea\n230-625-6\n7226-23-5\nRepr. 2\nAcute Tox. 4 *\nEye Dam. 1\nH361f***\nH302\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH361f***\nH302\nH318\n613-281-00-5\nquinoline\n202-051-6\n91-22-5\nCarc. 1B Muta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH350\nH341\nH312\nH302\nH319\nH315\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH341\nH312\nH302\nH319\nH315\nH411\n613-282-00-0\ntriticonazole (ISO);\n(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol\n—\n131983-72-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-283-00-6\nketoconazole;\n1-[4-[4-[[(2SR, 4RS)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone\n265-667-4\n65277-42-1\nRepr. 1B\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360F***\nH301\nH373**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360F***\nH301\nH373**\nH410\n613-284-00-1\nmetconazole (ISO);\n(1RS, 5RS;1RS, 5SR)-5-(4-chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol\n—\n125116-23-6\nRepr. 2\nAcute Tox. 4 *\nAquatic Chronic 2\nH361d***\nH302\nH411\nGHS08\nGHS07\nGHS09\nWng\nH361d***\nH302\nH411\n613-285-00-7\n1-hydroxybenzotriazole, anhydrous; [1]\n1-hydroxybenzotriazole, monohydrated [2]\n219-989-7 [1]\n219-989-7 [2]\n2592-95-2 [1]\n123333-53-9 [2]\nExpl. 1.3\nH203\nGHS01\nDgr\nH203\n613-286-00-2\npotassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate;\n[containing < 0,5 % N, N-dimethylformamide (EC no\n200-679-5)]\n418-260-2\n183196-57-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-286-01-X\npotassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate;\n[containing ≥ 0,5 % N, N-dimethylformamide (EC No 200-679-5)]\n418-260-2\n183196-57-8\nRepr. 1B\nSkin Sens. 1\nH360D*** H317\nGHS08\nGHS07\nDgr\nH360D*** H317\n613-287-00-8\n1-(3-iodo-4-aminobenzyl)-1H-1,2,4-triazole\n419-540-7\n160194-26-3\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n613-288-00-3\n1,3-bis(dimethylcarbamoyl)-imidazolium chloride\n420-930-4\n135756-61-5\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n613-289-00-9\n3-(4-chloro-2-fluoro-5-methylphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole\n432-020-4\n142623-48-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-290-00-4\n4-hydroxy-7-(2-aminoethyl)-1,3-benzothiazol-2(3H)-one hydrochloride\n432-470-1\n189012-93-9\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH410\n613-291-00-X\n2,4-dihydro-4-(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one\n434-820-9\n106461-41-0\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\n613-292-00-5\nN, N',N''-tris(2-methyl-2,3-epoxypropyl)-perhydro-2,4,6-oxo-1,3,5-triazine\n435-010-8\n26157-73-3\nMuta. 2\nAquatic Chronic 3\nH341\nH412\nGHS08\nWng\nH341\nH412\n613-293-00-0\n2-(4-tert-butylphenyl)-6-cyano-5-[bis(ethoxycarbonyl\nmethyl)carbamoyloxy]-1H-pyrrolo[1,2-b][1,2,4] triazole-7-carboxylic acid 2,6-di-tert-butyl-4-methylcyclohexylester\n448-050-6\n444065-11-6\nAquatic Chronic 4\nH413\n—\nH413\n613-294-00-6\n2-hexyldecanoic acid [4-(6-tert-butyl-7-chloro-1H-pyrazolo[1,5-b][1,2,4]triazol-2-yl)phenylcarbamoyl]methylester\n448-260-8\n379268-96-9\nAquatic Chronic 4\nH413\n—\nH413\n613-295-00-1\n11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c, f][1,2]thiazepine hydrochloride\n448-720-8\n363138-44-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n613-296-00-7\npentapotassium 2-(4-(5-[1-(2,5-disulfonatophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-methyl-1,3-pentadienyl)-3-methylcarbamoyl-5-oxidopyrazol-1yl)benzene-1,4-disulfonate\n418-270-7\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-297-00-2\n5-(2-bromophenyl)-2-tert-butyl-2H-tetrazole\n420-820-6\n—\nFlam. Liq. 3\nAcute Tox. 4 *\nAquatic Chronic 2\nH226\nH302\nH411\nGHS02\nGHS07\nGHS09\nWng\nH226\nH302\nH411\n613-298-00-8\nbis-(6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(4-phenylazo)-1H-pyridin-2-one)ethylene dilactate\n421-560-6\n—\nSTOT RE 2 *\nEye Dam. 1\nAquatic Chronic 2\nH373**\nH318\nH411\nGHS05\nGHS08\nGHS09\nDgr\nH373**\nH318\nH411\n613-299-00-3\nmain component 1 (isomer 1):\n2-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonapht-7-ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluoro-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt;\nmain component 1 (isomer 2):\n2-{6-fluoro-4-[3-(2,5-disulfophenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluoro-4-[3(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt;\nmain component 2: 2,3-bis-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt;\nmain component 3: 2,3-bis-{6-fluoro-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt\n422-610-1\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-300-00-7\n1-imidazol-1-yl-octadecan-2-ol\n434-120-3\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n613-301-00-2\ndimethyl-1-{[2-methoxy-5-(2-methyl-butoxycarbonyl)phenylcarbamoyl]-[2-octadecyl-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]methyl} imidazole-4,5-dicarboxylate\n443-910-7\n—\nAquatic Chronic 4\nH413\n—\nH413\n613-302-00-8\ndisodium 2-(5-carbamoyl-1-ethyl-2-hydroxy-4-methyl-6-oxo-1,6-dihydro-pyridine-3-ylazo)-4-(4-fluoro-6-(4-(2-sulfonyloxy-ethylsulfonyl)-phenylamino)-1,3,5-triazine-2-ylamino)benzene sulfonate\n432-980-4\n243858-60-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-303-00-3\n2-(1-methyl-2-(4-phenoxyphenoxy)ethoxy)pyridine\n429-800-1\n95737-68-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-304-00-9\n5,6-dihydroxy-2,3-dihydro-1H-indolium bromide\n421-170-6\n138937-28-7\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n613-305-00-4\n2-(2-hydroxy-4-octyloxyphenyl)-2H-benzotriazole\n448-630-9\n3147-77-1\nAquatic Chronic 4\nH413\n—\nH413\n613-306-00-X\n(2,5-dioxopyrrolidin-1-yl)-9H-fluoren-9-ylmethyl carbonate\n433-520-5\n82911-69-1\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n613-307-00-5\nclothianidin (ISO);\n3-[(2-chloro-1,3-thiazol-5-yl)methyl]-2-methyl-1-nitroguanidine\n—\n210880-92-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM=10\n613-308-00-0\n2-amino-5-methylthiazole\n423-800-5\n7305-71-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH410\n613-309-00-6\n1-methyl-3-phenyl-1-piperazine\n431-180-2\n5271-27-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH312\nH302\nH315\nH318\nH412\nGHS05\nGHS07\nDgr\nH312\nH302\nH315\nH318\nH412\n613-310-00-1\n(-)(3S, 4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxy-phenoxymethyl)-N-benzylpiperidine hydrochloride\n432-360-3\n105813-13-6\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n613-311-00-7\nmethyl-5-nitrophenyl-guanidine\n435-500-1\n152460-07-6\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH319\nH317\nH412\nGHS07\nWng\nH302\nH319\nH317\nH412\n613-312-00-2\n2-(4-methyl-2-phenyl-1-piperazinyl)benzenemethanol monohydrochloride\n420-200-5\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n613-313-00-8\n2-(4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)-1H-isoindole-1,3(2H)-dione\n442-780-9\n173838-67-0\nAquatic Chronic 3\nH412\n—\nH412\n613-314-00-3\n4-decyloxazolidin-2-one;\n4-decyl-1,3-oxazolidin-2-one\n443-770-7\n7693-82-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-315-00-9\ntetrapotassium 4-[5-[3-carboxylato-4,5-dihydro-5-oxo1-(4-sulfonatophenyl)pyrazol-4-ylidene]-3-(piperidinocarbonyl)penta-1,3-dienylidene]-5-hydroxy-1-(4-sulfonatophenyl)pyrazole-3-carboxylate\n430-390-1\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH412\nGHS07\nWng\nH332\nH412\n613-316-00-4\ntrimethylopropane tri(3-aziridinylpropanoate);\n(TAZ)\n257-765-0\n52234-82-9\nMuta. 2\nEye Dam. 1\nSkin Sens. 1\nH341\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH341\nH318\nH317\n613-317-00-X\npenconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole\n266-275-6\n66246-88-6\nRepr. 2\nAcute Tox. 4\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d\nH302\nH410\nM = 1\nM = 1\n614-002-00-X\nsalts of nicotine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Chronic 2\nH330\nH310\nH300\nH411\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH411\nA\n614-003-00-5\nstrychnine\n200-319-7\n57-24-9\nAcute Tox. 1\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH310\nH300\nH410\n614-004-00-0\nsalts of strychnine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH300\nH410\nA\n614-005-00-6\ncolchicine\n200-598-5\n64-86-8\nMuta. 1B\nAcute Tox. 2 *\nH340\nH300\nGHS06\nGHS08\nDgr\nH340\nH300\n614-006-00-1\nbrucine;\n2,3-dimethoxystrychnine\n206-614-7\n357-57-3\nAcute Tox. 2 *\nAcute Tox. 2 *\nAquatic Chronic 3\nH330\nH300\nH412\nGHS06\nDgr\nH330\nH300\nH412\n614-007-00-7\nbrucine sulphate; [1]\nbrucine nitrate; [2]\nstrychnidin-10-one, 2,3-dimethoxy-, mono[(R)-1-methylheptyl 1,2-benzenedicarboxylate]; [3]\nstrychnidin-10-one, 2,3-dimethoxy-, compd.with (S) mono(1-methylheptyl)-1,2-benzenedicarboxylate (1:1) [4]\n225-432-9 [1]\n227-317-9 [2]\n269-439-5 [3]\n269-710-8 [4]\n4845-99-2 [1]\n5786-97-0 [2]\n68239-26-9 [3]\n68310-42-9 [4]\nAcute Tox. 2 *\nAcute Tox. 2 *\nAquatic Chronic 3\nH330\nH300\nH412\nGHS06\nDgr\nH330\nH300\nH412\nA\n614-008-00-2\naconitine\n206-121-7\n302-27-2\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\n614-009-00-8\nsalts of aconitine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\nA\n614-010-00-3\natropine\n200-104-8\n51-55-8\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\n614-011-00-9\nsalts of atropine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\nA\n614-012-00-4\nhyoscyamine\n202-933-0\n101-31-5\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\n614-013-00-X\nsalts of hyoscyamine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\nA\n614-014-00-5\nhyoscine\n200-090-3\n51-34-3\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nH330\nH310\nH300\nGHS06\nDgr\nH330\nH310\nH300\n614-015-00-0\nsalts of hyoscine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 1\nAcute Tox. 2 *\nH330\nH310\nH300\nGHS06\nDgr\nH330\nH310\nH300\nA\n614-016-00-6\npilocarpine\n202-128-4\n92-13-7\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\n614-017-00-1\nsalts of pilocarpine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\nA\n614-018-00-7\npapaverine\n200-397-2\n58-74-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n614-019-00-2\nsalts of papaverine\n—\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\nA\n614-020-00-8\nphysostigmine\n200-332-8\n57-47-6\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\n614-021-00-3\nsalts of physostigmine\n—\n—\nAcute Tox. 2 *\nAcute Tox. 2 *\nH330\nH300\nGHS06\nDgr\nH330\nH300\nA\n614-022-00-9\ndigitoxin\n200-760-5\n71-63-6\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nH331\nH301\nH373 **\nGHS06\nGHS08\nDgr\nH331\nH301\nH373 **\n614-023-00-4\nephedrine\n206-080-5\n299-42-3\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n614-024-00-X\nsalts of ephedrine\n—\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\nA\n614-025-00-5\nouabain\n211-139-3\n630-60-4\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nH331\nH301\nH373 **\nGHS06\nGHS08\nDgr\nH331\nH301\nH373 **\n614-026-00-0\nstrophantin-K\n234-239-9\n11005-63-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nH331\nH301\nH373 **\nGHS06\nGHS08\nDgr\nH331\nH301\nH373 **\n614-027-00-6\nbufa-4,20,22-trienolide, 6-(acetyloxy)-3-(β-D-glucopyranosyloxy)-8,14-dihydroxy-, (3β, 6β)-;\nred squill;\nscilliroside\n208-077-4\n507-60-8\nAcute Tox. 2 *\nH300\nGHS06\nDgr\nH300\n614-028-00-1\nreaction mass of: 2-ethylhexyl mono-D-glucopyranoside;\n2-ethylhexyl di-D-glucopyranoside\n414-420-0\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n614-029-00-7\nconstitutional isomers of penta-O-allyl-β-D-fructofuranosyl-α-D-glucopyranoside;\nconstitutional isomers of hexa-O-allyl-β-D-fructofuranosyl-α-D-glucopyranoside;\nconstitutional isomers of hepta-O-allyl-β-D-fructofuransoyl-α-D-glucopyranoside\n419-640-0\n68784-14-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n615-001-00-7\nmethyl isocyanate\n210-866-3\n624-83-9\nFlam. Liq. 2\nRepr. 2\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nResp. Sens. 1\nSkin Sens. 1\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nH225\nH361d*** H330\nH311\nH301\nH334\nH317\nH335\nH315\nH318\nGHS02\nGHS06\nGHS05\nGHS08\nDgr\nH225\nH361d*** H330\nH311\nH301\nH334\nH317\nH335\nH315\nH318\n615-002-00-2\nmethyl isothiocyanate\n209-132-5\n556-61-6\nAcute Tox. 3 *\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH314\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH331\nH301\nH314\nH317\nH410\n615-003-00-8\nthiocyanic acid\n207-337-4\n463-56-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH312\nH302\nH412\nGHS07\nWng\nH332\nH312\nH302\nH412\nEUH032\n615-004-00-3\nsalts of thiocyanic acid, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH312\nH302\nH412\nGHS07\nWng\nH332\nH312\nH302\nH412\nEUH032\nA\n615-005-00-9\n4,4'-methylenediphenyl diisocyanate; diphenylmethane-4,4'-diisocyanate; [1]\n2,2'-methylenediphenyl diisocyanate; diphenylmethane-2,2'-diisocyanate; [2]\no-(p-isocyanatobenzyl)phenyl isocyanate;\ndiphenylmethane-2,4'-diisocyanate; [3]\nmethylenediphenyl diisocyanate [4]\n202-966-0 [1]\n219-799-4 [2]\n227-534-9 [3]\n247-714-0 [4]\n101-68-8 [1]\n2536-05-2 [2]\n5873-54-1 [3]\n26447-40-5 [4]\nCarc. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nH351\nH332\nH373**\nH319\nH335\nH315\nH334\nH317\nGHS08\nGHS07\nDgr\nH351\nH332\nH373**\nH319\nH335\nH315\nH334\nH317\nEye Irrit. 2; H319:\nC ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Resp. Sens. 1; H334: C ≥ 0,1 %\nSTOT SE 3; H335: C ≥ 5 %\nC2\n615-006-00-4\n2-methyl-m-phenylene diisocyanate;\ntoluene-2,4-di-isocyanate; [1]\n4-methyl-m-phenylene diisocyanate;\ntoluene-2,6-di-isocyanate; [2]\nm-tolylidene diisocyanate;\ntoluene-diisocyanate [3]\n202-039-0 [1]\n209-544-5 [2]\n247-722-4 [3]\n91-08-7 [1]\n584-84-9 [2]\n26471-62-5 [3]\nCarc. 2\nAcute Tox. 2 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH351\nH330\nH319\nH335\nH315\nH334\nH317\nH412\nGHS06\nGHS08\nDgr\nH351\nH330\nH319\nH335\nH315\nH334\nH317\nH412\nResp. Sens. 1; H334: C ≥\n0,1 %\nC\n615-007-00-X\n1,5-naphthylene diisocyanate\n221-641-4\n3173-72-6\nAcute Tox. 4 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nAquatic Chronic 3\nH332\nH319\nH335\nH315\nH334\nH412\nGHS08\nGHS07\nDgr\nH332\nH319\nH335\nH315\nH334\nH412\n615-008-00-5\n3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate; isophorone di-isocyanate\n223-861-6\n4098-71-9\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 2\nH331\nH319\nH335\nH315\nH334\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH319\nH335\nH315\nH334\nH317\nH411\n*\nResp. Sens. 1; H334: C ≥0,5 %\nSkin Sens.1; H317: C ≥0,5 %\n2\n615-009-00-0\n4,4'-methylenedi(cyclohexyl isocyanate); dicyclohexylmethane-4,4'-di-isocyanate\n225-863-2\n5124-30-1\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nH331\nH319\nH335\nH315\nH334\nH317\nGHS06\nGHS08\nDgr\nH331\nH319\nH335\nH315\nH334\nH317\n*\nResp. Sens. 1; H334: C ≥0,5 %\nSkin Sens. 1; H317: C ≥0,5 %\n2\n615-010-00-6\n2,2,4-trimethylhexamethylene-1,6-di-isocyanate; [1]\n2,4,4-trimethylhexamethylene-1,6-di-isocyanate [2]\n241-001-8 [1]\n239-714-4 [2]\n16938-22-0 [1]\n15646-96-5 [2]\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH331\nH319\nH335\nH315\nH334\nGHS06\nGHS08\nDgr\nH331\nH319\nH335\nH315\nH334\n*\nResp. Sens. 1; H334: C ≥0,5 %\nSkin Sens. 1; H317: C ≥0,5 %\nC2\n615-011-00-1\nhexamethylene-di-isocyanate\n212-485-8\n822-06-0\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nH331\nH319\nH335\nH315\nH334\nH317\nGHS06\nGHS08\nDgr\nH331\nH319\nH335\nH315\nH334\nH317\n*\nResp. Sens. 1; H334: C ≥\n0,5 %\nSkin Sens. 1; H317: C ≥0,5 %\n2\n615-012-00-7\n4-isocyanatosulphonyltoluene;\ntosyl isocyanate\n223-810-8\n4083-64-1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\nEUH014\nEye Irrit.;\nH319: C ≥ 5 %\nSTOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 %\n615-014-00-8\ntris(1-dodecyl-3-methyl-2-phenylbenzimidazolium)hexacyanoferrate\n—\n7276-58-6\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n615-015-00-3\n1,7,7-trimethylbicyclo(2,2,1)hept-2-yl thiocyanatoacetate;\nisobornyl thiocyanoacetate\n204-081-5\n115-31-1\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n615-016-00-9\npotassium cyanate\n209-676-3\n590-28-3\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n615-017-00-4\ncalcium cyanamide\n205-861-8\n156-62-7\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH302\nH335\nH318\nGHS05\nGHS07\nDgr\nH302\nH335\nH318\n615-018-00-X\n2-(2-butoxyethoxy)ethyl thiocyanate\n203-985-7\n112-56-1\nFlam. Liq. 3\nAcute Tox. 3 *\nAcute Tox. 3 *\nH226\nH311\nH301\nGHS02\nGHS06\nDgr\nH226\nH311\nH301\n615-019-00-5\ndicyclohexylcarbodiimide\n208-704-1\n538-75-0\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH311\nH302\nH318\nH317\nGHS06\nGHS05\nDgr\nH311\nH302\nH38\nH317\n615-020-00-0\nmethylene dithiocyanate\n228-652-3\n6317-18-6\nAcute Tox. 2 *\nAcute Tox. 3 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nH330\nH301\nH314\nH317\nH400\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH301\nH314\nH317\nH400\n615-021-00-6\n1,3,5-tris(oxiranylmethyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione;\nTGIC\n219-514-3\n2451-62-9\nMuta. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH340\nH331\nH301\nH373 **\nH318\nH317\nH412\nGHS06\nGHS08\nGHS05\nDgr\nH340\nH331\nH301\nH373 **\nH318\nH317\nH412\n615-022-00-1\nmethyl 3-isocyanatosulfonyl-2-thiophene-carboxylate\n410-550-7\n79277-18-2\nSTOT RE 2 *\nResp. Sens. 1\nSkin Sens. 1\nH373**\nH334\nH317\nGHS08\nDgr\nH373**\nH334\nH317\nEUH014\n615-023-00-7\n2-(isocyanatosulfonylmethyl)benzoic acid methyl ester; (alt.):methyl 2-(isocyanatosulfonylmethyl)benzoate\n410-900-9\n83056-32-0\nFlam. Liq. 3\nMuta. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nResp. Sens. 1\nH226\nH341\nH332\nH373 **\nH318\nH334\nGHS02\nGHS08\nGHS05\nGHS07\nDgr\nH226\nH341\nH332\nH373 **\nH318\nH334\nEUH014\n615-024-00-2\n2-phenylethylisocyanate\n413-080-0\n1943-82-4\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1A\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 2\nH331\nH302\nH314\nH334\nH317\nH411\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH331\nH302\nH314\nH334\nH317\nH411\n615-025-00-8\n4,4'-ethylidenediphenyl dicyanate\n405-740-1\n47073-92-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH373 **\nH318\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH302\nH373 **\nH318\nH410\n615-026-00-3\n4,4'-methylenebis(2,6-dimethylphenyl cyanate)\n405-790-4\n101657-77-6\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n615-028-00-4\nethyl 2-(isocyanatosulfonyl)benzoate\n410-220-2\n77375-79-2\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH302\nH373**\nH318\nH334\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\nH334\nH317\nEUH014\n615-029-00-X\n2,5-bis-isocyanatomethyl-bicyclo[2.2.1]heptane\n411-280-2\n—\nAcute Tox. 2 *\nAcute Tox. 4 *\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH330\nH302\nH314\nH334\nH317\nH412\nGHS06\nGHS08\nGHS05\nDgr\nH330\nH302\nH314\nH334\nH317\nH412\n615-030-00-5\nalkali salts and alkali earth salts of thiocyanic acid, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH312\nH302\nH412\nGHS07\nWng\nH332\nH312\nH302\nH412\nA\n615-031-00-0\nthallium thiocyanate\n222-571-7\n3535-84-0\nAcute Tox. 2 *\nAcute Tox. 2 *\nAcute Tox. 4 *\nSTOT RE 2\nAquatic Chronic 2\nH330\nH300\nH312\nH373**\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH300\nH312\nH373**\nH411\n615-032-00-6\nmetal salts of thiocyanic acid, with the exception of those specified elsewhere in this Annex\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH312\nH302\nH410\nA\n615-033-00-1\nreaction product of diphenylmethanediisocyanate, octylamine, oleylamine and cyclohexylamine (1:1.58:0.32:0097)\n430-980-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-034-00-7\nreaction product of diphenylmethanediisocyanate, octylamine,\n4-ethoxyaniline and ethylenediamine (1:0,37:1,53:0,05)\n430-750-8\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-035-00-2\nreaction product of diphenylmethanediisocyanate, octylamine and oleylamine (molar ratio\n1:1.86:0.14)\n430-930-6\n122886-55-9\nAquatic Chronic 4\nH413\n—\nH413\n615-036-00-8\nreaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction of isomers:\n65 % 2,4-and 35 % 2,6-diisocyanate), octylamine, oleylamine and 4-ethoxyaniline (molar ratio 4:1:7:1:2)\n430-940-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-037-00-3\nreaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction mass of isomers: 65 % 2,4-and 35 % 2,6-diisocyanate), octylamine and oleylamine (molar ratio 4:1:9:1)\n430-950-5\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-038-00-9\nreaction product of toluenediisocyanate (reaction mass of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate) and aniline\n(molarratio 1:2)\n430-960-1\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-039-00-4\nreaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction mass of isomers: 65 % 2,4-and 35 % 2,6-diisocyanate), octylamine, oleylamine and 4-ethoxyaniline (molar ratio 3.88:1:6.38:0.47:2.91)\n430-970-4\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-044-00-1\n4-chlorophenylisocyanate\n203-176-9\n104-12-1\nAcute Tox. 2 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH302\nH335\nH315\nH318\nH334\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH330\nH302\nH335\nH315\nH318\nH334\nH410\n615-045-00-7\n4,4'-methylene bis(3-chloro-2,6-di-ethylphenylisocyanate)\n420-530-1\n—\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 4\nH334\nH317\nH413\nGHS08\nDgr\nH334\nH317\nH413\n616-001-00-X\nN, N-dimethylformamide;\ndimethyl formamide\n200-679-5\n68-12-2\nRepr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nH360D *** H332\nH312\nH319\nGHS08\nGHS07\nDgr\nH360D *** H332\nH312\nH319\n616-002-00-5\n2-fluoroacetamide\n211-363-1\n640-19-7\nAcute Tox. 2 *\nAcute Tox. 3 *\nH300\nH311\nGHS06\nDgr\nH300\nH311\n616-003-00-0\nacrylamide;\nprop-2-enamide\n201-173-7\n79-06-1\nCarc. 1B\nMuta. 1B Repr. 2\nAcute Tox. 3 *\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH350\nH340\nH361f *** H301\nH372 **\nH332\nH312\nH319\nH315\nH317\nGHS06\nGHS08\nDgr\nH350\nH340\nH361f *** H301\nH372 **\nH332\nH312\nH319\nH315\nH317\nD\n616-004-00-6\nallidochlor (ISO);\nN,N-diallylchloroacetamide\n202-270-7\n93-71-0\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH312\nH302\nH319\nH315\nH411\nGHS07\nGHS09\nWng\nH312\nH302\nH319\nH315\nH411\n616-005-00-1\nchlorthiamid (ISO);\n2,6-dichloro (thiobenzamide)\n217-637-7\n1918-13-4\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n616-007-00-2\ndiphenamid (ISO);\nN, N-dimethyl-2,2-diphenylacetamide\n213-482-4\n957-51-7\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-008-00-8\npropachlor (ISO);\n2-chloro-N-isopropylacetanilide;\nα-chloro-N-isopropylacetanilide\n217-638-2\n1918-16-7\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH319\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH319\nH317\nH410\n616-009-00-3\npropanil (ISO);\n3',4'-dichloropropionanilide\n211-914-6\n709-98-8\nAcute Tox. 4 *\nAquatic Acute 1\nH302\nH400\nGHS07\nGHS09\nWng\nH302\nH400\nM=10\n616-010-00-9\ntosylchloramide sodium\n204-854-7\n127-65-1\nAcute Tox. 4 *\nSkin Corr. 1B\nResp. Sens. 1\nH302\nH314\nH334\nGHS08\nGHS05\nGHS07\nDg\nH302\nH314\nH334\nEUH031\n616-012-00-X\nN-(dichlorofluoromethylthio)phthalimide;\nN-(fluorodichloromethylthio)phthalimide\n211-952-3\n719-96-0\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n616-013-00-5\nbutyraldehyde oxime\n203-792-8\n110-69-0\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nH311\nH302\nH319\nGHS06\nDgr\nH311\nH302\nH319\n616-014-00-0\n2-butanone oxime;\nethyl methyl ketoxime;\nethyl methyl ketone oxime\n202-496-6\n96-29-7\nCarc. 2\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH351\nH312\nH318\nH317\nGHS08\nGHS05\nGHS07\nDgr\nH351\nH312\nH318\nH317\n616-015-00-6\nalachlor (ISO);\n2-chloro-2',6'-diethyl-N-(methoxymethyl)acetanilide\n240-110-8\n15972-60-8\nCarc. 2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH317\nH410\nM=10\n616-016-00-1\n1-(3,4-dichlorophenylimino)\nthiosemicarbazide\n—\n5836-73-7\nAcute Tox. 2 *\nH300\nGHS06\nDgr\nH300\n616-017-00-7\ncartap hydrochloride\n239-309-2\n15263-52-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH312\nH302\nH410\n616-018-00-2\nN,N-diethyl-m-toluamide;\ndeet\n205-149-7\n134-62-3\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 3\nH302\nH319\nH315\nH412\nGHS07\nWng\nH302\nH319\nH315\nH412\n616-019-00-8\nperfluidone (ISO);\n1,1,1-trifluoro-N-(4-phenylsulphonyl-o-tolyl)methanesulphonamide;\n253-718-3\n37924-13-3\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n616-020-00-3\ntebuthiuron (ISO);\n1-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-1,3-dimethylurea\n251-793-7\n34014-18-1\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n616-021-00-9\nthiazafluron (ISO);\n1,3-dimethyl-1-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)urea\n246-901-4\n25366-23-8\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n616-022-00-4\nacetamide\n200-473-5\n60-35-5\nCarc. 2\nH351\nGHS08\nWng\nH351\n616-023-00-X\nN-hexadecyl(or octadecyl)-N-hexadecyl (or octadecyl)benzamide\n401-980-6\n—\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n616-024-00-5\n2-(4,4-dimethyl-2,5-dioxooxazolidin-1-yl)-2-chloro-5-(2-(2,4-di-tert-pentylphenoxy)butyramido)-4,4-dimethyl-3-oxovaleranilide\n402-260-4\n54942-74-4\nAquatic Chronic 4\nH413\n—\nH413\n616-025-00-0\nvalinamide\n402-840-7\n20108-78-5\nRepr. 2\nEye Irrit. 2\nSkin Sens. 1\nH361f *** H319\nH317\nGHS08\nWng\nH361f *** H319\nH317\n616-026-00-6\nthioacetamide\n200-541-4\n62-55-5\nCarc. 1B\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 3\nH350\nH302\nH319\nH315\nH412\nGHS08\nGHS07\nDgr\nH350\nH302\nH319\nH315\nH412\n616-027-00-1\ntris(2-(2-hydroxyethoxy)ethyl)ammonium 3-acetoacetamido-4-methoxybenzenesulfonate\n403-760-5\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-028-00-7\nN-(4-(3-(4-cyanophenyl)ureido)-3-hydroxyphenyl)-2-(2,4-di-tert-pentylphenoxy)octanamide\n403-790-9\n108673-51-4\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-029-00-2\nN, N'-ethylenebis(vinylsulfonylacetamide)\n404-790-1\n66710-66-5\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n616-030-00-8\nethidimuron (ISO);\n1-(5-ethylsulphonyl-1,3,4-thiadiazol-2-yl)-1,3-dimethylurea\n250-010-6\n30043-49-3\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n616-031-00-3\ndimethachlor (ISO);\n2-chloro-N-(2,6-dimethylphenyl)-N-(2-methoxyethyl)acetamide;\n256-625-6\n50563-36-5\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n616-032-00-9\ndiflufenican (ISO);\nN-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide\n—\n83164-33-4\nAquatic Chronic 3\nH412\n—\nH412\n616-033-00-4\ncyprofuram (ISO);\nN-(3-chlorophenyl)-N-(tetrahydro-2-oxo-3-furyl)cyclopropanecarboxamide\n274-050-9\n69581-33-5\nAcute Tox. 3 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH312\nH410\n616-034-00-X\npyracarbolid; (ISO);\n3,4-dihydro-6-methyl-2H-pyran-5-carboxanilide\n246-419-4\n24691-76-7\nAquatic Chronic 3\nH412\n—\nH412\n616-035-00-5\ncymoxanil (ISO);\n2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide\n261-043-0\n57966-95-7\nRepr. 2\nAcute Tox. 4\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361fd\nH302\nH373 (blood, thymus)\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361fd\nH302\nH373 (blood, thymus)\nH317\nH410\nM = 1\nM = 1\n616-036-00-0\n2-chloracetamide\n201-174-2\n79-07-2\nRepr. 2\nAcute Tox. 3 *\nSkin Sens. 1\nH361f *** H301\nH317\nGHS06\nGHS08\nDgr\nH361f *** H301\nH317\nSkin Sens. 1; H317: C ≥ 0,1 %\n616-038-00-1\n(4-aminophenyl)-N-methylmethylensulfonamide hydrochloride\n406-010-5\n88918-84-7\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n616-039-00-7\n3',5'-dichloro-4'-ethyl-2'-hydroxypalmitanilide\n406-200-8\n117827-06-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-040-00-2\npotassium N-(4-toluenesulfonyl)-4-toluenesulfonamide\n406-650-5\n97888-41-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n616-041-00-8\n3',5'-dichloro-2-(2,4-di-tert-pentylphenoxy)-4'-ethyl-2'-hydroxyhexananilide\n406-840-8\n101664-25-9\nAquatic Chronic 4\nH413\n—\nH413\n616-042-00-3\nN-(2-(6-ethyl-7-(4-methylphenoxy)-1H-pyrazolo[1,5-b][1,2,4]triazol-2-yl)propyl)-2-octadecyloxybenzamide\n407-070-5\n142859-67-4\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-043-00-9\nisoxaben (ISO);\nN-[3-(1-ethyl-1-methylpropyl)-1,2-oxazol-5-yl]-2,6-dimethoxybenzamide\n407-190-8\n82558-50-7\nAquatic Chronic 4\nH413\n—\nH413\n616-044-00-4\nN-(3,5-dichloro-4-ethyl-2-hydroxyphenyl)-2-(3-pentadecylphenoxy)-butanamide\n402-510-2\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n616-045-00-X\n2'-(4-chloro-3-cyano-5-formyl-2-thienylazo)-5'-diethylamino-2-methoxyacetanilide\n405-190-2\n122371-93-1\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-046-00-5\nN-(2-(6-chloro-7-methylpyrazolo(1,5-b)-1,2,4-triazol-4-yl)propyl)-2-(2,4-di-tert-pentylphenoxy)octanamide\n406-390-2\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-047-00-0\nreaction mass of: 2,2',2'',2'''-(ethylenedinitrilotetrakis-N, N-di(C16)alkylacetamide;\n2,2',2'',2'''-(ethylenedinitrilotetrakis-N, N-di(C18)alkylacetamide\n406-640-0\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-048-00-6\n3'-trifluoromethylisobutyranilide\n406-740-4\n1939-27-1\nSTOT RE 2 *\nAquatic Chronic 2\nH373 **\nH411\nGHS08\nGHS09\nWng\nH373 **\nH411\n616-049-00-1\n2-(2,4-bis(1,1-dimethylethyl)phenoxy)-N-(3,5-dichloro-4-ethyl-2-hydroxyphenyl)-hexanamide\n408-150-2\n99141-89-6\nAquatic Chronic 4\nH413\n—\nH413\n616-050-00-7\nlufenuron (ISO);\nN-[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl-aminocarbonyl]-2,6-difluorobenzamide\n410-690-9\n103055-07-8\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n616-051-00-2\nreaction mass of: 2,4 -bis(N'-(4-methylphenyl)-ureido)-toluene;\n2,6 -bis(N'-(4-methylphenyl)-ureido)-toluene\n411-070-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-052-00-8\nformamide\n200-842-0\n75-12-7\nRepr. 1B\nH360D ***\nGHS08\nDgr\nH360D ***\n616-053-00-3\nN-methylacetamide\n201-182-6\n79-16-3\nRepr. 1B\nH360D ***\nGHS08\nDgr\nH360D ***\n616-054-00-9\niprodione (ISO);\n3-(3,5-dichlorophenyl)-2,4-dioxo-N-isopropylimidazolidine-1-carboxamide\n253-178-9\n36734-19-7\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n616-055-00-4\npropyzamide (ISO);\n3,5-dichloro-N-(1,1-dimethylprop-2-ynyl)benzamide\n245-951-4\n23950-58-5\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n616-056-00-X\nN-methylformamide\n204-624-6\n123-39-7\nRepr. 1B\nAcute Tox. 4 *\nH360D *** H312\nGHS08\nGHS07\nDg\nH360D *** H312\n616-057-00-5\nreaction mass of: N-[3-hydroxy-2-(2-methylacryloylaminomethoxy)propoxymethyl]-2-methylacrylamide;\nN-[2,3-bis-(2-methylacryloylaminomethoxy)propoxymethyl]-2-methylacrylamide; methacrylamide;\n2-methyl-N-(2-methylacryloylaminomethoxymethyl)-acrylamide;\nN-(2,3-dihydroxypropoxymethyl)-2-methylacrylamide\n412-790-8\n—\nCarc. 1B\nMuta. 2\nSTOT RE 2 *\nH350\nH341\nH373 **\nGHS08\nDgr\nH350\nH341\nH373 **\n616-058-00-0\n1,3-bis(3-methyl-2,5-dioxo-1H-pyrrolinylmethyl)benzene\n412-570-1\n119462-56-5\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH318\nH317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH373 **\nH318\nH317\nH410\n616-059-00-6\n4-((4-(diethylamino)-2-ethoxyphenyl)imino)-1,4-dihydro-1-oxo-N-propyl-2-naphthalenecarboxamide\n412-650-6\n121487-83-0\nAquatic Chronic 4\nH413\n—\nH413\n616-060-00-1\ncondensation product of: 3-(7-carboxyhept-1-yl)-6-hexyl-4-cyclohexene-1,2-dicarboxylic acid with polyamines (primarily\namino-ethyl-piperazine and triethylenetetramine)\n413-770-1\n—\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH317\nH410\n616-061-00-7\nN,N'—1,6-hexanediylbis(N-(2,2,6,6-tetramethyl-piperidin-4-yl)-formamide\n413-610-0\n124172-53-8\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n616-062-00-2\nN-[3-[(2-acetyloxy)ethyl](phenyl-methyl)amino]-4-methoxyphenylacetamide\n411-590-8\n70693-57-1\nSkin Corr. 1B\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\n616-063-00-8\n3-dodecyl-(1-(1,2,2,6,6-pentamethyl-4-piperidin)-yl)-2,5-pyrrolidindione\n411-920-0\n106917-30-0\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH302\nH373 **\nH314\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH331\nH302\nH373 **\nH314\nH410\n616-064-00-3\nN—tert-butyl-3-methylpicolinamide\n406-720-5\n32998-95-1\nAquatic Chronic 3\nH412\n—\nH412\n616-065-00-9\n3'-(3-acetyl-4-hydroxyphenyl)-1,1-diethylurea\n411-970-3\n79881-89-3\nAcute Tox. 4 *\nSTOT RE 2 *\nH302\nH373 **\nGHS08\nGHS07\nWng\nH302\nH373 **\n616-066-00-4\n5,6,12,13-tetrachloroanthra(2,1,9-def:6,5,10-d'e'f')diisoquinoline-1,3,8,10(2H,9H)-tetrone\n405-100-1\n115662-06-1\nRepr. 2\nH361f ***\nGHS08\nWng\nH361f ***\n616-067-00-X\ndodecyl 3-(2-(3-benzyl-4-ethoxy-2,5-dioxoimidazolidin-1-yl)-4,4-dimethyl-3-oxovaleramido)-4-chlorobenzoate\n407-300-4\n92683-20-0\nAquatic Chronic 4\nH413\n—\nH413\n616-068-00-5\npotassium 4-(11-methacrylamidoundecanamido)benzenesulfonate\n406-500-9\n174393-75-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-069-00-0\n1-hydroxy-5-(2-methylpropyloxycarbonylamino)-N-(3-dodecyloxypropyl)-2-naphthoamide\n406-210-2\n110560-22-0\nAquatic Chronic 4\nH413\n—\nH413\n616-070-00-6\nreaction mass of: 3,3'-dicyclohexyl-1,1'-methylenebis(4,1-phenylene)diurea;\n3-cyclohexyl-1-(4-(4-(3-octadecylureido)benzyl)phenyl)urea;\n3,3'-dioctadecyl-1,1'-methylenebis(4,1-phenylene)diurea\n406-530-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-071-00-1\nreaction mass of: bis(N-cyclohexyl-N'-phenyleneureido)methylene;\nbis(N-octadecyl-N'-phenyleneureido)methylene;\nbis(N-dicyclohexyl-N'-phenyleneureido)methylene (1:2:1)\n406-550-1\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-072-00-7\n1-(2-deoxy-5-O-trityl-β-D-threopentofuranosyl)thymine\n407-120-6\n55612-11-8\nAquatic Chronic 4\nH413\n—\nH413\n616-073-00-2\n4'-ethoxy-2-benzimidazoleanilide\n407-600-5\n120187-29-3\nMuta. 2\nAquatic Chronic 4\nH341\nH413\nGHS08\nWng\nH341\nH413\n616-074-00-8\nN-butyl-2-(4-morpholinylcarbonyl)benzamide\n407-730-2\n104958-67-0\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH319\nH317\nH412\nGHS07\nWng\nH319\nH317\nH412\n616-075-00-3\nD, L-(N,N-diethyl-2-hydroxy-2-phenylacetamide)\n408-120-9\n65197-96-8\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n616-076-00-9\ntebufenozide (ISO);\nN-tert-butyl-N'-(4-ethylbenzoyl)-3,5-dimethylbenzohydrazide\n412-850-3\n112410-23-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n616-077-00-4\nreaction mass of: 2-(9-methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro-(1H,8H)-anthra[2,1,9-def: 6,5,10-d'e'f']diisoquinolin-2-ylethansulfonic acid;\npotassium 2-(9-methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro-(1H,8H)-anthra[2,1,9-def: 6,5,10-d'e'f']diisoquinolin-2-ylethansulfate\n411-310-4\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n616-078-00-X\n2-[2,4-bis(1,1-dimethyl-ethyl)phenoxy]-N-(2-hydroxy-5-methyl-phenyl)hexanamide\n411-330-3\n104541-33-5\nAquatic Chronic 4\nH413\n—\nH413\n616-079-00-5\n1,6-hexanediyl-bis(2-(2-(1-ethylpentyl)-3-oxazolidinyl)ethyl)carbamate\n411-700-4\n140921-24-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-080-00-0\n4-(2-((3-ethyl-4-methyl-2-oxo-pyrrolin-1-yl)carboxamido)ethyl)benzenesulfonamide)\n411-850-0\n119018-29-0\nAquatic Chronic 3\nH412\n—\nH412\n616-081-00-6\n5-bromo-8-naphtholactam\n413-480-5\n24856-00-6\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n616-082-00-1\nN-(5-chloro-3-((4-(diethylamino)-2-methylphenyl)imino-4-methyl-6-oxo-1,4-cyclohexadien-1-yl)benzamide\n413-200-1\n129604-78-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-083-00-7\n[2-[(4-nitrophenyl)amino]ethyl]urea\n410-700-1\n27080-42-8\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n616-084-00-2\n2,4-bis[N'-(4-methylphenyl)ureido]toluene\n411-790-5\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-085-00-8\n3-(2,4-dichlorophenyl)-6-fluoro-quinazoline-2,4(1H,3H)-dione\n412-190-6\n168900-02-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-086-00-3\n2-acetylamino-6-chloro-4-[(4-diethylamino)2-methylphenyl-imino]-5-methyl-1-oxo-2,5-cyclohexadiene\n412-250-1\n102387-48-4\nAquatic Chronic 4\nH413\n—\nH413\n616-087-00-9\nreaction mass of: 7,9,9-trimethyl-3,14-dioxa-4,13-dioxo-5,12-diazahexadecane-1,16-diyl-prop-2-enoate;\n7,7,9-trimethyl-3,14-dioxa-4,13-dioxo-5,12-diazahexadecane-1,16-diyl-prop-2-enoate\n412-260-6\n52658-19-2\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH319\nH317\nH411\nGHS07\nGHS09\nWng\nH319\nH317\nH411\n616-088-00-4\n2-aminosulfonyl-N, N-dimethylnicotinamide\n413-440-7\n112006-75-4\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n616-089-00-X\n5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidine)-3-fluoro-2-hydroxymethyltetrahydrofuran\n415-360-8\n41107-56-6\nMuta. 2\nH341\nGHS08\nWng\nH341\n616-090-00-5\n1-(1,4-benzodioxan-2-ylcarbonyl)piperazine hydrochloride\n415-660-9\n70918-74-0\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Chronic 2\nH331\nH311\nH301\nH373 **\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH373 **\nH411\n616-091-00-0\n1,3,5-tris-[(2S and 2R)-2,3-epoxypropyl]-1,3,5-triazine-2,4,6-(1H,3H,5H)-trione\n423-400-0\n59653-74-6\nMuta. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH340\nH331\nH302\nH373 **\nH318\nH317\nGHS06\nGHS08\nGHS05\nDgr\nH340\nH331\nH302\nH373 **\nH318\nH317\n616-092-00-6\npolymeric reaction product of bicyclo[2.2.1]hepta-2,5-diene, ethene, 1,4-hexadiene, 1-propene with N, N-di-2-propenylformamide\n404-035-6\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-093-00-1\nreaction products of: aniline-terephthalaldehyde-o-toluidine condensate with maleic anhydride\n406-620-1\n129217-90-9\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-095-00-2\n3,3'-dioctadecyl-1,1'-methylene\nbis(4,1-phenylene)diurea\n406-690-3\n43136-14-7\nAquatic Chronic 4\nH413\n—\nH413\n616-096-00-8\nN-(3-hexadecyloxy-2-hydroxyprop-1-yl)-N-(2-hydroxyethyl)palmitamide\n408-110-4\n110483-07-3\nAquatic Chronic 4\nH413\n—\nH413\n616-097-00-3\nN,N'-1,4-phenylenebis(2-((2-methoxy-4-nitrophenyl)azo)-3-oxobutanamide\n411-840-6\n83372-55-8\nAquatic Chronic 4\nH413\n—\nH413\n616-098-00-9\n1-[4-chloro-3-((2,2,3,3,3-pentafluoropropoxy)methyl)phenyl]-5-phenyl-1H-1,2,4-triazole-3-carboxamide\n411-750-7\n119126-15-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n616-099-00-4\n2-[4-[(4-hydroxyphenyl)sulfonyl]phenoxy]-4,4-dimethyl-N-[5-[(methylsulfonyl)amino]-2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]phenyl]-3-oxopentanamide\n414-170-2\n135937-20-1\nAquatic Chronic 4\nH413\n—\nH413\n616-100-00-8\n1,3-dimethyl-1,3-bis(trimethylsilyl)urea\n414-180-7\n10218-17-4\nAcute Tox. 4 *\nSkin Irrit. 2\nH302\nH315\nGHS07\nWng\nH302\nH315\n616-101-00-3\n(S)-N-tert-butyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide\n414-600-9\n149182-72-9\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-102-00-9\nreaction mass of: α-[3-(3-mercaptopropanoxycarbonylamino)methylphenylaminocarbonyl]-ω-[3-(3-mercaptopropanoxycarbonylamino)methylphenylaminocarbonyloxy]-poly-(oxyethylene-co-oxypropylene);\n1,2-(or 1,3-)bis[α-(3-mercaptopropanoxycarbonylamino)methylphenylaminocarbonyl)-ω-oxy-poly(oxyethylene-co-oxypropylene)]-3-(or 2-)propanol;\n1,2,3-tris[α-(3-mercaptopropanoxycarbonyl-amino)methylphenylaminocarbonyl)-ω-oxy-poly-(oxyethylene-co-oxypropylene)]propane]\n415-870-0\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-103-00-4\n(S,S)-trans-4-(acetylamino)-5,6-dihydro-6-methyl-7,7-dioxo-4H-thieno[2,3-b]thiopyran-2-sulfonamide\n415-030-3\n120298-38-6\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n616-104-00-X\nbenalaxyl (ISO);\nmethyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate\n275-728-7\n71626-11-4\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-105-00-5\nchlorotoluron (ISO);\n3-(3-chloro-p-tolyl)-1,1-dimethylurea\n239-592-2\n15545-48-9\nCarc. 2\nRepr. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361d *** H400\nH410\nGHS08\nGHS09\nWng\nH351\nH361d *** H410\n616-106-00-0\nphenmedipham (ISO);\nmethyl 3-(3-methylcarbaniloyloxy)carbanilate\n237-199-0\n13684-63-4\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-107-00-6\ncinidon ethyl (ISO);\nethyl (Z)-2-chloro-3-[2-chloro-5-(cyclohex-1-ene-1,2-dicarboximido)phenyl]acrylate\n—\n142891-20-1\nCarc. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH317\nH410\n616-108-00-1\niodosulfuron-methyl-sodium; sodium ({[5-iodo-2-(methoxycarbonyl)phenyl]sulfonyl}carbamoyl)(4-methoxy-6-methyl-1,3,5-triazin-2-yl)azanide\n—\n144550-36-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-109-00-7\nsulfosulfuron (ISO);\n1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea\n—\n141776-32-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-110-00-2\ncyclanilide (ISO);\n1-(2,4-dichloroanilinocarbonyl)cyclopropanecarboxylic acid\n419-150-7\n113136-77-9\nAcute Tox. 4 * Aquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n616-111-00-8\nfenhexamid (ISO);\nN-(2,3-dichlor-4-hydroxyphenyl)-1-methylcyclohexancarboxamid\n422-530-5\n126833-17-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n616-112-00-3\noxasulfuron (ISO);\noxetan-3-yl 2-[(4,6-dimethylpyrimidin-2-yl)-carbamoylsulfamoyl]benzoate\n—\n144651-06-9\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373 **\nH400\nH410\nGHS08\nGHS09\nWng\nH373 **\nH410\n616-113-00-9\ndesmedipham (ISO);\nethyl 3-phenylcarbamoyloxyphenylcarbamate\n237-198-5\n13684-56-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=10\n616-114-00-4\ndodecanamide, N,N'-(9,9',10,10'-tetrahydro-9,9',10,10'-tetraoxo(1,1'-bianthracene)-4,4'-diyl)bis-\n418-010-2\n136897-58-0\nAquatic Chronic 4\nH413\n—\nH413\n616-115-00-X\nN-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide\n416-150-9\n136450-06-1\nAquatic Chronic 4\nH413\n—\nH413\n616-116-00-5\nN-(4-dimethylaminopyridinium)-3-methoxy-4-(1-methyl-5-nitroindol-3-ylmethyl)-N-(o-tolylsulfonyl)benzamidate\n416-790-9\n143052-96-4\nAquatic Chronic 4\nH413\n—\nH413\n616-117-00-0\nN-[2-(3-acetyl-5-nitrothiophen-2-ylazo)-5-diethylaminophenyl]acetamide\n416-860-9\n777891-21-1\nRepr. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f *** H317\nH400\nH410\nGHS08\nGHS09\nWng\nH361f *** H317\nH410\n616-118-00-6\nN-(2',6'-dimethylphenyl)-2-piperidinecarboxamide hydrochloride\n417-950-0\n65797-42-4\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-119-00-1\n2-(1-butyl-3,5-dioxo-2-phenyl-(1,2,4)-triazolidin-4-yl)-4,4-dimethyl-3-oxo-N-(2-methoxy-5-(2-(dodecyl-1-sulfonyl))propionylamino)-phenyl)-pentanamide\n418-060-5\n118020-93-2\nAquatic Chronic 4\nH413\n—\nH413\n616-120-00-7\nreaction mass of: N-(3-dimethylamino-4-methyl-phenyl)-benzamide;\nN-(3-dimethylamino-2-methyl-phenyl)-benzamide;\nN-(3-dimethylamino-3-methyl-phenyl)-benzamide\n420-600-1\n—\nSTOT RE 2 *\nAquatic Chronic 2\nH373 **\nH411\nGHS08\nGHS09\nWng\nH373 **\nH411\n616-121-00-2\n2,4-dihydroxy-N-(2-methoxyphenyl)benzamide\n419-090-1\n129205-19-2\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-122-00-8\nmethyl neodecanamide\n414-460-9\n105726-67-8\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n616-123-00-3\nN-[3-[[4-(diethylamino)-2-methylphenyl]imino]-6-oxo-1,4-cyclohexadienyl]acetamide\n414-740-0\n96141-86-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-124-00-9\nlithium bis(trifluoromethylsulfonyl)imide\n415-300-0\n90076-65-6\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 2 *\nSkin Corr. 1B\nAquatic Chronic 3\nH311\nH301\nH373**\nH314\nH412\nGHS06\nGHS05\nGHS08\nDgr\nH311\nH301\nH373**\nH314\nH412\n616-125-00-4\n3-cyano-N-(1,1-dimethylethyl)androsta-3,5-diene-17-β-carboxamide\n415-730-9\n151338-11-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\n410\n616-126-00-X\n1-methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide\n423-960-6\n139756-01-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n616-127-00-5\nreaction mass of: N, N'-Ethane-1,2-diylbis(decanamide);\n12-Hydroxy-N-[2-[1-oxydecyl)amino]ethyl]octadecanamide;\nN, N'-Ethane-1,2-diylbis(12hydroxyoctadecanamide)\n430-050-2\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-128-00-0\nN-(2-(1-allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)-acetamide\n417-530-7\n123590-00-1\nAquatic Chronic 4\nH413\n—\nH413\n616-129-00-6\nN,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide\n419-710-0\n42774-15-2\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n616-130-00-1\nN-(3-(2-(4,4-dimethyl-2,5-dioxo-imidazolin-1-yl)-4,4-dimethyl-3-oxo-pentanoylamino)-4-methoxy-phenyl)-octadecanamide\n421-780-2\n150919-56-5\nAquatic Chronic 4\nH413\n—\nH413\n616-131-00-7\n1-aminocyclopentanecarboxamide\n422-950-9\n17193-28-1\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nH372**\nH302\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH372**\nH302\nH318\n616-132-00-2\nN-[4-(4-cyano-2-furfurylidene-2,5-dihydro-5-oxo-3-furyl)phenyl]butane-1-sulfonamide\n423-250-6\n130016-98-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-133-00-8\nN-cyclohexyl-S, S-dioxo\nbenzo[b]tiophene-2-carboxamide\n423-990-1\n149118-66-1\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n616-134-00-3\n3,3'-bis(dioctyloxyphosphinothioylthio)-N, N'-oxybis(methylene)dipropionamide\n401-820-5\n793710-14-2\nAquatic Chronic 3\nH412\n—\nH412\n616-135-00-9\n(3S,4aS,8aS)-2-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-tert-butyldecahydroisoquinoline-3-carboxamide\n430-230-0\n136522-17-3\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-136-00-4\nreaction product of cocoalkyldiethanolamides and cocoalkylmonoglycerides and molybdenumtrioxide (1.75-2.2: 0.75-1.0:0.1-1.1)\n430-380-7\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n616-137-00-X\n4-dichloroacetyl-1-oxa-4-azaspiro[4.5]decane\n401-130-4\n71526-07-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-138-00-5\nbenzoic acid, N-tert-butyl-N'-(4-chlorobenzoyl)hydrazide\n431-600-4\n112226-61-6\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-139-00-0\n(3S, 4aS, 8aS)-N-tert-butyldecahydro-3-isoquinolinecarboxamide\n420-380-5\n136465-81-1\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n616-140-00-6\nN, N''-(methylenedi-4,1-phenylene)bis[N'-(4-methylphenyl)urea]\n429-380-1\n133336-92-2\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-141-00-1\nzoxamide (ISO);\n(RS)-3,5-dichloro-N-(3-chloro-1-ethyl-1-methyl-2-oxopropyl)-p-toluamide\n—\n156052-68-5\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM=10\n616-142-00-7\n1,3-bis(vinylsulfonylacetamido)propane\n428-350-3\n93629-90-4\nMuta. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH341\nH318\nH317\nH412\nGHS08\nGHS05\nGHS07\nDgr\nH341\nH318\nH317\nH412\n616-143-00-2\nN,N'-dihexadecyl-N,N'-bis(2-hydroxyethyl)propanediamide\n422-560-9\n149591-38-8\nRepr. 2\nEye Irrit. 2\nAquatic Chronic 4\nH361f *** H319\nH413\nGHS08\nWng\nH361f *** H319\nH413\n616-144-00-8\n3,4-dichloro-N-[5-chloro-4-[2-[4-dodecyloxyphenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamide\n431-130-1\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-145-00-3\npethoxamide (ISO);\n2-chloro-N-(2-ethoxyethyl)-N-(2-methyl-1-phenylprop-1enyl)acetamide\n—\n106700-29-2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nM=100\n616-146-00-9\nN-(2-methoxy-5-octadecanoylaminophenyl)-2-(3-benzyl-2,5-dioxoimidazolidin-1-yl)-4,4-dimethyl-3-oxopentanoic acidamide\n431-330-7\n142776-95-2\nAquatic Chronic 4\nH413\n—\nH413\n616-147-00-4\n1-methyl-4-(2-methyl-2H-tetrazol-5-yl)-1H-pyrazole-5-sulfonamide\n424-160-1\n139481-22-4\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-148-00-X\nN-[6,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6-oxo-1H-purin-2-yl]acetamide\n424-550-1\n84245-12-5\nCarc. 1B\nMuta. 1B\nRepr. 1B\nH350\nH340\nH360FD\nGHS08\nDgr\nH350\nH340\nH360FD\n616-150-00-0\n(2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzenesulfonamide hydrochloride\n425-260-6\n—\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH373**\nH318\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH373**\nH318\nH317\nH411\n616-151-00-6\nN-(2-amino-4,6-dichloropyrimidin-5-yl)formamide\n425-650-6\n171887-03-9\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n616-152-00-1\n4-(4-fluorophenyl)-2-(2-methyl-1-oxopropyl)-4-oxo-3,N-diphenylbutanamide\n425-850-3\n125971-96-2\nAquatic Chronic 4\nH413\n—\nH413\n616-153-00-7\n4-methyl-3-oxo-N-phenyl-2-(phenylmethylene)pentanamide\n425-860-8\n125971-57-5\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-154-00-2\n3,4-dichloro-N-[5-chloro-4-[2-[4-(hexadecyloxy)phenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamide\n431-110-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-155-00-8\nN,N,N',N'-tetracyclohexyl-1,3-benzenedicarboxamide\n431-040-0\n104560-40-9\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-156-00-3\n6-(2-chloro-6-cyano-4-nitrophenylazo)-4-methoxy-3-[N-(methoxycarbonylmethyl)-N-(1-methoxycarbonylethyl)amino]acetanilide\n430-500-8\n204277-61-2\nAquatic Chronic 4\nH413\n—\nH413\n616-157-00-9\n3-amino-4-hydroxy-N-(3-isopropoxypropyl)benzenesulfonamide hydrochloride\n427-780-9\n114565-70-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n616-158-00-4\nN-[4-cyano-3-trifluoromethylphenyl]methacrylamide\n427-880-2\n90357-53-2\nSTOT RE 2 *\nAquatic Chronic 2\nH373**\nH411\nGHS08\nGHS09\nWng\nH373**\nH411\n616-160-00-5\n2,2'-azobis[N-(2-hydroxyethyl)2-methylpropionamide]\n429-090-3\n61551-69-7\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n616-161-00-0\n2,4-dichloro-5-hydroxyacetanilide\n429-110-0\n67669-19-6\nAquatic Chronic 3\nH412\n—\nH412\n616-162-00-6\nisostearic acid monoisopropanolamide\n431-540-9\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n616-163-00-1\n4,4'-methylenebis[N-(4-chlorophenyl)-3-hydroxynaphthalene-2-carboxamide]\n430-350-3\n192463-88-0\nAquatic Chronic 4\nH413\n—\nH413\n616-164-00-7\ndimoxystrobin (ISO);\n(E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide\n—\n149961-52-4\nCarc. 2\nRepr. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361d***\nH332\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH361d***\nH332\nH410\nM=10\n616-165-00-2\nbeflubutamid (ISO);\n(RS)-N-benzyl-2-(α, α, α, 4-tetrafluoro-m-tolyoxy)butyramide\n—\n113614-08-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=100\n616-166-00-8\ncyazofamid (ISO);\n4-chloro-2-cyano-N, N-dimethyl-5-p-tolylimidazole-1-sulfonamide\n—\n120116-88-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=10\n616-167-00-3\nN, N-dibutyl-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)acetamide\n418-290-6\n168612-06-4\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n616-168-00-9\n1-dimethylcarbamoyl-4-(2-sulfonatoethyl)pyridinium\n418-440-0\n136997-71-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-169-00-4\n4-[4-(2,2-dimethyl-propanamido)]phenylazo-3-(2-chloro-5-(2-(3-pentadecylphenoxy)butylamido)anilino)-1-(2,4,6-trichlorophenyl)-2-pyrazoline-5-one\n420-220-4\n92771-56-7\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-170-00-X\n(2R)-2-amino-2-phenylacetamide\n420-370-0\n6485-67-2\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n616-171-00-5\n2-(para-chlorophenyl)glycineamide\n420-830-0\n102333-75-5\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n616-172-00-0\nN-(2,2,6,6-tetramethyl-1-oxylpiperidin-4-yl)acetamide;\n(4-acetamido-2,2,6,6-tetra\nmethyl-1-piperidinyl)oxidanyl\n423-840-3\n14691-89-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n616-174-00-1\n2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride\n424-560-4\n151257-01-1\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n616-175-00-7\n2-(2-hexyldecyloxy)benzamide\n431-230-3\n202483-62-3\nAquatic Chronic 4\nH413\n—\nH413\n616-176-00-2\n3-N, N-bis(methoxyethyl)aminoacetanilide\n432-530-7\n24294-01-7\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-177-00-8\n(3-(4-(2-(butyl-(4-methylphenylsulfonyl)amino)phenylthio)5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazole-3-ylamino)-4-chlorophenyl)tetradecanamide;\nN-[3-({4-[(2-{]butyl[}(4methylphenyl)sulfonyl{]amino[}phenyl)thio{]-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazol-3yl[}amino)-4-chlorophenyl]tetradecanamide\n432-970-1\n217324-98-6\nAquatic Chronic 4\nH413\n—\nH413\n616-178-00-3\nN-(5-(bis(2-methoxyethyl)amino)-2-((2-cyano-4,6-dinitrophenyl)-azo)phenyl)acetamide\n434-500-9\n52583-35-4\nAquatic Chronic 4\nH413\n—\nH413\n616-179-00-9\n2-chloro-N-(4-methylphenyl)acetamide\n435-170-9\n16634-82-5\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH410\n616-180-00-4\nN, N-(dimethylamino)thioacetamide hydrochloride\n435-470-1\n27366-72-9\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360D*** H400\nH410\nGHS08\nGHS09\nDgr\nH360D*** H410\n616-181-00-X\n4'-methyldodecane-1-sulfonanilide\n435-490-9\n17417-32-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-182-00-5\nN'-(1,3-dimethylbutylidene)-3-hydroxy-2-naphthohydrazide\n435-860-1\n214417-91-1\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-183-00-0\nN-dodecyl-4-methoxybenzamide\n442-340-6\n1854-15-5\nAquatic Chronic 4\nH413\n—\nH413\n616-184-00-6\n3-methyl-N-(5,8,13,14-tetrahydro-5,8,14-trioxonaphth[2,3-c]acridin-6-yl)benzamide\n442-560-2\n105043-55-8\nAquatic Chronic 4\nH413\n—\nH413\n616-186-00-7\nN, N'-(2-chloro-1,4-phenylene)bis(3-oxobutaneamide)\n443-010-4\n53641-10-4\nAquatic Chronic 3\nH412\n—\nH412\n616-188-00-8\n2-(5,5-dimethyl-2,4-dioxooxazolidin-3-yl)-4,4-dimethyl-3-oxo-N-(2-methoxy-5-octadecanoylaminophenyl)pentanoic acid amide\n443-980-9\n221215-20-9\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-189-00-3\nN-[5-(bis-(2-methoxy-ethyl)-amino]-2-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-phenyl]acetamide\n444-780-4\n452962-97-9\nAquatic Chronic 4\nH413\n—\nH413\n616-190-00-9\nN-decyl-4-nitrobenzamide\n445-880-0\n64026-19-3\nAquatic Chronic 4\nH413\n—\nH413\n616-191-00-4\n2-ethyl-N-methyl-N-(3-methylphenyl)butanamide\n446-190-2\n406488-30-0\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH319\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH319\nH315\nH317\nH411\n616-192-00-X\n2-[2-(3-butoxypropyl)-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]-5'-tert-butyl-2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-2'-[(2-ethylhexyl)thio]acetanilide\n448-060-0\n727678-39-9\nAquatic Chronic 4\nH413\n—\nH413\n616-193-00-5\nN-[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-5-diethylamino-phenyl]acetamide\n449-940-7\n368450-39-9\nAquatic Chronic 4\nH413\n—\nH413\n616-194-00-0\n2,2-diethoxy-N, N-dimethylacetamide\n449-950-1\n34640-92-1\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n616-196-00-1\ndisodium salt of 1-hydroxy-4-(β-(4-(1-hydroxy-3,6-disulfo-8-acetylamino-2-naphthylazo)phenoxy)ethoxy)-N-dodecyl-2-naphthamide\n419-990-4\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-197-00-7\nreaction mass of: potassium N-[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamidate; N-[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane\nsulfonamide\n422-500-1\n—\nSTOT RE 2 *\nH373**\nGHS08\nWng\nH373**\n616-198-00-2\n1,3-bis[12-hydroxy-octadecamide-N-methylene]-benzene\n423-300-7\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-200-00-1\nreaction mass of N, N’-ethane1,2-diylbis(hexanamide) and 12-hydroxy-N-[2-[(1-oxyhexyl)amino]ethyl]octadecanamide and N, N’-ethane-1,2-diylbis(12-hydroxyoctadecan amide)\n432-430-3\nAquatic Chronic 4\nH413\nH413\n616-201-00-7\n12-hydroxyoctadecanoic acid, reaction products with 1,3-benzenedimethanamine and hexamethylenediamine\n432-840-2\n220926-97-6\nAcute Tox. 4 *\nAquatic Chronic 4\nH332\nH413\nGHS07\nWng\nH332\nH413\n616-202-00-2\nreaction mass of: 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(2,4-dimethylphenyl)]-3-oxo-butanamide;\n2-[[3,3'-dichloro-4'-[[1[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'biphenyl]-4-yl]azo]-N-(2-methylphenyl)-3-oxo-butanamide;\n2-[[3,3'-dichloro-4'-[[1[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-carboxylphenyl)-3-oxo-butanamide\n434-330-5\n—\nCarc. 2\nSkin Sens. 1\nAquatic Chronic 4\nH351\nH317\nH413\nGHS08\nGHS07\nWng\nH351\nH317\nH413\n616-203-00-8\nreaction mass of: N-[5-[bis-(2-methoxyethyl)amino]-2-(2butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl-azo)phenyl]acetamide;\nN-[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol5-ylazo)5-diethylaminophenyl]acetamide\n442-280-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-204-00-3\nN, N''-(methylenedi-4,1-phenylene)bis[N'-octylurea]\n451-060-3\n122886-55-9\nAquatic Chronic 4\nH413\n—\nH413\n616-205-00-9\nmetazachlor (ISO);\n2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)-acetamide\n266-583-0\n67129-08-2\nSkin Sens. 1B\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH351\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH317\nH351\nH410\nM = 100\nM = 100\n616-206-00-4\nflufenoxuron (ISO);\n1-(4-(2-cloro-α, α,α-p-trifluorotolyloxy)-2-fluorophenyl)-3-(2,6-difluorobenzolyl)urea\n417-680-3\n101463-69-8\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH362\nH400\nH410\nGHS09\nWng\nH362\nH410\nM = 10 000\nM = 10 000\n616-208-00-5\nN-ethyl-2-pyrrolidone;\n1-ethylpyrrolidin-2-one\n220-250-6\n2687-91-4\nRepr. 1B\nH360D\nGHS08\nDgr\nH360D\n616-209-00-0\namidosulfuron (ISO);\n3-(4,6-dimethoxypyrimidin-2-yl)-1-((N-methyl-N-methylsulfonylamino)sulfonyl)urea\n407-380-0\n120923-37-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 100\nM = 100\n616-210-00-6\ntebufenpyrad (ISO);\nN-(4-tertbutylbenzyl)-4-chloro-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide\n119168-77-3\nAcute Tox. 3\nAcute Tox. 4\nSTOT RE 2\nSkin Sens. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH332\nH373 (gastro-intestinal tract) (Oral)\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH332\nH373 (gastro-intestinal tract) (Oral)\nH317\nH410\nM = 10\nM = 10\n616-211-00-1\nproquinazid (ISO);\n6-iodo-2-propoxy-3-propylquinazolin-4(3H)-one\n189278-12-4\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nM = 1\nM = 10\n616-212-00-7\n3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate\n259-627-5\n55406-53-6\nAcute Tox. 3\nAcute Tox. 4\nSTOT RE 1\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH302\nH372 (larynx) H318\nH317\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH331\nH302\nH372 (larynx) H318\nH317\nH410\nM = 10\nM = 1\n617-001-00-2\ndi-tert-butyl peroxide\n203-733-6\n110-05-4\nOrg. Perox. E Flam. Liq. 2 Muta. 2\nH242\nH225\nH341\nGHS02\nGHS08\nDgr\nH242\nH225\nH341\n617-002-00-8\nα, α-dimethylbenzyl hydroperoxide;\ncumene hydroperoxide\n201-254-7\n80-15-9\nOrg. Perox. E\nAcute Tox. 3 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nAquatic Chronic 2\nH242\nH331\nH312\nH302\nH373 **\nH314\nH411\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH242\nH331\nH312\nH302\nH373 **\nH314\nH411\nSkin Corr. 1B; H314: C ≥ 10 % Skin Irrit. 2; H315: 3 % ≤ C\n< 10 %\nEye Dam. 1; H318: 3 % ≤ C\n< 10 %\nEye Irrit. 2; H319: 1 % ≤ C\n< 3 %\nSTOT SE 3; H335: C < 10 %\n617-003-00-3\ndilauroyl peroxide\n203-326-3\n105-74-8\nOrg. Perox. D\nH242\nGHS02\nDgr\nH242\n617-004-00-9\n1,2,3,4-tetrahydro-1-naphthyl hydroperoxide\n212-230-0\n771-29-9\nOrg. Perox. D\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH242\nH302\nH314\nH400\nH410\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH242\nH302\nH314\nH410\nSTOT SE 3; H335: C ≥ 5 %\n617-006-00-X\nbis(α, α-dimethylbenzyl)\nperoxide\n201-279-3\n80-43-3\nOrg. Perox. F\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH242\nH319\nH315\nH411\nGHS02\nGHS07\nGHS09\nWng\nH242\nH319\nH315\nH411\n617-007-00-5\ntert-butyl α, α-dimethylbenzyl peroxide\n222-389-8\n3457-61-2\nOrg. Perox. E\nSkin Irrit. 2\nAquatic Chronic 2\nH242\nH315\nH411\nGHS02\nGHS07\nGHS09\nWng\nH242\nH315\nH411\n617-008-00-0\ndibenzoyl peroxide;\nbenzoyl peroxide\n202-327-6\n94-36-0\nOrg. Perox. B\nEye Irrit. 2\nSkin Sens. 1\nH241\nH319\nH317\nGHS01\nGHS02\nGHS07\nDgr\nH241\nH319\nH317\n617-010-00-1\n1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1]\n1,1’-dioxybiscyclohexan-1-ol; [2]\ncyclohexylidene hydroperoxide; [3]\ncyclohexanone, peroxide [4]\n201-091-1 [1]\n219-306-2 [2]\n220-279-4 [3]\n235-527-7 [4]\n78-18-2 [1]\n2407-94-5 [2]\n2699-11-8 [3]\n12262-58-7 [4]\nOrg. Perox. A\nSkin Corr. 1B\nAcute Tox. 4 *\nH240\nH314\nH302\nGHS01\nGHS05\nGHS07\nDgr\nH240\nH314\nH302\nSTOT SE 3; H335: C ≥ 5 %\nC\n617-010-01-9\n1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1]\n1,1'-dioxybiscyclohexan-1-ol; [2]\ncyclohexylidene hydroperoxide;\n[3] cyclohexanone, peroxide [4] [≤ 91 % solution]\n201-091-1 [1]\n219-306-2 [2]\n220-279-4 [3]\n235-527-7 [4]\n78-18-2 [1]\n2407-94-5 [2]\n2699-11-8 [3]\n12262-58-7 [4]\nOrg. Perox. C\nAcute Tox. 4 *\nSkin Corr. 1B\nH242\nH302\nH314\nGHS02\nGHS05\nGHS07\nDgr\nH242\nH302\nH314\nSTOT SE 3; H335: C ≥ 5 %\nC T\n617-012-00-2\n8-p-menthyl hydroperoxide;\np-menthane hydroperoxide\n201-281-4\n80-47-7\nOrg. Perox. D\nSkin Corr. 1B\nAcute Tox. 4 *\nH242\nH314\nH332\nGHS02\nGHS05\nGHS07\nDgr\nH242\nH314\nH332\nSTOT SE 3; H335: C ≥ 5 %\n617-013-00-8\nO, O-tert-butyl O-docosyl monoperoxyoxalate\n404-300-6\n116753-76-5\nOrg. Perox. C **** Aquatic Acute 1\nAquatic Chronic 1\nH242\nH400\nH410\nGHS02\nGHS09\nDgr\nH242\nH410\n617-014-00-3\n6-(nonylamino)-6-oxo-peroxyhexanoic acid\n406-680-9\n104788-63-8\nOrg. Perox. C **** Eye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH242\nH318\nH317\nH400\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH242\nH318\nH317\nH400\n617-015-00-9\nbis(4-methylbenzoyl)peroxide\n407-950-9\n895-85-2\nOrg. Perox. B **** Aquatic Acute 1\nAquatic Chronic 1\nH241\nH400\nH410\nGHS01\nGHS02\nGHS09\nDgr\nH241\nH410\n617-016-00-4\n3-hydroxy-1,1-dimethylbutyl 2-ethyl-2-methylheptaneperoxoate\n413-910-1\n—\nOrg. Perox. C **** Flam. Liq. 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH242\nH226\nH315\nH400\nH410\nGHS02\nGHS07\nGHS09\nDgr\nH242\nH226\nH315\nH410\n617-017-00-X\nreaction mass of: 2,2'-bis(tert-pentylperoxy)-p-diisopropylbenzene;\n2,2'-bis(tert-pentylperoxy)-m-diisopropylbenzene\n412-140-3\n32144-25-5\nOrg. Perox. D\nAquatic Chronic 4\nH242\nH413\nGHS02\nDgr\nH242\nH413\nT\n617-018-00-5\nreaction mass of: 1-methyl-1-(3-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxide,\n63 % by weight;\n1-methyl-1-(4-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxide, 31 % by weight\n410-840-3\n71566-50-2\nOrg. Perox. C **** Aquatic Chronic 2\nH242\nH411\nGHS02\nGHS09\nDgr\nH242\nH411\nT\n617-019-00-0\n6-(phthalimido)peroxyhexanoic acid\n410-850-8\n128275-31-0\nOrg. Perox. D\nEye Dam. 1\nAquatic Acute 1\nH242\nH318\nH400\nGHS02\nGHS05\nGHS09\nDgDgr\nH242\nH318\nH400\nT\n617-020-00-6\n1,3-di(prop-2,2-diyl)benzene bis(neodecanoylperoxide)\n420-060-5\n117663-11-3\nFlam. Liq. 3\nOrg. Perox. D **** Aquatic Chronic 2\nH226\nH242\nH411\nGHS02\nGHS09\nDgr\nH226\nH242\nH411\n617-021-00-1\nmethylethylketone peroxide trimer\n429-320-2\n—\nOrg. Perox. B****\nAsp. Tox. 1\nSkin Irrit. 2\nSkin Sens. 1\nH241\nH304\nH315\nH317\nGHS01\nGHS02\nGHS08\nGHS07\nDgr\nH241\nH304\nH315\nH317\n617-022-00-7\nreaction mass of: 1,2-dimethylpropylidene dihydroperoxide; dimethyl 1,2-benzenedicarboxylate\n442-480-8\n—\nOrg. Perox. C\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH242\nH302\nH314\nH317\nH411\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH242\nH302\nH314\nH317\nH411\n647-001-00-8\nglucosidase, β-\n232-589-7\n9001-22-3\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n647-002-00-3\ncellulase\n232-734-4\n9012-54-8\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n647-003-00-9\ncellobiohydrolase, exo-\n253-465-9\n37329-65-0\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n647-004-00-4\ncellulases with the exception of those specified elsewhere in this Annex\n—\n—\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\nA\n647-005-00-X\nbromelain, juice\n232-572-4\n9001-00-7\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-006-00-5\nficin\n232-599-1\n9001-33-6\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-007-00-0\npapain\n232-627-2\n9001-73-4\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-008-00-6\npepsin A\n232-629-3\n9001-75-6\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-009-00-1\nrennin\n232-645-0\n9001-98-3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-010-00-7\ntrypsin\n232-650-8\n9002-07-7\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-011-00-2\nchymotrypsin\n232-671-2\n9004-07-3\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-012-00-8\nsubtilisin\n232-752-2\n9014-01-1\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nH335\nH315\nH318\nH334\nGHS08\nGHS05\nGHS07\nDgr\nH335\nH315\nH318\nH334\n647-013-00-3\nproteinase, microbial neutral\n232-966-6\n9068-59-1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-014-00-9\nproteases with the exception of those specified elsewhere in this Annex\n—\n—\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nResp. Sens. 1\nH319\nH335\nH315\nH334\nGHS08\nGHS07\nDgr\nH319\nH335\nH315\nH334\n647-015-00-4\namylase, α-\n232-565-6\n9000-90-2\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n647-016-00-X\namylases with the exception of those specified elsewhere in this Annex\n—\n—\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n647-017-00-5\nlaccase\n420-150-4\n80498-15-3\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334\n648-001-00-0\nDistillates (coal tar), benzole fraction;\nLight Oil; [A complex combination of hydrocarbons obtained by the distillation of coal tar. It consists of hydrocarbons having carbon numbers primarily in the range of C4 to C10 and distilling in the approximate range of 80oC to 160 oC (175oF to 320oF).]\n283-482-7\n84650-02-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n648-002-00-6\nTar oils, brown-coal; Light Oil;\n[The distillate from lignite tar boiling in the range of approximately 80 o C to 250 o C (176oF to 482 oF). Composed primarily of aliphatic and aromatic hydrocarbons and monobasic phenols.]\n302-674-4\n94114-40-6\nCarc. 1B\nMuta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-003-00-1\nBenzol forerunnings (coal); Light Oil Redistillate, low boiling;\n[The distillate from coke oven light oil having an approximate distillation range below 100 o C (212 oF). Composed primarily of C4 to C6 aliphatic hydrocarbons.]\n266-023-5\n65996-88-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-004-00-7\nDistillates (coal tar), benzole fraction, BTX-rich;\nLight Oil Redistillate, low boiling;\n[A residue from the distillation of crude benzole to remove benzole fronts. Composed primarily of benzene, toluene and xylenes boiling in the range of approximately 75 oC to 200 oC (167 oF to 392 oF).]\n309-984-9\n101896-26-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-005-00-2\nAromatic hydrocarbons, C6-10, C8-rich; Light Oil Redistillate, low boiling\n292-697-5\n90989-41-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-006-00-8\nSolvent naphtha (coal), light; Light Oil Redistillate, low boiling\n287-498-5\n85536-17-0\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-007-00-3\nSolvent naphtha (coal), xylene-styrene cut; Light Oil Redistillate, intermediate boiling\n287-502-5\n85536-20-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-008-00-9\nSolvent naphtha (coal), coumarone-styrene contg.; Light Oil Redistillate, intermediate boiling\n287-500-4\n85536-19-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-009-00-4\nNaphtha (coal), distn. residues;\nLight Oil Redistillate, high boiling;\n[The residue remaining from the distillation of recovered naphtha. Composed primarily of naphthalene and condensation products of indene and styrene.]\n292-636-2\n90641-12-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-010-00-X\nAromatic hydrocarbons, C8; Light Oil Redistillate, high boiling\n292-694-9\n90989-38-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-012-00-0\nAromatic hydrocarbons, C8-9, hydrocarbon resin polymn. by-product;\nLight Oil Redistillate, high boiling;\n[A complex combination of hydrocarbons obtained from the evaporation of solven under vacuum from polymerized hydrocarbon resin. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C8 through C9 and boiling in the range of approximately 120 o C to 215 o C (248 oF to 419 oF).]\n295-281-1\n91995-20-9\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-013-00-6\nAromatic hydrocarbons, C9-12, benzene distn.;\nLight Oil Redistillate, high boiling\n295-551-9\n92062-36-7\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-014-00-1\nExtract residues (coal), benzole fraction alk., acid ext.;\nLight Oil Extract Residues, low boiling;\n[The redistillate from the distillate, freed of tar acids and tar bases, from bituminous coal high temperature tar boiling in the approximate range of 90o C to 160 o C (194oF to 320 oF). It consists predomi nantly of benzene, toluene and xylenes.]\n295-323-9\n91995-61-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-015-00-7\nExtract residues (coal tar), benzole fraction alk., acid ext.; Light Oil Extract Residues, low boiling;\n[A complex combination of hydrocarbons obtained by the redistillation of the distillate of high temperature coal tar (tar acid and tar base free). It consists predominantly of unsubstituted and substituted mononuclear aromatic hydrocarbons boiling in the range of 85 oC to 195o C (185oF to 383oF).]\n309-868-8\n101316-63-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-016-00-2\nExtract residues (coal), benzole fraction acid;\nLight Oil Extract Residues, low boiling;\n[An acid sludge by-product of the sulfuric acid refining of crude high temperature coal. Composed primarily of sulfuric acid and organic compounds.]\n298-725-2\n93821-38-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-017-00-8\nExtract residues (coal), light oil alk., distn. overheads;\nLight Oil Extract Residues, low boiling;\n[The first fraction from the distillation of aromatic hydrocarbons, coumarone, naphthalene and indene rich prefractionator bottoms or washed carbolic oil boiling substantially below 145o C (293 oF).\nComposed primarily of C7 and C8 aliphatic and aromatic hydrocarbons.]\n292-625-2\n90641-02-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-018-00-3\nExtract residues (coal), light oil alk., acid ext., indene fraction;\nLight Oil Extract Residues, intermediate boiling\n309-867-2\n101316-62-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-019-00-9\nExtract residues (coal), light oil alk., indene naphtha fraction; Light Oil Extract Residues, high boiling;\n[The distillate from aromatic hydrocarbons, coumarone, naphthalene and indene rich prefractionator bottoms or washed Carbolic oils, having an approximate boiling range of 155o C to 180o C (311 oF to 356 oF). Composed primarily of indene, indan and trimethylbenzenes.]\n292-626-8\n90641-03-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-020-00-4\nSolvent naphtha (coal);\nLight Oil Extract Residues, high boiling;\n[The distillate from either high temperature coal tar, coke oven light oil, or coal tar oil alkaline extract residue having an approximate distillation range of 130o C to 210o C (266oF to 410oF). Composed primarily of indene and other polycyclic ring systems containing a single aromatic ring. May contain phenolic compounds and aromatic nitrogen bases.]\n266-013-0\n65996-79-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-021-00-X\nDistillates (coal tar), light oils, neutral fraction; Light Oil Extract Residues, high boiling; [A distillate from the fractional distillation of high temperature coal tar. Composed primarily of alkyl-substituted one ring aromatic hydrocarbons boiling in the range of approximately 135o C to 210o C (275oF to 410oF). May also include unsaturated hydrocarbons such as indene and coumarone.]\n309-971-8\n101794-90-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-022-00-5\nDistillates (coal tar), light oils, acid exts.; Light Oil Extract Residues, high boiling;\n[This oil is a complex reaction mass of aromatic hydrocarbons, primarily indene, naphthalene, coumarone, phenol, and o-, m-and p-cresol and boiling in the range of 140o C to 215o C (284 oF to 419 oF).]\n292-609-5\n90640-87-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-023-00-0\nDistillates (coal tar), light oils; Carbolic Oil;\n[A complex combination of hydrocarbons obtained by distillation of coal tar. It consists of aromatic and other hydrocarbons, phenolic compounds and aromatic nitrogen compounds and distills at the approximate range of 150 o C to 210 o C (302 oF to 410 oF).]\n283-483-2\n84650-03-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-024-00-6\nTar oils, coal; Carbolic Oil;\n[The distillate from high temperature coal tar having an approximate distillation range of 130 o C to 250 o C (266 oF to 410 oF). Composed primarily of naphthalene, alkylnaphthalenes, phenolic compounds, and aromatic nitrogen bases.]\n266-016-7\n65996-82-9\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-026-00-7\nExtract residues (coal), light oil alk., acid ext.;\nCarbolic Oil Extract Residue; [The oil resulting from the acid washing of alkali-washed carbolic oil to remove the minor amounts of basic compounds (tar bases).\nComposed primarily of indene, indan and alkylbenzenes.]\n292-624-7\n90641-01-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-027-00-2\nExtract residues (coal), tar oil alk.;\nCarbolic Oil Extract Residue; [The residue obtained from coal tar oil by an alkaline wash such as aqueous sodium hydroxide after the removal of crude coal tar acids. Composed primarily of naphthalenes and aromatic nitrogen bases.]\n266-021-4\n65996-87-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-028-00-8\nExtract oils (coal), light oil; Acid Extract;\n[The aqueous extract produced by an acidic wash of alkali-washed carbolic oil. Composed primarily of acid salts of various aromatic nitrogen bases including pyridine, quinoline and their alkyl derivatives.]\n292-622-6\n90640-99-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-029-00-3\nPyridine, alkyl derivs.; Crude Tar Bases;\n[The complex combination of polyalkylated pyridines derived from coal tar distillation or as high-boiling distillates approxi mately above 150o C (302oF) from the reaction of ammonia with acetaldehyde, formaldehyde or paraformaldehyde.]\n269-929-9\n68391-11-7\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-030-00-9\nTar bases, coal, picoline fraction;\nDistillate Bases;\n[Pyridine bases boiling in the range of approximately 125o C to 160o C (257oF 320oF) obtained by distillation of neutralized acid extract of the base-containing tar fraction obtained by the distillation of bituminous coal tars. Composed chiefly of lutidines and picolines.]\n295-548-2\n92062-33-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-031-00-4\nTar bases, coal, lutidine fraction;\nDistillate Bases\n293-766-2\n91082-52-9\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-032-00-X\nExtract oils (coal), tar base, collidine fraction;\nDistillate Bases;\n[The extract produced by the acidic extraction of bases from crude coal tar aromatic oils, neutralization, and distillation of the bases. Composed primarily of collidines, aniline, toluidines, lutidines, xylidines.]\n273-077-3\n68937-63-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-033-00-5\nTar bases, coal, collidine fraction;\nDistillate Bases;\n[The distillation fraction boiling in the range of approximately 181 o C to 186 o C (356 oF to 367 oF) from the crude bases obtained from the neutralized, acid-extracted base-containing tar fractions obtained by the distillation of bituminous coal tar. It contains chiefly aniline and collidines.]\n295-543-5\n92062-28-7\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-034-00-0\nTar bases, coal, aniline fraction; Distillate Bases;\n[The distillation fraction boiling in the range of approximately 180o C to 200o C (356 oF to 392 oF) from the crude bases obtained by dephenolating and debasing the carbolated oil from the distillation of coal tar.\nIt contains chiefly aniline, collidines, lutidines and toluidines.]\n295-541-4\n92062-27-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-035-00-6\nTar bases, coal, toluidine fraction;\nDistillate Bases\n293-767-8\n91082-53-0\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-036-00-1\nDistillates (petroleum), alkene-alkyne manuf. pyrolysis oil, mixed with high-temp. coal tar, indene fraction;\nRedistillates;\n[A complex combination of hydrocarbons obtained as a redistillate from the fractional distillation of bituminous coal high temperature tar and residual oils that are obtained by the pyrolytic production of alkenes and alkynes from petroleum products or natural gas. It consists predominantly of indene and boils in a range of approximately160 o C to 190 o C (320 oF to 374 oF).]\n295-292-1\n91995-31-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-037-00-7\nDistillates (coal), coal tar-residual pyrolysis oils, naphthalene oils;\nRedistillates;\n[The redistillate obtained from the fractional distillation of bituminous coal high temperature tar and pyrolysis residual oils and boiling in the range of approximately 190o C to 270o C (374oF to 518oF). Composed primarily of substituted dinuclear aromatics.]\n295-295-8\n91995-35-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-038-00-2\nExtract oils (coal), coal tar-residual pyrolysis oils, naph thalene oil, redistillate; Redistillates;\n[The redistillate from the fractional distillation of dephe nolated and debased methylnaphthalene oil obtained from bituminous coal high temperature tar and pyrolysis residual oils boiling in the approximate range of 220o C to 230o C (428oF to 446oF). It consists predominantly of unsubstituted and substituted dinuclear aromatic hydrocarbons.]\n295-329-1\n91995-66-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-039-00-8\nExtract oils (coal), coal tar-residual pyrolysis oils, naphthalene oils;\nRedistillates;\n[A neutral oil obtained by debasing and dephenolating the oil obtained from the distillation of high temperature tar and pyrolysis residual oils which has a boiliing range of 225o C to 255o C (437oF to 491oF). Composed primarily of substituted dinuclear aromatic hydrocarbons.]\n310-170-0\n122070-79-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-040-00-3\nExtract oils (coal), coal tar residual pyrolysis oils, naph thalene oil, distn. residues; Redistillates;\n[Residue from the distillation of dephenolated and debased methylnaphthalene oil (from bituminous coal tar and pyrolysis residual oils) with a boiling range of 240 o C to 260o C (464oF to 500oF). Composed primarily of substituted dinuclear aromatic and heterocyclic hydrocarbons.]\n310-171-6\n122070-80-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-041-00-9\nAbsorption oils, bicyclo arom. and heterocyclic hydrocarbon fraction;\nWash Oil Redistillate;\n[A complex combination of hydrocarbons obtained as a redistillate from the distillation of wash oil. It consists predominantly of 2-ringed aromatic and heterocyclic hydrocarbons boiling in the range of approximately 260 oC to 290 oC (500oF to 554oF).]\n309-851-5\n101316-45-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-042-00-4\nDistillates (coal tar), upper, fluorene-rich;\nWash Oil Redistillate;\n[A complex combination of hydrocarbons obtained by the crystallization of tar oil. It consists af aromatic and polycyclic hydrocarbons primarily fluorene and some acenaphthene.]\n284-900-0\n84989-11-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-043-00-X\nCreosote oil, acenaphthene fraction, acenaphthene-free; Wash Oil Redistillate;\n[The oil remaining after removal by a crystallization process of acenaphthene from acenaphthene oil from coal tar. Composed primarily of naphthalene and alkylnaphthalenes.]\n292-606-9\n90640-85-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-044-00-5\nDistillates (coal tar), heavy oils; Heavy Anthracene Oil; [Distillate from the fractional distillation of coal tar of bituminous coal, with boiling range of 240oC to 400oC (464oF to 752 oF). Composed primarily of tri-and polynuclear hydrocarbons and heterocyclic compounds.]\n292-607-4\n90640-86-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n648-045-00-0\nDistillates (coal tar), upper; Heavy Anthracene Oil;\n[The distillate from coal tar having an approximate distillation range of 220oC to 450oC (428oF to 842oF). Composed primarily of three to four membered condensed ring aromatic hydrocarbons and other hydrocarbons.]\n266-026-1\n65996-91-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-046-00-6\nAnthracene oil, acid ext.; Anthracene Oil Extract Residue; [A complex combination of hydrocarbons from the base-freed fraction obtained from the distillation of coal tar and boiling in the range of approxi mately 325 oC to 365 oC (617 oF to 689 oF). It contains predominantly anthracene and phenanthrene and their alkyl derivatives.]\n295-274-3\n91995-14-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-047-00-1\nDistillates (coal tar); Heavy Anthracene Oil;\n[The distillate from coal tar having an approximate distil lationrange of 100oC to 450oC (212oF to 842oF). Composed primarily of two to four membered condensed ring aromatic hydrocarbons, phenolic compounds, and aromatic nitrogen bases.]\n266-027-7\n65996-92-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-048-00-7\nDistillates (coal tar), pitch, heavy oils;\nHeavy Anthracene Oil;\n[The distillate from the distillation of the pitch obtained from bituminous high temperature tar. Composed primarily of tri-and polynuclear aromatic hydrocarbons and boiling in the range of approximately 300 oC to 470 oC (572 oF to 878 oF). The product may also contain heteroatoms.]\n295-312-9\n91995-51-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-049-00-2\nDistillates (coal tar), pitch; Heavy Anthracene Oil;\n[The oil obtained from condensation of the vapors from the heat treatment of pitch.\nComposed primarily of two-to four-ring aromatic compounds boiling in the range of 200 oC to greater than 400 oC (392 oF to greater than 752 oF).]\n309-855-7\n101316-49-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-050-00-8\nDistillates (coal tar), heavy oils, pyrene fraction;\nHeavy Anthracene Oil Redistillate;\n[The redistillate obtained from the fractional distillation of pitch distillate boiling in the range of approximately 350 oC to 400 oC (662 oF to 752 oF). Consists predominantly of tri-and polynuclear aromatics and heterocyclic hydrocarbons.]\n295-304-5\n91995-42-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-051-00-3\nDistillates (coal tar), pitch, pyrene fraction;\nHeavy Anthracene Oil Redistillate;\n[The redistillate obtained from the fractional distillation of pitch distillate and boiling in the range of approximately 380 oC to 410 oC (7160 to 770 oF). Composed primarily of tri-and polynuclear aromatic hydrocarbons and heterocyclic compounds.]\n295-313-4\n91995-52-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-052-00-9\nParaffin waxes (coal), brown-coal high-temp. tar, carbon-treated;\nCoal Tar Extract; [A complet combination of hydrocarbons obtained by the treatment of lignite carbon ization tar with activated carbon for removal of trace constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-296-6\n97926-76-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-053-00-4\nParaffin waxes (coal), brown-coal high-temp tar, clay-treated; Coal Tar Extract;\n[A complex combination of hydrocarbons obtained by the treatment of lignite carbonization tar with bentonite for removal of trace constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-297-1\n97926-77-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-054-00-X\nPitch; Pitch\n263-072-4\n61789-60-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-055-00-5\nPitch, coal tar, high-temp.; Pitch; [The residue from the distillation of high temperature coal tar. A black solid with an approximate softening point from 30 oC to 180 oC (86oF to 356oF). Composed primarily of a complex mixture of three or more membered condensed ring aromatic hydrocarbons.]\n266-028-2\n65996-93-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n648-056-00-0\nPitch, coal tar, high-temp., heat-treated; Pitch; [The heat treated residue from the distillation of high temperature coal tar. A black solid with an approximate softening point from 80oC to180 oC (176 oF to 356 oF). Composed primarily of a complex mixture of three or more membered condensed ring aromatic hydrocarbons.]\n310-162-7\n121575-60-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-057-00-6\nPitch, coal tar, high-temp., secondary;\nPitch Redistillate; [The residue obtained during the distillation of high boiling fractions from bituminous coal high temperature tar and/or pitch coke oil, with a softening point of 140 oC to 170 oC (284 oF to 392 oF) according to DIN 52025. Composed primarily of tri-and polynuclear aromatic compounds which also contain heteroatoms.]\n302-650-3\n94114-13-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-058-00-1\nResidues (coal tar), pitch distn.; Pitch Redistillate;\n[Residue from the fractional distillation of pitch distillate boiling in the range of approximately 400oC to 470oC (752 oF to 846 oF). Composed primarily of polynuclear aromatic hydrocarbons, and heterocyclic compounds.]\n295-507-9\n92061-94-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-059-00-7\nTar, coal, high-temp., distn. and storage residues;\nCoal Tar Solids Residue;\n[Coke-and ash-containing solid residues that separate on distillation and thermal treatment of bituminous coal high temperature tar in distillation installations and storage vessels. Consists predominantly of carbon and contains a small quantity of hetero compounds as well as ash components.]\n295-535-1\n92062-20-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-060-00-2\nTar, coal, storage residues; Coal Tar Solids Residue;\n[The deposit removed from crude coal tar storages. Composed primarily of coal tar and carbonaceous particulate matter.]\n293-764-1\n91082-50-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-061-00-8\nTar, coal, high-temp., residues; Coal Tar Solids Residue;\n[Solids formed during the coking of bituminous coal to produce crude bituminous coal high temperature tar. Composed primarily of coke and coal particles, highly aromatized compounds and mineral substances.]\n309-726-5\n100684-51-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-062-00-3\nTar, coal, high-temp., high-solids;\nCoal Tar Solids Residue;\n[The condensation product obtained by cooling, to approximately ambient temperature, the gas evolved in the high temperature (greater than 700 oC (1292 oF)) destructive distillation of coal. Composed primarily of a complex mixture of condensed ring aromatic hydrocarbons with a high solid content of coal-type materials.]\n273-615-7\n68990-61-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-063-00-9\nWaste solids, coal-tar pitch coking;\nCoal Tar Solids Residue;\n[The combination of wastes formed by the coking of bituminous coal tar pitch. It consists predominantly of carbon.]\n295-549-8\n92062-34-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-064-00-4\nExtract residues (coal), brown; Coal Tar Extract;\n[The residue from extraction of dried coal.]\n294-285-0\n91697-23-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-065-00-X\nParaffin waxes (coal), brown-coal-high-temp. tar;\nCoal Tar Extract; [A complex combination of hydrocarbons obtained from lignite carbonization tar by solvent crystallisation (solvent deoiling), by sweating or an adducting process. It consists predominantly of straight and branched chain saturated hydrocarbons having carbon numbers predominantly greater than C12.]\n295-454-1\n92045-71-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-066-00-5\nParaffin waxes (coal), brown-coal-high-temp. tar, hydrotreated;\nCoal Tar Extract; [A complex combination of hydrocarbons obtained from lignite carbonization tar by solvent crystallisation (solvent deoiling), by sweating or an adducting process treated with hydrogen in the presence of a catalyst. It consists predomi nantly of straight and branched chain saturated hydrocarbons having carbon numbers predominantly greater than C12.]\n295-455-7\n92045-72-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-067-00-0\nParaffin waxes (coal), brown-coal high-temp tar, silicic acid-treated;\nCoal Tar Extract;\n[A complex combination of hydrocarbons obtained by the treatment of lignite carbonization tar with silicic acid for removal of trace constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-298-7\n97926-78-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-068-00-6\nTar, coal, low-temp, distn. residues;\nTar Oil, intermediate boiling; [Residues from fractional distillation of low temperature coal tar to remove oils that boil in a range up to approximately 300 oC (572 oF). Composed primarily of aromatic compounds.]\n309-887-1\n101316-85-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-069-00-1\nPitch, coal tar, low-temp; Pitch Residue;\n[A complex black solid or semi-solid obtained from the distillation of a low temperature coal tar. It has a softening point within the approximate range of 40 oC to 180 oC (104oF to 356 oF). Composed primarily of a complex mixture of hydrocarbons.]\n292-651-4\n90669-57-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-070-00-7\nPitch, coal tar, low-temp., oxidized;\nPitch Residue, oxidised;\n[The product obtained by air-blowing, at elevated temperature, low-temperature coal tar pitch. It has a softening-point within the approximate range of 70 oC to 180 oC (158 oF to 356 oF). Composed primarily of a complex mixture of hydrocarbons.]\n292-654-0\n90669-59-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-071-00-2\nPitch, coal tar, low-temp., heat-treated;\nPitch Residue, oxidised; Pitch Residue, heat-treated;\n[A complex black solid obtained by the heat treatment of low temperature coal tar pitch. It has a softening point within the approximate range of 50 oC to 140 oC (122oF to 284oF). Composed primarily of a complex mixture of aromatic compounds.]\n292-653-5\n90669-58-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-072-00-8\nDistillates (coal-petroleum), condensed-ring arom;\nDistillates;\n[The distillate from a mixture of coal and tar and aromatic petroleum streams having an approximate distillation range of 220 oC to 450 oC (428oF to 842oF). Composed primarily of 3-to 4-membered condensed ring aromatic hydrocarbons.]\n269-159-3\n68188-48-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-073-00-3\nAromatic hydrocarbons, C20-28, polycyclic, mixed coal-tar pitch-polyethylene-polypropylene pyrolysis-derived; Pyrolysis Products;\n[A complex combination hydrocarbons obtained from mixed coal tar pitch-polyethylene-polypropylene pyrolysis. Composed primarily of polycyclic aromatic hydrocarbons having carbon numbers predominantly in the range of C20 through C28 and having a softening point of 100 oC to 220 oC (212oF to 428oF) according to DIN 52025.];\n309-956-6\n101794-74-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-074-00-9\nAromatic hydrocarbons, C20-28, polycyclic, mixed coal-tar pitch-polyethylene pyrolysis-derived;\nPyrolysis Products;\n[A complex combination of hydrocarbonsobtained from mixed coal tar pitch-polyethylene pyrolysis. Composed primarily of polycyclic aromatic hydrocarbons having carbon numberspredominantly in the range of C20 through C28 and having a softening pointof 100oC to 220oC (212oF to 428oF) according to DIN 52025.]\n309-957-1\n101794-75-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-075-00-4\nAromatic hydrocarbons, C20-28, polycyclic, mixed coal-tar pitch-polystyrene pyrolysis-derived;\nPyrolysis Products;\n[A complex combination of hydrocarbons obtained from mixed coal tar pitch-polystyrene pyrolysis. Composed primarily of polycyclic aromatic hydrocarbons having carbon numbers predominantly in the range of C20 through C28 and having a softening point of 100oC to 220oC (212oF to 428oF) according to DIN 52025.]\n309-958-7\n101794-76-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-076-00-X\nPitch, coal tar-petroleum; Pitch Residues;\n[The residue from the distillation of a mixture of coal tar and aromatic petroleum streams. A solid with a softening point from 40oC to 180oC (140oF to 356oF). Composed; primarily of a complex combination of three or more membered condensed ring aromatic hydrocarbons.]\n269-109-0\n68187-57-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-077-00-5\nPhenanthrene, distn. residues; Heavy Anthracene Oi Redistillate;\n[Residue from the distillation of crude phenanthrene boiling in the approximate range of 340 oC to 420 oC (644oF to 788oF). It consists predominantly of phenanthrene, anthracene and carbazole.]\n310-169-5\n122070-78-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-078-00-0\nDistillates (coal tar), upper, fluorene-free; Wash Oil Redistillate;\n[A complex combination of hydrocarbons obtained by the crystallization of tar oil. It consists of aromatic polycyclic hydrocarbons, primarily diphenyl, dibenzofuran and acenaphthene.]\n284-899-7\n84989-10-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-079-00-6\nAnthracene oil; Anthracene oil;\n[A complex combination of polycyclic aromatic hydrocarbons obtained from coal tar having an approximate distillation range of 300 oC to 400 oC (572oF to 752oF). Composed primarily of phenanthrene, anthracene and carbazole.]\n292-602-7\n90640-80-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-080-00-1\nResidues (coal tar), creosote oil distn.; Wash Oil Redistillate;\n[The residue from the fractional distillation of wash oil boiling in the approximate range of 270 o C to 330 o C (518 oF to 626 oF). It consists predomi nantly of dinuclear aromatic and heterocyclic hydrocarbons.]\n295-506-3\n92061-93-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-081-00-7\nTar, coal; Coal tar;\n[The by-product from the destructive distillation of coal. Almost black semisolid. A complex combination of aromatic hydrocarbons, phenolic compounds, nitrogen bases and thiophene.]\n232-361-7\n8007-45-2\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n648-082-00-2\nTar, coal, high-temp.; Coal tar; [The condensation product obtained by cooling, to approxi mately ambient temperature, the gas evolved in the high temperature (greater than 700 oC (1292oF)) destructive distillation of coal. A black viscous liquid denser than water. Composed primarily of a complex mixture of condensed ring aromatic hydrocarbons. May contain minor amounts of phenolic compounds and aromatic nitrogen bases.]\n266-024-0\n65996-89-6\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n648-083-00-8\nTar, coal, low-temp.; Coal oil;\n[The condensation product obtained by cooling, to approximately ambient temperature, the gas evolved in low temperature (less than 700 oC (1292oF)) destructive distillation of coal. A black viscous liquid denser than water. Composed primarily of condensed ring aromatic hydrocarbons, phenolic compounds, aromatic nitrogen bases, and their alkyl derivatives.]\n266-025-6\n65996-90-9\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n648-084-00-3\nDistillates (coal), coke-oven light oil, naphthalene cut; Naphthalene Oil;\n[The complex combination of hydrocarbons obtained from prefractionation (continuous distillation) of coke oven light oil. It consists predominantly of naphthalene, coumarone and indene and boils above 148 oC (298oF).]\n285-076-5\n85029-51-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-085-00-9\nDistillates (coal tar), naphthalene oils; Naphthalene Oil;\n[A complex combination of hydrocarbons obtained by the distillation of coal tar. It consists primarily of aromatic and other hydrocarbons, phenolic compound and aromatic nitrogen compounds and distills in the approximate range of 200 oC to 250 oC (392oF to 482oF).]-\n283-484-8\n84650-04-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-086-00-4\nDistillates (coal tar), naph thalene oils, naphthalene-low; Naphthalene Oil Redistillate; [A complex combination of hydrocarbons obtained by crys tallization of naphthalene oil. Composed primarily of naphthalene, alkyl naphthalenes and phenolic compounds.]\n284-898-1\n84989-09-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-087-00-X\nDistillates (coal tar), naphthalene oil crystn. mother liquor; Naphthalene Oil Redistillate;\n[A complex combination of organic compounds obtained as a filtrate from the crystallization of the naphthalene fraction from coal tar and boiling in the range of approximately 200 oC to 230 oC (392oF to 446oF). Contains chiefly naphthalene, thionaphthene and alkylnaphthalenes.]\n295-310-8\n91995-49-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-088-00-5\nExtract residues (coal), naphthalene oil, alk.; Naphthalene Oil Extract Residue;\n[A complex combination of hydrocarbons obtained from the alkali washing of naphthalene oil to remove phenolic compounds (tar acids). It is composed of naphthalene and alkyl naphthalenes.]\n310-166-9\n121620-47-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-089-00-0\nExtract residues (coal), naphthalene oil, alk., naphthalene-low;\nNaphthalene Oil Extract Residue;\n[A complex combination of hydrocarbons remaining after the removal of naphthalene from alkali-washed naphthalene oil by a crystallization process. It is composed primarily of naphthalene and alkyl naphthalenes.]\n310-167-4\n121620-48-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-090-00-6\nDistillates (coal tar), naphthalene oils, naphthalene-free, alk. exts.;\nNaphthalene Oil Extract Residue;\n[The oil remaining after the removal of phenolic compounds (tar acids) from drained naphthalene oil by an alkali wash. Composed primarily of naphthalene and alkyl naphthalenes.]\n292-612-1\n90640-90-7\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-091-00-1\nExtract residues (coal), naphthalene oil alk., distn. overheads;\nNaphthalene Oil Extract Residue;\n[The distillate from alkali-washed naphthalene oil having an approximate distillation range of 180 oC to 220 oC (356oF to 428 oF). Composed primarily of naphthalene, alkylbenzenes, indene and indan.]\n292-627-3\n90641-04-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-092-00-7\nDistillates (coal tar), naphthalene oils, methylnaphthalene fraction;\nMethylnaphthalene Oil;\n[A distillate from the fractional distillation of high temperature coal tar. Composed primarily of substituted two ring aromatic hydrocarbons and aromatic nitrogen bases boiling in the range of approximately 225 oC to 255 oC (437oF to 491 oF).]\n309-985-4\n101896-27-9\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-093-00-2\nDistillates (coal tar), naphthalene oils, indole-methylnaphthalene fraction; Methylnaphthalene Oil;\n[A distillate from the fractional distillation of high temperature coal tar. Composed primarily of indole and methylnaphthalene boiling in the range of approximately 235 oC to 255 oC (455 oF to 491 oF).]\n309-972-3\n101794-91-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-094-00-8\nDistillates (coal tar), naphthalene oils, acid exts.; Methylnaphthalene Oil Extract Residue;\n[A complex combination of hydrocarbons obtained by debasing the methylnaphthalene fraction obtained by the distillation of coal tar and boiling in the range of approximately 230 oC to 255 oC (446oF to 491oF). Contains chiefly 1(2)-methylnaphthalene, naphthalene, dimethylnaphthalene and biphenyl.]\n295-309-2\n91995-48-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-095-00-3\nExtract residues (coal), naphthalene oil alk., distn. residues; Methylnaphthalene Oil Extract Residue; [The residue from the distillation of alkali-washed naphthalene oil having an approximate distillation range of 220 oC to 300 oC (428oF to 572oF). Composed primarily of naphthalene, alkylnaphthalenes and aromatic nitrogen bases.]\n292-628-9\n90641-05-7\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-096-00-9\nExtract oils (coal), acidic, tar-base free;\nMethylnaphthalene Oil Extract Residue; [The extract oil boiling in the range of approximately 220 oC to 265 oC (428oF to 509oF) from coal tar alkaline extract residue produced by an acidic wash such as aqueous sulfuric acid after distillation to remove tar bases. Composed primarily of alkylnaphthalenes.]\n284-901-6\n84989-12-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-097-00-4\nDistillates (coal tar), benzole fraction, distn. residues;\nWash Oil;\n[A complex combination of hydrocarbons obtained from the distillation of crude benzole (high temperature coal tar). It may be a liquid with the approximate distillation range of 150o C to 300 oC (302oF to 572oF) or a semi-solid or solid with a melting point up to 70 oC (158oF). It is composed primarily of naphthalene and alkyl naphthalenes.]\n310-165-3\n121620-46-0\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-098-00-X\nCreosote oil, acenaphthene fraction;\nWash Oil; [A complex combination of hydrocarbons produced by the distillation of coal tar and boiling in the range of approximately 240 o C to 280 o C (464oF to 536 oF). Composed primarily of acenaphthene, naphthalene and alkyl naphthalene.]\n292-605-3\n90640-84-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-099-00-5\nCreosote oil;\n[A complex combination of hydrocarbons obtained by the distillation of coal tar. It consists primarily of aromatic hydrocarbons and may contain appreciable quantities of tar acids and tar bases. It distills at the approximate range of 200 oC to 325 oC (392oF to 617oF).]\n263-047-8\n61789-28-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-100-00-9\nCreosote oil, high-boiling distillate;\nWash Oil;\n[The high-boiling distillation fraction obtained from the high temperature carbonization of bituminous coal which is further refined to remove excess crystalline salts. It consists primarily of creosote oil with some of the normal polynuclear aromatic salts, which are components of coal tar distillates, removed. It is crystal free at approximately 5 oC (41oF).]\n274-565-9\n70321-79-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-101-00-4\nCreosote;\n[The distillate of coal tar produced by the high temperature carbonization of bituminous coal. It consists primarily of aromatic hydrocarbons, tar acids and tar bases.]\n232-287-5\n8001-58-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n648-102-00-X\nExtract residues (coal), creosote oil acid;\nWash Oil Extract Residue;\n[A complex combination of hydrocarbons from the base-freed fraction from the distillation of coal tar, boiling in the range of approximately 250 oC to 280 oC (482oF to 536oF). It consists predominantly of biphenyl and isomeric diphenylnaphthalenes.]\n310-189-4\n122384-77-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-103-00-5\nAnthracene oil, anthracene paste;\nAnthracene Oil Fraction;\n[The anthracene-rich solid obtained by the crystallization and centrifuging of anthracene oil. It is composed primarily of anthracene, carbazole and phenanthrene.]\n292-603-2\n90640-81-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-104-00-0\nAnthracene oil, anthracene-low; Anthracene Oil Fraction;\n[The oil remaining after the removal, by a crystallization process, of an anthracene-rich solid (anthracene paste) from anthracene oil. It is composed primarily of two, three and four membered aromatic compounds.]\n292-604-8\n90640-82-7\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-105-00-6\nResidues (coal tar), anthracene oil distn.; Anthracene Oil Fraction;\n[The residue from the fraction distillation of crude anthracene boiling in the approximate range of 340 oC to 400 oC (644oF to 752oF). It consists predominantly of tri-and polynuclear aromatic and heterocyclic hydrocarbons.]\n295-505-8\n92061-92-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-106-00-1\nAnthracene oil, anthracene paste, anthracene fraction; Anthracene Oil Fraction;\n[A complex combination of hydrocarbons from the distillation of anthracene obtained by the crystallization of anthracene oil from bituminous high temperature tar and boiling in the range of 330 oC to 350 oC (626oF to 662oF). It contains chiefly anthracene, carbazole and phenanthrene.]\n295-275-9\n91995-15-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-107-00-7\nAnthracene oil, anthracene paste, carbazole fraction; Anthracene Oil Fraction;\n[A complex combination of hydrocarbons from the distil lation of anthracene obtained by crystallization of anthracene oil from bituminous coal high temperature tar and boiling in the approximate range of 350 oC to 360 oC (662oF to 680 oF). It contains chiefly anthracene, carbazole and phenanthrene.]\n295-276-4\n91995-16-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-108-00-2\nAnthracene oil, anthracene paste, distn. lights;\nAnthracene Oil Fraction;\n[A complex combination of hydrocarbons from the distillation of anthracene obtained by crystallization of anthracene oil from bituminous high temperature tar and boiling in the range of approximately 290 oC to 340 oC (554oF to 644 oF). It contains chiefly trinuclear aromatics and their dihydro derivatives.]\n295-278-5\n91995-17-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-109-00-8\nTar oils, coal, low-temp.; Tar Oil, high boiling;\n[A distillate from low-temperature coal tar. Composed primarily of hydrocarbons, phenolic compounds and aromatic nitrogen bases boiling in the range of approximately 160 oC to 340 oC (320oF to 644oF).]\n309-889-2\n101316-87-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-110-00-3\nExtract residues (coal), low temp. coal atar alk.;\n[The residue from low temperature coal tar oils after an alkaline wash, such as aqueous sodium hydroxide, to remove crude coal tar acids. Composed primarily of hydrocarbons and aromatic nitrogen bases.]\n310-191-5\n122384-78-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-111-00-9\nPhenols, ammonia liquor ext.; Alkaline Extract;\n[The combination of phenols extracted, using isobutyl acetate, from the ammonia liquor condensed from the gas evolved in low-temperature (less than 700 oC (1292oF)) destructive distillation of coal. It consists predominantly of a reaction mass of monohydric and dihydric phenols.]\n284-881-9\n84988-93-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-112-00-4\nDistillates (coal tar), light oils, alk. exts.;\nAlkaline Extract;\n[The aqueous extract from carbolic oil produced by an alkaline wash such as aqueous sodium hydroxide. Composed primarily of the alkali salts of various phenolic compounds.]\n292-610-0\n90640-88-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-113-00-X\nExtracts, coal tar oil alk.; Alkaline Extract;\n[The extract from coal tar oil produced by an alkaline wash such as aqueous sodium hydroxide. Composed primarily of the alkali salts of various phenolic compounds.]\n266-017-2\n65996-83-0\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-114-00-5\nDistillates (coal tar), naphthalene oils, alk. exts.; Alkaline Extract;\n[The aqueous extract from naphthalene oil produced by an alkaline wash such as aqueous sodium hydroxide. Composed primarily of the alkali salts of various phenolic compounds.]\n292-611-6\n90640-89-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-115-00-0\nExtract residues (coal), tar oil alk., carbonated, limed;\nCrude Phenols; [The product obtained by treatment of coal tar oil alkaline extract with CO2 and CaO. Composed primarily of CaCO3, Ca(OH)2, Na2CO3 and other organic and inorganic impurities.]\n292-629-4\n90641-06-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-116-00-6\nTar acids, coal, crude; Crude Phenols;\n[The reaction product obtained by neutralizing coal tar oil alkaline extract with an acidic solution, such as aqueous sulfuric acid, or gaseous carbon dioxide, to obtain the free acids. Composed primarily of tar acids such as phenol, cresols, and xylenols.]\n266-019-3\n65996-85-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-117-00-1\nTar acids, brown-coal, crude; Crude Phenols;\n[An acidified alkaline extract of brown coal tar distillate.\nComposed primarily of phenol and phenol homologs.]\n309-888-7\n101316-86-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-118-00-7\nTar acids, browncoal gasification;\nCrude Phenols;\n[A complex combination of organic compounds obtained from brown coal gasification. Composed primarily of C6-10 hydroxy aromatic phenols and their homologs.]\n295-536-7\n92062-22-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-119-00-2\nTar acids, distn. residues; Distillate Phenols;\n[A residue from the distillation of crude phenol from coal. It consists predominantly of phenols having carbon numbers in the range of C8 through C10 with a softening point of 60 oC to 80 oC (140oF to 176oF).]\n306-251-5\n96690-55-0\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-120-00-8\nTar acids, methylphenol fraction;\nDistillate Phenols;\n[The fraction of tar acid rich in 3-and 4-methylphenol, recovered by distillation of low-temperature coal tar crude tar acids.]\n284-892-9\n84989-04-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-121-00-3\nTar acids, polyalkylphenol fraction;\nDistillate Phenols;\n[The fraction of tar acids, recovered by distillation of low-temperature coal tar crude tar acids, having an approximate boiling range of 225 oC to 320 oC (437oF to 608oF). Composed primarily of polyalkylphenols.]\n284-893-4\n84989-05-9\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-122-00-9\nTar acids, xylenol fraction; Distillate Phenols;\n[The fraction of tar acids, rich in 2,4-and 2,5-dimethylphenol, recovered by distillation of low-temperature coal tar crude tar acids.]\n284-895-5\n84989-06-0\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-123-00-4\nTar acids, ethylphenol fraction; Distillate Phenols;\n[The fraction of tar acids, rich in 3-and 4-ethylphenol, recovered by distillation of low-temperature coal tar rude tar acids.]\n284-891-3\n84989-03-7\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-124-00-X\nTar acids, 3,5-xylenol fraction; Distillate Phenols;\n[The fraction of tar acids, rich in 3,5-dimethylphenol, recovered by distillation of low-temperature coal tar acids.]\n284-896-0\n84989-07-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-125-00-5\nTar acids, residues, distillates, first-cut;\nDistillate Phenols;\n[The residue from the distillation in the range of 235 oC to 355 oC (481oF to 697oF) of light carbolic oil.]\n270-713-1\n68477-23-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-126-00-0\nTar acids, cresylic, residues; Distillate Phenols;\n[The residue from crude coal tar acids after removal of phenol, cresols, xylenols and any higher boiling phenols. A black solid with a melting point approximately 80 oC (176oF). Composed primarily of polyalkylphenols, resin gums, and inorganic salts.]\n271-418-0\n68555-24-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-127-00-6\nPhenols, C9-11; Distillate Phenols\n293-435-2\n91079-47-9\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-128-00-1\nTar acids, cresylic; Distillate Phenols;\n[A complex combination of organic compounds obtained from brown coal and boiling in the range of approximately 200 oC to 230 oC (392oF to 446oF). It contains chiefly phenols and pyridine bases.]\n295-540-9\n92062-26-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-129-00-7\nTar acids, brown-coal, C2-alkylphenol fraction;\nDistillate Phenols;\n[The distillate from the acidification of alkaline washed lignite tar distillate boiling in the range of approximately 200 oC to 230 oC (392oF to 446oF). Composed primarily of m-and p-ethylphenol as well as cresols and xylenols.]\n302-662-9\n94114-29-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-130-00-2\nExtract oils (coal), naphthalene oils;\nAcid Extract;\n[The aqueous extract produced by an acidic wash of alkali- washed naphthalene oil. Composed primarily of acid salts of various aromatic nitrogen bases including pyridine, quinoline and their alkyl derivatives.]\n292-623-1\n90641-00-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-131-00-8\nTar bases, quinoline derivs.; Distillate Bases\n271-020-7\n68513-87-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-132-00-3\nTar bases, coal, quinoline derivs. fraction;\nDistillate Bases\n274-560-1\n70321-67-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-133-00-9\nTar bases, coal, distn. residues; Distillate Bases;\n[The distillation residue remaining after the distillation of the neutralized, acid-extracted base-containing tar fractions obtained by the distillation of oal tars. I contains chiefly aniline, collidines, quinoline and quinoline derivatives and toluidines.]\n295-544-0\n92062-29-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-134-00-4\nHydrocarbon oils, arom., mixed with polyethylene and polypropylene, pyrolyzed, light oil fraction;\nHeat Treatment Products; [The oil obtained from the heat treatment of a polyethylene/ polypropylene reaction mass with coal tar pitch or aromatic oils. It consists predominantly of benzene and its homologs boiling in a range of approximately 70 oC to 120 oC (158 oF to 248 oF).]\n309-745-9\n100801-63-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-135-00-X\nHydrocarbon oils, arom., mixed with polyethylene, pyrolyzed, light oil fraction;\nHeat Treatment Products;\n[The oil obtained from the heat treatment of polyethylene with coal tar pitch or aromatic oils. It consists predominantly of benzene and its homologs boiling in a range of 70 oC to 120 oC (158oF to 248oF).]\n309-748-5\n100801-65-8\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-136-00-5\nHydrocarbon oils, arom., mixed with polystyrene, pyrolyzed, light oil fraction;\nHeat Treatment Products;\n[The oil obtained from the heat treatment of polystyrene with coal tar pitch or aromatic oils.\nIt consists predominantly of benzene and its homologs boiling in a range of approximately 70 oC to 210 oC (158 oF to 410oF).]\n309-749-0\n100801-66-9\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-137-00-0\nExtract residues (coal), tar oil alk., naphthalene distn. residues; Naphthalene Oil Extract Residue;\n[The residue obtained from chemical oil extracted after the removal of naphthalene by distillation composed primarily of two to four membered condensed ring aromatic hydrocarbons and aromatic nitrogen bases.]\n277-567-8\n73665-18-6\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-138-00-6\nCreosote oil, low-boiling distillate;\nWash Oil;\n[The low-boiling distillation fraction obtained from the high temperature carbonization of bituminous coal, which is further refined to remove excess crystalline salts. It consists primarily of creosote oil with some of the normal polynuclear aromatic salts, which are components of coal tar distillate, removed. It is crystal free at approximately 38 o C (100 oF).]\n274-566-4\n70321-80-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-139-00-1\nTar acids, cresylic, sodium salts, caustic solns.; Alkaline Extract\n272-361-4\n68815-21-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-140-00-7\nExtract oils (coal), tar base; Acid Extract;\n[The extract from coal tar oil alkaline extract residue produced by an acidic wash such as aqueous sulfuric acid after distillation to remove naphthalene. Composed primarily of the acid salts of various aromatic nitrogen bases including pyridine, quinoline, and their alkyl derivatives.]\n266-020-9\n65996-86-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-141-00-2\nTar bases, coal, crude; Crude Tar Bases;\n[The reaction product obtained by neutralizing coal tar base extract oil with an alkaline solution, such as aqueous sodium hydroxide, to obtain the free bases. Composed primarily of such organic bases as acridine, phenanthridine, pyridine, quinoline and their alkyl derivatives.]\n266-018-8\n65996-84-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJM\n648-142-00-8\nResidues (coal), liq. solvent extn.;\n[A cohesive powder composed of coal mineral matter and undissolved coal remaining after extraction of coal by a liquid solvent.]\n302-681-2\n94114-46-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-143-00-3\nCoal liquids, liq. solvent extn. soln.;\n[The product obtained by filtration of coal mineral matter and undissolved coal from coal extract solution produced by digesting coal in a liquid solvent. A black, viscous, highly complex liquid combination composed primarily of aromatic and partly hydro-genated aromatic hydrocarbons, aromatic nitrogen compounds, aromatic sulfur compounds, phenolic and other aromatic oxygen compounds and their alkyl derivatives.]\n302-682-8\n94114-47-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-144-00-9\nCoal liquids, liq. solvent extn.; [The substantially solvent-free product obtained by the distillation of the solvent from filtered coal extract solution produced by digesting coal in a liquid solvent. A black semi-solid, composed primarily of a complex combination of condensed-ring aromatic hydrocarbons, aromatic nitrogen compounds, aromatic sulfur compounds, phenolic compounds and other aromatic oxygen compounds, and their alkyl derivatives.]\n302-683-3\n94114-48-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nM\n648-145-00-4\nTar brown-coal;\n[An oil distilled from brown-coal tar. Composed primarily of aliphatic, naphthenic and one-to three-ring aromatic hydrocarbons, their alkyl derivates, heteroaromatics and one-and two-ring phenols boiling in the range of approximately 150oC to 360 oC (302oF to 680oF).]\n309-885-0\n101316-83-0\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n648-146-00-X\nTar, brown-coal, low-temp.;\n[A tar obtained from low temperature carbonization and low temperature gasification of brown coal. Composed primarily of aliphatic, naphthenic and cyclic aromatic hydrocarbons, heteroaromatic hydrocarbons and cyclic phenols.]\n309-886-6\n101316-84-1\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n648-147-00-5\nLight oil (coal), coke-oven; Crude benzole;\n[The volatile organic liquid extracted from the gas evolved in the high temperature (greater than 700 oC (1 292oF)) destructive distillation of coal. Composed primarily of benzene, toluene, and xylenes. May contain other minor hydrocarbon constituents.]\n266-012-5\n65996-78-3\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-148-00-0\nDistillates (coal), liq. solvent extn., primary;\n[The liquid product of condensation of vapors emitted during the digestion of coal in a liquid solvent and boiling in the range of approximately 30 oC to 300 oC 86 oF to 572 oF).\nComposed primarily of partly hydrogenated condensed-ring aromatic hydrocarbons, aromatic compounds containing nitrogen, oxygen and sulfur, and their alkyl derivatives having carbon numbers predominantly in the range of C4 through C14.]\n302-688-0\n94114-52-0\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-149-00-6\nDistillates (coal), solvent extn., hydrocracked;\n[Distillate obtained by hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 30 oC to 300o C (86 oF to 572 oF). Composed primarily of aromatic, hydrogenated aromatic and naphthenic compounds, their alkyl derivatives and alkanes with carbon numbers predominantly in the range of C4 through C14. Nitrogen, sulfur and oxygen-containing aromatic and hydrogenated aromatic compounds are also present.]\n302-689-6\n94114-53-1\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-150-00-1\nNaphtha (coal), solvent extn., hydrocracked;\n[Fraction of the distillate obtained by hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 30 oC to 180 oC (86oF to 356oF). Composed primarily of aromatic, hydrogenated aromatic and naphthenic compounds, their alkyl derivatives and alkanes with carbon numbers predominantly in the range of C4 to C9. Nitrogen, sulfur and oxygen-containing aromatic and hydrogenated aromatic compounds are also present.]\n302-690-1\n94114-54-2\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-151-00-7\nGasoline, coal solvent extn., hydrocracked naphtha;\n[Motor fuel produced by the reforming of the refined naphtha fraction of the products of hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 30 oC to 180 oC (86 oF to 356oF). Composed primarily of aromatic and naphthenic hydrocarbons, their alkyl derivatives and alkyl hydrocarbons having carbon numbers in the range of C4 through C9.]\n302-691-7\n94114-55-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n648-152-00-2\nDistillates (coal), solvent extn., hydrocracked middle;\n[Distillate obtained from the hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 180 o C to 300 oC (356oF to 572oF. Composed primarily of two-ring aromatic, hydrogenated aromatic and naphthenic compounds, their alkyl derivatives and alkanes having carbon numbers predominantly in the range of C9 through C14. Nitrogen, sulfur and oxygen-containing compounds are also present.]\n302-692-2\n94114-56-4\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-153-00-8\nDistillates (coal), solvent extn., hydrocracked hydrogenated middle;\n[Distillate from the hydroge nation of hydrocracked middle distillate from coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 180 oC to 280 oC (356 F to 536oF). Composed primarily of hydrogenated two-ring carbon compounds and their alkyl derivatives having carbon numbers predominantly in the range of C9 through C14.]\n302-693-8\n94114-57-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n648-154-00-3\nFuels, jet aircraft, coal solvent extn.,hydrocracked hydro genated;\n[Jet engine fuel produced by hydrogenation of the middle distillate fraction of the products of hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 180oC to 225oC (356oF to 473oF). Composed primarily of hydrogenated two-ring hydrocarbons and their alkyl derivatives having carbon numbers predominantly in the range of C10 through C12.]\n302-694-3\n94114-58-6\nCarc. 2\nH351\nGHS08\nWng\nH350\n648-155-00-9\nFuels, diesel, coal solvent extn., hydrocracked hydrogenated; [Diesel engine fuel produced by the hydrogenation of the middle distillate fraction of the products of hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 200oC to 280oC (392oF to 536oF). Composed primarily of hydrogenated two-ring hydrocarbons andtheir alkylderivatives having carbon numbers predominantly in the range of C11 through C14.]\n302-695-9\n94114-59-7\nCarc. 2\nH351\nGHS08\nWng\nH350\n648-156-00-4\nLight oil (coal), semi-coking process; Fresh oil; [The volatile organic liquid condensed from the gasevolved in the low-temperature (less than 700 oC (1 292oF)) destructive distillation of coal. Composed primarily of C6-10 hydrocarbons.]\n292-635-7\n90641-11-5\nCarc. 1B Muta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340\nJ\n649-001-00-3\nExtracts (petroleum), light naphthenic distillate solvent\n265-102-1\n64742-03-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-002-00-9\nExtracts (petroleum), heavy paraffinic distillate solvent\n265-103-7\n64742-04-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-003-00-4\nExtracts (petroleum), light paraffinic distillate solvent\n265-104-2\n64742-05-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-004-00-X\nExtracts (petroleum), heavy naphthenic distillate solvent\n265-111-0\n64742-11-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-005-00-5\nExtracts (petroleum), light vacuum gas oil solvent\n295-341-7\n91995-78-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-006-00-0\nhydrocarbons C26-55, arom-rich\n307-753-7\n97722-04-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-007-00-6\nfatty acids, tall-oil, reaction products with iminodiethanol and boric acid\n400-160-5\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n649-008-00-1\nResidues (petroleum), atm. tower;\nHeavy Fuel oil;\n[A complex residuum from the atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly greater than C20 and boiling above approxi mately 350 oC (662 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-045-2\n64741-45-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-009-00-7\nGas oils (petroleum), heavy vacuum;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced by the vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and boiling in the range of approximately 350 oC to 600 oC (662 oF to 1112 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-058-3\n64741-57-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-010-00-2\nDistillates (petroleum), heavy catalytic cracked;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C35 and boiling in the range of approximately 260oC to 500oC (500oF to 932oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-063-0\n64741-61-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-011-00-8\nClarified oils (petroleum), catalytic cracked;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced as the residual fraction from distillation of the products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly greater than C20 and boiling above approximately 350oC (662oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-064-6\n64741-62-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-012-00-3\nResidues (petroleum), hydrocracked; Heavy Fuel oil;\n[A complex combination of hydrocarbons produced as the residual fraction from distillation of the products of a hydrocracking process. It consists of hydrocarbons having carbon numbers predominantly greater than C20 and boiling above approxi mately 350oC (662 oF).]\n265-076-1\n64741-75-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-013-00-9\nResidues (petroleum), thermal cracked; Heavy Fuel oil;\n[A complex combination of hydrocarbons produced as the residual fraction from distillation of the product from a thermal cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly greater than C20 and boiling above approximately 350oC (662 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-081-9\n64741-80-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-014-00-4\nDistillates (petroleum), heavy thermal cracked;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons from the distillation of the products from a thermal cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C15 through C36 and boiling in the range of approximately 260oC to 480 oC (500 oF to 896 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-082-4\n64741-81-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-015-00-X\nGas oils (petroleum), hydro-treated vacuum; Heavy Fuel oil;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C13 through C50 and boiling in the range of approximately 230oC to 600oC (446 oF to 1112 oF). This stream is likely to contain 5 wt.% or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-162-9\n64742-59-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-016-00-5\nResidues (petroleum), hydrodesulfurized atmospheric tower; Heavy Fuel oil;\n[A complex combination of hydrocarbons obtained by treating an atmospheric tower residuum with hydrogen in the presence of a catalyst under conditions primarily to remove organic sulfur compounds. It consists of hydrocarbons having carbon numbers predominantly greater than C20 and boiling above approximately 350 oC (662 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-181-2\n64742-78-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-017-00-0\nGas oils (petroleum), hydrodesulfurized heavy vacuum; Heavy Fuel oil; [A complex combination of hydrocarbons obtained from a catalytic hydrodesulfurization process. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and boiling in the range of approximately 350 oC to 600 oC (662 oF to 1112 oC). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n265-189-6\n64742-86-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-018-00-6\nResidues (petroleum), steam-cracked;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons obtained as the residual fraction from the distillation of the products of a steam cracking process (including steam cracking to produce ethylene). It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly greater than C14 and boiling above approximately 260 oC (500 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-memberedcondensed ring aromatic hydrocarbons.]\n265-193-8\n64742-90-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-019-00-1\nResidues (petroleum), atmospheric;\nHeavy Fuel oil;\n[A complex residuum from atmospheric distillation of crude oil.\nIt consists of hydrocarbons having carbon numbers predominantly greater than C11 and boiling above approxi mately 200oC (392 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n269-777-3\n68333-22-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-020-00-7\nClarified oils (petroleum), hydrodesulfurized catalytic cracked;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons obtained by treating catalytic cracked clarified oil with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists of hydrocarbons having carbon numbers predominantly greater than C20 and boiling above approximately 350 oC (662 oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n269-782-0\n68333-26-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-021-00-2\nDistillates (petroleum), hydrodesulfurized intermediate catalytic cracked;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons obtained by treating intermediate catalytic cracked distillates with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists of hydrocarbons having carbon numbers predominantly in the range of C11 through C30 and boiling in the range of approximately 205 oC to 450 oC (401 oF to 842 oF). It contains a relatively large proportion of tricyclic aromatic hydrocarbons.]\n269-783-6\n68333-27-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-022-00-8\nDistillates (petroleum), hydrodesulfurized heavy catalytic cracked;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons obtained by treatment of heavy catalytic cracked distillates with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C35 and boiling in the range of approximately 260oC to 500 oC (500oF to 932oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n269-784-1\n68333-28-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-023-00-3\nFuel oil, residues-straight-run gas oils, high-sulfur;\nHeavy Fuel oil\n270-674-0\n68476-32-4\nCarc. 1B\nH350\nHS08\nDgr\nH350\n649-024-00-9\nFuel oil, residual; Heavy Fuel oil;\n[The liquid product from various refinery streams, usually residues. The composition is complex and varies with the source of the crude oil.]\n270-675-6\n68476-33-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-025-00-4\nResidues (petroleum), catalytic reformer fractionator residue distn.;\nHeavy Fuel oil;\n[A complex residuum from the distillation of catalytic reformer fractionator residue. It boils approximately above 399oC (750oF).]\n270-792-2\n68478-13-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-026-00-X\nResidues,(petroleum), heavy coker gas oil and vacuum gas oil;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced as the residual fraction from the distillation of heavy coker gas oil and vacuum gas oil. It predomi nantly consists of hydrocarbons having carbon numbers predominantly greater than C13 and boiling above approximately 230 oC (446 oF).]\n270-796-4\n68478-17-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-027-00-5\nResidues (petroleum), heavy coker and light vacuum;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced as the residual fraction from the distillation of heavy coker gas oil and light vacuum gas oil. It consists predominantly of hydrocarbons having carbon numbers predominantly greater than C13 and boiling above approximately 230 oC (446 oF).]\n270-983-0\n68512-61-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-028-00-0\nResidues(petroleum), light vacuum;\nHeavy Fuel oil; [A complex residuum from the vacuum distillation of the residuum from the atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly greater than C13 and boiling above approximately 230 oC (446 oF).]\n270-984-6\n68512-62-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-029-00-6\nResidues (petroleum), steam-cracked light;\nHeavy Fuel oil;\n[A complex residuum from the distillation of the products from a steam-cracking process. It consists predominantly of aromatic and unsaturated hydrocarbons having carbon numbers greater than C7 and boiling in the range of approximately 101oC to 555 oC (214 oF to 1030oF).]\n271-013-9\n68513-69-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-030-00-1\nFuel oil, No 6; Heavy Fuel oil;\n[A distillate oil having a minimum viscosity of 900 SUS at 37.7 oC (100 oF) to a maximum of 9000 SUS at 37.7 oC (100 oF).]\n271-384-7\n68553-00-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-031-00-7\nResidues (petroleum), topping plant, low-sulfur;\nHeavy Fuel oil;\n[A low-sulfur complex combination of hydrocarbons produced as the residual fraction from the topping plant distillation of crude oil. It is the residuum after the straight-run gasoline cut, kerosene cut and gas oil cut have been removed.]\n271-763-7\n68607-30-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-032-00-2\nGas oils (petroleum), heavy atmospheric;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons obtained by the distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C7 through C35 and boiling in the range of approximately 121oC to 510 oC (250 oF to 950oF).]\n272-184-2\n68783-08-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-033-00-8\nResidues(petroleum), coker scrubber, Condensed-ring-arom.-contg.; Heavy Fuel oil; [A very complex combination of hydrocarbons produced as the residual fraction from the distillation of vaccum residuum and the products from a thermal cracking process. It consists predominantly of hydrocarbons having carbon numbers predominantly greater than C20 and boiling above approximately 350 oC (662 oF). This stream is likely to contain 5 wt.% or more of 4-to 6-membered condensed rind aromatic hydrocarbons.]\n272-187-9\n68783-13-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-034-00-3\nDistillates (petroleum), petroleum residues vacuum; Heavy Fuel oil;\n[A complex combination of hydrocarbons produced by the vacuum distillation of the residuum from the atmospheric distillation of crude oil.]\n273-263-4\n68955-27-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-035-00-9\nResidues (petroleum), steam-cracked, resinous;\nHeavy Fuel oil;\n[A complex residuum from the distillation of steam-cracked petroleum residues.]\n273-272-3\n68955-36-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-036-00-4\nDistillates (petroleum), intermediate vacuum;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced by the vacuum, distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C14 through C42 and boiling in the range of approximately 250oC to 545oC (482oF to 1013oF). This stream is likely to contain 5 wt. % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n274-683-0\n70592-76-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-037-00-X\nDistillates (petroleum), light vacuum;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced by the vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C11 through C35 and boiling in the range of approximately 250 oC to 545oC (482oF to 1013 oF).]\n274-684-6\n70592-77-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-038-00-5\nDistillates (petroleum), vacuum; Heavy Fuel oil;\n[A complex combination of hydrocarbons produced by the vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having numbers predominantly in the range of C15 through C50 and boiling in the range of approximately 270 oC to 600 oC (518oF to 1112 oF). This stream is likely to contain 5 wt.% or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n274-685-1\n70592-78-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-039-00-0\nGas oils (petroleum), hydrodesulfurized coker heavy vacuum; Heavy Fuel oil;\n[A complex combination of hydrocarbons obtained by hydrodesulfurization of heavy coker distillate stocks, It consists predominantly of hydrocarbons having carbon numbers predominantly in the range C18 to C44 and boiling in the range of approximately 304oC to 548oC (579oF to 1018oF). Likely to contain 5 % or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n285-555-9\n85117-03-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-040-00-6\nResidues (petroleum), steam-cracked, distillates;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons obtained during the production of refined petroleum tar by the distillation of steam cracked tar. It consists predominantly of aromatic and other hydrocarbons and organic sulfur compounds.]\n292-657-7\n90669-75-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-041-00-1\nResidues (petroleum), vacuum, light;\nHeavy Fuel oil;\n[A complex residuum from the vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists predominantly of hydrocarbons having carbon numbers predominantly greater than C24 and boiling above approximately 390 oC (734 oF).]\n292-658-2\n90669-76-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-042-00-7\nFuel oil, heavy, high-sulfur; Heavy Fuel oil;\n[A complex combination of hydrocarbons obtained by the distillation of crude petroleum. It consists predominantly of aliphatic, aromatic and cycloaliphatic hydrocarbons having carbon numbers predominantly higher than C25 and boiling above approximately 400 oC (752 oF).]\n295-396-7\n92045-14-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-043-00-2\nResidues (petroleum), catalytic cracking;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced as the residual fraction from the distillation of the products from a catalytic cracking process. It consists predominantly of hydrocarbons having carbon numbers predominantly greater than C11 and boiling above approximately 200oC (392oF).]\n295-511-0\n92061-97-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-044-00-8\nDistillates (petroleum), intermediate catalytic cracked, thermally degraded;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process which has been used as a heat transfer fluid. It consists predominantly of hydrocarbons boiling in the range of approximately 220 oC to 450 C (428 oF to 842 oF). This stream is likely to contain organic sulfur compounds.]\n295-990-6\n92201-59-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-045-00-3\nResidual oils (petroleum); Heavy Fuel oil;\n[A complex combination of hydrocarbons, sulfur compounds and metal-containing organic compounds obtained as the residue from refinery fractionation cracking processes. It produces a finished oil with a viscosity above 2cSt. at 100 oC.]\n298-754-0\n93821-66-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-046-00-9\nResidues, steam cracked, thermally treated;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons obtained by the treatment and distillation of raw steam-cracked naphtha. It consists predominantly of unsaturated hydrocarbons boiling in the range above approximately 180oC (356oF).]\n308-733-0\n98219-64-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-047-00-4\nDistillates (petroleum), hydrodesulfurized full-range middle; Heavy Fuel oil;\n[A complex combination of hydrocarbons obtained by treating a petroleum stock with hydrogen. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C9 through C25 and boiling in the range of approximately 150oC to 400oC (302 oF to 752 oF).]\n309-863-0\n101316-57-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-048-00-X\nResidues (petroleum), catalytic reformer fractionator;\nHeavy Fuel oil;\n[A complex combination of hydrocarbons produced as the residual fraction from distillation of the product from a catalytic reforming process. It consists of predominantly aromatic hydrocarbons having carbon numbers predominantly in the range of C10 through C25 and boiling in the range of approximately 160 oC to 400oC (320 oF to 725 oF). This stream is likely to contain 5 wt. % or more of 4-or 6-membered condensed ring aromatic hydrocarbons.]\n265-069-3\n64741-67-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-049-00-5\nPetroleum; Crude oil;\n[A complex combination of hydrocarbons, It consists predominantly of aliphatic, alicyclic and aromatic hydrocarbons. It may also contain small amounts of nitrogen, oxygen and sulfur compounds. This category encompasses light, medium, and heavy petroleums, as well as the oils extended from tar sands. Hydrocarbonaceous materials requiring major chemical changes for their recovery or conversion to petroleum refinery feedstocks such as crude shale oils; upgraded shale oils and liquid coal fuels are not included in this definition.]\n232-298-5\n8002-05-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-050-00-0\nDistillates (petroleum), light paraffinic;\nUnrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons produced by vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains a relatively large proportion of saturated aliphatic hydrocarbons normally present in this distillation range of crude oil.]\n265-051-5\n64741-50-0\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-051-00-6\nDistillates(petroleum), heavy paraffinic;\nUnrefined ormildly refined baseoil; [A complex combination of hydrocarbons produced by vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains a relatively large proportion of saturated aliphatic hydrocarbons.]\n265-052-0\n64741-51-1\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-052-00-1\nDistillates (petroleum), light naphthenic;\nUnrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons produced by vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-053-6\n64741-52-2\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-053-00-7\nDistillates (petroleum), heavy naphthenic;\nUnrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons produced by vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-054-1\n64741-53-3\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-054-00-2\nDistillates (petroleum), acid-treated heavy naphthenic; Unrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons obtained as a raffinate from a sulfuric acid treating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-117-3\n64742-18-3\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-055-00-8\nDistillates (petroleum), acid-treated light naphthenic; Unrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons obtained as a raffinate from a sulfuric acid treating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-118-9\n64742-19-4\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-056-00-3\nDistillates (petroleum), acid-treated heavy paraffinic; Unrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons btained as a raffinate from a sulfuric acid process. It consists predomi nantly of saturated hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil having a viscosity of a least 100 SUS at 100oF (19cSt at 40 oC).]\n265-119-4\n64742-20-7\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-057-00-9\nDistillates (petroleum), acid-treated light paraffinic; Unrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons obtained as a raffinate from a sulfuric acid treating process. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oi having aviscosity of less than 100 SUS at 100 oF (19cSt at 40oC).]\n265-121-5\n64742-21-8\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-058-00-4\nDistillates (petroleum), chemically neutralized heavy paraffinic;\nUnrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons obtained from a treating proces to remove acidic materials. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains a relatively large proportion of aliphatic hydrocarbons.]\n265-127-8\n64742-27-4\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-059-00-X\nDistillates (petroleum), chemically neutralized light paraffinic;\nUnrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity less than 100 SUS at 100 oF (19cSt at 40 oC).]\n265-128-3\n64742-28-5\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-060-00-5\nDistillates (petroleum), chemically neutralized heavy naphthenic;\nUnrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-135-1\n64742-34-3\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-061-00-0\nDistillates (petroleum), chemically neutralized light naphthenic;\nUnrefined or mildly refined baseoil;\n[A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS a 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-136-7\n64742-35-4\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n649-062-00-6\nGases (petroleum), catalytic cracked naphtha depropanizer overhead, C3-rich acid-free; Petroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation of catalytic cracked hydrocarbons and treated to remove acidic impurities. It consists of hydrocarbons having carbon numbers in the range of C2 through C4, predominantly C3.]\n270-755-0\n68477-73-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-063-00-1\nGases (petroleum), catalytic cracker;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of the products from a catalytic cracking process. It consists predominantly of aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-756-6\n68477-74-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-064-00-7\nGases (petroleum), catalytic cracker, C1-5-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process. It consists of aliphatic hydro carbons having carbon numbers in the range of C1 through C6, predominantly C1 through C5.]\n270-757-1\n68477-75-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-065-00-2\nGases (petroleum), catalytic polymd. naphtha stabilizer overhead, C2-4-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation stabilization of catalytic polymerized naphtha. It consists of aliphatic hydrocarbons having carbon numbers in the range of C2 through C6, predominantly C2 through C4.]\n270-758-7\n68477-76-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-066-00-8\nGases (petroleum), catalytic reformer, C1-4-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by distillation of products from a catalytic reforming process. It consists of hydrocarbons having carbon numbers in the range of C1 through C6, predominantly C1 through C4.]\n270-760-8\n68477-79-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-067-00-3\nGases (petroleum), C3-5 olefinic-paraffinic alkylation feed; Petroleum gas;\n[A complex combination of olefinic and paraffinic hydrocarbons having carbon numbers in the range of C3 through C5 which are used as alkylation feed. Ambient temperatures normally exceed the critical temperature of these combinations.]\n270-765-5\n68477-83-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-068-00-9\nGases (petroleum), C4-rich; Petroleum gas;\n[A complex combination of hydrocarbons produced by distillation of products from a catalytic fractionation process. It consists of aliphatic hydrocarbons having carbon numbers in the range of C3 through C5, predominantly C4.]\n270-767-6\n68477-85-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-069-00-4\nGases (petroleum), deethanizer overheads;\nPetroleum gas;\n[A complex combination of hydrocarbons produced from distillation of the gas and gasoline fractions from the catalytic cracking process. It contains predominantly ethane and ethylene.]\n270-768-1\n68477-86-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-070-00-X\nGasespetroleum),deisobutanizer tower overheads; Petroleum gas;\n[A complex combination of hydrocarbons produced by the atmospheric distillation of a butane-butylene stream. It consists of aliphatic hydro carbons having carbon numbers predominantly in the range of C3 through C4.]\n270-769-7\n68477-87-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-071-00-5\nGases (petroleum), depropanizer dry, propene-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of products from the gas and gasoline fractions of a catalytic cracking process. It consists predominantly of propylene withsome ethane and propane.]\n270-772-3\n68477-90-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-072-00-0\nGases (petroleum), depropanizer overheads;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by distillation of products from the gas and gasoline fractions of a catalytic cracking process. It consists of aliphatic hydrocarbons having carbon numbers predominantly in the range of C2 through C4.]\n270-773-9\n68477-91-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-073-00-6\nGases (petroleum), gas recovery plant depropanizer overheads; Petroleum gas;\n[A complex combination of hydrocarbons obtained by fractionation of miscellaneous hydrocarbon streams. It consists predominantly of hydrocarbons having carbon numbers in the range of C1 through C4, predominantly propane.]\n270-777-0\n68477-94-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-074-00-1\nGases (petroleum), Girbotol unit feed;\nPetroleum gas;\n[A complex combination of hydrocarbons that is used as the feed into the Girbatol unit to remove hydrogen sulfide. It consists of aliphatic hydro carbons having carbon numbers predominantly in the range of C2 through C4.]\n270-778-6\n68477-95-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-075-00-7\nGases (petroleum), isomerized naphtha fractionator, C4-rich, hydrogen sulfide-free;\nPetroleum gas\n270-782-8\n68477-99-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-076-00-2\nTail gas (petroleum), catalytic cracked clarified oil and thermal cracked vacuum residue fractionation reflux drum;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation of catalytic cracked clarified oil and thermal cracked vacuum residue. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-802-5\n68478-21-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-077-00-8\nTail gas (petroleum), catalytic cracked naphtha stabilization absorber;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the stabilization of catalytic cracked naphtha. It consists predomi nantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-803-0\n68478-22-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-078-00-3\nTail gas (petroleum), catalytic cracker, catalytic reformer and hydrodesulfurizer combined fractionater; Petroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation of products from catalytic cracking, catalytic reforming and hydrodesulfurizing processes treated to remove acidic impurities. It consists predominantly of hydrocarbons having cabon numbers predominantly in the range of C1 through C5.]\n270-804-6\n68478-24-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-079-00-9\nTail gas (petroleum), catalytic reformed naphtha fractionation stabilizer;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation stabilization of catalytic reformed naphtha. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n270-806-7\n68478-26-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-080-00-4\nTail gas (petroleum), saturate gas plant mixed stream, C4-rich; Petroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation stabilization of straight-run naphtha, distillation tail gas and catalytic reformed naphtha stabilizer tail gas. It consists of hydrocarbons having carbon numbers in the range of C3 through C6, predominantly butane and isobutane.]\n270-813-5\n68478-32-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-081-00-X\nTail gas (petroleum), saturate gas recovery plant, C1-2-rich; Petroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation of distillate tail gas, straight-run naphtha, catalytic reformed naphtha stabilizer tail gas. It consists predominantly of hydrocarbons having carbon numbers in the range of C1through C5, Predominantly methane and ethane.]\n270-814-0\n68478-33-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-082-00-5\nTail gas (petroleum), vacuum residues thermal cracker; Petroleum gas;\n[A complex combination of hydrocarbons obtained from the thermal cracking of vacuum residues. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n270-815-6\n68478-34-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-083-00-0\nHydrocarbons, C3-4-rich, petroleum distillate;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by distillation and condensation of crude oil. It consists of hydrocarbons having carbon numbers in the range of C3 through C5, predominantly C3 through C4.]\n270-990-9\n68512-91-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-084-00-6\nGases (petroleum), full-range straight-run naphtha dehexanizer off; petroleum gas; [A complex combination of hydrocarbons obtained by the fractionation of the full-range straight-run naphtha. It consists of hydrocarbons having carbon numbers predominantly in the range of C2 through C6.]\n271-000-8\n68513-15-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-085-00-1\nGases (petroleum), hydrocracking depropanizer off, hydrocarbon-rich;\nPetroleum gas;\n[A complex combination of hydrocarbon produced by the distillation of products from a hydrocracking process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C4. It may also contain small amounts of hydrogen and hydrogen sulfide.]\n271-001-3\n68513-16-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-086-00-7\nGases (petroleum), light straight-run naphtha stabilizer off;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by the stabilization of light straight-run naphtha. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C2 through C6.]\n271-002-9\n68513-17-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-087-00-2\nResidues (petroleum), alkylation splitter, C4-rich;\nPetroleum gas;\n[A complex residuum from the distillation of streams various refinery operations. It consists of hydrocarbons having carbon numbers in the range of C4 through C5, predominantly butane and boiling in the range of approximately - 11.7 o C to 27.8 o C (11 oF to 82 oF).]\n271-010-2\n68513-66-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-088-00-8\nHydrocarbons, C1-4; Petroleum gas;\n[A complex combination of hydrocarbons provided by thermal cracking and absorber operations and by distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C4 and boiling in the range of approximately minus164 o C to minus 0.5 o C (– 263 oF to 31 oF).]\n271-032-2\n68514-31-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-089-00-3\nHydrocarbons, C1-4, sweetened; Petroleum gas;\n[A complex combination of hydrocarbons obtaine by subjectin hydrocarbon gases to a sweetening process to convert mercaptans o to remove acidc impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C4 and boiling in the range of approximately –\n164o C to - 0.5 oC (– 263 oF to 31 oF).]\n271-038-5\n68514-36-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-090-00-9\nHydrocarbons, C1-3; Petroleum gas;\n[A complex combination of hydrocarbons having carbon numbers predominantly in the range of C1 through C3 and boiling in the range of approxi mately minus 164 o C to minus 42 oC (– 263 oF to - 44 oF).]\n271-259-7\n68527-16-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-091-00-4\nHydrocarbons, C1-4, debutanizer fraction;\nPetroleum gas\n271-261-8\n68527-19-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-092-00-X\nGases (petroleum), C1-5, wet; Petroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of crude oil and/or the cracking of tower gas oil.\nIt consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n271-624-0\n68602-83-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-093-00-5\nHydrocarbons, C2-4; Petroleum gas\n271-734-9\n68606-25-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-094-00-0\nHydrocarbons, C3; Petroleum gas\n271-735-4\n68606-26-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-095-00-6\nGases (petroleum), alkylation feed;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the catalytic cracking of gas oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C4.]\n271-737-5\n68606-27-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-096-00-1\nGases (petroleum), depropanizer bottoms fractionation off; Petroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation of depropanizer bottoms. It consists predominantly of butane, isobutane and butadiene.]\n271-742-2\n68606-34-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-097-00-7\nGases (petroleum), refinery blend;\nPetroleum gas;\n[A complex combination obtained from various processes.\nIt consists of hydrogen, hydrogen sulfide and hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-183-7\n68783-07-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-098-00-2\nGases (petroleum), catalytic cracking;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of the products from a catalytic cracking process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C3 through C5.]\n272-203-4\n68783-64-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-099-00-8\nGases (petroleum), C2-4, sweetened;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by subjecting a petroleum distillate to a sweetening process to convert mercaptans or to remove acidic impurities. It consists predominantly of saturated and unsaturated hydrocarbons having carbon numbers predominantly in the range of C2 through C4 and boiling in the range of approximately - 51 oC to - 34 oC (– 60oF to - 30oF).]\n272-205-5\n68783-65-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-100-00-1\nGases (petroleum), crude oil fractionation off;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the fractionation of crude oil. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-871-7\n68918-99-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-101-00-7\nGases (petroleum), dehexanizer off;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by the Fractionation of combined naphtha streams. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-872-2\n68919-00-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-102-00-2\nGases (petroleum), light straight run gasoline fractionation stabilizer off;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by the fractionation of light straight-run gasoline. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-878-5\n68919-05-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-103-00-8\nGases (petroleum), naphtha unifiner desulfurization stripper off;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by a naphtha unifiner desulfurization process and stripped from the naphtha product. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n272-879-0\n68919-06-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-104-00-3\nGases (petroleum), straight-run naphtha catalytic reforming off; Petroleum gas;\n[A complex combination of hydrocarbons obtained by the catalytic reforming of straight-run naphtha and fractionation of the total effluent. It consists of methane, ethane, and propane.]\n272-882-7\n68919-09-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-105-00-9\nGases(petroleum), fluidized catalytic cracker splitter overheads; Petroleum gas;\n[A complex combination of hydrocarbons produced by the fractionation of the charge to the C3-C4 splitter. It consists predominantly of C3 hydrocarbons.]\n272-893-7\n68919-20-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-106-00-4\nGases (petroleum), straight-run stabilizer off;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation of the liquid from the first tower used in the distillation of crude oil. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n272-883-2\n68919-10-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-107-00-X\nGases (petroleum), catalytic cracked naphtha debutanizer; Petroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation of catalytic cracked naphtha. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n273-169-3\n68952-76-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-108-00-5\nTail gas (petroleum), catalytic cracked distillate and naphtha stabilizer;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by the fractionation of catalytic cracked naphtha and distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n273-170-9\n68952-77-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-109-00-0\nTail gas (petroleum), thermal-cracked distillate, gas oil and naphtha absorber;\npetroleum gas;\n[A complex combination of hydrocarbons obtained from the separation of thermal-cracked distillates, naphtha and gas oil. It consists pedrominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n273-175-6\n68952-81-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-110-00-6\nTail gas (petroleum), thermal cracked hydrocarbon fractionation stabilizer, petroleum coking;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation stabilization of thermal cracked hydrocarbons from petroleum coking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n273-176-1\n68952-82-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-111-00-1\nGases (petroleum, light steam-cracked, butadiene conc.; Petroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of products from a thermal cracking process. It consists of hydrocarbons having a carbon number predominantly of C4.]\n273-265-5\n68955-28-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-112-00-7\nGases (petroleum), straight-run naphtha catalytic reformer stabilizer overhead;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by the catalytic reforming of straight-run naphtha and the frac tionation of the total effluent.\nIt consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C2 through C4.]\n273-270-2\n68955-34-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-113-00-2\nHydrocarbons, C4; Petroleum gas\n289-339-5\n87741-01-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-114-00-8\nAlkanes, C1-4, C3-rich; Petroleum gas\n292-456-4\n90622-55-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-115-00-3\nGases (petroleum), steam-cracker C3-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of products from a steam cracking process. It consists predominantly of propylene with some propane and boils in the range of approximately - 70 oC to 0 oC (– 94oF to 32oF).]\n295-404-9\n92045-22-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-116-00-9\nHydrocarbons, C4, steam-cracker distillate;\nPetroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of the products of a steam cracking process. It consists predominantly of hydrocarbons having a carbon number of C4, predominantly 1-butene and 2-butene, containing also butane and isobutene and boiling in the range of approximately minus 12 o C to 5 o C (10.4 oF to 41oF).]\n295-405-4\n92045-23-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-117-00-4\nPetroleum gases, liquefied, sweetened, C4 fraction; Petroleum gas;\n[A complex combination of hydrocarbons obtained by subjecting a liquified petroleum gas mix to a sweetening process to oxidize mercaptans or to remove acidic impurities. It consists predominantly of C4 saturated and unsaturated hydrocarbons.]\n295-463-0\n92045-80-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK S U\n649-118-00-X\nHydrocarbons, C4, 1,3-butadiene-and isobutene-free; Petroleum gas\n306-004-1\n95465-89-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-119-00-5\nRaffinates (petroleum), steam-cracked C4 fraction cuprous ammonium acetate extn., C3-5 and C3-5 unsatd., butadiene-free; Petroleum gas\n307-769-4\n97722-19-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-120-00-0\nGases (petroleum), amine system feed;\nRefinery gas;\n[The feed gas to the amine system for removal of hydrogen sulfide. It consists of hydrogen. Carbon monoxide, carbon dioxide, hydrogen sulfide and aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5 may also be present.]\n270-746-1\n68477-65-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-121-00-6\nGases (petroleum), benzene unit hydrodesulfurizer off;\nRefinery gas;\n[Off gases produced by the benzene unit. It consists primarily of hydrogen. Carbon monoxide and hydrocarbons having carbon numbers predominantly in the range of C1 through C6, including benzene, may also be present.]\n270-747-7\n68477-66-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-122-00-1\nGases (petroleum), benzene unit recycle, hydrogen-rich;\nRefinery gas;\n[A complex combination of hydrocarbons obtained by recycling the gases of the benzene unit. It consists primarily of hydrogen with various small amounts of carbon monoxide and hydro carbons having carbon numbers in the range of C1 through C6.]\n270-748-2\n68477-67-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-123-00-7\nGases (petroleum), blend oil, hydrogen-nitrogen-rich;\nRefinery gas;\n[A complex combination of hydrocarbons obtained by distillation of a blend oil. It consists primarily of hydrogen and nitrogen with various small amounts of carbon monoxide, carbon dioxide, and aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n270-749-8\n68477-68-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-124-00-2\nGases (petroleum), catalytic reformed naphtha stripper overheads;\nRefinery gas;\n[A complex combination of hydrocarbons obtained from stabilization of catalytic reformed naphtha. Its consists of hydrogen and saturated hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n270-759-2\n68477-77-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-125-00-8\nGases (petroleum), C6-8 catalytic reformer recycle;\nRefinery gas;\n[A complex combination of hydrocarbons produced by distillation of products from catalytic reforming of C6-C8 feed and recycled to conserve hydrogen. It consists primarily of hydrogen. It may also contain various small amounts of carbon monoxide, carbon dioxide, nitrogen, and hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-761-3\n68477-80-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-126-00-3\nGases (petroleum), C6-8 catalytic reformer;\nRefinery gas;\n[A complex combination of hydrocarbons produced by distillation of products from catalytic reforming of C6-C8feed. It consists of hydrocarbons having carbon numbers in the range of C1 through C5 and hydrogen.]\n270-762-9\n68477-81-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-127-00-9\nGases (petroleum), C6-8 catalytic reformer recycle, hydrogen-rich; Refinery gas\n270-763-4\n68477-82-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-128-00-4\nGases (petroleum), C2-return stream;\nRefinery gas;\n[A complex combination of hydrocarbons obtained by the extraction of hydrogen from a gas stream which consists primarily of hydroge with small amounts of nitrogen, carbon monoxide, methane, ethane, and ethylene. It contain predominantly hydrocarbons such as methane, ethane, and ethylene with small amounts of hydrogen, nitrogen and carbon monoxide.]\n270-766-0\n68477-84-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-129-00-X\nGases (petroleum), dry sour, gas-concn.-unit-off;\nRefinery gas;\n[The complex combination of dry gase from a gas concentration unit. It consists of hydrogen, hydrogen sulfide and hydrocarbons having carbon numbers predominantly in the range of C1 through C3.]\n270-774-4\n68477-92-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-130-00-5\nGases (petroleum), gas concn. reabsorber distn.;\nRefinery gas;\n[A complex combination of hydrocarbons produced by distillation of products from combined gas streams in a gas concentration reabsorber. It consists predominantly of hydrogen, carbon monoxide, carbon dioxide, nitrogen, hydrogen sulfide and hydrocarbons having carbon numbers in the range of C1 through C3.]\n270-776-5\n68477-93-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-131-00-0\nGases (petroleum), hydrogen absorber off;\nRefinery gas;\n[A complex combination obtained by absorbing hydrogen from a hydrogen rich stream. It consists of hydrogen, carbon monoxide, nitrogen, and methane with small amounts of C2 hydrocarbons.]\n270-779-1\n68477-96-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-132-00-6\nGases (petroleum), hydrogen-rich;\nRefinery gas;\n[A complex combination separated as a gas from hydrocarbon gases by chilling. It consists primarily of hydrogen with various small amounts of carbon monoxide, nitrogen, methane, and C2 hydrocarbons.]\n270-780-7\n68477-97-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-133-00-1\nGases (petroleum), hydrotreater blend oil recycle, hydrogen-nitrogen-rich;\nRefinery gas;\n[A complex combination obtained from recycled hydrotreated blend oil. It consists primarily of hydrogen and nitrogen with various small amounts of carbon monoxide, carbon dioxide and hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n270-781-2\n68477-98-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-134-00-7\nGases (petroleum), recycle, hydrogen-rich;\nRefinery gas;\n[A complex combination obtained from recycled reactor gases. It consists primarily of hydrogen with various small amounts of carbon monoxide, carbon dioxide, nitrogen, hydrogen sulfide, and saturated aliphatic hydrocarbons having carbon numbers in the range of C1 through C5.]\n270-783-3\n68478-00-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-135-00-2\nGases (petroleum), reformer make-up, hydrogen-rich; Refinery gas;\n[Acomplex combination obtained from the reformers. It consists primarily of hydrogen with variou smal amount of carbon monoxide and aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n270-784-9\n68478-01-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-136-00-8\nGases (petroleum), reforming hydrotreater;\nRefinery gas;\n[A complex combination obtained from the reforming hydrotreating process. It consists primarily of hydrogen, methane, and ethane with various small amounts of hydrogen sulfide and aliphatic hydrocarbons having carbon numbers predominantly in the range of C3 through C5.]\n270-785-4\n68478-02-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-137-00-3\nGases (petroleum), reforming hydrotreater, hydrogen-methane-rich;\nRefinery gas;\n[A complex combination obtained fromthe reforming hydrotreating process. It consists primarily of hydrogen and methane with various small amounts of carbon monoxide, carbon dioxide, nitrogen and saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C2 through C5.]\n270-787-5\n68478-03-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-138-00-9\nGases (petroleum), reforming hydrotreater make-up, hydrogen-rich;\nRefinery gas;\n[A complex combination obtained from the reforming hydrotreating process. It consists primarily of hydrogen with various small amounts of carbon monoxide and aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n270-788-0\n68478-04-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-139-00-4\nGases (petroleum), thermal cracking distn.;\nRefinery gas;\n[A complex combination produced by distillation of products from a thermal cracking process. It consists of hydrogen, hydrogen sulfide, carbon monoxide, carbon dioxide and hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-789-6\n68478-05-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-140-00-X\nTail gas (petroleum), catalytic cracker refractionation absorber; Refinery gas;\n[A complex combination of hydrocarbons obtained from refractionation of products from a catalytic cracking process. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C3.]\n270-805-1\n68478-25-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-141-00-5\nTail gas (petroleum), catalytic reformed naphtha separator; Refinery gas;\n[A complex combination of hydrocarbons obtained from the catalytic reforming of straight run naphtha. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-807-2\n68478-27-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-142-00-0\nTail gas (petroleum), catalytic reformed naphtha stabilizer; Refinery gas;\n[A complex combination of hydrocarbons obtained from the stabilization of catalytic reformed naphtha. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-808-8\n68478-28-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-143-00-6\nTail gas (petroleum), cracked distillate hydrotreater separator; Refinery gas; [A complex combination of hydrocarbons obtained by treating cracked distillates with hydrogen in the presence of a catalyst. It consists of hydrogen and saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n270-809-3\n68478-29-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-144-00-1\nTail gas (petroleum), hydrodesulfurized straight-run naphtha separator;\nRefinery gas;\n[A complex combination of hydrocarbons obtained from hydrodesulfurization of straight-run naphtha. It consists of hydrogen and saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n270-810-9\n68478-30-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-145-00-7\nGases (petroleum), catalytic reformed straight-run naphtha stabilizer overheads;\nRefinery gas;\n[A complex combination of hydrocarbons obtained from the catalytic reforming of straight-run naphtha followed by fractionation of the total effluent. It consists of hydrogen, methane, ethane and propane.]\n270-999-8\n68513-14-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-146-00-2\nGases (petroleum), reformer effluent high-pressure flash drum off;\nRefinery gas;\n[A complex combination produced by the high-pressure flashing of the effluent from the reforming reactor. It consists primarily of hydrogen with various small amounts of methane, ethane, and propane.]\n271-003-4\n68513-18-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-147-00-8\nGases (petroleum), reformer effluent low-pressure flash drum off;\nRefinery gas;\n[A complex combination produced by low-pressure flashing of the effluent from the reforming reactor. It consists primarily of hydrogen with various small amounts of methane, ethane, and propane.]\n271-005-5\n68513-19-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-148-00-3\nGases (petroleum), oil refinery gas distn. off;\nRefinery gas;\n[A complex combination separatedby distillation of a gas stream containing hydrogen, carbon monoxide, carbon dioxide and hydrocarbons having carbon numbers in the range of C1 through C6 or obtained by cracking ethane and propane. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C2, hydrogen, nitrogen, and carbon monoxide.]\n271-258-1\n68527-15-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-149-00-9\nGases (petroleum), benzene unit hydrotreater depentanizer overheads; Refinery gas;\n[A complex combination produced by treating the feed from the benzene unit with hydrogen in the presence of a catalyst followed by depentanizing. It consists primarily of hydrogen, ethane and propane with various small amounts of nitrogen, carbon monoxide, carbon dioxide and hydrocarbons having carbon numbers predominantly in the range of C1 through C6. It may contain trace amounts of benzene.]\n271-623-5\n68602-82-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-150-00-4\nGases (petroleum), secondary absorber off, fluidized catalytic cracker overheads fractionator; Refinery gas;\n[A complex combination produced by the fractionation of the overhead products from the catalyticcracking process in the fluidized catalytic cracker. It consists of hydrogen, nitrogen, and hydrocarbons having carbon numbers predominantly in the range of C1 through C3.]\n271-625-6\n68602-84-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-151-00-X\nPetroleum products, refinery gases;\nRefinery gas; [A complex combination which consists primarily of hydrogen with various small amounts of methane, ethane, and propane.]\n271-750-6\n68607-11-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-152-00-5\nGases (petroleum), hydrocracking low-pressure separator; Refinery gas;\n[A complex combination obtained by the liquid-vapor separation of the hydrocracking process reactor effluent. It consists predominantly of hydrogen and saturated hydrocarbons having carbon numbers predominantly in the range of C1 through C3.]\n272-182-1\n68783-06-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-153-00-0\nGases (petroleum), refinery; Refinery gas;\n[A complex combination obtained from various petroleum refining operations. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C3.]\n272-338-9\n68814-67-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-154-00-6\nGases (petroleum), platformer products separator off;\nRefinery gas;\n[A complex combination obtained from the chemical reforming of naphthenes to aromatics. It consists of hydrogen and saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C2 through C4.]\n272-343-6\n68814-90-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-155-00-1\nGases (petroleum), hydrotreated sour kerosine depentanizer stabilizer off;\nRefinery gas;\n[The complex combination obtained from the depentanizer stabilization of hydrotreated kerosine. It consists primarily of hydrogen, methane, ethane, and propane with various small amounts of nitrogen, hydrogen sulfide, carbon monoxide and hydrocarbons having carbon numbers predominantly in the range of C4 through C5.]\n272-775-5\n68911-58-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-156-00-7\nGases (petroleum), hydrotreated sour kerosine flash drum; Refinery gas;\n[A complex combination obtained from the flash drum of the unit treating sour kerosine with hydrogen in the presence of a catalyst. It consists primarily of hydrogen and methane with various small amounts of nitrogen, carbon monoxide, and hydrocarbons having carbon numbers predominantly in the range of C2 through C5.]\n272-776-0\n68911-59-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-157-00-2\nGases (petroleum), distillate unifiner desulfurization stripper off;\nRefinery gas;\n[A complex combination stripped from the liquid product of the unifiner desulfurization process. It consists of hydrogen sulfide, methane, ethane, and propane.]\n272-873-8\n68919-01-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-158-00-8\nGases (petroleum), fluidized catalytic cracker fractionation off;\nRefinery gas;\n[A complex combination produced by the fractionation of the overhead product of the fluidized catalytic cracking process. It consists of hydrogen, hydrogen sulfide, nitrogen, and hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-874-3\n68919-02-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-159-00-3\nGases (petroleum), fluidized catalytic cracker scrubbing secondary absorber off;\nRefinery gas;\n[A complex combination produced by scrubbing the overhead gas from the fluidized catalytic cracker. It consists of hydrogen, nitrogen, methane, ethane and propane.]\n272-875-9\n68919-03-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-160-00-9\nGases (petroleum), heavy distillate hydrotreater desulfurization stripper off;\nRefinery gas;\n[A complex combination stripped from the liquid product of the heavy distillate hydrotreater desulfurization process. It consists of hydrogen, hydrogen sulfide, and saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-876-4\n68919-04-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-161-00-4\nGases (petroleum), platformer stabilizer off, light ends fractionation;\nRefinery gas;\n[A complex combination obtained by the fractionation of the light ends of the platinum reactors of the platformer unit. It consists of hydrogen, methane, ethane and propane.]\n272-880-6\n68919-07-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-162-00-X\nGases (petroleum), preflash tower off, crude distn.;\nRefinery gas;\n[A complex combination produced from the first tower used in the distillation of crude oil. It consists of nitrogen and saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-881-1\n68919-08-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-163-00-5\nGases (petroleum), tar stripper off;\nRefinery gas;\n[A complex combination obtained by the fractionation of reduced crude oil. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n272-884-8\n68919-11-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-164-00-0\nGases (petroleum), unifiner stripper off;\nRefinery gas;\n[A combination of hydrogen and methane obtained by fractionation of the products from the unifiner unit.]\n272-885-3\n68919-12-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-165-00-6\nTail gas (petroleum), catalytic hydrodesulfurized naphtha separator;\nRefinery gas;\n[A complex combination of hydrocarbons obtained from the hydrodesulfurization of naphtha. It consists of hydrogen, methane, ethane, and propane.]\n273-173-5\n68952-79-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-166-00-1\nTail gas (petroleum), straight-run naphtha hydrodesulfurizer; Refinery gas;\n[A complex combination obtained from the hydrodesulfurization of straight-run naphtha. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n273-174-0\n68952-80-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-167-00-7\nGases (petroleum), sponge absorber off, fluidized catalytic cracker and gas oil desulfurizer overhead fractionation;\nRefinery gas;\n[A complex combination obtained by the fractionation of products from the fluidized catalytic cracker and gas oil desulfurizer. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n273-269-7\n68955-33-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-168-00-2\nGases (petroleum), crude distn. and catalytic cracking;\nRefinery gas;\n[A complex combination produced by crude distillation and catalytic cracking processes. It consists of hydrogen, hydrogen sulfide, nitrogen, carbon monoxide and paraffinic and olefinic hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n273-563-5\n68989-88-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-169-00-8\nGases (petroleum), gas oil diethanolamine scrubber off; Refinery gas;\n[A complex combination produced by desulfurization of gas oils with diethanolamine. It consists predominantly of hydrogen sulfide, hydrogen and aliphatic hydrocarbons having carbon numbers in the range of C1 through C5.]\n295-397-2\n92045-15-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-170-00-3\nGases (petroleum), gas oil hydrodesulfurization effluent; Refinery gas;\n[A complex combination obtained by separation of the liquid phase from the effluent from the hydrogenation reaction. It consists predominantly of hydrogen, hydrogen sulfide and aliphatic hydro carbons having carbon numbers predominantly in the range of C1 through C3.]\n295-398-8\n92045-16-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-171-00-9\nGases (petroleum), gas oil hydrodesulfurization purge; Refinery gas;\n[A complex combination of gases obtained from the reformer and from the purges from the hydrogenation reactor. It consists predominantly of hydrogen and aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n295-399-3\n92045-17-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-172-00-4\nGases (petroleum), hydrogenator effluent flash drum off;\nRefinery gas;\n[A complex combination of gases obtained from flash of the effluents after the hydroge nation reaction. It consists predominantly of hydrogen and aliphatic hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n295-400-7\n92045-18-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-173-00-X\nGases (petroleum), naphtha steam cracking high-pressure residual;\nRefinery gas;\n[A complex combination obtained as a reaction mass of the non-condensable portions from the product of a naphtha steam cracking process as well as residual gases obtained during the preparation of subsequent products. It consists predominantly of hydrogen and paraffinic and olefinic hydrocarbons having carbon numbers predominantly in the range of C1 through C5 with which natural gas may also be mixed.]\n295-401-2\n92045-19-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-174-00-5\nGases (petroleum), residue visbaking off;\nRefinery gas;\n[A complex combination obtained from viscosity reduction of residues in a furnace. It consists predominantly of hydrogen sulfide and paraffinic and olefinic hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n295-402-8\n92045-20-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-175-00-0\nFoots oil (petroleum), acid-treated;\nFoots oil;\n[A complex combination of hydrocarbons obtained by treatment of Foot's oil with sulfuric acid. It consists predominantly of branched-chain hydrocarbons with carbon numbers predominantly in the range of C20 through C50.]\n300-225-7\n93924-31-3\nFlam. Gas 1\nPress. Gas\nCarc. 1B\nH220\nH350\nH340\nGHS02\nGHS04\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-176-00-6\nFoots oil (petroleum), clay-treated;\nFoots oil;\n[A complex combination of hydrocarbons obtained by treatment of Foot's oil with natural or modified clay in either a contacting or percolation process to remove the trace amounts of polar compounds and impurities present. It consists predomi nantly of branched chain hydro carbons with carbon numbers predominantly in the range of C20 through C50.]\n300-226-2\n93924-32-4\nFlam. Gas 1\nPress. Gas\nCarc. 1B\nH220\nH350\nH340\nGHS02\nGHS04\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-177-00-1\nGases (petroleum), C3-4; Petroleum gas; [A complex combination of hydrocarbons produced by distillation of products from the cracking of crude oil. It consists of hydrocarbons having carbon numbers in the range of C3 through C4, predominantly of propane and propylene, and boiling in the range of approximately - 51 oC to - 1 oC (– 60 oF to 30 oF.)]\n268-629-5\n68131-75-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-178-00-7\nTail gas (petroleum), catalytic cracked distillate and catalytic cracked naphtha fractionation absorber; Petroleum gas;\n[The complex combination of hydrocarbons from the distillation of the products from catalytic cracked distillates and catalytic cracked naphtha. It consists predominantly of hydrocarbons having carbon numbers in the range of C1 through C4.]\n269-617-2\n68307-98-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-179-00-2\nTail gas (petroleum), catalytic polymn. naphtha fractionation stabilizer; Petroleum gas;\n[A complex combination of hydrocarbons from the fractionation stabilization products\nfrom polymerization of naphtha. It consists predominantly of hydrocarbons having carbon numbers in the range of C1 through C4.]\n269-618-8\n68307-99-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-180-00-8\nTail gas (petroleum), catalytic reformed naphtha fractionation stabilizer, hydrogen sulfide-free;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation stabilization of catalytic reformed naphtha and from which hydrogen sulfide has been removed by amine treatment. It consists predomi nantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n269-619-3\n68308-00-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-181-00-3\nTail gas (petroleum), cracked distillate hydrotreater stripper;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by treating thermal cracked distillates with hydrogen in the presence of a catalyst. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n269-620-9\n68308-01-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-182-00-9\nTail gas (petroleum), straight-run distillate hydrodesulfurizer, hydrogen sulfide-free; Petroleum gas;\n[A complex combination of hydrocarbons obtained from catalytic hydrodesulfurization of straight run distillates and from which hydrogen sulfide has been removed by amine treatment. It consists predomi nantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n269-630-3\n68308-10-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-183-00-4\nTail gas (petroleum), gas oil catalytic cracking absorber;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the distillation of products from the catalytic cracking of gas oil. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n269-623-5\n68308-03-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-184-00-X\nTail gas (petroleum), gas recovery plant;\nPetroleum gas;\n[A complex combination of hydrocarbons from the distillation of products from miscellaneous hydrocarbon streams. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n269-624-0\n68308-04-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-185-00-5\nTail gas (petroleum), gas recovery plant deethanizer;\nPetroleum gas;\n[A complex combination of hydrocarbons from the distillation of products from miscellaneous hydrocarbon streams. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n269-625-6\n68308-05-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-186-00-0\nTail gas (petroleum), hydrodesulfurized distillate and hydrodesulfurized naphtha fractionator, acid-free;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation of hydrodesul furized naphtha and distillate\nhydrocarbon streams and treated to remove acidic impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n269-626-1\n68308-06-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-187-00-6\nTail gas (petroleum), hydrodesulfurized vacuum gas oil stripper, hydrogen sulfide-free;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from stripping stabilization of catalytic hydrodesulfurized vacuum gas oil and from which hydrogen sulfide has been removed by amine treatment. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n269-627-7\n68308-07-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-188-00-1\nTail gas (petroleum), light straight-run naphtha stabilizer, hydrogen sulfide-free;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation stabilization of light straight run naphtha and from which hydrogen sulfide has been removed by amine treatment. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n269-629-8\n68308-09-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-189-00-7\nTail gas (petroleum), propane-propylene alkylation feed prep deethanizer;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the distillation of the reaction products of propane with propylene. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n269-631-9\n68308-11-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-190-00-2\nTail gas (petroleum), vacuum gas oil hydrodesulfurizer, hydrogen sulfide-free;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from catalytic hydrodesulfurization of vacuum gas oil and from which hydrogen sulfide has been removed by amine treatment. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C6.]\n269-632-4\n68308-12-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-191-00-8\nGases (petroleum), catalytic cracked overheads; Petroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of products from the catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C5 and boiling in the range of approximately –48 oC to 32 oC (– 54 oF to 90oF).]\n270-071-2\n68409-99-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-193-00-9\nAlkanes, C1-2; Petroleum gas\n270-651-5\n68475-57-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-194-00-4\nAlkanes, C2-3; Petroleum gas\n270-652-0\n68475-58-1\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-195-00-X\nAlkanes, C3-4;\npetroleum gas\n270-653-6\n68475-59-2\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-196-00-5\nAlkanes, C4-5; Petroleum gas\n270-654-1\n68475-60-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-197-00-0\nFuel gases; Petroleum gas;\n[A combination of light gases. It consists predominantly of hydrogen and/or low molecular weight hydrocarbons.]\n270-667-2\n68476-26-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-198-00-6\nFuel gases, crude oil of distillates;\nPetroleum gas;\n[A complex combination of light gases produced by distil lation of crude oil and by catalytic reforming of naphtha. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C4 and boiling in the range of approximately - 217o C to - 12 o C (– 423 oF to 10 oF).]\n270-670-9\n68476-29-9\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-199-00-1\nHydrocarbons, C3-4; Petroleum gas\n270-681-9\n68476-40-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-200-00-5\nHydrocarbons, C4-5; Petroleum gas\n270-682-4\n68476-42-6\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-201-00-0\nHydrocarbons, C2-4, C3-rich; Petroleum gas\n270-689-2\n68476-49-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-202-00-6\nPetroleum gases, liquefied; Petroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C7 and boiling in the range of approximately –\n40 oC to 80 oC (– 40oF to 176oF).]\n270-704-2\n68476-85-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK S U\n649-203-00-1\nPetroleum gases, liquefied, sweetened;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained by subjecting liquefied petroleum gas mix to a sweetening process to convert mercaptans or to remove acidic impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C7 and boiling in the range of approximately–40 o C to 80 o C (– 40 oF to176 oF).]\n270-705-8\n68476-86-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK S U\n649-204-00-7\nGases (petroleum), C3-4, isobutane-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons from the distillation of saturated and unsaturated hydrocarbons usually ranging in carbon numbers from C3 through C6, predominantly butane and isobutane. It consists of saturated and unsaturated hydrocarbons having carbon numbers in the range of C3 through C4, predominantly isobutane.]\n270-724-1\n68477-33-8\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-205-00-2\nDistillates (petroleum), C3-6, piperylene-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons from the distillation of saturated and unsaturated aliphatic hydrocarbons usually ranging in the carbon numbers C3 through C6. It consists of saturated and unsaturated hydrocarbons having carbon numbers in the range of C3 through C6, predominantly piperylenes.]\n270-726-2\n68477-35-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-206-00-8\nGases (petroleum), butane splitter overheads;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the distillation of the butane stream. It consists of aliphatic hydrocarbons having carbon numbers predominantly in the range of C3 through C4.]\n270-750-3\n68477-69-0\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-207-00-3\nGases (petroleum), C2-3-; Petroleum gas;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic fractionation process. It contains predominantly ethane, ethylene, propane, and propylene.]\n270-751-9\n68477-70-3\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-208-00-9\nGases (petroleum), catalytic-cracked gas oil depropanizer bottoms, C4-rich acid-free;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from fractionation of catalytic cracked gas oil hydrocarbon\nstream and treated to remove hydrogen sulfide and other acidic components. It consists of hydrocarbons having carbon numbers in the range of C3 through C5, predominantly C4.]\n270-752-4\n68477-71-4\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-209-00-4\nGases (petroleum), catalytic-cracked naphtha debutanizer bottoms, C3-5-rich;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the stabilization of catalytic cracked naphtha. It consists of aliphatic hydrocarbons having carbon numbers predominantly in the range of C3 through C5.]\n270-754-5\n68477-72-5\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-210-00-X\nTail gas (petroleum), isomerized naphtha fractionation stabilizer;\nPetroleum gas;\n[A complex combination of hydrocarbons obtained from the fractionation stabilization products from isomerized naphtha. It consists predomi nantly of hydrocarbons having carbon numbers predominantly in the range of C1 through C4.]\n269-628-2\n68308-08-7\nPress. Gas\nFlam. Gas 1\nCarc. 1A Muta. 1B\nH220\nH350\nH340\nGHS04\nGHS02\nGHS08\nDgr\nH220\nH350\nH340\nK U\n649-211-00-5\nFoots oil (petroleum), carbon-treated;\nFoots oil;\n[A complex combination of hydrocarbons obtained by the treatment of Foots oil with activated carbon for the removal of trace constituents and impurities. It consists predominantly of saturated straight chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-126-0\n97862-76-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-212-00-0\nDistillates (petroleum), sweetened middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained by subjecting a petroleum distillate to a sweetening process to convert mercaptans or to remove acidic impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C20 and boiling in the range of approximately 150oC to 345oC (302 o F to 653oF).]\n265-088-7\n64741-86-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-213-00-6\nGas oils (petroleum), solvent-refined;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists predominantly of aliphatic hydrocarbons having carbon numbers predominantly in the range of C11 through C25 and boiling in the range of approximately 205oC to 400oC (401oF to 752oF).]\n265-092-9\n64741-90-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-214-00-1\nDistillates (petroleum), solvent-refined middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists predominantly of aliphatic hydrocarbons having carbon numbers predominantly in the range of C9 through C20 and boiling in the range of approximately 150oC to 345oC (302oF to 653 oF).]\n265-093-4\n64741-91-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-215-00-7\nGas oils (petroleum), acid-treated;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained as a raffinate from a sulfuric acid treating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C13 through C25 and boiling in the range of approximately 230oC to 400oC (446oF to 752 oF).]\n265-112-6\n64742-12-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-216-00-2\nDistillates (petroleum), acid-treated middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained as a raffinate from a sulfuric acid treating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C11 through C20 and boiling in the range of approximately 205 oC to 345 oC (401 oF to 653 oF).]\n265-113-1\n64742-13-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-217-00-8\nDistillates (petroleum), acid-treated light;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained as a raffinate from a sulfuric acid treating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of approximately 150oC to 290oC (302oF to 554oF).]\n265-114-7\n64742-14-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-218-00-3\nGas oils (petroleum), chemically neutralized;\nGasoil — unspecified;\n[A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C13 through C25 and boiling in the range of approximately 230 oC to 400 oC (446oF to 752 oF).]\n265-129-9\n64742-29-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-219-00-9\nDistillates (petroleum), chemically neutralized middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C11 through C20 and boiling in the range of approximately 205oC to 345oC (401oF to 653oF).]\n265-130-4\n64742-30-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-220-00-4\nDistillates (petroleum), clay-treated middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons resulting from treatment of a petroleum fraction with natural or modified clay, usually in a percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C20 and boiling in the range of approximately 150oC to 345oC (302oF to 653oF).]\n265-139-3\n64742-38-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-221-00-X\nDistillates (petroleum), hydrotreated middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C11 through C25 and boiling in the range of approximately\n205oC to 400oC (401 oF to 752 oF).]\n265-148-2\n64742-46-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-222-00-5\nGas oils (petroleum), hydrodesulfurized;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained from a petroleum stock by treating with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C13 through C25 and boiling in the range of approximately 230oC to 400oC (446oF to 752 oF).]\n265-182-8\n64742-79-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-223-00-0\nDistillates (petroleum), hydrodesulfurized middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained from a petroleum stock by treating with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists of hydrocarbons having carbon numbers predominantly in the range of C11 through C25 and boiling in the range of approximately 205oC to 400oC (401oF to 752oF).]\n265-183-3\n64742-80-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-224-00-6\nFuels, diesel;\nGasoil — unspecified;\n[A complex combination of hydrocarbons produced by the distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C20 and boiling in the range of approximately 163oC to 357oC (325oF to 675oF).]\n269-822-7\n68334-30-5\nCarc. 2\nH351\nGHS08\nWng\nH351\nN\n649-225-00-1\nFuel oil, No 2;\nGasoil — unspecified;\n[A distillate oil having a minimum viscosity of 32,6 SUS at 37,7oC (100oF) to a maximum of 37,9 SUS at 37,7oC (100 oF).]\n270-671-4\n68476-30-2\nCarc. 2\nH351\nGHS08\nWng\nH351\n649-226-00-7\nFuel oil, No 4;\nGasoil — unspecified;\n[A distillate oil having a minimum viscosity of 45 SUS at 37,7oC (100oF) to a maximum of 125 SUS at 37,7 oC (100 oF).]\n270-673-5\n68476-31-3\nCarc. 2\nH351\nGHS08\nWng\nH351\n649-227-00-2\nFuels, diesel, No 2; Gasoil — unspecified;\n[A distillate oil having a minimum viscosity of 32,6 SUS at 37,7 oC (100 oF).]\n270-676-1\n68476-34-6\nCarc. 2\nH351\nGHS08\nWng\nH351\n649-228-00-8\nDistillates (petroleum), catalytic reformer fractionator residue, high-boiling;\nGasoil — unspecified;\n[A complex combination of hydrocarbons from the distillation of catalytic reformer fracftionator residue. It boils in the range of approximately 343 oC to 99oC (650oF to 750 oF).]\n270-719-4\n68477-29-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-229-00-3\nDistillates (petroleum), catalytic reformer fractionator residue, intermediate-boiling;\nGasoil — unspecified;\n[A complex combination of hydrocarbons from the distillation of catalytic reformer fractionator residue. It boils in the range of approximately 288oC to 371oC (550oF to 700oF).]\n270-721-5\n68477-30-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-230-00-9\nDistillates (petroleum), catalytic reformer fractionator residue, low-boiling;\nGasoil — unspecified;\n[The complex combination of hydrocarbons from the distillation of catalytic reformer fractionator residue. It boils approximately below 288 oC (550oF).]\n270-722-0\n68477-31-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-231-00-4\nDistillates (petroleum), highly refined middle;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained by the subjection of a petroleum fraction to several of the following steps: filtration, centrifugation, atmospheric distillation, vacuum distillation, acidification, neutralization and clay treatment. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C10 through C20.]\n292-615-8\n90640-93-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-232-00-X\nDistillates (petroleum) catalytic reformer, heavy arom. conc.; Gasoil — unspecified; [A complex combination of hydrocarbons obtained from the distillation of a catalytically reformed petroleum cut. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C10 through C16 and boiling in the range of approximately 200oC to 300oC (392 oF to 572 oF).]\n295-294-2\n91995-34-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-233-00-5\nGas oils, paraffinic; Gasoil — unspecified;\n[A distillate obtained from the redistillation of a complex combination of hydrocarbons obtained by the distillation of the effluents from a severe catalytic hydrotreatment of paraffins. It boils in the range of approximately 190oC to 330oC (374oF to 594oF).]\n300-227-8\n93924-33-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-234-00-0\nNaphtha (petroleum), solvent-refined hydrodesulfurized heavy;\nGasoil — unspecified\n307-035-3\n97488-96-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-235-00-6\nHydrocarbons, C16-20, hydrotreated middle distillate, distn. lights;\nGasoil — unspecified; [A complex combination of hydrocarbons obtained as first runnings from the vacuum distillation of effluents from the treatment of a middle distillate with hydrogen. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C16 through C20 and boiling in the range of approximately 290 oC to 350 oC (554 oF to 662 oF). It produces a finished oil having a viscosity of 2cSt at 100 oC (212 oF).]\n307-659-6\n97675-85-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-236-00-1\nHydrocarbons, C12-20, hydrotreated paraffinic, distn. lights;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained as first runnings from the vacuum distillation of effluent from the treatment of heavy paraffins with hydrogen in the presence of a catalyst. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C12 through C20 and boiling in the range of approximately 230 oC to 350 oC (446 oF to 662 oF). It produces a finished oil having viscosity of 2cSt at 100oC (212oF).]\n307-660-1\n97675-86-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-237-00-7\nHydrocarbons, C11-17, solvent-extd. light naphthenic;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained by extraction of the aromatics from a light naphthenic distillate having a visciosity of 2.2 cSt at 40 oC (104 oF). It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C11 through C17 and boiling in the range of approximately 200oC to 300oC (392oF to 572 oF).]\n307-757-9\n97722-08-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-238-00-2\nGas oils, hydrotreated; Gasoil — unspecified;\n[A complex combination of hydrocarbons obtained from the redistillation of the effluents from the treatment of paraffins with hydrogen in the presence of a catalyst. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C17 through C27 and boiling in the range of approximately 330oC to 340oC (626oF to 644oF).]\n308-128-1\n97862-78-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-239-00-8\nDistillates (petroleum), carbon-treated light paraffinic;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained by the treatment of a petroleum oil fraction with activated charcoal for the removal of traces of polar constituents and impur ities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C12 through C28.]\n309-667-5\n100683-97-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-240-00-3\nDistillates (petroleum), intermediate paraffinic, carbon-treated;\nGasoil — unspecified;\n[A complex combination of hydrocarbons obtained by the treatment of petroleum with activated charcoal for the removal of trace polar consti tuents and impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C16 through C36.]\n309-668-0\n100683-98-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-241-00-9\nDistillates (petroleum), intermediate paraffinic, clay-treated; Gasoil — unspecified; [A complex combination of hydrocarbons obtained by the treatment of petroleum with bleaching earth for the removal of trace polar constituents and impurities. It consists predomi nantly of hydrocarbons having carbon numbers predominantly in the range of C16 through C36.]\n309-669-6\n100683-99-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-242-00-4\nAlkanes, C12-26-branched and linear\n292-454-3\n90622-53-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-243-00-X\nLubricating greases; Grease;\n[A complex combination of hydrocarbons having carbon numbers predominantly in the range of C12 through C50. May contain organic salts of alkali metals, alkaline earth metals, and/or aluminium compounds.]\n278-011-7\n74869-21-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-244-00-5\nSlack wax (petroleum); Slack wax;\n[A complex combination of hydrocarbons obtained from a petroleum fraction by solvent crystallization (solvent dewaxing) or as a distillation fraction from a very waxy crude. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C20.]\n265-165-5\n64742-61-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-245-00-0\nSlack wax (petroleum), acid-treated;\nSlack wax;\n[A complex combination of hydrocarbons obtained as a raffinate by treatment of a petroleum slack wax fraction with sulfuric acid treating process. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C20.]\n292-659-8\n90669-77-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-246-00-6\nSlack wax (petroleum), clay-treated;\nSlack wax;\n[A complex combination of hydrocarbons obtained by treatment of a petroleum slack wax fraction with natural or modified clay in either a contacting or percolation process. It consists predomi nantly of saturated straight and branched hydrocarbons having carbon numbers predominantly greater than C20.]\n292-660-3\n90669-78-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-247-00-1\nSlack wax (petroleum), hydrotreated;\nSlack wax;\n[A complex combination of hydrocarbons obtained by treating slack wax with hydrogen in the presence of a catalyst. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C20.]\n295-523-6\n92062-09-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-248-00-7\nSlack wax (petroleum), low-melting;\nSlack wax;\n[A complex combination of hydrocarbons obtained from a petroleum fraction by solvent deparaffination. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n295-524-1\n92062-10-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-249-00-2\nSlack wax (petroleum), low-melting, hydrotreated;\nSlack wax;\n[A complex combination of hydrocarbons obtained by treatment of low-melting petroleum slack wax with hydrogen in the presence of a catalyst. It consists predomi nantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n295-525-7\n92062-11-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-250-00-8\nSlack wax (petroleum), low-melting, carbon-treated;\nSlack wax;\n[A complex combination of hydrocarbons obtained by the treatment of low-melting slack wax with activated carbon for the removal of trace polar constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-155-9\n97863-04-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-251-00-3\nSlack wax (petroleum), low-melting, clay-treated;\nSlack wax;\n[A complex combination of hydrocarbons obtained by the treatment of low-melting petroleum slack wax with bentonite for removal of trace polar constituents and impur ities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-156-4\n97863-05-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-252-00-9\nSlack wax (petroleum), low-melting, silicic acid-treated; Slack wax; [A complex combination of hydrocarbons obtained by the treatment of low-melting petroleum slack wax with silicic acid for the removal of trace polar constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-158-5\n97863-06-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-253-00-4\nSlack wax (petroleum), carbon-treated;\nSlack wax;\n[A complex combination of hydrocarbons obtained by treatment of petroleum slack wax with activated charcoal for the removal of trace polar constituents and impurities.]\n309-723-9\n100684-49-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-254-00-X\nPetrolatum; Petrolatum;\n[A complex combination of hydrocarbons obtained as a semi-solid from dewaxing paraffinic residual oil. It consists predominantly of saturated crystalline and liquid hydrocarbons having carbon numbers predominantly greater than C25.]\n232-373-2\n8009-03-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-255-00-5\nPetrolatum (petroleum), oxidized;\nPetrolatum;\n[A complex combination of organic compounds, predominantly high molecular weight carboxylic acids, obtained by the air oxidation of petrolatum.]\n265-206-7\n64743-01-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-256-00-0\nPetrolatum (petroleum), alumina-treated;\nPetrolatum;\n[A complex combination of hydrocarbons obtained when petrolatum is treated with Al2O3 to remove polar components and impurities. It consists predominantly of saturated, crystalline, and liquid hydrocarbons having carbon numbers predominantly greater than C25.]\n285-098-5\n85029-74-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-257-00-6\nPetrolatum (petroleum), hydrotreated;\nPetrolatum;\n[A complex combination of hydrocarbons obtained as a semi-solid from dewaxed paraffinic residual oil treated with hydrogen in the presence of a catalyst. It consists predominantly of saturated microcrystalline and liquid hydrocarbons having carbon numbers predominantly greater than C20.]\n295-459-9\n92045-77-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-258-00-1\nPetrolatum (petroleum), carbon-treated;\nPetrolatum;\n[A complex combination of hydrocarbons obtained by the treatment of petroleum petrolatum with activated carbon for the removal of trace polar constituents and impur ities. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly greater than C20.]\n308-149-6\n97862-97-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-259-00-7\nPetrolatum (petroleum), silicic acid-treated;\nPetrolatum;\n[A complex combination of hydrocarbons obtained by the treatment of petroleum petrolatum with silicic acid for the removal of trace polar constituents and impurities. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly greater than C20.]\n308-150-1\n97862-98-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-260-00-2\nPetrolatum (petroleum), clay-treated;\nPetrolatum; [A complex combination of hydrocarbons obtained by treatment of petrolatum with bleaching earth for the removal of traces of polar constituents and impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of greater than C25.]\n309-706-6\n100684-33-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nN\n649-261-00-8\nGasoline, natural;\nLow boiling point naphtha;\n[A complex combination of hydrocarbons separated from natural gas by processes such as refrigeration or absorption. It consists predominantly of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C4 through C8 and boiling in the range of approximately minus 20 oC to 120 oC (– 4oF to 248oF).]\n232-349-1\n8006-61-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-262-00-3\nNaphtha;\nLow boiling point naphtha; [Refined, partly refined, or unrefined petroleum products produced by the distillation of natural gas. It consists of hydrocarbons having carbon numbers predominantly in the range of C5 through C6 and boiling in the range of approximately 100o C to 200o C (212oF to 392oF).]\n232-443-2\n8030-30-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-263-00-9\nLigroine;\nLow boiling point naphtha;\n[A complex combination of hydrocarbons obtained by the fractional distillation of petroleum. This fraction boils in a range of approximately 20 oC to 135 oC (58oF to 275oF).]\n232-453-7\n8032-32-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-264-00-4\nNaphtha (petroleum), heavy straight-run; Low boiling point naphtha; [A complex combination of hydrocarbons produced by distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C6 through C12 and boiling in the range of approximately 65 oC to 230 oC (149oF to 446oF).]\n265-041-0\n64741-41-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-265-00-X\nNaphtha (petroleum), full-range straight-run;\nLow boiling point naphtha;\n[A complex combination of hydrocarbons produced by distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately - 20 oC to 220 oC (– 4 oF to 428oF).]\n265-042-6\n64741-42-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-266-00-5\nNaphtha (petroleum), light straight-run;\nLow boiling point naphtha;\n[A complex combination of hydrocarbons produced by distillation of crude oil. It consists predominantly of aliphatic hydrocarbons having carbon numbers predominantly in the range of C4 through C10 and boiling in the range of approximately - 20 oC to 180 oC (– 4oF to 356oF).]\n265-046-8\n64741-46-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-267-00-0\nSolvent naphtha (petroleum), light aliph.;\nLow boiling point naphtha;\n[A complex combination of hydrocarbons obtained from the distillation of crude oil or natural gasoline. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C5 through C10 and boiling in the range of approximately 35o C to 160o C (95oF to 320oF).]\n265-192-2\n64742-89-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-268-00-6\nDistillates (petroleum), straight-run light;\nLow boiling point naphtha;\n[A complex combination of hydrocarbons produced by the distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C2 through C7 and boiling in the range of approximately– 88 oC to 99o C (– 127oF to 210oF).]\n270-077-5\n68410-05-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-269-00-1\nGasoline, vapor-recovery; Low boiling point naphtha;\n[A complex combination of hydrocarbons separated from the gases from vapor recovery systems by cooling. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately - 20 oC to 196 oC (– 4oF to 384oF).]\n271-025-4\n68514-15-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-270-00-7\nGasoline, straight-run, topping-plant; Low boiling point naphtha;\n[A complex combination of hydrocarbons produced from the topping plant by the distillation of crude oil. It boils in the range of approximately 36,1 oC to 193,3 oC (97oF to 380oF).]\n271-727-0\n68606-11-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-271-00-2\nNaphtha (petroleum), unsweetened; Low boiling point naphtha; [A complex combination of hydrocarbons produced from the distillation of naphtha streams from various refinery processes. It consists of hydrocarbons having carbon numbers predominantly in the range of C5 through C12 and boiling in the range of approximately 0 oC to 230 oC (25oF to 446oF).]\n272-186-3\n68783-12-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-272-00-8\nDistillates (petroleum), light straight-run gasoline frac tionation stabilizer overheads; Low boiling point naphtha;\n[A complex combination of hydrocarbons obtained by the fractionation of light straight-run gasoline. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in he range of C3 through C6.]\n272-931-2\n68921-08-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-273-00-3\nNaphtha (petroleum), heavy straight run, arom.-contg.;\nLow boiling point naphtha;\n[A complex combination of hydrocarbons obtained from a distillation process of crude petroleum. It consists predominantly of hydrocarbons having carbon numbers in the range of C8 through C12 and boiling in the range of approximately 130 oC to 210 oC (266oF to 410oF).]\n309-945-6\n101631-20-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-274-00-9\nNaphtha (petroleum), full-range alkylate;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons produced by distillation of the reaction products of isobutane with monoolefinic hydrocarbons usually ranging in carbon numbers from C3 through C5 It consists of predominantly branched chain saturated hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 90 oC to 220 oC (194oF to 428oF).]\n265-066-7\n64741-64-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-275-00-4\nNaphtha (petroleum), heavy alkylate;\nLow boiling point modified naphtha; [A complex combination of hydrocarbons produced by distillation of the reaction products of isobutane with monoolefinic hydrocarbons usually ranging in carbon numbers from C3 to C5. It consists of predominantly branched chain saturated hydrocarbons having carbon numbers predominantly in the range of C9 through C12 and boiling in the range of approximately 150 oC to 220 oC (302oF to 428oF).]\n265-067-2\n64741-65-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-276-00-X\nNaphtha (petroleum), light alkylate;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons produced by distillation of the reaction products of isobutane with monoolefinic hydrocarbons usually ranging in carbon numbers from C3 through C5. It consists of predominantly branched chain saturated hydrocarbons having carbon numbers predominantly in the range of C7 through C10 and boiling in the range of approximately 90 oC to 160 oC (194oF to 320 oF).]\n265-068-8\n64741-66-8\nCarc. 1B Muta. 1B Asp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-277-00-5\nNaphtha (petroleum), isomerization;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained from catalytic isomerization of straight chain paraffinic C4 through C6 hydrocarbons. It consists predominantly of saturated hydrocarbons such as isobutane, isopentane, 2,2-dimethylbutane, 2-methylpentane, and 3-methylpentane.]\n265-073-5\n64741-70-4\nCarc. 1B Muta. 1B Asp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-278-00-0\nNaphtha (petroleum), solvent-refined light;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists predominantly of aliphatic hydrocarbons having carbon numbers predominantly in the range of C5 through C11 and boiling in the range of approxi mately 35 oC to 190 oC (95oF to 374oF).]\n265-086-6\n64741-84-0\nCarc. 1B Muta. 1B Asp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-279-00-6\nNaphtha (petroleum), solvent-refined heavy;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists predominantly of aliphatic hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 90 oC to 230 oC (194oF to 446oF).]\n265-095-5\n64741-92-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-280-00-1\nRaffinates (petroleum), catalytic reformer ethylene glycol-water countercurrent exts.;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained as the raffinate from the UDEX extraction process on the catalytic reformer stream. It consists of saturated hydrocarbons having carbon numbers predominantly in the range of C6 through C9.]\n270-088-5\n68410-71-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-281-00-7\nRaffinates (petroleum), reformer, Lurgi unit-sepd.;\nLow boiling point modified naphtha;\n[The complex combination of hydrocarbons obtained as a raffinate from a Lurgi separation unit. It consists predominantly of non-aromatic hydrocarbons with various small amounts of aromatic hydrocarbons having carbon numbers predominantly in the range of C6 through C8.]\n270-349-3\n68425-35-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-28-00-2\nNaphtha (petroleum), full-range alkylate, butane-contg.;\nLow boiling point modified naphta;\n[A complex combination of hydrocarbons produced by the distillation of the reaction products of isobutane with monoolefinic hydrocarbons usually ranging in carbon numbers from C3 through C5. It consists of predominantly branched chain saturated hydrocarbons having carbon numbers predominantly in the range of C7 through C12 with some butanes and boiling in the range of approximately 35 oC to 200 oC (95 oF to 428 oF).]\n271-267-0\n68527-27-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-283-00-8\nDistillates (petroleum), naphtha steam cracking-derived, solvent-refined light hydrotreated;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained as the raffinates from a solvent extraction process of hydrotreated light distillate from steam-cracked naphtha.]\n295-315-5\n91995-53-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-284-00-3\nNaphtha (petroleum),C4-12, butane-alkylate, isooctane-rich; Low boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained by alkylation of butanes. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C4 through C12, rich in isooctane, and boiling in the range of approximately 35 oC to 210 oC (95oF to 410oF).]\n295-430-0\n92045-49-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-285-00-9\nHydrocarbons, hydrotreated light naphtha distillates, solvent-refined;\nLow boiling point modified naphtha; [A combination of hydrocarbons obtained from the distillation of hydrotreated naphtha followed by a solvent extraction and distillation process. It consists predominantly of saturated hydrocarbons boiling in the range of approximately 94 o C to 99 o C (201 oF to 210 oF).]\n295-436-3\n92045-55-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-286-00-4\nNaphtha (petroleum), isomerisation, C6-fraction;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained by distillation of a gasoline which has been catalyticall isomerized. It consists predominantly of hexane isomers boiling in the range of approximately 60 oC to 66 oC (140oF to 151oF).]\n295-440-5\n92045-58-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-287-00-X\nHydrocarbons, C6-7, naphtha-cracking, solvent-refined;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained by the sorption of benzene from a catalytically fully hydrogenated benzene-rich hydrocarbon cut that was distillatively obtained from prehydrogenated cracked naphtha. It consists predomi nantly of paraffinic and naphthenic hydrocarbons having carbon numbers predominantly in the range of C6 through C7 and boiling in the range of approximately 70 oC to 100 oC (158oF to 212oF).]\n295-446-8\n92045-64-2\nCarc. 1B\nmuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-288-00-5\nHydrocarbons, C6-rich, hydrotreated light naphtha distillates, solvent-refined;\nLow boiling point modified naphtha;\n[A complex combination of hydrocarbons obtained by distillation of hydrotreated naphtha followed by solvent extraction. It consists predominantly of saturated hydrocarbons and boiling in the range of approximately 65o C to 70o C (149oF to 158oF).]\n309-871-4\n101316-67-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-289-00-0\nNaphtha (petroleum), heavy catalytic cracked;\nLow boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons produced by a distillation of products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C6 through C12 and boiling in the range of approximately 65 oC to 230 oC (148oF to 446 oF). It contains a relatively large proportion of unsaturated hydrocarbons.]\n265-055-7\n64741-54-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-290-00-6\nNaphtha (petroleum), light catalytic cracked;\nLow boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately - 20 oC to 190 oC (– 4 oF to 374 oF). It contains a relatively large proportion of unsaturated hydrocarbons.]\n265-056-2\n64741-55-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-291-00-1\nHydrocarbons, C3-11, catalytic cracker distillates;\nLow boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons produced by the distillations of products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C11 and boiling in a range approximately up to 204 oC (400oF).]\n270-686-6\n68476-46-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-292-00-7\nNaphtha (petroleum), catalytic cracked light distd.;\nLow boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C1 through C5.]\n272-185-8\n68783-09-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-293-00-2\nDistillates (petroleum), naphtha steam cracking-derived, hydro-treated light arom.;\nLow boiling point cat-cracked naphtha.;\n[A complex combination of hydrocarbons obtained by treating a light distillate from steam-cracked naphtha. It consists predominantly of aromatic hydrocarbons.]\n295-311-3\n91995-50-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-294-00-8\nNaphtha (petroleum), heavy catalytic cracked, sweetened; Low boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons obtained by subjecting a catalytic cracked petroleum distillate to a sweetening process to convert mercaptans or to remove acidic impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C6 through C12 and boiling in the range of approximately 60 oC to200 oC (140oF to 392oF).]\n295-431-6\n92045-50-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-295-00-3\nNaphtha (petroleum), light catalytic cracked sweetened; Low boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons obtained by subjecting naphtha from a catalytic cracking process to a sweetening process to convert mercaptans or to remove acidic impurities. It consists predomi nantly of hydrocarbons boiling in a range of approximately 35 oC to 210 oC (95oF to 410oF).]\n295-441-0\n92045-59-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-296-00-9\nHydrocarbons, C8-12, catalytic-cracking, chem. neutralized;\nLow boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons produced by the distillation of a cut from the catalytic cracking process, having undergone an alkaline washing. It consists predomi nantly of hydrocarbons having carbon numbers in the range of C8 through C12 and boiling in the range of approximately 130 oC to 210 oC (266oF to 410oF).]\n295-794-0\n92128-94-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-297-00-4\nHydrocarbons, C8-12, catalytic cracker distillates;\nLow boiling point cat-cracked naphtha;\n[A complex combination of hydrocarbons obtained by distillation of products from a catalytic cracking process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C8 through C12 and boiling in the range of approxi mately 140 oC to 210 oC (284oF to 410oF).]\n309-974-4\n101794-97-2\nCarc. 1B\nMuta. 1B A\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-298-00-X\nHydrocarbons, C8-12, catalytic cracking, chem. neutralized, sweetened; Low boiling point cat-cracked naphtha\n309-987-5\n101896-28-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-299-00-5\nNaphtha (petroleum), light catalytic reformed;\nLow boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons produced from the distillation of products from a catalytic reforming process. It consists of hydrocarbons having carbon numbers predominantly in the range of C5 through C11 and boiling in the range of approximately 35 oC to 190o C (95oF to 374oF). It contains a relatively large proportion of aromatic and branched chain hydrocarbons. This stream may contain 10 vol.% or more benzene.]\n265-065-1\n64741-63-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-300-00-9\nNaphtha (petroleum), heavy catalytic reformed;\nLow boiling point cat-reformed naphtha; [A complex combination of hydrocarbons produced from the distillation of products from a catalytic reforming process. It consists of predominantly aromatic hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 90 oC to 230 oC (194oF to 446oF).]\n265-070-9\n64741-68-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-301-00-4\nDistillates (petroleum), catalytic reformed depentanizer;\nLow boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons from the distillation of products from a catalytic reforming process. It consists predominantly of aliphatic hydrocarbons having carbon numbers predominantly in the range of C3 through C6 and boiling in the range of approximately - 49 oC to 63 oC (–57oF to 145oF).]\n270-660-4\n68475-79-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-302-00-X\nHydrocarbons, C2-6, C6-8 catalytic reformer;\nLow boiling point cat-reformed naphtha\n270-687-1\n68476-47-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-303-00-5\nResidues (petroleum), C6-8 catalytic reformer;\nLow boiling point cat-reformed naphtha;\n[A complex residuum from the catalytic reforming of C6-8 feed. It consists of hydrocarbons having carbon numbers predominantly in the range of C2 through C6.]\n270-794-3\n68478-15-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-304-00-0\nNaphtha (petroleum), light catalytic reformed, arom.-free; Low boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons obtained from distillation of products from a catalytic reforming process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 through C8 and boiling in the range of approxi mately 35o C to 120o C (95 oF to 248 oF). It contains a relatively large proportion of branched chain hydrocarbons with the aromatic components removed.]\n270-993-5\n68513-03-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-305-00-6\nDistillates (petroleum), catalytic reformed straight-run naphtha overheads;\nLow boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons obtained by the catalytic reforming of straight-run naphtha followed by the fractionation of the total effluent. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C2 through C6.]\n271-008-1\n68513-63-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-306-00-1\nPetroleum products, hydrofiner-powerformer reformates;\nLow boiling point cat-reformed naphtha;\n[The complex combination of hydrocarbons obtained in a hydrofiner-powerformer process and boiling in a range of approximately 27 oC to 210 oC (80oF to 410oF).]\n271-058-4\n68514-79-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-307-00-7\nNaphtha (petroleum), full-range reformed;\nLow boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons produced by the distillation of the products from a catalytic reforming process. It consists of hydrocarbons having carbon numbers predominantly in the range of C5 through C12 and boiling in the range of approximately 35o C to 230 oC (95oF to 446oF).]\n272-895-8\n68919-37-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-308-00-2\nNaphtha (petroleum), catalytic reformed;\nLow boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic reforming process. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C12 and boiling in the range of approximately 30 oC to 220 oC (90oF to 430oF). It contains a relatively large proportion of aromatic and branched chain hydrocarbons. This stream may contain 10 vol. % or more benzene.]\n273-271-8\n68955-35-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-309-00-8\nDistillates (petroleum), catalytic reformed hydrotreated light, C8-12 arom. fraction;-Low boiling point cat-reformed naphtha;\n[A complex combination of alkylbenzenes obtained by the catalytic reforming of petroleum naphtha. It consists predominantly of alkylbenzenes having carbon numbers predominantly in the range of C8 through C10 and boiling in the range of approximately 160 oC to 180 oC (320oF to 356oF).]\n285-509-8\n85116-58-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-310-00-3\nAromatic hydrocarbons, C8, catalytic reforming-derived;\nLow boiling point cat-reformed naphtha\n295-279-0\n91995-18-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-311-00-9\nAromatic hydrocarbons, C7-12, C8-rich;\nLow boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons obtained by separation from the platformate-containing fraction. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C7 through C12 (primarily C8) and can contain nonaromatic hydrocarbons, both boiling in the range of approximately 130 oC to 200 oC (266oF to 392oF).]\n297-401-8\n93571-75-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-312-00-4\nGasoline, C5-11, high-octane stabilised reformed;\nLow boiling point cat-reformed naphtha; -\n[A complex high octane combination of hydrocarbons obtained by the catalytic dehydrogenation of a predominantly naphthenic naphtha. It consists predominantly of aromatics and non-aromatics having carbon numbers predominantly in the range of C5 through C11 and boiling in the range of approxi mately 45 oC to 185 oC (113oF to 365 oF).]\n297-458-9\n93572-29-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-313-00-X\nHydrocarbons, C7-12, C≥9-arom.-rich, reforming heavy fraction; Low boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons obtained by separation from the platformate-containing fraction. It consists predominantly of nonaromatic hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 120 oC to 210 oC (248oF to380oF) and C9 and higher aromatic hydrocarbons.]\n297-465-7\n93572-35-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-314-00-5\nHydrocarbons, C5-11, nonaroms.-rich, reforming light fraction;\nLow boiling point cat-reformed naphtha;\n[A complex combination of hydrocarbons obtained by separation from the platformate-containing fraction. It consists predominantly of nonaromatic hydrocarbons having carbon numbers predominantly in the range of C5 through C11 and boiling in the range of approximately 35 oC to 125 oC (94oF to 257oF), benzene and toluene.]\n297-466-2\n93572-36-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-315-00-0\nFoots oil (petroleum), silicic acid-treated;\nFoots oil;\n[A complex combination of hydrocarbons obtained by the treatment of Foots oil with silicic acid for removal of trace constituents and impurities. It consists predominantly of straight chain hydrocarbons having carbon numbers predominantly greater than C12.]\n308-127-6\n97862-77-6\nCarc. 1B\nH350\nH304\nGHS08\nDgr\nH350\nH304\nL\n649-316-00-6\nNaphtha (petroleum), light thermal cracked;\nLow boiling point thermally cracked naphtha;\n[A complexcombination of hydrocarbons from distillation of products from a thermal cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C4 through C8 and boiling in the range of approximately - 10 oC to 130 oC (14oF to 266oF).]\n265-075-6\n64741-74-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-317-00-1\nNaphtha (petroleum), heavy thermal cracked;\nLow boiling point thermally cracked naphtha;\n[A complex combination of hydrocarbons from distillation of the products from a thermal cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C6 through C12 and boiling in the range of approximately 65o C to 220 oC (148oF to 428oF).]\n265-085-0\n64741-83-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-318-00-7\nDistillates (petroleum), heavy arom.;\nLow boiling point thermally cracked naphtha;\n[The complex combination of hydrocarbons from the distillation of the products from the thermal cracking of ethane and propane. This higher boiling fraction consists predominantly of C5-7 aromatic hydrocarbons with some unsaturated aliphatic hydrocarbons having carbon number predominantly of C5. This stream may contain benzene.]\n267-563-4\n67891-79-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-319-00-2\nDistillates (petroleum), light arom.;\nLow boiling point thermally cracked naphtha; [The complex combination of hydrocarbons from the distillation of the products from the thermal cracking of ethane and propane. This lower boiling fraction consists predominantly of C5-7 aromatic hydrocarbons with some unsaturated aliphatic hydrocarbons having a carbon number predominantly of C5. This stream may contain benzene.]\n267-565-5\n67891-80-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nHS08\nDgr\nH350\nH340\nH304\nP\n649-320-00-8\nDistillates (petroleum), naphtha-raffinate pyrolyzate-derived, gasoline-blending;\nLow boiling point thermally cracked naphtha; [The complex combination of hydrocarbons obtained by the pyrolysis fractionation at 816o C (1 500oF) of naphtha and raffinate. It consists predominantly of hydrocarbons having a carbon number of C9 and boiling at approximately 204 oC (400oF).]\n270-344-6\n68425-29-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-321-00-3\nAromatic hydrocarbons, C6-8, naphtha-raffinate pyrolyzate-derived; Low boiling point thermally cracked naphtha; [A complex combination of hydrocarbons obtained by the fractionation pyrolysis at 816 o C (1 500oF) of naphtha and raffinate. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C6 through C8, including benzene.]\n270-658-3\n68475-70-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-322-00-9\nDistillates (petroleum), thermal cracked naphtha and gas oil; Low boiling point thermally cracked naphtha;\n[A complex combination of hydrocarbons produced by distillation of thermally cracked naphtha and/or gas oil. It consists predominantly of olefinic hydrocarbons having a carbon number of C5 and boiling in the range of approxi mately 33 o C to 60 o C (91 oF to 140 oF).]\n271-631-9\n68603-00-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-323-00-4\nDistillates (petroleum), thermal cracked naphtha and gas oil, C5-dimer-contg.;\nLow boiling point thermally cracked naphtha; [A complex combination of hydrocarbons produced by the extractive distillation of thermal cracked naphtha and/or gas oil. It consists predominantly of hydrocarbons having a carbon number of C5 with some dimerized C5 olefins and boiling in the range of approximately 33o C to 184 o C (91oF to 363 oF).]\n271-632-4\n68603-01-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-324-00-X\nDistillates (petroleum), thermal cracked naphtha and gas oil, extractive;\nLow boiling point thermally cracked naphtha;\n[A complex combination of hydrocarbons produced by the extractive distillation of thermal cracked naphtha and/or gas oil. It consists of paraffinic and olefinic hydrocarbons, predomi nantly isoamylenes such as 2-methyl-1-buteneand 2-methyl-2-butene and boiling in the rangeof approximately 31o C to 40o C (88oF to 104oF).]\n271-634-5\n68603-03-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-325-00-5\nDistillates (petroleum), light thermal cracked, debutanized arom.;\nLow boiling point thermally cracked naphtha; [A complex combination of hydrocarbons produced by the distillation of products from a thermal cracking process. It consists predominantly of aromatic hydrocarbons, primarily benzene.]\n273-266-0\n68955-29-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-326-00-0\nNaphtha (petroleum), light thermal cracked, sweetened;\nLow boiling point thermally cracked naphtha;\n[A complex combination of hydrocarbons obtained by subjecting a petroleum distillate From the high temperature thermal cracking of heavy oil fractions to a sweetening process to convert mercaptans. It consists predominantly of aromatics, olefins and saturated hydrocarbons boiling in the range of approximately 20 oC to 100 o C (68 oF to 212 oF).]\n295-447-3\n92045-65-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-327-00-6\nNaphtha (petroleum), hydrotreated heavy;\nLow boiling point ydrogen treated naphtha; [A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C6 through C13 and boiling in the range of approximately 65o C to 230o C (149oF to 446oF).]\n265-150-3\n64742-48-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-328-00-1\nNaphtha (petroleum), hydrotreated light;\nLow boiling point hydrogen treated naphtha; [A complex combination of hydrocarbons obtained by treating a petroleum fraction With hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately minus 20o C to 190o C (– 4oF to 374oF).]\n265-151-9\n64742-49-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-329-00-7\nNaphtha (petroleum), hydrodesulfurized light;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained from a catalytic hydrodesulfurization process. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in The range of approximately - 20o C to 190o C (– 4oF to 374oF).]\n265-178-6\n64742-73-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-330-00-2\nnaphtha (petroleum), hydrodesulphurized heavy;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained from a catalytic hydrodesulfurization process. It consists of hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 90o C to 230o C (194oF to 446 oF).]\n265-185-4\n64742-82-1\nCarc. 1B\nMuta. 1B\nSTOT RE 1\nAsp. Tox. 1\nH350\nH340\nH372 (central nervous system)\nH304\nGHS08\nDgr\nH350\nH340\nH372 (central nervous system)\nH304\nP\n649-331-00-8\nDistillates (petroleum), hydrotreated middle, intermediate boiling;\nLow boiling point hydrogen treated naphtha; [A complex combination of hydrocarbons obtained by the distillation of products from a middle distillate hydrotreating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C5 through C10 and boiling in the range of approximately 127o C to 188o C (262oF to 370oF).]\n270-092-7\n68410-96-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-332-00-3\nDistillates (petroleum), light distillate hydrotreating process, low-boiling;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained by the distillation of products from the light distillate hydrotreating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C6 through C9 and boiling in the range of approximately 3 o C to 194 o C (37 oF to 382 oF).]\n270-093-2\n68410-97-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-333-00-9\nDistillates (petroleum), hydrotreated heavy naphtha, deisohexanizer overheads;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained by distillation of the products from a heavy naphtha hydrotreating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C6 and boiling in the range of approximately - 49 oC to 68 oC (– 57oF to 155oF).]\n270-094-8\n68410-98-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-334-00-4\nSolvent naphtha (petroleum), light arom., hydrotreated;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C8 through C10 and boiling in the range of approxi mately 135 oC to 210 oC (275oF to 410oF).]\n270-988-8\n68512-78-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-335-00-X\nNaphtha (petroleum), hydrodesulfurized thermal cracked light; Low boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained by fractionation of hydrodesulfurized thermal cracker distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 to C11 and boiling in the range of approximately 23 oC to 195 oC (73oF to 383oF).]\n285-511-9\n85116-60-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-336-00-5\nNaphtha (petroleum), hydrotreated light, cycloalkane-contg.; Low boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained from the distillation of a petroleum fraction. It consists predominantly of alkanes and cycloalkanes boiling in the range of approximately - 20o C to 190 oC (– 4oF to 374oF).]\n285-512-4\n85116-61-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-337-00-0\nNaphtha (petroleum),heavy steam-cracked, hydrogenated; Low boiling point hydrogen treated naphtha\n295-432-1\n92045-51-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-338-00-6\nNaphtha (petroleum), hydrodesulfurized full-range;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained from a catalytic hydrodesulfurization process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately 30 oC to 250 oC (86oF to 482oF).]\n295-433-7\n92045-52-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-339-00-1\nNaphtha (petroleum), hydrotreated light steam-cracked;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction, derived from a pyrolysis process, with hydrogen in the presence of a catalyst. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C5 through C11 and boiling in the range of approximately 35o C to 190 oC (95oF to 374oF).]\n295-438-4\n92045-57-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-340-00-7\nHydrocarbons, C4-12, naphtha-cracking, hydrotreated;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained by distallation from the product of a naphtha steam cracking process and subsequent catalytic selective hydrogenation of gum formers. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C12 and boiling in the range of approximately 30 oC to 230o C (86oF to 446oF).]\n295-443-1\n92045-61-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-341-00-2\nSolvent naphtha (petroleum), hydrotreated light naphthenic; Low boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists predominantly of cycloparaffinic hydrocarbons having carbon numbers predominantly in the range of C6 through C7 and boiling in the range of approxi mately 73o C to 85o C (163 oF to 185 oF).]\n295-529-9\n92062-15-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-342-00-8\nNaphtha (petroleum), light steam-cracked, hydrogenated; Low boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons produced from the separation and subsequent Hydrogenation of the products of a steam-cracking process to produce ethylene. It consists predominantly of saturated and unsaturated paraffins, cyclic paraffins and cyclic aromatic hydrocarbons having carbon numbers predominantly in the range of C4 through C10 and boiling in the range of approximately 50o C to 200o C (122 oF to 392 oF). The proportion of benzene hydrocarbons may vary up to 30 wt. % and the stream may also contain small amounts ofsulfur and oxygenated compounds.]\n296-942-7\n93165-55-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-343-00-3\nHydrocarbons, C6-11, hydrotreated, dearomatized;\nLow boiling point hydrogen treated naphtha;\n[A complex combination of hydrocarbons obtained as solvents which have been subjected to hydrotreatment in order to convert aromatics to naphthenes by catalytic hydrogenation.]\n297-852-0\n93763-33-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-344-00-9\nHydrocarbons, C9-12, hydrotreated, dearomatized;\nLow boiling point hydrogen treated naphtha; [A complex combination of hydrocarbons obtained as solvents which have been subjected to hydrotreatment in order to convert aromatics to naphthenes by catalytic hydrogenation.]\n297-853-6\n93763-34-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-345-00-4\nstoddard solvent;\nLow boiling point naphtha —\nunspecified;\n[A colourless, refined petroleum distillate that is free from rancid or objectionable odours and that boils in a range of approximately 148,8 oC to 204,4 o C (300oF to 400oF).]\n232-489-3\n8052-41-3\nCarc. 1B\nMuta. 1B\nSTOT RE 1\nAsp. Tox. 1\nH350\nH340\nH372 (central nervous system)\nH304\nGHS08\nDgr\nH350\nH340\nH372 (central nervous system)\nH304\nP\n649-346-00-X\nNatural gas condensates (petroleum);\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons separated as a liquid from natural gas in a surface separator by retrograde condensation. It consists mainly of hydrocarbons having carbon numbers predominantly in the range of C2 to C20. It is a liquid at atmospheric temperature and pressure.]\n265-047-3\n64741-47-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-347-00-5\nNatural gas (petroleum), raw liq. mix; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons separated as a liquid from natural gas in a gas recycling plant by processes such as refrigeration or absorption. It consists mainly of saturated aliphatic hydrocarbons having carbon numbers in the range of C2 through C8.]\n265-048-9\n64741-48-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-348-00-0\nNaphtha (petroleum), light hydrocracked;\nLow boiling naphtha — unspecified;\n[A complex combination of hydrocarbons from distillation of the products from a hydrocracking process. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C4 through C10, and boiling in the range of approxi mately - 20 o C to 180 o C (– 4 oF to 356 oF).]\n265-071-4\n64741-69-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-349-00-6\nNaphtha (petroleum), heavy hydrocracked;\nLow boiling point naphtha -unspecified; [A complex combination of hydrocarbons from distillation of the products from a hydrocracking process. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C6 through C12, and boiling in the range of approximately 65 oC to 230 oC (148oF to 446oF).]\n265-079-8\n64741-78-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-350-00-1\nNaphtha (petroleum) sweetened;\nLow boiling point naphtha -unspecified; [A complex combination of hydrocarbons obtained by subjecting a petroleum naphtha to a sweetening process to convert mercaptans or to remove acidic impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C12 and boiling in the range of approximately - 10o C to 230o C (14oF to 446oF).]\n265-089-2\n64741-87-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-351-00-7\nNaphtha(petroleum), acid-treated;\nLow boilingpoint naphtha -unspecified; [A complex combination of hydrocarbons obtained as a raffinate from a sulfuric acid treating process. It consists of hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 90 o C to 230 o C (194 oF to 446 oF).]\n265-115-2\n64742-15-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-352-00-2\nNaphtha (petroleum), chemically neutralized heavy;\nLow boilingpoint naphtha — unspecified;\n[A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C6 through C12 and boiling in the range of approximately 65o C to 230o C (149oF to 446oF).]\n265-122-0\n64742-22-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-353-00-8\nNaphtha (petroleum), chemically neutralized light;\nLow boilingpoint naphtha -unspecified; [A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately - 20 oC to 190o C (–4 oF to 374 oF).]\n265-123-6\n64742-23-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-354-00-3\nNaphtha (petroleum), catalytic dewaxed;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained from the catalytic dewaxing of a petroleum fraction. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 through C12 and boiling in the range of approximately 35o C to 230 oC (95oF to 446oF).]\n265-170-2\n64742-66-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-355-00-9\nNaphtha (petroleum), light steam-cracked;\nLow boiling point naphtha -unspecified; [A complex combination of hydrocarbons obtained by the distillation of the products from a steam cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately minus 20 oC to 190 oC (– 4oF to 374oF). This stream is likely to contain 10 vol.% or more benzene.]\n265-187-5\n64742-83-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-356-00-4\nSolvent naphtha (petroleum), light arom.;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained from distillation of aromatic streams. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C8 through C10 and boiling in the range of approximately 135 oC to 210 oC (275oF to 410oF).]\n265-199-0\n64742-95-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-357-00-X\nAromatic hydrocarbons, C6-10, acid-treated, neutralized;\nLow boiling point naphtha — unspecified\n268-618-5\n68131-49-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-358-00-5\nDistillates (petroleum), C3-5, 2-methyl-2-butene-rich;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons from the distil lation of hydrocarbons usually ranging in carbon numbers from C3 through C5, predominantly isopentane and 3-methyl-1-butene. It consists of saturated and unsaturated hydrocarbons having carbon numbers in the range of C3 through C5, predominantly 2-methyl-2-butene.]\n270-725-7\n68477-34-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-359-00-0\nDistillates (petroleum), polymd. steam-cracked petroleum distillates, C5-12 fraction;\nLow boiling point naphtha- unspecified;\n[A complex combination of hydrocarbons obtained from the distillation of polymerized steam-cracked petroleum distillate. It consists predomi nantly of hydrocarbons having carbon numbers predominantly in the range of C5 through C12.]\n270-735-1\n68477-50-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-360-00-6\nDistillates (petroleum), steam-cracked, C5-12 fraction;\nLow boiling point naphtha -unspecified;\n[A complex combination of organic compounds obtained by the distillation of products from a steam cracking process. It consists of unsaturated hydrocarbons having carbon numbers predominantly in the range of C5 through C12.]\n270-736-7\n68477-53-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-361-00-1\nDistillates (petroleum), steam-cracked, C5-10 fraction, mixed with light steam-cracked petroleum naphtha C5 fraction; Low boiling point naphtha -unspecified\n270-738-8\n68477-55-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-362-00-7\nExtracts (petroleum), cold-acid, C4-6; Low boiling point naphtha — unspecified; [A complex combination of organic compounds produced by cold acid unit extraction of saturated and unsaturated aliphatic hydrocarbons usually ranging in carbon numbers from C3 through C6, predominantly pentanes and amylenes. It consists predominantly of saturated and unsaturated hydrocarbons having carbon numbers in the range of C4 through C6, predominantly C5.]\n270-741-4\n68477-61-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-363-00-2\nDistillates (petroleum), depentanizer overheads;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained from a catalytic cracked gas stream. It consists of aliphatic hydro carbons having carbon numbers predominantly in the range of C4 through C6.]\n270-771-8\n68477-89-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-364-00-8\nResidues (petroleum), butane splitter bottoms;\nLow boiling point naphtha -unspecified;\n[A complex residuum from the distillation of butane stream. It consists of aliphatic hydro carbons having carbon numbers predominantly in the range of C4 through C6.]\n270-791-7\n68478-12-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-365-00-3\nResidual oils (petroleum), deisobutanizer tower;\nLow boiling point naphtha -unspecified;\n[A complex residuum from the atmospheric distillation of the butane-butylene stream. It consists of aliphatic hydrocarbons having carbon numbers predominantly in the range of C4 through C6.]\n270-795-9\n68478-16-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-366-00-9\nNaphtha (petroleum), full-range coker;\nLow boiling point naphtha — unspecified;\n[A complex combination of hydrocarbons produced by the distillation of products from a fluid coker. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C4 through C15 and boiling in the range of approximately 43o C to 250o C (110oF-500oF).]\n270-991-4\n68513-02-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-367-00-4\nNaphtha (petroleum), steam-cracked middle arom.;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons produced by the distillation of products from a steam-cracking process. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 130o C to 220o C (266oF to 428oF).]\n271-138-9\n68516-20-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-368-00-X\nNaphtha (petroleum), clay-treated full-range straight-run; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons resulting from treatment of full-range straight- run naphtha with natural or modified clay, usually in a percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately - 20o C to 220o C (– 4oF to 429oF).]\n271-262-3\n68527-21-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-369-00-5\nNaphtha (petroleum), clay-treated light straight-run;\nLow boiling point naphtha — unspecified;\n[A complex combination of hydrocarbons resulting from treatment of light straight-run naphtha with a natural or modified clay, usually in a percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydrocarbons having carbon numbers predominantly in the range of C7 through C10 and boiling in the range of approximately 93 oC to 180 oC (200oF to 356oF).]\n271-263-9\n68527-22-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-370-00-0\nNaphtha (petroleum), light steam-cracked arom.;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons produced by distillation of products from a steam-cracking process. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C7 through C9 and boiling in the range of approximately 110o C to 165 o C (230 oF to 329 oF).]\n271-264-4\n68527-23-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-371-00-6\nNaphtha (petroleum),light steam-cracked, debenzenized; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons produced by distillation of products from a steam-cracking process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C4 through C12 and boiling in the range of approximately 80o C to 218o C (176oF to 424oF).]\n271-266-5\n68527-26-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-372-00-1\nNaphtha (petroleum), arom.-contg.;\nLow boilingpoint naphtha — unspecified\n271-635-0\n68603-08-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-373-00-7\nGasoline, pyrolysis, debutanizer bottoms;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained from the fractionation of depropanizer bottoms. It consists of hydrocarbons having carbon numbers predominantly greater than C5.]\n271-726-5\n68606-10-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-374-00-2\nNaphtha (petroleum), light, sweetened;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by subjecting a petroleum distillate to a sweetening process to convert mercaptans or to remove acidic impurities. It consists predominantly of saturated and unsaturated hydro carbons having carbon numbers predominantly in the range of C3 through C6 and boiling in the range of approximately - 20o C to 100o C (– 4oF to 212 oF).]\n272-206-0\n68783-66-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-375-00-8\nNatural gas condensates;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons separated and/or condensed from natural gas during transportation and collected at the wellhead and/or from the production, gathering, transmission, and distribution pipelines in deeps, scrubbers, etc. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C2 through C8.]\n272-896-3\n68919-39-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-376-00-3\nDistillates (petroleum), naphtha unifiner stripper;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons produced by stripping the products from the naphtha unifiner. It consists of saturated aliphatic hydrocarbons having carbon numbers predominantly in the range of C2 through C6.]\n272-932-8\n68921-09-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-377-00-9\nNaphtha (petroleum), catalytic reformed light, arom.-free fraction;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons remaining after removal of aromatic compounds from catalytic reformed light naphtha in a selective absorption process. It consists predominantly of paraffinic and cyclic compounds having carbon numbers predominantly in the range of C5 to C8 and boiling in the range of approximately 66o C to 121o C (151oF to250oF).]\n285-510-3\n85116-59-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-378-00-4\nGasoline;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons consisting primarily of paraffins, cycloparaffins, aromatic and olefinic hydrocarbons having carbon numbers predominantly greater than C3 and boiling in the range of 30 oC to 260o C (86oF to 500oF).]\n289-220-8\n86290-81-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-379-00-X\nAromatic hydrocarbons, C7-8, dealkylation products, distn. residues;\nLow boiling point naphtha — unspecified\n292-698-0\n90989-42-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-380-00-5\nHydrocarbons, C4-6, depentanizer lights, arom. hydrotreater; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained as first runnings from the depentanizer column before hydrotreatment of the aromatic charges. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C4 through C6, predominantly pentanes and pentenes and boiling in the range of approximately 25 oC to 40 o C (77oF to 104oF).]\n295-298-4\n91995-38-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-381-00-0\nDistillates (petroleum), heat-soaked steam-cracked naphtha, C5-rich;\nLow boiling point naphtha — unspecified;\n[A complex combination of hydrocarbons obtained by distillation of heat-soaked steam- cracked naphtha. It consists predominantly of hydrocarbons having carbon numbers in the range of C4 through C6, predominantly C5.]\n295-302-4\n91995-41-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-382-00-6\nExtracts (petroleum), catalytic reformed light naphtha solvent; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained as the extract from the solvent extraction of a catalytically reformed petroleum cut. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C7 through C8 and boiling in the range of approximately 100 oC to 200 oC (212oF to 392oF).]\n295-331-2\n91995-68-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-383-00-1\nNaphtha (petroleum), hydrodesulfurized light, dearomatized; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by distillation of hydrodesulfurized and dearomatized light petroleum fractions. It consists predominantly of C7 paraffins and cycloparaffins boiling in a range of approximately 90o C to 100o C (194oF to 212oF).]\n295-434-2\n92045-53-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-384-00-7\nNaphtha (petroleum), light, C5-rich, sweetened;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by subjecting a petroleum naphtha to a sweetening process to convert mercaptans or to remove acidic impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C5, predominantly C5, and boiling in the range of approximately minus 10 oC to 35o C (14oF to 95oF).]\n295-442-6\n92045-60-8\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-385-00-2\nHydrocarbons, C8-11, naphtha-cracking, toluene cut;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by distillation from prehydrogenated cracked naphtha. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C8 through C11 and boiling in the range of approximately 130o C to 205o C (266oF to 401oF).]\n295-444-7\n92045-62-0\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-386-00-8\nHydrocarbons, C4-11, naphtha-cracking, arom.-free;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained from prehydrogenated cracked naphtha after distillative separation of benzene-and toluene-containing hydrocarbon cuts and a higher boiling fraction. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C4 through C11 and boiling in the range of approximately 30 o C to 205 o C (86 oF to 401 oF).]\n295-445-2\n92045-63-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-387-00-3\nNaphtha (petroleum), light heat-soaked, steam-cracked;\nLow boiling point naphtha — unspecified;\n[A complex combination of hydrocarbons obtained by the fractionation of steam cracked naphtha after recovery from a heat soaking process. It consists predominantly of hydrocarbons having a carbon number predominantly in the range of C4 through C6 and boiling in the range of approxi mately 0o C to 80o C (32oF to 176oF).]\n296-028-8\n92201-97-3\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-388-00-9\nDistillates (petroleum), C6-rich; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained from the distillation of a petroleum feedstock. It consists predominantly of hydrocarbons having carbon numbers of C5 through C7, rich in C6, and boiling in the range of approximately 60o C to70o C (140 oF to 158 oF).]\n296-903-4\n93165-19-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-389-00-4\nGasoline, pyrolysis, hydrogenated;\nLow boiling point naphtha-unspecified;\n[A distillation fraction from the hydrogenation of pyrolysis gasoline boiling in the range of approximately 20o C to 200o C (68oF to 392oF).]\n302-639-3\n94114-03-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-390-00-X\nDistillates (petroleum), steam-cracked, C8-12 fraction, polymd., distn. lights;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by distillation of the polymerized C8 through C12 fraction from steam-cracked petroleum distillates. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C8 through C12.]\n305-750-5\n95009-23-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-391-00-5\nExtracts (petroleum) heavy naphtha solvent, clay-treated; Low boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by the treatment of heavy naphthic solvent petroleum extract with bleaching earth. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C6 through C10 and boiling in the range of approximately 80 o C to 180 o C (175 oF to 356 oF).]\n308-261-5\n97926-43-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-392-00-0\nNaphtha (petroleum), light steam-cracked, debenzenized, thermally treated;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by the treatment and distillation of debenzenized light steam-cracked petroleum naphtha. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 95 oC to 200o C (203oF to 392oF).]\n308-713-1\n98219-46-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-393-00-6\nNaphtha (petroleum), light steam-cracked, thermally treated;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by the treatment and distillation of light steam-cracked petroleum naphtha. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 through C6 and boiling in the range of approximately 35 o C to 80 o C (95 oF to 176 oF).]\n308-714-7\n98219-47-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-394-00-1\nDistillates (petroleum), C7-9, C8-rich, hydrodesulfurized dearomatized;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by the distillation of petroleum light fraction, hydrodesulfurized and dearomatized. It consists predominantly of hydrocarbons having carbon numbers in the range of C7 through C9, predominantly C8 paraffins and cycloparaffins, boiling in the range of approximately 120 o C to 130 o C (248 oF to 266 oF).]\n309-862-5\n101316-56-7\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-395-00-7\nHydrocarbons, C6-8, hydrogenated sorption-dearomatized, toluene raffination;\nLow boiling point naphtha — unspecified;\n[A complex combination of hydrocarbons obtained during the sorptions of toluene from a hydrocarbon fraction from cracked gasoline treated with hydrogen in the presence of a catalyst. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C6 through C8 and boiling in the range of approximately 80o C to 135o C (176oF to 275oF).]\n309-870-9\n101316-66-9\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-396-00-2\nNaphtha (petroleum), hydrodesulfurised full-range coker;\nLow boiling point naphtha -unspecified;\n[A complex ombination of hydrocarbons obtained by fractionation from hydrodesulfurised coker distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 to C11 and boiling in the range of approximately 23 oC to 196 o C (73 oF to 385 oF).]\n309-879-8\n101316-76-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-397-00-8\nNaphtha (petroleum), sweetened light;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by subjecting a petroleum naphtha to a sweetening process to convert mercaptans or to remove acidic impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 through C8 and boiling in the range of approximately 20 o C to 130 o C (68 oF to 266 oF).]\n309-976-5\n101795-01-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-398-00-3\nHydrocarbons, C3-6, C5-rich, steam-cracked naphtha;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by distillation of steam-cracked naphtha. It consists predominantly of hydrocarbons having carbon numbers in the range of C3 through C6, predominantly C5.]\n310-012-0\n102110-14-5\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-399-00-9\nHydrocarbons, C5-rich, dicyclopentadiene-contg.;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by distillation of the products from a steam-cracking process. It consists predominantly of hydrocarbons having carbon numbers of C5 and dicyclopentadiene and boiling in the range of approximately 30o C to 170o C (86oF to 338oF).]\n310-013-6\n102110-15-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-400-00-2\nResidues (petroleum), steam-cracked light, arom.;\nLow boiling point naphtha -unspecified;\n[A complex combination of hydrocarbons obtained by the distillation of the products of steamcracking or similar processes after taking off the very light products resulting in a residue starting with hydrocarbons having carbon numbers greater than C5. It consists predominantly of aromatic hydrocarbons having carbon numbers greater than C5 and boiling above approximately 40o C (104oF).]\n310-057-6\n102110-55-4\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-401-00-8\nHydrocarbons, C≥5, C5-6-rich; Low boiling point naphtha -unspecified\n270-690-8\n68476-50-6\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-402-00-3\nHydrocarbons, C5-rich;\nLow boiling point naphtha — unspecified\n270-695-5\n68476-55-1\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-403-00-9\nAromatic hydrocarbons, C8-10; Low boiling point naphtha -unspecified\n292-695-4\n90989-39-2\nCarc. 1B\nMuta. 1B\nAsp. Tox. 1\nH350\nH340\nH304\nGHS08\nDgr\nH350\nH340\nH304\nP\n649-404-00-4\nKerosine (petroleum); Straight run kerosine;\n[A complex combination of hydrocarbons produced by the distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of approximately 150oC to 290oC (320oF to 554oF).]\n232-366-4\n8008-20-6\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-405-00-X\nsolvent naphtha (petroleum), medium aliph.;\nStraight run kerosine;\n[A complex combination of hydrocarbons obtained from the distillation of crude oil or natural gasoline. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C9 through C12 and boiling in the range of approximately 140o C to 220o C (284oF to 428oF).]\n265-191-7\n64742-88-7\nSTOT RE 1\nAsp. Tox. 1\nH372 (central nervous system)\nH304\nGHS08\nDgr\nH372 (central nervous system)\nH304\n649-406-00-5\nSolvent naphtha (petroleum) heavy aliph.;\nStraight run kerosine;\n[A complex combination of hydrocarbons obtained from the distillation of crude oil or natural gasoline. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C11 through C16 and boiling in the range of approximately 190 oC to 290 oC (374 oF to 554 oF).]\n265-200-4\n64742-96-7\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-407-00-0\nKerosine (petroleum), straight-run wide-cut;\nStraight run kerosine;\n[A complex combination of hydrocarbons obtained as a wide cut hydrocarbon fuel cut from atmospheric distillation and boiling in the range of approximately 70 oC to 220 oC (158 oF to 428 oF).]\n295-418-5\n92045-37-9\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-408-00-6\nDistillates (petroleum), steam-cracked;\nCracked kerosine;\n[A complex combination of hydrocarbons obtained by the distillation of the products from a steam cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C7 through C16 and boiling in the range of approximately 90 oC to 290 oC (190 oF to 554 oF).]\n265-194-3\n64742-91-2\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-409-00-1\nDistillates (petroleum), cracked stripped steam-cracked petroleum distillates, C8-10 fraction;\nCracked kerosine;\n[A complex combination of hydrocarbons obtained by distilling cracked stripped steam-cracked distillates. It consists of hydrocarbons having carbon numbers in the range of C8 through C10 and boiling in the range of approximately 129oC to 194oC (264 oF to 382 oF).]\n270-728-3\n68477-39-4\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-410-00-7\nDistillates (petroleum), cracked stripped steam-cracked petroleum distillates, C10-12 fraction;\nCracked kerosine;\n[A complex combination of hydrocarbons obtained by distilling cracked stripped steam-cracked distillates. It consists predominantly of aromatic hydrocarbons having carbon numbers in the range of C10 through C12.]\n270-729-9\n68477-40-7\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-411-00-2\nDistillates (petroleum), steam-cracked, C8-12 fraction;\nCracked kerosine;\n[A complex combination of organic compounds obtained by the distillation of products from a steam cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C8 through C12.]\n270-737-2\n68477-54-3\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-412-00-8\nKerosine (petroleum), hydrodesulfurized thermal cracked; Cracked kerosine;\n[A complex combination of hydrocarbons obtained by fractionation from hydrodesulfurized thermal cracker distillate. It consists predomi nantly of hydrocarbons predominantly in the range of C8 to C16 and boiling in the range of approximately 120oC to 283oC (284oF to 541oF).]\n285-507-7\n85116-55-8\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-413-00-3\nAromtic hydrocarbons, C≥10, steam-cracking, hydrotreated; Cracked kerosine;\n[A complex combination of hydrocarbons produced by the distillation of the products from a steam cracking process treated with hydrogen in the presence of a catalyst. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly greater than C10 and boiling in the range of approximately 150 oC to 320 oC (302 oF to 608 oF).]\n292-621-0\n90640-98-5\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-414-00-9\nNaphtha (petroleum), steam-cracked, hydrotreated, C9-10-arom.-rich; Cracked kerosine;\n[A complex combination of hydrocarbons produced by the distillation of the products from a steam cracking process thereafter treated with hydrogen in the presence of a catalyst. It consists predominantly of aromatic hydrocarbons having carbon numbers in the range of C9 through C10 and boiling in the range of approximately 140oC to 200oC (284oF to 392oF).]\n292-637-8\n90641-13-7\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-415-00-4\nDistillates (petroleum), thermal-cracked, alkylarom. hydrocarbon-rich;\nCracked kerosine;\n[A complex combination of hydrocarbons obtained by distillation of thermal-cracking heavy tars. It consists predominantly of highly alkylated aromatic hydrocarbons boiling in the range of approximately 100 oC to 250oC (212oF to 482oF.]\n309-866-7\n101316-61-4\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-416-00-X\nDistillates (petroleum), catalytic cracked heavy tar light;\nCracked kerosine;\n[A complex combination of hydrocarbons obtained by distillation of catalytic cracking heavy tars. It consists predomi nantly of highly alkylated aromatic hydrocarbons boiling in the range of approximately 100 oC to 250 oC (212 oF to 482 oF).]\n309-938-8\n101631-13-4\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-417-00-5\nSolvent naphtha (petroleum), hydrocracked heavy arom.; Cracked kerosine;\n[A complex combination of hydrocarbons obtained by the distillation of hydrocracked petroleum distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of approximately 235 oC to 290 oC (455 oF to 554 oF).]\n309-881-9\n101316-80-7\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-418-00-0\nDistillates (petroleum), steam-cracked heavy tar light;\nCracked kerosine;\n[A complex combination of hydrocarbons obtained by distillation of steam cracking heavy tars. It consists predominantly of highly alkylated aromatic hydrocarbons boiling in the range of approximately 100 oC to 250 oC (212 oF to 482 oF).]\n309-940-9\n101631-15-6\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-419-00-6\nDistillates (petroleum), alkylate; Kerosine — unspecified;\n[A complex combination of hydrocarbons produced by distillation of the reaction products of isobutane with monoolefinic hydrocarbons usually ranging in carbon numbers from C3 through C5. It consists of predominantly branched chain saturated hydrocarbons having carbon numbers predominantly in the range of C11 through C17 and boiling in the range of approximately 205oC to 320oC (401oF to 608oF).]\n265-074-0\n64741-73-7\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-420-00-1\nExtracts (petroleum), heavy naphtha solvent;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained as the extract from a solvent extraction process. It consists predomi nantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C7 through C12 and boiling in the range of approximately 90oC to 220oC (194 oF to 428 oF).]\n265-099-7\n64741-98-6\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-421-00-7\nDistillates (petroleum), chemically neutralized light; Kerosine — unspecified;\n[A complex combination of hydrocarbons produced by a treating process to remove acidic materials. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of approximately 150 oC to 290 oC (302 oF to 554 oF).]\n265-132-5\n64742-31-0\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-422-00-2\nDistillates (petroleum), hydro- treated light;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of approxi mately 150 oC to 290 oC (302 oF to 554 oF).]\n265-149-8\n64742-47-8\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-423-00-8\nKerosine (petroleum), hydrodesulfurized; Kerosine — unspecified;\n[A complex combination of hydrocarbons obtained from a petroleum stock by treating with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of approximately 150 oC to 290 oC (302 oF to 554 oF).]\n265-184-9\n64742-81-0\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-424-00-3\nSolvent naphtha (petroleum), heavy arom.;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained from distillation of aromatic streams. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of approximately 165 oC to 290 oC (330 oF to 554 oF).]\n265-198-5\n64742-94-5\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-425-00-9\nNaphtha (petroleum), heavy coker;\nKerosine — unspecified;\n[A complex combination of hydrocarbons from the distillation of products from a fluid coker. It consists predominantly of unsaturated hydrocarbons\nhaving carbon numbers predominantly in the range of C6 through C15 and boiling in the range of approximately 157 oC to 288 oC (315 oF to 550 oF).]\n269-778-9\n68333-23-3\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-426-00-4\nNaphtha (petroleum), catalytic reformed hydrodesulfurized heavy, arom. fraction;\nKerosine — unspecified;\n[A complex combination of hydrocarbons produced by fractionation from catalytically reformed hydrodesulfurized naphtha. It consists predominantly of aromatic hydrocarbons having carbon numbers predominently in the range of C7 to C 13 and boiling in the range of approximately 98oC to 218oC (208oF to 424oF).]\n285-508-2\n85116-57-0\nAsp. Tox. 1\nH304\nGHS08-Dgr\nH304\n649-427-00-X\nKerosine (petroleum), sweetened;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained by subjecting a petroleum distillate to a sweetening process to convert mercaptans or to remove acidic impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C9 through C16 and boiling in the range of 130 oC to 290 oC (266 oF to 554 oF).]\n294-799-5\n91770-15-9\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-428-00-5\nKerosine (petroleum), solvent-refined sweetened;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained from a petroleum stock by solvent refining and sweetening and boiling in the range of approximately 150 oC to 260 oC (302 oF to 500 oF).]\n295-416-4\n92045-36-8\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-429-00-0\nHydrocarbons, C9-16, hydrotreated, dearomatized;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained as solvents which have been subjected to hydrotreatment in order to convert aromatics to naphthenes by catalytic hydrogenation.]\n297-854-1\n93763-35-0\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-430-00-6\nKerosine (petroleum), solvent-refined hydrodesulfurized; Kerosine — unspecified\n307-033-2\n97488-94-3\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-431-00-1\nDistillates (petroleum), hydrodesulfurized full-range middle coker;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained by fractionation from hydrodesulfurized coker distillate. It consists predominantly of hydrocarbons having carbon\nnumbers predominantly in the range of C8 through C16 and boiling in the range of approximately 120 oC to 283 oC (248 oF to 541 oF).]\n309-864-6\n101316-58-9\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-432-00-7\nSolvent naphtha (petroleum), hydrodesulfurized heavy arom.; Kerosine — unspecified;\n[A complex combination of hydrocarbons obtained by the catalytic hydrodesulfurization of a petroleum fraction. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C10 through C13 and boiling in the range of approximately 180 oC to 240 oC (356 oF to 464 oF).]\n309-882-4\n101316-81-8\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-433-00-2\nSolvent naphtha (petroleum), hydrodesulfurized medium; Kerosine — unspecified;\n[A complex combination of hydrocarbons obtained by the catalytic hydrodesulfurization of a petroleum fraction. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C10 through C13 and boiling in the range of approximately 175 oC to 220 oC (347 oF to 428 oF).]\n309-884-5\n101316-82-9\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-434-00-8\nKerosine (petroleum), hydrotreated;\nKerosine — unspecified;\n[A complex combination of hydrocarbons obtained from the distillation of petroleum and subsequent hydrotreatment. It consists predominantly of alkanes, cycloalkanes and alkylbenzenes having carbon numbers predominantly in the range of C12 through C16 and boiling in the range of approximately 230 oC to 270 oC (446 oF to 518 oF).]\n309-944-0\n101631-19-0\nAsp. Tox. 1\nH304\nGHS08\nDgr\nH304\n649-435-00-3\nDistillates (petroleum), light catalytic cracked;\nCracked gasoil;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C25 and boiling in the range of approximately 150 oC to 400 oC (302 oF to 752 oF). It contains a relatively large proportion of bicyclic aromatic hydrocarbons.]\n265-060-4\n64741-59-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-436-00-9\nDistillates (petroleum), intermediate catalytic cracked; Cracked gasoil;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C11 through C30 and boiling in the range of approximately 205 oC to 450 oC (401 oF to 842 oF). It contains a relatively large proportion of tricyclic aromatic hydrocarbons.]\n265-062-5\n64741-60-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-437-00-4\nDistillates (petroleum), light hydrocracked;\nCracked gasoil;\n[A complex combination of hydrocarbons from distillation of the products from a hydrocracking process. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C10 through C18 and boiling in the range of approxi mately 160oC to 320oC (320 oF to 608 oF).]\n265-078-2\n64741-77-1\nCarc. 2\nH351\nGHS08\nWng\nH351\n649-438-00-X\nDistillates (petroleum), light thermal cracked;\nCracked gasoil;\n[A complex combination of hydrocarbons from the distillation of the products from a thermal cracking process. It consists predominantly of unsaturated hydrocarbons having carbon numbers predominantly in the range of C10 through C22 and boiling in the range of approximately 160oC to 370 oC (320oF to 698oF).]\n265-084-5\n64741-82-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-439-00-5\nDistillates (petroleum), hydrodesulfurized light catalytic cracked;\nCracked gasoil;\n[A complex combination of hydrocarbons obtained by treating light catalytic cracked distillates with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists of hydrocarbons having carbon numbers predominantly in the range of C9 through C25 and boiling in the range of approximately 150 oC to 400 oC (302 oF to 752 oF). It contains a relatively large proportion of bicyclic aromatic hydrocarbons.]\n269-781-5\n68333-25-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-440-00-0\nDistillates (petroleum),light steam-cracked naphtha;\nCracked gasoil;\n[A complex combination of hydrocarbons from the multiple distillation of products from a steam cracking process. It consists of hydrocarbons having carbon numbers predominantly in the range of C10 through C18.]\n270-662-5\n68475-80-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-441-00-6\nDistillates (petroleum), cracked steam-cracked petroleum distillates;\nCracked gasoil;\n[A complex combination of hydrocarbons produced by distilling cracked steam cracked distillate and/or its fractionation products. It consists of hydrocarbons having carbon numbers predominently in the range of C10 to low molecular weight polymers.]\n270-727-8\n68477-38-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-442-00-1\nGas oils (petroleum), steam-cracked;\nCracked gasoil;\n[A complex combination of hydrocarbons produced by distillation of the products from a steam cracking process. It consists of hydrocarbons having carbon numbers predominantly greater than C9 and boiling in the range of from approximately 205 oC to 400 oC (400 oF to 752 oF).]\n271-260-2\n68527-18-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-443-00-7\nDistillates (petroleum), hydrodesulfurized thermal cracked middle;\nCracked gasoil;\n[A complex combination of hydrocarbons obtained by fractionation from hydrodesulfurized themal cracker distillate stocks. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C11 to C25 and boiling in the range of approximately 205 oC to 400ooC (401oF to 752oF).]\n285-505-6\n85116-53-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-444-00-2\nGas oils (petroleum), thermal-cracked, hydrodesulfurized; Cracked gasoil\n295-411-7\n92045-29-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-445-00-8\nResidues (petroleum), hydrogenated steam-cracked naphtha; Cracked gasoil;\n[A complex combination of hydrocarbons obtained as a residual fraction from the distillation of hydrotreated steam-cracked naphtha. It consists predominantly of hydrocarbons boiling in the range of approximately 200oC to 350oC (32 oF to 662 oF).]\n295-514-7\n92062-00-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-446-00-3\nResidues (petroleum), steam-cracked naphtha distn.;\nCracked gasoil;\n[A complex combination of hydrocarbons obtained as a column bottom from the separation of effluents from steam cracking naphtha at a high temperature. It boils in the range of approximately 147 oC to 300 oC (297 oF to 572 oF) and produces a finished oil having a viscosity of 18cSt at 50 oC.]\n295-517-3\n92062-04-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-447-00-9\nDistillates (petroleum), light catalytic cracked, thermally degraded;\nCracked gasoil;\n[A complex combination of hydrocarbons produced by the distillation of products from a catalytic cracking process which has been used as a heat transfer fluid. It consists predominantly of hydrocarbons boiling in the range of approximately 190oC to 340oC (374oF to 644oF). This stream is likely to contain organic sulfur compounds.]\n295-991-1\n92201-60-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-448-00-4\nResidues (petroleum), steam-cracked heat-soaked naphtha; Cracked gasoil;\n[A complex combination of hydrocarbons obtained as residue from the distillation of steam cracked heat soaked naphtha and boiling in the range of approximately 150 oC to 350 oC (302 oF to 662 oF).]\n297-905-8\n93763-85-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-449-00-X\nHydrocarbons, C16-20, solvent-dewaxed hydrocracked paraffinic distn. residue;\nCracked gasoil;\n[A complex combination of hydrocarbons obtained by solvent dewaxing of a distillation residue from a hydrocracked paraffinic distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C16 through C20 and boiling in the range of approximately 360 oC to 500 oC (680 oF to 932 oF). It produces a finished oil having a viscosity of 4,5 cSt at approximately 100 oC (212 oF).]\n307-662-2\n97675-88-2\nCarc. 2\nH351\nGHS08\nWng\nH351\n649-450-00-5\nGas oils (petroleum), light vacuum, thermal-cracked hydrodesulfurized;\nCracked gasoil;\n[A complex combination of hydrocarbons obtained by catalytic dehydrosulfurization of thermal-cracked light vacuum petroleum. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C14 through C20 and boiling in the range of approximately 270 oC to 370 oC (518 oF to 698 oF).]\n308-278-8\n97926-59-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-451-00-0\nDistillates (petroleum), hydrodesulfurized middle coker; Cracked gasoil;\n[A complex combination of hydrocarbons by fractionation from hydrodesulfurised coker distillate stocks. Is consists of hydrocarbons having carbon numbers predominantly in the range of C12 through C21 and boiling in the range of approximately 200 oC to 360 oC (392 oF to 680 oF).]\n309-865-1\n101316-59-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-452-00-6\nDistillates (petroleum), heavy steam-cracked;\nCracked gasoil;\n[A complex combination of hydrocarbons obtained by distillation of steam cracking heavy residues. It consists predominantly of highly alkylated heavy aromatic hydrocarbons boiling in the range of approximately 250 oC to 400 oC (482 oF to 752 oF).]\n309-939-3\n101631-14-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\n649-453-00-1\nDistillates (petroleum), heavy hydrocracked;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons from the distillation of the products from a hydrocracking process. It consists predominantly of saturated hydrocarbons having carbon numbers in the range of C15-C39 and boiling in the range of approximately 260 oC to 600 oC (500 oF to 1112 oF).]\n265-077-7\n64741-76-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-454-00-7\nDistillates (petroleum), solvent-refined heavy paraffinic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC).]\n265-090-8\n64741-88-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-455-00-2\nDistillates (petroleum), solvent-refined light paraffinic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC).]\n265-091-3\n64741-89-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-456-00-8\nResidual oils (petroleum), solvent deasphalted;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained as the solvent soluble fraction from C3-C4 solvent deasphalting of a residuum. It consists of hydrocarbons having carbon numbers predominantly higher than C25 and boiling above approximately 400 oC (752 oF).]\n265-096-0\n64741-95-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-457-00-3\nDistillates (petroleum), solvent-refined heavy naphthenic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt a 40 oC). It contains relatively few normal paraffins.]\n265-097-6\n64741-96-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-458-00-9\nDistillates (petroleum), solvent-refined light naphthenic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained as the raffinate from a solvent extraction process. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-098-1\n64741-97-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-459-00-4\nResidual oils (petroleum,) solvent-refined;\nBaseoil — unspecified;\n[A complex combination by hydrocarbons obtained as the solvent insoluble fraction from solvent refining of a residuum using a polar organic solvent such as phenol or furfural. It consists of hydrocarbons having carbon numbers predominantly higher than C25 and boiling above approximately 400oC (752oF).]\n265-101-6\n64742-01-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-460-00-X\nDistillates (petroleum), clay-treated paraffinic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons resulting from treatment of a petroleum fraction with natural or modified clay in either a contacting or percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains a relatively large proportion of saturated hydrocarbons.]\n265-137-2\n64742-36-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-461-00-5\nDistillates (petroleum), clay-treated light paraffinic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons resulting from treatment of a petroleum fraction with natural or modified clay in either a contacting or percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains a relatively large proportion of saturated hydrocarbons.]\n265-138-8\n64742-37-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-462-00-0\nResidual oils (petroleum), clay-treated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treatment of a residual oil with a natural or modified clay in either a contacting or percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydro-carbons having carbon numbers predominantly higher than C25 and boiling above approximately 400oC (752 oF).]\n265-143-5\n64742-41-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-463-00-6\nDistillates (petroleum), clay-treated heavy naphthenic; Baseoil — unspecified; [A complex combination of hydrocarbons resulting from treatment of a petroleum fraction with natural or modified clay in either a contacting or percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-146-1\n64742-44-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-464-00-1\nDistillates (petroleum), clay-treated light naphthenic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons resulting from treatment of a petroleum fraction with natural or modified clay in either a contacting or percolation process to remove the trace amounts of polar compounds and impurities present. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-147-7\n64742-45-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-465-00-7\nDistillates (petroleum), hydrotreated heavy naphthenic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil of at least 100 SUS at 100oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-155-0\n64742-52-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-466-00-2\nDistillates (petroleum), hydrotreated light naphthenic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-156-6\n64742-53-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-467-00-8\nDistillates (petroleum), hydrotreated heavy paraffinic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil of at least 100 SUS at 100oF (19cSt at 40 oC). It contains a relatively large proportion of saturated hydrocarbons.]\n265-157-1\n64742-54-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-468-00-3\nDistillates (petroleum), hydrotreated light paraffinic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains a relatively large proportion of saturated hydrocarbons.]\n265-158-7\n64742-55-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-469-00-9\nDistillates (petroleum), solvent-dewaxed light paraffinic;\nBaseoil — unspecified;\n[A complex comination of hydrocarbons obtained by removal of normal paraffins from a petroleum fraction by solvent crystallization. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC).]\n265-159-2\n64742-56-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-470-00-4\nResidual oils (petroleum), hydrotreated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst. It consists of hydrocarbons having carbon numbers predominantly greater than C25 and boiling above approximately 400 oC (752 oF).]\n265-160-8\n64742-57-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-471-00-X\nResidual oils (petroleum), solvent-dewaxed;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by removal of ong, branched chain hydrocarbons from a residual oil by solvent crystalli zation. It consists of hydrocarbons having carbon numbers predominantly greater than C25 and boiling above approxi mately 400 oC (752 oF).]\n265-166-0\n64742-62-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-472-00-5\nDistillates (petroleum), solvent-dewaxed heavy naphthenic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by removal of normal paraffins from a petroleum fraction by solvent crystallization. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 . through C50 and produces a finished oil of not less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-167-6\n64742-63-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-473-00-0\nDistillates (petroleum), solvent-dewaxed light naphthenic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by removal of normal paraffins from a petroleum fraction by solvent crystallization. It consists of hydrocarbons having carbon numbers predominantly in the range C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-168-1\n64742-64-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-474-00-6\nDistillates (petroleum), solvent-dewaxed heavy paraffinic; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by removal of normal paraffins from a petroleum fraction by solvent crystallization. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity not less than 100 SUS at 100 oF (19cSt at 40 oC).]\n265-169-7\n64742-65-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-475-00-1\nNaphthenic oils (petroleum), catalytic dewaxed heavy;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained from a catalytic dewaxing process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-172-3\n64742-68-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-476-00-7\nNaphthenic oils (petroleum), catalytic dewaxed light;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained from a catalytic dewaxing process. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-173-9\n64742-69-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-477-00-2\nParaffin oils (petroleum), catalytic dewaxed heavy;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained from a catalytic dewaxing process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC).]\n265-174-4\n64742-70-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-478-00-8\nParaffin oils (petroleum), catalytic dewaxed light;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained from a catalytic dewxing process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC).]\n265-176-5\n64742-71-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-479-00-3\nNaphthenic oils (petroleum), complex dewaxed heavy;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by removing straight chain\nparaffin hydrocarbons as a solid by treatment with an agent such as urea. It consists of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil having a viscosity of at least 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-179-1\n64742-75-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-480-00-9\nNaphthenic oils (petroleum), complex dewaxed light;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained from a catalytic dewaxing process. It consists of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil having a viscosity less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n265-180-7\n64742-76-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-481-00-4\nLubricating oils (petroleum), C20-50, hydrotreated neutral oil-based, high-viscosity;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating light vacuum gas oil, heavy vacuum gas oil, and\nsolvent deasphalted residual oil with hydrogen in the presence of a catalyst in a two stage process with dewaxing being carried out between the two stages. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil having a viscosity of approximately 112cSt at 40 oC. It contains a relatively large proportion of saturated hydrocarbons.]\n276-736-3\n72623-85-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-482-00-X\nLubricating oils (petroleum), C15-30, hydrotreated neutral oil-based;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating light vacuum gas oil and heavy vacuum gas oil with hydrogen in the presence of a catalyst in a two stage process with dewaxing being carried out between the two stages. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil having a viscosity of approximately 15cSt at 40 oC. It contains a relatively large proportion of saturated hydrocabons.]\n276-737-9\n72623-86-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-483-00-5\nLubricating oils (petroleum), C20-50, hydrotreated neutral oil-based;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating light vacuum gas oil, heavy vacuum gas oil and solvent deasphalted residual oil with hydrogen in the presence of a catalyst in a two stage process with dewaxing being carried out between the two stages. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of approximately 32cSt at 40 oC. It contains a relatively large proportion of saturated hydrocarbons.]\n276-738-4\n72623-87-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-484-00-0\nLubricating oils;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained from solvent extraction and dewaxing processes. It consists predominantly of saturated hydrocarbons having carbon numbers in the range C15 through C50.]\n278-012-2\n74869-22-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-485-00-6\nDistillates (petroleum), complex dewaxed heavy paraffinci; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by dewaxing heavy paraffinic distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of equal to or greater than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n292-613-7\n90640-91-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-486-00-1\nDistillates (petroleum), complex dewaxed light paraffinic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by dewaxing light paraffinic distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C12 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100 oF (19cSt at 40 oC). It contains relatively few normal paraffins.]\n292-614-2\n90640-92-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-487-00-7\nDistillates (petroleum), solvent dewaxed heavy paraffinic, clay-treated; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating dewaxed heavy paraffinic distillate with neutral or modified clay in either a contacting or percolation process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50.]\n292-616-3\n90640-94-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-488-00-2\nHydrocarbons, C20-50, solvent dewaxed heavy paraffinic, hydrotreated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons produced by treating dewaxed heavy paraffinic distillate with hydrogen in the presence of a catalyst. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50.]\n292-617-9\n90640-95-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-489-00-8\nDistillates (petroleum), solvent dewaxed light paraffinic, clay-treated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons resulting from treatment of dewaxed light paraffinic distillate with natural or modified clay in either a contacting or percolation process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C30.]\n292-618-4\n90640-96-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-490-00-3\nDistillates (petroleum), solvent dewaxed light paraffinic, hydrotreated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons produced by Treating a dewaxed light paraffinic distillate with hydrogen in the presence of a catalyst. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C30.]\n292-620-5\n90640-97-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-491-00-9\nResidual oils (petroleum), hydrotreated solvent dewaxed; Baseoil — unspecified\n292-656-1\n90669-74-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-492-00-4\nResidual oils (petroleum), catalytic dewaxed;\nBaseoil — unspecified\n294-843-3\n91770-57-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-493-00-X\nDistillates (petroleum), dewaxed heavy paraffinic, hydrotreated; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained from an intensive treatment of dewaxed distillate by hydrogenation in the presence of a catalyst. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C25 through C39 and produces a finished oil with a viscosity of approximately 44 cSt at 50 oC.]\n295-300-3\n91995-39-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-494-00-5\nDistillates (petroleum), dewaxed light paraffinic, hydrotreated; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained from an intensive treatment of dewaxed distillate by hydrogenation in the presence of a catalyst. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C21 through C29 and produces a finished oil with a viscosity of approximately 13 cSt at 50 oC.]\n295-301-9\n91995-40-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-495-00-0\nDistillates (petroleum), hydrocracked solvent-refined, dewaxed;\nBaseoil — unspecified; [A complex combination of liquid hydrocarbons obtained by recrystallization of dewaxed hydrocracked solvent-refined petroleum distillates.]\n295-306-6\n91995-45-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-496-00-6\nDistillates (petroleum), solvent-refined light naphthenic, hydrotreated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treating a petroleum fraction with hydrogen in the presence of a catalyst and removing the aromatic hydrocarbons by solvent extraction. It consists predominantly of naphthenic hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of between 13-15cSt at 40 oC.]\n295-316-0\n91995-54-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-497-00-1\nLubricating oils (petroleum), C17-35, solvent-extd., dewaxed, hydrotreated;\nBaseoil — unspecified\n295-423-2\n92045-42-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-498-00-7\nLubricating oils (petroleum), hydrocracked nonarom. solvent-deparaffined;\nBaseoil — unspecified\n295-424-8\n92045-43-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-499-00-2\nResidual oils (petroleum), hydrocracked acid-treated solvent-dewaxed;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons produced by solvent removal of paraffins from the residue of the distil lation of acid-treated, hydrocracked heavy paraffins and boiling approximately above 380 oC (716 oF).]\n295-499-7\n92061-86-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-500-00-6\nParaffin oils (petroleum), solvent-refined dewaxed heavy; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained from sulfur-containing paraffinic crude oil. It consists predominantly of a solvent refined deparaffinated lubricating oil with a viscosity of 65cSt at 50 oC.]\n295-810-6\n92129-09-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-501-00-1\nLubricating oils (petroleum), base oils, paraffinic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by refining of crude oil. It consists predominantly of aromatics, naphthenics and paraffinics and produces a finished oil with a viscosity of 120 SUS at 100 oF (23cSt at 40 oC).]\n297-474-6\n93572-43-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-502-00-7\nHydrocarbons, hydrocracked paraffinic distn. residues, solvent-dewaxed;\nBaseoil — unspecified\n297-857-8\n93763-38-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-503-00-2\nHydrocarbons, C20-50, residual oil hydrogenation vacuum distillate;\nBaseoil — unspecified\n300-257-1\n93924-61-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-504-00-8\nDistillates (petroleum), solvent-refined hydrotreated heavy; hydrogenated;\nBaseoil — unspecified\n305-588-5\n94733-08-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-505-00-3\nDistillates (petroleum), solvent-refined hydrocracked light; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by solvent dearomatization of the residue of hydrocracked petroleum. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C18 through C27 and boiling in the range of approximately 370oC to 450oC (698oF to 842oF).]\n305-589-0\n94733-09-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-506-00-9\nLubricating oils (petroleum), C18-40, solvent-dewaxed hydrocracked distillate-based;\nBaseoil — unspecified; [A complex combination of hydrocarbons obtained by solvent deparaffination of the distillation residue from hydrocracked petroleum. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C18 through C40 and boiling in the range of approximately 370oC to 550 oC (698 oF to 1022oF).]\n305-594-8\n94733-15-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-507-00-4\nLubricating oils (petroleum), C18-40, solvent-dewaxed hydrogenated raffinate-based;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by solvent deparaffination of the hydrogenated raffinate obtained by solvent extraction of a hydrotreated petroleum distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C18 through C40 and boiling in the range of approximately 370 oC to 550 oC (698 oF to 1022 oF).]\n305-595-3\n94733-16-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-508-00-X\nHydrocarbons, C13-30, arom.-rich, solvent-extd. naphthenic distillate;\nBaseoil — unspecified\n305-971-7\n95371-04-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-509-00-5\nHydrocarbons, C16-32, arom. rich, solvent-extd. naphthenic distillate;\nBaseoil — unspecified\n305-972-2\n95371-05-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-510-00-0\nHydrocarbons, C37-68, dewaxed deasphalted hydrotreated vacuum distn. residues;\nBaseoil — unspecified\n305-974-3\n95371-07-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-511-00-6\nHydrocarbons, C37-65, hydrotreated deasphalted vacuum distn. residues;\nBaseoil — unspecified\n305-975-9\n95371-08-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-512-00-1\nDistillates (petroleum), hydrocracked solvent-refined light; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by the solvent treatment of a distillate from hydrocracked petroleum distillates. It consists predomiantly of hydrocarbons having carbon numbers predominantly in the range of C18 through C27 and boiling in the range of approximately 370 oC to 450oC (698 oF to 842 oF.]\n307-010-7\n97488-73-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-513-00-7\nDistillates (petroleum), solvent-refined hydrogenated heavy; Baseoil — unspecified; [A complex combination of hydrocarbons, obtained by the treatment of a hydrogenated petroleum distillate with a solvent. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C19 through C40 and boiling in the range of approximately 390 oC to 550 oC (734 oF to 1022 oF).]\n307-011-2\n97488-74-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-514-00-2\nLubricating oils (petroleum), C18-27, hydrocracked solvent-dewaxed;\nBaseoil — unspecified\n307-034-8\n97488-95-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-515-00-8\nHydrocarbons, C17-30, hydrotreated solvent-deasphalted atm. distn. residue, distn. lights; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained as first runnings from the vacuum distillation of effluents from the treatment of a solvent deasphalted short residue with hydrogen in the presence of a catalyst. It consists predomi nantly of hydrocarbons having carbon numbers predominantly in the range of C17 through C30 and boiling in the range of approximately 300 oC to 400 oC (572 oF to 752 oF). It produces a finished oil having a viscosity of 4cSt at approximately 100 oC (212 oF).]\n307-661-7\n97675-87-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-516-00-3\nHydrocarbons, C17-40, hydrotreated solvent-deasphalted distn. residue, vacuum distn. lights;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained as first runnings from the vacuum distillation of effluents from the catalytic hydrotreatment of a solvent deasphalted short residue having a viscosity of 8cSt at approximately 100 oC (212 oF). It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C17 through C40 and boiling in the range of approximately 300 oC to 500 oC (592 oF to 932 oF).]\n307-755-8\n97722-06-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-517-00-9\nHydrocarbons, C13-27, solvent-extd. light naphthenic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by extraction of the aromatics from a light naphthenic distillate having a viscosity of 9.5cSt at 40 oC (104 oF). It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C13 through C27 and boiling in the range of approximately 240 oC to 400 oC (464 oF to 752 oF).]\n307-758-4\n97722-09-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-518-00-4\nHydrocarbons, C14-29, solvent-extd. light naphthenic;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by extraction of the aromatics from a light naphthenic distillate having a viscosity of 16cSt at 40oC (104oF). It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C14 through C29 and boiling in the range of approximately 250 oC to 425 oC (482 oF to 797 oF).]\n307-760-5\n97722-10-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-519-00-X\nHydrocarbons, C27-42, dearomatized;\nBaseoil — unspecified\n308-131-8\n97862-81-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-520-00-5\nHydrocarbons, C17-30, hydrotreated distillates, distn. lights; Baseoil — unspecified\n308-132-3\n97862-82-3\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-521-00-0\nHydrocarbons, C27-45, naphthenic vacuum distn.;\nBaseoil — unspecified\n308-133-9\n97862-83-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-522-00-6\nHydrocarbons, C27-45, dearomatized;\nBaseoil — unspecified\n308-287-7\n97926-68-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-523-00-1\nHydrocarbons, C20-58, hydrotreated;\nBaseoil — unspecified\n308-289-8\n97926-70-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-524-00-7\nHydrocarbons, C27-42, naphthenic;\nBaseoil — unspecified\n308-290-3\n97926-71-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-525-00-2\nResidual oils (petroleum), carbon-treated solvent-dewaxed; Baseoil — unspecified;\n[A complex combination of hydrocarbons obtained by the treatment of solvent-dewaxed petroleum residual oils with activated charcoal for the removal of trace polar constituents and impurities.]\n309-710-8\n100684-37-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-526-00-8\nResidual oils (petroleum), clay-treated solvent-dewaxed;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by treatment of solvent-dewaxed petroleum residual oils with bleaching earth for the removal of trace polar constituents and impurities.]\n309-711-3\n100684-38-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-527-00-3\nLubricating oils (petroleum), C>25, solvent-extd., deasphalted, dewaxed, hydrogenated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by solvent extraction and hydrogenation of vacuum distillation residues. It consists predominantly of hydrocarbons having carbon numbers predominantly greater than C25 and produces a finished oil with a viscosity in the order of 32cSt to 37cSt at 100 oC (212 oF).]\n309-874-0\n101316-69-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-528-00-9\nLubricating oils (petroleum), C17-32, solvent-extd., dewaxed, hydrogenated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by solvent extraction and hydrogenation of atmospheric distillation residues. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C17 through C32 and produced a finished oil with a viscosity in the order of 17cSt to 23cSt at 40 oC (104 oF.]\n309-875-6\n101316-70-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-529-00-4\nLubricating oils (petroleum), C20-35, solvent-extd., dewaxed, hydrogenated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by solvent extraction and hydrogenation of atmospheric distillation residues. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C35 and produces a finished oil with a viscosity in the order of 37cSt to 44cSt at 40 oC (104 oF).]\n309-876-1\n101316-71-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-530-00-X\nLubricating oils (petroleum), C24-50, solvent-extd., dewaxed, hydrogenated;\nBaseoil — unspecified;\n[A complex combination of hydrocarbons obtained by solvent extraction and hydrogenation of atmospheric distillation residues. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C24 through C50 and produces a finished oil with a viscosity in the order of 16cSt to 75cSt at 40 oC (104 oF).]\n309-877-7\n101316-72-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-531-00-5\nExtracts (petroleum), heavy naphthenic distillate solvent, arom. conc.;\nDistillate aromatic extract (treated);\n[An aromatic concentrate produced by adding water to heavy naphthenic distillate solvent extract and extraction solvent.]\n272-175-3\n68783-00-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-532-00-0\nExtracts (petroleum), solvent-refined heavy paraffinic distillate solvent;\nDistillate aromaticextract (treated); [A complex combination of hydrocarbons obtained as the extractfrom the re-extraction of solvent-refined heavy paraffinic distillate. It consists of saturated and aromatic hydrocarbons having carbon numbers predominantly in the range of C20 through C50.]\n272-180-0\n68783-04-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-533-00-6\nExtracts (petroleum), heavy paraffinic distillates, solvent-deasphalted;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained as the extract from a solvent extraction of heavy paraffinic distillate.]\n272-342-0\n68814-89-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-534-00-1\nExtracts (petroleum), heavy naphthenic distillate solvent, hydrotreated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained by treating a heavy naphthenic distillate solvent extract with hydrogen in the presence of a catalyst. It consists predomi nantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil of at least 19cSt at 40 oC (100 SUS at 100 oF).]\n292-631-5\n90641-07-9\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-535-00-7\nExtracts (petroleum), heavy paraffinic distillate solvent, hydrotreated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons produced by treating a heavy paraffinic distillate solvent extract with hydrogen in the presence of a catalyst. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C21 through C33 and boiling in the range of approximately 350oC to 480oC (662oF to 896oF).\n292-632-0\n90641-08-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-536-00-2\nExtracts (petroleum), light paraffinic distillate solvent, hydrotreated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons produced by treating a lightparaffinic distillate solvent extract with hydrogen in the presence of acatalyst. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C17 through C26 and boiling in the range of approximately 280oC to 400oC (536 oF to 752 oF).]\n292-633-6\n90641-09-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-537-00-8\nExtracts (petroleum), hydrotreated light paraffinic distillate solvent;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained as the extract from solvent extraction of intermediate paraffinic top solvent distillate that is treated with hydrogen in the presence of a catalyst. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C16 through C36.]\n295-335-4\n91995-73-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-538-00-3\nExtracts (petroleum), light naphthenic distillate solvent, hydrodesulfurized;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained by treating the extract, obtained from a solvent extraction process, with hydrogen in the presence of a catalyst under conditions primarily to remove sulfur compounds. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C15 through C30. This stream is likely to contain 5 wt.% or more of 4-to 6-membered condensed ring aromatic hydrocarbons.]\n295-338-0\n91995-75-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-539-00-9\nExtracts(petroleum), light paraffinic distillate solvent, acid-treated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained as a fraction of the distillation of an extract from the solvent extraction of light paraffinic top petroleum distillates that is subjected to a sulfuric acid refining. It consists predomi nantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C16 through C32.]\n295-339-6\n91995-76-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-540-00-4\nExtracts (petroleum), light paraffinic distillate solvent, hydrodesulfurized;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained by solvent extraction of a light paraffin distillate and treated with hydrogen to convert the organic sulfur to hydrogen sulfide which is eliminated. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C40 and produces a finished oil with a viscosity of greater than 10cSt at 40 oC.]\n295-340-1\n91995-77-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-541-00-X\nExtracts (petroleum), light vacuum gas oil solvent, hydrotreated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons, obtained by solvent extraction from light vacuum petroleum gas oils and treated with hydrogen in the presence of a catalyst. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C13 through C30.]\n295-342-2\n91995-79-8\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-542-00-5\nExtracts (petroleum), heavy paraffinic distillate solvent, clay-treated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons resulting from treatment of a petroleum fraction with natural or modified clay in either a contact or percolation process to remove the trace amounts of polar compounds and impurities present. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C20 through C50. This stream is likely to contain 5 wt.% or more 4-6 membered ring aromatic hydrocarbons.]\n296-437-1\n92704-08-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-543-00-0\nExtracts (petroleum), heavy naphthenic distillate solvent, hydrodesulfurized;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained from a petroleum stock by treating with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C50 and produces a finished oil with a viscosity of greater than 19cSt at 40 oC.]\n297-827-4\n93763-10-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-544-00-6\nExtracts (petroleum), solvent-dewaxed heavy paraffinic distillate solvent, hydrodesulfurized;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained from a solvent dewaxed petroleum stock by treating with hydrogen to convert organic sulfur to hydrogen sulfide which is removed. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C50 and produces a finished oil with a viscosity of greater than 19cSt at 40 oC.]\n297-829-5\n93763-11-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-545-00-1\nExtracts (petroleum), light paraffinic distillate solvent, carbon-treated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained as a fraction from distillation of an extract recovered by solvent extraction of light paraffinic top petroleum distillate treated with activated charcoal to remove traces of polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C16 through C32.]\n309-672-2\n100684-02-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-546-00-7\nExtracts (petroleum), light paraffinic distillate solvent, clay-treated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained as a fraction from distillation of an extract recovered by solvent extraction of light paraffinic top petroleum distillates treated with bleaching earth to remove traces of polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C16 through C32.]\n309-673-8\n100684-03-5\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-547-00-2\nExtracts (petroleum), light vacuum, gas oil solvent, carbon-treated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained by solvent extraction of light vacuum petroleum gas oil treated with activated charcoal for the removal of trace polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C13 through C30.]\n309-674-3\n100684-04-6\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-548-00-8\nExtracts (petroleum), light vacuum gas oil solvent, clay-treated;\nDistillate aromatic extract (treated);\n[A complex combination of hydrocarbons obtained by solvent extraction of light vacuum petroleum gas oils treated with bleaching earth for removal of trace polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C13 through C30.]\n309-675-9\n100684-05-7\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-549-00-3\nFoots oil (petroleum); Foots oil;\n[A complex combination of hydrocarbons obtained as the oil fraction from a solvent deoiling or a wax sweating process. It consists predomi nantly of branched chain hydro carbons having carbon numbers predominantly in the range of C20 through C50.]\n265-171-8\n64742-67-2\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n649-550-00-9\nFoots oil (petroleum), hydrotreated; Foots oil\n295-394-6\n92045-12-0\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nL\n650-002-00-6\nturpentine, oil\n232-350-7\n8006-64-2\nFlam. Liq. 3\nAcute Tox. 4 * Acute Tox. 4 *\nAcute Tox. 4 *\nAsp. Tox. 1\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH226\nH332\nH312\nH302\nH304\nH319\nH315\nH317\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH332\nH312\nH302\nH304\nH319\nH315\nH317\nH411\n650-003-00-1\nfenson (ISO);\n4-chlorophenyl benzenesulphonate;\n201-274-6\n80-38-6\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 2\nH302\nH319\nH411\nGHS07\nGHS09\nWng\nH302\nH319\nH411\n650-004-00-7\nnorbormide (ISO);\n5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-pyridylbenzylidene)bicycle [2.2.1] hept-5-ene-2,3-dicarboximide\n213-589-6\n991-42-4\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n650-005-00-2\n(2R,6aS,12aS)-1,2,6,6a,12,12a-hexahydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-b]furo[2,3-h]chromen-6-one, rotenone\n201-501-9\n83-79-4\nAcute Tox. 3 *\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH319\nH335\nH315\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH319\nH335\nH315\nH410\n650-006-00-8\nbenquinox (ISO);\np-benzoquinone 1-benzoylhydrazone 4-oxime\n207-807-9\n495-73-8\nAcute Tox. 3 * Acute Tox. 4 *\nH301\nH312\nGHS06\nDgr\nH301\nH312\n650-007-00-3\nchlordimeform (ISO);\nN2-(4-chloro-o-tolyl)-N1,N1-dimethylformamidine\n228-200-5\n6164-98-3\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH351\nH312\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH312\nH302\nH410\n650-008-00-9\ndrazoxolon (ISO);\n4-(2-chlorophenylhydrazone)-3-methyl-5-isoxazolone\n227-197-8\n5707-69-7\nAcute Tox. 3 * Aquatic Acute 1\nAquatic Chronic 1\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH301\nH410\n650-009-00-4\nchlordimeform hydrochloride; N'-(4-chloro-o-tolyl)-N,N-dimethylformamidine monohydrochloride;\nN2-(4-chloro-o-tolyl)-N1,N1-dimethylformamidine hydorchloride\n243-269-1\n19750-95-9\nCarc. 2\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH410\n650-010-00-X\nbenzyl violet 4B;\nα-[4-(4-dimethylamino-α-{4-[ethyl(3-sodiosulphonato benzyl)amino] phenyl}benzylidene)cyclohexa-2,5-dienylidene(ethyl)ammonio]toluene-3-sulphonate\n216-901-9\n1694-09-3\nCarc. 2\nH351\nGHS08\nWng\nH351\n650-012-00-0\nerionite\n—\n12510-42-8\nCarc. 1A\nH350\nGHS08\nDgr\nH350\n650-013-00-6\nasbestos\n—\n—\n—\n—\n—\n—\n—\n12001-28-4\n132207-32-0\n12172-73-5\n77536-66-4\n77536-68-6\n77536-67-5\n12001-29-5\nCarc. 1A\nSTOT RE 1\nH350\nH372 **\nGHS08\nDgr\nH350\nH372 **\n650-014-00-1\ndiethyl 2,4-dihydroxycyclodisiloxane-2,4-diylbis(trimethylene)diphosphonate, tetrasodium salt, reaction products with disodium metasilicate\n401-770-4\n—\nSkin Corr. 1B\nAcute Tox. 4 *\nH314\nH302\nGHS05\nGHS07\nDgr\nH314\nH302\n650-015-00-7\nrosin;\ncolophony\n232-475-7\n232-484-6\n277-299-1\n8050-09-7\n8052-10-6\n73138-82-6\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n650-016-00-2\nMineral wool, with the exception of those specified elsewhere in this Annex;\n[Man-made vitreous (silicate) fibres with random orientation with alkaline oxide and alkali earth oxide (Na2O+K2O+CaO+MgO+BaO) content greater than 18 % by weight]\n—\n—\nCarc. 2\nH351\nGHS08\nWng\nH351\nAQR\n650-017-00-8\nRefractory Ceramic Fibres, Special Purpose Fibres, with the exception of those specified elsewhere in this Annex;\n[Man-made vitreous (silicate) fibres with random orientation with alkaline oxide and alkali earth oxide (Na2O+K2O+CaO+ MgO+BaO) content less or equal to 18 % by weight]\n—\n—\nCarc. 1B\nH350i\nGHS08\nDgr\nH350i\nAR\n650-018-00-3\nReaction product of: acetophenone, formaldehyde, cyclohexylamine, methanol and acetic acid\n406-230-1\n—\nFlam. Liq. 3\nCarc. 2\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH351\nH314\nH332\nH317\nH400\nH410\nGHS02\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH226\nH351\nH314\nH332\nH317\nH410\n650-031-00-4\nbis(4-hydroxy-N-methylanilinium) sulphate\n200-237-1\n55-55-0\nAcute Tox. 4 * STOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 ** H317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 ** H317\nH410\n650-041-00-9\ntriasulfuron (ISO);\n1-[2-(2-chloroethoxy)phenylsulfonyl]-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)urea\n—\n82097-50-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n650-042-00-4\nReaction product of: polyethylene-polyamine-(C16-C18)-alkylamides with monothio-(C2)-alkyl phosphonates\n417-450-2\n—\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH319\nH315\nH317\nH412\nGHS07\nWng\nH319\nH315\nH317\nH412\n650-043-00-X\nreaction product of: 3,5-bis-tert-butylsalicylic acid and aluminiumsulfate\n420-310-3\n—\nAcute Tox. 4 * Aquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n650-044-00-5\nmixed linear and branched C14-15 alcohols ethoxylated, reaction product with epichlorohydrin\n420-480-9\n158570-99-1\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n650-045-00-0\nReaction product of: 1,2,3-propanetricarboxylic acid, 2-hydroxy, diethyl ester, 1-propanol and zirconium tetra-n-propanolate\n417-110-3\n—\nFlam. Liq. 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH225\nH315\nH318\nH411\nGHS02\nGHS05\nGHS09\nDgr\nH225\nH315\nH318\nH411\n650-046-00-6\ndi(tetramethylammonium)(29H,31H-phthalocyanin-N29,N30,N31,N32)disulfonamide disulfonate, cuprate(2-)complex, derivates\n416-180-2\n12222-04-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH302\nH373 ** H411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373 ** H411\n650-047-00-1\ndibenzylphenylsulfonium hexafluoroantimonate\n417-760-8\n134164-24-2\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH372 ** H302\nH318\nH317\nH411\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH372 **\nH302\nH318\nH317\nH411\n650-048-00-7\nreaction product of: borax, hydrogen peroxide, acetic acid anhydride and acetic acid\n420-070-1\n—\nOrg. Perox. D **** Acute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A Aquatic Acute 1\nH242\nH332\nH312\nH302\nH314\nH400\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH242\nH332\nH312\nH302\nH314\nH400\n650-049-00-2\n2-alkoyloxyethyl hydrogen maleate, where alkoyl represents (by weight 70 to 85 % unsaturated octadecoyl, 0.5 to 10 % saturated octadecoyl, and 2 to 18 % saturated hexadecoyl\n417-960-5\n—\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n650-050-00-8\nreaction mass of: 1-methyl-3-hydroxypropyl 3,5-[1,1-dimethylethyl]-4-hydroxydihydro-cinnamate and/or 3-hydroxybutyl 3,5-[1,1-dimethylethyl]-4-hydroxydihydrocinnamate;\n1,3-butanediol bis[3-(3'-(1,1-dimethylethyl)4'-hydroxy-phenyl)propionate] isomers;\n1,3-butanediol bis[3-(3',5'-(1,1-dimethylethyl)-4'-hydroxyphenyl)propionate] isomers\n423-600-8\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n650-055-00-5\nsilver sodium zirconium hydrogenphosphate\n422-570-3\n155925-27-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2018/669/annex",
    "retrieved_at": "2026-11-01T14:44:10.307170+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}